"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,WO,A1,WO 2017/223249 A1,152-096-074-552-969,2017-12-28,2017,US 2017/0038619 W,2017-06-21,US 201615188912 A,2016-06-21,ASSET PROTECTION APPARATUS SYSTEM AND METHOD,"An asset protection system, apparatus and method are disclosed in which threat attack data that is data about a plurality of previous attacks against a plurality of targets is used to generate a threat profile for a particular threat in which the threat profile contains a threat that has a relationship to an attack mechanism that has a relationship to a victim profile based on the threat attack data. The system, apparatus and method may then protect an asset from the particular threat using the threat profile in which the asset is matched to the victim profile and a defensive response to the particular threat is identified for the asset based on the attack mechanism of the threat.",NTT INNOVATION INST INC,BOYER RICHARD,,https://lens.org/152-096-074-552-969,Patent Application,yes,5,0,2,2,0,H04L63/1416;;H04L63/1425;;H04L63/1433;;G06F16/22;;H04L63/1416;;H04L63/1425;;H04L63/1433,G06F21/55;;G06F21/00;;G06F21/56;;G06F21/57,,1,0,,,"GLOBAL CYBER THREAT INTELLIGENCE BY KENJI TAKAHASHI, 6 August 2016 (2016-08-06), Retrieved from the Internet <URL:https://www.slideshare.net/nfti3/global-cyber-threat-intelligence> [retrieved on 20170816]",PENDING
2,US,A1,US 2017/0366571 A1,193-847-671-940-769,2017-12-21,2017,US 201615188912 A,2016-06-21,US 201615188912 A,2016-06-21,"ASSET PROTECTION APPARATUS, SYSTEM AND METHOD","An asset protection system, apparatus and method are disclosed in which threat attack data that is data about a plurality of previous attacks against a plurality of targets is used to generate a threat profile for a particular threat in which the threat profile contains a threat that has a relationship to an attack mechanism that has a relationship to a victim profile based on the threat attack data. The system, apparatus and method may then protect an asset from the particular threat using the threat profile in which the asset is matched to the victim profile and a defensive response to the particular threat is identified for the asset based on the attack mechanism of the threat.",NTT INNOVATION INST INC,BOYER RICHARD,NTT RESEARCH INC (2017-10-17),https://lens.org/193-847-671-940-769,Patent Application,yes,0,13,2,2,0,H04L63/1416;;H04L63/1425;;H04L63/1433;;G06F16/22;;H04L63/1416;;H04L63/1425;;H04L63/1433,H04L29/06;;G06F17/30,,0,0,,,,DISCONTINUED
3,US,A,US 1246388 A,025-320-370-137-259,1917-11-13,1917,US 11242216 A,1916-07-31,US 11242216 A,1916-07-31,CYLINDER-HARROW.,,CHARLES HOOVER;;BOYER RICHARD M,BOYER RICHARD M,,https://lens.org/025-320-370-137-259,Granted Patent,no,0,0,1,1,0,A01B1/24;;A01B1/24,,,0,0,,,,EXPIRED
4,US,A,US 3121768 A,025-817-788-477-326,1964-02-18,1964,US 22668862 A,1962-09-27,US 22668862 A,1962-09-27,Method of casting,,POLYMER PROCESSES INC,BOYER RICHARD W,,https://lens.org/025-817-788-477-326,Granted Patent,no,3,17,4,4,0,B29C39/006;;B29C39/38;;B29K2077/00;;B29K2905/02;;B29K2909/02;;C08G69/18;;Y10S264/56;;C08G69/18;;B29K2905/02;;B29C39/006;;B29K2909/02;;B29K2077/00;;B29C39/38;;Y10S264/56,B29C39/00;;B29C39/38;;C08G69/18,,0,0,,,,EXPIRED
5,DE,D1,DE 3485573 D1,067-213-707-221-510,1992-04-16,1992,DE 3485573 T,1984-12-18,US 56486983 A,1983-12-23,SPANNUNGSBEGRENZUNGSSCHALTUNG MIT NIEDRIGER IMPEDANZ.,,PHILIPS NV,BOYER RICHARD MYRON,"PHILIPS ELECTRONICS N.V., EINDHOVEN, NL (1995-06-22)",https://lens.org/067-213-707-221-510,Granted Patent,no,0,0,6,6,0,G05F3/225;;G05F3/225;;H03K19/0136;;H03K19/0136;;H03K19/088;;H03K19/088,H03K19/003;;G05F3/22;;H03K17/60;;H03K19/013;;H03K19/088,,0,0,,,,EXPIRED
6,WO,A1,WO 2013/185017 A1,052-540-908-754-894,2013-12-12,2013,US 2013/0044684 W,2013-06-07,US 201261656866 P;;US 201313782737 A,2012-06-07,COVER SHELL FOR REDUCING DAMAGE TO FOOD PRODUCT,A cover shell and container assembly comprising the cover shell and a tray or pan is disclosed. The cover shell includes inward projecting standoffs which restrict movement of a food product in the pan or tray and reduces damage to decorative elements of the food product during distribution and/or transport.,SCHWAN S GLOBAL SUPPLY CHAIN INC,BOYER STEPHEN RICHARD,,https://lens.org/052-540-908-754-894,Patent Application,yes,5,1,5,5,0,B65D2543/00296;;B65D25/10;;B65D43/0214;;B65D2543/00092;;B65D2543/00361;;B65D2543/00407;;B65D2543/00527;;B65D2543/00537;;A47G23/00;;B65D85/36;;B65D25/107;;B65D2543/00296;;B65D25/10;;B65D43/0214;;B65D2543/00092;;B65D2543/00361;;B65D2543/00407;;B65D2543/00527;;B65D2543/00537;;B65D43/0212,B65D85/36;;B65D43/02;;B65D77/20,,0,0,,,,PENDING
7,US,A,US 4542331 A,158-630-707-821-440,1985-09-17,1985,US 56486983 A,1983-12-23,US 56486983 A;;US 51944083 A,1983-08-01,Low-impedance voltage reference,A voltage reference for providing a reference voltage (V.sub.AB) between a pair of terminals (A and B) contains a diode (D) and a bipolar transistor (Q) whose base is coupled to one electrode of the diode. The collector of the transistor is coupled to a node (C) between one of the terminals (A) and the other electrode of the diode. The emitter of the transistor is coupled to the other terminal (B).,SIGNETICS CORP,BOYER RICHARD M,SIGNETICS CORPORATION A CA CORP (1983-12-19),https://lens.org/158-630-707-821-440,Granted Patent,yes,5,12,6,6,0,G05F3/225;;G05F3/225;;H03K19/0136;;H03K19/0136;;H03K19/088;;H03K19/088,H03K19/003;;G05F3/22;;H03K17/60;;H03K19/013;;H03K19/088,323/313;;307/446;;307/458,1,0,,,"Signetics Logic TTL Data Manual, Product Information , Signetics Corp., May 1978, pp. 27 28.",EXPIRED
8,EP,B1,EP 0147898 B1,117-338-328-397-859,1992-03-11,1992,EP 84201894 A,1984-12-18,US 56486983 A,1983-12-23,LOW-IMPEDANCE VOLTAGE LIMITING CIRCUIT,,N.V. PHILIPS' GLOEILAMPENFABRIEKEN,"BOYER, RICHARD MYRON",CAMBIO RAGIONE SOCIALE;PHILIPS ELECTRONICS N.V. (1995-04-19);;PHILIPS ELECTRONICS N.V. (1995-08-01),https://lens.org/117-338-328-397-859,Granted Patent,yes,0,0,6,6,0,G05F3/225;;G05F3/225;;H03K19/0136;;H03K19/0136;;H03K19/088;;H03K19/088,H03K19/003;;G05F3/22;;H03K17/60;;H03K19/013;;H03K19/088,,1,0,,,"TIETZE,SCHENK,""Halbleiter-Schaltungstechnik""Korrigierter Nachdruck der dritten Auflage.Abschnitt 16 ""Kippschltungen"" 1976 Springer Verlag page 468",EXPIRED
9,US,A,US 5139169 A,184-868-538-330-271,1992-08-18,1992,US 65851491 A,1991-02-21,US 65851491 A;;CA 2119248 A;;US 9206434 W,1991-02-21,Carbonated beverage dispensing system,There is provided an improved carbonated drink dispensing system including a semi-rigid plastic collapsible bladder which holds the carbonated beverage and a dispensing apparatus which receives the semi-rigid bladder. The bladder includes a plurality of ribs to provide additional strength. The dispensing apparatus and bladder are generally cylindrical in shape. The dispensing apparatus includes a top pressure plate for applying downward pressure to the top of the bladder as the beverage is dispensed thereby collapsing a portion of the bladder so as to keep appropriate pressure within the bag thus preventing the escape of carbonation from the beverage. A gearing mechanism to provide a mechanical advantage is utilized in connection with the movement of the pressure plate.,BOYER RICHARD L,BOYER RICHARD L,,https://lens.org/184-868-538-330-271,Granted Patent,yes,12,47,4,5,0,B67D1/0001;;Y10T74/18816;;Y10T74/18816;;B67D1/0001,B67D1/00,222/103;;222/105;;222/107;;222/326;;74/89.18;;100/288;;383/119,0,0,,,,EXPIRED
10,MX,A,MX 2014014964 A,043-090-151-900-105,2015-07-06,2015,MX 2014014964 A,2013-06-07,US 201261656866 P;;US 201313782737 A;;US 2013/0044684 W,2012-06-07,COVER SHELL FOR REDUCING DAMAGE TO FOOD PRODUCT.,A cover shell and container assembly comprising the cover shell and a tray or pan is disclosed. The cover shell includes inward projecting standoffs which restrict movement of a food product in the pan or tray and reduces damage to decorative elements of the food product during distribution and/or transport.,SCHWAN S GLOBAL SUPPLY CHAIN INC,BOYER STEPHEN RICHARD,,https://lens.org/043-090-151-900-105,Patent Application,no,0,1,5,5,0,B65D2543/00296;;B65D25/10;;B65D43/0214;;B65D2543/00092;;B65D2543/00361;;B65D2543/00407;;B65D2543/00527;;B65D2543/00537;;A47G23/00;;B65D85/36;;B65D25/107;;B65D2543/00296;;B65D25/10;;B65D43/0214;;B65D2543/00092;;B65D2543/00361;;B65D2543/00407;;B65D2543/00527;;B65D2543/00537;;B65D43/0212,B65D43/02;;B65D85/36;;B65D77/20,,0,0,,,,PENDING
11,DE,B,DE 1132097 B,073-955-881-731-815,1962-06-28,1962,DE P0022565 A,1959-04-09,US 72744158 A,1958-04-09,Vorrichtung zum Ziehen von Kristallen aus einer Schmelze,,PHILCO CORP,DUNKLE RICHARD BOYER,,https://lens.org/073-955-881-731-815,Patent Application,no,3,2,6,6,0,C30B15/02;;C30B15/02;;C30B15/10;;C30B15/10;;Y10S117/90;;Y10S117/90;;Y10S438/925;;Y10S438/925;;Y10T117/1056;;Y10T117/1056;;Y10T117/1068;;Y10T117/1068,C30B15/02;;C30B15/10,,0,0,,,,DISCONTINUED
12,CA,A,CA 732528 A,177-184-327-022-286,1966-04-19,1966,CA 732528D A,,CA 732528T A,,METHOD OF CASTING,,POLYMER PROCESSES,BOYER RICHARD W,,https://lens.org/177-184-327-022-286,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
13,EP,A3,EP 0147898 A3,192-273-956-794-316,1986-11-05,1986,EP 84201894 A,1984-12-18,US 56486983 A,1983-12-23,LOW-IMPEDANCE VOLTAGE LIMITING CIRCUIT,A voltage limiting circuit for providing a reference voltage (V AB ) between a pair of terminals (A and B) contains a diode (D) and a bipolar transistor (Q) whose base is coupled to one electrode of the diode. The collector of the transistor is coupled to a node (C) between one of the terminals (A) and the other electrode of the diode. The emitter of the transistor is coupled to the other terminal (B).,N.V. PHILIPS' GLOEILAMPENFABRIEKEN,"BOYER, RICHARD MYRON",CAMBIO RAGIONE SOCIALE;PHILIPS ELECTRONICS N.V. (1995-04-19);;PHILIPS ELECTRONICS N.V. (1995-08-01),https://lens.org/192-273-956-794-316,Search Report,yes,2,0,6,6,0,G05F3/225;;G05F3/225;;H03K19/0136;;H03K19/0136;;H03K19/088;;H03K19/088,H03K19/003;;G05F3/22;;H03K17/60;;H03K19/013;;H03K19/088,,0,0,,,,EXPIRED
14,CA,A1,CA 2119248 A1,042-811-986-454-239,1994-02-17,1994,CA 2119248 A,1992-08-03,CA 2119248 A;;US 9206434 W;;US 65851491 A,1991-02-21,Carbonated Beverage Dispensing System,,BOYER RICHARD L,BOYER RICHARD L,,https://lens.org/042-811-986-454-239,Patent Application,no,0,0,4,5,0,B67D1/0001;;Y10T74/18816;;Y10T74/18816;;B67D1/0001,B67D1/00,,0,0,,,,EXPIRED
15,US,A,US 4593210 A,145-687-176-110-003,1986-06-03,1986,US 51944083 A,1983-08-01,US 51944083 A,1983-08-01,Switching circuit with active pull-off,"A bipolar gate has an output transistor (Q5) that switches in response to the voltage at an emitter of a drive transistor (Q2 or Q10). An active pull-off circuit (14) discharges the base of the output transistor (Q5) when it turns off. The discharge path is provided through a pull-off transistor (Q7) whose collector is coupled to the base of the output transistor. The switching of the pull-off transistor is regulated with a control circuit containing a trigger circuit and a bias circuit. The trigger circuit is coupled between the bias circuit and a collector of the drive transistor. A ""kicker"" circuit formed with an input transistor (QC1) and a voltage reference (18) speeds up the switching of the drive transistor.",SIGNETICS CORP,BOYER RICHARD M,SIGNETICS A CORP OF CA (1983-07-28),https://lens.org/145-687-176-110-003,Granted Patent,yes,10,8,1,1,0,H03K19/088;;H03K19/088;;H03K19/0136;;H03K19/0136,H03K19/013;;H03K19/088,307/443;;307/456;;307/270;;307/300,1,0,,,"Signetics TTL Logic Data Manual 1982, pp. 2 1 and 2 2.",EXPIRED
16,CA,A1,CA 2870167 A1,153-236-601-582-077,2013-12-12,2013,CA 2870167 A,2013-06-07,US 201261656866 P;;US 201313782737 A;;US 2013/0044684 W,2012-06-07,COVER SHELL FOR REDUCING DAMAGE TO FOOD PRODUCT,A cover shell and container assembly comprising the cover shell and a tray or pan is disclosed. The cover shell includes inward projecting standoffs which restrict movement of a food product in the pan or tray and reduces damage to decorative elements of the food product during distribution and/or transport.,SCHWAN S GLOBAL SUPPLY CHAIN INC,BOYER STEPHEN RICHARD,,https://lens.org/153-236-601-582-077,Patent Application,no,0,0,5,5,0,B65D2543/00296;;B65D25/10;;B65D43/0214;;B65D2543/00092;;B65D2543/00361;;B65D2543/00407;;B65D2543/00527;;B65D2543/00537;;A47G23/00;;B65D85/36;;B65D25/107;;B65D2543/00296;;B65D25/10;;B65D43/0214;;B65D2543/00092;;B65D2543/00361;;B65D2543/00407;;B65D2543/00527;;B65D2543/00537;;B65D43/0212,B65D85/36;;B65D43/02;;B65D77/20,,0,0,,,,DISCONTINUED
17,EP,A2,EP 0147898 A2,171-048-898-658-128,1985-07-10,1985,EP 84201894 A,1984-12-18,US 56486983 A,1983-12-23,Low-impedance voltage limiting circuit.,A voltage limiting circuit for providing a reference voltage (V AB ) between a pair of terminals (A and B) contains a diode (D) and a bipolar transistor (Q) whose base is coupled to one electrode of the diode. The collector of the transistor is coupled to a node (C) between one of the terminals (A) and the other electrode of the diode. The emitter of the transistor is coupled to the other terminal (B).,PHILIPS NV,BOYER RICHARD MYRON,CAMBIO RAGIONE SOCIALE;PHILIPS ELECTRONICS N.V. (1995-04-19);;PHILIPS ELECTRONICS N.V. (1995-08-01),https://lens.org/171-048-898-658-128,Patent Application,yes,0,1,6,6,0,G05F3/225;;G05F3/225;;H03K19/0136;;H03K19/0136;;H03K19/088;;H03K19/088,H03K19/003;;G05F3/22;;H03K17/60;;H03K19/013;;H03K19/088,,0,0,,,,EXPIRED
18,DE,A1,DE 1520568 A1,050-644-545-107-674,1970-01-08,1970,DE 1520568 A,1963-09-27,US 22668862 A,1962-09-27,Verfahren zur Herstellung eines geformten Polylactamgegenstandes,,POLYMER CORP,WILLIAM BOYER RICHARD,,https://lens.org/050-644-545-107-674,Patent Application,no,0,0,4,4,0,B29C39/006;;B29C39/38;;B29K2077/00;;B29K2905/02;;B29K2909/02;;C08G69/18;;Y10S264/56;;C08G69/18;;B29K2905/02;;B29C39/006;;B29K2909/02;;B29K2077/00;;B29C39/38;;Y10S264/56,B29C39/00;;B29C39/38;;C08G69/18,,0,0,,,,DISCONTINUED
19,US,A,US 5112156 A,113-545-784-284-926,1992-05-12,1992,US 69448491 A,1991-05-02,US 69448491 A,1991-05-02,Tool handle/extension coupler,"Couplers for hand tools and extension handles are made up of two one piece fittings. Each fitting has an attachment element for connection to one of the tool and extension handle and a connecting element for joining the two fittings. Normally, one of the attachment elements will be a threaded male element and the other a threaded female element. The connector elements also are composed of a male and female element. The male connector element is a tube or rod with a dually tapered flange. The flange fits into a channel (depression) in the female connector element. The connecting elements are complementary in shape and size.",BOYER RICHARD L,BOYER RICHARD L,,https://lens.org/113-545-784-284-926,Granted Patent,yes,7,36,1,1,0,F16B7/0413;;F16B21/088;;Y10T403/51;;F16B2200/10;;Y10T403/51;;F16B2200/10;;F16B21/088;;F16B7/0413,F16B7/04;;F16B21/08,403/287;;403/299;;403/361,0,0,,,,EXPIRED
20,WO,A1,WO 1994/003376 A1,118-120-245-973-181,1994-02-17,1994,US 9206434 W,1992-08-03,US 9206434 W;;CA 2119248 A;;US 65851491 A,1991-02-21,CARBONATED BEVERAGE DISPENSING SYSTEM,"A carbonated drink dispensing system including a semi-rigid plastic collapsible bladder (14) which holds the carbonated beverage and a dispensing apparatus (10) which receives the semi-rigid bladder (14). The bladder (14) includes a plurality of ribs (104) to provide additional strength. The dispensing apparatus (10) and bladder (14) are generally cylindrical in shape. The dispensing apparatus (10) includes a top pressure plate (16) for applying downward pressure to the top of the bladder (14) as the beverage is dispensed thereby collapsing a portion of the bladder (14) so as to keep appropriate pressure within the bladder (14) thus preventing the escape of carbonation from the beverage. A gearing mechanism (24, 26) to provide a mechanical advantage is utilized in connection with the movement of the pressure plate (16).",BOYER RICHARD L,BOYER RICHARD L,,https://lens.org/118-120-245-973-181,Patent Application,yes,6,6,4,5,0,B67D1/0001,B67D1/00,,0,0,,,,PENDING
21,US,A1,US 2013/0327777 A1,189-374-709-498-047,2013-12-12,2013,US 201313782737 A,2013-03-01,US 201313782737 A;;US 201261656866 P,2012-06-07,COVER SHELL FOR REDUCING DAMAGE TO FOOD PRODUCT,A cover shell and container assembly comprising the cover shell and a tray or pan is disclosed. The cover shell includes inward projecting standoffs which restrict movement of a food product in the pan or tray and reduces damage to decorative elements of the food product during distribution and/or transport.,SCHWAN S GLOBAL SUPPLY CHAIN INC,BOYER STEPHEN RICHARD,SFC GLOBAL SUPPLY CHAIN INC (2013-06-06),https://lens.org/189-374-709-498-047,Patent Application,yes,10,1,5,5,0,B65D2543/00296;;B65D25/10;;B65D43/0214;;B65D2543/00092;;B65D2543/00361;;B65D2543/00407;;B65D2543/00527;;B65D2543/00537;;A47G23/00;;B65D85/36;;B65D25/107;;B65D2543/00296;;B65D25/10;;B65D43/0214;;B65D2543/00092;;B65D2543/00361;;B65D2543/00407;;B65D2543/00527;;B65D2543/00537;;B65D43/0212,A47G23/00,220/573.1,0,0,,,,ACTIVE
22,EP,A1,EP 0605441 A1,066-189-455-994-74X,1994-07-13,1994,EP 92917067 A,1992-08-03,CA 2119248 A;;US 9206434 W;;US 65851491 A,1991-02-21,CARBONATED BEVERAGE DISPENSING SYSTEM.,"L'invention concerne un système de distribution de boissons gazeuses constitué d'une vessie pliable (14) en plastique semi-rigide qui renferme la boisson gazeuse, et d'un appareil de distribution (10) destiné à recevoir ladite vessie semi-rigide (14). Cette vessie (14) se compose d'une pluralité de renforts (104) destinés à lui donner une résistance supplémentaire. L'appareil de distribution (10) et la vessie (14) sont de forme générale cylindrique. Ledit appareil de distribution (10) comprend une plaque supérieure (16) de pression conçue pour appliquer une pression descendante sur le sommet de la vessie (14) au fur et à mesure que la boisson est soutirée, ce qui replie une partie de la vessie (14) de manière à maintenir une pression appropriée dans celle-ci (14) et à éviter que le gaz carbonique ne s'échappe de la boisson. Un mécanisme à engrenage (24, 26) donnant un avantage mécanique est utilisé en combinaison avec la plaque (16) de pression.",BOYER RICHARD L,BOYER RICHARD L,,https://lens.org/066-189-455-994-74X,Patent Application,yes,0,0,1,5,0,B67D1/0001;;Y10T74/18816;;Y10T74/18816;;B67D1/0001,B67D1/00,,0,0,,,,DISCONTINUED
23,US,A,US 805837 A,076-273-408-410-400,1905-11-28,1905,US 1905/0240915 A,1905-01-13,US 1905/0240915 A,1905-01-13,WHEEL.,,BOYER RICHARD A,BOYER RICHARD A,,https://lens.org/076-273-408-410-400,Granted Patent,no,0,0,1,1,0,B60B9/005;;B60B9/005,,,0,0,,,,EXPIRED
24,US,A,US 2650877 A,142-790-072-697-176,1953-09-01,1953,US 13219949 A,1949-12-09,US 13219949 A,1949-12-09,Process of producing etched printing plates,,DU PONT,RICHARD BOYER MAHLON,,https://lens.org/142-790-072-697-176,Granted Patent,no,6,8,1,1,0,G03F7/06;;G03F7/06,G03F7/06,,0,0,,,,EXPIRED
25,CA,C,CA 2119248 C,172-185-266-596-392,1997-03-18,1997,CA 2119248 A,1992-08-03,CA 2119248 A;;US 9206434 W;;US 65851491 A,1991-02-21,CARBONATED BEVERAGE DISPENSING SYSTEM,"A carbonated drink dispensing system including a semi-rigid plastic collapsible bladder (14) which holds the carbonated beverage and a dispensing apparatus (10) which receives the semi-rigid bladder (14). The bladder (14) includes a plurality of ribs (104) to provide additional strength. The dispensing apparatus (10) and bladder (14) are generally cylindrical in shape. The dispensing apparatus (10) includes a top pressure plate (16) for applying downward pressure to the top of the bladder (14) as the beverage is dispensed thereby collapsing a portion of the bladder (14) so as to keep appropriate pressure within the bladder (14) thus preventing the escape of carbonation from the beverage. A gearing mechanism (24, 26) to provide a mechanical advantage is utilized in connection with the movement of the pressure plate (16).",BOYER RICHARD L,BOYER RICHARD L,,https://lens.org/172-185-266-596-392,Granted Patent,no,0,0,4,5,0,B67D1/0001;;Y10T74/18816;;Y10T74/18816;;B67D1/0001,B67D1/00,,0,0,,,,EXPIRED
26,US,A,US 3652092 A,188-583-018-164-579,1972-03-28,1972,US 3652092D A,1969-10-24,US 86900969 A,1969-10-24,ASTROLOGY BOARD GAME APPARATUS,"An astrology game board comprising a flat stationary board having positioned on a surface thereof a circular indicator means rotatable about a fixed axis, disposed around said indicator means twelve radially extending bands, each of said bands having within its field in radially disposed fashion; an image of the earth having therein a orbiting flag receiving aperture, a plurality of zodiac sign symbols in circularly disposed arrangement, in proximity to each of said symbols a peg receiving aperture, and a plurality of peg receiving apertures in circularly disposed arrangement; between said bands and each associated with one of said bands a circularly disposed degree scale, said scale having at regular increments a orbiting flag receiving aperture. Each of said bands is identified by a color associated with a particular zodiac sign. The bands are arranged in the cosmic order of the zodiac signs around the indicator means. The degree scale has at its center the planet symbol and name of the planet which cosmically rules the zodiac sign of the band associated with said scale. Alternatively, said indicator means may be deleted in favor of twelve suits of astrological playing cards.",RICHARD G BOYER;;LOLA ELIZABETH BOYER,BOYER RICHARD G;;BOYER LOLA ELIZABETH,,https://lens.org/188-583-018-164-579,Granted Patent,no,4,23,1,1,0,A63F3/00006;;A63F3/001;;A63F3/001;;A63F3/00006,A63F3/00,273134   C;;273134   E;;273141   R,0,0,,,,EXPIRED
27,FR,E,FR 72908 E,050-678-414-868-196,1960-09-21,1960,FR 72908D A,1954-01-20,DE 329942X A;;US 32980253 A;;US 35976153 A;;US 81015859 A,1953-01-06,Système téléphonique à barres croisées réparti en primaires et secondaires,,CONSTR TELEPHONIQUES;;MATERIEL TELEPHONIQUE,BOYER RICHARD PORTER,,https://lens.org/050-678-414-868-196,Amended Patent,no,0,0,20,20,0,H04Q3/0004;;H04Q3/0004;;H01H67/26;;H01H67/26,H01H67/26;;H04Q3/00,,0,0,,,,DISCONTINUED
28,US,B2,US 8895091 B2,118-576-328-945-261,2014-11-25,2014,US 201313782737 A,2013-03-01,US 201313782737 A;;US 201261656866 P,2012-06-07,Cover shell for reducing damage to food product,A cover shell and container assembly comprising the cover shell and a tray or pan is disclosed. The cover shell includes inward projecting standoffs which restrict movement of a food product in the pan or tray and reduces damage to decorative elements of the food product during distribution and/or transport.,SCHWAN S GLOBAL SUPPLY CHAIN INC,BOYER STEPHEN RICHARD,SFC GLOBAL SUPPLY CHAIN INC (2013-06-06),https://lens.org/118-576-328-945-261,Granted Patent,yes,25,6,5,5,0,B65D2543/00296;;B65D25/10;;B65D43/0214;;B65D2543/00092;;B65D2543/00361;;B65D2543/00407;;B65D2543/00527;;B65D2543/00537;;A47G23/00;;B65D85/36;;B65D25/107;;B65D2543/00296;;B65D25/10;;B65D43/0214;;B65D2543/00092;;B65D2543/00361;;B65D2543/00407;;B65D2543/00527;;B65D2543/00537;;B65D43/0212,B65D85/36;;A47G23/00;;B65D25/10;;B65D43/02,426/112;;426/128;;426/394;;426/397;;220/608;;220/671;;220/675;;206/551;;D7/610,1,0,,,"International Search Report and Written Opinion for PCT/US2013/044684 mailed Aug. 19, 2013.",ACTIVE
29,US,A,US 2553168 A,045-855-662-841-287,1951-05-15,1951,US 78397547 A,1947-11-04,US 78397547 A,1947-11-04,Concentric shell type hot-air heater,,BOYER RICHARD J,BOYER RICHARD J,,https://lens.org/045-855-662-841-287,Granted Patent,no,4,1,1,1,0,F24H3/065;;F26B21/002;;F24H3/065;;F26B21/002,F24H3/06;;F26B21/00,,0,0,,,,EXPIRED
30,US,A,US 4011951 A,100-752-953-710-966,1977-03-15,1977,US 65461976 A,1976-02-02,US 65461976 A,1976-02-02,Bracket for small animal feeder,"Apparatus for use in feeding or watering confined animals comprising a bracket to hold one or more feed buckets on an elevated rail member for engagement by the chest of a feeding animal, the buckets being on the opposite side of the rail from the animal. The bracket includes hoop members to support the rims of feed buckets, hook members aligned with the hoop members to fit over the top edge of a rail member, and lip members extending from the hook members beneath the hoop members for supporting buckets from below, all being rigidly connected together.",BOYER RICHARD J,BOYER RICHARD J,,https://lens.org/100-752-953-710-966,Granted Patent,yes,4,48,1,1,0,A01K5/008;;A01K5/008;;A01K5/01;;A01K5/01,A01K5/00,211/71,0,0,,,,EXPIRED
31,FR,A1,FR 2544492 A1,040-725-484-343-48X,1984-10-19,1984,FR 8306297 A,1983-04-18,FR 8306297 A,1983-04-18,PROCEDE ET DISPOSITIF DE DOSAGE PONDERAL D'UNE POUDRE,"Method of and apparatus for dosing powders by weight. To introduce a weight of powder with a predetermined final value P3 into a weighing receptacle, the functioning of mechanism for positively feeding the powder to the receptacle is controlled by a continuous comparison between the effective weight of powder received by the receptacle following an initial instant t0 and a theoretical weight conforming to an ideal evolution of such weight of powder as a function of time; at a final predetermined instant t2 with reference to the initial instant t0, the positive feeding mechanism is stopped and the powder remaining is allowed to run into the weighing receptacle in an amount corresponding to the amount of poweder which is lost during its transmission by the feeding mechanism.",MANURHIN,BOYER RICHARD;;DIQUET JOEL,,https://lens.org/040-725-484-343-48X,Patent Application,no,5,2,7,7,0,G01G13/2851;;G01G13/2857;;G01G13/2906;;G01G13/2937;;G01G13/2851;;G01G13/2906;;G01G13/2937;;G01G13/2857,G01G13/12;;G01G13/285;;G01G13/29,,0,0,,,,EXPIRED
32,US,A,US 2718557 A,087-442-166-750-931,1955-09-20,1955,US 25431551 A,1951-11-01,US 25431551 A,1951-11-01,Auxiliary-service telephone system,,ITT,BOYER JR RICHARD P,,https://lens.org/087-442-166-750-931,Granted Patent,no,5,1,1,1,0,H04M3/12;;H04M3/12;;H04Q3/0004;;H04Q3/0004,H04M3/12;;H04Q3/00,,0,0,,,,EXPIRED
33,US,A,US 2869046 A,191-514-306-469-798,1959-01-13,1959,US 57882256 A,1956-04-17,US 57882256 A,1956-04-17,Signaling systems,,GEN DYNAMICS CORP,BOYER JR RICHARD P,,https://lens.org/191-514-306-469-798,Granted Patent,no,7,2,1,1,0,H04M19/02;;H04M19/02,H04M19/02,,0,0,,,,EXPIRED
34,US,A,US 2686841 A,065-941-332-352-049,1954-08-17,1954,US 19003050 A,1950-10-13,US 19003050 A,1950-10-13,Block coupler,,ITT,BOYER JR RICHARD P,,https://lens.org/065-941-332-352-049,Granted Patent,no,9,2,1,1,0,H04Q3/0004;;H04Q3/0004,H04Q3/00,,0,0,,,,EXPIRED
35,DE,D1,DE 3461565 D1,117-404-645-477-417,1987-01-15,1987,DE 3461565 T,1984-04-17,FR 8306297 A,1983-04-18,PROCESS AND DEVICE FOR THE DOSAGE BY WEIGHT OF A POWDER,"Method of and apparatus for dosing powders by weight. To introduce a weight of powder with a predetermined final value P3 into a weighing receptacle, the functioning of mechanism for positively feeding the powder to the receptacle is controlled by a continuous comparison between the effective weight of powder received by the receptacle following an initial instant t0 and a theoretical weight conforming to an ideal evolution of such weight of powder as a function of time; at a final predetermined instant t2 with reference to the initial instant t0, the positive feeding mechanism is stopped and the powder remaining is allowed to run into the weighing receptacle in an amount corresponding to the amount of poweder which is lost during its transmission by the feeding mechanism.",HAUT RHIN MANUFACTURE MACHINES,BOYER RICHARD;;DIQUET JOEL,,https://lens.org/117-404-645-477-417,Granted Patent,no,0,0,7,7,0,G01G13/2851;;G01G13/2857;;G01G13/2906;;G01G13/2937;;G01G13/2851;;G01G13/2906;;G01G13/2937;;G01G13/2857,G01G13/12;;G01G13/285;;G01G13/29,,0,0,,,,EXPIRED
36,US,B1,US 6597709 B1,134-685-584-508-696,2003-07-22,2003,US 67935500 A,2000-10-05,US 67935500 A,2000-10-05,Method and apparatus for aligning a solar concentrator using two lasers,"
    A method and apparatus are provided for aligning the facets of a solar concentrator. A first laser directs a first laser beam onto a selected facet of the concentrator such that a target board positioned adjacent to the first laser at approximately one focal length behind the focal point of the concentrator is illuminated by the beam after reflection thereof off of the selected facet. A second laser, located adjacent to the vertex of the optical axis of the concentrator, is used to direct a second laser beam onto the target board at a target point thereon. By adjusting the selected facet to cause the first beam to illuminate the target point on the target board produced by the second beam, the selected facet can be brought into alignment with the target point. These steps are repeated for other selected facets of the concentrator, as necessary, to provide overall alignment of the concentrator. 
",US ENERGY,DIVER JR RICHARD BOYER,UNITED STATES DEPARTMENT OF ENERGY (2000-09-13),https://lens.org/134-685-584-508-696,Granted Patent,yes,9,45,1,1,0,F24S23/70;;F24S23/70;;F24S2023/832;;F24S2023/832;;Y02E10/40;;Y02E10/40,F24S23/70,372/9;;372/107,3,0,,,"R. Diver, ""Mirror Alignment Techniques for Point-Focus Solar Concentrators,"" Sandia National Laboratories, SAND92-0668, Jun. 1992.;;J. Blackmon, et al., ""Application of the digital Image Radiometer to Optical Measurement and allignment of Space and Terrestrial solar Power Systems,"" 28th Intersociety Energt Conversion Engineering Conference Proceedings, vol. 2, pp. 2.563-2.570, Aug. 1993.;;R. Diver, ""Mirror Alignment and Focus of Point-Focus Concentrators,"" Proceedings of the 1995 ASME/JSME/JSES International Solar Energy Conference,, pp. 1-8, Mar. 1995.",EXPIRED
37,FR,B1,FR 2544492 B1,196-954-432-012-212,1986-11-21,1986,FR 8306297 A,1983-04-18,FR 8306297 A,1983-04-18,PROCEDE ET DISPOSITIF DE DOSAGE PONDERAL D'UNE POUDRE,"Method of and apparatus for dosing powders by weight. To introduce a weight of powder with a predetermined final value P3 into a weighing receptacle, the functioning of mechanism for positively feeding the powder to the receptacle is controlled by a continuous comparison between the effective weight of powder received by the receptacle following an initial instant t0 and a theoretical weight conforming to an ideal evolution of such weight of powder as a function of time; at a final predetermined instant t2 with reference to the initial instant t0, the positive feeding mechanism is stopped and the powder remaining is allowed to run into the weighing receptacle in an amount corresponding to the amount of poweder which is lost during its transmission by the feeding mechanism.",MANURHIN,BOYER RICHARD;;DIQUET JOEL,,https://lens.org/196-954-432-012-212,Granted Patent,no,0,0,7,7,0,G01G13/2851;;G01G13/2857;;G01G13/2906;;G01G13/2937;;G01G13/2851;;G01G13/2906;;G01G13/2937;;G01G13/2857,G01G13/12;;G01G13/285;;G01G13/29,,0,0,,,,EXPIRED
38,US,A,US 2685052 A,062-817-253-039-903,1954-07-27,1954,US 22881051 A,1951-05-29,US 22881051 A,1951-05-29,Condenser-timed relay interrupter,,ITT,BOYER JR RICHARD P,,https://lens.org/062-817-253-039-903,Granted Patent,no,3,9,1,1,0,H04M19/02;;H04M19/02,H04M19/02,,0,0,,,,EXPIRED
39,US,A,US 2941194 A,164-010-115-162-971,1960-06-14,1960,US 64996457 A,1957-04-01,US 64996457 A,1957-04-01,Indicator for telephone systems,,GEN DYNAMICS CORP,BOYER JR RICHARD P,,https://lens.org/164-010-115-162-971,Granted Patent,no,5,0,1,1,0,H04M3/08;;H04M3/08,H04M3/08,,0,0,,,,EXPIRED
40,CA,A,CA 614337 A,131-756-861-956-662,1961-02-14,1961,CA 614337D A,,CA 614337T A,,AUTOMATIC TELEPHONE SYSTEM AND TRANSLATOR THEREFOR,,INT STANDARD ELECTRIC CORP,BOYER RICHARD P JR,,https://lens.org/131-756-861-956-662,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
41,AT,T1,AT E24053 T1,142-392-882-194-067,1986-12-15,1986,AT 84400762 T,1984-04-17,EP 84400762 A;;FR 8306297 A,1983-04-18,VERFAHREN UND APPARAT ZUR GEWICHTSMAESSIGEN DOSIERUNG EINES PULVERS.,"Method of and apparatus for dosing powders by weight. To introduce a weight of powder with a predetermined final value P3 into a weighing receptacle, the functioning of mechanism for positively feeding the powder to the receptacle is controlled by a continuous comparison between the effective weight of powder received by the receptacle following an initial instant t0 and a theoretical weight conforming to an ideal evolution of such weight of powder as a function of time; at a final predetermined instant t2 with reference to the initial instant t0, the positive feeding mechanism is stopped and the powder remaining is allowed to run into the weighing receptacle in an amount corresponding to the amount of poweder which is lost during its transmission by the feeding mechanism.",HAUT RHIN MANUFACTURE MACHINES,BOYER RICHARD;;DIQUET JOEL,,https://lens.org/142-392-882-194-067,Granted Patent,no,0,0,7,7,0,G01G13/2851;;G01G13/2857;;G01G13/2906;;G01G13/2937;;G01G13/2851;;G01G13/2906;;G01G13/2937;;G01G13/2857,G01G13/12;;G01G13/285;;G01G13/29,,0,0,,,,DISCONTINUED
42,US,A,US 2184268 A,041-123-610-332-473,1939-12-26,1939,US 25469339 A,1939-02-04,US 25469339 A,1939-02-04,Supervisory circuit for telephone switchboards,,BOYER JR RICHARD P,BOYER JR RICHARD P,,https://lens.org/041-123-610-332-473,Granted Patent,no,0,0,1,1,0,H04M5/10;;H04M5/10,H04M5/10,,0,0,,,,EXPIRED
43,EP,B1,EP 0126662 B1,176-192-677-185-361,1986-12-03,1986,EP 84400762 A,1984-04-17,FR 8306297 A,1983-04-18,PROCESS AND DEVICE FOR THE DOSAGE BY WEIGHT OF A POWDER,"Method of and apparatus for dosing powders by weight. To introduce a weight of powder with a predetermined final value P3 into a weighing receptacle, the functioning of mechanism for positively feeding the powder to the receptacle is controlled by a continuous comparison between the effective weight of powder received by the receptacle following an initial instant t0 and a theoretical weight conforming to an ideal evolution of such weight of powder as a function of time; at a final predetermined instant t2 with reference to the initial instant t0, the positive feeding mechanism is stopped and the powder remaining is allowed to run into the weighing receptacle in an amount corresponding to the amount of poweder which is lost during its transmission by the feeding mechanism.",MANUFACTURE DE MACHINES DU HAUT-RHIN S.A. (MANURHIN),"BOYER, RICHARD;;DIQUET, JOEL",,https://lens.org/176-192-677-185-361,Granted Patent,yes,0,0,7,7,0,G01G13/2851;;G01G13/2857;;G01G13/2906;;G01G13/2937;;G01G13/2851;;G01G13/2906;;G01G13/2937;;G01G13/2857,G01G13/12;;G01G13/285;;G01G13/29,,0,0,,,,EXPIRED
44,US,A,US 4619336 A,016-592-263-906-852,1986-10-28,1986,US 59746384 A,1984-04-06,FR 8306297 A,1983-04-18,Method of and apparatus for weighing doses of powder,"Method of and apparatus for dosing powders by weight. To introduce a weight of powder with a predetermined final value P.sub.3 into a weighing receptacle, the functioning of mechanism for positively feeding the powder to the receptacle is controlled by a continuous comparison between the effective weight of powder received by the receptacle following an initial instant t.sub.0 and a theoretical weight conforming to an ideal evolution of such weight of powder as a function of time; at a final predetermined instant t.sub.2 with reference to the initial instant t.sub.0, the positive feeding mechanism is stopped and the powder remaining is allowed to run into the weighing receptacle in an amount corresponding to the amount of poweder which is lost during its transmission by the feeding mechanism.",HAUT RHIN MANUFACTURE MACHINES,BOYER RICHARD;;DIQUET JOEEL,MANUFACTURE DE MACHINES (1984-02-05),https://lens.org/016-592-263-906-852,Granted Patent,yes,5,25,7,7,0,G01G13/2851;;G01G13/2857;;G01G13/2906;;G01G13/2937;;G01G13/2851;;G01G13/2906;;G01G13/2937;;G01G13/2857,G01G13/12;;G01G13/285;;G01G13/29,G3N NGLA          GLA,0,0,,,,EXPIRED
45,EP,A1,EP 0126662 A1,111-563-389-592-992,1984-11-28,1984,EP 84400762 A,1984-04-17,FR 8306297 A,1983-04-18,Process and device for the dosage by weight of a powder.,"Procédé et dispositif de dosage pondéral d'une poudre. Pour introduire un poids de poudre d'une valeur prédéterminée finale (P 3 ) dans un récipient de pesage, on asservit le fonctionnement de moyens d'acheminement de poudre vers ce récipient à une comparaison en continu entre le poids effectif de poudre (II) reçu par le récipient depuis un instant initial (t o ) et un poids théorique conforme à une évolution idéale (I) de ce poids en fonction du temps; à un instant final (t 2 ) prédéterminé en référence à l'instant initial (t o ), les moyens d'acheminement sont arrêtés et on laisse s'écouler dans le récipient la poudre résiduelle correspondant à l'erreur de jetée. Application à un dosage pondéral précis dans un temps déterminé.",HAUT RHIN MANUFACTURE MACHINES,BOYER RICHARD;;DIQUET JOEL,,https://lens.org/111-563-389-592-992,Patent Application,yes,5,3,7,7,0,G01G13/2851;;G01G13/2857;;G01G13/2906;;G01G13/2937;;G01G13/2851;;G01G13/2906;;G01G13/2937;;G01G13/2857,G01G13/12;;G01G13/285;;G01G13/29,,0,0,,,,EXPIRED
46,US,A,US 2710893 A,128-723-913-703-618,1955-06-14,1955,US 21779151 A,1951-03-27,US 21779151 A,1951-03-27,Automatic telephone system and translator therefor,,ITT,BOYER JR RICHARD P,,https://lens.org/128-723-913-703-618,Granted Patent,no,8,1,1,1,0,H04Q3/0004;;H04Q3/0004,H04Q3/00,,0,0,,,,EXPIRED
47,US,A,US 2587103 A,179-642-293-152-231,1952-02-26,1952,US 12961749 A,1949-11-26,US 12961749 A,1949-11-26,Path-selection control arrangement for primary-secondary switching systems,,KELLOGG SWITCHBOARD & SUPPLY,BOYER JR RICHARD P,,https://lens.org/179-642-293-152-231,Granted Patent,no,0,4,1,1,0,H04Q3/0004;;H04Q3/0004,H04Q3/00,,0,0,,,,EXPIRED
48,US,A1,US 2013/0255681 A1,186-554-184-591-36X,2013-10-03,2013,US 201213435398 A,2012-03-30,US 201213435398 A,2012-03-30,DATA COLLECTION SYSTEM AND METHOD USING PARAMETRIC-BASED SAMPLING RATES,The present disclosure relates to a system and method for sampling parametric data provided with a patient monitoring device. A disclosed method includes sampling parametric data associated with a patient and adjusting a sampling interval during the sampling of the parametric data based on a change in a frequency of a periodic physiological event associated with the patient. A disclosed system includes a server computer operative to sample parametric data associated with a patient and to adjust a sampling interval during the sampling of the parametric data based on a change in a frequency of a periodic physiological event associated with the patient.,BATCH RICHARD;;BOYER ROBERT T;;NELLCOR PURITAN BENNETT LLC,BATCH RICHARD;;BOYER ROBERT T,COVIDIEN LP (2012-09-29);;NELLCOR PURITAN BENNETT LLC (2012-03-29),https://lens.org/186-554-184-591-36X,Patent Application,yes,4,39,1,1,0,A61B5/0205;;A61B5/7285;;A61B5/0816;;A61M2016/0027;;A61M2016/003;;A61M2205/3553;;A61M2205/3584;;A61M2205/3592;;A61M2205/502;;A61M2205/52;;A61M2230/04;;A61M2230/205;;A61M2230/30;;A61M2230/42;;A61M16/0051;;A61M16/024;;G16H40/63;;G16H20/40;;G16H40/63;;A61B5/7285;;A61B5/0205;;A61B5/0816;;A61M2205/502;;A61M2205/3592;;A61M2230/04;;A61M2205/3553;;A61M2205/52;;A61M2230/42;;A61M2016/0027;;A61M2205/3584;;A61M2230/30;;A61M2230/205;;A61M2016/003;;A61M16/024;;A61M16/0051;;G16H20/40,A61B5/00;;A61B5/0205;;A61M16/00,128/204.21;;600/300;;600/484,0,0,,,,DISCONTINUED
49,US,A,US 805444 A,159-784-194-040-099,1905-11-28,1905,US 1904/0224989 A,1904-09-19,US 1904/0224989 A,1904-09-19,INCUBATOR.,,BOYER RICHARD A;;KINNEY FRED,BOYER RICHARD A;;KINNEY FRED,,https://lens.org/159-784-194-040-099,Granted Patent,no,0,0,1,1,0,A01K41/00;;A01K41/00,,,0,0,,,,EXPIRED
50,FR,A,FR 740038 A,073-846-852-765-597,1933-01-20,1933,FR 740038D A,1932-07-16,FR 740038T A,1932-07-16,Perfectionnements à la pasteurisation de la bière et de toutes boissons analogues à base de malt,,,SLAMA RICHARD;;BOYER MURRAY CHESTON,,https://lens.org/073-846-852-765-597,Granted Patent,no,0,0,1,1,0,A23L3/08,A23L3/08,,0,0,,,,EXPIRED
51,CA,A,CA 124826 A,111-489-745-109-264,1910-04-05,1910,CA 124826D A,1910-01-21,CA 124826T A,1910-01-21,TANK HEATER,,SCOTT HAL;;BOYER RICHARD M,SCOTT HAL;;BOYER RICHARD M,,https://lens.org/111-489-745-109-264,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
52,US,A,US 951428 A,097-357-764-837-400,1910-03-08,1910,US 1909/0496964 A,1909-05-19,US 1909/0496964 A,1909-05-19,TANK-HEATER.,,SCOTT HAL;;BOYER RICHARD M,SCOTT HAL;;BOYER RICHARD M,,https://lens.org/097-357-764-837-400,Granted Patent,no,0,1,1,1,0,A47J27/10;;A47J27/10,,,0,0,,,,EXPIRED
53,US,B1,US 7130139 B1,002-005-596-526-615,2006-10-31,2006,US 17603505 A,2005-07-07,US 17603505 A;;US 86258604 A,2004-06-07,Write velocity identification,"A drive and method of identifying write velocity during reading are provided. When a track is being read, the data signal is processed prior to determining the data stream to identify the velocity with which the track data were written. The read channel is adjusted based on the identified velocity to compensate for write channel transfer function variation.",STORAGE TECHNOLOGY CORP,BOYER KEITH GARY;;GILL RICHARD ALLEN,,https://lens.org/002-005-596-526-615,Granted Patent,yes,20,0,2,2,0,G11B15/52;;G11B15/52;;G11B5/00813;;G11B5/00813;;G11B15/46;;G11B15/46;;G11B20/10009;;G11B20/10009;;G11B20/10055;;G11B20/10055;;G11B27/328;;G11B27/328;;G11B27/36;;G11B27/36;;G11B2005/001;;G11B2005/001;;G11B2020/10981;;G11B2020/10981;;G11B2220/90;;G11B2220/90,G11B5/09;;G11B5/00;;G11B5/008;;G11B15/46;;G11B20/10;;G11B27/32;;G11B27/36,360/46;;360/25;;360/73.01;;360/73.11;;360/73.14,0,0,,,,ACTIVE
54,CN,A,CN 102256809 A,004-570-119-018-794,2011-11-23,2011,CN 200980150911 A,2009-11-10,EP 2009064916 W;;FR 0858728 A,2008-12-17,"Tyre for heavy vehicles, with a crown reinforcement comprising at least one layer of circumferential reinforcing elements","The invention relates to a tyre including a crown reinforcement (4) radially covered by a tread, the crown reinforcement including at least one layer of circumferential reinforcing elements (42) axially distributed according to a variable spacing. According to the invention, the layer of circumferential reinforcing elements comprises at least five portions, i.e. a central portion (421), two intermediate portions (422) and two axially outer portions (423), the value of the spacing in the central portion being 1 to 1.5 times the value of the spacing in the axially outer portions, and the value of the spacing in an intermediate portion being 1.6 to 2 times the value of the spacing in the axially outer portions.",MICHELIN SOC TECH;;MICHELIN RECH TECH,CHRISTELLE CHAULET;;RICHARD AUDIGIER;;CHRIS BOYER,COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (2012-11-13),https://lens.org/004-570-119-018-794,Patent Application,no,0,5,13,13,0,B60C9/2006;;B60C9/22;;B60C9/28;;B60C2200/06;;Y10T152/1081;;Y10T152/10801;;Y10T152/10765;;B60C9/28;;B60C9/2006;;B60C9/22;;B60C2200/06,B60C9/20;;B60C9/22,,0,0,,,,ACTIVE
55,EP,A1,EP 2289359 A1,037-244-244-931-201,2011-03-02,2011,EP 10181071 A,2006-07-21,EP 09167407 A;;EP 06788212 A;;US 19411205 A,2005-07-29,Soccer glove,"The invention relates to an athletic glove for supporting a hand of a wearer. The soccer glove improves performance through the use a three dimensional finger cap (1101) which forms at least a portion of at least one digit of the wearer's hand. The athletic glove also comprises an open wrist feature (1305) which allows for a greater degree of support, adjustability, comfort, and ease of access and removal.",NIKE INTERNATIONAL LTD,AVIS RICHARD;;BOYER CLANCY;;FISHER SAM,NIKE INNOVATE C.V. (2014-08-06),https://lens.org/037-244-244-931-201,Patent Application,yes,6,0,25,25,0,A41D19/01523;;A63B71/148;;A63B2243/0025;;A41D19/01523;;A63B2243/0025;;A63B71/148,A41D19/015;;A63B71/14,,0,0,,,,ACTIVE
56,CA,A,CA 883732 A,118-072-987-912-843,1971-10-19,1971,CA 883732D A,,CA 883732T A,,ULTRAVIOLET STABILIZED PETROLEUM HYDROCARBONS,,SUN OIL CO,BOYER JACKSON S;;CASSAR RICHARD D,,https://lens.org/118-072-987-912-843,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
57,WO,A1,WO 2013/067342 A1,103-093-707-615-800,2013-05-10,2013,US 2012/0063307 W,2012-11-02,US 201161554613 P;;US 201213663066 A,2011-11-02,"SYSTEM, METHOD, AND SOFTWARE FOR DISPLAYING PARAMETER VALUES WITH HISTORICAL RANGES",A method for patient monitoring includes receiving one or more first patient parameters from at least one medical device. The method further includes transforming the one or more first patient parameters into one or more gauge display parameters. The method further includes generating data operable to display the one or more gauge display parameters individually in a particular portion of a display device. The one or more gauge display parameters include at least a historical range and a current value within the historical range. The method further includes analyzing one or more second patient parameters to adjust the one or more gauge display parameters.,COVIDIEN LP;;BOYER ROBERT;;TRENOUTH JOHN;;BATCH RICHARD,BOYER ROBERT;;TRENOUTH JOHN;;BATCH RICHARD,,https://lens.org/103-093-707-615-800,Patent Application,yes,5,0,3,3,0,G06T11/206;;G06T11/206;;G16H15/00;;G16H15/00;;G16H40/40;;G16H40/40;;G16H40/67;;G16H40/67,A61B5/02;;G06Q90/00,,0,0,,,,PENDING
58,WO,A1,WO 2015/116372 A1,115-329-615-430-589,2015-08-06,2015,US 2015/0011097 W,2015-01-13,US 201461932399 P,2014-01-28,TAPE WRAPPED UNSHIELDED TWISTED PAIR CABLE FOR HIGH SPEED DATA TRANSMISSIONS,A method (100) to construct a tape wrapped unshielded twisted pair (UTP) cable (10) is provided. The method (100) includes the step of twisting (112) a first wire (12) and a second wire (14) together to form a twisted pair (16). The method (100) further includes the step of wrapping (116) tape (18) around the twisted pair (16) with an effective amount of tension (34) on the tape (18) such that a separation distance (20) between the first wire (12) and second wire (14) does not substantially vary along the length of the twisted pair (16).,DELPHI TECH INC,BOYER RICHARD J;;HEFFRON JOHN F,,https://lens.org/115-329-615-430-589,Patent Application,yes,5,2,8,8,0,H01B13/22;;H01B13/02;;H01B11/02;;H01B13/01263;;H01B7/17;;H01B11/02;;H01B13/01263;;H01B13/02;;H01B13/22;;H01B11/02;;H01B13/02;;H01B13/22;;H01B7/17;;H01B13/01263,H01B13/02;;H01B13/22,,1,0,,,See also references of EP 3100284A4,PENDING
59,US,A,US 3547880 A,131-339-497-801-324,1970-12-15,1970,US 3547880D A,1967-12-18,US 69119967 A,1967-12-18,ULTRAVIOLET STABILIZED ELASTOMERIC COMPOSITION,,SUN OIL CO,BOYER JACKSON S;;CASSAR RICHARD D,,https://lens.org/131-339-497-801-324,Granted Patent,no,9,0,1,9,0,C08K5/11;;C08K5/11;;C08K5/526;;C08K5/526;;Y10S524/929;;Y10S524/929,C08K5/11;;C08K5/526,C3K KCN           KCN;;C3K K293          KCN;;C3K K296          KCN;;C3K K297          KCN;;C3M MXC           MXCS;;C3M M110          MXCS;;C3M M112A         MXCS;;C3M M127          MXCS;;C3M M128          MXCS;;C3M M129          MXCS;;C3M M130          MXCS;;C3M M131          MXCS;;C3M M132          MXCS;;C3M M133          MXCS;;C3M M134          MXCS,0,0,,,,EXPIRED
60,US,A1,US 2013/0106864 A1,129-354-842-955-679,2013-05-02,2013,US 201213663066 A,2012-10-29,US 201213663066 A;;US 201161554613 P,2011-11-02,"SYSTEM, METHOD, AND SOFTWARE FOR DISPLAYING PARAMETER VALUES WITH HISTORICAL RANGES",A method for patient monitoring includes receiving one or more first patient parameters from at least one medical device. The method further includes transforming the one or more first patient parameters into one or more gauge display parameters. The method further includes generating data operable to display the one or more gauge display parameters individually in a particular portion of a display device. The one or more gauge display parameters include at least a historical range and a current value within the historical range. The method further includes analyzing one or more second patient parameters to adjust the one or more gauge display parameters.,COVIDIEN LP;;COVIDIEN LP,BOYER ROBERT;;TRENOUTH JOHN;;BATCH RICHARD,COVIDIEN LP (2012-10-24),https://lens.org/129-354-842-955-679,Patent Application,yes,7,8,3,3,0,G06T11/206;;G06T11/206;;G16H15/00;;G16H15/00;;G16H40/40;;G16H40/40;;G16H40/67;;G16H40/67,G06T11/20,345/440.2;;345/440,0,0,,,,ACTIVE
61,GB,A,GB 1117299 A,129-099-881-372-833,1968-06-19,1968,GB 1424667 A,1967-03-29,US 54967166 A,1966-05-12,Semiconductor devices,,INT RECTIFIER CORP,BOYER JOHN L;;HARTMAN RICHARD A,,https://lens.org/129-099-881-372-833,Granted Patent,no,0,0,4,4,0,H01L23/488;;H01L23/488;;H01L23/051;;H01L23/051;;H01L23/492;;H01L23/492;;H01L29/00;;H01L29/00;;H01L2924/0002;;H01L2924/0002,H01L23/051;;H01L23/488;;H01L23/492;;H01L29/00,H1K KRX           RX;;H1K K1A1          HB;;H1K K2S20         HB;;H1K K4C1U         HB;;H1K K4C2B         HB;;H1K K4C5Y         HB;;H1K K4F7B         HB;;H1K K4F7C         HB;;H1K K5A           HB;;H1K K5A1          HB;;H1K K5A3          HB;;H1K K5A4          HB;;H1K K5H1          HB;;H1K K9R           HB,0,0,,,,EXPIRED
62,US,B2,US 7784111 B2,198-039-915-508-013,2010-08-31,2010,US 16850508 A,2008-07-07,US 16850508 A;;US 19411205 A,2005-07-29,Soccer glove,"The invention relates to an athletic glove for supporting a hand of a wearer. The soccer glove improves performance through the use a three dimensional finger cap which forms at least a portion of at least one digit of the wearer's hand. The athletic glove also comprises an open wrist feature which allows for a greater degree of support, adjustability, comfort, and ease of access and removal.",NIKE INC,AVIS RICHARD;;BOYER CLANCY;;FISHER SAM,NIKE INC (2005-12-05),https://lens.org/198-039-915-508-013,Granted Patent,yes,26,0,25,25,0,A41D19/01523;;A63B71/148;;A63B2243/0025;;A41D19/01523;;A63B2243/0025;;A63B71/148,A41D19/00,2/161.1,8,0,,,"Exhibit 1, Uhlsport glove, top view, May 2005.;;Exhibit 2, Uhlsport glove, top/back view, May 2005.;;Exhibit 3, Nike glove, top/side view, Mar.-Apr. 2004.;;Exhibit 4 Nike glove, top/back view, Mar.-Apr. 2004.;;Exhibit 5 Nike glove palm view, Mar.-Apr. 2004.;;Exhibit 6 Nike glove, top/back view, Mar.-Apr. 2004.;;Exhibit 7 Nike glove, top view, Mar.-Apr. 2004.;;International Preliminary Report on Patentability for PCT/US2006/028517 mailed Jan. 28, 2008, including Written Opinion and International Search Report.",ACTIVE
63,US,B2,US 9152762 B2,000-973-803-712-636,2015-10-06,2015,US 201313768268 A,2013-02-15,US 201313768268 A,2013-02-15,"System, method, and software for positive patient identification","A system including a database storing a plurality of patient data corresponding to a plurality of patients, where the patient data corresponds to a particular patient and includes at least one image of the particular patient; and a component configured to receive patient identification information previously assigned to one of the particular patients, extract the patient data corresponding to the particular patient identification information received, and display the patient data on a display including at least one image of the particular patient.",COVIDIEN LP,BOYER ROBERT T;;BATCH RICHARD M,COVIDIEN LP (2013-02-12),https://lens.org/000-973-803-712-636,Granted Patent,yes,18,0,2,2,0,G16H10/60;;G16H10/60;;G16H10/65;;G16H10/65;;G16Z99/00;;G16Z99/00,G06F17/30;;G06F19/00,,0,0,,,,ACTIVE
64,CA,A,CA 911699 A,032-437-905-494-360,1972-10-10,1972,CA 911699D A,,CA 911699T A,,PETROLEUM HYDROCARBONS CONTAINING POLYESTER STABILIZERS,,SUN RESEARCH DEVELOPMENT,CASSAR RICHARD D;;BOYER JACKSON S,,https://lens.org/032-437-905-494-360,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
65,US,A,US 3562209 A,090-936-592-320-852,1971-02-09,1971,US 3562209D A,1969-03-10,US 80583569 A,1969-03-10,ALPHA-OLEFIN POLYMERS CONTAINING POLYESTER STABILIZERS,,SUN OIL CO,CASSAR RICHARD D;;BOYER JACKSON S,,https://lens.org/090-936-592-320-852,Granted Patent,no,0,0,1,1,0,C08G63/676;;C08L23/02;;C08L23/10;;C08G63/676;;C08L23/02;;C08L23/10,C08G63/676;;C08L23/02,C3M MXC           MXCS;;C3M M110          MXCS;;C3M M112A         MXCS;;C3M M140          MXCS,0,0,,,,EXPIRED
66,JP,A,JP 2016145028 A,163-846-378-777-242,2016-08-12,2016,JP 2015252823 A,2015-12-25,US 201514592408 A,2015-01-08,SYSTEM AND METHOD OF TAKING SAFETY MEASURES BY DETECTING UNACCOMPANIED OCCUPANT IN VEHICLE,"PROBLEM TO BE SOLVED: To provide a safety system and method configured to determine whether or not a passenger room of a vehicle is occupied and whether or not the temperature of the passenger room is out of an allowable temperature range, and take safety measures as needed.SOLUTION: An occupant 12 is detected with a sound received by an audio transducer of a passenger room 14 connected to an information entertainment system. A temperature is detected by a temperature sensor 26 connected to a heating, ventilation, air-conditioning system of the vehicle. For example, safety measures include operating a horn 40, transmitting a radio signal indicating that an unaccompanied occupant is in the vehicle to a remote receiver, and/or at least partially opening a vehicle window 44. A pair of high frequency speakers connected to the information entertainment system may be used for transmitting/receiving an ultrasonic signal. Consequently, the occupant can be detected by using an ultrasonic operation detection technique.SELECTED DRAWING: Figure 1",DELPHI TECH INC,RICHARD J BOYER;;JOHN F HEFFRON,,https://lens.org/163-846-378-777-242,Patent Application,no,0,2,8,8,0,B60R16/037;;B60H1/00778;;B60H1/00978;;B60H1/00742;;H04R19/04;;G10K11/18;;B60Q5/005;;H04R2410/00;;B60H1/00778;;B60H1/00978;;B60H1/00742,B60H1/00;;F02D29/02;;F02N11/08;;F24F11/02;;G08B21/02,,0,0,,,,PENDING
67,BR,A2,BR PI0923408 A2,036-508-345-741-669,2016-01-05,2016,BR PI0923408 A,2009-11-10,EP 2009064916 W;;FR 0858728 A,2008-12-17,pneumático com armadura de carcaça radial.,,MICHELIN RECH TECH;;SOCIÉTÉ DE TECHNOLOGIE MICHELIN,BOYER CHRIS;;CHAULET CHRISTELLE;;AUDIGIER RICHARD,"MICHELIN RECHERCHE ET TECHNIQUE S.A. (CH) , COMPAG (2016-06-28)",https://lens.org/036-508-345-741-669,Patent Application,no,0,0,13,13,0,B60C9/2006;;B60C9/22;;B60C9/28;;B60C2200/06;;Y10T152/1081;;Y10T152/10801;;Y10T152/10765;;B60C9/28;;B60C9/2006;;B60C9/22;;B60C2200/06,B60C9/20;;B60C9/22,,0,0,,,,DISCONTINUED
68,US,A1,US 2015/0336463 A1,110-629-893-172-367,2015-11-26,2015,US 201414283739 A,2014-05-21,US 201414283739 A,2014-05-21,ACTIVE ELECTROMAGNETIC INTERFERENCE MITIGATION SYSTEM AND METHOD,"A system and method to mitigate electromagnetic interference generated by a source resonator of a wireless charging system is presented. The system includes a receiver that configured to receive a wireless charging signal transmitted by the source resonator, a phase shifter in communication with the receiver and configured to generate a canceling signal that is 180° out of phase with the wireless charging signal currently received by the receiver, and a transmitter in communication with the phase shifter and configured to electromagnetically transmit the canceling signal, thereby canceling at least a portion of the wireless charging signal. The canceling signal being at the same frequency and 180° out of phase interferes with the charging signal to reduce or eliminate electromagnetic interference in the vicinity of the vehicle being charged.",DELPHI TECH INC,BOYER RICHARD J;;HEFFRON JOHN F,DELPHI TECHNOLOGIES INC (2014-05-20),https://lens.org/110-629-893-172-367,Patent Application,yes,59,11,2,2,0,H02J50/70;;B60L53/12;;H02J2310/48;;Y02T90/16;;Y02T10/70;;Y02T10/7072;;Y02T90/14;;H02J50/12;;H04B5/79;;H02J50/12;;H02J50/70;;H02J50/10;;B60L53/12;;H02J2310/48;;H04B5/79,B60L11/18,,0,0,,,,DISCONTINUED
69,US,A,US 3382419 A,113-785-445-974-642,1968-05-07,1968,US 54967166 A,1966-05-12,US 54967166 A,1966-05-12,Large area wafer semiconductor device,,INT RECTIFIER CORP,BOYER JOHN L;;HARTMAN RICHARD A,,https://lens.org/113-785-445-974-642,Granted Patent,no,5,3,4,4,0,H01L23/488;;H01L23/488;;H01L23/051;;H01L23/051;;H01L23/492;;H01L23/492;;H01L29/00;;H01L29/00;;H01L2924/0002;;H01L2924/0002,H01L23/051;;H01L23/488;;H01L23/492;;H01L29/00,317/234,0,0,,,,EXPIRED
70,WO,A1,WO 2010/069676 A1,125-461-519-974-106,2010-06-24,2010,EP 2009064916 W,2009-11-10,FR 0858728 A,2008-12-17,"TYRE FOR HEAVY VEHICLES, WITH A CROWN REINFORCEMENT COMPRISING AT LEAST ONE LAYER OF CIRCUMFERENTIAL REINFORCING ELEMENTS","The invention relates to a tyre including a crown reinforcement (4) radially covered by a tread, the crown reinforcement including at least one layer of circumferential reinforcing elements (42) axially distributed according to a variable spacing. According to the invention, the layer of circumferential reinforcing elements comprises at least five portions, i.e. a central portion (421), two intermediate portions (422) and two axially outer portions (423), the value of the spacing in the central portion being 1 to 1.5 times the value of the spacing in the axially outer portions, and the value of the spacing in an intermediate portion being 1.6 to 2 times the value of the spacing in the axially outer portions.",MICHELIN SOC TECH;;MICHELIN RECH TECH;;CHAULET CHRISTELLE;;AUDIGIER RICHARD;;BOYER CHRIS,CHAULET CHRISTELLE;;AUDIGIER RICHARD;;BOYER CHRIS,,https://lens.org/125-461-519-974-106,Patent Application,yes,5,10,13,13,0,B60C9/2006;;B60C9/22;;B60C9/28;;B60C2200/06;;Y10T152/1081;;Y10T152/10801;;Y10T152/10765;;B60C9/28;;B60C9/2006;;B60C9/22;;B60C2200/06,B60C9/20;;B60C9/22,,0,0,,,,PENDING
71,US,A,US 3511806 A,006-772-209-168-25X,1970-05-12,1970,US 3511806D A,1967-12-18,US 69112967 A,1967-12-18,ALPHA-OLEFIN POLYMERS HAVING IMPROVED ULTRAVIOLET STABILITY,,SUN OIL CO,BOYER JACKSON S;;CASSAR RICHARD D,,https://lens.org/006-772-209-168-25X,Granted Patent,no,1,0,1,1,0,C08K5/11;;C08K5/11,C08K5/11,C3K KCN           KCN;;C3K K297          KCN,0,0,,,,EXPIRED
72,US,B1,US 7137914 B1,014-406-427-058-921,2006-11-21,2006,US 45790003 A,2003-06-10,US 45790003 A,2003-06-10,Ball with receptacle to receive a key,"An inflatable ball capable of being attached to an external device includes an inflatable ball and a receptacle. The receptacle includes a cavity and an opening in communication with the cavity. The cavity and opening are configured to receive a key, which may be releasingly engaged in the receptacle and secured to a strap in order to conveniently carry the ball.",NIKE INC,BOYER CLANCY G;;AVIS RICHARD G,NIKE INC (2003-06-06);;NIKE INTERNATIONAL LTD (2003-06-09),https://lens.org/014-406-427-058-921,Granted Patent,yes,12,10,1,1,0,A63B43/007;;A63B43/007;;A63B43/02;;A63B43/02,A63B43/02,473/575;;473/596,0,0,,,,EXPIRED
73,US,A,US 2667804 A,072-416-904-903-650,1954-02-02,1954,US 10045249 A,1949-06-21,US 10045249 A,1949-06-21,High-temperature packing,,DU PONT,BOYER JOHN R;;LUCKRING RICHARD M,,https://lens.org/072-416-904-903-650,Granted Patent,no,10,11,1,2,0,F16J15/22;;F16L19/00;;F16L49/02;;F16L27/12751;;F16L49/02;;F16J15/22;;F16L19/00;;F16L27/12751,F16J15/22;;F16L19/00;;F16L27/12;;F16L49/02,,0,0,,,,EXPIRED
74,US,A1,US 2002/0162070 A1,067-346-726-324-098,2002-10-31,2002,US 84326901 A,2001-04-26,US 84326901 A,2001-04-26,Dynamic error correction code shortening,"
   A method and system are provided for dynamically shortening a number of error correction codewords to correspond to an amount of user data to be recorded on a recording medium. The system and method determine in advance that the number of bytes of user data will only fill a portion of a codeword matrix, and automatically shortens the size of ECC word segments to match the actual user data fill. This allows an ECC interleave to be completed with only a partial fill of the matrix, thereby reducing the required number of recording passes and associated processing time. 
",STORAGE TECHNOLOGY CORP,BOYER KEITH GARY;;GILL RICHARD ALLEN,SUN MICROSYSTEMS INC (2006-12-22);;ORACLE AMERICA INC (2010-02-12);;STORAGE TECHNOLOGY CORPORATION (2001-04-25),https://lens.org/067-346-726-324-098,Patent Application,yes,7,5,2,2,0,G06F11/1008;;G11B20/1833;;H03M13/2707;;H03M13/618;;H03M13/6356;;G06F11/1008;;H03M13/6356;;G11B20/1833;;H03M13/2707;;H03M13/618,G06F11/10;;G11B20/18;;G11C29/00;;H03M13/00;;H03M13/27,71477,0,0,,,,EXPIRED
75,DE,A1,DE 1815444 A1,106-713-447-385-060,1969-08-07,1969,DE 1815444 A,1968-12-18,US 69119967 A;;US 73161968 A;;US 75857468 A,1967-12-18,Elastomerenmasse mit erhoehter Stabilitaet gegen UV-Strahlung,,SUN OIL CO,SCHELL BOYER JACKSON;;DOUGLASS CASSAR RICHARD,,https://lens.org/106-713-447-385-060,Patent Application,no,0,0,6,9,0,C08K5/11;;C07C51/42;;C08K5/09;;C08K5/526,C07C51/42;;C08K5/09;;C08K5/11;;C08K5/526,,0,0,,,,DISCONTINUED
76,CN,B,CN 102256809 B,141-419-825-924-992,2015-03-18,2015,CN 200980150911 A,2009-11-10,EP 2009064916 W;;FR 0858728 A,2008-12-17,"Tyre for heavy vehicles, with a crown reinforcement comprising at least one layer of circumferential reinforcing elements",,MICHELIN SOC TECH;;MICHELIN RECH TECH,CHAULET CHRISTELLE;;AUDIGIER RICHARD;;BOYER CHRIS,COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (2012-11-13),https://lens.org/141-419-825-924-992,Granted Patent,no,0,0,13,13,0,B60C9/2006;;B60C9/22;;B60C9/28;;B60C2200/06;;Y10T152/1081;;Y10T152/10801;;Y10T152/10765;;B60C9/28;;B60C9/2006;;B60C9/22;;B60C2200/06,B60C9/20;;B60C9/22,,0,0,,,,ACTIVE
77,KR,A,KR 20160115678 A,036-438-060-403-526,2016-10-06,2016,KR 20157031194 A,2015-01-13,US 201461932399 P;;US 2015/0011097 W,2014-01-28,TAPE WRAPPED UNSHIELDED TWISTED PAIR CABLE FOR HIGH SPEED DATA TRANSMISSIONS,"테이프 랩핑된 미차폐형의 꼬인 쌍(UTP) 케이블(10)을 구성하기 위한 방법(100)이 제공된다. 그러한 방법(100)은 꼬인 쌍(16)을 형성하기 위해서 제1 와이어(12) 및 제2 와이어(14)를 함께 꼬는 단계(112)를 포함한다. 그러한 방법(100)은, 제1 와이어(12)와 제2 와이어(14) 사이의 분리 거리(20)가 꼬인 쌍(16)의 길이를 따라서 실질적으로 변화되지 않도록, 테이프(18) 상의 유효량의 장력(34)으로 꼬인 쌍(16) 주위로 테이프(18)를 랩핑하는 단계(116)를 더 포함한다.",DELPHI TECH INC,BOYER RICHARD J;;HEFFRON JOHN F,,https://lens.org/036-438-060-403-526,Patent Application,no,0,0,8,8,0,H01B13/22;;H01B13/02;;H01B11/02;;H01B13/01263;;H01B7/17;;H01B11/02;;H01B13/01263;;H01B13/02;;H01B13/22;;H01B11/02;;H01B13/02;;H01B13/22;;H01B7/17;;H01B13/01263,H01B11/02;;H01B7/17;;H01B13/012;;H01B13/02;;H01B13/22,,0,0,,,,DISCONTINUED
78,BR,A8,BR PI0613666 A8,042-276-634-058-951,2018-04-17,2018,BR PI0613666 A,2006-07-21,US 19411205 A;;US 2006/0028517 W,2005-07-29,luva para futebol,"The invention relates to an athletic glove for supporting a hand of a wearer. The soccer glove improves performance through the use a three dimensional finger cap (1101) which forms at least a portion of at least one digit of the wearer's hand. The athletic glove also comprises an open wrist feature (1305) which allows for a greater degree of support, adjustability, comfort, and ease of access and removal.",NIKE INNOVATE CV;;NIKE INT LTD,CLANCY BOYER;;RICHARD AVIS;;SAM FISHER,NIKE INNOVATE C.V. (US) (2015-05-19),https://lens.org/042-276-634-058-951,Patent Application,no,0,0,25,25,0,A41D19/01523;;A63B71/148;;A63B2243/0025;;A41D19/01523;;A63B2243/0025;;A63B71/148,A63B71/14;;A41D19/015,,0,0,,,,DISCONTINUED
79,US,A,US 3562211 A,063-468-926-242-388,1971-02-09,1971,US 3562211D A,1969-03-10,US 80587269 A,1969-03-10,PLASTIC SURFACE COVERINGS OF IMPROVED ULTRAVIOLET LIGHT STABILITY,,SUN OIL CO,CASSAR RICHARD D;;BOYER JACKSON S,,https://lens.org/063-468-926-242-388,Granted Patent,no,0,2,1,1,0,C08L27/06;;C08L27/06;;C08G63/676;;C08G63/676;;C08L67/02;;C08L67/02;;C08L67/06;;C08L67/06,C08G63/676;;C08L27/06;;C08L67/02;;C08L67/06,C3M MXC           MXCS;;C3M M110          MXCS;;C3M M112A         MXCS;;C3M M155          MXCS,0,0,,,,EXPIRED
80,CN,B,CN 102258858 B,095-757-908-392-923,2014-09-10,2014,CN 201110192363 A,2006-07-21,US 19411205 A,2005-07-29,Soccer glove,"The invention relates to an athletic glove for supporting a hand of a wearer. The soccer glove improves performance through the use a three dimensional finger cap (1101) which forms at least a portion of at least one digit of the wearer's hand. The athletic glove also comprises an open wrist feature (1305) which allows for a greater degree of support, adjustability, comfort, and ease of access and removal.",NIKE INTERNATIONAL LTD,RICHARD AVIS;;CLANCY BOYER;;SAM FISHER,NIKE INNOVATION LIMITED PARTNERSHIP (2014-09-24),https://lens.org/095-757-908-392-923,Granted Patent,no,0,0,25,25,0,A41D19/01523;;A63B71/148;;A63B2243/0025;;A41D19/01523;;A63B2243/0025;;A63B71/148,A63B71/14,,0,0,,,,ACTIVE
81,US,A,US 3632846 A,124-815-078-112-883,1972-01-04,1972,US 3632846D A,1969-03-10,US 80581969 A,1969-03-10,PETROLEUM HYDROCARBONS CONTAINING POLYESTER STABILIZERS,,SUN OIL CO,CASSAR RICHARD D;;BOYER JACKSON S,,https://lens.org/124-815-078-112-883,Granted Patent,no,0,1,1,1,0,C10M5/00;;C10M5/00;;C08G63/676;;C08G63/676;;C08L91/08;;C08L91/08;;C10L1/1985;;C10L1/1985;;C10M2205/14;;C10M2205/14;;C10M2205/16;;C10M2205/16;;C10M2205/17;;C10M2205/17;;C10M2207/282;;C10M2207/282;;C10M2207/288;;C10M2207/288;;C10M2207/34;;C10M2207/34;;C10M2209/104;;C10M2209/104;;C10N2050/10;;C10N2050/10,C08G63/676;;C08L67/00;;C08L91/08;;C10G32/04;;C10L1/18;;C10L1/198,C5F F456          -;;C5F F533          -;;C5F F537          -;;C5F F808          -,0,0,,,,EXPIRED
82,DE,D1,DE 602006009400 D1,141-003-182-222-153,2009-11-05,2009,DE 602006009400 T,2006-07-21,US 19411205 A;;US 2006/0028517 W,2005-07-29,FUSSBALLHANDSCHUH,"The invention relates to an athletic glove for supporting a hand of a wearer. The soccer glove improves performance through the use a three dimensional finger cap (1101) which forms at least a portion of at least one digit of the wearer's hand. The athletic glove also comprises an open wrist feature (1305) which allows for a greater degree of support, adjustability, comfort, and ease of access and removal.",NIKE INTERNATIONAL LTD,AVIS RICHARD;;BOYER CLANCY;;FISHER SAM,,https://lens.org/141-003-182-222-153,Granted Patent,no,0,0,25,25,0,A41D19/01523;;A63B71/148;;A63B2243/0025;;A41D19/01523;;A63B2243/0025;;A63B71/148,A63B71/14;;A41D19/015,,0,0,,,,ACTIVE
83,CA,A,CA 899535 A,142-457-539-405-511,1972-05-02,1972,CA 899535D A,,CA 899535T A,,ELASTOMERIC COMPOSITION CONTAINING POLYESTER STABILIZERS,,SUN RESEARCH DEVELOPMENT,CASSAR RICHARD D;;BOYER JACKSON S,,https://lens.org/142-457-539-405-511,Granted Patent,no,0,0,1,1,0,,C08L21/00;;C08L23/16;;C08L23/22,,0,0,,,,EXPIRED
84,US,A,US 2667684 A,149-026-136-452-559,1954-02-02,1954,US 24425151 A,1951-08-29,US 24425151 A;;US 10045249 A,1949-06-21,High-temperature packing,,DU PONT,BOYER JOHN R;;LUCKRING RICHARD M,,https://lens.org/149-026-136-452-559,Granted Patent,no,10,14,1,2,0,F16J15/22;;Y10S277/936;;F16J15/22;;Y10S277/936,F16J15/22,,0,0,,,,EXPIRED
85,CN,A,CN 104704202 A,172-741-002-663-920,2015-06-10,2015,CN 201380051904 A,2013-10-04,US 2013/0063359 W;;US 201213646023 A,2012-10-05,Turbine blades with platform cooling and corresponding gas turbine,"A turbine blade generally includes a platform having a pressure side, a suction side, a leading edge, a trailing edge, a pressure side slash face and a suction side slash face. A platform cooling circuit extends within the platform. The platform cooling circuit may extend from the suction side of the platform to the pressure side of the platform. The platform cooling circuit generally defines a fluid flow path that directs a cooling medium from the platform suction side to the platform pressure side.",GEN ELECTRIC,BOYER BRADLEY TAYLOR;;GOOD RANDALL RICHARD,,https://lens.org/172-741-002-663-920,Patent Application,no,9,0,5,5,0,F01D5/187;;F05D2240/81;;F05D2260/205;;F01D5/187;;F05D2240/81;;F05D2260/205;;F01D5/081,F01D5/18,,0,0,,,,DISCONTINUED
86,US,A,US 5298699 A,014-017-103-512-64X,1994-03-29,1994,US 2258693 A,1993-02-25,US 2258693 A,1993-02-25,Rotor for an ignition distributor,An ignition distributor rotor that is formed of electrical insulating material. The rotor has a retainer portion that is adapted to be pressed onto the end of a distributor drive shaft. This retainer portion has an axially extending wall that has an undulated shape defined by circumferentially spaced undulated portions. The inner surfaces between the undulated portions tightly engage outer surface portions of the shaft. One of the undulated portions is located in a slot in the shaft to form a driving connection between the shaft and the rotor. The retainer portion has a plurality of flexible circumferentially spaced latch arms. The ends of the latch arms are shaped to enter an annular groove on the distributor shaft to thereby lock the rotor from a axial movement relative to the distributor shaft.,GEN MOTORS CORP,BALLENTINE RICHARD E;;BOYER JAMES A,GENERAL MOTORS CORPORATION (1993-02-17),https://lens.org/014-017-103-512-64X,Granted Patent,yes,6,2,1,1,0,H01R39/60;;H01R39/60,H01R39/60,200 19DR,0,0,,,,EXPIRED
87,EP,A3,EP 3042795 A3,060-911-638-995-953,2016-11-23,2016,EP 15200965 A,2015-12-17,US 201514592408 A,2015-01-08,SYSTEM AND METHOD TO DETECT AN UNATTENDED OCCUPANT IN A VEHICLE AND TAKE SAFETY COUNTERMEASURES,"A safety system (10) and a method (100) configured to determine whether a passenger compartment (14) of a vehicle (16) is occupied whether the temperature of the passenger compartment (14) is outside an acceptable temperature range, and to take a safety countermeasure if needed. An occupant (12) is detected by sounds received by an audio transducer (24) within the passenger compartment (14) connected to an infotainment system (22). The temperature is detected by a temperature sensor (26) connected to the heating, ventilation and air condition system of the vehicle (16). Example safety countermeasures include activating the horn (40), transmitting a wireless signal indicating that an unattended occupant (12) is in the vehicle (16) to a remote wireless receiver, and/or at least partially opening a vehicle window (44). A pair of high frequency speakers (24C, 24D) connected to the infotainment system (22) may be used to transmit and receive ultrasonic signals so that an occupant (12) may be detected using ultrasonic motion detection techniques.
",DELPHI TECH INC,BOYER RICHARD J;;HEFFRON JOHN F,APTIV TECHNOLOGIES LIMITED (2018-12-19),https://lens.org/060-911-638-995-953,Search Report,yes,4,0,8,8,0,B60R16/037;;B60H1/00778;;B60H1/00978;;B60H1/00742;;H04R19/04;;G10K11/18;;B60Q5/005;;H04R2410/00;;B60H1/00778;;B60H1/00978;;B60H1/00742,B60H1/00;;B60Q5/00;;G10K11/18;;H04R19/04,,0,0,,,,ACTIVE
88,CA,A,CA 829379 A,059-441-374-097-201,1969-12-09,1969,CA 829379D A,,CA 829379T A,,ULTRAVIOLET STABILIZED ELASTOMERIC COMPOSITION,,SUN OIL CO,BOYER JACKSON S;;CASSAR RICHARD D,,https://lens.org/059-441-374-097-201,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
89,US,B2,US 9469176 B2,080-719-005-245-883,2016-10-18,2016,US 201514592408 A,2015-01-08,US 201514592408 A,2015-01-08,System and method to detect an unattended occupant in a vehicle and take safety countermeasures,"A safety system and a method configured to determine whether a passenger compartment of a vehicle is occupied whether the temperature of the passenger compartment is outside an acceptable temperature range, and to take a safety countermeasure if needed. An occupant is detected by sounds received by an audio transducer within the passenger compartment connected to an infotainment system. The temperature is detected by a temperature sensor connected to the heating, ventilation and air condition system of the vehicle. Example safety countermeasures include activating the horn, transmitting a wireless signal indicating that an unattended occupant is in the vehicle to a remote wireless receiver, and/or at least partially opening a vehicle window. A pair of high frequency speakers connected to the infotainment system may be used to transmit and receive ultrasonic signals so that an occupant may be detected using ultrasonic motion detection techniques.",DELPHI TECH INC,BOYER RICHARD J;;HEFFRON JOHN F,APTIV TECHNOLOGIES LIMITED (2018-01-01);;DELPHI TECHNOLOGIES INC (2015-01-07);;APTIV TECHNOLOGIES AG (2023-10-06),https://lens.org/080-719-005-245-883,Granted Patent,yes,18,11,8,8,0,B60R16/037;;B60H1/00778;;B60H1/00978;;B60H1/00742;;H04R19/04;;G10K11/18;;B60Q5/005;;H04R2410/00;;B60H1/00778;;B60H1/00978;;B60H1/00742,B60H1/00;;B60Q5/00;;G10K11/18;;H04R19/04,,0,0,,,,ACTIVE
90,CA,A,CA 899534 A,092-155-166-618-307,1972-05-02,1972,CA 899534D A,,CA 899534T A,,ALPHA-OLEFIN POLYMERS CONTAINING POLYESTER STABILIZERS,,SUN RESEARCH DEVELOPMENT,CASSAR RICHARD D;;BOYER JACKSON S,,https://lens.org/092-155-166-618-307,Granted Patent,no,0,0,1,1,0,,C08G63/676;;C08L23/02,,0,0,,,,EXPIRED
91,US,B2,US 6981198 B2,135-167-674-139-413,2005-12-27,2005,US 84326901 A,2001-04-26,US 84326901 A,2001-04-26,Dynamic error correction code shortening,"A method and system are provided for dynamically shortening a number of error correction codewords to correspond to an amount of user data to be recorded on a recording medium. The system and method determine in advance that the number of bytes of user data will only fill a portion of a codeword matrix, and automatically shortens the size of ECC word segments to match the actual user data fill. This allows an ECC interleave to be completed with only a partial fill of the matrix, thereby reducing the required number of recording passes and associated processing time.",STORAGE TECHNOLOGY CORP,BOYER KEITH GARY;;GILL RICHARD ALLEN,SUN MICROSYSTEMS INC (2006-12-22);;ORACLE AMERICA INC (2010-02-12);;STORAGE TECHNOLOGY CORPORATION (2001-04-25),https://lens.org/135-167-674-139-413,Granted Patent,yes,7,8,2,2,0,G06F11/1008;;G11B20/1833;;H03M13/2707;;H03M13/618;;H03M13/6356;;G06F11/1008;;H03M13/6356;;G11B20/1833;;H03M13/2707;;H03M13/618,G06F11/10;;G11B20/18;;G11C29/00;;H03M13/00;;H03M13/27,714/774;;714/779,0,0,,,,EXPIRED
92,US,B2,US 6877128 B2,142-795-830-488-756,2005-04-05,2005,US 1754801 A,2001-12-14,US 1754801 A,2001-12-14,Weighted error/erasure correction in a multi-track storage medium,"A method, computer program product, and data processing system for recovering corrupted data in a multi-track storage medium, such as magnetic tape, using a Reed-Solomon or other similar error correcting code system, is disclosed. A correction history keeping a tally of actual corrected instances of corruption in the storage medium is established. The “N” tracks requiring the greatest number of actual error corrections are designated as erasures. Any errors in the remaining tracks must be found on an individual basis before being corrected.",STORAGE TECHNOLOGY CORP,BOYER KEITH GARY;;GILL RICHARD ALLEN,SUN MICROSYSTEMS INC (2006-12-22);;ORACLE AMERICA INC (2010-02-12);;STORAGE TECHNOLOGY CORPORATION (2001-12-14),https://lens.org/142-795-830-488-756,Granted Patent,yes,3,12,2,2,0,G11B20/1833;;G11B20/1833;;G11B2020/1836;;G11B2020/1836;;G11B2220/90;;G11B2220/90,G11C29/00;;H03M13/00,714/771;;714/784,0,0,,,,EXPIRED
93,US,A1,US 2002/0159747 A1,148-610-463-059-435,2002-10-31,2002,US 6094602 A,2002-01-30,US 6094602 A;;US 26494901 P,2001-01-30,Multiplexer/demultiplexer,"
   A module comprising: (a) a housing; (b) a tray mounted in the housing, wherein the tray comprises at least: (i) a first and second submodule, each submodule having one or more compartments for containing individual add/drop filters; (ii) a first plurality of cascaded add/drop filters installed in the first submodule; and (iii) a second plurality of cascaded add/drops filters installed in the second submodule; and (c) connectors mounted to the housing and optically connected to the fibers at the ends of the first and second plurality of cascaded add/drop filters. 
",STRAUSBAUGH WILLIAM;;BOYER ERIC;;BUTERBAUGH RICHARD,STRAUSBAUGH WILLIAM;;BOYER ERIC;;BUTERBAUGH RICHARD,TE CONNECTIVITY SERVICES GMBH (2018-09-28);;TE CONNECTIVITY CORPORATION (2017-01-01);;TE CONNECTIVITY SOLUTIONS GMBH (2022-03-01),https://lens.org/148-610-463-059-435,Patent Application,yes,0,3,2,2,0,G02B6/4453;;G02B6/4453;;G02B6/29364;;G02B6/29364;;G02B6/29383;;G02B6/29383,G02B6/34;;G02B6/44,385/135;;385/24,0,0,,,,EXPIRED
94,ES,T3,ES 2551560 T3,146-138-168-722-645,2015-11-19,2015,ES 10181071 T,2006-07-21,US 19411205 A,2005-07-29,Guante de fútbol,"The invention relates to an athletic glove for supporting a hand of a wearer. The soccer glove improves performance through the use a three dimensional finger cap (1101) which forms at least a portion of at least one digit of the wearer's hand. The athletic glove also comprises an open wrist feature (1305) which allows for a greater degree of support, adjustability, comfort, and ease of access and removal.",NIKE INNOVATE CV,AVIS RICHARD;;BOYER CLANCY;;FISHER SAM,,https://lens.org/146-138-168-722-645,Granted Patent,no,0,0,25,25,0,A41D19/01523;;A63B71/148;;A63B2243/0025;;A41D19/01523;;A63B2243/0025;;A63B71/148,A41D19/015;;A63B71/14,,0,0,,,,ACTIVE
95,WO,A3,WO 2007/015994 A3,155-880-860-486-32X,2007-06-07,2007,US 2006/0028517 W,2006-07-21,US 19411205 A,2005-07-29,SOCCER GLOVE,"The invention relates to an athletic glove for supporting a hand of a wearer. The soccer glove improves performance through the use a three dimensional finger cap (1101) which forms at least a portion of at least one digit of the wearer's hand. The athletic glove also comprises an open wrist feature (1305) which allows for a greater degree of support, adjustability, comfort, and ease of access and removal.",NIKE INC;;NIKE INTERNATIONAL LTD;;AVIS RICHARD;;BOYER CLANCY;;FISHER SAM,AVIS RICHARD;;BOYER CLANCY;;FISHER SAM,,https://lens.org/155-880-860-486-32X,Search Report,yes,3,0,25,25,0,A41D19/01523;;A63B71/148;;A63B2243/0025;;A41D19/01523;;A63B2243/0025;;A63B71/148,A63B71/14;;A41D19/015,,0,0,,,,PENDING
96,CA,A,CA 847405 A,147-951-697-145-693,1970-07-21,1970,CA 847405D A,,CA 847405T A,,STABILIZED LATEX EMULSIONS,,SUN OIL CO,BOYER JACKSON S;;CASSAR RICHARD D,,https://lens.org/147-951-697-145-693,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
97,CA,A,CA 912190 A,199-648-459-582-171,1972-10-10,1972,CA 912190D A,,CA 912190T A,,ELASTOMERIC COMPOSITION CONTAINING PHOSPHITE ESTER AND POLYESTER STABILIZERS,,SUN RESEARCH DEVELOPMENT,CASSAR RICHARD D;;BOYER JACKSON S,,https://lens.org/199-648-459-582-171,Granted Patent,no,0,0,1,1,0,,C08G63/676;;C08K5/526;;C08L67/06,,0,0,,,,EXPIRED
98,US,A,US 2650878 A,019-084-925-391-72X,1953-09-01,1953,US 13220049 A,1949-12-09,US 13220049 A,1949-12-09,Method of producing etched printing plates,,DU PONT,RICHARD BOYER MAHLON;;WILLIAM GRUMBINE ARTHUR,,https://lens.org/019-084-925-391-72X,Granted Patent,no,9,8,1,1,0,G03F7/06;;G03F7/06,G03F7/06,,0,0,,,,EXPIRED
99,CA,A,CA 902289 A,033-605-791-141-810,1972-06-06,1972,CA 902289D A,,CA 902289T A,,POLYMETHYLATED MUCONIC ACIDS AND PHOSPHITE ESTERS SYNERGISTIC STABILIZER COMBINATION FOR ELASTOMER COMPOSITION,,SUN RESEARCH DEVELOPMENT,BOYER JACKSON S;;CASSAR RICHARD D,,https://lens.org/033-605-791-141-810,Granted Patent,no,0,0,1,1,0,,C07C51/42;;C08K5/09;;C08K5/11;;C08K5/526,,0,0,,,,EXPIRED
100,US,B2,US 8770246 B2,053-949-894-109-113,2014-07-08,2014,US 200913140733 A,2009-11-10,FR 0858728 A;;EP 2009064916 W,2008-12-17,"Tire for heavy vehicles, with a crown reinforcement comprising at least one layer of circumferential reinforcing elements","A tire comprising a crown reinforcement which is itself capped radially with a tread, the crown reinforcement containing at least one layer of circumferential reinforcing elements distributed axially at a variable pitch. The layer of circumferential reinforcing elements comprising five parts, these being a central part, two intermediate parts and two axially exterior parts, the pitch in the central part being in the range between 1 and 1.5 times the pitch of the axially exterior parts and the pitch in an intermediate part being in the range between 1.6 and 2 times the pitch of the axially exterior parts.",CHAULET CHRISTELLE;;AUDIGIER RICHARD;;BOYER CHRIS;;MICHELIN RECH TECH;;MICHELIN & CIE,CHAULET CHRISTELLE;;AUDIGIER RICHARD;;BOYER CHRIS,MICHELIN RECHERCHE ET TECHNIQUE S.A (2011-08-25);;SOCIETE DE TECHNOLOGIE MICHELIN (2011-08-25);;COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (2012-03-13),https://lens.org/053-949-894-109-113,Granted Patent,yes,10,0,13,13,0,B60C9/2006;;B60C9/22;;B60C9/28;;B60C2200/06;;Y10T152/1081;;Y10T152/10801;;Y10T152/10765;;B60C9/28;;B60C9/2006;;B60C9/22;;B60C2200/06,B60C9/18;;B60C9/22,152/531;;152/526;;152/535;;152/538,0,0,,,,INACTIVE
101,GB,A,GB 1157041 A,070-360-593-217-860,1969-07-02,1969,GB 1298467 A,1967-03-20,US 54636066 A,1966-04-29,Improvements in Semiconductor Device Assemblies,"1,157,041. Semi-conductor devices. INTERNATIONAL RECTIFIER CORP. 20 March, 1967 [29 April, 1966], No. 12984/67. Heading H1K. A semi-conductor device, consists of a wafer 11 containing a PN junction and sandwiched between expansion plates 12, 13, e.g. of molybdenum, of which the former is preferably smaller and the latter larger than the wafer, and is held between a housing base 10 forming one terminal and a stud 15 forming another by means of a spring constituted by one or more dished washers 24-26. The washer or washers act between the housing and an annular shoulder 16 on the stud 15. The spring tension depends on the distance between the base and top of the housing and this is adjusted in assembly by inserting shims 43, 44 before welding the body 41 of the housing to its base 10. The housing is assembled by first placing the spring washers in a cup-shaped insulator 40 and fitting this on the stud 15. The housing body 41 is then placed over the stud 15 and the shims 43, 44 are inserted between the body and the base of the housing. The number of shims is adjusted to attain the requisite spring pressure and a weld is then effected between the members 10 and 41.",INT RECTIFIER CORP,BOYER JOHN L;;HARTMAN RICHARD A,,https://lens.org/070-360-593-217-860,Granted Patent,no,0,1,2,3,0,H01L21/48;;H01L23/02;;H01L2924/0002,H01L21/48;;H01L23/02,H1K KPB           PB;;H1K KRB           RB;;H1K K1A1          PB;;H1K K2S20         PB;;H1K K4C1PY        PB;;H1K K4C1P2        PB;;H1K K4C5Y         PB;;H1K K4F7B         PB;;H1K K5A           PB;;H1K K5A3          PB;;H1K K5PY          PB;;H1K K5P1          PB;;H1K K5P4U         PB,0,0,,,,EXPIRED
102,CA,A,CA 829378 A,126-055-164-876-226,1969-12-09,1969,CA 829378D A,,CA 829378T A,,ALPHA-OLEFIN POLYMERS HAVING IMPROVED ULTRAVIOLET STABILITY,,SUN OIL CO,BOYER JACKSON S;;CASSAR RICHARD D,,https://lens.org/126-055-164-876-226,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
103,KR,A,KR 20160085706 A,194-971-111-193-229,2016-07-18,2016,KR 20160000780 A,2016-01-05,US 201514592408 A,2015-01-08,SYSTEM AND METHOD TO DETECT AN UNATTENDED OCCUPANT IN A VEHICLE AND TAKE SAFETY COUNTERMEASURES,"The present invention relates to a safety system (10) and a method, which determine whether the temperature of a cabin (14) is out of an allowable temperature and whether the cabin (14) of a vehicle (16) is occupied and, also, take safety countermeasures. An occupant (12) is detected by sound received by an audio transducer (24) in the cabin (14) connected to an infotainment system (22). The temperature is detected by a temperature sensor (25) connected to a heating ventilation and air-conditioning system. An exemplary safety countermeasures include: operating a horn (40); transmitting a wireless signal indicating that the unattended occupant is in the vehicle (16) to a remote receiver; and/or opening at least a part of a vehicle window (44). A pair of high frequency speakers (24C, 24D) connected to the infotainment system (22) may be used to transmit and receive an ultrasonic signal so that the occupant (12) is detected by an ultrasonic motion detection technique.",DELPHI TECH INC,BOYER RICHARD J;;HEFFRON JOHN F,,https://lens.org/194-971-111-193-229,Patent Application,no,0,1,8,8,0,B60R16/037;;B60H1/00778;;B60H1/00978;;B60H1/00742;;H04R19/04;;G10K11/18;;B60Q5/005;;H04R2410/00;;B60H1/00778;;B60H1/00978;;B60H1/00742,E05F15/57;;E05F15/71;;H04R17/00,,0,0,,,,PENDING
104,CA,A,CA 905999 A,196-772-548-600-684,1972-07-25,1972,CA 905999D A,,CA 905999T A,,DIHYDRAZIDES OF NAPHTHALENE DICARBOXYLIC ACIDS,,SUN RESEARCH DEVELOPMENT,BOYER JACKSON S;;CASSAR RICHARD D,,https://lens.org/196-772-548-600-684,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
105,US,B2,US 6788869 B2,002-982-097-626-411,2004-09-07,2004,US 6094602 A,2002-01-30,US 6094602 A;;US 26494901 P,2001-01-30,Method for packaging passive optoelectric assemblies in a limited space,"
    A module comprising: (a) a housing; (b) a tray mounted in the housing, wherein the tray comprises at least: (i) a first and second submodule, each submodule having one or more compartments for containing individual add/drop filters; (ii) a first plurality of cascaded add/drop filters installed in the first submodule; and (iii) a second plurality of cascaded add/drops filters installed in the second submodule; and (c) connectors mounted to the housing and optically connected to the fibers at the ends of the first and second plurality of cascaded add/drop filters. 
",STRAUSBAUGH WILLIAM;;BOYER ERIC;;BUTERBAUGH RICHARD,STRAUSBAUGH WILLIAM;;BOYER ERIC;;BUTERBAUGH RICHARD,TE CONNECTIVITY SERVICES GMBH (2018-09-28);;TE CONNECTIVITY CORPORATION (2017-01-01);;TE CONNECTIVITY SOLUTIONS GMBH (2022-03-01),https://lens.org/002-982-097-626-411,Granted Patent,yes,5,0,2,2,0,G02B6/4453;;G02B6/4453;;G02B6/29364;;G02B6/29364;;G02B6/29383;;G02B6/29383,G02B6/34;;G02B6/44,385/135,0,0,,,,EXPIRED
106,FR,A1,FR 2939722 A1,045-620-327-706-292,2010-06-18,2010,FR 0858728 A,2008-12-17,FR 0858728 A,2008-12-17,PNEUMATIQUE POUR VEHICULES LOURDS DONT L'ARMATURE DE SOMMET COMPORTE AU MOINS UNE COUCHE D'ELEMENTS DE RENFORCEMENT CIRCONFERENTIELS,"L'invention concerne un pneumatique comprenant une armature de sommet elle-même coiffée radialement d'une bande de roulement, l'armature de sommet comportant au moins une couche d'éléments de renforcement circonférentiels répartis axialement selon un pas variable. Selon l'invention, la couche d'éléments de renforcement circonférentiels est constituée d'au moins cinq parties dont une partie centrale, deux parties intermédiaires et deux parties axialement extérieures, la valeur du pas dans la partie centrale étant comprise entre 1 et 1.5 fois la valeur du pas des parties axialement extérieures et la valeur du pas dans une partie intermédiaire étant comprise entre 1.6 et 2 fois la valeur du pas des parties axialement extérieures.",MICHELIN SOC TECH;;MICHELIN RECH TECH,CHAULET CHRISTELLE;;AUDIGIER RICHARD;;BOYER CHRIS,,https://lens.org/045-620-327-706-292,Patent Application,no,5,1,13,13,0,B60C9/2006;;B60C9/22;;B60C9/28;;B60C2200/06;;Y10T152/1081;;Y10T152/10801;;Y10T152/10765;;B60C9/28;;B60C9/2006;;B60C9/22;;B60C2200/06,B60C9/22;;B60C9/18;;B60C9/20,,0,0,,,,INACTIVE
107,US,A1,US 2014/0236922 A1,065-370-767-688-995,2014-08-21,2014,US 201313768268 A,2013-02-15,US 201313768268 A,2013-02-15,"SYSTEM, METHOD, AND SOFTWARE FOR POSITIVE PATIENT IDENTIFICATION","A system including a database storing a plurality of patient data corresponding to a plurality of patients, where the patient data corresponds to a particular patient and includes at least one image of the particular patient; and a component configured to receive patient identification information previously assigned to one of the particular patients, extract the patient data corresponding to the particular patient identification information received, and display the patient data on a display including at least one image of the particular patient.",CAVIDIEN LP;;COVIDIEN LP,BOYER ROBERT T;;BATCH RICHARD M,COVIDIEN LP (2013-02-12),https://lens.org/065-370-767-688-995,Patent Application,yes,7,10,2,2,0,G16H10/60;;G16H10/60;;G16H10/65;;G16H10/65;;G16Z99/00;;G16Z99/00,G06F17/30,707/722,0,0,,,,ACTIVE
108,US,B2,US 8631620 B2,070-374-719-905-632,2014-01-21,2014,US 72697710 A,2010-03-18,US 72697710 A;;US 65418107 A;;US 76080406 P,2006-01-20,Advanced building envelope delivery system and method,"A building wall system includes first and second barrier panels, and an exterior facade system. Each panel includes an inner sheet and an outer sheet with a foam core positioned between the inner and outer sheets. Each of the inner and outer sheets defines an inner surface and an outer surface, respectively. A joint is defined by the first and second barrier panels. The exterior facade is secured to the first and second barrier panels via a fastener extending through the outer and inner sheets of the first barrier panel and the inner sheet of the second barrier panel without penetrating the inner surfaces of the first and second barrier panels.",GUINN RICHARD A;;BOYER KEITH D;;CENTRIA,GUINN RICHARD A;;BOYER KEITH D,CENTRIA (2010-02-27);;NCI GROUP INC (2017-06-26);;NUCOR INSULATED PANEL GROUP LLC (2021-07-27),https://lens.org/070-374-719-905-632,Granted Patent,yes,50,5,4,5,0,E04B1/4178;;E04B2/58;;E04C2/292;;E04C2/296;;E04B2002/565;;E04B1/4178;;E04B2/58;;E04C2/292;;E04C2/205;;E04C2/243;;E04C2/34;;E04C2/46,E04B2/00,52/478;;52/404.2;;52/404.4;;52/309.11;;52/506.05,4,0,,,"Koreteck-Home page (1 page) dated Nov. 4, 2005.;;Koreteck-Panelized Building System (22 pages) dated Nov. 4, 2005.;;BASF-Walltite Insulating Air Barrier System (3 pages) dated Nov. 18, 2005.;;BASF-Spray Applied Technologies (3 pages) dated Nov. 18, 2005.",ACTIVE
109,US,A1,US 2016/0027558 A1,083-580-998-455-230,2016-01-28,2016,US 201514775870 A,2015-01-13,US 201514775870 A;;US 201461932399 P;;US 2015/0011097 W,2014-01-28,Tape Wrapped Unshielded Twisted Pair Cable For High Speed Data Transmissions,A method to construct a tape wrapped unshielded twisted pair (UTP) cable is provided. The method includes the step of twisting a first wire and a second wire together to form a twisted pair. The method further includes the step of wrapping tape around the twisted pair with an effective amount of tension on the tape such that a separation distance between the first wire and second wire does not substantially vary along the length of the twisted pair.,DELPHI TECH INC,BOYER RICHARD J;;HEFFRON JOHN F,DELPHI TECHNOLOGIES INC (2015-09-10),https://lens.org/083-580-998-455-230,Patent Application,yes,4,7,8,8,0,H01B13/22;;H01B13/02;;H01B11/02;;H01B13/01263;;H01B7/17;;H01B11/02;;H01B13/01263;;H01B13/02;;H01B13/22;;H01B11/02;;H01B13/02;;H01B13/22;;H01B7/17;;H01B13/01263,H01B13/012;;H01B7/17;;H01B11/02,,0,0,,,,DISCONTINUED
110,CA,A,CA 902290 A,127-412-744-283-864,1972-06-06,1972,CA 902290D A,,CA 902290T A,,PLASTIC SURFACE COVERINGS OF IMPROVED ULTRAVIOLET STABILITY,,SUN RESEARCH DEVELOPMENT,BOYER JACKSON S;;CASSAR RICHARD D,,https://lens.org/127-412-744-283-864,Granted Patent,no,0,0,1,1,0,,C08G63/676;;C08L27/06;;C08L67/06,,0,0,,,,EXPIRED
111,US,A1,US 2007/0022513 A1,145-938-219-353-501,2007-02-01,2007,US 19411205 A,2005-07-29,US 19411205 A,2005-07-29,Soccer glove,"The invention relates to an athletic glove for supporting a hand of a wearer. The soccer glove improves performance through the use a three dimensional finger cap which forms at least a portion of at least one digit of the wearer's hand. The athletic glove also comprises an open wrist feature which allows for a greater degree of support, adjustability, comfort, and ease of access and removal",NIKE INC,AVIS RICHARD;;BOYER CLANCY;;FISHER SAM,NIKE INC (2005-12-05),https://lens.org/145-938-219-353-501,Patent Application,yes,16,9,25,25,0,A41D19/01523;;A63B71/148;;A63B2243/0025;;A41D19/01523;;A63B2243/0025;;A63B71/148,A41D19/02,2/169,0,0,,,,ACTIVE
112,BR,A2,BR PI0613666 A2,015-947-713-731-53X,2011-01-25,2011,BR PI0613666 A,2006-07-21,US 19411205 A;;US 2006/0028517 W,2005-07-29,luva atlética,"The invention relates to an athletic glove for supporting a hand of a wearer. The soccer glove improves performance through the use a three dimensional finger cap (1101) which forms at least a portion of at least one digit of the wearer's hand. The athletic glove also comprises an open wrist feature (1305) which allows for a greater degree of support, adjustability, comfort, and ease of access and removal.",NIKE INTERNATIONAL LTD,BOYER CLANCY;;FISHER SAM;;AVIS RICHARD,NIKE INNOVATE C.V. (US) (2015-05-19),https://lens.org/015-947-713-731-53X,Patent Application,no,0,0,25,25,0,A41D19/01523;;A63B71/148;;A63B2243/0025;;A41D19/01523;;A63B2243/0025;;A63B71/148,A63B71/14;;A41D19/015,,0,0,,,,DISCONTINUED
113,AT,T1,AT E443550 T1,047-375-022-943-197,2009-10-15,2009,AT 06788212 T,2006-07-21,US 19411205 A;;US 2006/0028517 W,2005-07-29,FUSSBALLHANDSCHUH,"The invention relates to an athletic glove for supporting a hand of a wearer. The soccer glove improves performance through the use a three dimensional finger cap (1101) which forms at least a portion of at least one digit of the wearer's hand. The athletic glove also comprises an open wrist feature (1305) which allows for a greater degree of support, adjustability, comfort, and ease of access and removal.",NIKE INTERNATIONAL LTD,AVIS RICHARD;;BOYER CLANCY;;FISHER SAM,,https://lens.org/047-375-022-943-197,Granted Patent,no,0,0,25,25,0,A41D19/01523;;A63B71/148;;A63B2243/0025;;A41D19/01523;;A63B2243/0025;;A63B71/148,,,0,0,,,,INACTIVE
114,US,B2,US 9159148 B2,063-456-809-184-213,2015-10-13,2015,US 201213663066 A,2012-10-29,US 201213663066 A;;US 201161554613 P,2011-11-02,"System, method, and software for displaying parameter values with historical ranges",A method for patient monitoring includes receiving one or more first patient parameters from at least one medical device. The method further includes transforming the one or more first patient parameters into one or more gauge display parameters. The method further includes generating data operable to display the one or more gauge display parameters individually in a particular portion of a display device. The one or more gauge display parameters include at least a historical range and a current value within the historical range. The method further includes analyzing one or more second patient parameters to adjust the one or more gauge display parameters.,COVIDIEN LP,BOYER ROBERT;;TRENOUTH JOHN;;BATCH RICHARD,COVIDIEN LP (2012-10-24),https://lens.org/063-456-809-184-213,Granted Patent,yes,10,34,3,3,0,G06T11/206;;G06T11/206;;G16H15/00;;G16H15/00;;G16H40/40;;G16H40/40;;G16H40/67;;G16H40/67,G06T11/20;;G06F19/00,,0,0,,,,ACTIVE
115,EP,A2,EP 1909929 A2,105-944-389-660-029,2008-04-16,2008,EP 06788212 A,2006-07-21,US 2006/0028517 W;;US 19411205 A,2005-07-29,SOCCER GLOVE,"The invention relates to an athletic glove for supporting a hand of a wearer. The soccer glove improves performance through the use a three dimensional finger cap (1101) which forms at least a portion of at least one digit of the wearer's hand. The athletic glove also comprises an open wrist feature (1305) which allows for a greater degree of support, adjustability, comfort, and ease of access and removal.",NIKE INTERNATIONAL LTD,AVIS RICHARD;;BOYER CLANCY;;FISHER SAM,"NIKE INNOVATE C.V., US (2015-04-20);;NIKE INNOVATE C.V. (KOMMANDITGESELLSCHAFT NIED, US (2015-04-01)",https://lens.org/105-944-389-660-029,Patent Application,yes,0,0,25,25,0,A41D19/01523;;A63B71/148;;A63B2243/0025;;A41D19/01523;;A63B2243/0025;;A63B71/148,A63B71/14;;A41D19/015,,0,0,,,,ACTIVE
116,CA,A,CA 893166 A,105-144-279-569-165,1972-02-15,1972,CA 893166D A,,CA 893166T A,,PLASTIC SURFACE COVERINGS OF IMPROVED ULTRAVIOLET STABILITY,,SUN OIL CO,CASSAR RICHARD D;;BOYER JACKSON S,,https://lens.org/105-144-279-569-165,Granted Patent,no,0,0,1,1,0,,C08G63/676;;C08L27/06;;C08L67/06,,0,0,,,,EXPIRED
117,WO,A2,WO 2007/015994 A2,127-909-782-288-598,2007-02-08,2007,US 2006/0028517 W,2006-07-21,US 19411205 A,2005-07-29,SOCCER GLOVE,"The invention relates to an athletic glove for supporting a hand of a wearer. The soccer glove improves performance through the use a three dimensional finger cap (1101) which forms at least a portion of at least one digit of the wearer's hand. The athletic glove also comprises an open wrist feature (1305) which allows for a greater degree of support, adjustability, comfort, and ease of access and removal.",NIKE INC;;NIKE INTERNATIONAL LTD;;AVIS RICHARD;;BOYER CLANCY;;FISHER SAM,AVIS RICHARD;;BOYER CLANCY;;FISHER SAM,,https://lens.org/127-909-782-288-598,Patent Application,yes,0,0,25,25,0,A41D19/01523;;A63B71/148;;A63B2243/0025;;A41D19/01523;;A63B2243/0025;;A63B71/148,A63B71/14;;A41D19/015,,0,0,,,,PENDING
118,EP,A4,EP 3100284 A4,126-568-949-429-251,2017-09-13,2017,EP 15743023 A,2015-01-13,US 201461932399 P;;US 2015/0011097 W,2014-01-28,TAPE WRAPPED UNSHIELDED TWISTED PAIR CABLE FOR HIGH SPEED DATA TRANSMISSIONS,,DELPHI TECH INC,BOYER RICHARD J;;HEFFRON JOHN F,,https://lens.org/126-568-949-429-251,Search Report,no,5,0,8,8,0,H01B13/22;;H01B13/02;;H01B11/02;;H01B13/01263;;H01B7/17;;H01B11/02;;H01B13/01263;;H01B13/02;;H01B13/22;;H01B11/02;;H01B13/02;;H01B13/22;;H01B7/17;;H01B13/01263,H01B13/012;;H01B11/02;;H01B13/02;;H01B13/22,,1,0,,,See also references of WO 2015116372A1,DISCONTINUED
119,US,A1,US 2014/0096538 A1,154-689-144-869-459,2014-04-10,2014,US 201213646023 A,2012-10-05,US 201213646023 A,2012-10-05,PLATFORM COOLING OF A TURBINE BLADE ASSEMBLY,"A turbine blade generally includes a platform having a pressure side, a suction side, a leading edge, a trailing edge, a pressure side slash face and a suction side slash face. A platform cooling circuit extends within the platform. The platform cooling circuit may extend from the suction side of the platform to the pressure side of the platform. The platform cooling circuit generally defines a fluid flow path that directs a cooling medium from the platform suction side to the platform pressure side.",GEN ELECTRIC;;GEN ELECTRIC,BOYER BRADLEY TAYLOR;;GOOD RANDALL RICHARD,GENERAL ELECTRIC COMPANY (2012-10-04),https://lens.org/154-689-144-869-459,Patent Application,yes,7,21,5,5,0,F01D5/187;;F05D2240/81;;F05D2260/205;;F01D5/187;;F05D2240/81;;F05D2260/205;;F01D5/081,F01D5/08,60/806;;X416 96  R,0,0,,,,DISCONTINUED
120,US,A1,US 2017/0199829 A1,199-553-541-344-920,2017-07-13,2017,US 201614990237 A,2016-01-07,US 201614990237 A,2016-01-07,Universal Serial Bus Cable With Active Signal Conditioning Circuitry,"A Universal Serial Bus (USB) cable assembly is configured to interconnect a USB device, such as a smartphone or digital music player, disposed within a motor vehicle with a USB hub disposed within the motor vehicle, such as in the vehicle's infotainment system. The USB cable assembly includes a first connector configured to interface with the USB hub, a second connector configured to interface with the USB device, and a plurality of wire cables interconnecting the first connector and the second connector. The USB cable assembly further includes a signal conditioning circuit in communication with the first connector, the second connector and the plurality of wire cables. The signal conditioning circuit is disposed intermediate the first connector and the second connector.",DELPHI TECH INC,BOYER RICHARD J;;HEFFRON JOHN F,APTIV TECHNOLOGIES LIMITED (2018-01-01);;DELPHI TECHNOLOGIES INC (2016-01-07),https://lens.org/199-553-541-344-920,Patent Application,yes,1,2,1,1,0,G06F13/102;;G06F13/102;;G06F13/4068;;G06F13/4068;;G06F13/4282;;G06F13/4282,G06F13/10;;G06F13/40;;G06F13/42,,0,0,,,,DISCONTINUED
121,EP,A1,EP 2379347 A1,030-256-609-513-525,2011-10-26,2011,EP 09748353 A,2009-11-10,EP 2009064916 W;;FR 0858728 A,2008-12-17,"TYRE FOR HEAVY VEHICLES, WITH A CROWN REINFORCEMENT COMPRISING AT LEAST ONE LAYER OF CIRCUMFERENTIAL REINFORCING ELEMENTS",,MICHELIN SOC TECH;;MICHELIN RECH TECH,CHAULET CHRISTELLE;;AUDIGIER RICHARD;;BOYER CHRIS,MICHELIN RECHERCHE ET TECHNIQUE S.A. (2012-08-15);;COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (2012-08-15),https://lens.org/030-256-609-513-525,Patent Application,yes,0,0,13,13,0,B60C9/2006;;B60C9/22;;B60C9/28;;B60C2200/06;;Y10T152/1081;;Y10T152/10801;;Y10T152/10765;;B60C9/28;;B60C9/2006;;B60C9/22;;B60C2200/06,B60C9/20;;B60C9/22,,0,0,,,,ACTIVE
122,US,A1,US 2008/0263748 A1,045-765-715-535-250,2008-10-30,2008,US 16850508 A,2008-07-07,US 16850508 A;;US 19411205 A,2005-07-29,Soccer Glove,"The invention relates to an athletic glove for supporting a hand of a wearer. The soccer glove improves performance through the use a three dimensional finger cap which forms at least a portion of at least one digit of the wearer's hand. The athletic glove also comprises an open wrist feature which allows for a greater degree of support, adjustability, comfort, and ease of access and removal",NIKE INC,AVIS RICHARD;;BOYER CLANCY;;FISHER SAM,NIKE INC (2005-12-05),https://lens.org/045-765-715-535-250,Patent Application,yes,23,2,25,25,0,A41D19/01523;;A63B71/148;;A63B2243/0025;;A41D19/01523;;A63B2243/0025;;A63B71/148,A63B71/14,2/161.1,0,0,,,,ACTIVE
123,US,B2,US 7565703 B2,056-322-841-088-929,2009-07-28,2009,US 19411205 A,2005-07-29,US 19411205 A,2005-07-29,Soccer glove,"The invention relates to an athletic glove for supporting a hand of a wearer. The soccer glove improves performance through the use a three dimensional finger cap which forms at least a portion of at least one digit of the wearer's hand. The athletic glove also comprises an open wrist feature which allows for a greater degree of support, adjustability, comfort, and ease of access and removal",NIKE INC,AVIS RICHARD;;BOYER CLANCY;;FISHER SAM,NIKE INC (2005-12-05),https://lens.org/056-322-841-088-929,Granted Patent,yes,24,4,25,25,0,A41D19/01523;;A63B71/148;;A63B2243/0025;;A41D19/01523;;A63B2243/0025;;A63B71/148,A41D19/00,2/161.1,14,0,,,"Exhibit 1, Uhlsport glove, top view, May 2005.;;Exhibit 2, Uhlsport glove, top/back view, May 2005.;;Exhibit 3, Nike glove, top/side view, Mar.-Apr. 2004.;;Exhibit 4, Nike glove, top/back view, Mar.-Apr. 2004.;;Exhibit 5, Nike glove, palm view, Mar.-Apr. 2004.;;Exhibit 6, Nike glove, top/back view, Mar. -Apr. 2004.;;Exhibit 7, Nike glove, top view, Mar.-Apr. 2004.;;International Preliminary Report on Patentability for PCT/US2006/028517 mailed Jan. 28, 2008, including Written Opinion and International Search Report.;;Exhibit 4 Nike glove, top/back view, Mar.-Apr. 2004.;;Exhibit 5 Nike glove palm view, Mar.-Apr. 2004.;;Exhibit 6 Nike glove top view, Mar.-Apr. 2004.;;Exhibit 7 Nike glove, top/back view, Mar.-Apr. 2004.;;Exhibit 8 Nike glove, top/back view, Mar.-Apr. 2004.;;Exhibit 9 Nike glove, top view, Mar.-Apr. 2004.",ACTIVE
124,EP,B1,EP 1909929 B1,056-342-098-832-501,2009-09-23,2009,EP 06788212 A,2006-07-21,US 2006/0028517 W;;US 19411205 A,2005-07-29,SOCCER GLOVE,"The invention relates to an athletic glove for supporting a hand of a wearer. The soccer glove improves performance through the use a three dimensional finger cap (1101) which forms at least a portion of at least one digit of the wearer's hand. The athletic glove also comprises an open wrist feature (1305) which allows for a greater degree of support, adjustability, comfort, and ease of access and removal.",NIKE INTERNATIONAL LTD,AVIS RICHARD;;BOYER CLANCY;;FISHER SAM,"NIKE INNOVATE C.V., US (2015-04-20);;NIKE INNOVATE C.V. (KOMMANDITGESELLSCHAFT NIED, US (2015-04-01)",https://lens.org/056-342-098-832-501,Granted Patent,yes,3,0,25,25,0,A41D19/01523;;A63B71/148;;A63B2243/0025;;A41D19/01523;;A63B2243/0025;;A63B71/148,A63B71/14;;A41D19/015,,0,0,,,,ACTIVE
125,WO,A1,WO 2014/055811 A1,122-810-742-433-090,2014-04-10,2014,US 2013/0063359 W,2013-10-04,US 201213646023 A,2012-10-05,TURBINE BLADES WITH PLATFORM COOLING AND CORRESPONDING GAS TURBINE,"A turbine blade generally includes a platform having a pressure side, a suction side, a leading edge, a trailing edge, a pressure side slash face and a suction side slash face. A platform cooling circuit extends within the platform. The platform cooling circuit may extend from the suction side of the platform to the pressure side of the platform. The platform cooling circuit generally defines a fluid flow path that directs a cooling medium from the platform suction side to the platform pressure side.",GEN ELECTRIC,BOYER BRADLEY TAYLOR;;GOOD RANDALL RICHARD,,https://lens.org/122-810-742-433-090,Patent Application,yes,6,0,5,5,0,F01D5/187;;F05D2240/81;;F05D2260/205;;F01D5/187;;F05D2240/81;;F05D2260/205;;F01D5/081,F01D5/18,,0,0,,,,PENDING
126,US,A1,US 2010/0170173 A1,129-610-320-481-912,2010-07-08,2010,US 72697710 A,2010-03-18,US 72697710 A;;US 65418107 A;;US 76080406 P,2006-01-20,ADVANCED BUILDING ENVELOPE DELIVERY SYSTEM AND METHOD,"A building wall system includes first and second barrier panels, and an exterior facade system. Each panel includes an inner sheet and an outer sheet with a foam core positioned between the inner and outer sheets. Each of the inner and outer sheets defines an inner surface and an outer surface, respectively. A joint is defined by the first and second barrier panels. The exterior facade is secured to the first and second barrier panels via a fastener extending through the outer and inner sheets of the first barrier panel and the inner sheet of the second barrier panel without penetrating the inner surfaces of the first and second barrier panels.",CENTRIA,BOYER KEITH D;;GUINN RICHARD A,CENTRIA (2010-02-27);;NCI GROUP INC (2017-06-26);;NUCOR INSULATED PANEL GROUP LLC (2021-07-27),https://lens.org/129-610-320-481-912,Patent Application,yes,50,15,4,5,0,E04B1/4178;;E04B2/58;;E04C2/292;;E04C2/296;;E04B2002/565;;E04B1/4178;;E04B2/58;;E04C2/292;;E04C2/205;;E04C2/243;;E04C2/34;;E04C2/46,E04B2/88;;E04C2/20;;E04C2/34,52/235;;52/788.1;;52/309.1,0,0,,,,ACTIVE
127,BR,A2,BR 112015027583 A2,168-589-275-873-562,2017-09-19,2017,BR 112015027583 A,2015-01-13,US 2015/0011097 W;;US 201461932399 P,2014-01-28,"MÉTODO PARA CONSTRUIR UM CABO DE PAR TORCIDO ENVOLVIDO EM FITA, E, CABO DE PAR TORCIDO NÃO BLINDADO ENVOLVIDO EM FITA","MÉTODO PARA CONSTRUIR UM CABO DE PAR TORCIDO ENVOLVIDO EM FITA, E, CABO DE PAR TORCIDO NÃO BLINDADO ENVOLVIDO EM FITA. Método (100) para construir um cabo de par torcido (UTP) não blindado envolvido em fita (10) é proporcionado. O método (100) inclui a etapa de torcer (112) um primeiro fio (12) e um segundo fio (14) em conjunto para formar um par torcido (16). O método (100) inclui ainda a etapa de envolver (116) a fita (18) em torno do par torcido (16) com uma quantidade eficaz de tensão (34) na fita (18) de tal modo que uma distância de separação (20) entre o primeiro fio (12) e o segundo fio (14) não varie substancialmente ao longo do comprimento do par torcido (16).",DELPHI TECH INC,JOHN F HEFFRON;;RICHARD J BOYER,,https://lens.org/168-589-275-873-562,Patent Application,no,0,0,8,8,0,H01B13/22;;H01B13/02;;H01B11/02;;H01B13/01263;;H01B7/17;;H01B11/02;;H01B13/01263;;H01B13/02;;H01B13/22;;H01B11/02;;H01B13/02;;H01B13/22;;H01B7/17;;H01B13/01263,H01B13/02;;H01B13/22,,0,0,,,,DISCONTINUED
128,EP,A1,EP 2912273 A1,188-549-500-678-325,2015-09-02,2015,EP 13780004 A,2013-10-04,US 201213646023 A;;US 2013/0063359 W,2012-10-05,TURBINE BLADES WITH PLATFORM COOLING AND CORRESPONDING GAS TURBINE,,GEN ELECTRIC,BOYER BRADLEY TAYLOR;;GOOD RANDALL RICHARD,,https://lens.org/188-549-500-678-325,Patent Application,yes,0,0,5,5,0,F01D5/187;;F05D2240/81;;F05D2260/205;;F01D5/187;;F05D2240/81;;F05D2260/205;;F01D5/081,F01D5/18,,0,0,,,,DISCONTINUED
129,EP,A2,EP 3042795 A2,016-200-817-939-272,2016-07-13,2016,EP 15200965 A,2015-12-17,US 201514592408 A,2015-01-08,SYSTEM AND METHOD TO DETECT AN UNATTENDED OCCUPANT IN A VEHICLE AND TAKE SAFETY COUNTERMEASURES,"A safety system (10) and a method (100) configured to determine whether a passenger compartment (14) of a vehicle (16) is occupied whether the temperature of the passenger compartment (14) is outside an acceptable temperature range, and to take a safety countermeasure if needed. An occupant (12) is detected by sounds received by an audio transducer (24) within the passenger compartment (14) connected to an infotainment system (22). The temperature is detected by a temperature sensor (26) connected to the heating, ventilation and air condition system of the vehicle (16). Example safety countermeasures include activating the horn (40), transmitting a wireless signal indicating that an unattended occupant (12) is in the vehicle (16) to a remote wireless receiver, and/or at least partially opening a vehicle window (44). A pair of high frequency speakers (24C, 24D) connected to the infotainment system (22) may be used to transmit and receive ultrasonic signals so that an occupant (12) may be detected using ultrasonic motion detection techniques.
",DELPHI TECH INC,BOYER RICHARD J;;HEFFRON JOHN F,APTIV TECHNOLOGIES LIMITED (2018-12-19),https://lens.org/016-200-817-939-272,Patent Application,yes,0,0,8,8,0,B60R16/037;;B60H1/00778;;B60H1/00978;;B60H1/00742;;H04R19/04;;G10K11/18;;B60Q5/005;;H04R2410/00;;B60H1/00778;;B60H1/00978;;B60H1/00742,B60H1/00;;B60Q5/00;;G10K11/18;;H04R19/04,,0,0,,,,ACTIVE
130,CN,A,CN 105774704 A,014-792-238-148-571,2016-07-20,2016,CN 201610008577 A,2016-01-07,US 201514592408 A,2015-01-08,SYSTEM AND METHOD TO DETECT AN UNATTENDED OCCUPANT IN A VEHICLE AND TAKE SAFETY COUNTERMEASURES,"The invention provides a system and a method to detect an unattended occupant in a vehicle and take safety countermeasures. A safety system (10) and a method (100) configured to determine whether a passenger compartment (14) of a vehicle (16) is occupied and whether the temperature of the passenger compartment (14) is outside an acceptable temperature range, and to take a safety countermeasure if needed. An occupant (12) is detected by sounds received by an audio transducer (24) within the passenger compartment (14) connected to an infotainment system (22). The temperature is detected by a temperature sensor (26) connected to the heating, ventilation and air condition system of the vehicle (16). Example safety countermeasures include activating the horn (40), transmitting a wireless signal indicating that an unattended occupant (12) is in the vehicle (16) to a remote wireless receiver, and/or at least partially opening a vehicle window (44). A pair of high frequency speakers (24C, 24D) connected to the infotainment system (22) may be used to transmit and receive ultrasonic signals so that an occupant may be detected using ultrasonic motion detection techniques.",DELPHI TECH INC,JOHN F HEFFRON;;RICHARD J BOYER,,https://lens.org/014-792-238-148-571,Patent Application,no,7,6,8,8,0,B60R16/037;;B60H1/00778;;B60H1/00978;;B60H1/00742;;H04R19/04;;G10K11/18;;B60Q5/005;;H04R2410/00;;B60H1/00778;;B60H1/00978;;B60H1/00742,B60R16/037,,0,0,,,,DISCONTINUED
131,EP,A1,EP 3100284 A1,072-357-337-503-791,2016-12-07,2016,EP 15743023 A,2015-01-13,US 201461932399 P;;US 2015/0011097 W,2014-01-28,TAPE WRAPPED UNSHIELDED TWISTED PAIR CABLE FOR HIGH SPEED DATA TRANSMISSIONS,,DELPHI TECH INC,BOYER RICHARD J;;HEFFRON JOHN F,,https://lens.org/072-357-337-503-791,Patent Application,yes,0,0,8,8,0,H01B13/22;;H01B13/02;;H01B11/02;;H01B13/01263;;H01B7/17;;H01B11/02;;H01B13/01263;;H01B13/02;;H01B13/22;;H01B11/02;;H01B13/02;;H01B13/22;;H01B7/17;;H01B13/01263,H01B13/02;;H01B13/22,,0,0,,,,DISCONTINUED
132,FR,B1,FR 2939722 B1,099-821-867-259-083,2010-12-31,2010,FR 0858728 A,2008-12-17,FR 0858728 A,2008-12-17,PNEUMATIQUE POUR VEHICULES LOURDS DONT L'ARMATURE DE SOMMET COMPORTE AU MOINS UNE COUCHE D'ELEMENTS DE RENFORCEMENT CIRCONFERENTIELS,,MICHELIN SOC TECH;;MICHELIN RECH TECH,CHAULET CHRISTELLE;;AUDIGIER RICHARD;;BOYER CHRIS,,https://lens.org/099-821-867-259-083,Granted Patent,no,0,0,13,13,0,B60C9/2006;;B60C9/22;;B60C9/28;;B60C2200/06;;Y10T152/1081;;Y10T152/10801;;Y10T152/10765;;B60C9/28;;B60C9/2006;;B60C9/22;;B60C2200/06,B60C9/22;;B60C9/18;;B60C9/20,,0,0,,,,INACTIVE
133,AT,T1,AT E496662 T1,096-667-332-856-656,2011-02-15,2011,AT 09167407 T,2006-07-21,US 19411205 A,2005-07-29,FUSSBALLHANDSCHUH,"The invention relates to an athletic glove for supporting a hand of a wearer. The soccer glove improves performance through the use a three dimensional finger cap (1101) which forms at least a portion of at least one digit of the wearer's hand. The athletic glove also comprises an open wrist feature (1305) which allows for a greater degree of support, adjustability, comfort, and ease of access and removal.",NIKE INTERNATIONAL LTD,AVIS RICHARD;;BOYER CLANCY;;FISHER SAM,,https://lens.org/096-667-332-856-656,Granted Patent,no,0,0,25,25,0,A41D19/01523;;A63B71/148;;A63B2243/0025;;A41D19/01523;;A63B2243/0025;;A63B71/148,,,0,0,,,,INACTIVE
134,EP,A1,EP 2113291 A1,110-926-012-454-77X,2009-11-04,2009,EP 09167407 A,2006-07-21,EP 06788212 A;;US 19411205 A,2005-07-29,Soccer glove,"The invention relates to an athletic glove for supporting a hand of a wearer. The soccer glove improves performance through the use a three dimensional finger cap (1101) which forms at least a portion of at least one digit of the wearer's hand. The athletic glove also comprises an open wrist feature (1305) which allows for a greater degree of support, adjustability, comfort, and ease of access and removal.
",NIKE INTERNATIONAL LTD,AVIS RICHARD;;BOYER CLANCY;;FISHER SAM,"NIKE INNOVATE C.V., US (2015-04-20);;NIKE INNOVATE C.V. (KOMMANDITGESELLSCHAFT NIED, US (2015-04-01)",https://lens.org/110-926-012-454-77X,Patent Application,yes,4,0,25,25,0,A41D19/01523;;A63B71/148;;A63B2243/0025;;A41D19/01523;;A63B2243/0025;;A63B71/148,A63B71/14;;A41D19/015,,0,0,,,,ACTIVE
135,US,A,US 3518196 A,143-486-587-939-330,1970-06-30,1970,US 3518196D A,1967-12-18,US 69115367 A,1967-12-18,ULTRAVIOLET STABILIZED PETROLEUM HYDROCARBONS,,SUN OIL CO,BOYER JACKSON S;;CASSAR RICHARD D,,https://lens.org/143-486-587-939-330,Granted Patent,no,3,0,7,7,0,C10M1/08;;C10M1/08;;C08K5/11;;C08K5/11;;C10L1/18;;C10L1/18;;C10L1/1883;;C10L1/1883;;C10L1/1905;;C10L1/1905;;C10M2207/123;;C10M2207/123;;C10M2207/129;;C10M2207/129;;C10M2207/22;;C10M2207/22;;C10M2207/282;;C10M2207/282;;C10M2207/34;;C10M2207/34;;C10N2030/32;;C10N2030/32,C08K5/11;;C10G32/04;;C10G71/00;;C10L1/18,252/56,0,0,,,,EXPIRED
136,US,A,US 3544502 A,158-139-062-684-230,1970-12-01,1970,US 3544502D A,1968-05-23,US 73161968 A,1968-05-23,LATEX STABILIZED WITH SALTS OF POLYMETHYLATED MUCONIC ACIDS,,SUN OIL CO,BOYER JACKSON S;;CASSAR RICHARD D,,https://lens.org/158-139-062-684-230,Granted Patent,no,2,8,1,9,0,C07C51/42;;C08K5/09;;C08K5/11;;C08K5/526;;Y10S524/926;;C08K5/11;;C07C51/42;;C08K5/09;;C08K5/526;;Y10S524/926,C07C51/42;;C08K5/09;;C08K5/11;;C08K5/526,C3V VAS           VAS,0,0,,,,EXPIRED
137,DE,A1,DE 2131197 A1,156-723-118-245-801,1972-04-20,1972,DE 2131197 A,1971-06-23,US 4917770 A;;US 4917870 A;;US 4917970 A,1970-06-23,Elastomermasse mit verbesserter Viskositaetsstabilitaet,,SUN OIL CO,SCHELL BOYER JACKSON;;DOUGLASS CASSAR RICHARD,,https://lens.org/156-723-118-245-801,Patent Application,no,0,0,5,8,0,C08K5/25;;C08L23/16;;C08L91/00;;C08L2666/02,C08K5/25;;C08L23/16,,0,0,,,,PENDING
138,CA,A,CA 903941 A,028-595-831-997-65X,1972-06-27,1972,CA 903941D A,,CA 903941T A,,STABILIZED OIL EXTENDED RUBBER COMPOSITIONS,,SUN RESEARCH DEVELOPMENT,BOYER JACKSON S;;CASSAR RICHARD D,,https://lens.org/028-595-831-997-65X,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
139,US,A,US 3562210 A,065-089-893-224-732,1971-02-09,1971,US 3562210D A,1969-03-10,US 80587169 A,1969-03-10,ELASTOMERIC COMPOSITION CONTAINING PHOSPHITE ESTER AND POLYESTER STABILIZERS,,SUN OIL CO,CASSAR RICHARD D;;BOYER JACKSON S,,https://lens.org/065-089-893-224-732,Granted Patent,no,0,3,1,1,0,C08G63/676;;C08K5/526;;C08L67/06;;Y10S524/925;;C08K5/526;;C08L67/06;;C08G63/676;;Y10S524/925,C08G63/676;;C08K5/526;;C08L67/06,C3K KCZ           KCZ;;C3K K201          KCZ;;C3K K251          KCZ;;C3K K292          KCZ;;C3K K298          KCZ,0,0,,,,EXPIRED
140,WO,A1,WO 2015/179000 A1,132-623-782-970-084,2015-11-26,2015,US 2015/0019370 W,2015-03-09,US 201414283739 A,2014-05-21,ACTIVE ELECTROMAGNETIC INTERFERENCE MITIGATION SYSTEM AND METHOD,"A system (10) and method (400) to mitigate electromagnetic interference generated by a source resonator (102) of a wireless charging system (100) is presented. The system (10) includes a receiver (12) that configured to receive a wireless charging signal (104) transmitted by the source resonator (102), a phase shifter (14) in communication with the receiver (12) and configured to generate a canceling signal (16) that is 180°out of phase with the wireless charging signal (104) currently received by the receiver (12), and a transmitter (18) in communication with the phase shifter (14) and configured to electromagnetically transmit the canceling signal (16), thereby canceling at least a portion of the wireless charging signal (104). The canceling signal (16) being at the same frequency and 180° out of phase interferes with the charging signal (104) to reduce or eliminate electromagnetic interference in the vicinity of the vehicle (2) being charged.",DELPHI TECH INC,BOYER RICHARD J;;HEFFRON JOHN F,,https://lens.org/132-623-782-970-084,Patent Application,yes,5,0,2,2,0,H02J50/70;;B60L53/12;;H02J2310/48;;Y02T90/16;;Y02T10/70;;Y02T10/7072;;Y02T90/14;;H02J50/12;;H04B5/79;;H02J50/12;;H02J50/70;;H02J50/10;;B60L53/12;;H02J2310/48;;H04B5/79,H01F27/36;;H01F27/34;;H02J17/00,,0,0,,,,PENDING
141,US,A1,US 2016/0200168 A1,140-846-240-251-294,2016-07-14,2016,US 201514592408 A,2015-01-08,US 201514592408 A,2015-01-08,SYSTEM AND METHOD TO DETECT AN UNATTENDED OCCUPANT IN A VEHICLE AND TAKE SAFETY COUNTERMEASURES,"A safety system and a method configured to determine whether a passenger compartment of a vehicle is occupied whether the temperature of the passenger compartment is outside an acceptable temperature range, and to take a safety countermeasure if needed. An occupant is detected by sounds received by an audio transducer within the passenger compartment connected to an infotainment system. The temperature is detected by a temperature sensor connected to the heating, ventilation and air condition system of the vehicle. Example safety countermeasures include activating the horn, transmitting a wireless signal indicating that an unattended occupant is in the vehicle to a remote wireless receiver, and/or at least partially opening a vehicle window. A pair of high frequency speakers connected to the infotainment system may be used to transmit and receive ultrasonic signals so that an occupant may be detected using ultrasonic motion detection techniques.",DELPHI TECH INC,BOYER RICHARD J;;HEFFRON JOHN F,APTIV TECHNOLOGIES LIMITED (2018-01-01);;DELPHI TECHNOLOGIES INC (2015-01-07);;APTIV TECHNOLOGIES AG (2023-10-06),https://lens.org/140-846-240-251-294,Patent Application,yes,0,33,8,8,0,B60R16/037;;B60H1/00778;;B60H1/00978;;B60H1/00742;;H04R19/04;;G10K11/18;;B60Q5/005;;H04R2410/00;;B60H1/00778;;B60H1/00978;;B60H1/00742,B60H1/00;;B60Q5/00;;G10K11/18;;H04R19/04,,0,0,,,,ACTIVE
142,EP,B1,EP 2289359 B1,157-141-446-967-391,2015-08-19,2015,EP 10181071 A,2006-07-21,EP 09167407 A;;EP 06788212 A;;US 19411205 A,2005-07-29,Soccer glove,"The invention relates to an athletic glove for supporting a hand of a wearer. The soccer glove improves performance through the use a three dimensional finger cap (1101) which forms at least a portion of at least one digit of the wearer's hand. The athletic glove also comprises an open wrist feature (1305) which allows for a greater degree of support, adjustability, comfort, and ease of access and removal.",NIKE INNOVATE CV,AVIS RICHARD;;BOYER CLANCY;;FISHER SAM,NIKE INNOVATE C.V. (2014-08-06),https://lens.org/157-141-446-967-391,Granted Patent,yes,1,0,25,25,0,A41D19/01523;;A63B71/148;;A63B2243/0025;;A41D19/01523;;A63B2243/0025;;A63B71/148,A41D19/015;;A63B71/14,,0,0,,,,ACTIVE
143,DE,A1,DE 1814019 A1,162-460-098-582-987,1969-06-26,1969,DE 1814019 A,1968-12-11,US 69115367 A,1967-12-18,Erdoelkohlenwasserstoffgemisch mit verbesserter UV-Stabilitaet,,SUN OIL CO,SCHELL BOYER JACKSON;;DOUGLASS CASSAR RICHARD,,https://lens.org/162-460-098-582-987,Patent Application,no,0,0,7,7,0,C10M1/08;;C10M1/08;;C08K5/11;;C08K5/11;;C10L1/18;;C10L1/18;;C10L1/1883;;C10L1/1883;;C10L1/1905;;C10L1/1905;;C10M2207/123;;C10M2207/123;;C10M2207/129;;C10M2207/129;;C10M2207/22;;C10M2207/22;;C10M2207/282;;C10M2207/282;;C10M2207/34;;C10M2207/34;;C10N2030/32;;C10N2030/32,C08K5/11;;C10G32/04;;C10G71/00;;C10L1/18,,0,0,,,,DISCONTINUED
144,US,A1,US 2011/0308686 A1,188-316-695-215-605,2011-12-22,2011,US 200913140733 A,2009-11-10,FR 0858728 A;;EP 2009064916 W,2008-12-17,"Tire for Heavy Vehicles, with a Crown Reinforcement Comprising at Least One Layer of Circumferential Reinforcing Elements","A tire comprising a crown reinforcement which is itself capped radially with a tread, the crown reinforcement containing at least one layer of circumferential reinforcing elements distributed axially at a variable pitch. The layer of circumferential reinforcing elements comprising five parts, these being a central part, two intermediate parts and two axially exterior parts, the pitch in the central part being in the range between 1 and 1.5 times the pitch of the axially exterior parts and the pitch in an intermediate part being in the range between 1.6 and 2 times the pitch of the axially exterior parts.",CHAULET CHRISTELLE;;AUDIGIER RICHARD;;BOYER CHRIS,CHAULET CHRISTELLE;;AUDIGIER RICHARD;;BOYER CHRIS,MICHELIN RECHERCHE ET TECHNIQUE S.A (2011-08-25);;SOCIETE DE TECHNOLOGIE MICHELIN (2011-08-25);;COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (2012-03-13),https://lens.org/188-316-695-215-605,Patent Application,yes,5,7,13,13,0,B60C9/2006;;B60C9/22;;B60C9/28;;B60C2200/06;;Y10T152/1081;;Y10T152/10801;;Y10T152/10765;;B60C9/28;;B60C9/2006;;B60C9/22;;B60C2200/06,B60C9/18,152/537;;152/526,0,0,,,,INACTIVE
145,EP,B1,EP 3042795 B1,000-940-461-479-537,2019-01-09,2019,EP 15200965 A,2015-12-17,US 201514592408 A,2015-01-08,SYSTEM AND METHOD TO DETECT AN UNATTENDED OCCUPANT IN A VEHICLE AND TAKE SAFETY COUNTERMEASURES,,APTIV TECH LTD,BOYER RICHARD J;;HEFFRON JOHN F,APTIV TECHNOLOGIES LIMITED (2018-12-19),https://lens.org/000-940-461-479-537,Granted Patent,yes,4,0,8,8,0,B60R16/037;;B60H1/00778;;B60H1/00978;;B60H1/00742;;H04R19/04;;G10K11/18;;B60Q5/005;;H04R2410/00;;B60H1/00778;;B60H1/00978;;B60H1/00742,B60H1/00;;B60Q5/00;;G10K11/18;;H04R19/04,,0,0,,,,ACTIVE
146,EP,B1,EP 2379347 B1,083-562-818-553-951,2013-02-06,2013,EP 09748353 A,2009-11-10,EP 2009064916 W;;FR 0858728 A,2008-12-17,"TYRE FOR HEAVY VEHICLES, WITH A CROWN REINFORCEMENT COMPRISING AT LEAST ONE LAYER OF CIRCUMFERENTIAL REINFORCING ELEMENTS",,MICHELIN & CIE;;MICHELIN RECH TECH,CHAULET CHRISTELLE;;AUDIGIER RICHARD;;BOYER CHRIS,MICHELIN RECHERCHE ET TECHNIQUE S.A. (2012-08-15);;COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (2012-08-15),https://lens.org/083-562-818-553-951,Granted Patent,yes,5,0,13,13,0,B60C9/2006;;B60C9/22;;B60C9/28;;B60C2200/06;;Y10T152/1081;;Y10T152/10801;;Y10T152/10765;;B60C9/28;;B60C9/2006;;B60C9/22;;B60C2200/06,B60C9/20;;B60C9/22,,0,0,,,,ACTIVE
147,US,A,US 3644284 A,116-072-042-625-033,1972-02-22,1972,US 3644284D A,1969-03-10,US 80587469 A,1969-03-10,ELASTOMERIC COMPOSITION CONTAINING POLYESTER STABILIZERS,,SUN OIL CO,CASSAR RICHARD D;;BOYER JACKSON S,,https://lens.org/116-072-042-625-033,Granted Patent,no,0,1,1,1,0,B60C1/00;;B60C1/00;;C08L21/00;;C08L21/00;;C08K3/06;;C08K3/06;;C08K3/22;;C08K3/22;;C08L7/00;;C08L7/00;;C08L9/06;;C08L9/06;;C08L23/16;;C08L23/16;;C08L23/22;;C08L23/22;;C08L29/04;;C08L29/04;;C08L67/00;;C08L67/00;;C08L91/00;;C08L91/00;;C08L97/00;;C08L97/00;;C08L2201/08;;C08L2201/08;;C08L2207/324;;C08L2207/324;;C08L2312/00;;C08L2312/00;;C08L2666/18;;C08L2666/18;;Y10S524/925;;Y10S524/925,C08L21/00;;C08L23/16;;C08L23/22,C3K KCN           KCN;;C3K K201          KCN;;C3K K291          KCN;;C3K K292          KCN,0,0,,,,EXPIRED
148,US,A,US 5345899 A,163-540-179-279-070,1994-09-13,1994,US 11202293 A,1993-08-26,US 11202293 A,1993-08-26,Ignition distributor drive,An ignition distributor where the rotor of the distributor is driven by the camshaft of an internal combustion engine. The end of the camshaft has an axially extending bore. The ignition distributor has a coupling. The coupling has an axially extending shaft portion that is located in the bore of the camshaft. The coupling has a laterally extending portion that has a radially extending slot. The camshaft carries a drive pin. One end of the drive pin is located in the slot with the pin engaging internal side wall surfaces of the slot. The pin forms a drive means for driving the coupling from the camshaft. The coupling drives the rotor of the distributor.,GEN MOTORS CORP,BOYER JAMES A;;BALLENTINE RICHARD E,GENERAL MOTORS CORPORATION (1993-08-16),https://lens.org/163-540-179-279-070,Granted Patent,yes,7,0,1,1,0,F02P7/10;;F02P7/10,F02P7/10,1231465 A,0,0,,,,EXPIRED
149,US,A1,US 2003/0115537 A1,158-307-132-514-107,2003-06-19,2003,US 1754801 A,2001-12-14,US 1754801 A,2001-12-14,Weighted error/erasure correction in a multi-track storage medium,"
   A method, computer program product, and data processing system for recovering corrupted data in a multi-track storage medium, such as magnetic tape, using a Reed-Solomon or other similar error correcting code system, is disclosed. A correction history keeping a tally of actual corrected instances of corruption in the storage medium is established. The N tracks requiring the greatest number of actual error corrections are designated as erasures. Any errors in the remaining tracks must be found on an individual basis before being corrected. 
",STORAGE TECHNOLOGY CORP,BOYER KEITH GARY;;GILL RICHARD ALLEN,SUN MICROSYSTEMS INC (2006-12-22);;ORACLE AMERICA INC (2010-02-12);;STORAGE TECHNOLOGY CORPORATION (2001-12-14),https://lens.org/158-307-132-514-107,Patent Application,yes,3,24,2,2,0,G11B20/1833;;G11B20/1833;;G11B2020/1836;;G11B2020/1836;;G11B2220/90;;G11B2220/90,G11C29/00;;H03M13/00,714/769,0,0,,,,EXPIRED
150,CN,A,CN 105340027 A,003-727-213-061-381,2016-02-17,2016,CN 201580000481 A,2015-01-13,US 2015/0011097 W;;US 201461932399 P,2014-01-28,Tape wrapped unshielded twisted pair cable for high speed data transmissions,A method (100) to construct a tape wrapped unshielded twisted pair (UTP) cable (10) is provided. The method (100) includes the step of twisting (112) a first wire (12) and a second wire (14) together to form a twisted pair (16). The method (100) further includes the step of wrapping (116) tape (18) around the twisted pair (16) with an effective amount of tension (34) on the tape (18) such that a separation distance (20) between the first wire (12) and second wire (14) does not substantially vary along the length of the twisted pair (16).,DELPHI TECH INC,BOYER RICHARD J;;HEFFRON JOHN F,,https://lens.org/003-727-213-061-381,Patent Application,no,4,1,8,8,0,H01B13/22;;H01B13/02;;H01B11/02;;H01B13/01263;;H01B7/17;;H01B11/02;;H01B13/01263;;H01B13/02;;H01B13/22;;H01B11/02;;H01B13/02;;H01B13/22;;H01B7/17;;H01B13/01263,H01B13/02;;H01B13/22,,0,0,,,,DISCONTINUED
151,US,A,US 3541047 A,085-664-192-559-39X,1970-11-17,1970,US 3541047D A,1968-11-20,US 77747668 A,1968-11-20,PLASTIC VINYL CHLORIDE SURFACE COVERINGS OF IMPROVED ULTRAVIOLET STABILITY,,SUN OIL CO,BOYER JACKSON S;;CASSAR RICHARD D,,https://lens.org/085-664-192-559-39X,Granted Patent,no,1,2,1,1,0,C08K5/092;;C08K5/092;;C08K5/11;;C08K5/11,C08K5/092;;C08K5/11,C3K KCN           KCN;;C3K K297          KCN,0,0,,,,EXPIRED
152,CA,A,CA 905657 A,088-493-447-761-57X,1972-07-25,1972,CA 905657D A,,CA 905657T A,,STABILIZED OIL EXTENDED RUBBER COMPOSITIONS,,SUN RESEARCH DEVELOPMENT,CASSAR RICHARD D;;BOYER JACKSON S,,https://lens.org/088-493-447-761-57X,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
153,EP,B1,EP 2113291 B1,092-598-683-509-259,2011-01-26,2011,EP 09167407 A,2006-07-21,EP 06788212 A;;US 19411205 A,2005-07-29,Soccer glove,"The invention relates to an athletic glove for supporting a hand of a wearer. The soccer glove improves performance through the use a three dimensional finger cap (1101) which forms at least a portion of at least one digit of the wearer's hand. The athletic glove also comprises an open wrist feature (1305) which allows for a greater degree of support, adjustability, comfort, and ease of access and removal.",NIKE INTERNATIONAL LTD,AVIS RICHARD;;BOYER CLANCY;;FISHER SAM,"NIKE INNOVATE C.V., US (2015-04-20);;NIKE INNOVATE C.V. (KOMMANDITGESELLSCHAFT NIED, US (2015-04-01)",https://lens.org/092-598-683-509-259,Granted Patent,yes,3,0,25,25,0,A41D19/01523;;A63B71/148;;A63B2243/0025;;A41D19/01523;;A63B2243/0025;;A63B71/148,A63B71/14;;A41D19/015,,0,0,,,,ACTIVE
154,US,A1,US 2010/0287682 A1,177-460-960-773-710,2010-11-18,2010,US 84419610 A,2010-07-27,US 84419610 A;;US 16850508 A;;US 19411205 A,2005-07-29,Soccer Glove,"The invention relates to an athletic glove for supporting a hand of a wearer. The soccer glove improves performance through the use a three dimensional finger cap which forms at least a portion of at least one digit of the wearer's hand. The athletic glove also comprises an open wrist feature which allows for a greater degree of support, adjustability, comfort, and ease of access and removal",NIKE INC,AVIS RICHARD;;BOYER CLANCY;;FISHER SAM,NIKE INC (2005-12-05),https://lens.org/177-460-960-773-710,Patent Application,yes,27,0,25,25,0,A41D19/01523;;A63B71/148;;A63B2243/0025;;A41D19/01523;;A63B2243/0025;;A63B71/148,A41D19/00,2/161.1;;2/163;;2/168;;2/162,0,0,,,,ACTIVE
155,US,A1,US 2002/0173827 A1,194-405-052-199-471,2002-11-21,2002,US 3747601 A,2001-10-29,US 3747601 A;;US 44871999 A,1999-11-24,Apparatus and method for inducing epileptic seizures in test animals for anticonvulsant drug screening,"
   A stimulator for electrically inducing a maximal seizure in a test animal for screening candidate anticonvulsant drugs is disclosed. A stimulator according to this invention includes stimulus generation and control circuitry for generating the stimulus, a display for displaying the duration of three phases of the induced seizure, and user input configured to allow the user to control delivery of the stimulus and to record seizure phase transitions to be displayed on the display. The stimulator may also include a foot switch, electrodes, a computer interface and an optional computer. A method of measuring the phases of an electrically induced seizure is disclosed. A method of analyzing the efficacy of a candidate anticonvulsant drug is also disclosed. 
",JONES GARY L.;;BOYER RICHARD M.,JONES GARY L;;BOYER RICHARD M,HAMIT-DARWIN-FREESH INC (2002-06-28),https://lens.org/194-405-052-199-471,Patent Application,yes,0,10,1,2,0,A61N1/36017;;A61N1/36017;;A61N1/025;;A61N1/025;;A61N1/36025;;A61N1/36025;;A61N1/36064;;A61N1/36064,A61N1/36,607/45,0,0,,,,DISCONTINUED
156,US,A,US 3518225 A,000-755-465-144-30X,1970-06-30,1970,US 3518225D A,1968-09-09,US 75857468 A,1968-09-09,POLYMETHYLATED MUCONIC ACIDS AND PHOSPHITE ESTERS SYNERGISTIC STABILIZER COMBINATION FOR ELASTOMER COMPOSITION,,SUN OIL CO,BOYER JACKSON S;;CASSAR RICHARD D,,https://lens.org/000-755-465-144-30X,Granted Patent,no,5,0,1,9,0,C08K5/11;;C08K5/11;;C07C51/42;;C07C51/42;;C08K5/09;;C08K5/09;;C08K5/526;;C08K5/526;;Y10S524/925;;Y10S524/925,C07C51/42;;C08K5/09;;C08K5/11;;C08K5/526,C3K KCZ           KCZ;;C3K K251          KCZ;;C3K K293          KCZ;;C3K K296          KCZ;;C3K K297          KCZ,0,0,,,,EXPIRED
157,CN,B,CN 101232924 B,047-176-964-922-793,2011-08-31,2011,CN 200680027379 A,2006-07-21,US 2006/0028517 W;;US 19411205 A,2005-07-29,Soccer glove,"The invention relates to an athletic glove for supporting a hand of a wearer. The soccer glove improves performance through the use a three dimensional finger cap (1101) which forms at least a portion of at least one digit of the wearer's hand. The athletic glove also comprises an open wrist feature (1305) which allows for a greater degree of support, adjustability, comfort, and ease of access and removal.",NIKE INC,SAM FISHER;;RICHARD AVIS;;CLANCY BOYER,NIKE INNOVATION LIMITED PARTNERSHIP (2014-10-14),https://lens.org/047-176-964-922-793,Granted Patent,no,0,0,25,25,0,A41D19/01523;;A63B71/148;;A63B2243/0025;;A41D19/01523;;A63B2243/0025;;A63B71/148,A63B71/14;;A41D19/015,,0,0,,,,ACTIVE
158,US,B2,US 8528116 B2,106-745-651-277-805,2013-09-10,2013,US 84419610 A,2010-07-27,US 84419610 A;;US 16850508 A;;US 19411205 A,2005-07-29,Soccer glove,"The invention relates to an athletic glove for supporting a hand of a wearer. The soccer glove improves performance through the use a three dimensional finger cap which forms at least a portion of at least one digit of the wearer's hand. The athletic glove also comprises an open wrist feature which allows for a greater degree of support, adjustability, comfort, and ease of access and removal.",AVIS RICHARD;;BOYER CLANCY;;FISHER SAM;;NIKE INC,AVIS RICHARD;;BOYER CLANCY;;FISHER SAM,NIKE INC (2005-12-05),https://lens.org/106-745-651-277-805,Granted Patent,yes,33,0,25,25,0,A41D19/01523;;A63B71/148;;A63B2243/0025;;A41D19/01523;;A63B2243/0025;;A63B71/148,A41D19/00,2/161.1,14,0,,,"Exhibit 1, Uhlsport glove, top view, May 2005.;;Exhibit 2, Uhlsport glove, top/back view, May 2005.;;Exhibit 3, Nike glove, top/side view, Mar.-Apr. 2004.;;Exhibit 4 Nike glove, top/back view, Mar.-Apr. 2004.;;Exhibit 5 Nike glove palm view, Mar.-Apr. 2004.;;Exhibit 6 Nike glove top view, Mar.-Apr. 2004.;;Exhibit 7 Nike glove, top/back view, Mar.-Apr. 2004.;;Exhibit 8 Nike glove, top/back view, Mar.-Apr. 2004.;;Exhibit 9 Nike glove, top view, Mar.-Apr. 2004.;;International Preliminary Report on Patentability and Written Opinion for PCT/US2006/028517 mailed Feb. 7, 2008, 11 pages.;;Written Opinion and International Search Report for PCT/US2006/028517 mailed Mar. 19, 2007, 17 pages.;;Office Action for CN Application No. 200680027379.9 mailed Oct. 16, 2009, 7 pages.;;Extended European Search Report for European Application No. 09167407.7-1260 mailed Oct. 6, 2009, 5 pages.;;Extended European Search Report for European Application No. 10181071.1 mailed Nov. 3, 2010, 8 pages.",ACTIVE
159,WO,A1,WO 1998/052240 A1,176-766-450-536-26X,1998-11-19,1998,US 9807782 W,1998-04-22,US 85448497 A,1997-05-12,SEPARATOR FOR LEAD-ACID STORAGE BATTERY,"The electrical resistivity of a porous battery separator comprising: (a) a matrix consisting essentially of substantially water-insoluble thermoplastic organic polymer, at least 75 percent by weight of which is polyolefin, (b) finely divided amorphous silica particles distributed throughout the matrix, and (c) a network of interconnecting pores communicating substantially throughout the porous battery separator, wherein the porous battery separator has a silica to matrix polymer weight ratio in the range of from 2:1 to 3:1, may be reduced by treating the separators with corona discharge.",PPG INDUSTRIES INC,PEKALA RICHARD W;;BOYER JAMES L,,https://lens.org/176-766-450-536-26X,Patent Application,yes,1,13,1,1,0,H01M10/06;;Y02E60/10;;H01M50/417;;H01M50/417,H01M10/06;;H01M50/417,,3,0,,,"PATENT ABSTRACTS OF JAPAN vol. 095, no. 009 31 October 1995 (1995-10-31);;PATENT ABSTRACTS OF JAPAN vol. 095, no. 008 29 September 1995 (1995-09-29);;PATENT ABSTRACTS OF JAPAN vol. 017, no. 261 (E - 1369) 21 May 1993 (1993-05-21)",PENDING
160,US,B1,US 6956709 B1,051-105-588-357-984,2005-10-18,2005,US 86258604 A,2004-06-07,US 86258604 A,2004-06-07,Write velocity identification in a PRML system,"A tape drive and method of identifying write velocity during reading are provided. When a track is being read, a lead-in code of the data signal is processed prior to determining the data stream. The lead-in code identifies the velocity with which the track data were written. The equalization/detection channel is adjusted based on the identified velocity to compensate for write channel transfer function variation. The lead-in code is coded in a way that is reasonably immune to write channel transfer function variation such that the lead-in code is comprehended prior to adjusting the equalization/detection channel.",STORAGE TECHNOLOGY CORP,BOYER KEITH GARY;;GILL RICHARD ALLEN,SUN MICROSYSTEMS INC (2006-12-22);;ORACLE AMERICA INC (2010-02-12);;STORAGE TECHNOLOGY CORPORATION (2004-06-01),https://lens.org/051-105-588-357-984,Granted Patent,yes,7,1,2,2,0,G11B15/52;;G11B15/52;;G11B5/00813;;G11B5/00813;;G11B15/46;;G11B15/46;;G11B20/10009;;G11B20/10009;;G11B20/10055;;G11B20/10055;;G11B27/328;;G11B27/328;;G11B27/36;;G11B27/36;;G11B2005/001;;G11B2005/001;;G11B2020/10981;;G11B2020/10981;;G11B2220/90;;G11B2220/90,G11B5/00;;G11B5/008;;G11B5/09;;G11B15/46;;G11B20/10;;G11B27/32;;G11B27/36,360/46;;360/25;;360/31;;360/46;;360/51;;360/26;;360/27;;360/73.01;;360/73.11;;360/65;;360/48;;360/73.08,0,0,,,,ACTIVE
161,DE,D1,DE 602006019927 D1,087-628-457-087-522,2011-03-10,2011,DE 602006019927 T,2006-07-21,US 19411205 A,2005-07-29,Fussballhandschuh,"The invention relates to an athletic glove for supporting a hand of a wearer. The soccer glove improves performance through the use a three dimensional finger cap (1101) which forms at least a portion of at least one digit of the wearer's hand. The athletic glove also comprises an open wrist feature (1305) which allows for a greater degree of support, adjustability, comfort, and ease of access and removal.",NIKE INTERNATIONAL LTD,AVIS RICHARD;;BOYER CLANCY;;FISHER SAM,,https://lens.org/087-628-457-087-522,Granted Patent,no,0,0,25,25,0,A41D19/01523;;A63B71/148;;A63B2243/0025;;A41D19/01523;;A63B2243/0025;;A63B71/148,A63B71/14;;A41D19/015,,0,0,,,,ACTIVE
162,US,A,US 3568736 A,093-338-839-555-813,1971-03-09,1971,US 3568736D A,1967-08-30,US 66446667 A,1967-08-30,PORTABLE INFLATOR,,WESTERN IND INC,LINCH RICHARD E;;BOYER RALPH K,,https://lens.org/093-338-839-555-813,Granted Patent,no,6,17,1,1,0,B01J7/02;;B60S5/043;;F17C5/00;;F17C2205/0382;;F17C2201/0119;;F17C2205/0323;;Y10T137/87957;;Y10T137/87957;;F17C5/00;;B60S5/043;;B01J7/02;;F17C2205/0323;;F17C2205/0382;;F17C2201/0119,B01J7/02;;B60S5/04;;F17C5/00,141/349,0,0,,,,EXPIRED
163,CN,A,CN 101232924 A,153-791-586-587-189,2008-07-30,2008,CN 200680027379 A,2006-07-21,US 2006/0028517 W;;US 19411205 A,2005-07-29,Soccer glove,"The invention relates to an athletic glove for supporting a hand of a wearer. The soccer glove improves performance through the use a three dimensional finger cap (1101) which forms at least a portion of at least one digit of the wearer's hand. The athletic glove also comprises an open wrist feature (1305) which allows for a greater degree of support, adjustability, comfort, and ease of access and removal.",NIKE INTERNATIONAL LTD,RICHARD AVIS;;CLANCY BOYER;;SAM FISHER,NIKE INNOVATION LIMITED PARTNERSHIP (2014-10-14),https://lens.org/153-791-586-587-189,Patent Application,no,0,1,25,25,0,A41D19/01523;;A63B71/148;;A63B2243/0025;;A41D19/01523;;A63B2243/0025;;A63B71/148,A63B71/14;;A41D19/015,,0,0,,,,ACTIVE
164,EA,B1,EA 018706 B1,197-969-899-745-012,2013-10-30,2013,EA 201170827 A,2009-11-10,FR 0858728 A;;EP 2009064916 W,2008-12-17,"TYRE FOR HEAVY VEHICLES, WITH A CROWN REINFORCEMENT COMPRISING AT LEAST ONE LAYER OF CIRCUMFERENTIAL REINFORCING ELEMENTS","The invention relates to a tyre including a crown reinforcement (4) radially covered by a tread, the crown reinforcement including at least one layer of circumferential reinforcing elements (42) axially distributed according to a variable spacing. According to the invention, the layer of circumferential reinforcing elements comprises at least five portions, i.e. a central portion (421), two intermediate portions (422) and two axially outer portions (423), the value of the spacing in the central portion being 1 to 1.5 times the value of the spacing in the axially outer portions, and the value of the spacing in an intermediate portion being 1.6 to 2 times the value of the spacing in the axially outer portions.",MICHELIN & CIE;;MICHELIN RECH TECH,CHAULET CHRISTELLE;;AUDIGIER RICHARD;;BOYER CHRIS,,https://lens.org/197-969-899-745-012,Granted Patent,no,5,0,13,13,0,B60C9/2006;;B60C9/22;;B60C9/28;;B60C2200/06;;Y10T152/1081;;Y10T152/10801;;Y10T152/10765;;B60C9/28;;B60C9/2006;;B60C9/22;;B60C2200/06,B60C9/20;;B60C9/22,,0,0,,,,ACTIVE
165,EP,A4,EP 2946548 A4,106-390-548-005-502,2017-01-11,2017,EP 13872145 A,2013-10-07,US 201313744618 A;;US 2013/0063657 W,2013-01-18,OBJECT DETECTION SYSTEM FOR SOURCE RESONATOR,,DELPHI TECH INC,HOFFMAN PETER F;;BOYER RICHARD J;;HENDERSON RICHARD A,,https://lens.org/106-390-548-005-502,Search Report,no,5,0,11,11,0,B60L2240/36;;B60L2250/10;;B60L2270/147;;G01V3/12;;Y02T90/12;;Y02T90/14;;G01J5/0859;;G01J3/463;;G01J3/50;;G01J5/0846;;Y02T10/7072;;G01J5/0896;;G01J5/0025;;B60L53/36;;B60L53/37;;B60L53/124;;G01J5/0022;;Y02T10/70;;H02J50/12;;H02J50/60;;G01J5/0022;;H02J50/12;;H02J50/60;;Y02T90/12;;Y02T90/14;;G01J5/0859;;G01J3/463;;G01J3/50;;G01J5/0846;;B60L2240/36;;B60L2250/10;;B60L2270/147;;G01V3/12;;Y02T10/7072;;G01J5/0896;;G01J5/0025;;B60L53/36;;B60L53/37;;B60L53/124;;Y02T10/70,H04N5/33;;B60L9/00;;G01J3/46;;G01J5/00;;G01J5/08;;G05D23/20,,1,0,,,See also references of WO 2014113093A1,DISCONTINUED
166,US,B2,US 9304042 B2,114-744-619-746-566,2016-04-05,2016,US 201313744618 A,2013-01-18,US 201313744618 A,2013-01-18,Foreign object detection system and method suitable for source resonator of wireless energy transfer system,"A system and method to detect a foreign object proximate to a source resonator that is part of a wireless energy transfer system. The wireless energy transfer system may be one used to wirelessly charge the batteries of an electric vehicle. Data from a visible light camera and a multiple zone temperature sensor are combined or fused to determine whether a foreign object, such a metallic object or an animal, is in the vicinity of, or in close proximity to, a source resonator. The system controls an electric current provided to the source resonator based on whether a foreign object is detected to reduce or inhibit energy emitted by the source resonator. The visible light camera may be a monochrome or color camera and the temperature sensor may be an infrared camera or a thermopile array.",DELPHI TECH INC,HOFFMAN PETER F;;BOYER RICHARD J;;HENDERSON RICHARD A,APTIV TECHNOLOGIES LIMITED (2018-01-01);;DELPHI TECHNOLOGIES INC (2013-01-18);;APTIV TECHNOLOGIES AG (2023-10-06),https://lens.org/114-744-619-746-566,Granted Patent,yes,16,1,11,11,0,B60L2240/36;;B60L2250/10;;B60L2270/147;;G01V3/12;;Y02T90/12;;Y02T90/14;;G01J5/0859;;G01J3/463;;G01J3/50;;G01J5/0846;;Y02T10/7072;;G01J5/0896;;G01J5/0025;;B60L53/36;;B60L53/37;;B60L53/124;;G01J5/0022;;Y02T10/70;;H02J50/12;;H02J50/60;;G01J5/0022;;H02J50/12;;H02J50/60;;Y02T90/12;;Y02T90/14;;G01J5/0859;;G01J3/463;;G01J3/50;;G01J5/0846;;B60L2240/36;;B60L2250/10;;B60L2270/147;;G01V3/12;;Y02T10/7072;;G01J5/0896;;G01J5/0025;;B60L53/36;;B60L53/37;;B60L53/124;;Y02T10/70,H02G3/00;;B60L1/00;;B60L3/00;;B60L11/18;;G01J3/46;;G01J3/50;;G01J5/00;;G01J5/08;;G01V3/12;;H02J5/00,,1,0,,,"International Search Report for PCT/US2013/063657 published Mar. 12, 2014.",ACTIVE
167,KR,A,KR 20150108829 A,106-845-397-118-89X,2015-09-30,2015,KR 20157018978 A,2013-10-07,US 201313744618 A;;US 2013/0063657 W,2013-01-18,OBJECT DETECTION SYSTEM FOR SOURCE RESONATOR,,DELPHI TECH INC,HOFFMAN PETER F;;BOYER RICHARD J;;HENDERSON RICHARD A,,https://lens.org/106-845-397-118-89X,Patent Application,no,1,1,11,11,0,B60L2240/36;;B60L2250/10;;B60L2270/147;;G01V3/12;;Y02T90/12;;Y02T90/14;;G01J5/0859;;G01J3/463;;G01J3/50;;G01J5/0846;;Y02T10/7072;;G01J5/0896;;G01J5/0025;;B60L53/36;;B60L53/37;;B60L53/124;;G01J5/0022;;Y02T10/70;;H02J50/12;;H02J50/60;;G01J5/0022;;H02J50/12;;H02J50/60;;Y02T90/12;;Y02T90/14;;G01J5/0859;;G01J3/463;;G01J3/50;;G01J5/0846;;B60L2240/36;;B60L2250/10;;B60L2270/147;;G01V3/12;;Y02T10/7072;;G01J5/0896;;G01J5/0025;;B60L53/36;;B60L53/37;;B60L53/124;;Y02T10/70,B60L11/18;;G01J3/46;;G01J3/50;;G01J5/00;;H02J5/00;;H02J17/00,,0,0,,,,ACTIVE
168,EP,A1,EP 2946548 A1,049-510-306-580-211,2015-11-25,2015,EP 13872145 A,2013-10-07,US 201313744618 A;;US 2013/0063657 W,2013-01-18,OBJECT DETECTION SYSTEM FOR SOURCE RESONATOR,,DELPHI TECH INC,HOFFMAN PETER F;;BOYER RICHARD J;;HENDERSON RICHARD A,,https://lens.org/049-510-306-580-211,Patent Application,yes,0,0,11,11,0,B60L2240/36;;B60L2250/10;;B60L2270/147;;G01V3/12;;Y02T90/12;;Y02T90/14;;G01J5/0859;;G01J3/463;;G01J3/50;;G01J5/0846;;Y02T10/7072;;G01J5/0896;;G01J5/0025;;B60L53/36;;B60L53/37;;B60L53/124;;G01J5/0022;;Y02T10/70;;H02J50/12;;H02J50/60;;G01J5/0022;;H02J50/12;;H02J50/60;;Y02T90/12;;Y02T90/14;;G01J5/0859;;G01J3/463;;G01J3/50;;G01J5/0846;;B60L2240/36;;B60L2250/10;;B60L2270/147;;G01V3/12;;Y02T10/7072;;G01J5/0896;;G01J5/0025;;B60L53/36;;B60L53/37;;B60L53/124;;Y02T10/70,H04N5/33;;B60L9/00;;G01J3/46;;G01J5/00;;G01J5/08;;G05D23/20,,0,0,,,,DISCONTINUED
169,US,A1,US 2014/0203629 A1,031-988-383-441-134,2014-07-24,2014,US 201313744618 A,2013-01-18,US 201313744618 A,2013-01-18,FOREIGN OBJECT DETECTION SYSTEM AND METHOD SUITABLE FOR SOURCE RESONATOR OF WIRELESS ENERGY TRANSFER SYSTEM,"A system and method to detect a foreign object proximate to a source resonator that is part of a wireless energy transfer system. The wireless energy transfer system may be one used to wirelessly charge the batteries of an electric vehicle. Data from a visible light camera and a multiple zone temperature sensor are combined or fused to determine whether a foreign object, such a metallic object or an animal, is in the vicinity of, or in close proximity to, a source resonator. The system controls an electric current provided to the source resonator based on whether a foreign object is detected to reduce or inhibit energy emitted by the source resonator. The visible light camera may be a monochrome or color camera and the temperature sensor may be an infrared camera or a thermopile array.",DELPHI TECH INC,HOFFMAN PETER F;;BOYER RICHARD J;;HENDERSON RICHARD A,APTIV TECHNOLOGIES LIMITED (2018-01-01);;DELPHI TECHNOLOGIES INC (2013-01-18);;APTIV TECHNOLOGIES AG (2023-10-06),https://lens.org/031-988-383-441-134,Patent Application,yes,11,92,11,11,0,B60L2240/36;;B60L2250/10;;B60L2270/147;;G01V3/12;;Y02T90/12;;Y02T90/14;;G01J5/0859;;G01J3/463;;G01J3/50;;G01J5/0846;;Y02T10/7072;;G01J5/0896;;G01J5/0025;;B60L53/36;;B60L53/37;;B60L53/124;;G01J5/0022;;Y02T10/70;;H02J50/12;;H02J50/60;;G01J5/0022;;H02J50/12;;H02J50/60;;Y02T90/12;;Y02T90/14;;G01J5/0859;;G01J3/463;;G01J3/50;;G01J5/0846;;B60L2240/36;;B60L2250/10;;B60L2270/147;;G01V3/12;;Y02T10/7072;;G01J5/0896;;G01J5/0025;;B60L53/36;;B60L53/37;;B60L53/124;;Y02T10/70,G01J5/00;;B60L11/00;;H02J17/00,307/9.1;;307/104,0,0,,,,ACTIVE
170,CN,A,CN 104919793 A,026-760-170-105-178,2015-09-16,2015,CN 201380070772 A,2013-10-07,US 2013/0063657 W;;US 201313744618 A,2013-01-18,Object detection system for source resonator,"A system and a method to detect a foreign object proximate to a source resonator that is part of a wireless energy transfer system are provided. The wireless energy transfer system may be one used to wirelessly charge the batteries of an electric vehicle. Data from a visible light camera and a multiple zone temperature sensor are combined or fused to determine whether a foreign object, such a metallic object or an animal, is in the vicinity of, or in close proximity to, a source resonator. The system controls an electric current provided to the source resonator based on whether a foreign object is detected to reduce or inhibit energy emitted by the source resonator. The visible light camera may be a monochrome or color camera and the temperature sensor may be an infrared camera or a thermopile array.",DELPHI TECH INC,HOFFMAN PETER F;;BOYER RICHARD J;;HENDERSON RICHARD A,,https://lens.org/026-760-170-105-178,Patent Application,no,3,4,11,11,0,B60L2240/36;;B60L2250/10;;B60L2270/147;;G01V3/12;;Y02T90/12;;Y02T90/14;;G01J5/0859;;G01J3/463;;G01J3/50;;G01J5/0846;;Y02T10/7072;;G01J5/0896;;G01J5/0025;;B60L53/36;;B60L53/37;;B60L53/124;;G01J5/0022;;Y02T10/70;;H02J50/12;;H02J50/60;;G01J5/0022;;H02J50/12;;H02J50/60;;Y02T90/12;;Y02T90/14;;G01J5/0859;;G01J3/463;;G01J3/50;;G01J5/0846;;B60L2240/36;;B60L2250/10;;B60L2270/147;;G01V3/12;;Y02T10/7072;;G01J5/0896;;G01J5/0025;;B60L53/36;;B60L53/37;;B60L53/124;;Y02T10/70,H04N5/33;;B60L9/00;;G05D23/20,,0,0,,,,ACTIVE
171,WO,A1,WO 2014/113093 A1,024-790-311-628-971,2014-07-24,2014,US 2013/0063657 W,2013-10-07,US 201313744618 A,2013-01-18,OBJECT DETECTION SYSTEM FOR SOURCE RESONATOR,"A system and method to detect a foreign object proximate to a source resonator that is part of a wireless energy transfer system. The wireless energy transfer system may be one used to wirelessly charge the batteries of an electric vehicle. Data from a visible light camera and a multiple zone temperature sensor are combined or fused to determine whether a foreign object, such a metallic object or an animal, is in the vicinity of, or in close proximity to, a source resonator. The system controls an electric current provided to the source resonator based on whether a foreign object is detected to reduce or inhibit energy emitted by the source resonator. The visible light camera may be a monochrome or color camera and the temperature sensor may be an infrared camera or a thermopile array.",DELPHI TECH INC,HOFFMAN PETER F;;BOYER RICHARD J;;HENDERSON RICHARD A,,https://lens.org/024-790-311-628-971,Patent Application,yes,3,26,11,11,0,B60L2240/36;;B60L2250/10;;B60L2270/147;;G01V3/12;;Y02T90/12;;Y02T90/14;;G01J5/0859;;G01J3/463;;G01J3/50;;G01J5/0846;;Y02T10/7072;;G01J5/0896;;G01J5/0025;;B60L53/36;;B60L53/37;;B60L53/124;;G01J5/0022;;Y02T10/70;;H02J50/12;;H02J50/60;;G01J5/0022;;H02J50/12;;H02J50/60;;Y02T90/12;;Y02T90/14;;G01J5/0859;;G01J3/463;;G01J3/50;;G01J5/0846;;B60L2240/36;;B60L2250/10;;B60L2270/147;;G01V3/12;;Y02T10/7072;;G01J5/0896;;G01J5/0025;;B60L53/36;;B60L53/37;;B60L53/124;;Y02T10/70,B60L9/00;;H04N5/33;;G05D23/20,,1,0,,,See also references of EP 2946548A4,PENDING
172,US,S,US D0332435 S,163-522-245-795-489,1993-01-12,1993,US 69727891 F,1991-05-08,CA 68579 F,1990-11-21,Bicycle rack,,PLASTIQUES ANCHOR LTEE,DELAGE ALAIN;;LAMOUREUX RICHARD;;BOYER JEAN-PIERRE,PLASTIQUES ANCHOR LTEE (1991-04-30),https://lens.org/163-522-245-795-489,Design Right,yes,4,2,1,1,0,,,D12/115,0,0,,,,EXPIRED
173,US,B1,US 6635290 B1,077-198-338-363-192,2003-10-21,2003,US 27086799 A,1999-03-17,US 27086799 A,1999-03-17,Shelf stable kit for making chili,"
    A process for preserving foodstuff by acidifying it with a phosphoric acid water solution. The foodstuff is immersed in the phosphoric acid solution with appropriate time pressure and temperature conditions to result in a state of equilibrium in which a pH of 4.6 or less is achieved. Any unwanted tart aftertaste is masked with a sweetening agent added to the acid solution. The process is used to produce a chili mix including rehydrated beans, vegetables, and spices, all of which are packaged in a shelf stable pouch particularly suited for the restaurant trade. 
",FURMAN FOODS INC,BOYER JR RICHARD B;;BAKKER JAMES L,FURMAN FOODS INC (1999-05-05),https://lens.org/077-198-338-363-192,Granted Patent,yes,28,8,1,1,0,A23B7/10;;A23B9/26;;A23B9/30;;A23V2002/00;;A23L11/01;;A23B9/26;;A23B7/10;;A23B9/30;;A23V2002/00;;A23L11/01,A23B7/10;;A23B9/26;;A23B9/30;;A23L11/00,426/106;;426/324;;426/326;;426/634,0,0,,,,EXPIRED
174,US,A,US 3548614 A,118-475-572-742-842,1970-12-22,1970,US 3548614D A,1969-04-07,US 81402769 A,1969-04-07,METHOD OF CLOSING THE TOE OF A TUBULAR STOCKING,,NORTH AMERICAN ROCKWELL,BOYER JAMES H JR;;JANDA RICHARD M,,https://lens.org/118-475-572-742-842,Granted Patent,no,7,8,4,4,0,D04B1/108;;D04B1/26;;D04B1/108;;D04B1/26,D04B1/26,66/95,0,0,,,,EXPIRED
175,DE,A1,DE 1520577 A1,125-536-644-500-202,1970-01-22,1970,DE 1520577 A,1963-12-04,US 24211162 A,1962-12-04,Verfahren zur Herstellung geformter Polylactam-Gegenstaende und Formen dafuer,,POLYMER CORP,WILLIAM DAMES JUN CARL;;WILLIAM BOYER RICHARD,,https://lens.org/125-536-644-500-202,Patent Application,no,0,0,3,3,0,B29C33/0011;;B29C33/0011;;B29C33/405;;B29C33/405;;B29C39/006;;B29C39/006;;B29C39/38;;B29C39/38;;B29C39/40;;B29C39/40;;B29K2077/00;;B29K2077/00;;B29K2883/00;;B29K2883/00;;C08G69/18;;C08G69/18;;Y10S264/56;;Y10S264/56,B29C33/00;;B29C33/40;;B29C39/00;;B29C39/38;;B29C39/40;;C08G69/18,,0,0,,,,DISCONTINUED
176,US,A,US 4071896 A,123-471-144-481-765,1978-01-31,1978,US 75189576 A,1976-12-17,US 75189576 A,1976-12-17,Numerical control system for finishing machines,A method and apparatus for automatically positioning the various appurtenances of a Printer-Slotter-Folder-Gluer to form box blanks of various dimensional characteristics. The position of each appurtenance of the system is preselected by a binary numbering input representing each absolute position. The binary input is selected by thumbwheel switches employing binary coded decimal input. The input data is stored and can be retrieved and utilized to position the appurtenances for a blank of specific dimensional characteristics in response to a production order code.,KOPPERS CO INC,BOYER III DAVID HARRISON;;MITCHELL RICHARD DALE,UNITED CONTAINER MACHINERY GROUP INC (1988-09-29),https://lens.org/123-471-144-481-765,Granted Patent,yes,5,13,4,4,0,G05B19/188;;G05B2219/41249;;B31B50/006;;G05B19/188;;G05B2219/41249;;B31B50/006,B31B50/25;;B31B50/22;;G05B19/18,364/471,0,0,,,,EXPIRED
177,US,B1,US 7006317 B1,144-486-761-352-372,2006-02-28,2006,US 72964603 A,2003-12-05,US 72964603 A,2003-12-05,Dynamically allocated parallel equalization and detection of a PRML read channel in a multi-channel drive,"A tape drive for use with magnetic tapes includes a housing for receiving a magnetic tape having multiple parallel tracks, and a tape head for reading and writing the parallel tracks of the magnetic tape. A plurality of partial response maximum likelihood (PRML) equalization/detection channels are provided for processing the data signals to determine the data stream for each data signal. The plurality of PRML equalization/detection channels includes at least one PRML equalization/detection channel pre-assigned to each track. The plurality of PRML equalization/detection channels further includes at least one floating PRML equalization/detection channel dynamically assignable on an as-needed basis. The invention also contemplates an ASIC, a generic drive, and a PRML method.",STORAGE TECHNOLOGY CORP,HENNECKEN MARK;;GILL RICHARD A;;BOYER KEITH,SUN MICROSYSTEMS INC (2006-12-22);;ORACLE AMERICA INC (2010-02-12);;STORAGE TECHNOLOGY CORPORATION (2004-05-11),https://lens.org/144-486-761-352-372,Granted Patent,yes,2,8,1,1,0,G11B20/10009;;G11B20/10009;;G11B20/10055;;G11B20/10055;;G11B2220/90;;G11B2220/90,G11B5/035,360/65,0,0,,,,ACTIVE
178,US,A,US 2600729 A,023-554-177-346-429,1952-06-17,1952,US 13444849 A,1949-12-22,US 13444849 A,1949-12-22,Endless chain of counting relays,,KELLOGG SWITCHBOARD & SUPPLY,BOYER JR RICHARD P;;BELLAMY JOHN I,,https://lens.org/023-554-177-346-429,Granted Patent,no,4,10,1,1,0,H03K23/74;;H03K23/74,H03K23/74,,0,0,,,,EXPIRED
179,MX,A,MX 143452 A,076-050-528-666-285,1981-05-12,1981,MX 17183577 A,1977-12-16,US 75189576 A,1976-12-17,METODO Y APARATO PARA LA PRODUCCION DE RECIPIENTES DE CARTON,,KOPPERS CO INC,BOYER DAVID H III;;MITCHELL RICHARD D,,https://lens.org/076-050-528-666-285,Granted Patent,no,0,0,4,4,0,G05B19/188;;G05B2219/41249;;B31B50/006;;G05B19/188;;G05B2219/41249;;B31B50/006,B31B50/25;;B31B50/22;;G05B19/18,48-3,0,0,,,,EXPIRED
180,CA,A,CA 1116271 A,145-290-753-743-914,1982-01-12,1982,CA 292950 A,1977-12-13,US 75189576 A,1976-12-17,NUMERICAL CONTROL SYSTEM FOR FINISHING MACHINES,A method and apparatus for automatically positioning the various appurtenances of a Printer-Slotter-Folder-Gluer to form box blanks of various dimensional characteristics. The position of each appurtenance of the system is preselected by a binary numbering input representing each absolute position. The binary input is selected by thumbwheel switches employing binary coded decimal input. The input data is stored and can be retrieved and utilized to position the appurtenances for a blank of specific dimensional characteristics in response to a production order code.,KOPPERS CO INC,BOYER DAVID H III;;MITCHELL RICHARD D,,https://lens.org/145-290-753-743-914,Granted Patent,no,0,0,4,4,0,G05B19/188;;G05B2219/41249;;B31B50/006;;G05B19/188;;G05B2219/41249;;B31B50/006,B31B50/22;;B31B50/25;;G05B19/18,341-99,0,0,,,,EXPIRED
181,US,A,US 2590926 A,019-628-860-738-261,1952-04-01,1952,US 14292450 A,1950-02-07,US 14292450 A,1950-02-07,Multirelay electric timer,,KELLOGG SWITCHBOARD & SUPPLY,BOYER JR RICHARD P;;BELLAMY JOHN L,,https://lens.org/019-628-860-738-261,Granted Patent,no,2,4,1,1,0,H04M3/12;;H04M3/12,H04M3/12,,0,0,,,,EXPIRED
182,US,A,US 3222443 A,152-279-866-264-131,1965-12-07,1965,US 24211162 A,1962-12-04,US 24211162 A,1962-12-04,Method of molding lactams in a polysiloxane mold,,POLYMER CORP,DAMES JR CARL W;;BOYER RICHARD W,,https://lens.org/152-279-866-264-131,Granted Patent,no,3,14,3,3,0,B29C33/0011;;B29C33/0011;;B29C33/405;;B29C33/405;;B29C39/006;;B29C39/006;;B29C39/38;;B29C39/38;;B29C39/40;;B29C39/40;;B29K2077/00;;B29K2077/00;;B29K2883/00;;B29K2883/00;;C08G69/18;;C08G69/18;;Y10S264/56;;Y10S264/56,B29C33/00;;B29C33/40;;B29C39/00;;B29C39/38;;B29C39/40;;C08G69/18,,0,0,,,,EXPIRED
183,US,B1,US 10729860 B1,043-983-095-615-454,2020-08-04,2020,US 201916420002 A,2019-05-22,US 201916420002 A,2019-05-22,Computerized oral prescription administration for securely dispensing a medication and associated systems and methods,"In one embodiment, a member for securely dispensing a substance to an intended user includes a first member configured to threadedly engage with a housing containing the substance; a second member coupled to the first member, the second member configured to fixedly secure the first member to the housing; a third member including a cavity sized and shaped to selectively receive the second member; and a valve coupled to the first member such that: when the second member is received within the cavity, the valve is in an open state that allows the substance to be dispensed from the housing to the intended user in response to a processor determining that a unique biometric attribute of the intended user is detected, and when the second member is not received within the cavity, the valve is in a closed state that prevents the substance from being dispensed from the housing.",BERKSHIRE BIOMEDICAL LLC,BOYER ROBERT;;COREY CHRISTY;;CRONENBERG RICHARD;;KIRKPATRICK JOHN,BERKSHIRE BIOMEDICAL CORPORATION (2019-05-07),https://lens.org/043-983-095-615-454,Granted Patent,yes,320,2,9,9,0,A61J7/0053;;A61J2200/70;;A61M15/0066;;A61M15/0021;;A61M15/0025;;A61M2205/609;;A61M2205/6009;;A61M2205/3317;;A61M2205/13;;A61M2205/276;;A61M2205/3303;;A61M2205/50;;G07C9/257,A61M15/00;;G07C9/25,,4,0,,,"International Search Report issued in PCT/US2019/022287 dated Jul. 16, 2019.;;Written Opinion issued in PCT/US2019/022287 dated Jul. 16, 2019.;;International Search Report issued in PCT/US2018/013440 dated Mar. 9, 2018.;;Written Opinion issued in PCT/US2018/013440 dated Mar. 9, 2018.",ACTIVE
184,US,S,US D0351823 S,011-284-019-241-792,1994-10-25,1994,US 829093 F,1993-05-13,US 829093 F,1993-05-13,Enclosure canopy for a utility truck,,STAHL/SCOTT FETZER COMPANY,LEWELLEN RICHARD;;LAPSLEY ROBERT M;;BOYER THOMAS J,STAHL/SCOTT FETZER COMPANY (1993-03-30),https://lens.org/011-284-019-241-792,Design Right,yes,3,4,1,1,0,,,D12/405,0,0,,,,EXPIRED
185,WO,A3,WO 2021/195483 A3,048-410-398-579-861,2021-11-04,2021,US 2021/0024337 W,2021-03-26,US 202063001122 P,2020-03-27,"IMPROVED SYSTEMS, COMPONENTS, AND COMBINATIONS THEREOF FOR PEN-TYPE INJECTION DEVICES","The disclosure provides driver components, systems and drive methods that facilitate improved dose setting, correcting, and/or dispensing in a multiple use pen-type injection device. In particular, various novel braking systems are disclosed that can be implemented within pen-type injection devices to achieve such improvements.",BECTON DICKINSON CO,QUINN MICHAEL;;CRONENBERG RICHARD;;BOYER ROBERT;;GORSHKOV ALEXANDER,,https://lens.org/048-410-398-579-861,Search Report,yes,5,0,10,10,0,A61M5/31541;;A61M5/2422;;A61M5/31585;;A61M5/31551;;A61M5/2033;;A61M5/31551;;A61M5/31563,A61M5/20;;A61M5/00;;A61M5/315,,0,0,,,,PENDING
186,WO,A1,WO 2018/140239 A1,165-373-587-805-76X,2018-08-02,2018,US 2018/0013247 W,2018-01-11,US 201715413589 A,2017-01-24,SIGNAL TRANSMISSION CABLE ASSEMBLY WITH UNGROUNDED SHEATH CONTAINING ELECTRICALLY CONDUCTIVE PARTICLES,"A data transmission cable assembly (110) includes an elongate first conductor, an elongate second conductor, and a sheath (118) at least partially axially surrounding the first and second conductors (112A, 112B). The sheath (118) contains a plurality of electrically conductive particles (122) interspersed within a matrix formed of an electrically insulative polymeric material (120). The conductive particles (122) may be formed of a metallic material or and inherently conductive polymer material. The plurality conductive particles (122) may be filaments that form a plurality of electrically interconnected networks. Each network is electrically isolated from every other network. Each network contains less than 125 filaments and/or has a length less than 13 millimeters. The bulk conductivity of the sheath (118) is substantially equal to the conductivity of the electrically insulative polymeric material (120). The data transmission cable assembly (110) does not include a terminal that is configured to connect the sheath (118) to an electrical ground.",DELPHI TECH INC,BOYER RICHARD;;HEFFRON JOHN;;RUBINO EVANGELIA;;RICHMAND ZACHARY,,https://lens.org/165-373-587-805-76X,Patent Application,yes,5,0,2,2,0,H01B11/1058;;H01B1/22;;H01B1/24;;H01B7/187;;H01B13/24;;H01B11/10;;H01B7/18;;H01B1/22;;H01B1/24;;H01B7/187;;H01B13/24;;H01B13/26;;H01B11/002;;H01B11/1058,H01B9/00;;H01B9/02;;H01B11/02;;H01B11/18,,0,0,,,,PENDING
187,US,A1,US 2021/0299359 A1,169-755-395-409-85X,2021-09-30,2021,US 202117213777 A,2021-03-26,US 202117213777 A;;US 202063001122 P,2020-03-27,"SYSTEMS, COMPONENTS, AND COMBINATIONS THEREOF FOR PEN-TYPE INJECTION DEVICES","The disclosure provides driver components, systems and drive methods that facilitate improved dose setting, correcting, and/or dispensing in a multiple use pen-type injection device. In particular, various novel braking systems are disclosed that can be implemented within pen-type injection devices to achieve such improvements.",BECTON DICKINSON CO,QUINN MICHAEL;;CRONENBERG RICHARD;;BOYER ROBERT;;GORSHKOV ALEXANDER,BECTON DICKINSON AND COMPANY (2022-11-10),https://lens.org/169-755-395-409-85X,Patent Application,yes,1,1,10,10,0,A61M5/31541;;A61M5/2422;;A61M5/31585;;A61M5/31551;;A61M5/2033;;A61M5/31551;;A61M5/31563,A61M5/315;;A61M5/20,,0,0,,,,PENDING
188,MX,A,MX 2022012016 A,111-654-399-213-734,2022-12-15,2022,MX 2022012016 A,2021-03-26,US 202063001122 P;;US 2021/0024337 W,2020-03-27,"IMPROVED SYSTEMS, COMPONENTS, AND COMBINATIONS THEREOF FOR PEN-TYPE INJECTION DEVICES.","The disclosure provides driver components, systems and drive methods that facilitate improved dose setting, correcting, and/or dispensing in a multiple use pen-type injection device. In particular, various novel braking systems are disclosed that can be implemented within pen-type injection devices to achieve such improvements.",BECTON DICKINSON CO,QUINN MICHAEL;;CRONENBERG RICHARD;;BOYER ROBERT;;GORSHKOV ALEXANDER,,https://lens.org/111-654-399-213-734,Patent Application,no,0,0,10,10,0,A61M5/31541;;A61M5/2422;;A61M5/31585;;A61M5/31551;;A61M5/2033;;A61M5/31551;;A61M5/31563,A61M5/20;;A61M5/00;;A61M5/315,,0,0,,,,PENDING
189,DE,T2,DE 69929790 T2,163-040-341-498-853,2006-11-02,2006,DE 69929790 T,1999-06-10,US 11058298 A;;US 9913207 W,1998-07-06,NICHT-MAKROPORÖSE INORGANISCHE VORRICHTUNG ZUR BIOLOGISCHEN ENTSORGUNG,"A porous inorganic oxide carrier body for immobilizing living cells is prepared from inorganic oxide particles such as clay particles. The particles have an average particle size of from 0.01 to 20 microns, and the carrier body has a total pore volume of 0.05 to 1.0 cc/g and an average pore diameter of 50 to 700 ANGSTROM , and has substantially no pore volume in the range of 800 ANGSTROM or greater. The carrier is prepared by forming a mixture containing the particles, a liquid medium and optional ingredients including zeolite and activated carbon, and forming the mixture into a shaped carrier body which may be optionally dried and calcined. Typical shapes of the carrier include spheres, cylinders, rings, honeycombs and shaped monoliths. Bacteria and other microorganisms immobilized on the carrier are useful for treatment of contaminated waste streams or contaminated vapors, or for other uses for which microorganisms are used such as the synthesis of chemicals.",GRACE W R & CO,MILLER GEORGE;;BATES HAYWOOD;;BOYER ALLEN;;DURHAM RICHARD,,https://lens.org/163-040-341-498-853,Granted Patent,no,0,0,9,9,0,C02F3/10;;C12N11/14;;Y02W10/10;;C12N11/14;;C02F3/10;;Y02W10/10,C12N11/14;;B01J35/10;;C02F3/00;;C02F3/10;;C12N1/04;;C12N5/00,,0,0,,,,EXPIRED
190,WO,A2,WO 2021/195483 A2,180-011-162-530-823,2021-09-30,2021,US 2021/0024337 W,2021-03-26,US 202063001122 P,2020-03-27,"IMPROVED SYSTEMS, COMPONENTS, AND COMBINATIONS THEREOF FOR PEN-TYPE INJECTION DEVICES","The disclosure provides driver components, systems and drive methods that facilitate improved dose setting, correcting, and/or dispensing in a multiple use pen-type injection device. In particular, various novel braking systems are disclosed that can be implemented within pen-type injection devices to achieve such improvements.",BECTON DICKINSON CO,QUINN MICHAEL;;CRONENBERG RICHARD;;BOYER ROBERT;;GORSHKOV ALEXANDER,,https://lens.org/180-011-162-530-823,Patent Application,yes,0,0,10,10,0,A61M5/31541;;A61M5/2422;;A61M5/31585;;A61M5/31551;;A61M5/2033;;A61M5/31551;;A61M5/31563,A61M5/178,,0,0,,,,PENDING
191,US,A1,US 2020/0368460 A1,096-931-666-142-16X,2020-11-26,2020,US 202016932629 A,2020-07-17,US 202016932629 A;;US 201916420002 A,2019-05-22,COMPUTERIZED ORAL PRESCRIPTION ADMINISTRATION FOR SECURELY DISPENSING MEDICATION AND ASSOCIATED SYSTEMS AND METHODS,"Methods of securely dispensing a substance to an intended user are provided. In some instances, a method of securely dispensing a substance to an intended user includes moving a valve of a locking cap fixedly secured to a housing containing the substance to an open state that allows the substance to be dispensed from the housing to the intended user; determining that a unique biometric attribute of the intended user is detected; and dispensing the substance from the housing to the intended user in response to determining that the unique biometric attribute of the intended user is detected.",BERKSHIRE BIOMEDICAL LLC,BOYER ROBERT;;COREY CHRISTY;;CRONENBERG RICHARD;;KIRKPATRICK JOHN,BERKSHIRE BIOMEDICAL CORPORATION (2019-05-07),https://lens.org/096-931-666-142-16X,Patent Application,yes,3,0,9,9,0,A61J7/0053;;A61J2200/70;;A61M15/0066;;A61M15/0021;;A61M15/0025;;A61M2205/609;;A61M2205/6009;;A61M2205/3317;;A61M2205/13;;A61M2205/276;;A61M2205/3303;;A61M2205/50;;G07C9/257,A61M15/00;;G07C9/25,,0,0,,,,PENDING
192,AU,A1,AU 2020/279376 A1,089-072-500-516-962,2021-12-16,2021,AU 2020/279376 A,2020-05-21,US 201916420002 A;;US 2020/0034044 W,2019-05-22,Computerized oral prescription administration for securely dispensing a medication and associated systems and methods,"In one embodiment, a member for securely dispensing a substance to an intended user includes a first member configured to threadedly engage with a housing containing the substance; a second member coupled to the first member, the second member configured to fixedly secure the first member to the housing; a third member including a cavity sized and shaped to selectively receive the second member; and a valve coupled to the first member such that: when the second member is received within the cavity, the valve is in an open state that allows the substance to be dispensed from the housing to the intended user in response to a processor determining that a unique biometric attribute of the intended user is detected, and when the second member is not received within the cavity, the valve is in a closed state that prevents the substance from being dispensed from the housing.",BERKSHIRE BIOMEDICAL CORP,BOYER ROBERT;;COREY CHRISTY;;CRONENBERG RICHARD;;KIRKPATRICK JOHN,,https://lens.org/089-072-500-516-962,Patent Application,no,0,0,9,9,0,A61J7/0053;;A61J2200/70;;A61M15/0066;;A61M15/0021;;A61M15/0025;;A61M2205/609;;A61M2205/6009;;A61M2205/3317;;A61M2205/13;;A61M2205/276;;A61M2205/3303;;A61M2205/50;;G07C9/257,B67D7/08;;A61B5/00;;A61B5/1178;;A61J1/05;;A61J7/00;;A61J7/02,,0,0,,,,PENDING
193,DE,D1,DE 69929790 D1,158-990-575-237-574,2006-04-20,2006,DE 69929790 T,1999-06-10,US 11058298 A;;US 9913207 W,1998-07-06,NICHT-MAKROPORÖSE INORGANISCHE VORRICHTUNG ZUR BIOLOGISCHEN ENTSORGUNG,"A porous inorganic oxide carrier body for immobilizing living cells is prepared from inorganic oxide particles such as clay particles. The particles have an average particle size of from 0.01 to 20 microns, and the carrier body has a total pore volume of 0.05 to 1.0 cc/g and an average pore diameter of 50 to 700 ANGSTROM , and has substantially no pore volume in the range of 800 ANGSTROM or greater. The carrier is prepared by forming a mixture containing the particles, a liquid medium and optional ingredients including zeolite and activated carbon, and forming the mixture into a shaped carrier body which may be optionally dried and calcined. Typical shapes of the carrier include spheres, cylinders, rings, honeycombs and shaped monoliths. Bacteria and other microorganisms immobilized on the carrier are useful for treatment of contaminated waste streams or contaminated vapors, or for other uses for which microorganisms are used such as the synthesis of chemicals.",GRACE W R & CO,MILLER GEORGE;;BATES HAYWOOD;;BOYER ALLEN;;DURHAM RICHARD,,https://lens.org/158-990-575-237-574,Granted Patent,no,0,0,9,9,0,C02F3/10;;C12N11/14;;Y02W10/10;;C12N11/14;;C02F3/10;;Y02W10/10,C12N11/14;;B01J35/10;;C02F3/00;;C02F3/10;;C12N1/04;;C12N5/00,,0,0,,,,EXPIRED
194,EP,A1,EP 3972930 A1,017-765-413-942-71X,2022-03-30,2022,EP 20808665 A,2020-05-21,US 201916420002 A;;US 2020/0034044 W,2019-05-22,COMPUTERIZED ORAL PRESCRIPTION ADMINISTRATION FOR SECURELY DISPENSING A MEDICATION AND ASSOCIATED SYSTEMS AND METHODS,,BERKSHIRE BIOMEDICALCORPORATION,COREY CHRISTY;;BOYER ROBERT;;CRONENBERG RICHARD;;KIRKPATRICK JOHN,,https://lens.org/017-765-413-942-71X,Patent Application,yes,0,0,9,9,0,A61J7/0053;;A61J2200/70;;A61M15/0066;;A61M15/0021;;A61M15/0025;;A61M2205/609;;A61M2205/6009;;A61M2205/3317;;A61M2205/13;;A61M2205/276;;A61M2205/3303;;A61M2205/50;;G07C9/257,B67D7/08;;A61B5/00;;A61B5/1178;;A61J1/05;;A61J7/00;;A61J7/02,,0,0,,,,PENDING
195,CN,A,CN 113853353 A,042-071-739-320-486,2021-12-28,2021,CN 202080037613 A,2020-05-21,US 201916420002 A;;US 2020/0034044 W,2019-05-22,COMPUTERIZED ORAL PRESCRIPTION ADMINISTRATION FOR SECURELY DISPENSING A MEDICATION AND ASSOCIATED SYSTEMS AND METHODS,"In one embodiment, a member for securely dispensing a substance to an intended user includes a first member configured to threadedly engage with a housing containing the substance; a second member coupled to the first member, the second member configured to fixedly secure the first member to the housing; a third member including a cavity sized and shaped to selectively receive the second member; and a valve coupled to the first member such that: when the second member is received within the cavity, the valve is in an open state that allows the substance to be dispensed from the housing to the intended user in response to a processor determining that a unique biometric attribute of the intended user is detected, and when the second member is not received within the cavity, the valve is in a closed state that prevents the substance from being dispensed from the housing.",BERKSHIRE BIOMEDICAL LLC,BOYER ROBERT;;COREY CHRISTY;;CRONENBERG RICHARD;;KIRKPATRICK JOHN,,https://lens.org/042-071-739-320-486,Patent Application,no,13,0,9,9,0,A61J7/0053;;A61J2200/70;;A61M15/0066;;A61M15/0021;;A61M15/0025;;A61M2205/609;;A61M2205/6009;;A61M2205/3317;;A61M2205/13;;A61M2205/276;;A61M2205/3303;;A61M2205/50;;G07C9/257,B67D7/08,,0,0,,,,PENDING
196,CA,A1,CA 3173662 A1,112-405-849-141-811,2021-09-30,2021,CA 3173662 A,2021-03-26,US 202063001122 P;;US 2021/0024337 W,2020-03-27,"IMPROVED SYSTEMS, COMPONENTS, AND COMBINATIONS THEREOF FOR PEN-TYPE INJECTION DEVICES","The disclosure provides driver components, systems and drive methods that facilitate improved dose setting, correcting, and/or dispensing in a multiple use pen-type injection device. In particular, various novel braking systems are disclosed that can be implemented within pen-type injection devices to achieve such improvements.",BECTON DICKINSON CO,QUINN MICHAEL;;CRONENBERG RICHARD;;BOYER ROBERT;;GORSHKOV ALEXANDER,,https://lens.org/112-405-849-141-811,Patent Application,no,0,0,10,10,0,A61M5/31541;;A61M5/2422;;A61M5/31585;;A61M5/31551;;A61M5/2033;;A61M5/31551;;A61M5/31563,A61M5/00;;A61M5/20;;A61M5/315,,0,0,,,,PENDING
197,WO,A1,WO 2020/237075 A1,067-292-993-354-207,2020-11-26,2020,US 2020/0034044 W,2020-05-21,US 201916420002 A,2019-05-22,COMPUTERIZED ORAL PRESCRIPTION ADMINISTRATION FOR SECURELY DISPENSING A MEDICATION AND ASSOCIATED SYSTEMS AND METHODS,"In one embodiment, a member for securely dispensing a substance to an intended user includes a first member configured to threadedly engage with a housing containing the substance; a second member coupled to the first member, the second member configured to fixedly secure the first member to the housing; a third member including a cavity sized and shaped to selectively receive the second member; and a valve coupled to the first member such that: when the second member is received within the cavity, the valve is in an open state that allows the substance to be dispensed from the housing to the intended user in response to a processor determining that a unique biometric attribute of the intended user is detected, and when the second member is not received within the cavity, the valve is in a closed state that prevents the substance from being dispensed from the housing.",BERKSHIRE BIOMEDICAL LLC,BOYER ROBERT;;COREY CHRISTY;;CRONENBERG RICHARD;;KIRKPATRICK JOHN,,https://lens.org/067-292-993-354-207,Patent Application,yes,7,0,9,9,0,A61J7/0053;;A61J2200/70;;A61M15/0066;;A61M15/0021;;A61M15/0025;;A61M2205/609;;A61M2205/6009;;A61M2205/3317;;A61M2205/13;;A61M2205/276;;A61M2205/3303;;A61M2205/50;;G07C9/257,B67D7/08;;A61B5/00;;A61B5/1178;;A61J1/05;;A61J7/00;;A61J7/02,,1,0,,,See also references of EP 3972930A4,PENDING
198,BR,A2,BR 112022019499 A2,189-433-682-886-396,2022-12-06,2022,BR 112022019499 A,2021-03-26,US 2021/0024337 W;;US 202063001122 P,2020-03-27,"SISTEMAS APERFEIÇOADOS, COMPONENTES E SUAS COMBINAÇÕES PARA DISPOSITIVOS DE INJEÇÃO DO TIPO CANETA","SISTEMAS APERFEIÇOADOS, COMPONENTES E SUAS COMBINAÇÕES PARA DISPOSITIVOS DE INJEÇÃO DO TIPO CANETA. A revelação provê componentes de acionador, sistemas e métodos de acionamento que facilitam ajuste, correção e/ou dispensa melhorados de dose em um dispositivo de injeção do tipo de caneta de uso múltiplo. Em particular, vários sistemas de frenagem novos são revelados que podem ser implementados nos dispositivos de injeção do tipo caneta para obter tais aperfeiçoamentos.",BECTON DICKINSON CO,MICHAEL QUINN;;RICHARD CRONENBERG;;ROBERT BOYER;;ALEXANDER GORSHKOV,,https://lens.org/189-433-682-886-396,Patent Application,no,0,0,10,10,0,A61M5/31541;;A61M5/2422;;A61M5/31585;;A61M5/31551;;A61M5/2033;;A61M5/31551;;A61M5/31563,A61M5/00;;A61M5/20;;A61M5/315,,0,0,,,,PENDING
199,EP,A4,EP 3972930 A4,162-243-355-548-43X,2023-06-14,2023,EP 20808665 A,2020-05-21,US 201916420002 A;;US 2020/0034044 W,2019-05-22,COMPUTERIZED ORAL PRESCRIPTION ADMINISTRATION FOR SECURELY DISPENSING A MEDICATION AND ASSOCIATED SYSTEMS AND METHODS,,BERKSHIRE BIOMEDICALCORPORATION,BOYER ROBERT;;COREY CHRISTY;;CRONENBERG RICHARD;;KIRKPATRICK JOHN,,https://lens.org/162-243-355-548-43X,Search Report,no,2,0,9,9,0,A61J7/0053;;A61J2200/70;;A61M15/0066;;A61M15/0021;;A61M15/0025;;A61M2205/609;;A61M2205/6009;;A61M2205/3317;;A61M2205/13;;A61M2205/276;;A61M2205/3303;;A61M2205/50;;G07C9/257,B67D7/08;;A61B5/00;;A61B5/1178;;A61J1/05;;A61J7/00;;A61J7/02,,1,0,,,See also references of WO 2020237075A1,PENDING
200,EP,A1,EP 3884974 A1,066-436-145-238-776,2021-09-29,2021,EP 21165221 A,2021-03-26,US 202063001122 P,2020-03-27,"IMPROVED SYSTEMS, COMPONENTS, AND COMBINATIONS THEREOF FOR PEN-TYPE INJECTION DEVICES","The disclosure provides driver components, systems and drive methods that facilitate improved dose setting, correcting, and/or dispensing in a multiple use pen-type injection device. In particular, various novel braking systems are disclosed that can be implemented within pen-type injection devices to achieve such improvements.
",BECTON DICKINSON CO,QUINN MICHAEL;;CRONENBERG RICHARD;;BOYER ROBERT;;GORSHIKOV ALEX,,https://lens.org/066-436-145-238-776,Patent Application,yes,10,0,10,10,0,A61M5/31541;;A61M5/2422;;A61M5/31585;;A61M5/31551;;A61M5/2033;;A61M5/31551;;A61M5/31563,A61M5/24;;A61M5/315,,0,0,,,,PENDING
201,AU,A1,AU 2021/244590 A1,156-004-792-788-647,2022-11-10,2022,AU 2021/244590 A,2021-03-26,US 202063001122 P;;US 2021/0024337 W,2020-03-27,"Improved systems, components, and combinations thereof for pen-type injection devices","The disclosure provides driver components, systems and drive methods that facilitate improved dose setting, correcting, and/or dispensing in a multiple use pen-type injection device. In particular, various novel braking systems are disclosed that can be implemented within pen-type injection devices to achieve such improvements.",BECTON DICKINSON CO,QUINN MICHAEL;;CRONENBERG RICHARD;;BOYER ROBERT;;GORSHKOV ALEXANDER,,https://lens.org/156-004-792-788-647,Patent Application,no,0,0,10,10,0,A61M5/31541;;A61M5/2422;;A61M5/31585;;A61M5/31551;;A61M5/2033;;A61M5/31551;;A61M5/31563,A61M5/00;;A61M5/20;;A61M5/315,,0,0,,,,PENDING
202,WO,A1,WO 2019/135833 A1,084-334-246-316-986,2019-07-11,2019,US 2018/0062115 W,2018-11-20,US 201815861961 A,2018-01-04,SYSTEMS AND METHODS FOR PROVIDING ANTI-SPOOFING CAPABILITY TO A GLOBAL NAVIGATION SATELLITE SYSTEM RECEIVER,"Apparatus and methods provide anti-spoofing capability from a first global navigation satellite system (GNSS) receiver to a second GNSS receiver. These GNSS receivers can be, for example, global positioning satellite (GPS) receivers. Via an authentication technique, signals from authentic GNSS sources are distinguished from signals from spoofers. Timing information, such as numerically-controlled oscillator (NCO) settings, used for tracking authenticated signals are then used to generate replica GNSS signals, which are then provided to the second GNSS receiver. As a result, the second GNSS receiver can provide accurate positioning system information in the presence of GNSS spoofers.",INTERSTATE ELECTRONICS CORP,BOYER DEREK MICHAEL LOOMER;;ALEXANDER STEVEN;;REDHEAD RICHARD,,https://lens.org/084-334-246-316-986,Patent Application,yes,3,0,6,6,0,G01S19/215;;G01S19/36;;G01S19/03;;G01S19/24;;G01S19/215;;G01S19/36;;G01S19/03,G01S19/21;;G01S3/14,,0,0,,,,PENDING
203,JP,A,JP 2023099532 A,191-224-490-487-471,2023-07-13,2023,JP 2023065553 A,2023-04-13,JP 2021569062 A;;US 201916420002 A,2019-05-22,"COMPUTERIZED ORAL PRESCRIPTION ADMINISTRATION FOR SECURELY DISPENSING MEDICATION, AND ASSOCIATED SYSTEMS AND METHODS","To provide pharmaceutical oral administration devices and computerized oral prescription administration (COPA) devices.SOLUTION: In one embodiment, an element member for securely dispensing a substance to an intended user includes a first component configured to threadedly engage with a drug housing containing the substance; a second component coupled to the first component, the second component being configured to fixedly secure the first component to the drug housing; a third component including a cavity sized and shaped to selectively receive the second component; and a valve coupled to the first component. When the second component is received in the cavity, the valve is in an open state that allows the substance to be dispensed from the drug housing to the intended user in response to a processor determining that a unique biometric attribute of the intended user is detected. When the second component is not received in the cavity, the valve is in a closed state that prevents the substance from being dispensed from the housing.SELECTED DRAWING: Figure 2",BERKSHIRE BIOMEDICAL CORP,ROBERT BOYER;;CHRISTY COREY;;RICHARD CRONENBERG;;JOHN KIRKPATRICK,,https://lens.org/191-224-490-487-471,Patent Application,no,0,0,9,9,0,A61J7/0053;;A61J2200/70;;A61M15/0066;;A61M15/0021;;A61M15/0025;;A61M2205/609;;A61M2205/6009;;A61M2205/3317;;A61M2205/13;;A61M2205/276;;A61M2205/3303;;A61M2205/50;;G07C9/257,A61J1/05;;A61J7/00;;G16H20/10,,0,0,,,,PENDING
204,CA,A1,CA 2197268 A1,029-261-157-721-366,1997-08-21,1997,CA 2197268 A,1997-02-11,US 60461696 A;;US 74170396 A,1996-02-21,USE OF LIGHT FLESHED VEGETABLES IN BABY FOOD,"Baby foods comprising water and celeriac root crown, Hamburg parsley root or a combination thereof, white carrots and/or yellow carrots and methods for preparation of such baby foods.",BEECH NUT NUTRITION CORP,THEUER RICHARD C;;RUSSO RICHARD F;;BOYER CRAIG S;;SHAUL GERALD E,,https://lens.org/029-261-157-721-366,Patent Application,no,0,0,3,4,0,A23L35/00;;A23L35/00;;A23L19/09;;A23L19/09;;A23L19/10;;A23L19/10;;A23L19/105;;A23L19/105;;A23L33/155;;A23L33/155;;Y10S426/801;;Y10S426/801,A23L19/00;;A23L19/10;;A23L33/155;;A23L35/00,,0,0,,,,DISCONTINUED
205,US,A,US 5723166 A,040-022-697-391-118,1998-03-03,1998,US 60461696 A,1996-02-21,US 60461696 A,1996-02-21,Use of light fleshed vegetables in baby food,"Orange carrots have a beta-carotene content of 75-150 ppm. Orange carrots are commonly used in strained baby foods. The high beta-carotene content of orange carrots results in a high vitamin A statement on the product label and causes the product to have an orange color. White carrots and yellow carrots have a beta-carotene content of less than 10 ppm. White carrots and/or yellow carrots can be used in lieu of, or in combination with, orange carrots to control beta-carotene levels and the color of baby foods. White sweet potatoes can be used in lieu of, or in combination with, white carrots, orange carrots and orange sweet potatoes to control beta-carotene levels and the color of baby foods. The term white sweet potatoes refers to tubers of light colored flesh of the species Ipomea batata, of the morning glory family, Convolvulaceae.",BEECH NUT NUTRITION CORP,THEUER RICHARD C;;BOYER CRAIG S;;RUSSO RICHARD F;;SHAUL GERALD E,BEECH-NUT NUTRITION CORP (1996-02-09),https://lens.org/040-022-697-391-118,Granted Patent,yes,9,13,1,4,0,A23L35/00;;A23L35/00;;A23L19/09;;A23L19/09;;A23L19/10;;A23L19/10;;A23L19/105;;A23L19/105;;A23L33/155;;A23L33/155;;Y10S426/801;;Y10S426/801,A23L19/00;;A23L19/10;;A23L33/155;;A23L35/00,426/615;;426/637;;426/801,16,3,009-502-128-890-661;;002-694-035-771-510;;183-206-339-534-176,7247441;;pmc1627223;;10.1136/adc.56.4.292;;7449242;;10.1177/000992288102000103;;2871351,"Accashian, Carmen, How Safe Are Some Baby Foods from Denver Post, Sep. 8, 1985, cutout.;;Congdon, P.J. et al, Benign Carotenemia in Children from Archives of Disease in Childhood, 1981, pp. 292 294.;;Food & Nutrition Board, Commission On Life Sciences National Research Council, Selections from Chapter 7, Fat Soluble Vitamins from Recommended Dietary Allowances, 10th Ed., 1989, pp. 78 81.;;Hunter Associates Laboratory, Inc., Workshop course notes from Hunterlab Colorlab, 1992 93.;;Lascari, Andre D., M.D., Carotenemia, A Review from Clinical Pediatrics, 1981,pp. 25 29.;;Lopez, Anthony/Editor, Chapter 11 from A Complete Course in Canning , 12th Ed., 1987, pp. 437 447.;;Lui, Nan Sen Tseng & Roels, Oswald A., Selections from Chap 6, The Vitamins from Modern Nutrition in Health & Disease, 6th Ed., 1980, pp. 148 149, 154 159.;;Olson, James A., Selections from Chapter 11, Vitamin A from Present Knowledge in Nutrition, 6th Ed., 1990, pp. 96 97.;;O Neil, R.R., M.D., Lowe, C.U., M.D., Benign Carotenemia of Infancy from Pediatrics, 1963, pp. 692 693.;;Rubatzky, Vince, et al, Announcement concerning 1994 Hybrid Carrot Trial, Jan. 26, 1994, letter and 4 page attachment.;;Stirling, H.F., et al, Hypercarotenaemia & Vitamin A Overdosage from Proprietary Baby Food, The Lancet, May 10, 1986, p. 1089.;;Theuer, Richard C., Ph.D., Feeding Baby Right, How Food Can Turn Your Baby Yellow , late 1980s, one page.;;Treneman, Ann, Baby Foods May Couse Carotenemia from The Evening Press, Oct. 10, 1983,Sec. B.;;Unknown, Vitamins in Baby Food from New York Times, May 4, 1983, cutout.;;C.F.R. 113, Thermally Processed Low Acid Foods Packaged in Hermetically Sealed Containers , Apr. 1, 1994, pp. 227 253.;;Burros, Marian, Eating Well from The New York Times, Feb. 21, 1996, Sec. B.",EXPIRED
206,EP,A2,EP 2546950 A2,034-294-620-161-156,2013-01-16,2013,EP 12173342 A,2012-06-25,US 201161506242 P;;US 201213450881 A,2011-07-11,Electrical charging system having energy coupling arrangement for wireless energy transmission therebetween.,"An electrical charging system (ECS) to electrically charge a battery includes a power transmitter, an energy coupling arrangement, at least one electrical signal shaping device (ESSD) including a controller, and an alignment means. The arrangement includes a first transducer disposed external to the vehicle and a second transducer attached with the vehicle. The alignment means communicates with the vehicle to ensure repeatable vehicle positioning so that the second transducer is positioned relative to the first transducer so that the second transducer receives the energy produced by the power transmitter wirelessly transmitted from the first transducer. The energy received by the second transducer is electrically shaped by the ESSD and further electrically transmitted through the ESSD as controlled by the controller to electrically charge the ESD. Methods to operate and electrically transmit energy through the ECS to electrically charge the EDS are also presented.
",DELPHI TECH INC,BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN VICTOR,,https://lens.org/034-294-620-161-156,Patent Application,yes,55,3,18,18,0,B60L2240/62;;Y02T90/16;;Y02T90/14;;Y04S30/14;;Y02T10/7072;;H02J50/10;;H02J50/80;;B60L53/35;;B60L53/38;;B60L53/665;;H02J50/90;;H02J7/00036;;B60L53/126;;B60L53/122;;H02J2310/48;;H02J7/00047;;Y02T10/70;;Y02T10/72;;Y02T90/12;;Y02T90/167;;H02J50/80;;H02J50/90;;H02J50/10;;B60L53/12;;B60L53/665;;B60L53/38;;B60L2240/62;;Y02T90/14;;Y04S30/14;;Y02T10/7072;;H02J7/00036;;B60Y2200/91;;B60Y2200/92;;H02J50/90;;H02J50/12;;B60L2240/62;;Y02T10/7072;;Y02T90/16;;Y02T90/14;;Y04S30/14;;H02J50/80;;H02J50/10;;H02J7/00;;B60L53/35;;B60L53/38;;B60L53/665;;H02J7/00036;;B60L53/122;;B60L53/126;;Y02T10/70;;Y02T10/72;;Y02T90/12;;Y02T90/167;;H02J7/00047;;H02J2310/48,H02J7/00,,0,0,,,,DISCONTINUED
207,US,B2,US 6779615 B2,096-504-762-782-806,2004-08-24,2004,US 15205502 A,2002-05-21,US 15205502 A;;US 29234901 P,2001-05-21,Powertrain module for zero turn radius vehicle,"
    A powertrain module for a zero turn radius vehicle, such as a tractor or mower, the powertrain module generally including a structural member or mounting plate to which an engine, a pair of hydrostatic transmission modules, and a pair of axle drive units are attached to form a self-contained powertrain module which may be shipped as a single packaged unit for installation into the zero turn radius implement. The mounting plate provides structural rigidity between the powertrain components attached thereto, and the mounting plate of the powertrain module may be attached directly to the frame of the vehicle, or alternatively, may itself serve as a structural frame member for the vehicle. 
",TECUMSEH PRODUCTS CO,BOYER SCOTT G;;MCDONNER ORVILLE R;;RUEBUSCH RICHARD T,TECUMSEH PRODUCTS COMPANY (2002-07-29);;TECUMSEH POWER COMPANY (2007-11-09),https://lens.org/096-504-762-782-806,Granted Patent,yes,37,20,4,4,0,B60K17/04;;B60K17/04;;B60K17/043;;B60K17/043;;B60K17/10;;B60K17/10;;B60K17/105;;B60K17/105,B60K17/04;;B60K17/10,180/6.48;;180/6.66,1,0,,,"US 4,970,914, 11/1990, Takagi (withdrawn)",EXPIRED
208,US,A1,US 2015/0255928 A1,175-148-348-638-433,2015-09-10,2015,US 201514717345 A,2015-05-20,US 201514717345 A;;US 201314101472 A;;US 201313804245 A,2013-03-14,SHIELDED CABLE ASSEMBLY,"A shielded cable assembly capable of transmitting signals at speeds of 3.5 Gigabits per second (Gb/s) or higher without modulation or encoding over a single pair of conductors. The cable has a characteristic impedance of 95 Ohms and can support transmission data according to either USB 3.0 or HDMI 1.4 performance specifications. The wire cable includes a pair of conductors, a shield surrounding the conductors, and a dielectric structure configured to maintain a first predetermined spacing between the conductors and a second predetermined spacing between said conductors and said shield. The shield includes an inner shield conductor enclosing the dielectric structure and an outer shield conductor enclosing the inner shield conductor.",DELPHI TECH INC,LIPTAK NICOLE L;;TAYLOR BRUCE D;;BOYER RICHARD J,APTIV TECHNOLOGIES LIMITED (2018-01-01);;DELPHI TECHNOLOGIES INC (2015-05-20);;APTIV TECHNOLOGIES AG (2023-10-06),https://lens.org/175-148-348-638-433,Patent Application,yes,21,17,2,39,0,H01B11/002;;H01R13/6473;;H01B7/1875;;H01R13/6581;;H01R13/6592;;H01B11/1091;;H01R13/65915;;H01R13/6581;;H01R13/6592;;H01B11/1091;;H01B7/0216;;H01B11/002;;H01B7/1875;;H01B11/06;;H01B11/1033,H01R13/6581;;H01B7/02;;H01B11/10;;H01B11/18;;H01R13/627;;H01R13/6592,,0,0,,,,ACTIVE
209,US,A,US 4738205 A,181-243-590-059-854,1988-04-19,1988,US 5777887 A,1987-06-03,US 5777887 A,1987-06-03,Heating stove which includes a pyrolysis gasifier,The heating stove system includes a fuel hopper (10) from which fuel is fed into a pyrolysis gasifier (12) by means of a fuel auger apparatus (14). Controlling the entry of biomass input and air into the gasifier and ignition of the material in the gasifier is a head valve apparatus (16) which includes an igniter (129). The gasifier (12) in operation produces carbon and fuel gas which are moved into a stove burner (90) by a blower apparatus (18). The operation of the heating stove system is automatically controlled from a thermostat (150).,ABLESTIEN IND INC,BEIERLE FREDERICK P;;BOYER BRIDELL T;;SUISSE RICHARD A,ABLESTIEN INDUSTRIES INC. 1442 SUNSET DR. PROSSER WA. 99350 (1987-05-28);;CENTER FOR STRATEGIC ALLIANCE INC. THE (2005-08-24),https://lens.org/181-243-590-059-854,Granted Patent,yes,5,23,10,12,0,C10B53/02;;F23B90/06;;F23N1/022;;F23C2900/10008;;Y02E50/10;;F23G5/12;;F23B90/06;;F23N1/022;;C10B53/02;;F23C2900/10008;;Y02E50/10,C10B53/02;;F23N5/02;;F23B80/00;;F23G5/027;;F23G5/12;;F23G7/02;;F23K1/04;;F23K5/00;;F23N1/02;;F23N5/08;;F23N5/10;;F23Q3/00,110/229;;48/76;;48/111;;X110101CD,0,0,,,,EXPIRED
210,CN,A,CN 107683555 A,193-936-225-926-662,2018-02-09,2018,CN 201680027367 A,2016-05-10,US 201514708526 A;;US 2016/0031601 W,2015-05-11,Wireless Battery Charging System Varying Magnetic Field Frequency To Maintain A Desire Voltage-Current Phase Relationship,"An electrical charging system (12) configured to wirelessly charge an energy storage device (14), such as a battery (14). The charging system (12) includes an off- transducer (18) in electrical communication with an alternating power source (48) and electromagnetically coupled to an on- vehicle transducer (20) connected to the energy storage device (14). A controller (53) adjusts a variable frequency oscillator (71) within the power transmitter (16), thereby changing the frequency of the sourced electrical power. The charging system (12) further includes a phase detection circuit (72) in communication with the controller (53) and the off-transducer (18) and configured to determine a phase difference between the alternating voltage and the alternating current supplied by the power source (48). The controller (53) is configured to adjust the variable frequency oscillator (71) based on the phase difference such that the frequency of the sourced electrical power maintains the phase difference within a desired range.",DELPHI TECH INC,BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN VICTOR,,https://lens.org/193-936-225-926-662,Patent Application,no,7,1,6,15,0,B60L53/38;;B60L53/126;;B60L53/126;;B60L53/60;;B60Y2200/91;;B60Y2200/92;;H02J50/12;;H02J50/12;;H02J50/12;;H02J7/025;;H02J50/12;;H02J50/80;;H02J50/80;;H02J50/80;;Y02T10/70;;Y02T10/7072;;Y02T90/12;;Y02T90/14;;Y02T90/16;;Y02T90/16,H02J50/12;;H02J7/00;;H02J50/80,,0,0,,,,DISCONTINUED
211,KR,A,KR 20130007985 A,006-546-823-063-364,2013-01-21,2013,KR 20120075102 A,2012-07-10,US 201213450881 A;;US 201161506242 P,2011-07-11,ELECTRICAL CHARGING SYSTEM HAVING ENERGY COUPLING ARRANGEMENT FOR WIRELESS ENERGY TRANSMISSION THEREBETWEEN,PURPOSE: An electric charge system having an energy coupling apparatus for wireless energy transmission is provided to reduce manufacturing costs which manufactures an ECS(electrical charging system) by reducing a distinct electricity composition component. CONSTITUTION: A high power ECS(10) consists of to charge an ESD(12). The ESD includes a traction battery. The ESD is arranged in a weather based vehicle(13) in order to supply energy. The ESD is comprised in order to operate the driving force of the vehicle. The vehicle consists of a vehicle having a battery. The ESD is formed as the battery. A first part of the ECS is arranged outside the vehicle. A second part of the ECS is arranged in the vehicle. [Reference numerals] (10) High power electrical charging system; (13) Vehicle; (14) Voltage transmitter; (16) Open vehicle transducer; (18) On vehicle transducer; (22) Arrangement unit; (24) Charger; (26) Power; (28) Energy coupling device,DELPHI TECH INC,BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN VICTOR,,https://lens.org/006-546-823-063-364,Patent Application,no,0,16,18,18,0,B60L2240/62;;Y02T90/16;;Y02T90/14;;Y04S30/14;;Y02T10/7072;;H02J50/10;;H02J50/80;;B60L53/35;;B60L53/38;;B60L53/665;;H02J50/90;;H02J7/00036;;B60L53/126;;B60L53/122;;H02J2310/48;;H02J7/00047;;Y02T10/70;;Y02T10/72;;Y02T90/12;;Y02T90/167;;H02J50/80;;H02J50/90;;H02J50/10;;B60L53/12;;B60L53/665;;B60L53/38;;B60L2240/62;;Y02T90/14;;Y04S30/14;;Y02T10/7072;;H02J7/00036;;B60Y2200/91;;B60Y2200/92;;H02J50/90;;H02J50/12;;B60L2240/62;;Y02T10/7072;;Y02T90/16;;Y02T90/14;;Y04S30/14;;H02J50/80;;H02J50/10;;H02J7/00;;B60L53/35;;B60L53/38;;B60L53/665;;H02J7/00036;;B60L53/122;;B60L53/126;;Y02T10/70;;Y02T10/72;;Y02T90/12;;Y02T90/167;;H02J7/00047;;H02J2310/48,B60L11/18;;H02J7/00,,0,0,,,,DISCONTINUED
212,US,A,US 4846668 A,081-057-118-278-047,1989-07-11,1989,US 16012388 A,1988-02-25,US 16012388 A;;US 5777887 A,1987-06-03,Heating stove which includes a pyrolysis gasifier,The heating stove system includes a fuel hopper (10) from which fuel is fed into a pyrolysis gasifier (12) by means of a fuel auger apparatus (14). Controlling the entry of biomass input and air into the gasifier and ignition of the material in the gasifier is a head valve apparatus (16) which includes an igniter (129). The gasifier (12) in operation produces carbon and fuel gas which are moved into a stove burner (90) by a blower apparatus (18). The operation of the heating stove system is automatically controlled from a thermostat (150).,ABLESTIEN IND INC,BEIERLE FREDERICK P;;BOYER BIRDELL T;;SUISSE RICHARD A,CENTER FOR STRATEGIC ALLIANCE INC. THE (2005-08-24),https://lens.org/081-057-118-278-047,Granted Patent,yes,4,5,1,12,0,C10B53/02;;C10B53/02;;F23B90/06;;F23B90/06;;F23N1/022;;F23N1/022;;Y02E50/10;;Y02E50/10,C10B53/02;;F23C5/32;;F23N1/02,431/173;;110/264,0,0,,,,EXPIRED
213,US,A,US 5276283 A,094-069-032-689-603,1994-01-04,1994,US 2820193 A,1993-03-08,US 2820193 A,1993-03-08,Distributor cap,A distributor cap for an ignition distributor. The cap is formed of electrical insulating material. A plurality of electrical connector and terminal assemblies are molded into the cap. Each assembly is comprised of a length of plastic moldable material that supports a metallic insert and a metallic terminal. The ends of the length of plastic material are molded respectively to the insert and the terminal. The length of plastic material is plated or coated with a metallic material such as aluminum and this material also coats portions of the terminal and insert. The metallic coating on the length of plastic material electrically connects the terminal to the insert.,GEN MOTORS CORP,BALLENTINE RICHARD E;;TUMULTY JAMES R;;BOYER JAMES A,GENERAL MOTORS CORPORATION (1993-02-26),https://lens.org/094-069-032-689-603,Granted Patent,yes,11,2,1,1,0,F02P7/021;;H01R39/60;;F02P7/021;;H01R39/60,F02P7/02;;H01R39/60,200 19DC,0,0,,,,EXPIRED
214,US,A1,US 2002/0069501 A1,153-847-139-169-460,2002-06-13,2002,US 6162502 A,2002-02-01,US 6162502 A;;US 39753499 A,1999-09-16,Back-lit fascia with spring loaded fascia tensioner,"
   A sign frame assembly for supporting a flexible fascia. In one embodiment, a frame member extends in a first direction and has first and second bracket-mounting sections spaced apart from each other in the first direction. First and second brackets have inner and outer opposite ends. The inner end of the first bracket is attached to the first bracket-mounting section of the first frame member. The inner end of the second bracket are pivotally mounted to the second bracket-mounting section of the frame member. First and second elongated fascia attachment members are affixed respectively to the outer ends of the first and second brackets. A flexible fascia having oppositely disposed edges is connected to the first and second elongated members. A bias member is operatively disposed between the frame member and the second bracket such that the bias member exerts a rotational force on the second bracket in a direction tending to spread apart the elongated fascia attachment members and tension the flexible fascia therebetween. Additional embodiments utilizing biased pivotal fascia tension members are disclosed. 
",LSI INDUSTRIES INC,BOYER JOHN D;;MAKSTALLER RONALD W;;GRIMES RICHARD SCOTT,,https://lens.org/153-847-139-169-460,Patent Application,yes,0,0,6,6,0,G09F17/00;;G09F17/00;;G09F13/04;;G09F13/04;;G09F15/0025;;G09F15/0025;;Y10T29/49716;;Y10T29/49716;;Y10T29/4984;;Y10T29/4984;;Y10T29/49863;;Y10T29/49863;;Y10T29/49867;;Y10T29/49867;;Y10T29/4987;;Y10T29/4987,G09F13/04;;G09F15/00;;G09F17/00,29/401.1;;29/434;;X02945,0,0,,,,EXPIRED
215,CN,A,CN 1030470 A,174-739-699-135-107,1989-01-18,1989,CN 88103350 A,1988-06-03,US 5777887 A,1987-06-03,HEATING STOVE WHICH INCLUDES PYROLYSIS GASIFIER,,ABLESTIEN IND INC,PEIERLE FREDERICK P;;BOYER BIRDELL T;;SUISSE RICHARD A,,https://lens.org/174-739-699-135-107,Patent Application,no,0,0,10,12,0,C10B53/02;;F23B90/06;;F23N1/022;;F23C2900/10008;;Y02E50/10;;F23G5/12;;F23B90/06;;F23N1/022;;C10B53/02;;F23C2900/10008;;Y02E50/10,F23N5/02;;C10B53/02;;F23B80/00;;F23G5/027;;F23G5/12;;F23G7/02;;F23K1/04;;F23K5/00;;F23N1/02;;F23N5/08;;F23N5/10;;F23Q3/00,,0,0,,,,EXPIRED
216,EP,A3,EP 2546953 A3,095-103-003-850-034,2017-10-25,2017,EP 12173344 A,2012-06-25,US 201161506242 P;;US 201213450881 A,2011-07-11,Electrical charging system having energy coupling arrangement for wireless energy transmission therebetween.,"An electrical charging system (ECS) to electrically charge a battery includes a power transmitter, an energy coupling arrangement, at least one electrical signal shaping device (ESSD) including a controller, and an alignment means. The arrangement includes a first transducer disposed external to the vehicle and a second transducer attached with the vehicle. The alignment means communicates with the vehicle to ensure repeatable vehicle positioning so that the second transducer is positioned relative to the first transducer so that the second transducer receives the energy produced by the power transmitter wirelessly transmitted from the first transducer. The energy received by the second transducer is electrically shaped by the ESSD and further electrically transmitted through the ESSD as controlled by the controller to electrically charge the ESD. Methods to operate and electrically transmit energy through the ECS to electrically charge the EDS are also presented.
",DELPHI TECH INC,BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN VICTOR,,https://lens.org/095-103-003-850-034,Search Report,yes,4,0,18,18,0,B60L2240/62;;Y02T90/16;;Y02T90/14;;Y04S30/14;;Y02T10/7072;;H02J50/10;;H02J50/80;;B60L53/35;;B60L53/38;;B60L53/665;;H02J50/90;;H02J7/00036;;B60L53/126;;B60L53/122;;H02J2310/48;;H02J7/00047;;Y02T10/70;;Y02T10/72;;Y02T90/12;;Y02T90/167;;H02J50/80;;H02J50/90;;H02J50/10;;B60L53/12;;B60L53/665;;B60L53/38;;B60L2240/62;;Y02T90/14;;Y04S30/14;;Y02T10/7072;;H02J7/00036;;B60Y2200/91;;B60Y2200/92;;H02J50/90;;H02J50/12;;B60L2240/62;;Y02T10/7072;;Y02T90/16;;Y02T90/14;;Y04S30/14;;H02J50/80;;H02J50/10;;H02J7/00;;B60L53/35;;B60L53/38;;B60L53/665;;H02J7/00036;;B60L53/122;;B60L53/126;;Y02T10/70;;Y02T10/72;;Y02T90/12;;Y02T90/167;;H02J7/00047;;H02J2310/48,B60L11/18;;H02J7/00;;H02J7/02,,0,0,,,,DISCONTINUED
217,US,A,US 3346631 A,101-171-518-722-971,1967-10-10,1967,US 31969663 A,1963-10-29,US 31969663 A,1963-10-29,Liquid carboxylated polymers and method of preparing the same,,AMERICAN SYNTHETIC RUBBER CORP,BOYER THOMAS W;;CHANG RICHARD C;;RIES EDWARD L,,https://lens.org/101-171-518-722-971,Granted Patent,no,4,12,1,1,0,C08C19/04;;C08C19/04,C08C19/04,,0,0,,,,EXPIRED
218,GB,A,GB 1143308 A,124-811-113-122-107,1969-02-19,1969,GB 1298367 A,1967-03-20,US 54263966 A,1966-04-14,A semiconductor device assembly,"1,143,308. Semi-conductor devices. INTERNATIONAL RECTIFIER CORP. 20 March, 1967 [14 April. 1966], No. 12983/67. Heading H1K. A semi-conductor wafer-which may constitute a junction diode and be mounted between molybdenum plates-is secured to a housing base 13 and surrounded by a hollow cylindrical wall 30 bonded to the base. The lead 19 to the upper surface of the wafer is a flat strip conductor having at least one reentrant bend. As shown, there are two such bends 20 and 21, but in Fig. 5 (not shown) there is only one. A resilient solid filler 32 covers both the wafer and the bend or bends in the lead, so that the contact is of the flexible-link type. Above the resilient filler there may be a rigid filler 33, so that the projecting terminal portion 26 of the lead 19 is effectively rigid with the housing.",INT RECTIFIER CORP,SCOTT ANGUS A;;BOYER JOHN L;;HARTMAN RICHARD A,,https://lens.org/124-811-113-122-107,Granted Patent,no,0,0,5,6,0,H01L23/49562;;H01L23/49562;;H01L23/24;;H01L23/24;;H01L23/488;;H01L23/488;;H01L2924/0002;;H01L2924/0002,H01L23/24;;H01L23/488;;H01L23/495,H1K KPB           PB;;H1K KRL           RL;;H1K K4C1F         PB;;H1K K4F7B         PB;;H1K K4F9          PB;;H1K K5A           PB;;H1K K5A1          PB;;H1K K5A3          PB;;H1K K5F2          PB;;H1K K5PY          PB,0,0,,,,EXPIRED
219,US,A,US 4799437 A,116-291-774-642-04X,1989-01-24,1989,US 15911388 A,1988-02-22,US 15911388 A;;US 5777887 A,1987-06-03,Heating stove which includes a pyrolysis gasifier,"A blower apparatus (18) for use in a gasifier and burner combination, the blower including a housing (60) which includes an inlet for gas from the gasifier and an exit nozzle (64) leading to the burner. A vertical blower shaft (66) extends up into the housing (60) as well as down below the housing (60), wherein the blower shaft (66) includes a hollow portion which is in communication with the environment. A first fan (62) is positioned on the upper end of the blower shaft (66) within the housing (60) and a second fan (80) is positioned on the blower shaft (66) beneath the housing (60). A motor (70) drives the blower shaft (66) through a belt and pulley arrangement (72,68).",ABLESTIEN IND INC,BEIERLE FREDERICK P;;BOYER BIRDELL T;;SUISSE RICHARD A,CENTER FOR STRATEGIC ALLIANCE INC. THE (2005-08-24),https://lens.org/116-291-774-642-04X,Granted Patent,yes,5,1,1,12,0,C10B53/02;;C10B53/02;;F23B90/06;;F23B90/06;;F23N1/022;;F23N1/022;;Y02E50/10;;Y02E50/10,C10B53/02;;F23G5/027;;F23N1/02,110/229;;415/125;;415/129,0,0,,,,EXPIRED
220,US,A1,US 2013/0035814 A1,188-169-424-491-600,2013-02-07,2013,US 201213564754 A,2012-08-02,US 201213564754 A;;US 201161515865 P,2011-08-06,ELECTRICAL CHARGING SYSTEM THAT INCLUDES VOLTAGE-CONTROLLED OSCILLATOR WHICH OPERATIVELY CONTROLS WIRELESS ELECTROMAGNETIC OR WIRELESS INDUCTIVE CHARGING OF A BATTERY,"An electrical charging system (ECS) is used to electrically charge an energy storage device (ESD) using wireless electromagnetic or inductive charging. The ECS includes a voltage-controlled oscillator (VCO) electrical circuit, a first transducer, and a plurality of second transducers. The VCO electrical circuit sequentially excites a plurality of coils in a first transducer to select one of a plurality of second transducers in which to transfer energy when the ESD is electrically charged. ECS power efficiency is measured during the excitation of the plurality of coils and used to determine whether the ECS uses the electromagnetic or inductive approach to electrically charge the ESD. The VCO electrical circuit also assists to maintain an optimum ECS power efficiency during electrical charging of the ESD. A method to electrically charge an ESD associated with a first vehicle and an ESD associated with a second vehicle with the ECS is also presented.",DELPHI TECH INC;;BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN VICTOR,BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN VICTOR,DELPHI TECHNOLOGIES INC (2012-08-02),https://lens.org/188-169-424-491-600,Patent Application,yes,5,23,7,15,0,B60L2210/30;;B60L2210/40;;Y02T90/14;;Y02T10/7072;;B60L53/14;;B60L53/36;;B60L50/66;;B60L53/122;;B60L53/126;;H02J2310/48;;H02J7/00712;;Y02T10/70;;Y02T10/72;;Y02T90/12;;H02J50/402;;H02J50/90;;H02J50/10;;H02J50/80;;H02J50/10;;H02J50/40;;B60L53/12;;B60L50/66;;B60L53/14;;B60L53/36;;B60L2210/30;;B60L2210/40;;Y02T10/7072;;Y02T90/14;;Y02T10/70;;Y02T10/72;;Y02T90/12;;H02J50/80;;H02J50/10;;B60L2210/30;;B60L2210/40;;Y02T90/14;;Y02T10/7072;;B60L50/66;;B60L53/36;;B60L53/14;;B60L53/122;;B60L53/126;;Y02T10/70;;Y02T10/72;;Y02T90/12;;H02J50/402;;H02J50/90;;H02J2310/48;;H02J7/00712,B60L11/00;;H02J7/00,701/22;;320/108;;903/903,0,0,,,,DISCONTINUED
221,WO,A1,WO 1988/009903 A1,184-633-860-198-540,1988-12-15,1988,US 8801884 W,1988-06-02,US 5777887 A,1987-06-03,HEATING STOVE WHICH INCLUDES A PYROLYSIS GASIFIER,The heating stove system includes a fuel hopper (10) from which fuel is fed into a pyrolysis gasifier (12) by means of a fuel auger apparatus (14). Controlling the entry of biomass input and air into the gasifier and ignition of the material in the gasifier is a head valve apparatus (16) which includes an igniter (129). The gasifier (12) in operation produces carbon and fuel gas which are moved into a stove burner (90) by a blower apparatus (18). The operation of the heating stove system is automatically controlled from a thermostat (150).,ABLESTIEN IND INC,BEIERLE FREDERICK PETER;;BOYER BIRDELL TALMADGE;;SUISSE RICHARD ALLEN,,https://lens.org/184-633-860-198-540,Patent Application,yes,5,0,10,12,0,C10B53/02;;F23B90/06;;F23N1/022;;F23C2900/10008;;Y02E50/10;;F23G5/12;;F23B90/06;;F23N1/022;;C10B53/02;;F23C2900/10008;;Y02E50/10,C10B53/02;;F23B80/00;;F23N5/02;;F23G5/027;;F23G5/12;;F23G7/02;;F23K1/04;;F23K5/00;;F23N1/02;;F23N5/08;;F23N5/10;;F23Q3/00,C5E EAF           EAF;;C5E EAW           EAW,0,0,,,,PENDING
222,US,A1,US 2003/0123175 A1,019-813-433-916-048,2003-07-03,2003,US 4477301 A,2001-12-31,US 4477301 A,2001-12-31,System and method for recovery from writing errors during data storage,"
   A system and method for recovering from write errors during writing of a moving storage medium suspend write current while allowing the storage medium to continue moving. The system and method continue to format data for writing while the write current is suspended and resequence the data for subsequent storage. Information is recorded to distinguish previously written data from current data with error correction pointers adjusted accordingly. Write errors may be detected in a track following streaming tape system based on data errors from a read back check or based on positioning errors of a read/write head servo system, for example. By allowing the storage medium to continue moving through the error event, the system and method improve speed, capacity utilization, and throughput of the storage and retrieval process. 
",GILL RICHARD ALLEN;;BOYER KEITH GARY;;TRABERT STEVEN GREGORY,GILL RICHARD ALLEN;;BOYER KEITH GARY;;TRABERT STEVEN GREGORY,SUN MICROSYSTEMS INC (2006-12-22);;ORACLE AMERICA INC (2010-02-12);;STORAGE TECHNOLOGY CORPORATION (2002-04-30),https://lens.org/019-813-433-916-048,Patent Application,yes,8,13,2,2,0,G11B5/584;;G11B5/584,G11B5/584,360/53;;X360 6;;360/77.13,0,0,,,,EXPIRED
223,EP,A1,EP 1260402 A1,013-074-781-679-259,2002-11-27,2002,EP 02011176 A,2002-05-21,US 29234901 P,2001-05-21,Powertrain module for zero turn radius vehicle,"A powertrain module (14) for a zero turn radius vehicle (10), such as a tractor or mower, the powertrain module generally including a structural member (24) or mounting plate to which an engine (30), a pair of hydrostatic transmission modules (26a, 26b), and a pair of axle drive units (28a, 28b) are attached to form a self-contained powertrain module which may be shipped as a single packaged unit for installation into the zero turn radius implement. The mounting plate provides structural rigidity between the powertrain components attached thereto, and the mounting plate of the powertrain module may be attached directly to the frame (12) of the vehicle, or alternatively, may itself serve as a structural frame member for the vehicle.",TECUMSEH PRODUCTS CO,BOYER SCOTT G;;MCDONNER ORVILLE R;;RUEBUSCH RICHARD T,,https://lens.org/013-074-781-679-259,Patent Application,yes,1,0,4,4,0,B60K17/04;;B60K17/043;;B60K17/10;;B60K17/105;;B60K17/04;;B60K17/043;;B60K17/10;;B60K17/105,B60K17/04;;B60K17/10,,1,0,,,"PATENT ABSTRACTS OF JAPAN vol. 018, no. 348 (M - 1630) 30 June 1994 (1994-06-30)",DISCONTINUED
224,US,B2,US 6898036 B2,067-520-972-467-845,2005-05-24,2005,US 4477301 A,2001-12-31,US 4477301 A,2001-12-31,System and method for recovery from writing errors during data storage,"A system and method for recovering from write errors during writing of a moving storage medium suspend write current while allowing the storage medium to continue moving. The system and method continue to format data for writing while the write current is suspended and resequence the data for subsequent storage. Information is recorded to distinguish previously written data from current data with error correction pointers adjusted accordingly. Write errors may be detected in a track following streaming tape system based on data errors from a read back check or based on positioning errors of a read/write head servo system, for example. By allowing the storage medium to continue moving through the error event, the system and method improve speed, capacity utilization, and throughput of the storage and retrieval process.",STORAGE TECHNOLOGY CORP,GILL RICHARD ALLEN;;BOYER KEITH GARY;;TRABERT STEVEN GREGORY,SUN MICROSYSTEMS INC (2006-12-22);;ORACLE AMERICA INC (2010-02-12);;STORAGE TECHNOLOGY CORPORATION (2002-04-30),https://lens.org/067-520-972-467-845,Granted Patent,yes,9,33,2,2,0,G11B5/584;;G11B5/584,G11B5/584,360/53;;360/31;;360/46,0,0,,,,EXPIRED
225,CA,C,CA 1306939 C,118-570-679-158-289,1992-09-01,1992,CA 568091 A,1988-05-30,US 5777887 A,1987-06-03,HEATING STOVE WHICH INCLUDES A PYROLYSIS GASIFIER,HEATING STOVE WHICH INCLUDES A PYROLYSIS GASIFIER The heating stove system includes a fuel hopper (10) from which fuel is fed into a pyrolysis gasifier (12) by means of a fuel auger apparatus (14). Controlling the entry of biomass input and air into the gasifier and ignition of the material in the gasifier is a head valve apparatus (16) which includes an igniter (129). The gasifier (12) in operation produces carbon and fuel gas which are moved into a stove burner (90) by a blower apparatus (18). The operation of the heating stove system is automatically controlled from a thermostat (150).,ABLESTIEN IND INC,BEIERLE FREDERICK P;;BOYER BIRDELL T;;SUISSE RICHARD A,,https://lens.org/118-570-679-158-289,Granted Patent,no,0,0,10,12,0,C10B53/02;;F23B90/06;;F23N1/022;;F23C2900/10008;;Y02E50/10;;F23G5/12;;F23B90/06;;F23N1/022;;C10B53/02;;F23C2900/10008;;Y02E50/10,F23N5/02;;C10B53/02;;F23B80/00;;F23G5/027;;F23G5/12;;F23G7/02;;F23K1/04;;F23K5/00;;F23N1/02;;F23N5/08;;F23N5/10;;F23Q3/00,D41580160    M;;0480007    S;;2300001    S,0,0,,,,EXPIRED
226,DE,T2,DE 69025424 T2,164-293-959-576-755,1996-09-26,1996,DE 69025424 T,1990-05-16,US 35301089 A,1989-05-17,Mikrowellendämpfer zur direkten Oberflächenbelegung,,MINNESOTA MINING & MFG,BOYER CHARLES E;;KUO RICHARD J;;LOGIUDICE STEPHEN M,,https://lens.org/164-293-959-576-755,Granted Patent,no,0,0,7,7,0,H01Q17/004;;H05K9/0088;;Y10T428/256;;Y10T428/268;;Y10T428/28;;B32B7/025;;H01Q17/00;;B32B7/025;;Y10T428/256;;Y10T428/268;;Y10T428/28;;B32B7/12;;B32B2307/208;;B32B2307/202;;H05K9/0088;;H01Q17/004;;B32B7/025,B32B5/02;;B32B7/025;;B32B5/16;;B32B7/12;;H01Q17/00;;H05K9/00,,0,0,,,,EXPIRED
227,EP,A3,EP 2546951 A3,066-088-417-658-427,2017-10-25,2017,EP 12173350 A,2012-06-25,US 201161506242 P;;US 201213450881 A,2011-07-11,Electrical charging system having energy coupling arrangement for wireless energy transmission therebetween,"An electrical charging system (ECS) to electrically charge a battery includes a power transmitter, an energy coupling arrangement, at least one electrical signal shaping device (ESSD) including a controller, and an alignment means. The arrangement includes a first transducer disposed external to the vehicle and a second transducer attached with the vehicle. The alignment means communicates with the vehicle to ensure repeatable vehicle positioning so that the second transducer is positioned relative to the first transducer so that the second transducer receives the energy produced by the power transmitter wirelessly transmitted from the first transducer. The energy received by the second transducer is electrically shaped by the ESSD and further electrically transmitted through the ESSD as controlled by the controller to electrically charge the ESD. Methods to operate and electrically transmit energy through the ECS to electrically charge the EDS are also presented.
",DELPHI TECH INC,BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN VICTOR,,https://lens.org/066-088-417-658-427,Search Report,yes,3,0,18,18,0,B60L2240/62;;Y02T90/16;;Y02T90/14;;Y04S30/14;;Y02T10/7072;;H02J50/10;;H02J50/80;;B60L53/35;;B60L53/38;;B60L53/665;;H02J50/90;;H02J7/00036;;B60L53/126;;B60L53/122;;H02J2310/48;;H02J7/00047;;Y02T10/70;;Y02T10/72;;Y02T90/12;;Y02T90/167;;H02J50/80;;H02J50/90;;H02J50/10;;B60L53/12;;B60L53/665;;B60L53/38;;B60L2240/62;;Y02T90/14;;Y04S30/14;;Y02T10/7072;;H02J7/00036;;B60Y2200/91;;B60Y2200/92;;H02J50/90;;H02J50/12;;B60L2240/62;;Y02T10/7072;;Y02T90/16;;Y02T90/14;;Y04S30/14;;H02J50/80;;H02J50/10;;H02J7/00;;B60L53/35;;B60L53/38;;B60L53/665;;H02J7/00036;;B60L53/122;;B60L53/126;;Y02T10/70;;Y02T10/72;;Y02T90/12;;Y02T90/167;;H02J7/00047;;H02J2310/48,H02J7/02;;B60L11/18,,0,0,,,,DISCONTINUED
228,KR,A,KR 20160137381 A,077-306-407-103-26X,2016-11-30,2016,KR 20160059948 A,2016-05-17,US 201514717345 A,2015-05-20,SHIELDED CABLE ASSEMBLY,"The present invention relates to a shielded cable assembly. The shielded cable assembly (100) can transmit a signal at a speed of 3.5 Gb/s or greater without encoding or modulation all over a single pair of conductors (102b, 104b). The cable (100) can support transmission data in accordance with each performance specification of USB 3.0 or HDMI 1.4 and has a property impedance of 95 Ohm. A wire cable (100f) includes: the pair of conductors; a shielding unit (116, 124) enclosing the conductor; and a conductive structure (113) maintaining a first predetermined interval between the conductors and a second predetermined interval between the conductor (102b, 104b) and the shielding unit (116, 124). The shielding unit includes: an inner shielding unit (116) conductor enclosing the conductive structure (113) and an outer shielding unit (124) conductor enclosing the inner shielding unit (116) conductor.",DELPHI TECH INC,LIPTAK NICOLE L;;TAYLOR BRUCE D;;BOYER RICHARD J,,https://lens.org/077-306-407-103-26X,Patent Application,no,0,0,5,39,0,H01B11/18;;H01B11/203;;H01R13/6592;;H01B7/0045;;H01B7/02;;H01B7/17;;H01B7/18;;H01B7/1895;;H01B11/002;;H01B11/1839;;H01B11/1869;;H01B11/20,H01B11/18;;H01B7/02;;H01B11/20,,0,0,,,,PENDING
229,WO,A1,WO 2013/022722 A1,154-234-258-740-839,2013-02-14,2013,US 2012/0049426 W,2012-08-03,US 201161515865 P;;US 201213564754 A,2011-08-06,ELECTRICAL CHARGING SYSTEM,"An electrical charging system (ECS) is used to electrically charge an energy storage device (ESD) using wireless electromagnetic or inductive charging. The ECS includes a voltage-controlled oscillator (VCO) electrical circuit, a first transducer, and a plurality of second transducers. The VCO electrical circuit sequentially excites a plurality of coils in a first transducer to select one of a plurality of second transducers in which to transfer energy when the ESD is electrically charged. ECS power efficiency is measured during the excitation of the plurality of coils and used to determine whether the ECS uses the electromagnetic or inductive approach to electrically charge the ESD. The VCO electrical circuit also assists to maintain an optimum ECS power efficiency during electrical charging of the ESD. A method to electrically charge an ESD associated with a first vehicle and an ESD associated with a second vehicle with the ECS is also presented.",DELPHI TECH INC;;BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN VICTOR,BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN VICTOR,,https://lens.org/154-234-258-740-839,Patent Application,yes,6,1,7,15,0,B60L2210/30;;B60L2210/40;;Y02T90/14;;Y02T10/7072;;B60L53/14;;B60L53/36;;B60L50/66;;B60L53/122;;B60L53/126;;H02J2310/48;;H02J7/00712;;Y02T10/70;;Y02T10/72;;Y02T90/12;;H02J50/402;;H02J50/90;;H02J50/10;;H02J50/80;;H02J50/10;;H02J50/40;;B60L53/12;;B60L50/66;;B60L53/14;;B60L53/36;;B60L2210/30;;B60L2210/40;;Y02T10/7072;;Y02T90/14;;Y02T10/70;;Y02T10/72;;Y02T90/12;;H02J50/80;;H02J50/10;;B60L2210/30;;B60L2210/40;;Y02T90/14;;Y02T10/7072;;B60L50/66;;B60L53/36;;B60L53/14;;B60L53/122;;B60L53/126;;Y02T10/70;;Y02T10/72;;Y02T90/12;;H02J50/402;;H02J50/90;;H02J2310/48;;H02J7/00712,H02J7/00,,1,0,,,See also references of EP 2740192A4,PENDING
230,US,B2,US 11336058 B2,174-891-425-706-650,2022-05-17,2022,US 201514717345 A,2015-05-20,US 201514717345 A;;US 201314101472 A;;US 201313804245 A,2013-03-14,Shielded cable assembly,"A shielded cable assembly capable of transmitting signals at speeds of 3.5 Gigabits per second (Gb/s) or higher without modulation or encoding over a single pair of conductors. The cable has a characteristic impedance of 95 Ohms and can support transmission data according to either USB 3.0 or HDMI 1.4 performance specifications. The wire cable includes a pair of conductors, a shield surrounding the conductors, and a dielectric structure configured to maintain a first predetermined spacing between the conductors and a second predetermined spacing between said conductors and said shield. The shield includes an inner shield conductor enclosing the dielectric structure and an outer shield conductor enclosing the inner shield conductor.",APTIV TECH LTD,LIPTAK NICOLE L;;TAYLOR BRUCE D;;BOYER RICHARD J,APTIV TECHNOLOGIES LIMITED (2018-01-01);;DELPHI TECHNOLOGIES INC (2015-05-20);;APTIV TECHNOLOGIES AG (2023-10-06),https://lens.org/174-891-425-706-650,Granted Patent,yes,61,0,2,39,0,H01B11/002;;H01R13/6473;;H01B7/1875;;H01R13/6581;;H01R13/6592;;H01B11/1091;;H01R13/65915;;H01R13/6581;;H01R13/6592;;H01B11/1091;;H01B7/0216;;H01B11/002;;H01B7/1875;;H01B11/06;;H01B11/1033,H01B11/06;;H01B7/02;;H01B7/18;;H01B11/00;;H01B11/10;;H01R13/6581;;H01R13/6592,,1,0,,,Machine Translation of CN 202134270.,ACTIVE
231,CA,A1,CA 3042372 A1,051-883-435-143-695,2018-04-26,2018,CA 3042372 A,2017-10-19,US 201662410671 P;;US 2017/0057398 W,2016-10-20,LOW PROFILE NYLON INSERT LOCK NUT,"The present invention relates to prevailing torque lock nuts and, more particularly, to a low profile lock nut that maintains the same strength as its higher profile counterparts. The present lock nut is a non-metallic lock having an inner recess so as to receive a plastic insert, such as a nylon insert. In some embodiments, the plastic insert is a temperature resistant plastic insert capable of withstanding high temperatures. Further, in some embodiments, the present lock nut is manufactured to have increased hardness levels and subject to enhanced plating process that ensure superior corrosion resistance.",RAMCO SPECIALTIES INC,BOYER MARK S;;MALSON RICHARD A;;DONOVAN DANIEL B,,https://lens.org/051-883-435-143-695,Patent Application,no,0,0,6,6,0,F16B39/34;;F16B33/06;;F16B33/008;;C25D7/003;;F16B33/008;;F16B39/34,F16B39/34;;F16B37/00;;F16B39/00;;F16B39/01;;F16B39/22;;F16B39/28,,0,0,,,,DISCONTINUED
232,US,B2,US 8474202 B2,085-304-747-866-619,2013-07-02,2013,US 201213494290 A,2012-06-12,US 201213494290 A;;US 42657509 A;;US 4619408 P,2008-04-18,Extruded seal plate for horizontal insulated composite architectural panel vertical end joints,A seal plate for building panels includes an elongate body having a first side and a second side. The first side of the elongate body includes first and second seals and a recessed channel. The first and second seals and the recessed channel extend at least a portion of the length of the elongate body. The recessed channel is positioned between the first and second seals.,BOYER KEITH D;;BROW RICHARD A;;BERTRAM RALPH E;;CENTRIA,BOYER KEITH D;;BROW RICHARD A;;BERTRAM RALPH E,CENTRIA (2009-04-16);;NCI GROUP INC (2020-02-17);;NUCOR INSULATED PANEL GROUP LLC (2021-07-27),https://lens.org/085-304-747-866-619,Granted Patent,yes,19,2,4,4,0,E04F13/0889;;E04F13/0889,E04B2/62,52/235;;52/396.04,0,0,,,,ACTIVE
233,US,A1,US 2013/0015812 A1,149-776-694-385-808,2013-01-17,2013,US 201213450881 A,2012-04-19,US 201213450881 A;;US 201161506242 P,2011-07-11,ELECTRICAL CHARGING SYSTEM HAVING ENERGY COUPLING ARRANGEMENT FOR WIRELESS ENERGY TRANSMISSION THEREBETWEEN,"An electrical charging system (ECS) to electrically charge a battery includes a power transmitter, an energy coupling arrangement, at least one electrical signal shaping device (ESSD) including a controller, and an alignment means. The arrangement includes a first transducer disposed external to the vehicle and a second transducer attached with the vehicle. The alignment means communicates with the vehicle to ensure repeatable vehicle positioning so that the second transducer is positioned relative to the first transducer so that the second transducer receives the energy produced by the power transmitter wirelessly transmitted from the first transducer. The energy received by the second transducer is electrically shaped by the ESSD and further electrically transmitted through the ESSD as controlled by the controller to electrically charge the ESD. Methods to operate and electrically transmit energy through the ECS to electrically charge the EDS are also presented.",DELPHI TECH INC;;BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN VICTOR,BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN VICTOR,APTIV TECHNOLOGIES LIMITED (2018-01-01);;DELPHI TECHNOLOGIES INC (2012-04-18);;APTIV TECHNOLOGIES AG (2023-10-06),https://lens.org/149-776-694-385-808,Patent Application,yes,2,38,18,18,0,B60L2240/62;;Y02T90/16;;Y02T90/14;;Y04S30/14;;Y02T10/7072;;H02J50/10;;H02J50/80;;B60L53/35;;B60L53/38;;B60L53/665;;H02J50/90;;H02J7/00036;;B60L53/126;;B60L53/122;;H02J2310/48;;H02J7/00047;;Y02T10/70;;Y02T10/72;;Y02T90/12;;Y02T90/167;;H02J50/80;;H02J50/90;;H02J50/10;;B60L53/12;;B60L53/665;;B60L53/38;;B60L2240/62;;Y02T90/14;;Y04S30/14;;Y02T10/7072;;H02J7/00036;;B60Y2200/91;;B60Y2200/92;;H02J50/90;;H02J50/12;;B60L2240/62;;Y02T10/7072;;Y02T90/16;;Y02T90/14;;Y04S30/14;;H02J50/80;;H02J50/10;;H02J7/00;;B60L53/35;;B60L53/38;;B60L53/665;;H02J7/00036;;B60L53/122;;B60L53/126;;Y02T10/70;;Y02T10/72;;Y02T90/12;;Y02T90/167;;H02J7/00047;;H02J2310/48,H02J7/00;;H02J7/04,320/108;;320/137;;320/162;;320/139,0,0,,,,ACTIVE
234,US,A,US 5795232 A,177-228-446-470-489,1998-08-18,1998,US 81665897 A,1997-03-13,US 81665897 A,1997-03-13,Drive assembly coupler,"A drive assembly coupler to transfer torque from a motor shaft. The coupler includes a body having a first end, a second opposed end, and an axial opening through the body extending between the ends. A first pair of opposed channels is provided in the body, each channel parallel to the other and parallel to the opening. A second pair of opposed channels is provided in the body, each channel parallel to the other and parallel to the opening. A first U-shaped insert has a threaded opening receivable in the first end and has a first pair of extending legs receivable in the first channels. A second U-shaped insert has a threaded opening receivable in the second end and has a second pair of extending legs receivable in the second channels.",R L HUDSON & COMPANY,SITZBERGER CARL R;;HUDSON RICHARD L;;BOYER THOMAS W,R.L. HUDSON & COMPANY (1997-02-24),https://lens.org/177-228-446-470-489,Granted Patent,yes,18,1,1,1,0,F16D3/74;;F16D3/74;;F16D3/68;;F16D3/68,F16D3/68;;F16D3/74,464/73;;464/81;;464/87,0,0,,,,EXPIRED
235,EP,A2,EP 0673982 A2,061-886-117-354-709,1995-09-27,1995,EP 95810165 A,1995-03-13,US 21097894 A,1994-03-21,Process for the manufacture of honeycomb products.,The substitution of a water-based phenolic thermosetting resin for a phenolic thermosetting resin in an organic solvent provides a safer and environmentally improved method for making honeycomb core. Improved processing characteristics in components manufactured from such honeycomb core are observed.,CIBA GEIGY AG,DANVER DALE;;CAO LIQUN;;BOYER RONALD;;HEITKAMP RICHARD RENFREW,HEXCEL CORPORATION (1996-08-07),https://lens.org/061-886-117-354-709,Patent Application,yes,0,0,7,7,0,B29D99/0089;;B29L2031/608;;C09D161/06;;B29D99/0089;;C09D161/06;;B29L2031/608,B32B3/12;;B29B15/12;;B29D99/00;;B32B27/42;;C09D161/06,,0,0,,,,EXPIRED
236,US,A,US 3099650 A,148-858-619-328-902,1963-07-30,1963,US 14619161 A,1961-10-19,US 14619161 A,1961-10-19,Process for preparing liquid polymers and copolymers with reduced modifier levels,,AMERICAN SYNTHETIC RUBBER CORP,BOYER THOMAS W;;STUCKER RICHARD O;;RIES EDWARD L,,https://lens.org/148-858-619-328-902,Granted Patent,no,1,1,1,1,0,C08F36/04;;C08F36/04,C08F36/04,,0,0,,,,EXPIRED
237,US,B2,US 8393436 B2,160-657-026-183-780,2013-03-12,2013,US 201113066503 A,2011-04-15,US 201113066503 A,2011-04-15,Flexible muffler for use in aircraft environmental control systems and method of manufacture,A flexible muffler for use in an aircraft environmental system includes a flexible body having a porous inner layer and an air impervious outer layer both supported by a helically wound adhesively attached reinforcing cord. The flexible body includes a pair of connecting end caps at opposed ends thereof which are joined to the flexible body in an air tight attachment. The resulting muffler provides acoustic energy absorptive and is readily flexed and bent to accommodate space restrictions within the environmental control system of the aircraft.,TOMERLIN REG;;HARWOOD ALLEN W;;HOFF RICHARD;;BOYER DAVID;;ARROWHEAD PRODUCTS CORP,TOMERLIN REG;;HARWOOD ALLEN W;;HOFF RICHARD;;BOYER DAVID,,https://lens.org/160-657-026-183-780,Granted Patent,yes,22,4,2,2,0,F01N13/1816;;F01N13/1816;;F01N1/04;;F01N1/04;;F01N1/24;;F01N1/24,F16L11/26,181/222;;138/129,0,0,,,,INACTIVE
238,EP,A4,EP 0317615 A4,003-468-728-031-874,1989-09-26,1989,EP 88905538 A,1988-06-02,US 5777887 A,1987-06-03,HEATING STOVE WHICH INCLUDES A PYROLYSIS GASIFIER.,,ABLESTIEN INSUSTRIES INC,BEIERLE FREDERICK PETER;;BOYER BIRDELL TALMADGE;;SUISSE RICHARD ALLEN,,https://lens.org/003-468-728-031-874,Search Report,no,1,0,10,12,0,C10B53/02;;F23B90/06;;F23N1/022;;F23C2900/10008;;Y02E50/10;;F23G5/12;;F23B90/06;;F23N1/022;;C10B53/02;;F23C2900/10008;;Y02E50/10,F23N5/02;;C10B53/02;;F23B80/00;;F23G5/027;;F23G5/12;;F23G7/02;;F23K1/04;;F23K5/00;;F23N1/02;;F23N5/08;;F23N5/10;;F23Q3/00,,0,0,,,,DISCONTINUED
239,CN,A,CN 102882245 A,006-655-816-492-163,2013-01-16,2013,CN 201210238236 A,2012-07-10,US 201161506242 P;;US 201213450881 A,2011-07-11,Electrical charging system having energy coupling arrangement for wireless energy transmission therebetween,"An electrical charging system (ECS) to electrically charge a battery includes a power transmitter, an energy coupling arrangement, at least one electrical signal shaping device (ESSD) including a controller, and an alignment means. The arrangement includes a first transducer disposed external to the vehicle and a second transducer attached with the vehicle. The alignment means communicates with the vehicle to ensure repeatable vehicle positioning so that the second transducer is positioned relative to the first transducer so that the second transducer receives the energy produced by the power transmitter wirelessly transmitted from the first transducer. The energy received by the second transducer is electrically shaped by the ESSD and further electrically transmitted through the ESSD as controlled by the controller to electrically charge the ESD. Methods to operate and electrically transmit energy through the ECS to electrically charge the EDS are also presented.",DELPHI TECH INC,BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN VICTOR,,https://lens.org/006-655-816-492-163,Patent Application,no,5,13,18,18,0,B60L2240/62;;Y02T90/16;;Y02T90/14;;Y04S30/14;;Y02T10/7072;;H02J50/10;;H02J50/80;;B60L53/35;;B60L53/38;;B60L53/665;;H02J50/90;;H02J7/00036;;B60L53/126;;B60L53/122;;H02J2310/48;;H02J7/00047;;Y02T10/70;;Y02T10/72;;Y02T90/12;;Y02T90/167;;H02J50/80;;H02J50/90;;H02J50/10;;B60L53/12;;B60L53/665;;B60L53/38;;B60L2240/62;;Y02T90/14;;Y04S30/14;;Y02T10/7072;;H02J7/00036;;B60Y2200/91;;B60Y2200/92;;H02J50/90;;H02J50/12;;B60L2240/62;;Y02T10/7072;;Y02T90/16;;Y02T90/14;;Y04S30/14;;H02J50/80;;H02J50/10;;H02J7/00;;B60L53/35;;B60L53/38;;B60L53/665;;H02J7/00036;;B60L53/122;;B60L53/126;;Y02T10/70;;Y02T10/72;;Y02T90/12;;Y02T90/167;;H02J7/00047;;H02J2310/48,H02J7/00;;B60L11/18;;H02J17/00,,0,0,,,,INACTIVE
240,EP,A3,EP 2546092 A3,093-030-344-127-824,2017-11-08,2017,EP 12173352 A,2012-06-25,US 201161506242 P;;US 201213450881 A,2011-07-11,Electrical charging system having energy coupling arrangement for wireless energy transmission therebetween,"An electrical charging system (ECS) to electrically charge a battery includes a power transmitter, an energy coupling arrangement, at least one electrical signal shaping device (ESSD) including a controller, and an alignment means. The arrangement includes a first transducer disposed external to the vehicle and a second transducer attached with the vehicle. The alignment means communicates with the vehicle to ensure repeatable vehicle positioning so that the second transducer is positioned relative to the first transducer so that the second transducer receives the energy produced by the power transmitter wirelessly transmitted from the first transducer. The energy received by the second transducer is electrically shaped by the ESSD and further electrically transmitted through the ESSD as controlled by the controller to electrically charge the ESD. Methods to operate and electrically transmit energy through the ECS to electrically charge the EDS are also presented.
",DELPHI TECH INC,BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN VICTOR,,https://lens.org/093-030-344-127-824,Search Report,yes,2,0,18,18,0,B60L2240/62;;Y02T90/16;;Y02T90/14;;Y04S30/14;;Y02T10/7072;;H02J50/10;;H02J50/80;;B60L53/35;;B60L53/38;;B60L53/665;;H02J50/90;;H02J7/00036;;B60L53/126;;B60L53/122;;H02J2310/48;;H02J7/00047;;Y02T10/70;;Y02T10/72;;Y02T90/12;;Y02T90/167;;H02J50/80;;H02J50/90;;H02J50/10;;B60L53/12;;B60L53/665;;B60L53/38;;B60L2240/62;;Y02T90/14;;Y04S30/14;;Y02T10/7072;;H02J7/00036;;B60Y2200/91;;B60Y2200/92;;H02J50/90;;H02J50/12;;B60L2240/62;;Y02T10/7072;;Y02T90/16;;Y02T90/14;;Y04S30/14;;H02J50/80;;H02J50/10;;H02J7/00;;B60L53/35;;B60L53/38;;B60L53/665;;H02J7/00036;;B60L53/122;;B60L53/126;;Y02T10/70;;Y02T10/72;;Y02T90/12;;Y02T90/167;;H02J7/00047;;H02J2310/48,B60L11/18;;H02J5/00;;H02J7/00;;H02J7/02,,1,0,,,"ANONYMOUS: ""Acknowledgement (data networks) - Wikipedia"", 11 October 2010 (2010-10-11), XP055404867, Retrieved from the Internet <URL:https://en.wikipedia.org/w/index.php?title=Acknowledgement_(data_networks)&oldid=390010387> [retrieved on 20170907]",DISCONTINUED
241,DE,D1,DE 69025424 D1,164-162-809-859-602,1996-03-28,1996,DE 69025424 T,1990-05-16,US 35301089 A,1989-05-17,Mikrowellendämpfer zur direkten Oberflächenbelegung,,MINNESOTA MINING & MFG,BOYER CHARLES E;;KUO RICHARD J;;LOGIUDICE STEPHEN M,,https://lens.org/164-162-809-859-602,Granted Patent,no,0,0,7,7,0,H01Q17/004;;H05K9/0088;;Y10T428/256;;Y10T428/268;;Y10T428/28;;B32B7/025;;H01Q17/00;;B32B7/025;;Y10T428/256;;Y10T428/268;;Y10T428/28;;B32B7/12;;B32B2307/208;;B32B2307/202;;H05K9/0088;;H01Q17/004;;B32B7/025,B32B5/02;;B32B7/025;;B32B5/16;;B32B7/12;;H01Q17/00;;H05K9/00,,0,0,,,,EXPIRED
242,JP,A,JP 2013034369 A,013-123-724-126-170,2013-02-14,2013,JP 2012149022 A,2012-07-03,US 201161506242 P;;US 201213450881 A,2011-07-11,ELECTRICAL CHARGING SYSTEM HAVING ENERGY COUPLING ARRANGEMENT FOR WIRELESS ENERGY TRANSMISSION THEREBETWEEN,PROBLEM TO BE SOLVED: To provide a reliable and robust vehicular electrical charging system that enables repeatable electrical charging of a battery in a short amount of time and provides user convenience and safety for the human operator of the electrical charging system.SOLUTION: An energy coupling arrangement includes a first transducer disposed external to a vehicle and a second transducer attached with the vehicle. Alignment means communicates with the vehicle to ensure repeatable vehicle positioning so that the second transducer is positioned relative to the first transducer so that the second transducer receives the energy produced by the power transmitter wirelessly transmitted from the first transducer. The energy received by the second transducer is electrically shaped by an electrical signal shaping device (ESSD) and further electrically transmitted through the ESSD as controlled by a controller to electrically charge an energy storage device (ESD).,DELPHI TECH INC,RICHARD J BOYER;;BRIAN E PASHA;;JOHN VICTOR FUZO,,https://lens.org/013-123-724-126-170,Patent Application,no,5,1,18,18,0,B60L2240/62;;Y02T90/16;;Y02T90/14;;Y04S30/14;;Y02T10/7072;;H02J50/10;;H02J50/80;;B60L53/35;;B60L53/38;;B60L53/665;;H02J50/90;;H02J7/00036;;B60L53/126;;B60L53/122;;H02J2310/48;;H02J7/00047;;Y02T10/70;;Y02T10/72;;Y02T90/12;;Y02T90/167;;H02J50/80;;H02J50/90;;H02J50/10;;B60L53/12;;B60L53/665;;B60L53/38;;B60L2240/62;;Y02T90/14;;Y04S30/14;;Y02T10/7072;;H02J7/00036;;B60Y2200/91;;B60Y2200/92;;H02J50/90;;H02J50/12;;B60L2240/62;;Y02T10/7072;;Y02T90/16;;Y02T90/14;;Y04S30/14;;H02J50/80;;H02J50/10;;H02J7/00;;B60L53/35;;B60L53/38;;B60L53/665;;H02J7/00036;;B60L53/122;;B60L53/126;;Y02T10/70;;Y02T10/72;;Y02T90/12;;Y02T90/167;;H02J7/00047;;H02J2310/48,H02J17/00;;B60L11/18;;H01M10/44;;H01M10/46;;H01M10/48;;H02J7/00,,0,0,,,,PENDING
243,US,B1,US 6937412 B1,073-858-905-027-749,2005-08-30,2005,US 20631702 A,2002-07-26,US 20631702 A,2002-07-26,Method and apparatus for creating a format identification block on a magnetic tape,"A method, apparatus, and computer instructions for writing data to a magnetic media. A first frequency is written on a first track on the magnetic media on a first track width. A second frequency is written on the first track in which a combination of the first frequency and the second frequency encodes a bit of data on the first track. An erase pattern is created on a second track on the magnetic media, the second track being adjacent to the first track in which the bit of data on the first track is readable by a tape drive system having a second track width wider than the track width of the first track.",STORAGE TECHNOLOGY CORP,GILL RICHARD ALLEN;;HAYES ROGER D;;BOYER KEITH GARY,SUN MICROSYSTEMS INC (2006-12-22);;ORACLE AMERICA INC (2010-02-12);;STORAGE TECHNOLOGY CORPORATION (2002-07-25),https://lens.org/073-858-905-027-749,Granted Patent,yes,3,11,1,1,0,G11B5/00813;;G11B5/00878;;G11B5/02;;G11B5/09;;G11B15/087;;G11B20/10;;G11B20/1201;;G11B2020/10879;;G11B20/10;;G11B2020/10879;;G11B5/00878;;G11B5/02;;G11B5/00813;;G11B15/087;;G11B20/1201;;G11B5/09,G11B5/008;;G11B5/02;;G11B5/09;;G11B15/087;;G11B20/10;;G11B20/12,360/48,0,0,,,,EXPIRED
244,US,B1,US 6311259 B1,057-993-953-149-486,2001-10-30,2001,US 77705496 A,1996-12-30,US 77705496 A;;US 32251194 A,1994-10-14,System and method for reading unidirectionally recorded data bidirectionally,A system and method for allowing uni-directional data to be read in the reverse direction as well as the forward direction uses a data buffer to reverse the order of data read from storage media. Data are read from the storage media in the reverse direction and stored in a data buffer. Pointers are set up to track record boundaries of the data storedin the data buffer. The data are read from the data buffer in the opposite direction from which they are stored and sent to a host in the forward direction. Cyclic redundancy checks can be performed as data are read from the storage media in the reverse direction and read from the data buffer in the forward direction.,STORAGE TECHNOLOGY CORP,BOYER KEITH G;;GILL RICHARD A;;GOHL THOMAS H,,https://lens.org/057-993-953-149-486,Granted Patent,yes,5,5,1,1,0,G06F7/785;;G06F7/785;;G11B20/00086;;G11B20/00086;;G11B20/0021;;G11B20/0021,G06F7/78;;G11B20/00,711/201;;711/100;;711/152;;711/154;;711/211;;710/52;;710/65,0,0,,,,EXPIRED
245,EP,B1,EP 0673982 B1,112-900-170-218-614,1999-09-01,1999,EP 95810165 A,1995-03-13,US 21097894 A,1994-03-21,Process for the manufacture of honeycomb products,,HEXCEL CORP,DANVER DALE;;CAO LIQUN;;BOYER RONALD;;HEITKAMP RICHARD RENFREW,HEXCEL CORPORATION (1996-08-07),https://lens.org/112-900-170-218-614,Granted Patent,yes,3,1,7,7,0,B29D99/0089;;B29L2031/608;;C09D161/06;;B29D99/0089;;C09D161/06;;B29L2031/608,B32B3/12;;B29B15/12;;B29D99/00;;B32B27/42;;C09D161/06,,0,0,,,,EXPIRED
246,EP,A4,EP 3529506 A4,173-539-535-113-259,2020-06-10,2020,EP 17863118 A,2017-10-19,US 201662410671 P;;US 2017/0057398 W,2016-10-20,LOW PROFILE NYLON INSERT LOCK NUT,,RAMCO SPECIALTIES INC,BOYER MARK S;;MALSON RICHARD A;;DONOVAN DANIEL B,,https://lens.org/173-539-535-113-259,Search Report,no,4,0,6,6,0,C25D7/003;;F16B39/34;;F16B39/34;;F16B33/008;;F16B33/008;;F16B33/06,F16B39/34;;F16B33/00;;F16B33/06;;F16B37/00;;F16B39/00;;F16B39/01;;F16B39/22;;F16B39/28,,2,0,,,"ANONYMOUS: ""Technical Reference Guide s7028"", FASTENAL INDUSTRIAL & CONSTRUCTION SUPPLIES, 13 September 2015 (2015-09-13), pages 1 - 62, XP055598692, Retrieved from the Internet <URL:https://www.fastenal.com/content/documents/FastenalTechnicalReferenceGuide.pdf> [retrieved on 20190624];;See also references of WO 2018075774A1",DISCONTINUED
247,KR,A,KR 20140076552 A,003-351-396-139-635,2014-06-20,2014,KR 20147005867 A,2012-08-03,US 201213564754 A;;US 201161515865 P;;US 2012/0049426 W,2011-08-06,ELECTRICAL CHARGING SYSTEM,,DELPHI TECH INC,BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN VICTOR,,https://lens.org/003-351-396-139-635,Patent Application,no,0,3,7,15,0,B60L2210/30;;B60L2210/40;;Y02T90/14;;Y02T10/7072;;B60L53/14;;B60L53/36;;B60L50/66;;B60L53/122;;B60L53/126;;H02J2310/48;;H02J7/00712;;Y02T10/70;;Y02T10/72;;Y02T90/12;;H02J50/402;;H02J50/90;;H02J50/10;;H02J50/80;;H02J50/10;;H02J50/40;;B60L53/12;;B60L50/66;;B60L53/14;;B60L53/36;;B60L2210/30;;B60L2210/40;;Y02T10/7072;;Y02T90/14;;Y02T10/70;;Y02T10/72;;Y02T90/12;;H02J50/80;;H02J50/10;;B60L2210/30;;B60L2210/40;;Y02T90/14;;Y02T10/7072;;B60L50/66;;B60L53/36;;B60L53/14;;B60L53/122;;B60L53/126;;Y02T10/70;;Y02T10/72;;Y02T90/12;;H02J50/402;;H02J50/90;;H02J2310/48;;H02J7/00712,H02J17/00;;B60L11/18;;B60W10/26;;H01M10/44;;H02J7/00,,0,0,,,,DISCONTINUED
248,US,A1,US 2015/0239356 A1,031-044-738-605-903,2015-08-27,2015,US 201514708526 A,2015-05-11,US 201514708526 A;;US 201213564754 A;;US 201161515865 P,2011-08-06,Wireless Battery Charging System Varying Magnetic Field Frequency To Maintain A Desired Voltage-Current Phase Relationship,"An electrical charging system configured to wirelessly charge an energy storage device, such as a battery. The charging system includes an off-transducer in electrical communication with an alternating power source and electromagnetically coupled to an on-vehicle transducer connected to the energy storage device. A controller adjusts a variable frequency oscillator within the power transmitter, thereby changing the frequency of the sourced electrical power. The charging system further includes a phase detection circuit in communication with the controller and the off-transducer and configured to determine a phase difference between the alternating voltage and the alternating current supplied by the power source. The controller is configured to adjust the variable frequency oscillator based on the phase difference such that the frequency of the sourced electrical power maintains the phase difference within a desired range.",DELPHI TECH INC,BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN VICTOR,APTIV TECHNOLOGIES LIMITED (2018-01-01);;DELPHI TECHNOLOGIES INC (2015-05-11);;APTIV TECHNOLOGIES AG (2023-10-06),https://lens.org/031-044-738-605-903,Patent Application,yes,5,3,2,15,0,Y02T90/14;;B60L2210/30;;B60L2210/40;;B60L2240/36;;Y02T90/16;;Y02T10/7072;;B60L53/14;;B60L50/66;;B60L53/126;;B60L53/122;;H02J2310/48;;H02J7/00712;;Y02T10/70;;Y02T10/72;;H02J50/80;;H02J50/90;;H02J50/12;;H02J50/12;;H02J50/80;;H02J50/90;;Y02T90/14;;B60L2210/30;;B60L2210/40;;B60L2240/36;;Y02T90/16;;Y02T10/7072;;B60L53/14;;B60L50/66;;B60L53/122;;B60L53/126;;Y02T10/70;;Y02T10/72;;Y02T90/12;;B60L53/12;;H02J2310/48;;H02J7/00712,B60L11/18,,0,0,,,,ACTIVE
249,EP,A1,EP 0317615 A1,154-024-090-314-071,1989-05-31,1989,EP 88905538 A,1988-06-02,US 5777887 A,1987-06-03,HEATING STOVE WHICH INCLUDES A PYROLYSIS GASIFIER.,"Le système à poêle de chauffage comprend une trémie de combustible (10) assurant l'alimentation en combustible à un gazéificateur à pyrolyse (12) au moyen d'un appareil d'amenée (14) du combustible. Un appareil (16) à valve de tête, comprenant un dispositif d'allumage (129), assure la régulation de l'entrée de biomasse et d'air dans le gazéificateur ainsi que l'allumage du matériau dans le gazéificateur. Le gazéificateur (12) produit du carbone et du gaz combustibles qui sont amenés dans un brûleur (90) du poêle au moyen d'une soufflante (18). Le fonctionnement du système à poêle de chauffage est commandé automatiquement à partir d'un thermostat (150).",ABLESTIEN INSUSTRIES INC,BEIERLE FREDERICK PETER;;BOYER BIRDELL TALMADGE;;SUISSE RICHARD ALLEN,,https://lens.org/154-024-090-314-071,Patent Application,yes,0,0,10,12,0,C10B53/02;;F23B90/06;;F23N1/022;;F23C2900/10008;;Y02E50/10;;F23G5/12;;F23B90/06;;F23N1/022;;C10B53/02;;F23C2900/10008;;Y02E50/10,F23N5/02;;C10B53/02;;F23B80/00;;F23G5/027;;F23G5/12;;F23G7/02;;F23K1/04;;F23K5/00;;F23N1/02;;F23N5/08;;F23N5/10;;F23Q3/00,,0,0,,,,DISCONTINUED
250,CN,A,CN 106169677 A,183-570-583-600-279,2016-11-30,2016,CN 201610334522 A,2016-05-19,US 201514717345 A,2015-05-20,Shielded cable assembly,"A shielded cable assembly 100 capable of transmitting signals at speeds of 3.5 Gigabits per second (Gb/s) or higher without modulation or encoding over a single pair of conductors (102b, 104b). The cable 100 has a characteristic impedance of 95 Ohms and can support transmission data according to either USB 3.0 or HDMI 1.4 performance specifications. The wire cable (100f) includes a pair of conductors, a shield (116, 124) surrounding the conductors, and a dielectric structure (113) configured to maintain a first predetermined spacing between the conductors and a second predetermined spacing between the conductors (102b, 104b) and the shield (116, 124). The shield includes an inner shield (116) conductor enclosing the dielectric structure (113) and an outer shield (124) conductor enclosing the inner shield (116) conductor.",DELPHI TECH INC,NICOLE L LIPTAK;;BRUCE D TAYLOR;;RICHARD J BOYER,,https://lens.org/183-570-583-600-279,Patent Application,no,5,4,5,39,0,H01B11/18;;H01B11/203;;H01R13/6592;;H01B7/0045;;H01B7/02;;H01B7/17;;H01B7/18;;H01B7/1895;;H01B11/002;;H01B11/1839;;H01B11/1869;;H01B11/20,H01R13/6592;;H01B7/00;;H01B7/17;;H01B7/18,,0,0,,,,ACTIVE
251,EP,A1,EP 3096331 A1,192-781-226-249-296,2016-11-23,2016,EP 16170209 A,2016-05-18,US 201514717345 A,2015-05-20,SHIELDED CABLE ASSEMBLY,"A shielded cable assembly 100 capable of transmitting signals at speeds of 3.5 Gigabits per second (Gb/s) or higher without modulation or encoding over a single pair of conductors (102b, 104b). The cable 100 has a characteristic impedance of 95 Ohms and can support transmission data according to either USB 3.0 or HDMI 1.4 performance specifications. The wire cable (100f) includes a pair of conductors, a shield (116, 124) surrounding the conductors, and a dielectric structure (113) configured to maintain a first predetermined spacing between the conductors and a second predetermined spacing between the conductors (102b, 104b) and the shield (116, 124). The shield includes an inner shield (116) conductor enclosing the dielectric structure (113) and an outer shield (124) conductor enclosing the inner shield (116) conductor.
",DELPHI TECH INC,LIPTAK NICOLE L;;TAYLOR BRUCE D;;BOYER RICHARD J,"APTIV TECHNOLOGIES LIMITED, BB (2018-12-06)",https://lens.org/192-781-226-249-296,Patent Application,yes,4,3,5,39,0,H01B11/18;;H01B11/203;;H01R13/6592;;H01B7/0045;;H01B7/02;;H01B7/17;;H01B7/18;;H01B7/1895;;H01B11/002;;H01B11/1839;;H01B11/1869;;H01B11/20,H01B11/20,,0,0,,,,ACTIVE
252,EP,A4,EP 3294588 A4,010-058-071-776-151,2018-11-14,2018,EP 16793361 A,2016-05-10,US 201514708526 A;;US 2016/0031601 W,2015-05-11,WIRELESS BATTERY CHARGING SYSTEM VARYING MAGNETIC FIELD FREQUENCY TO MAINTAIN A DESIRE VOLTAGE-CURRENT PHASE RELATIONSHIP,,DELPHI TECH INC,BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN VICTOR,APTIV TECHNOLOGIES LIMITED (2018-12-19),https://lens.org/010-058-071-776-151,Search Report,no,2,0,6,15,0,B60L53/38;;B60L53/126;;B60L53/126;;B60L53/60;;B60Y2200/91;;B60Y2200/92;;H02J50/12;;H02J50/12;;H02J50/12;;H02J7/025;;H02J50/12;;H02J50/80;;H02J50/80;;H02J50/80;;Y02T10/70;;Y02T10/7072;;Y02T90/12;;Y02T90/14;;Y02T90/16;;Y02T90/16,H02J50/12;;B60L11/18;;H02J50/80,,1,0,,,See also references of WO 2016183058A1,DISCONTINUED
253,US,A1,US 2009/0260311 A1,015-569-581-314-340,2009-10-22,2009,US 42657509 A,2009-04-20,US 42657509 A;;US 4619408 P,2008-04-18,Extruded Seal Plate For Horizontal Insulated Composite Architectural Panel Vertical End Joints,A seal plate for building panels includes an elongate body having a first side and second side. The first side of the elongate body includes first and second seals and a recessed channel. The first and second seals and the recessed channel extend at least a portion of the length of the elongate body. The recessed channel is positioned between the first and second seals.,CENTRIA,BOYER KEITH D;;BROW RICHARD A;;BERTRAM RALPH E,CENTRIA (2009-04-16);;NCI GROUP INC (2020-02-17);;NUCOR INSULATED PANEL GROUP LLC (2021-07-27),https://lens.org/015-569-581-314-340,Patent Application,yes,15,29,4,4,0,E04F13/0889;;E04F13/0889,F16J15/00;;E04B1/66,52/506.06;;277/590;;52/741.4,0,0,,,,ACTIVE
254,US,A1,US 2019/0277329 A1,024-898-791-205-138,2019-09-12,2019,US 201716343655 A,2017-10-19,US 201716343655 A;;US 201662410671 P;;US 2017/0057398 W,2016-10-20,LOW PROFILE NYLON INSERT LOCK NUT,"The present invention relates to prevailing torque lock nuts and, more particularly, to a low profile lock nut that maintains the same strength as its higher profile counterparts. The present lock nut is a non-metallic lock having an inner recess so as to receive a plastic insert, such as a nylon insert. In some embodiments, the plastic insert is a temperature resistant plastic insert capable of withstanding high temperatures. Further, in some embodiments, the present lock nut is manufactured to have increased hardness levels and subject to enhanced plating process that ensure superior corrosion resistance.",RAMCO SPECIALTIES INC,BOYER MARK S;;MALSON RICHARD A;;DONOVAN DANIEL B,RAMCO SPECIALTIES INC (2019-04-16),https://lens.org/024-898-791-205-138,Patent Application,yes,0,6,6,6,0,C25D7/003;;F16B39/34;;F16B39/34;;F16B33/008;;F16B33/008;;F16B33/06,F16B39/34;;C25D7/00;;F16B33/00,,0,0,,,,DISCONTINUED
255,EP,B1,EP 3096331 B1,019-197-172-748-034,2017-12-13,2017,EP 16170209 A,2016-05-18,US 201514717345 A,2015-05-20,SHIELDED CABLE ASSEMBLY,,DELPHI TECH INC,LIPTAK NICOLE L;;TAYLOR BRUCE D;;BOYER RICHARD J,"APTIV TECHNOLOGIES LIMITED, BB (2018-12-06)",https://lens.org/019-197-172-748-034,Granted Patent,yes,3,0,5,39,0,H01B7/0045;;H01B7/17;;H01B7/18;;H01B7/1895;;H01R13/6592;;H01B11/002;;H01B11/203;;H01B11/18;;H01B11/1839;;H01B11/20;;H01B11/1869;;H01B7/02,H01B11/20,,0,0,,,,ACTIVE
256,EP,A2,EP 2546092 A2,026-955-029-413-948,2013-01-16,2013,EP 12173352 A,2012-06-25,US 201161506242 P;;US 201213450881 A,2011-07-11,Electrical charging system having energy coupling arrangement for wireless energy transmission therebetween,"An electrical charging system (ECS) to electrically charge a battery includes a power transmitter, an energy coupling arrangement, at least one electrical signal shaping device (ESSD) including a controller, and an alignment means. The arrangement includes a first transducer disposed external to the vehicle and a second transducer attached with the vehicle. The alignment means communicates with the vehicle to ensure repeatable vehicle positioning so that the second transducer is positioned relative to the first transducer so that the second transducer receives the energy produced by the power transmitter wirelessly transmitted from the first transducer. The energy received by the second transducer is electrically shaped by the ESSD and further electrically transmitted through the ESSD as controlled by the controller to electrically charge the ESD. Methods to operate and electrically transmit energy through the ECS to electrically charge the EDS are also presented.
",DELPHI TECH INC,BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN VICTOR,,https://lens.org/026-955-029-413-948,Patent Application,yes,55,5,18,18,0,B60L2240/62;;Y02T90/16;;Y02T90/14;;Y04S30/14;;Y02T10/7072;;H02J50/10;;H02J50/80;;B60L53/35;;B60L53/38;;B60L53/665;;H02J50/90;;H02J7/00036;;B60L53/126;;B60L53/122;;H02J2310/48;;H02J7/00047;;Y02T10/70;;Y02T10/72;;Y02T90/12;;Y02T90/167;;H02J50/80;;H02J50/90;;H02J50/10;;B60L53/12;;B60L53/665;;B60L53/38;;B60L2240/62;;Y02T90/14;;Y04S30/14;;Y02T10/7072;;H02J7/00036;;B60Y2200/91;;B60Y2200/92;;H02J50/90;;H02J50/12;;B60L2240/62;;Y02T10/7072;;Y02T90/16;;Y02T90/14;;Y04S30/14;;H02J50/80;;H02J50/10;;H02J7/00;;B60L53/35;;B60L53/38;;B60L53/665;;H02J7/00036;;B60L53/122;;B60L53/126;;Y02T10/70;;Y02T10/72;;Y02T90/12;;Y02T90/167;;H02J7/00047;;H02J2310/48,B60L11/18;;H02J7/02,,0,0,,,,DISCONTINUED
257,US,B1,US 11655418 B1,071-457-445-527-004,2023-05-23,2023,US 202117389071 A,2021-07-29,US 202117389071 A;;US 202062706141 P,2020-08-03,Ultra purified pitch process,"A process for producing isotropic and mesophase pitch with reduced solids contamination from aromatic liquids contaminated with solids, such as catalyst fines or semi-coke. Contaminated feed is charged through one or more pitch forming reactors which discharge a pitch rich liquid and a vapor phase with reduced solids contamination. The vapor phase is cooled, condensed and may be charged continuously to another pitch forming reactor in parallel or used intermittently as a total or partial replacement for solids contaminated feed.",HOLCOMBE THOMAS C;;BOYER DAVID C;;STONE RICHARD D;;ACP TECH LLC,HOLCOMBE THOMAS C;;BOYER DAVID C;;STONE RICHARD D,ADVANCED CARBON PRODUCTS LLC (2021-12-01);;ACP TECHNOLOGIES LLC (2023-03-13),https://lens.org/071-457-445-527-004,Granted Patent,yes,3,0,1,1,0,C10C3/002;;C10C3/002;;C10C3/06,C10C1/19;;C10C3/00;;C10C3/06,,1,0,,,"U.S. Appl. No. 17/731,923, filed Jul. 30, 2021, Boyer, et al.",ACTIVE
258,US,B1,US 6947241 B1,147-703-537-517-918,2005-09-20,2005,US 21394502 A,2002-08-07,US 21394502 A,2002-08-07,Pre-block ID mark for multi-directional block location when using a unidirectional coding format,"An asynchronous method for locating individual blocks of data in a tape drive, without having to read the blocks of data is provided. The invention comprises placing an ID mark adjacent to the data blocks and inter-block gaps on the tape. The ID mark contains a small amount of information about the next respective data block on the tape. The ID mark is encoded such that the same detection mechanism that detects the inter-block gap can also retrieve the ID mark information, without having to process the entire block of data associated with a particular ID mark. The ID mark is symmetrical such that it can be detected and decoded in the forward and backward direction, allowing the tape drive to find a desired block of data by searching either forward or backward, even when the magnetic tape uses a unidirectional data format.",STORAGE TECHNOLOGY CORP,GILL RICHARD ALLEN;;HAYES ROGER D;;BOYER KEITH GARY,SUN MICROSYSTEMS INC (2006-12-22);;ORACLE AMERICA INC (2010-02-12);;STORAGE TECHNOLOGY CORPORATION (2002-08-06),https://lens.org/147-703-537-517-918,Granted Patent,yes,3,2,1,1,0,G11B5/584;;G11B5/584,G11B5/584;;G11B19/02,360/72.2,0,0,,,,EXPIRED
259,EP,A2,EP 2546093 A2,153-981-378-540-551,2013-01-16,2013,EP 12173353 A,2012-06-25,US 201161506242 P;;US 201213450881 A,2011-07-11,Electrical charging system having energy coupling arrangement for wireless energy transmission therebetween,"An electrical charging system (ECS) to electrically charge a battery includes a power transmitter, an energy coupling arrangement, at least one electrical signal shaping device (ESSD) including a controller, and an alignment means. The arrangement includes a first transducer disposed external to the vehicle and a second transducer attached with the vehicle. The alignment means communicates with the vehicle to ensure repeatable vehicle positioning so that the second transducer is positioned relative to the first transducer so that the second transducer receives the energy produced by the power transmitter wirelessly transmitted from the first transducer. The energy received by the second transducer is electrically shaped by the ESSD and further electrically transmitted through the ESSD as controlled by the controller to electrically charge the ESD. Methods to operate and electrically transmit energy through the ECS to electrically charge the EDS are also presented.
",DELPHI TECH INC,BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN VICTOR,,https://lens.org/153-981-378-540-551,Patent Application,yes,55,4,18,18,0,B60L2240/62;;Y02T90/16;;Y02T90/14;;Y04S30/14;;Y02T10/7072;;H02J50/10;;H02J50/80;;B60L53/35;;B60L53/38;;B60L53/665;;H02J50/90;;H02J7/00036;;B60L53/126;;B60L53/122;;H02J2310/48;;H02J7/00047;;Y02T10/70;;Y02T10/72;;Y02T90/12;;Y02T90/167;;H02J50/80;;H02J50/90;;H02J50/10;;B60L53/12;;B60L53/665;;B60L53/38;;B60L2240/62;;Y02T90/14;;Y04S30/14;;Y02T10/7072;;H02J7/00036;;B60Y2200/91;;B60Y2200/92;;H02J50/90;;H02J50/12;;B60L2240/62;;Y02T10/7072;;Y02T90/16;;Y02T90/14;;Y04S30/14;;H02J50/80;;H02J50/10;;H02J7/00;;B60L53/35;;B60L53/38;;B60L53/665;;H02J7/00036;;B60L53/122;;B60L53/126;;Y02T10/70;;Y02T10/72;;Y02T90/12;;Y02T90/167;;H02J7/00047;;H02J2310/48,B60L11/18;;H02J7/02,,0,0,,,,DISCONTINUED
260,WO,A1,WO 2016/183058 A1,005-868-446-036-402,2016-11-17,2016,US 2016/0031601 W,2016-05-10,US 201514708526 A,2015-05-11,WIRELESS BATTERY CHARGING SYSTEM VARYING MAGNETIC FIELD FREQUENCY TO MAINTAIN A DESIRE VOLTAGE-CURRENT PHASE RELATIONSHIP,"An electrical charging system (12) configured to wirelessly charge an energy storage device (14), such as a battery (14). The charging system (12) includes an off- transducer (18) in electrical communication with an alternating power source (48) and electromagnetically coupled to an on- vehicle transducer (20) connected to the energy storage device (14). A controller (53) adjusts a variable frequency oscillator (71) within the power transmitter (16), thereby changing the frequency of the sourced electrical power. The charging system (12) further includes a phase detection circuit (72) in communication with the controller (53) and the off-transducer (18) and configured to determine a phase difference between the alternating voltage and the alternating current supplied by the power source (48). The controller (53) is configured to adjust the variable frequency oscillator (71) based on the phase difference such that the frequency of the sourced electrical power maintains the phase difference within a desired range.",DELPHI TECH INC,BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN VICTOR,,https://lens.org/005-868-446-036-402,Patent Application,yes,5,1,6,15,0,B60L53/38;;B60L53/126;;B60L53/126;;B60L53/60;;B60Y2200/91;;B60Y2200/92;;H02J50/12;;H02J50/12;;H02J50/12;;H02J7/025;;H02J50/12;;H02J50/80;;H02J50/80;;H02J50/80;;Y02T10/70;;Y02T10/7072;;Y02T90/12;;Y02T90/14;;Y02T90/16;;Y02T90/16,B60L11/18;;H02J7/00;;H02J50/12;;H02J50/90,,1,0,,,See also references of EP 3294588A4,PENDING
261,EP,A1,EP 2740192 A1,026-659-410-440-21X,2014-06-11,2014,EP 12822929 A,2012-08-03,US 201161515865 P;;US 201213564754 A;;US 2012/0049426 W,2011-08-06,ELECTRICAL CHARGING SYSTEM,,DELPHI TECH INC,BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN VICTOR,,https://lens.org/026-659-410-440-21X,Patent Application,yes,0,0,7,15,0,B60L2210/30;;B60L2210/40;;Y02T90/14;;Y02T10/7072;;B60L53/14;;B60L53/36;;B60L50/66;;B60L53/122;;B60L53/126;;H02J2310/48;;H02J7/00712;;Y02T10/70;;Y02T10/72;;Y02T90/12;;H02J50/402;;H02J50/90;;H02J50/10;;H02J50/80;;H02J50/10;;H02J50/40;;B60L53/12;;B60L50/66;;B60L53/14;;B60L53/36;;B60L2210/30;;B60L2210/40;;Y02T10/7072;;Y02T90/14;;Y02T10/70;;Y02T10/72;;Y02T90/12;;H02J50/80;;H02J50/10;;B60L2210/30;;B60L2210/40;;Y02T90/14;;Y02T10/7072;;B60L50/66;;B60L53/36;;B60L53/14;;B60L53/122;;B60L53/126;;Y02T10/70;;Y02T10/72;;Y02T90/12;;H02J50/402;;H02J50/90;;H02J2310/48;;H02J7/00712,H02J7/00;;B60L11/18;;H02J5/00;;H02J7/02,,0,0,,,,DISCONTINUED
262,EP,A1,EP 3294588 A1,029-330-643-705-632,2018-03-21,2018,EP 16793361 A,2016-05-10,US 201514708526 A;;US 2016/0031601 W,2015-05-11,WIRELESS BATTERY CHARGING SYSTEM VARYING MAGNETIC FIELD FREQUENCY TO MAINTAIN A DESIRE VOLTAGE-CURRENT PHASE RELATIONSHIP,,DELPHI TECH INC,BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN VICTOR,APTIV TECHNOLOGIES LIMITED (2018-12-19),https://lens.org/029-330-643-705-632,Patent Application,yes,0,0,6,15,0,B60L53/38;;B60L53/126;;B60L53/126;;B60L53/60;;B60Y2200/91;;B60Y2200/92;;H02J50/12;;H02J50/12;;H02J50/12;;H02J7/025;;H02J50/12;;H02J50/80;;H02J50/80;;H02J50/80;;Y02T10/70;;Y02T10/7072;;Y02T90/12;;Y02T90/14;;Y02T90/16;;Y02T90/16,B60L11/18;;H02J7/00;;H02J50/12;;H02J50/90,,0,0,,,,DISCONTINUED
263,US,A1,US 2013/0033229 A1,092-973-350-492-278,2013-02-07,2013,US 201213562954 A,2012-07-31,US 201213562954 A;;US 201161515866 P,2011-08-06,METHOD AND SYSTEM TO ELECTRICALLY CHARGE AND DISCHARGE A BATTERY USING AN ELECTRICAL CHARGING SYSTEM THAT ELECTRICALLY COMMUNICATES WITH A REGENERATIVE BRAKING ELECTRICAL CIRCUIT,"A method to electrically charge an energy storage device (ESD) includes a step of electrically charging the ESD with energy transmitted through a regenerative braking electrical circuit (RBEC) disposed on vehicle by an electrical charging system (ECS) in electrical connection therewith. The ESD may be electrically charged by the ECS or a motor/generator that is also in electrical communication with the RBEC. The method also includes another step of electrically transmitting energy from the ESD through the RBEC and the ECS to supply energy to a power grid disposed external to the vehicle. An ECS for electrically charging an ESD is also presented that includes a first transducer, a second transducer that wirelessly receives energy from the first transducer, a motor/generator, and at least one electrical component which receives energy from the second transducer or energy from the motor/generator to electrically charge the ESD.",DELPHI TECH INC;;BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN VICTOR,BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN VICTOR,DELPHI TECHNOLOGIES INC (2012-08-02),https://lens.org/092-973-350-492-278,Patent Application,yes,5,10,2,3,0,H02J3/381;;Y02T90/16;;Y02T90/14;;Y04S10/126;;Y02T10/7072;;B60L53/38;;B60L53/36;;B60L55/00;;H02J7/00036;;B60L53/126;;H02J2310/48;;H02J50/90;;H02J7/00047;;Y02E60/00;;Y02T10/70;;Y02T90/12;;H02J50/10;;H02J50/20;;H02J50/80;;H02J50/90;;H02J3/381;;Y02T90/16;;Y04S10/126;;Y02T90/14;;Y02T10/7072;;B60L53/36;;B60L55/00;;B60L53/38;;H02J7/00036;;B60L53/126;;Y02E60/00;;Y02T10/70;;Y02T90/12;;H02J7/00047;;H02J2310/48,H02J7/00,320/109;;320/138,0,0,,,,DISCONTINUED
264,EP,A3,EP 0673982 A3,113-853-494-860-221,1996-01-10,1996,EP 95810165 A,1995-03-13,US 21097894 A,1994-03-21,Process for the manufacture of honeycomb products.,The substitution of a water-based phenolic thermosetting resin for a phenolic thermosetting resin in an organic solvent provides a safer and environmentally improved method for making honeycomb core. Improved processing characteristics in components manufactured from such honeycomb core are observed.,CIBA GEIGY AG,DANVER DALE;;CAO LIQUN;;BOYER RONALD;;HEITKAMP RICHARD RENFREW,HEXCEL CORPORATION (1996-08-07),https://lens.org/113-853-494-860-221,Search Report,yes,3,0,7,7,0,B29D99/0089;;B29L2031/608;;C09D161/06;;B29D99/0089;;C09D161/06;;B29L2031/608,B32B3/12;;B29B15/12;;B29D99/00;;B32B27/42;;C09D161/06,,0,0,,,,EXPIRED
265,US,B2,US 9379571 B2,135-968-104-111-54X,2016-06-28,2016,US 201213450881 A,2012-04-19,US 201213450881 A;;US 201161506242 P,2011-07-11,Electrical charging system having energy coupling arrangement for wireless energy transmission therebetween,"An electrical charging system configured to charge a battery includes a power transmitter, an energy coupling arrangement, an electrical signal shaping device including a controller, and an alignment means. The arrangement includes a first inductive coil disposed external to the vehicle and a second inductive coil attached with the vehicle. The alignment means communicates with the vehicle to ensure repeatable vehicle positioning so that the second inductive coil is positioned relative to the first inductive coil so that the second inductive coil receives the energy produced by the power transmitter wirelessly transmitted from the first inductive coil. The energy received by the second inductive coil is electrically shaped by the electrical signal shaping device and further transmitted through the electrical signal shaping device as controlled by the controller to charge the battery. Methods for transmitting energy through the electrical charging system to charge the battery are also presented.",BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN VICTOR;;DELPHI TECH INC,BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN VICTOR,APTIV TECHNOLOGIES LIMITED (2018-01-01);;DELPHI TECHNOLOGIES INC (2012-04-18);;APTIV TECHNOLOGIES AG (2023-10-06),https://lens.org/135-968-104-111-54X,Granted Patent,yes,13,16,18,18,0,B60L2240/62;;Y02T90/16;;Y02T90/14;;Y04S30/14;;Y02T10/7072;;H02J50/10;;H02J50/80;;B60L53/35;;B60L53/38;;B60L53/665;;H02J50/90;;H02J7/00036;;B60L53/126;;B60L53/122;;H02J2310/48;;H02J7/00047;;Y02T10/70;;Y02T10/72;;Y02T90/12;;Y02T90/167;;H02J50/80;;H02J50/90;;H02J50/10;;B60L53/12;;B60L53/665;;B60L53/38;;B60L2240/62;;Y02T90/14;;Y04S30/14;;Y02T10/7072;;H02J7/00036;;B60Y2200/91;;B60Y2200/92;;H02J50/90;;H02J50/12;;B60L2240/62;;Y02T10/7072;;Y02T90/16;;Y02T90/14;;Y04S30/14;;H02J50/80;;H02J50/10;;H02J7/00;;B60L53/35;;B60L53/38;;B60L53/665;;H02J7/00036;;B60L53/122;;B60L53/126;;Y02T10/70;;Y02T10/72;;Y02T90/12;;Y02T90/167;;H02J7/00047;;H02J2310/48,H02J7/00;;B60K1/00;;B60K6/20;;B60L11/18;;B60W10/24;;H02J7/02,,0,0,,,,ACTIVE
266,DE,T2,DE 69511747 T2,166-044-970-622-72X,2000-03-23,2000,DE 69511747 T,1995-03-13,US 21097894 A,1994-03-21,Verfahren zur Herstellung von Wabenkörpern,,HEXCEL CORP,DANVER DALE;;CAO LIQUN;;BOYER RONALD;;HEITKAMP RICHARD RENFREW,,https://lens.org/166-044-970-622-72X,Granted Patent,no,0,0,7,7,0,B29D99/0089;;B29L2031/608;;C09D161/06;;B29D99/0089;;C09D161/06;;B29L2031/608,B32B3/12;;B29B15/12;;B29D99/00;;B32B27/42;;C09D161/06,,0,0,,,,EXPIRED
267,EP,A3,EP 2546950 A3,183-942-333-948-779,2017-11-01,2017,EP 12173342 A,2012-06-25,US 201161506242 P;;US 201213450881 A,2011-07-11,Electrical charging system having energy coupling arrangement for wireless energy transmission therebetween.,"An electrical charging system (ECS) to electrically charge a battery includes a power transmitter, an energy coupling arrangement, at least one electrical signal shaping device (ESSD) including a controller, and an alignment means. The arrangement includes a first transducer disposed external to the vehicle and a second transducer attached with the vehicle. The alignment means communicates with the vehicle to ensure repeatable vehicle positioning so that the second transducer is positioned relative to the first transducer so that the second transducer receives the energy produced by the power transmitter wirelessly transmitted from the first transducer. The energy received by the second transducer is electrically shaped by the ESSD and further electrically transmitted through the ESSD as controlled by the controller to electrically charge the ESD. Methods to operate and electrically transmit energy through the ECS to electrically charge the EDS are also presented.
",DELPHI TECH INC,BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN VICTOR,,https://lens.org/183-942-333-948-779,Search Report,yes,2,0,18,18,0,B60L2240/62;;Y02T90/16;;Y02T90/14;;Y04S30/14;;Y02T10/7072;;H02J50/10;;H02J50/80;;B60L53/35;;B60L53/38;;B60L53/665;;H02J50/90;;H02J7/00036;;B60L53/126;;B60L53/122;;H02J2310/48;;H02J7/00047;;Y02T10/70;;Y02T10/72;;Y02T90/12;;Y02T90/167;;H02J50/80;;H02J50/90;;H02J50/10;;B60L53/12;;B60L53/665;;B60L53/38;;B60L2240/62;;Y02T90/14;;Y04S30/14;;Y02T10/7072;;H02J7/00036;;B60Y2200/91;;B60Y2200/92;;H02J50/90;;H02J50/12;;B60L2240/62;;Y02T10/7072;;Y02T90/16;;Y02T90/14;;Y04S30/14;;H02J50/80;;H02J50/10;;H02J7/00;;B60L53/35;;B60L53/38;;B60L53/665;;H02J7/00036;;B60L53/122;;B60L53/126;;Y02T10/70;;Y02T10/72;;Y02T90/12;;Y02T90/167;;H02J7/00047;;H02J2310/48,H02J7/02;;B60L11/18,,0,0,,,,DISCONTINUED
268,MX,A,MX 2019004564 A,058-485-910-126-36X,2019-09-18,2019,MX 2019004564 A,2017-10-19,US 201662410671 P;;US 2017/0057398 W,2016-10-20,LOW PROFILE NYLON INSERT LOCK NUT.,"The present invention relates to prevailing torque lock nuts and, more particularly, to a low profile lock nut that maintains the same strength as its higher profile counterparts. The present lock nut is a non-metallic lock having an inner recess so as to receive a plastic insert, such as a nylon insert. In some embodiments, the plastic insert is a temperature resistant plastic insert capable of withstanding high temperatures. Further, in some embodiments, the present lock nut is manufactured to have increased hardness levels and subject to enhanced plating process that ensure superior corrosion resistance.",RAMCO SPECIALTIES INC,MARK S BOYER;;RICHARD A MALSON;;DANIEL B DONOVAN,,https://lens.org/058-485-910-126-36X,Patent Application,no,0,0,6,6,0,C25D7/003;;F16B39/34;;F16B39/34;;F16B33/008;;F16B33/008;;F16B33/06,F16B39/34;;F16B37/00;;F16B39/00;;F16B39/01;;F16B39/22;;F16B39/28,,0,0,,,,PENDING
269,US,A,US 3975408 A,078-792-951-327-788,1976-08-17,1976,US 30262472 A,1972-10-31,US 30262472 A;;US 4111670 A,1970-05-27,Color stabilization of refined dicarboxylic acid anhydrides,"Refined dicarboxylic acid anhydrides such as maleic anhydride are provided with improved color stability by a treating agent selected from the group consisting of chlorine and halides or elements in group IVb of the periodic table, the transition elements, vanadium, chromium, manganese, mercury, silicon, phosphorus, bismuth, antimony, lead, cerium and sulfur.",MONSANTO CO,BOYER RONALD J;;STENSETH RAYMOND E;;SHEEHAN RICHARD J,,https://lens.org/078-792-951-327-788,Granted Patent,yes,6,9,1,9,0,C07C51/573;;C07C51/573,C07C51/573,2603468 R,0,0,,,,EXPIRED
270,US,A1,US 2012/0247039 A1,105-453-996-465-253,2012-10-04,2012,US 201213494290 A,2012-06-12,US 201213494290 A;;US 42657509 A;;US 4619408 P,2008-04-18,Extruded Seal Plate for Horizontal Insulated Composite Architectural Panel Vertical End Joints,A seal plate for building panels includes an elongate body having a first side and a second side. The first side of the elongate body includes first and second seals and a recessed channel. The first and second seals and the recessed channel extend at least a portion of the length of the elongate body. The recessed channel is positioned between the first and second seals.,BOYER KEITH D;;BROW RICHARD A;;BERTRAM RALPH E;;CENTRIA,BOYER KEITH D;;BROW RICHARD A;;BERTRAM RALPH E,CENTRIA (2009-04-16);;NCI GROUP INC (2020-02-17);;NUCOR INSULATED PANEL GROUP LLC (2021-07-27),https://lens.org/105-453-996-465-253,Patent Application,yes,0,1,4,4,0,E04F13/0889;;E04F13/0889,E04B1/684,52/272;;277/648,0,0,,,,ACTIVE
271,EP,A2,EP 2546951 A2,137-838-095-406-801,2013-01-16,2013,EP 12173350 A,2012-06-25,US 201161506242 P;;US 201213450881 A,2011-07-11,Electrical charging system having energy coupling arrangement for wireless energy transmission therebetween,"An electrical charging system (ECS) to electrically charge a battery includes a power transmitter, an energy coupling arrangement, at least one electrical signal shaping device (ESSD) including a controller, and an alignment means. The arrangement includes a first transducer disposed external to the vehicle and a second transducer attached with the vehicle. The alignment means communicates with the vehicle to ensure repeatable vehicle positioning so that the second transducer is positioned relative to the first transducer so that the second transducer receives the energy produced by the power transmitter wirelessly transmitted from the first transducer. The energy received by the second transducer is electrically shaped by the ESSD and further electrically transmitted through the ESSD as controlled by the controller to electrically charge the ESD. Methods to operate and electrically transmit energy through the ECS to electrically charge the EDS are also presented.
",DELPHI TECH INC,BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN VICTOR,,https://lens.org/137-838-095-406-801,Patent Application,yes,55,0,18,18,0,B60L2240/62;;Y02T90/16;;Y02T90/14;;Y04S30/14;;Y02T10/7072;;H02J50/10;;H02J50/80;;B60L53/35;;B60L53/38;;B60L53/665;;H02J50/90;;H02J7/00036;;B60L53/126;;B60L53/122;;H02J2310/48;;H02J7/00047;;Y02T10/70;;Y02T10/72;;Y02T90/12;;Y02T90/167;;H02J50/80;;H02J50/90;;H02J50/10;;B60L53/12;;B60L53/665;;B60L53/38;;B60L2240/62;;Y02T90/14;;Y04S30/14;;Y02T10/7072;;H02J7/00036;;B60Y2200/91;;B60Y2200/92;;H02J50/90;;H02J50/12;;B60L2240/62;;Y02T10/7072;;Y02T90/16;;Y02T90/14;;Y04S30/14;;H02J50/80;;H02J50/10;;H02J7/00;;B60L53/35;;B60L53/38;;B60L53/665;;H02J7/00036;;B60L53/122;;B60L53/126;;Y02T10/70;;Y02T10/72;;Y02T90/12;;Y02T90/167;;H02J7/00047;;H02J2310/48,H02J7/00,,0,0,,,,DISCONTINUED
272,CA,A1,CA 2387233 A1,138-322-607-461-273,2002-11-21,2002,CA 2387233 A,2002-05-21,US 29234901 P,2001-05-21,POWERTRAIN MODULE FOR ZERO TURN RADIUS VEHICLE,"A powertrain module for a zero turn radius vehicle, such as a tractor o r mower, the powertrain module generally including a structural member or mounting plate to which an engine, a pair of hydrostatic transmission modules, and a pair of axle drive units are attached to form a self contained powertrain module whi ch may be shipped as a single packaged unit for installation into the zero turn radius implement. The mounting plate provides structural rigidity between the powertrain components attached thereto, and the mounting plate of the powertrain module may be attached directly to the frame of the vehicle, or alternatively, may itse lf serve as a structural frame member for the vehicle.",TECUMSEH PRODUCTS CO,RUEBUSCH RICHARD T;;BOYER SCOTT G;;MCDONNER ORVILLE R,,https://lens.org/138-322-607-461-273,Patent Application,no,0,0,4,4,0,B60K17/04;;B60K17/04;;B60K17/043;;B60K17/043;;B60K17/10;;B60K17/10;;B60K17/105;;B60K17/105,B60K17/04;;B60K17/10,,0,0,,,,DISCONTINUED
273,US,B1,US 6175319 B1,145-257-829-437-389,2001-01-16,2001,US 31556599 A,1999-05-20,US 31556599 A,1999-05-20,Power-tailored write-current method,"A method of generating an encoded signal from a sequential stream of digital data, where the encoded signal has a non-power carrying null state and a power carrying active state with two opposing polarities. Logical one bits are distinguished from logical zero bits by inverting the encoded signal's polarity at the start of only the logical one bits. The encoded signal is set to the active state during a bit set-up period before, and held in the active state during a bit hold period after each polarity inversion. At other times the encoded signal is set to the null state. The method may include the addition of equalization pulses during strings of consecutive logical zero bits to keep the encoded signal from remaining in the null state for extended periods. Each equalization pulse may be preceded by an equalization set-up period and followed by an equalization hold period where the encoded signal is in the active state. In the preferred embodiment the set-up periods, hold periods, and equalization pulse periods are one-third the duration period of the logical bits.",STORAGE TECHNOLOGY CORP,SCHNEIDER RICHARD CRANE;;BOYER KEITH GARY;;KOREN NORMAN LEE,STORAGE TECHNOLOGY CORP (1999-05-19),https://lens.org/145-257-829-437-389,Granted Patent,yes,2,21,1,1,0,G11B20/10009;;G11B20/10009;;H03M5/06;;H03M5/06,G11B20/10;;H03M5/06,341/68;;360/65,0,0,,,,EXPIRED
274,DE,T2,DE 60208682 T2,176-245-373-083-637,2006-08-24,2006,DE 60208682 T,2002-05-29,GB 0113232 A;;EP 0205884 W,2001-05-31,VERFAHREN ZUR HERSTELLUNG EINES THIAZOL-PPAR-LIGANDEN SOWIE DESSEN POLYMORPHE,,SMITHKLINE BEECHAM CORP,BOYER THIERRY;;DAY JANE;;WHITEHEAD JONATHAN;;HENSON RICHARD ANTHONY,,https://lens.org/176-245-373-083-637,Granted Patent,no,0,0,27,27,0,C07D277/56;;A61P1/14;;A61P29/00;;A61P3/00;;A61P3/10;;A61P3/04;;A61P3/06;;A61P9/04;;A61P9/10;;C07D277/56;;C07D277/56,C07D277/20;;A61K31/426;;C07D277/56;;A61P1/14;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/04;;A61P9/10;;A61P29/00,,0,0,,,,EXPIRED
275,US,B2,US 9725003 B2,180-614-511-103-962,2017-08-08,2017,US 201514708526 A,2015-05-11,US 201514708526 A;;US 201213564754 A;;US 201161515865 P,2011-08-06,Wireless battery charging system varying magnetic field frequency to maintain a desired voltage-current phase relationship,"An electrical charging system configured to wirelessly charge an energy storage device, such as a battery. The charging system includes an off-transducer in electrical communication with an alternating power source and electromagnetically coupled to an on-vehicle transducer connected to the energy storage device. A controller adjusts a variable frequency oscillator within the power transmitter, thereby changing the frequency of the sourced electrical power. The charging system further includes a phase detection circuit in communication with the controller and the off-transducer and configured to determine a phase difference between the alternating voltage and the alternating current supplied by the power source. The controller is configured to adjust the variable frequency oscillator based on the phase difference such that the frequency of the sourced electrical power maintains the phase difference within a desired range.",DELPHI TECH INC,BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN VICTOR,APTIV TECHNOLOGIES LIMITED (2018-01-01);;DELPHI TECHNOLOGIES INC (2015-05-11);;APTIV TECHNOLOGIES AG (2023-10-06),https://lens.org/180-614-511-103-962,Granted Patent,yes,31,0,2,15,0,Y02T90/14;;B60L2210/30;;B60L2210/40;;B60L2240/36;;Y02T90/16;;Y02T10/7072;;B60L53/14;;B60L50/66;;B60L53/126;;B60L53/122;;H02J2310/48;;H02J7/00712;;Y02T10/70;;Y02T10/72;;H02J50/80;;H02J50/90;;H02J50/12;;H02J50/12;;H02J50/80;;H02J50/90;;Y02T90/14;;B60L2210/30;;B60L2210/40;;B60L2240/36;;Y02T90/16;;Y02T10/7072;;B60L53/14;;B60L50/66;;B60L53/122;;B60L53/126;;Y02T10/70;;Y02T10/72;;Y02T90/12;;B60L53/12;;H02J2310/48;;H02J7/00712,H02J7/00;;B60L11/18;;H02J5/00;;H02J7/02,,0,0,,,,ACTIVE
276,US,A,US 3428871 A,052-350-032-436-498,1969-02-18,1969,US 3428871D A,1966-04-14,US 54263966 A,1966-04-14,SEMICONDUCTOR HOUSING STRUCTURE HAVING FLAT STRAP WITH RE-ENTRANT BENDS FOR ONE TERMINAL,,INT RECTIFIER CORP,SCOTT ANGUS A;;BOYER JOHN L;;HARTMAN RICHARD A,,https://lens.org/052-350-032-436-498,Granted Patent,no,8,14,5,6,0,H01L23/49562;;H01L23/49562;;H01L23/24;;H01L23/24;;H01L23/488;;H01L23/488;;H01L2924/0002;;H01L2924/0002,H01L23/24;;H01L23/488;;H01L23/495,317/234,0,0,,,,EXPIRED
277,US,A,US 3903117 A,060-261-735-382-401,1975-09-02,1975,US 27654972 A,1972-07-31,US 27654972 A;;US 4111670 A,1970-05-27,Color stabilization of refined maleic acid anhydride,Refined maleic anhydride is provided with improved color stability by the addition of a treating agent comprising organic compounds containing a labile halogen.,MONSANTO CO,STENSETH RAYMOND E;;BOYER RONALD J;;SHEEHAN RICHARD J,,https://lens.org/060-261-735-382-401,Granted Patent,no,1,10,1,9,0,C07C51/573;;C07C51/573,C07C51/573,260/346.8,0,0,,,,EXPIRED
278,KR,A,KR 20170135950 A,093-510-352-145-988,2017-12-08,2017,KR 20177032511 A,2016-05-10,US 201514708526 A;;US 2016/0031601 W,2015-05-11,자기장 주파수를 가변시켜 바람직한 전압-전류 위상 관계를 유지하는 무선 배터리 충전 시스템,"에너지 저장 디바이스(14), 이를테면 배터리(14)를 무선으로 충전하도록 구성되는 전기 충전 시스템(12). 충전 시스템(12)은 교류 전력원(48)과 전기 통신하는 그리고 에너지 저장 디바이스(14)에 접속된 온-차량 트랜스듀서(20)에 전자기적으로 커플링된 오프-트랜스듀서(18)를 포함한다. 제어기(53)가 전력 송신기(16) 내의 가변 주파수 발진기(71)를 조절함으로써, 소싱되는 전기 전력의 주파수를 변경한다. 충전 시스템(12)은 제어기(53) 및 오프-트랜스듀서(18)와 통신하는 그리고 전력원(48)에 의해 공급된 교류 전압과 교류 전류 사이의 위상 차이를 결정하도록 구성되는 위상 검출 회로(72)를 더 포함한다. 제어기(53)는 위상 차이에 기초하여 가변 주파수 발진기(71)를 조절하도록 구성되어, 소싱된 전기 전력의 주파수가 바람직한 범위 내의 위상 차이를 유지하도록 한다.",DELPHI TECH INC,BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN VICTOR,,https://lens.org/093-510-352-145-988,Patent Application,no,0,0,6,15,0,B60L53/38;;B60L53/126;;B60L53/126;;B60L53/60;;B60Y2200/91;;B60Y2200/92;;H02J50/12;;H02J50/12;;H02J50/12;;H02J7/025;;H02J50/12;;H02J50/80;;H02J50/80;;H02J50/80;;Y02T10/70;;Y02T10/7072;;Y02T90/12;;Y02T90/14;;Y02T90/16;;Y02T90/16,B60L11/18;;H02J50/12;;H02J50/80,,0,0,,,,DISCONTINUED
279,EP,A3,EP 2546093 A3,096-530-527-433-349,2018-03-07,2018,EP 12173353 A,2012-06-25,US 201161506242 P;;US 201213450881 A,2011-07-11,Electrical charging system having energy coupling arrangement for wireless energy transmission therebetween,"An electrical charging system (ECS) to electrically charge a battery includes a power transmitter, an energy coupling arrangement, at least one electrical signal shaping device (ESSD) including a controller, and an alignment means. The arrangement includes a first transducer disposed external to the vehicle and a second transducer attached with the vehicle. The alignment means communicates with the vehicle to ensure repeatable vehicle positioning so that the second transducer is positioned relative to the first transducer so that the second transducer receives the energy produced by the power transmitter wirelessly transmitted from the first transducer. The energy received by the second transducer is electrically shaped by the ESSD and further electrically transmitted through the ESSD as controlled by the controller to electrically charge the ESD. Methods to operate and electrically transmit energy through the ECS to electrically charge the EDS are also presented.
",DELPHI TECH INC,BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN VICTOR,,https://lens.org/096-530-527-433-349,Search Report,yes,3,0,18,18,0,B60L2240/62;;Y02T90/16;;Y02T90/14;;Y04S30/14;;Y02T10/7072;;H02J50/10;;H02J50/80;;B60L53/35;;B60L53/38;;B60L53/665;;H02J50/90;;H02J7/00036;;B60L53/126;;B60L53/122;;H02J2310/48;;H02J7/00047;;Y02T10/70;;Y02T10/72;;Y02T90/12;;Y02T90/167;;H02J50/80;;H02J50/90;;H02J50/10;;B60L53/12;;B60L53/665;;B60L53/38;;B60L2240/62;;Y02T90/14;;Y04S30/14;;Y02T10/7072;;H02J7/00036;;B60Y2200/91;;B60Y2200/92;;H02J50/90;;H02J50/12;;B60L2240/62;;Y02T10/7072;;Y02T90/16;;Y02T90/14;;Y04S30/14;;H02J50/80;;H02J50/10;;H02J7/00;;B60L53/35;;B60L53/38;;B60L53/665;;H02J7/00036;;B60L53/122;;B60L53/126;;Y02T10/70;;Y02T10/72;;Y02T90/12;;Y02T90/167;;H02J7/00047;;H02J2310/48,B60L11/18;;H02J7/00;;H02J7/02,,0,0,,,,DISCONTINUED
280,EP,A2,EP 2546953 A2,136-071-977-504-721,2013-01-16,2013,EP 12173344 A,2012-06-25,US 201161506242 P;;US 201213450881 A,2011-07-11,Electrical charging system having energy coupling arrangement for wireless energy transmission therebetween.,"An electrical charging system (ECS) to electrically charge a battery includes a power transmitter, an energy coupling arrangement, at least one electrical signal shaping device (ESSD) including a controller, and an alignment means. The arrangement includes a first transducer disposed external to the vehicle and a second transducer attached with the vehicle. The alignment means communicates with the vehicle to ensure repeatable vehicle positioning so that the second transducer is positioned relative to the first transducer so that the second transducer receives the energy produced by the power transmitter wirelessly transmitted from the first transducer. The energy received by the second transducer is electrically shaped by the ESSD and further electrically transmitted through the ESSD as controlled by the controller to electrically charge the ESD. Methods to operate and electrically transmit energy through the ECS to electrically charge the EDS are also presented.
",DELPHI TECH INC,BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN VICTOR,,https://lens.org/136-071-977-504-721,Patent Application,yes,55,1,18,18,0,B60L2240/62;;Y02T90/16;;Y02T90/14;;Y04S30/14;;Y02T10/7072;;H02J50/10;;H02J50/80;;B60L53/35;;B60L53/38;;B60L53/665;;H02J50/90;;H02J7/00036;;B60L53/126;;B60L53/122;;H02J2310/48;;H02J7/00047;;Y02T10/70;;Y02T10/72;;Y02T90/12;;Y02T90/167;;H02J50/80;;H02J50/90;;H02J50/10;;B60L53/12;;B60L53/665;;B60L53/38;;B60L2240/62;;Y02T90/14;;Y04S30/14;;Y02T10/7072;;H02J7/00036;;B60Y2200/91;;B60Y2200/92;;H02J50/90;;H02J50/12;;B60L2240/62;;Y02T10/7072;;Y02T90/16;;Y02T90/14;;Y04S30/14;;H02J50/80;;H02J50/10;;H02J7/00;;B60L53/35;;B60L53/38;;B60L53/665;;H02J7/00036;;B60L53/122;;B60L53/126;;Y02T10/70;;Y02T10/72;;Y02T90/12;;Y02T90/167;;H02J7/00047;;H02J2310/48,H02J7/02,,0,0,,,,DISCONTINUED
281,WO,A1,WO 2013/022681 A1,179-057-297-907-315,2013-02-14,2013,US 2012/0049241 W,2012-08-02,US 201161515866 P;;US 201213562954 A,2011-08-06,METHOD AND SYSTEM TO ELECTRICALLY CHARGE AND DISCHARGE A BATTERY USING AN ELECTRICAL CHARGING SYSTEM THAT ELECTRICALLY COMMUNICATES WITH A REGENERATIVE BRAKING ELECTRICAL CIRCUIT,"A method to electrically charge an energy storage device (ESD) includes a step of electrically charging the ESD with energy transmitted through a regenerative braking electrical circuit (RBEC) disposed on vehicle by an electrical charging system (ECS) in electrical connection therewith. The ESD may be electrically charged by the ECS or a motor/generator that is also in electrical communication with the RBEC. The method also includes another step of electrically transmitting energy from the ESD through the RBEC and the ECS to supply energy to a power grid disposed external to the vehicle. An ECS for electrically charging an ESD is also presented that includes a first transducer, a second transducer that wirelessly receives energy from the first transducer, a motor/generator, and at least one electrical component which receives energy from the second transducer or energy from the motor/generator to electrically charge the ESD.",DELPHI TECH INC;;BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN VICTOR,BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN VICTOR,,https://lens.org/179-057-297-907-315,Patent Application,yes,5,2,2,3,0,H02J3/381;;Y02T90/16;;Y02T90/14;;Y04S10/126;;Y02T10/7072;;B60L53/38;;B60L53/36;;B60L55/00;;H02J7/00036;;B60L53/126;;H02J2310/48;;H02J50/90;;H02J7/00047;;Y02E60/00;;Y02T10/70;;Y02T90/12;;H02J50/10;;H02J50/20;;H02J50/80;;H02J50/90;;H02J3/381;;Y02T90/16;;Y04S10/126;;Y02T90/14;;Y02T10/7072;;B60L53/36;;B60L55/00;;B60L53/38;;H02J7/00036;;B60L53/126;;Y02E60/00;;Y02T10/70;;Y02T90/12;;H02J7/00047;;H02J2310/48,B60K16/00,,0,0,,,,PENDING
282,EP,A1,EP 3529506 A1,026-539-852-857-438,2019-08-28,2019,EP 17863118 A,2017-10-19,US 201662410671 P;;US 2017/0057398 W,2016-10-20,LOW PROFILE NYLON INSERT LOCK NUT,,RAMCO SPECIALTIES INC,BOYER MARK S;;MALSON RICHARD A;;DONOVAN DANIEL B,,https://lens.org/026-539-852-857-438,Patent Application,yes,0,0,6,6,0,C25D7/003;;F16B39/34;;F16B39/34;;F16B33/008;;F16B33/008;;F16B33/06,F16B39/34;;F16B37/00;;F16B39/00;;F16B39/01;;F16B39/22;;F16B39/28,,0,0,,,,DISCONTINUED
283,EP,A4,EP 2740192 A4,007-224-790-363-882,2015-04-29,2015,EP 12822929 A,2012-08-03,US 201161515865 P;;US 201213564754 A;;US 2012/0049426 W,2011-08-06,ELECTRICAL CHARGING SYSTEM,,DELPHI TECH INC,BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN VICTOR,,https://lens.org/007-224-790-363-882,Search Report,no,4,0,7,15,0,B60L2210/30;;B60L2210/40;;Y02T90/14;;Y02T10/7072;;B60L53/14;;B60L53/36;;B60L50/66;;B60L53/122;;B60L53/126;;H02J2310/48;;H02J7/00712;;Y02T10/70;;Y02T10/72;;Y02T90/12;;H02J50/402;;H02J50/90;;H02J50/10;;H02J50/80;;H02J50/10;;H02J50/40;;B60L53/12;;B60L50/66;;B60L53/14;;B60L53/36;;B60L2210/30;;B60L2210/40;;Y02T10/7072;;Y02T90/14;;Y02T10/70;;Y02T10/72;;Y02T90/12;;H02J50/80;;H02J50/10;;B60L2210/30;;B60L2210/40;;Y02T90/14;;Y02T10/7072;;B60L50/66;;B60L53/36;;B60L53/14;;B60L53/122;;B60L53/126;;Y02T10/70;;Y02T10/72;;Y02T90/12;;H02J50/402;;H02J50/90;;H02J2310/48;;H02J7/00712,H02J7/00;;B60L11/18;;H02J5/00;;H02J7/02,,1,0,,,See also references of WO 2013022722A1,DISCONTINUED
284,DE,D1,DE 69511747 D1,036-492-255-147-910,1999-10-07,1999,DE 69511747 T,1995-03-13,US 21097894 A,1994-03-21,Verfahren zur Herstellung von Wabenkörpern,,HEXCEL CORP,DANVER DALE;;CAO LIQUN;;BOYER RONALD;;HEITKAMP RICHARD RENFREW,,https://lens.org/036-492-255-147-910,Granted Patent,no,0,0,7,7,0,B29D99/0089;;B29L2031/608;;C09D161/06;;B29D99/0089;;C09D161/06;;B29L2031/608,B32B3/12;;B29B15/12;;B29D99/00;;B32B27/42;;C09D161/06,,0,0,,,,EXPIRED
285,CN,A,CN 103858306 A,037-609-394-326-858,2014-06-11,2014,CN 201280049035 A,2012-08-03,US 2012/0049426 W;;US 201161515865 P;;US 201213564754 A,2011-08-06,Electrical charging system,"An electrical charging system (ECS) is used to electrically charge an energy storage device (ESD) using wireless electromagnetic or inductive charging. The ECS includes a voltage-controlled oscillator (VCO) electrical circuit, a first transducer, and a plurality of second transducers. The VCO electrical circuit sequentially excites a plurality of coils in a first transducer to select one of a plurality of second transducers in which to transfer energy when the ESD is electrically charged. ECS power efficiency is measured during the excitation of the plurality of coils and used to determine whether the ECS uses the electromagnetic or inductive approach to electrically charge the ESD. The VCO electrical circuit also assists to maintain an optimum ECS power efficiency during electrical charging of the ESD. A method to electrically charge an ESD associated with a first vehicle and an ESD associated with a second vehicle with the ECS is also presented.",DELPHI TECH INC,BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN VICTOR,,https://lens.org/037-609-394-326-858,Patent Application,no,5,4,7,15,0,B60L2210/30;;B60L2210/40;;Y02T90/14;;Y02T10/7072;;B60L53/14;;B60L53/36;;B60L50/66;;B60L53/122;;B60L53/126;;H02J2310/48;;H02J7/00712;;Y02T10/70;;Y02T10/72;;Y02T90/12;;H02J50/402;;H02J50/90;;H02J50/10;;H02J50/80;;H02J50/10;;H02J50/40;;B60L53/12;;B60L50/66;;B60L53/14;;B60L53/36;;B60L2210/30;;B60L2210/40;;Y02T10/7072;;Y02T90/14;;Y02T10/70;;Y02T10/72;;Y02T90/12;;H02J50/80;;H02J50/10;;B60L2210/30;;B60L2210/40;;Y02T90/14;;Y02T10/7072;;B60L50/66;;B60L53/36;;B60L53/14;;B60L53/122;;B60L53/126;;Y02T10/70;;Y02T10/72;;Y02T90/12;;H02J50/402;;H02J50/90;;H02J2310/48;;H02J7/00712,H02J7/00,,0,0,,,,DISCONTINUED
286,US,B2,US 8261499 B2,085-368-016-222-708,2012-09-11,2012,US 42657509 A,2009-04-20,US 42657509 A;;US 4619408 P,2008-04-18,Extruded seal plate for horizontal insulated composite architectural panel vertical end joints,A seal plate for building panels includes an elongate body having a first side and second side. The first side of the elongate body includes first and second seals and a recessed channel. The first and second seals and the recessed channel extend at least a portion of the length of the elongate body. The recessed channel is positioned between the first and second seals.,BOYER KEITH D;;BROW RICHARD A;;BERTRAM RALPH E;;CENTRIA,BOYER KEITH D;;BROW RICHARD A;;BERTRAM RALPH E,CENTRIA (2009-04-16);;NCI GROUP INC (2020-02-17);;NUCOR INSULATED PANEL GROUP LLC (2021-07-27),https://lens.org/085-368-016-222-708,Granted Patent,yes,19,2,4,4,0,E04F13/0889;;E04F13/0889,E04B2/62,52/235;;52/396.04,0,0,,,,ACTIVE
287,US,B2,US 6578250 B2,097-843-813-378-014,2003-06-17,2003,US 6162502 A,2002-02-01,US 6162502 A;;US 39753499 A,1999-09-16,Method for constructing a sign frame assembly,"
    A sign frame assembly for supporting a flexible fascia. In one embodiment, a frame member extends in a first direction and has first and second bracket-mounting sections spaced apart from each other in the first direction. First and second brackets have inner and outer opposite ends. The inner end of the first bracket is attached to the first bracket-mounting section of the first frame member. The inner end of the second bracket are pivotally mounted to the second bracket-mounting section of the frame member. First and second elongated fascia attachment members are affixed respectively to the outer ends of the first and second brackets. A flexible fascia having oppositely disposed edges is connected to the first and second elongated members. A bias member is operatively disposed between the frame member and the second bracket such that the bias member exerts a rotational force on the second bracket in a direction tending to spread apart the elongated fascia attachment members and tension the flexible fascia therebetween. Additional embodiments utilizing biased pivotal fascia tension members are disclosed. 
",LSI INDUSTRIES INC,BOYER JOHN D;;MAKSTALLER RONALD W;;GRIMES RICHARD SCOTT,,https://lens.org/097-843-813-378-014,Granted Patent,yes,20,2,6,6,0,G09F17/00;;G09F17/00;;G09F13/04;;G09F13/04;;G09F15/0025;;G09F15/0025;;Y10T29/49716;;Y10T29/49716;;Y10T29/4984;;Y10T29/4984;;Y10T29/49863;;Y10T29/49863;;Y10T29/49867;;Y10T29/49867;;Y10T29/4987;;Y10T29/4987,G09F13/04;;G09F15/00;;G09F17/00,29/446;;29/448;;40/603,0,0,,,,EXPIRED
288,US,A1,US 2012/0261211 A1,144-219-241-292-429,2012-10-18,2012,US 201113066503 A,2011-04-15,US 201113066503 A,2011-04-15,Flexible muffler for use in aircraft environmental control systems and method of manufacture,A flexible muffler for use in an aircraft environmental system includes a flexible body having a porous inner layer and an air impervious outer layer both supported by a helically wound adhesively attached reinforcing cord. The flexible body includes a pair of connecting end caps at opposed ends thereof which are joined to the flexible body in an air tight attachment. The resulting muffler provides acoustic energy absorptive and is readily flexed and bent to accommodate space restrictions within the environmental control system of the aircraft.,TOMERLIN REG;;HARWOOD ALLEN W;;HOFF RICHARD;;BOYER DAVID,TOMERLIN REG;;HARWOOD ALLEN W;;HOFF RICHARD;;BOYER DAVID,,https://lens.org/144-219-241-292-429,Patent Application,yes,0,4,2,2,0,F01N13/1816;;F01N13/1816;;F01N1/04;;F01N1/04;;F01N1/24;;F01N1/24,F01N1/24;;B29C53/58,181/256;;156/173,0,0,,,,INACTIVE
289,US,A1,US 2002/0179341 A1,172-908-792-506-154,2002-12-05,2002,US 15205502 A,2002-05-21,US 15205502 A;;US 29234901 P,2001-05-21,Powertrain module for zero turn radius vehicle,"
   A powertrain module for a zero turn radius vehicle, such as a tractor or mower, the powertrain module generally including a structural member or mounting plate to which an engine, a pair of hydrostatic transmission modules, and a pair of axle drive units are attached to form a self-contained powertrain module which may be shipped as a single packaged unit for installation into the zero turn radius implement. The mounting plate provides structural rigidity between the powertrain components attached thereto, and the mounting plate of the powertrain module may be attached directly to the frame of the vehicle, or alternatively, may itself serve as a structural frame member for the vehicle. 
",BOYER SCOTT G.;;MCDONNER ORVILLE R.;;RUEBUSCH RICHARD T.,BOYER SCOTT G;;MCDONNER ORVILLE R;;RUEBUSCH RICHARD T,TECUMSEH PRODUCTS COMPANY (2002-07-29);;TECUMSEH POWER COMPANY (2007-11-09),https://lens.org/172-908-792-506-154,Patent Application,yes,0,24,4,4,0,B60K17/04;;B60K17/04;;B60K17/043;;B60K17/043;;B60K17/10;;B60K17/10;;B60K17/105;;B60K17/105,B60K17/04;;B60K17/10,180/6.48,0,0,,,,EXPIRED
290,MX,A,MX 2017003272 A,181-762-168-788-810,2017-07-07,2017,MX 2017003272 A,2015-09-14,US 201462049829 P;;US 201514853504 A;;US 2015/0050001 W,2014-09-12,HYPOVOLEMIA/HYPERVOLEMIA DETECTION USING PERIPHERAL INTRAVENOUS WAVEFORM ANALYSIS (PIVA) AND APPLICATIONS OF SAME.,"Aspects of the invention relates to systems and methods for hypovolemia and/or hypervolemia detection of a living subject using peripheral intravenous waveform analysis. In one embodiment, the method includes: acquiring, from a vein of the living subject, peripheral venous signals; performing a spectral analysis on the acquired peripheral venous signals to obtain a peripheral venous pressure frequency spectrum; and performing a statistical analysis on amplitudes of peaks of the peripheral venous pressure frequency spectrum to determine the blood volume status of the living subject in real time. Specifically, at least two peaks, respectively corresponding to a first frequency and a second frequency, are obtained on the peripheral venous pressure frequency spectrum. Amplitude change of the second peak is used to determine the blood volume status of the living subject. Hemorrhage may be detected when a significant amplitude decrease is detected from the second baseline peak to the second peak.",UNIV VANDERBILT,RICHARD BOYER;;FRANZ BAUDENBACHER;;KYLE HOCKING;;COLLEEN BROPHY;;SUSAN EAGLE,,https://lens.org/181-762-168-788-810,Patent Application,no,0,0,16,51,0,A61B5/02042;;A61B5/02152;;A61B5/02042;;A61B5/02152;;A61B5/02152;;A61B5/02042,A61B5/021;;A61B5/00;;A61B5/02,,0,0,,,,PENDING
291,EP,B1,EP 2346916 B1,046-687-016-601-912,2016-01-06,2016,EP 09752074 A,2009-11-09,US 2009/0063725 W;;US 11319108 P,2008-11-10,"AN ISOCYANATE TRIMERISATION CATALYST SYSTEM, A PRECURSOR FORMULATION, A PROCESS FOR TRIMERISING ISOCYANATES, RIGID POLYISOCYANURATE/POLYURETHANE FOAMS MADE THEREFROM, AND A PROCESS FOR MAKING SUCH FOAMS",,DOW GLOBAL TECHNOLOGIES LLC,ATHEY PHILLIP;;WILMOT NATHAN;;KEATON RICHARD;;BOYER CECILE;;MORLEY TIMOTHY,,https://lens.org/046-687-016-601-912,Granted Patent,yes,1,0,9,9,0,C08G18/022;;C08G18/022;;C08G18/092;;C08G18/092;;C08G18/168;;C08G18/168;;C08G18/1858;;C08G18/1858;;C08G18/1883;;C08G18/1883;;C08G18/791;;C08G18/791;;C08G2110/0025;;C08G2110/0025;;C08G2115/02;;C08G2115/02,C08G18/02;;C08G18/09;;C08G18/16;;C08G18/18;;C08G18/79,,0,0,,,,ACTIVE
292,ES,T3,ES 2434990 T3,084-289-423-266-562,2013-12-18,2013,ES 09752075 T,2009-11-09,US 11319308 P;;US 2009/0063728 W,2008-11-10,"Un sistema catalítico de trimerización de isocianato, una formulación precursora, un procedimiento para trimerizar isocianatos, espumas rígidas de poliisocianurato/poliuretano hechas a partir del mismo y un procedimiento para hacer dichas espumas","Un procedimiento para formar una espuma rígida de poliisocianurato/poliuretano que comprende las etapas de:proporcionar uno o más monómeros seleccionados del grupo que consiste en un isocianato, undiisocianato, un triisocianato, isocianato oligomérico, una sal de cualquiera de los mismos y una mezcla decualquiera de los mismos; proporcionar poliol; proporcionar un sistema catalítico de trimerización que comprende; un catión fosfonio; y un anión que induce trímero de isocianato; en donde dicho sistema catalítico de trimerización tiene una temperatura de activación de trimerización enel intervalo de igual a o menor que 73°C como se determina por calorimetría de barrido diferencial, y endonde dicho anión que induce el trímero de isocianato se selecciona del grupo que consiste en carboxilato,carbonato, fenóxido, amida, amidinato, imidas, fosfuros, tiocianato, tioisocianato y fluoruro,opcionalmente proporcionar uno o más tensioactivos, uno o más retardantes de llama, agua, uno o másantioxidantes, uno o más agentes de soplado auxiliares, uno o más catalizadores de uretano, uno o máscatalizadores de trimerización auxiliares o combinaciones de los mismos; poner en contacto dichos uno o más monómeros, y dicho poliol, y opcionalmente dichos uno o mástensioactivos, y opcionalmente dichos uno o más retardantes de llama, y opcionalmente dicha agua, yopcionalmente dichos uno o más antioxidantes, y opcionalmente dichos uno o más agentes de sopladoauxiliares en presencia de dicho sistema catalítico de trimerización y opcionalmente dicho uno o máscatalizadores de uretano, y opcionalmente dicho uno o más catalizadores de trimerización auxiliares;formar así dicha espuma rígida de poliisocianurato/poliuretano.",DOW GLOBAL TECHNOLOGIES LLC,ATHEY PHILLIP;;WILMOT NATHAN;;KEATON RICHARD;;BOYER CECILE;;MORLEY TIMOTHY,,https://lens.org/084-289-423-266-562,Granted Patent,no,0,0,10,10,0,C08G18/022;;C08G18/022;;C08G18/092;;C08G18/092;;C08G18/168;;C08G18/168;;C08G2110/0025;;C08G2110/0025;;C08G2115/02;;C08G2115/02,C08G18/02;;C08G18/09;;C08G18/16,,0,0,,,,ACTIVE
293,SG,A,SG 11201703795S A,076-685-267-341-405,2017-06-29,2017,SG 11201703795S A,2015-11-13,US 201462079367 P;;US 201514853504 A;;US 2015/0060697 W,2014-11-13,DEVICE AND METHOD FOR HEMORRHAGE DETECTION AND GUIDED RESUSCITATION AND APPLICATIONS OF SAME,,UNIV VANDERBILT,EAGLE SUSAN;;BROPHY COLLEEN;;HOCKING KYLE;;BAUDENBACHER FRANZ;;BOYER RICHARD,,https://lens.org/076-685-267-341-405,Unknown,no,0,0,14,51,0,A61B5/02007;;A61B5/02028;;A61B5/02042;;A61B5/681;;A61B5/7257;;A61B5/0816;;A61B5/0002;;A61B5/02438;;A61B5/7221;;A61B5/4875;;A61B5/7221;;A61B5/0002;;A61B5/02007;;A61B5/02028;;A61B5/02042;;A61B5/02438;;A61B5/0816;;A61B5/4875;;A61B5/681;;A61B5/7257;;G16H40/63;;G16H40/63;;A61B5/0002;;A61B5/02007;;A61B5/02028;;A61B5/02042;;A61B5/02438;;A61B5/0816;;A61B5/4875;;A61B5/681;;A61B5/7221;;A61B5/7257;;G16H40/63,A61B5/02;;A61B5/00,,0,0,,,,PENDING
294,EP,A1,EP 3217863 A1,003-992-138-320-634,2017-09-20,2017,EP 15859906 A,2015-11-13,US 201462079367 P;;US 201514853504 A;;US 2015/0060697 W,2014-11-13,DEVICE AND METHOD FOR HEMORRHAGE DETECTION AND GUIDED RESUSCITATION AND APPLICATIONS OF SAME,,UNIV VANDERBILT,EAGLE SUSAN;;BROPHY COLLEEN;;HOCKING KYLE;;BAUDENBACHER FRANZ;;BOYER RICHARD,,https://lens.org/003-992-138-320-634,Patent Application,yes,0,0,14,51,0,A61B5/02007;;A61B5/02028;;A61B5/02042;;A61B5/681;;A61B5/7257;;A61B5/0816;;A61B5/0002;;A61B5/02438;;A61B5/7221;;A61B5/4875;;A61B5/7221;;A61B5/0002;;A61B5/02007;;A61B5/02028;;A61B5/02042;;A61B5/02438;;A61B5/0816;;A61B5/4875;;A61B5/681;;A61B5/7257;;G16H40/63;;G16H40/63;;A61B5/0002;;A61B5/02007;;A61B5/02028;;A61B5/02042;;A61B5/02438;;A61B5/0816;;A61B5/4875;;A61B5/681;;A61B5/7221;;A61B5/7257;;G16H40/63,A61B5/02;;A61B5/00,,0,0,,,,PENDING
295,WO,A1,WO 2021/071985 A1,025-056-296-109-03X,2021-04-15,2021,US 2020/0054633 W,2020-10-07,US 202062995171 P;;US 201962974541 P;;US 201962973538 P;;US 202063102597 P;;US 202063204482 P,2019-10-07,SURFACE WATER MANAGEMENT SYSTEM INCLUDING WEIR WALL AND DETENTION POND,"An integrated system comprising a barrier, such as a weir with movable gates, controllably blocks water flow in a natural or concrete lined channel. Without substantially impeding flow in normal conditions, the barrier is configured to back up flood waters to spill into an upstream prepared detention basin. Water is thus kept from downstream areas until subsequently drained through a controlled spill. Multiple units installed in a watershed can store significant amounts of flood water, e.g., during a hurricane, protecting life and property downstream. The electromechanically-operated gates can be operated locally or from a remote control center. Gauges and sensors positioned near the weir and/ or throughout the watershed can provide data used to control one or more barriers in the watershed, and the data may be used to train a machine learning model to control the system.",RSA PROTECTIVE TECH LLC,ADLER RICHARD;;BOYER MARK;;DOLAND GEORGE;;SALO RISTO;;AGHA MAJED,,https://lens.org/025-056-296-109-03X,Patent Application,yes,2,0,4,4,0,E02B3/02;;G06N20/00;;E02B7/28;;E02B3/10;;E02B7/16;;E02B7/20,E02B3/02;;E02B3/04;;G06N3/02,,1,1,056-908-801-190-994,10.3390/w10111536,"AMIR MOSAVI ET AL: ""Flood Prediction Using Machine Learning Models: Literature Review"", WATER, vol. 10, no. 11, 27 October 2018 (2018-10-27), CH, pages 1536, XP055695114, ISSN: 2073-4441, DOI: 10.3390/w10111536",PENDING
296,JP,A,JP 2020157080 A,087-220-529-006-201,2020-10-01,2020,JP 2020096542 A,2020-06-03,US 201462049829 P;;US 201514853504 A,2014-09-12,HYPOVOLEMIA/HYPERVOLEMIA DETECTION USING PERIPHERAL INTRAVENOUS WAVEFORM ANALYSIS (PIVA) AND APPLICATIONS OF SAME,"To provide a peripheral intravenous (IV) waveform analysis (PIVA) system for hypovolemia and/or hypervolemia detection of a living subject using peripheral intravenous waveform analysis.SOLUTION: This system comprises: a peripheral IV device 110 configured to acquire peripheral venous signals from a vein of a living subject; and a processing device 120 communicably connected to the peripheral IV device. The processing device is configured to perform steps of: acquiring, from the peripheral IV device, the peripheral venous signals; performing a spectral analysis on the peripheral venous signals to obtain a peripheral venous pressure frequency spectrum; and performing a statistical analysis on amplitudes of peaks of the peripheral venous pressure frequency spectrum to determine blood volume status of the living subject in real time.SELECTED DRAWING: Figure 1",UNIV VANDERBILT,SUSAN EAGLE;;COLLEEN BROPHY;;KYLE HOCKING;;FRANZ BAUDENBACHER;;RICHARD BOYER,,https://lens.org/087-220-529-006-201,Patent Application,no,7,0,16,51,0,A61B5/02042;;A61B5/02152;;A61B5/02042;;A61B5/02152;;A61B5/02152;;A61B5/02042,A61B5/026;;A61B5/0215;;A61M1/16;;A61M1/36,,0,0,,,,ACTIVE
297,EP,A4,EP 3190960 A4,088-710-470-409-759,2018-05-02,2018,EP 15840046 A,2015-09-14,US 201462049829 P;;US 2015/0050001 W,2014-09-12,HYPOVOLEMIA/HYPERVOLEMIA DETECTION USING PERIPHERAL INTRAVENOUS WAVEFORM ANALYSIS (PIVA) AND APPLICATIONS OF SAME,,UNIV VANDERBILT,EAGLE SUSAN;;BROPHY COLLEEN;;HOCKING KYLE;;BAUDENBACHER FRANZ;;BOYER RICHARD,,https://lens.org/088-710-470-409-759,Search Report,no,0,0,16,51,0,A61B5/02042;;A61B5/02152;;A61B5/02042;;A61B5/02152;;A61B5/02152;;A61B5/02042,A61B5/021;;A61B5/00;;A61B5/02,,1,0,,,No further relevant documents disclosed,ACTIVE
298,US,B2,US 10725182 B2,168-528-234-361-940,2020-07-28,2020,US 201815861961 A,2018-01-04,US 201815861961 A,2018-01-04,Systems and methods for providing anti-spoofing capability to a global navigation satellite system receiver,"Apparatus and methods provide anti-spoofing capability from a first global navigation satellite system (GNSS) receiver to a second GNSS receiver. These GNSS receivers can be, for example, global positioning satellite (GPS) receivers. Via an authentication technique, signals from authentic GNSS sources are distinguished from signals from spoofers. Timing information, such as numerically-controlled oscillator (NCO) settings, used for tracking authenticated signals are then used to generate replica GNSS signals, which are then provided to the second GNSS receiver. As a result, the second GNSS receiver can provide accurate positioning system information in the presence of GNSS spoofers.",INTERSTATE ELECTRONICS CORP,BOYER DEREK MICHAEL LOOMER;;ALEXANDER STEVEN B;;REDHEAD RICHARD F,L3HARRIS INTERSTATE ELECTRONICS CORPORATION (2018-03-20),https://lens.org/168-528-234-361-940,Granted Patent,yes,119,8,6,6,0,G01S19/215;;G01S19/36;;G01S19/03;;G01S19/24;;G01S19/215;;G01S19/36;;G01S19/03,G01S19/21;;G01S19/03;;G01S19/24;;G01S19/36,,9,0,,,"Todd E. Humphreys, et al., “The GPS Assimilator: a Method for Upgrading Existing GPS User Equipment to Improve Accuracy, Robustness, and Resistance to Spoofing,” [online], Preprint of the 2010 ION GNSS Conference, Portland, Oregon, Sep. 21-24, 2010, [online], [retrieved on Apr. 26, 2017], retrieved from: <URL: https://radionavlab.ae.utexas.edu/images/stories/files/papers/assimilator_for_distribution.pdf>.;;Todd Humphreys, et al., “Assessing the Civil GPS Spoofing Threat,” [online], The University of Texas at Austin Radionavigation Laboratory, Powerpoint presentation, 2009, [retrieved on Apr. 26, 2017], retrieved from <URL: https://radionavlab.ae.utexas.edu/images/stories/files/presentations/assessingSpoofingThreat.pdf>.;;Jackson Labs, “RSR GPS RF=Transcoder / 10—Channel GPS Simulator, 2.3 x 1.6 inches,” [online], Jan. 22, 2017, [retrieved on Jun. 1, 2017], retrieved from <URL: http://www.jackson-labs.com/assets/uploads/main/RSR_Transcoder_specsheet.pdf>.;;U.S. Appl. No. 14/678,755, filed Apr. 3, 2015, Alexander.;;U.S. Appl. No. 14/678,768, filed Apr. 3, 2015, Alexander.;;Chen, et al., “Off-the-Shelf Antennas for Controlled-Reception-Pattern Antenna Arrays”; GPS World; Innovation: Getting Control; Feb. 1, 2013, [retrieved on Feb. 26, 2014]. Retrieved from the Internet: URL: http://gpsworld.com/innovation-getting-control-off-the-shelf-antennas-for-controlled-reception-pattern-antenna-arrays/.;;Office Action dated Aug. 28, 2017, from related U.S. Appl. No. 14/678,755 (filed Apr. 3, 2015).;;Wen, et al., “Countermeasures for GPS Signal Spoofing”; Proceedings of the 18th International Technical Meeting of the Satellite Division of the Institute of Navigation (ION GNSS 2005); Long Beach, CA, Sep. 2005, pp. 1285-1290, [retrieved on Sep. 24, 2013]. Retrieved from the Internet: URL: http://lens.ou.edu/Download/ION/ION%202005%20Wen_Spoof.doc.;;PCT International Search Report and Written Opinion of the International Searching Authority regarding International Application No. PCT/US18/62115, dated Feb. 5, 2019, 19 Pages.",ACTIVE
299,DE,A1,DE 1585423 A1,185-351-914-105-903,1970-11-19,1970,DE 1585423 A,1965-12-15,US 41846064 A,1964-12-15,Mustervorrichtung fuer Rundstrickmaschinen,,NORTH AMERICAN ROCKWELL,HAROLD IMBODEN WALTER;;MARTIN JANDA RICHARD;;HEILIG BOYER JUN JAMES,,https://lens.org/185-351-914-105-903,Patent Application,no,0,0,4,5,0,D04B9/20;;D04B9/56;;D04B15/82;;D04B9/56;;D04B9/20;;D04B15/82,D04B9/20;;D04B9/46;;D04B15/82,,0,0,,,,EXPIRED
300,AU,B2,AU 2015/346054 B2,041-373-823-355-427,2020-04-09,2020,AU 2015/346054 A,2015-11-13,US 201514853504 A;;US 201462079367 P;;US 2015/0060697 W,2014-11-13,Device and method for hemorrhage detection and guided resuscitation and applications of same,"Aspects of the invention relates to systems and methods for detecting volume status, volume overload, dehydration, hemorrhage and real time assessment of resuscitation, as well as organ failure including but not limited cardiac, renal, and hepatic dysfunction, of a living subject using non-invasive vascular analysis (NIVA). In one embodiment, a non-invasive device, which includes at least one sensor, is used to acquire vascular signals from the living subject in real time. The vascular signals are sent to a controller, which processes the vascular signals to determine at least one hemodynamic parameter, such as the volume status of the living subject. In certain embodiments, the vascular signals are processed by a spectral fast Fourier transform (FFT) analysis to obtain the peripheral vascular signal frequency spectrum, and the volume status of the living subject may be determined by comparing amplitudes of the peaks of the peripheral vascular signal frequency spectrum.",UNIV VANDERBILT,EAGLE SUSAN;;BROPHY COLLEEN;;HOCKING KYLE;;BAUDENBACHER FRANZ;;BOYER RICHARD,,https://lens.org/041-373-823-355-427,Granted Patent,no,4,2,14,51,0,A61B5/02007;;A61B5/02028;;A61B5/02042;;A61B5/681;;A61B5/7257;;A61B5/0816;;A61B5/0002;;A61B5/02438;;A61B5/7221;;A61B5/4875;;A61B5/7221;;A61B5/0002;;A61B5/02007;;A61B5/02028;;A61B5/02042;;A61B5/02438;;A61B5/0816;;A61B5/4875;;A61B5/681;;A61B5/7257;;G16H40/63;;G16H40/63;;A61B5/0002;;A61B5/02007;;A61B5/02028;;A61B5/02042;;A61B5/02438;;A61B5/0816;;A61B5/4875;;A61B5/681;;A61B5/7221;;A61B5/7257;;G16H40/63,A61B5/02;;A61B5/00,,0,0,,,,ACTIVE
301,MX,A,MX 2017006318 A,065-765-194-856-096,2018-02-13,2018,MX 2017006318 A,2015-11-13,US 201462079367 P;;US 201514853504 A;;US 2015/0060697 W,2014-11-13,DEVICE AND METHOD FOR HEMORRHAGE DETECTION AND GUIDED RESUSCITATION AND APPLICATIONS OF SAME.,"Aspects of the invention relates to systems and methods for detecting volume status, volume overload, dehydration, hemorrhage and real time assessment of resuscitation, as well as organ failure including but not limited cardiac, renal, and hepatic dysfunction, of a living subject using non-invasive vascular analysis (NIVA). In one embodiment, a non-invasive device, which includes at least one sensor, is used to acquire vascular signals from the living subject in real time. The vascular signals are sent to a controller, which processes the vascular signals to determine at least one hemodynamic parameter, such as the volume status of the living subject. In certain embodiments, the vascular signals are processed by a spectral fast Fourier transform (FFT) analysis to obtain the peripheral vascular signal frequency spectrum, and the volume status of the living subject may be determined by comparing amplitudes of the peaks of the peripheral vascular signal frequency spectrum.",UNIV VANDERBILT,RICHARD BOYER;;FRANZ BAUDENBACHER;;KYLE HOCKING;;COLLEEN BROPHY;;SUSAN EAGLE,,https://lens.org/065-765-194-856-096,Patent Application,no,0,0,14,51,0,A61B5/02007;;A61B5/02028;;A61B5/02042;;A61B5/681;;A61B5/7257;;A61B5/0816;;A61B5/0002;;A61B5/02438;;A61B5/7221;;A61B5/4875;;A61B5/7221;;A61B5/0002;;A61B5/02007;;A61B5/02028;;A61B5/02042;;A61B5/02438;;A61B5/0816;;A61B5/4875;;A61B5/681;;A61B5/7257;;G16H40/63;;G16H40/63;;A61B5/0002;;A61B5/02007;;A61B5/02028;;A61B5/02042;;A61B5/02438;;A61B5/0816;;A61B5/4875;;A61B5/681;;A61B5/7221;;A61B5/7257;;G16H40/63,A61B5/02;;A61B5/00,,0,0,,,,PENDING
302,CN,A,CN 106999064 A,078-309-515-917-527,2017-08-01,2017,CN 201580063695 A,2015-11-13,US 201462079367 P;;US 201514853504 A;;US 2015/0060697 W,2014-11-13,Device and method for hemorrhage detection and guided resuscitation and applications of same,"Aspects of the invention relates to systems and methods for detecting volume status, volume overload, dehydration, hemorrhage and real time assessment of resuscitation, as well as organ failure including but not limited cardiac, renal, and hepatic dysfunction, of a living subject using non-invasive vascular analysis (NIVA). In one embodiment, a non-invasive device, which includes at least one sensor, is used to acquire vascular signals from the living subject in real time. The vascular signals are sent to a controller, which processes the vascular signals to determine at least one hemodynamic parameter, such as the volume status of the living subject. In certain embodiments, the vascular signals are processed by a spectral fast Fourier transform (FFT) analysis to obtain the peripheral vascular signal frequency spectrum, and the volume status of the living subject may be determined by comparing amplitudes of the peaks of the peripheral vascular signal frequency spectrum.",UNIV VANDERBILT,EAGLE SUSAN;;BROPHY COLLEEN;;HOCKING KYLE;;BAUDENBACHER FRANZ;;BOYER RICHARD,,https://lens.org/078-309-515-917-527,Patent Application,no,4,2,14,51,0,A61B5/02007;;A61B5/02028;;A61B5/02042;;A61B5/681;;A61B5/7257;;A61B5/0816;;A61B5/0002;;A61B5/02438;;A61B5/7221;;A61B5/4875;;A61B5/7221;;A61B5/0002;;A61B5/02007;;A61B5/02028;;A61B5/02042;;A61B5/02438;;A61B5/0816;;A61B5/4875;;A61B5/681;;A61B5/7257;;G16H40/63;;G16H40/63;;A61B5/0002;;A61B5/02007;;A61B5/02028;;A61B5/02042;;A61B5/02438;;A61B5/0816;;A61B5/4875;;A61B5/681;;A61B5/7221;;A61B5/7257;;G16H40/63,A61B5/02;;A61B5/00;;A61B5/024;;A61B5/08;;G06F19/00,,0,0,,,,ACTIVE
303,US,A,US 3360488 A,122-455-749-226-146,1967-12-26,1967,US 45351365 A,1965-05-05,US 45351365 A;;US 43876765 A;;US 44217465 A;;US 44219565 A;;US 45349365 A,1965-03-10,Adhesive compositions comprising atactic polypropylene and tall oil,,SUN OIL CO,HALL JR LEWIS W;;BOYER JACKSON S;;WARE RICHARD E,,https://lens.org/122-455-749-226-146,Granted Patent,no,6,8,8,18,0,C09J123/12;;C09J123/12;;C08L2666/02;;C08L2666/02;;Y10T428/31902;;Y10T428/31902,C09J123/12,,0,0,,,,EXPIRED
304,WO,A2,WO 2010/054313 A2,144-191-752-332-996,2010-05-14,2010,US 2009/0063728 W,2009-11-09,US 11319308 P,2008-11-10,"AN ISOCYANATE TRIMERISATION CATALYST SYSTEM, A PRECURSOR FORMULATION, A PROCESS FOR TRIMERISING ISOCYANATES, RIGID POLYISOCYANURATE/POLYURETHANE FOAMS MADE THEREFROM, AND A PROCESS FOR MAKING SUCH FOAMS","The instant invention provides an isocyanate trimerisation catalyst system, a precursor formulation, a process for trimerising isocyanates, rigid foams made therefrom, and a process for making such foams. The trimerisation catalyst system comprises: (a) a phosphonium cation; and (b) an isocyanate-trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73 °C. The precursor formulation comprises (1) at least 25 percent by weight of polyol, based on the weight of the precursor formulation; (2) less than 15 percent by weight of a trimerisation catalyst system, based on the weight of the precursor formulation, comprising; (a) a phosphonium cation; and (c) an isocyanate- trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73 °C; and (3) optionally one or more surfactants, one or more flame retardants, water, one or more antioxidants, one or more auxiliary blowing agents, one or more urethane catalysts, one or more auxiliary trimerisation catalysts, or combinations thereof. The process for trimerisation of isocyanates comprises the steps of: (1) providing one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture of any thereof; (2) providing a trimerisation catalyst system comprising; (a) an phosphonium cation; and (b) an isocyanate-trimer inducing anion; (c) wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73 °C; (3) trimerising said one or more monomers in the presence of said trimerisation catalyst; (4) thereby forming an isocyanurate trimer. The process for making the PIR foam comprises the steps of: (1) providing one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture of any thereof; (2) providing polyol; (3) providing a trimerisation catalyst system comprising; (a) a phosphonium cation; and (b) an isocyanate-trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73 °C; and (4) optionally providing one or more surfactants, one or more flame retardants, water, one or more antioxidants, one or more auxiliary blowing agents, one or more urethane catalysts, one or more auxiliary trimerisation catalysts, or combinations thereof; (5) contacting said one or more monomers, and said polyol, and optionally said one or more surfactants, and optionally said one or more flame retardants, and optionally said water, and optionally said one or more antioxidants, and optionally said one or more auxiliary blowing agents in the presence of said trimerisation catalyst system and optionally said one or more urethane catalysts, and optionally said one or more auxiliary trimerisation catalysts; (6) thereby forming said polyisocyanurate/polyurethane rigid foam. The PIR foam comprises the reaction product of one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture of any thereof with polyol in the presence of a trimerisation catalyst system comprising a phosphonium cation, and an isocyanate-trimer inducing anion, and optionally one or more surfactants, optionally one or more flame retardants, optionally water, optionally one or more antioxidants, optionally one or more auxiliary blowing agents, optionally one or more additional urethane catalysts, and optionally one or more auxiliary trimerisation catalysts, or optionally combinations thereof, wherein the trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73 °C. The PIR foam comprises the reaction product of one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture of any thereof with polyol in the presence of a trimerisation catalyst system comprising a phosphonium cation, and an isocyanate-trimer inducing anion, and optionally one or more surfactants, optionally one or more flame retardants, optionally water, optionally one or more antioxidants, optionally one or more auxiliary blowing agents, optionally one or more additional polyurethane catalysts, and optionally one or more auxiliary trimerisation catalysts, or optionally combinations thereof, wherein the PIR foam has a polyisocyanurate trimer ratio (Abs 1410 /Abs 1595 ) of at least 5 at a depth of 12 mm from the rising surface of the rigid foam, measured via ATR-FTIR spectroscopy.",DOW GLOBAL TECHNOLOGIES INC;;ATHEY PHILLIP;;WILMOT NATHAN;;KEATON RICHARD;;BOYER CECILE;;MORLEY TIMOTHY,ATHEY PHILLIP;;WILMOT NATHAN;;KEATON RICHARD;;BOYER CECILE;;MORLEY TIMOTHY,,https://lens.org/144-191-752-332-996,Patent Application,yes,0,0,10,10,0,C08G18/022;;C08G18/022;;C08G18/092;;C08G18/092;;C08G18/168;;C08G18/168;;C08G2110/0025;;C08G2110/0025;;C08G2115/02;;C08G2115/02,C08G18/18,,0,0,,,,PENDING
305,KR,A,KR 20170082621 A,016-706-890-397-754,2017-07-14,2017,KR 20177016035 A,2015-11-13,US 201462079367 P;;US 201514853504 A;;US 2015/0060697 W,2014-11-13,DEVICE AND METHOD FOR HEMORRHAGE DETECTION AND GUIDED RESUSCITATION AND APPLICATIONS OF SAME,"본 발명의 측면들은, 비-침습 혈관 분석(NIVA)를 사용하여, 비제한적으로, 생체의 심장, 신장, 및 간 기능 부전을 포함하는 장기 부전뿐만 아니라 용적 상태, 용적 과부하, 탈수, 출혈의 검출 및 소생법의 실시간 평가를 위한 시스템들 및 방법들에 관한 것이다. 일 실시예에 있어서, 적어도 하나의 센서를 포함하는 비-침습 디바이스가 생체로부터 실시간으로 혈관 신호들을 획득하기 위하여 사용된다. 혈관 신호들은, 생체의 용적 상태와 같은 적어도 하나의 혈류역학 파라미터를 결정하기 위하여 혈관 신호들을 프로세싱하는 제어기로 전송된다. 특정 실시예들에 있어서, 혈관 신호들은 말초 혈관 신호 주파수 스펙트럼을 획득하기 위하여 스펙트럼 고속 푸리에 변환(FFT) 분석에 의해 프로세싱되며, 생체의 용적 상태는 말초 혈관 신호 주파수 스펙트럼의 피크들의 진폭들을 비교함으로써 결정될 수 있다.",UNIV VANDERBILT,EAGLE SUSAN;;BROPHY COLLEEN;;HOCKING KYLE;;BAUDENBACHER FRANZ;;BOYER RICHARD,,https://lens.org/016-706-890-397-754,Patent Application,no,2,0,14,51,0,A61B5/02007;;A61B5/02028;;A61B5/02042;;A61B5/681;;A61B5/7257;;A61B5/0816;;A61B5/0002;;A61B5/02438;;A61B5/7221;;A61B5/4875;;A61B5/7221;;A61B5/0002;;A61B5/02007;;A61B5/02028;;A61B5/02042;;A61B5/02438;;A61B5/0816;;A61B5/4875;;A61B5/681;;A61B5/7257;;G16H40/63;;G16H40/63;;A61B5/0002;;A61B5/02007;;A61B5/02028;;A61B5/02042;;A61B5/02438;;A61B5/0816;;A61B5/4875;;A61B5/681;;A61B5/7221;;A61B5/7257;;G16H40/63,A61B5/02;;A61B5/00;;A61B5/024;;A61B5/08;;G06F19/00,,0,0,,,,ACTIVE
306,US,A,US 3370106 A,172-242-306-110-800,1968-02-20,1968,US 44217465 A,1965-03-23,US 44217465 A;;US 43876765 A;;US 44219565 A;;US 45349365 A;;US 45351365 A,1965-03-10,Hot melt adhesive containing atactic polypropylene and polyethylene,,SUN OIL CO,HALL JR LEWIS W;;BOYER JACKSON S;;WARE RICHARD E,,https://lens.org/172-242-306-110-800,Granted Patent,no,3,37,8,18,0,C09J123/12;;C09J123/12;;C08L2666/02;;C08L2666/02;;Y10T428/31902;;Y10T428/31902,C09J123/12,260/897,0,0,,,,EXPIRED
307,US,A1,US 2016/0073959 A1,103-219-225-827-684,2016-03-17,2016,US 201514853504 A,2015-09-14,US 201514853504 A;;US 201462049829 P,2014-09-12,HYPOVOLEMIA/HYPERVOLEMIA DETECTION USING PERIPHERAL INTRAVENOUS WAVEFORM ANALYSIS (PIVA) AND APPLICATIONS OF SAME,"Aspects of the invention relates to systems and methods for hypovolemia and/or hypervolemia detection of a living subject using peripheral intravenous waveform analysis. In one embodiment, the method includes: acquiring, from a vein of the living subject, peripheral venous signals; performing a spectral analysis on the acquired peripheral venous signals to obtain a peripheral venous pressure frequency spectrum; and performing a statistical analysis on amplitudes of peaks of the peripheral venous pressure frequency spectrum to determine the blood volume status of the living subject in real time. Specifically, at least two peaks, respectively corresponding to a first frequency and a second frequency, are obtained on the peripheral venous pressure frequency spectrum. Amplitude change of the second peak is used to determine the blood volume status of the living subject. Hemorrhage may be detected when a significant amplitude decrease is detected from the second baseline peak to the second peak.",UNIV VANDERBILT,EAGLE SUSAN;;BROPHY COLLEEN;;HOCKING KYLE;;BAUDENBACHER FRANZ;;BOYER RICHARD,VANDERBILT UNIVERSITY (2016-08-22),https://lens.org/103-219-225-827-684,Patent Application,yes,8,20,16,51,0,A61B5/02042;;A61B5/02152;;A61B5/02042;;A61B5/02152;;A61B5/02152;;A61B5/02042,A61B5/00;;A61B5/02;;A61B5/0215,,0,0,,,,DISCONTINUED
308,EP,B1,EP 3190960 B1,108-975-828-047-236,2022-01-12,2022,EP 15840046 A,2015-09-14,US 201462049829 P;;US 2015/0050001 W,2014-09-12,HYPOVOLEMIA/HYPERVOLEMIA DETECTION USING PERIPHERAL INTRAVENOUS WAVEFORM ANALYSIS (PIVA) AND APPLICATIONS OF SAME,,UNIV VANDERBILT,EAGLE SUSAN;;BROPHY COLLEEN;;HOCKING KYLE;;BAUDENBACHER FRANZ;;BOYER RICHARD,,https://lens.org/108-975-828-047-236,Granted Patent,yes,5,0,16,51,0,A61B5/02042;;A61B5/02152;;A61B5/02042;;A61B5/02152;;A61B5/02152;;A61B5/02042,A61B5/021;;A61B5/00;;A61B5/02,,1,0,,,None,ACTIVE
309,EP,A2,EP 2346917 A2,158-304-734-151-100,2011-07-27,2011,EP 09752075 A,2009-11-09,US 2009/0063728 W;;US 11319308 P,2008-11-10,"AN ISOCYANATE TRIMERISATION CATALYST SYSTEM, A PRECURSOR FORMULATION, A PROCESS FOR TRIMERISING ISOCYANATES, RIGID POLYISOCYANURATE/POLYURETHANE FOAMS MADE THEREFROM, AND A PROCESS FOR MAKING SUCH FOAMS",,DOW GLOBAL TECHNOLOGIES LLC,ATHEY PHILLIP;;WILMOT NATHAN;;KEATON RICHARD;;BOYER CECILE;;MORLEY TIMOTHY,,https://lens.org/158-304-734-151-100,Patent Application,yes,0,0,10,10,0,C08G18/022;;C08G18/022;;C08G18/092;;C08G18/092;;C08G18/168;;C08G18/168;;C08G2110/0025;;C08G2110/0025;;C08G2115/02;;C08G2115/02,C08G18/02;;C08G18/09;;C08G18/16,,1,0,,,See references of WO 2010054313A3,ACTIVE
310,CA,A,CA 756678 A,192-311-522-119-561,1967-04-11,1967,CA 756678D A,,CA 756678T A,,HOT MELT ADHESIVE,,SUN OIL CO,HALL LEWIS W JR;;BOYER JACKSON S;;WARE RICHARD E,,https://lens.org/192-311-522-119-561,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
311,WO,A2,WO 2010/054311 A2,043-550-932-673-579,2010-05-14,2010,US 2009/0063725 W,2009-11-09,US 11319108 P,2008-11-10,"AN ISOCYANATE TRIMERISATION CATALYST SYSTEM, A PRECURSOR FORMULATION, A PROCESS FOR TRIMERISING ISOCYANATES, RIGID POLYISOCYANURATE/POLYURETHANE FOAMS MADE THEREFROM, AND A PROCESS FOR MAKING SUCH FOAMS","The instant invention provides an isocyanate trimerisation catalyst system, a precursor formulation, a process for trimerising isocyanates, rigid foams made therefrom, and a process for making such foams. The trimerisation catalyst system comprises: (a) a substituted iminium cation; and (b) an isocyanate-trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73 0C. The precursor formulation comprises (1) at least 25 percent by weight of polyol, based on the weight of the precursor formulation; (2) less than 15 percent by weight of a trimerisation catalyst system, based on the weight of the precursor formulation, comprising; (a) a substituted iminium cation; and (c) an isocyanate-trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73 0C; and (4) optionally one or more surfactants, one or more flame retardants, water, one or more antioxidants, one or more auxiliary blowing agents, one or more urethane catalysts, one or more auxiliary trimerisation catalysts, or combinations thereof. The process for trimerisation of isocyanates comprises the steps of: (1) providing one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture of any thereof; (2) providing a trimerisation catalyst system comprising; (a) an substituted iminium cation; and (b) an isocyanate-trimer inducing anion; (c) wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73 0C; (3) trimerising said one or more monomers in the presence of said trimerisation catalyst; (4) thereby forming an isocyanurate ring. The process for making the PIR foam comprises the steps of: (1) providing one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture of any thereof; (2) providing polyol; (3) providing a trimerisation catalyst system comprising; (a) a substituted iminium cation; and (b) an isocyanate-trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73 0C; and (4) optionally providing one or more surfactants, one or more flame retardants, water, one or more antioxidants, one or more auxiliary blowing agents, one or more urethane catalysts, one or more auxiliary trimerisation catalysts, or combinations thereof; (5) contacting said one or more monomers, and said polyol, and optionally said one or more surfactants, and optionally said one or more flame retardants, and optionally said water, and optionally said one or more antioxidants, and optionally said one or more auxiliary blowing agents in the presence of said trimerisation catalyst system and optionally said one or more urethane catalysts, and optionally said one or more auxiliary trimerisation catalysts; (6) thereby forming said polyisocyanurate/polyurethane rigid foam. The PIR foam comprises the reaction product of one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture of any thereof with polyol in the presence of a trimerisation catalyst system comprising a substituted iminium cation, and an isocyanate-trimer inducing anion, and optionally one or more surfactants, optionally one or more flame retardants, optionally water, optionally one or more antioxidants, optionally one or more auxiliary blowing agents, optionally one or more additional urethane catalysts, and optionally one or more auxiliary trimerisation catalysts, or optionally combinations thereof, wherein the trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73 0C. The PIR foam comprises the reaction product of one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture of any thereof with polyol in the presence of a trimerisation catalyst system comprising a substituted iminium cation, and an isocyanate-trimer inducing anion, and optionally one or more surfactants, optionally one or more flame retardants, optionally water, optionally one or more antioxidants, optionally one or more auxiliary blowing agents, optionally one or more additional polyurethane catalysts, and optionally one or more auxiliary trimerisation catalysts, or optionally combinations thereof, wherein the PIR foam has a polyisocyanurate trimer ratio (Abs1410/Abs1595) of at least 5 at a depth of 12 mm from the rising surface of the rigid foam, measured via ATR-FTIR spectroscopy.",DOW GLOBAL TECHNOLOGIES INC;;ATHEY PHILLIP;;WILMOT NATHAN;;KEATON RICHARD;;BOYER CECILE;;MORLEY TIMOTHY,ATHEY PHILLIP;;WILMOT NATHAN;;KEATON RICHARD;;BOYER CECILE;;MORLEY TIMOTHY,,https://lens.org/043-550-932-673-579,Patent Application,yes,0,0,9,9,0,C08G18/022;;C08G18/092;;C08G18/168;;C08G18/1858;;C08G18/1883;;C08G18/791;;C08G2115/02;;C08G2110/0025;;C08G18/022;;C08G18/1858;;C08G18/092;;C08G18/1883;;C08G18/168;;C08G18/791;;C08G2110/0025;;C08G2115/02,C08G18/18,,0,0,,,,PENDING
312,US,A,US 5275880 A,081-667-826-398-232,1994-01-04,1994,US 35301089 A,1989-05-17,US 35301089 A,1989-05-17,Microwave absorber for direct surface application,"A layered microwave radiation absorber comprises an absorbing layer bound to one side of a conductive layer (such as a metallic plate or foil), and an adhesive layer bound on the other side of the conductive layer. The combination may be applied directly to the surface of any object, but especially to an existing conductive object coated with an nonconductive coating (such as paint) without removing the nonconductive coating from the surface. Several types of absorbing materials may be used, and other layers may be included. The absorber has superior resistance to delamination.",MINNESOTA MINING & MFG,BOYER III CHARLES E;;KUO RICHARD J;;LOGIUDICE STEPHEN M,MINNESOTA MINING AND MANUFACTURING COMPANY A CORP. OF DE (1989-05-17),https://lens.org/081-667-826-398-232,Granted Patent,yes,38,35,7,7,0,H01Q17/004;;H05K9/0088;;Y10T428/256;;Y10T428/268;;Y10T428/28;;B32B7/025;;H01Q17/00;;B32B7/025;;Y10T428/256;;Y10T428/268;;Y10T428/28;;B32B7/12;;B32B2307/208;;B32B2307/202;;H05K9/0088;;H01Q17/004;;B32B7/025,B32B5/02;;B32B7/025;;B32B5/16;;B32B7/12;;H01Q17/00;;H05K9/00,428/328;;428/338;;428/343;;342/1;;342/2;;342/3;;426/107,3,0,,,"David L. Dye et al., Theoretical Investigation of Fibers, Boeing Aerospace Company, Seattle, Washington, draft report for Department of Defense contract DAAK11 82 C 0152, 1983, pp. 3 5, 10 11, 13 19, 27 44, 101 111, 142 144.;;RAM Maintenance Procedures (Interim), U.S. Navy, Oct. 1985.;;Ruck et al., Radar Cross Section Handbook, vol. 2, pp. 617 622, Section 8.3.2.1.1.3, Plenum Press 1970.",EXPIRED
313,CA,A1,CA 2961195 A1,080-376-739-621-508,2016-03-17,2016,CA 2961195 A,2015-09-14,US 201462049829 P;;US 201514853504 A;;US 2015/0050001 W,2014-09-12,HYPOVOLEMIA/HYPERVOLEMIA DETECTION USING PERIPHERAL INTRAVENOUS WAVEFORM ANALYSIS (PIVA) AND APPLICATIONS OF SAME,"Aspects of the invention relates to systems and methods for hypovolemia and/or hypervolemia detection of a living subject using peripheral intravenous waveform analysis. In one embodiment, the method includes: acquiring, from a vein of the living subject, peripheral venous signals; performing a spectral analysis on the acquired peripheral venous signals to obtain a peripheral venous pressure frequency spectrum; and performing a statistical analysis on amplitudes of peaks of the peripheral venous pressure frequency spectrum to determine the blood volume status of the living subject in real time. Specifically, at least two peaks, respectively corresponding to a first frequency and a second frequency, are obtained on the peripheral venous pressure frequency spectrum. Amplitude change of the second peak is used to determine the blood volume status of the living subject. Hemorrhage may be detected when a significant amplitude decrease is detected from the second baseline peak to the second peak.",UNIV VANDERBILT,EAGLE SUSAN;;BROPHY COLLEEN;;HOCKING KYLE;;BAUDENBACHER FRANZ;;BOYER RICHARD,,https://lens.org/080-376-739-621-508,Patent Application,no,0,0,16,51,0,A61B5/02042;;A61B5/02152;;A61B5/02042;;A61B5/02152;;A61B5/02152;;A61B5/02042,A61B5/021;;A61B5/00;;A61B5/02;;A61B5/0215,,0,0,,,,PENDING
314,WO,A3,WO 2010/054313 A3,098-151-817-510-878,2011-02-24,2011,US 2009/0063728 W,2009-11-09,US 11319308 P,2008-11-10,"AN ISOCYANATE TRIMERISATION CATALYST SYSTEM, A PRECURSOR FORMULATION, A PROCESS FOR TRIMERISING ISOCYANATES, RIGID POLYISOCYANURATE/POLYURETHANE FOAMS MADE THEREFROM, AND A PROCESS FOR MAKING SUCH FOAMS","The instant invention provides an isocyanate trimerisation catalyst system, a precursor formulation, a process for trimerising isocyanates, rigid foams made therefrom, and a process for making such foams. The trimerisation catalyst system comprises: (a) a phosphonium cation; and (b) an isocyanate-trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73 °C. The precursor formulation comprises (1) at least 25 percent by weight of polyol, based on the weight of the precursor formulation; (2) less than 15 percent by weight of a trimerisation catalyst system, based on the weight of the precursor formulation, comprising; (a) a phosphonium cation; and (c) an isocyanate- trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73 °C; and (3) optionally one or more surfactants, one or more flame retardants, water, one or more antioxidants, one or more auxiliary blowing agents, one or more urethane catalysts, one or more auxiliary trimerisation catalysts, or combinations thereof. The process for trimerisation of isocyanates comprises the steps of: (1) providing one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture of any thereof; (2) providing a trimerisation catalyst system comprising; (a) an phosphonium cation; and (b) an isocyanate-trimer inducing anion; (c) wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73 °C; (3) trimerising said one or more monomers in the presence of said trimerisation catalyst; (4) thereby forming an isocyanurate trimer. The process for making the PIR foam comprises the steps of: (1) providing one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture of any thereof; (2) providing polyol; (3) providing a trimerisation catalyst system comprising; (a) a phosphonium cation; and (b) an isocyanate-trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73 °C; and (4) optionally providing one or more surfactants, one or more flame retardants, water, one or more antioxidants, one or more auxiliary blowing agents, one or more urethane catalysts, one or more auxiliary trimerisation catalysts, or combinations thereof; (5) contacting said one or more monomers, and said polyol, and optionally said one or more surfactants, and optionally said one or more flame retardants, and optionally said water, and optionally said one or more antioxidants, and optionally said one or more auxiliary blowing agents in the presence of said trimerisation catalyst system and optionally said one or more urethane catalysts, and optionally said one or more auxiliary trimerisation catalysts; (6) thereby forming said polyisocyanurate/polyurethane rigid foam. The PIR foam comprises the reaction product of one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture of any thereof with polyol in the presence of a trimerisation catalyst system comprising a phosphonium cation, and an isocyanate-trimer inducing anion, and optionally one or more surfactants, optionally one or more flame retardants, optionally water, optionally one or more antioxidants, optionally one or more auxiliary blowing agents, optionally one or more additional urethane catalysts, and optionally one or more auxiliary trimerisation catalysts, or optionally combinations thereof, wherein the trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73 °C. The PIR foam comprises the reaction product of one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture of any thereof with polyol in the presence of a trimerisation catalyst system comprising a phosphonium cation, and an isocyanate-trimer inducing anion, and optionally one or more surfactants, optionally one or more flame retardants, optionally water, optionally one or more antioxidants, optionally one or more auxiliary blowing agents, optionally one or more additional polyurethane catalysts, and optionally one or more auxiliary trimerisation catalysts, or optionally combinations thereof, wherein the PIR foam has a polyisocyanurate trimer ratio (Abs 1410 /Abs 1595 ) of at least 5 at a depth of 12 mm from the rising surface of the rigid foam, measured via ATR-FTIR spectroscopy.",DOW GLOBAL TECHNOLOGIES INC;;ATHEY PHILLIP;;WILMOT NATHAN;;KEATON RICHARD;;BOYER CECILE;;MORLEY TIMOTHY,ATHEY PHILLIP;;WILMOT NATHAN;;KEATON RICHARD;;BOYER CECILE;;MORLEY TIMOTHY,,https://lens.org/098-151-817-510-878,Search Report,yes,3,0,10,10,0,C08G18/022;;C08G18/022;;C08G18/092;;C08G18/092;;C08G18/168;;C08G18/168;;C08G2110/0025;;C08G2110/0025;;C08G2115/02;;C08G2115/02,C08G18/02;;C08G18/09;;C08G18/16,,0,0,,,,PENDING
315,US,A,US 3372562 A,045-406-108-625-428,1968-03-12,1968,US 45577665 A,1965-05-14,US 45577665 A;;US 41846064 A,1964-12-15,SINKER OPERATING CONTROL FOR CIRCULAR KNITTING MACHINES,,TEXTILE MACHINE WORKS,IMBODEN WALTER H;;JANDA RICHARD M;;BOYER JAMES H JR,,https://lens.org/045-406-108-625-428,Granted Patent,no,7,4,1,5,0,D04B9/20;;D04B9/20;;D04B1/26;;D04B1/26;;D04B9/46;;D04B9/46,D04B9/20;;D04B9/46,66/108,0,0,,,,EXPIRED
316,US,A,US 3041399 A,066-981-128-636-637,1962-06-26,1962,US 73225358 A,1958-05-01,US 73225358 A,1958-05-01,Toll ticketing system,,GEN DYNAMICS CORP,BERCH WILLIAM H;;BOYER JR RICHARD P;;GATZERT ERNEST H,,https://lens.org/066-981-128-636-637,Granted Patent,no,6,1,1,1,0,H04M15/38;;H04M15/38,H04M15/38,,0,0,,,,EXPIRED
317,US,A1,US 2022/0137233 A1,107-083-210-141-028,2022-05-05,2022,US 202117455191 A,2021-11-16,US 202117455191 A;;US 202016902858 A;;US 201815861961 A,2018-01-04,SYSTEMS AND METHODS FOR PROVIDING ANTI-SPOOFING CAPABILITY TO A GLOBAL NAVIGATION SATELLITE SYSTEM RECEIVER,"Apparatus and methods provide anti-spoofing capability from a first global navigation satellite system (GNSS) receiver to a second GNSS receiver. These GNSS receivers can be, for example, global positioning satellite (GPS) receivers. Via an authentication technique, signals from authentic GNSS sources are distinguished from signals from spoofers. Timing information, such as numerically-controlled oscillator (NCO) settings, used for tracking authenticated signals are then used to generate replica GNSS signals, which are then provided to the second GNSS receiver. As a result, the second GNSS receiver can provide accurate positioning system information in the presence of GNSS spoofers.",INTERSTATE ELECTRONICS CORP,BOYER DEREK MICHAEL LOOMER;;ALEXANDER STEVEN B;;REDHEAD RICHARD F,L3HARRIS INTERSTATE ELECTRONICS CORPORATION (2021-10-18),https://lens.org/107-083-210-141-028,Patent Application,yes,2,0,6,6,0,G01S19/215;;G01S19/36;;G01S19/03;;G01S19/24;;G01S19/215;;G01S19/36;;G01S19/03,G01S19/21;;G01S19/03;;G01S19/36,,0,0,,,,PENDING
318,US,A1,US 2020/0309958 A1,133-726-512-333-833,2020-10-01,2020,US 202016902858 A,2020-06-16,US 202016902858 A;;US 201815861961 A,2018-01-04,SYSTEMS AND METHODS FOR PROVIDING ANTI-SPOOFING CAPABILITY TO A GLOBAL NAVIGATION SATELLITE SYSTEM RECEIVER,"Apparatus and methods provide anti-spoofing capability from a first global navigation satellite system (GNSS) receiver to a second GNSS receiver. These GNSS receivers can be, for example, global positioning satellite (GPS) receivers. Via an authentication technique, signals from authentic GNSS sources are distinguished from signals from spoofers. Timing information, such as numerically-controlled oscillator (NCO) settings, used for tracking authenticated signals are then used to generate replica GNSS signals, which are then provided to the second GNSS receiver. As a result, the second GNSS receiver can provide accurate positioning system information in the presence of GNSS spoofers.",INTERSTATE ELECTRONICS CORP,BOYER DEREK MICHAEL LOOMER;;ALEXANDER STEVEN B;;REDHEAD RICHARD F,L3HARRIS INTERSTATE ELECTRONICS CORPORATION (2021-10-18),https://lens.org/133-726-512-333-833,Patent Application,yes,0,0,6,6,0,G01S19/215;;G01S19/36;;G01S19/03;;G01S19/24;;G01S19/215;;G01S19/36;;G01S19/03,G01S19/21;;G01S19/03;;G01S19/36,,0,0,,,,ACTIVE
319,EP,B1,EP 2346917 B1,147-067-403-491-041,2013-08-28,2013,EP 09752075 A,2009-11-09,US 2009/0063728 W;;US 11319308 P,2008-11-10,"AN ISOCYANATE TRIMERISATION CATALYST SYSTEM, A PRECURSOR FORMULATION, A PROCESS FOR TRIMERISING ISOCYANATES, RIGID POLYISOCYANURATE/POLYURETHANE FOAMS MADE THEREFROM, AND A PROCESS FOR MAKING SUCH FOAMS",,DOW GLOBAL TECHNOLOGIES LLC,ATHEY PHILLIP;;WILMOT NATHAN;;KEATON RICHARD;;BOYER CECILE;;MORLEY TIMOTHY,,https://lens.org/147-067-403-491-041,Granted Patent,yes,3,0,10,10,0,C08G18/022;;C08G18/022;;C08G18/092;;C08G18/092;;C08G18/168;;C08G18/168;;C08G2110/0025;;C08G2110/0025;;C08G2115/02;;C08G2115/02,C08G18/02;;C08G18/09;;C08G18/16,,0,0,,,,ACTIVE
320,CA,A1,CA 2967634 A1,198-117-795-410-855,2016-05-19,2016,CA 2967634 A,2015-11-13,US 201462079367 P;;US 201514853504 A;;US 2015/0060697 W,2014-11-13,DEVICE AND METHOD FOR HEMORRHAGE DETECTION AND GUIDED RESUSCITATION AND APPLICATIONS OF SAME,"Aspects of the invention relates to systems and methods for detecting volume status, volume overload, dehydration, hemorrhage and real time assessment of resuscitation, as well as organ failure including but not limited cardiac, renal, and hepatic dysfunction, of a living subject using non-invasive vascular analysis (NIVA). In one embodiment, a non-invasive device, which includes at least one sensor, is used to acquire vascular signals from the living subject in real time. The vascular signals are sent to a controller, which processes the vascular signals to determine at least one hemodynamic parameter, such as the volume status of the living subject. In certain embodiments, the vascular signals are processed by a spectral fast Fourier transform (FFT) analysis to obtain the peripheral vascular signal frequency spectrum, and the volume status of the living subject may be determined by comparing amplitudes of the peaks of the peripheral vascular signal frequency spectrum.",VANDERBILT UNIVERSTIY,EAGLE SUSAN;;BROPHY COLLEEN;;HOCKING KYLE;;BAUDENBACHER FRANZ;;BOYER RICHARD,,https://lens.org/198-117-795-410-855,Patent Application,no,0,0,14,51,0,A61B5/02007;;A61B5/02028;;A61B5/02042;;A61B5/681;;A61B5/7257;;A61B5/0816;;A61B5/0002;;A61B5/02438;;A61B5/7221;;A61B5/4875;;A61B5/7221;;A61B5/0002;;A61B5/02007;;A61B5/02028;;A61B5/02042;;A61B5/02438;;A61B5/0816;;A61B5/4875;;A61B5/681;;A61B5/7257;;G16H40/63;;G16H40/63;;A61B5/0002;;A61B5/02007;;A61B5/02028;;A61B5/02042;;A61B5/02438;;A61B5/0816;;A61B5/4875;;A61B5/681;;A61B5/7221;;A61B5/7257;;G16H40/63,A61B5/02;;A61B5/00;;A61B5/021,,0,0,,,,PENDING
321,EP,A1,EP 3190960 A1,144-447-559-909-710,2017-07-19,2017,EP 15840046 A,2015-09-14,US 201462049829 P;;US 2015/0050001 W,2014-09-12,HYPOVOLEMIA/HYPERVOLEMIA DETECTION USING PERIPHERAL INTRAVENOUS WAVEFORM ANALYSIS (PIVA) AND APPLICATIONS OF SAME,,UNIV VANDERBILT,EAGLE SUSAN;;BROPHY COLLEEN;;HOCKING KYLE;;BAUDENBACHER FRANZ;;BOYER RICHARD,,https://lens.org/144-447-559-909-710,Patent Application,yes,0,0,16,51,0,A61B5/02042;;A61B5/02152;;A61B5/02042;;A61B5/02152;;A61B5/02152;;A61B5/02042,A61B5/021;;A61B5/00;;A61B5/02,,0,0,,,,ACTIVE
322,WO,A3,WO 2010/054311 A3,155-821-241-736-940,2010-12-02,2010,US 2009/0063725 W,2009-11-09,US 11319108 P,2008-11-10,"AN ISOCYANATE TRIMERISATION CATALYST SYSTEM, A PRECURSOR FORMULATION, A PROCESS FOR TRIMERISING ISOCYANATES, RIGID POLYISOCYANURATE/POLYURETHANE FOAMS MADE THEREFROM, AND A PROCESS FOR MAKING SUCH FOAMS","The instant invention provides an isocyanate trimerisation catalyst system, a precursor formulation, a process for trimerising isocyanates, rigid foams made therefrom, and a process for making such foams. The trimerisation catalyst system comprises: (a) a substituted iminium cation; and (b) an isocyanate-trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73 0C. The precursor formulation comprises (1) at least 25 percent by weight of polyol, based on the weight of the precursor formulation; (2) less than 15 percent by weight of a trimerisation catalyst system, based on the weight of the precursor formulation, comprising; (a) a substituted iminium cation; and (c) an isocyanate-trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73 0C; and (4) optionally one or more surfactants, one or more flame retardants, water, one or more antioxidants, one or more auxiliary blowing agents, one or more urethane catalysts, one or more auxiliary trimerisation catalysts, or combinations thereof. The process for trimerisation of isocyanates comprises the steps of: (1) providing one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture of any thereof; (2) providing a trimerisation catalyst system comprising; (a) an substituted iminium cation; and (b) an isocyanate-trimer inducing anion; (c) wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73 0C; (3) trimerising said one or more monomers in the presence of said trimerisation catalyst; (4) thereby forming an isocyanurate ring. The process for making the PIR foam comprises the steps of: (1) providing one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture of any thereof; (2) providing polyol; (3) providing a trimerisation catalyst system comprising; (a) a substituted iminium cation; and (b) an isocyanate-trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73 0C; and (4) optionally providing one or more surfactants, one or more flame retardants, water, one or more antioxidants, one or more auxiliary blowing agents, one or more urethane catalysts, one or more auxiliary trimerisation catalysts, or combinations thereof; (5) contacting said one or more monomers, and said polyol, and optionally said one or more surfactants, and optionally said one or more flame retardants, and optionally said water, and optionally said one or more antioxidants, and optionally said one or more auxiliary blowing agents in the presence of said trimerisation catalyst system and optionally said one or more urethane catalysts, and optionally said one or more auxiliary trimerisation catalysts; (6) thereby forming said polyisocyanurate/polyurethane rigid foam. The PIR foam comprises the reaction product of one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture of any thereof with polyol in the presence of a trimerisation catalyst system comprising a substituted iminium cation, and an isocyanate-trimer inducing anion, and optionally one or more surfactants, optionally one or more flame retardants, optionally water, optionally one or more antioxidants, optionally one or more auxiliary blowing agents, optionally one or more additional urethane catalysts, and optionally one or more auxiliary trimerisation catalysts, or optionally combinations thereof, wherein the trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73 0C. The PIR foam comprises the reaction product of one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture of any thereof with polyol in the presence of a trimerisation catalyst system comprising a substituted iminium cation, and an isocyanate-trimer inducing anion, and optionally one or more surfactants, optionally one or more flame retardants, optionally water, optionally one or more antioxidants, optionally one or more auxiliary blowing agents, optionally one or more additional polyurethane catalysts, and optionally one or more auxiliary trimerisation catalysts, or optionally combinations thereof, wherein the PIR foam has a polyisocyanurate trimer ratio (Abs1410/Abs1595) of at least 5 at a depth of 12 mm from the rising surface of the rigid foam, measured via ATR-FTIR spectroscopy.",DOW GLOBAL TECHNOLOGIES INC;;ATHEY PHILLIP;;WILMOT NATHAN;;KEATON RICHARD;;BOYER CECILE;;MORLEY TIMOTHY,ATHEY PHILLIP;;WILMOT NATHAN;;KEATON RICHARD;;BOYER CECILE;;MORLEY TIMOTHY,,https://lens.org/155-821-241-736-940,Search Report,yes,1,0,9,9,0,C08G18/022;;C08G18/022;;C08G18/092;;C08G18/092;;C08G18/168;;C08G18/168;;C08G18/1858;;C08G18/1858;;C08G18/1883;;C08G18/1883;;C08G18/791;;C08G18/791;;C08G2110/0025;;C08G2110/0025;;C08G2115/02;;C08G2115/02,C08G18/02;;C08G18/09;;C08G18/16;;C08G18/18;;C08G18/79,,0,0,,,,PENDING
323,US,A,US 3381499 A,164-088-608-351-316,1968-05-07,1968,US 41846064 A,1964-12-15,US 41846064 A,1964-12-15,Patterning means for circular knitting machines,,TEXTILE MACHINE WORKS,IMBODEN WALTER H;;JANDA RICHARD M;;BOYER JR JAMES H,,https://lens.org/164-088-608-351-316,Granted Patent,no,10,2,4,5,0,D04B9/20;;D04B9/56;;D04B15/82;;D04B9/56;;D04B9/20;;D04B15/82,D04B9/20;;D04B9/46;;D04B15/82,66/48,0,0,,,,EXPIRED
324,BR,A2,BR 112017005003 A2,177-587-105-486-09X,2018-06-05,2018,BR 112017005003 A,2015-09-14,US 2015/0050001 W;;US 201462049829 P;;US 201514853504 A,2014-09-12,detecção de hipovolemia/hipervolemia utilizando análise de forma de onda intravenosa periférica (piva) e aplicações da mesma,,UNIV VANDERBILT,COLLEEN BROPHY;;FRANZ BAUDENBACHER;;KYLE HOCKING;;RICHARD BOYER;;SUSAN EAGLE,,https://lens.org/177-587-105-486-09X,Patent Application,no,0,0,16,51,0,A61B5/02042;;A61B5/02152;;A61B5/02042;;A61B5/02152;;A61B5/02152;;A61B5/02042,A61B5/02;;A61B5/00;;A61B5/021,,0,0,,,,DISCONTINUED
325,US,A1,US 2019/0204451 A1,079-929-082-391-593,2019-07-04,2019,US 201815861961 A,2018-01-04,US 201815861961 A,2018-01-04,SYSTEMS AND METHODS FOR PROVIDING ANTI-SPOOFING CAPABILITY TO A GLOBAL NAVIGATION SATELLITE SYSTEM RECEIVER,"Apparatus and methods provide anti-spoofing capability from a first global navigation satellite system (GNSS) receiver to a second GNSS receiver. These GNSS receivers can be, for example, global positioning satellite (GPS) receivers. Via an authentication technique, signals from authentic GNSS sources are distinguished from signals from spoofers. Timing information, such as numerically-controlled oscillator (NCO) settings, used for tracking authenticated signals are then used to generate replica GNSS signals, which are then provided to the second GNSS receiver. As a result, the second GNSS receiver can provide accurate positioning system information in the presence of GNSS spoofers.",INTERSTATE ELECTRONICS CORP,BOYER DEREK MICHAEL LOOMER;;ALEXANDER STEVEN B;;REDHEAD RICHARD F,L3HARRIS INTERSTATE ELECTRONICS CORPORATION (2018-03-20),https://lens.org/079-929-082-391-593,Patent Application,yes,0,9,6,6,0,G01S19/215;;G01S19/36;;G01S19/03;;G01S19/24;;G01S19/215;;G01S19/36;;G01S19/03,G01S19/21,,0,0,,,,ACTIVE
326,US,A,US 2974268 A,118-110-039-652-097,1961-03-07,1961,US 61898856 A,1956-10-20,US 61898856 A,1956-10-20,Model railroad control system,,BLAKE FRANCIS E;;HENSON FLOYD H;;BOYER JR RICHARD P,BLAKE FRANCIS E;;HENSON FLOYD H;;BOYER JR RICHARD P,,https://lens.org/118-110-039-652-097,Granted Patent,no,6,5,1,1,0,A63H19/24;;A63H19/24,A63H19/24,,0,0,,,,EXPIRED
327,CN,B,CN 102245665 B,131-965-086-410-028,2013-11-13,2013,CN 200980149754 A,2009-11-09,US 2009/0063728 W;;US 11319308 P,2008-11-10,"An isocyanate trimerisation catalyst system, a precursor formulation, a process for trimerising isocyanates, rigid polyisocyanurate/polyurethane foams made therefrom, and a process for making such foams",,DOW GLOBAL TECHNOLOGIES INC,ATHEY PHILLIP;;WILMOT NATHAN;;KEATON RICHARD;;BOYER CECILE;;MORLEY TIMOTHY,,https://lens.org/131-965-086-410-028,Granted Patent,no,0,0,10,10,0,C08G18/022;;C08G18/022;;C08G18/092;;C08G18/092;;C08G18/168;;C08G18/168;;C08G2110/0025;;C08G2110/0025;;C08G2115/02;;C08G2115/02,C08G18/02;;C08G18/09;;C08G18/16,,0,0,,,,INACTIVE
328,EP,A2,EP 2346916 A2,159-034-408-875-663,2011-07-27,2011,EP 09752074 A,2009-11-09,US 2009/0063725 W;;US 11319108 P,2008-11-10,"AN ISOCYANATE TRIMERISATION CATALYST SYSTEM, A PRECURSOR FORMULATION, A PROCESS FOR TRIMERISING ISOCYANATES, RIGID POLYISOCYANURATE/POLYURETHANE FOAMS MADE THEREFROM, AND A PROCESS FOR MAKING SUCH FOAMS",,DOW GLOBAL TECHNOLOGIES LLC,ATHEY PHILLIP;;WILMOT NATHAN;;KEATON RICHARD;;BOYER CECILE;;MORLEY TIMOTHY,,https://lens.org/159-034-408-875-663,Patent Application,yes,0,0,9,9,0,C08G18/022;;C08G18/022;;C08G18/092;;C08G18/092;;C08G18/168;;C08G18/168;;C08G18/1858;;C08G18/1858;;C08G18/1883;;C08G18/1883;;C08G18/791;;C08G18/791;;C08G2110/0025;;C08G2110/0025;;C08G2115/02;;C08G2115/02,C08G18/02;;C08G18/09;;C08G18/16;;C08G18/18;;C08G18/79,,1,0,,,See references of WO 2010054311A2,ACTIVE
329,CN,A,CN 102245665 A,010-923-116-600-613,2011-11-16,2011,CN 200980149754 A,2009-11-09,US 2009/0063728 W;;US 11319308 P,2008-11-10,"An isocyanate trimerisation catalyst system, a precursor formulation, a process for trimerising isocyanates, rigid polyisocyanurate/polyurethane foams made therefrom, and a process for making such foams","The instant invention provides an isocyanate trimerisation catalyst system, a precursor formulation, a process for trimerising isocyanates, rigid foams made therefrom, and a process for making such foams. The trimerisation catalyst system comprises: (a) a phosphonium cation; and (b) an isocyanate-trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73 DEG C. The precursor formulation comprises (1) at least 25 percent by weight of polyol, based on the weight of the precursor formulation; (2) less than 15 percent by weight of a trimerisation catalyst system, based on the weight of the precursor formulation, comprising; (a) a phosphonium cation; and (c) an isocyanate- trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73 DEG C; and (3) optionally one or more surfactants, one or more flame retardants, water, one or more antioxidants, one or more auxiliary blowing agents, one or more urethane catalysts, one or more auxiliary trimerisation catalysts, or combinations thereof. The process for trimerisation of isocyanates comprises the steps of: (1) providing one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture of any thereof; (2) providing a trimerisation catalyst system comprising; (a) an phosphonium cation; and (b) an isocyanate-trimer inducing anion; (c) wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73 DEG C; (3) trimerising said one or more monomers in the presence of said trimerisation catalyst; (4) thereby forming an isocyanurate trimer. The process for making the PIR foam comprises the steps of.",DOW GLOBAL TECHNOLOGIES INC,PHILLIP ATHEY;;NATHAN WILMOT;;RICHARD KEATON;;CECILE BOYER;;TIMOTHY MORLEY,,https://lens.org/010-923-116-600-613,Patent Application,no,5,0,10,10,0,C08G18/022;;C08G18/022;;C08G18/092;;C08G18/092;;C08G18/168;;C08G18/168;;C08G2110/0025;;C08G2110/0025;;C08G2115/02;;C08G2115/02,C08G18/02;;C08G18/09;;C08G18/16,,1,0,,,"杨梅,张维芬,郭占军,等: ""催化自聚法降低聚氨酯粘合剂异氰酸酯预聚物中游离NCO含量"", 《吉林化工学院学报》",INACTIVE
330,WO,A1,WO 2018/217376 A1,035-122-793-042-054,2018-11-29,2018,US 2018/0029089 W,2018-04-24,US 201715604812 A,2017-05-25,ELECTRICAL CABLE CONNECTOR,"An electrical connector assembly (16) is presented herein. The electrical connector (16) includes a pair of connector blocks (18) each defining a groove in an end surface (18B) that is configured to have an electrical conductor of an electrical cable (12) partially disposed within it, e.g. a carbon nanotube conductor. The electrical connector (16) also includes a housing (20) configured to receive connector blocks (18), align the groove of one connector block (18) with the groove of the other connector block (18), and hold the connector blocks (18) together such that the electrical conductors (12A) within the grooves are in direct physical and electrical contact with the one another and are compressed. An electrical cable assembly (10) incorporating such a connector (16) and an method (100) of manufacturing a cable assembly (10) using such a connector (16) is also presented.",DELPHI TECH INC,BOYER RICHARD;;HEFFRON JOHN;;RUBINO EVANGELIA;;BRANTINGHAM DUANE;;RICHMOND ZACHARY,,https://lens.org/035-122-793-042-054,Patent Application,yes,5,0,2,2,0,H01R13/28;;H01R13/28;;H01R13/025;;H01R13/025;;H01R13/6272;;H01R13/6272,H01R13/629;;H01R13/639,,0,0,,,,PENDING
331,CO,A2,CO 2017003535 A2,101-888-754-424-587,2017-07-19,2017,CO 2017003535 A,2017-04-12,US 2015/0050001 W;;US 201462049829 P;;US 201514853504 A,2014-09-12,Detección de hipovolemia/hipervolemia usando análisisde forma de onda intravenosa periférica (piva),"Los aspectos de la invención se refieren a sistemas y métodos para detección de hipovolemia e/o hipervolemia de un sujeto vivo usando análisis de forma de onda intravenosa periférica. En una modalidad, el método incluye: adquirir, de una vena del sujeto vivo, señales venosas periféricas; realizar un análisis espectral en las señales venosas periféricas adquiridas para obtener espectros de frecuencia de presión venosa periférica; y realizar un análisis estadístico en las amplitudes de los picos de los espectros de frecuencia de presión venosa periférica para determinar el estado del volumen sanguíneo del sujeto vivo en tiempo real. Específicamente, al menos dos picos, respectivamente correspondientes a la primera frecuencia y la segunda frecuencia, se obtienen en los espectros de frecuencia de presión venosa periférica. Se usa cambio de amplitud del segundo pico para determinar el estado del volumen sanguíneo del sujeto vivo. Puede detectarse hemorragia cuando se detecta una reducción de amplitud importante a partir del segundo pico de valor de referencia al segundo pico.",UNIV VANDERBILT,EAGLE SUSAN;;BROPHY COLLEEN;;HOCKING KYLE;;BAUDENBACHER FRANZ;;BOYER RICHARD,,https://lens.org/101-888-754-424-587,Patent Application,no,0,0,16,51,0,A61B5/02042;;A61B5/02152;;A61B5/02042;;A61B5/02152;;A61B5/02152;;A61B5/02042,A61B5/021;;A61B5/00;;A61B5/02,,0,0,,,,PENDING
332,US,A1,US 2017/0332919 A1,158-775-110-629-39X,2017-11-23,2017,US 201515525748 A,2015-11-13,US 201515525748 A;;US 201514853504 A;;US 201462079367 P;;US 201462049829 P;;US 2015/0060697 W,2014-09-12,Device and Method for Hemorrhage Detection and Guided Resuscitation and Applications of Same,"Aspects of the invention relates to systems and methods for detecting volume status, volume overload, dehydration, hemorrhage and real time assessment of resuscitation, as well as organ failure including but not limited cardiac, renal, and hepatic dysfunction, of a living subject using non-invasive vascular analysis (NIVA). In one embodiment, a non-invasive device, which includes at least one sensor, is used to acquire vascular signals from the living subject in real time. The vascular signals are sent to a controller, which processes the vascular signals to determine at least one hemodynamic parameter, such as the volume status of the living subject. In certain embodiments, the vascular signals are processed by a spectral fast Fourier transform (FFT) analysis to obtain the peripheral vascular signal frequency spectrum, and the volume status of the living subject may be determined by comparing amplitudes of the peaks of the peripheral vascular signal frequency spectrum.",UNIV VANDERBILT,EAGLE SUSAN;;BROPHY COLLEEN;;HOCKING KYLE;;BAUDENBACHER FRANZ;;BOYER RICHARD,VANDERBILT UNIVERSITY (2016-08-22),https://lens.org/158-775-110-629-39X,Patent Application,yes,48,12,2,51,0,A61B5/02028;;A61B5/02028;;A61B5/0002;;A61B5/0002;;A61B5/02007;;A61B5/02007;;A61B5/02042;;A61B5/02042;;A61B5/02152;;A61B5/02152;;A61B5/02438;;A61B5/02438;;A61B5/0816;;A61B5/0816;;A61B5/4875;;A61B5/4875;;A61B5/681;;A61B5/681;;A61B5/7221;;A61B5/7221;;A61B5/7257;;A61B5/7257,A61B5/02;;A61B5/00;;A61B5/024;;A61B5/08,,0,0,,,,ACTIVE
333,AU,A1,AU 2015/346054 A1,139-558-925-986-240,2017-06-01,2017,AU 2015/346054 A,2015-11-13,US 201514853504 A;;US 201462079367 P;;US 2015/0060697 W,2014-11-13,Device and method for hemorrhage detection and guided resuscitation and applications of same,"Aspects of the invention relates to systems and methods for detecting volume status, volume overload, dehydration, hemorrhage and real time assessment of resuscitation, as well as organ failure including but not limited cardiac, renal, and hepatic dysfunction, of a living subject using non-invasive vascular analysis (NIVA). In one embodiment, a non-invasive device, which includes at least one sensor, is used to acquire vascular signals from the living subject in real time. The vascular signals are sent to a controller, which processes the vascular signals to determine at least one hemodynamic parameter, such as the volume status of the living subject. In certain embodiments, the vascular signals are processed by a spectral fast Fourier transform (FFT) analysis to obtain the peripheral vascular signal frequency spectrum, and the volume status of the living subject may be determined by comparing amplitudes of the peaks of the peripheral vascular signal frequency spectrum.",UNIV VANDERBILT,BAUDENBACHER FRANZ;;BOYER RICHARD;;EAGLE SUSAN;;BROPHY COLLEEN;;HOCKING KYLE,,https://lens.org/139-558-925-986-240,Patent Application,no,0,0,14,51,0,A61B5/02007;;A61B5/02028;;A61B5/02042;;A61B5/681;;A61B5/7257;;A61B5/0816;;A61B5/0002;;A61B5/02438;;A61B5/7221;;A61B5/4875;;A61B5/7221;;A61B5/0002;;A61B5/02007;;A61B5/02028;;A61B5/02042;;A61B5/02438;;A61B5/0816;;A61B5/4875;;A61B5/681;;A61B5/7257;;G16H40/63;;G16H40/63;;A61B5/0002;;A61B5/02007;;A61B5/02028;;A61B5/02042;;A61B5/02438;;A61B5/0816;;A61B5/4875;;A61B5/681;;A61B5/7221;;A61B5/7257;;G16H40/63,A61B5/02;;A61B5/00,,0,0,,,,ACTIVE
334,CA,C,CA 2961195 C,177-141-677-920-510,2023-01-17,2023,CA 2961195 A,2015-09-14,US 201462049829 P;;US 201514853504 A;;US 2015/0050001 W,2014-09-12,HYPOVOLEMIA/HYPERVOLEMIA DETECTION USING PERIPHERAL INTRAVENOUS WAVEFORM ANALYSIS (PIVA) AND APPLICATIONS OF SAME,"Aspects of the invention relates to systems and methods for hypovolemia and/or hypervolemia detection of a living subject using peripheral intravenous waveform analysis. In one embodiment, the method includes: acquiring, from a vein of the living subject, peripheral venous signals; performing a spectral analysis on the acquired peripheral venous signals to obtain a peripheral venous pressure frequency spectrum; and performing a statistical analysis on amplitudes of peaks of the peripheral venous pressure frequency spectrum to determine the blood volume status of the living subject in real time. Specifically, at least two peaks, respectively corresponding to a first frequency and a second frequency, are obtained on the peripheral venous pressure frequency spectrum. Amplitude change of the second peak is used to determine the blood volume status of the living subject. Hemorrhage may be detected when a significant amplitude decrease is detected from the second baseline peak to the second peak.",UNIV VANDERBILT,EAGLE SUSAN;;BROPHY COLLEEN;;HOCKING KYLE;;BAUDENBACHER FRANZ;;BOYER RICHARD,,https://lens.org/177-141-677-920-510,Granted Patent,no,0,0,16,51,0,A61B5/02042;;A61B5/02152;;A61B5/02042;;A61B5/02152;;A61B5/02152;;A61B5/02042,A61B5/021;;A61B5/00;;A61B5/02;;A61B5/0215,,0,0,,,,PENDING
335,SG,A,SG 11201701987V A,002-191-214-979-419,2017-04-27,2017,SG 11201701987V A,2015-09-14,US 201462049829 P;;US 201514853504 A;;US 2015/0050001 W,2014-09-12,HYPOVOLEMIA/HYPERVOLEMIA DETECTION USING PERIPHERAL INTRAVENOUS WAVEFORM ANALYSIS (PIVA) AND APPLICATIONS OF SAME,,UNIV VANDERBILT,EAGLE SUSAN;;BROPHY COLLEEN;;HOCKING KYLE;;BAUDENBACHER FRANZ;;BOYER RICHARD,,https://lens.org/002-191-214-979-419,Unknown,no,0,0,16,51,0,A61B5/02042;;A61B5/02152;;A61B5/02042;;A61B5/02152;;A61B5/02152;;A61B5/02042,A61B5/021;;A61B5/00;;A61B5/02,,0,0,,,,PENDING
336,US,B2,US 10456046 B2,091-206-509-735-339,2019-10-29,2019,US 201515525748 A,2015-11-13,US 201515525748 A;;US 201514853504 A;;US 201462079367 P;;US 201462049829 P;;US 2015/0060697 W,2014-09-12,Device and method for hemorrhage detection and guided resuscitation and applications of same,"Aspects of the invention relates to systems and methods for detecting volume status, volume overload, dehydration, hemorrhage and real time assessment of resuscitation, as well as organ failure including but not limited cardiac, renal, and hepatic dysfunction, of a living subject using non-invasive vascular analysis (NIVA). In one embodiment, a non-invasive device, which includes at least one sensor, is used to acquire vascular signals from the living subject in real time. The vascular signals are sent to a controller, which processes the vascular signals to determine at least one hemodynamic parameter, such as the volume status of the living subject. In certain embodiments, the vascular signals are processed by a spectral fast Fourier transform (FFT) analysis to obtain the peripheral vascular signal frequency spectrum, and the volume status of the living subject may be determined by comparing amplitudes of the peaks of the peripheral vascular signal frequency spectrum.",UNIV VANDERBILT,EAGLE SUSAN;;BROPHY COLLEEN;;HOCKING KYLE;;BAUDENBACHER FRANZ;;BOYER RICHARD,VANDERBILT UNIVERSITY (2016-08-22),https://lens.org/091-206-509-735-339,Granted Patent,yes,35,0,2,51,0,A61B5/02028;;A61B5/02028;;A61B5/0002;;A61B5/0002;;A61B5/02007;;A61B5/02007;;A61B5/02042;;A61B5/02042;;A61B5/02152;;A61B5/02152;;A61B5/02438;;A61B5/02438;;A61B5/0816;;A61B5/0816;;A61B5/4875;;A61B5/4875;;A61B5/681;;A61B5/681;;A61B5/7221;;A61B5/7221;;A61B5/7257;;A61B5/7257,A61B6/02;;A61B5/00;;A61B5/02;;A61B5/0215;;A61B5/024;;A61B5/08,,1,0,,,"Langley, P. et al., “Computer Algorithm for Tracking ECG Spectral Dynamics in Ventricular Tachyarrhythmias,” Computers in Cardiology 2009; 36:329-332.",ACTIVE
337,CN,B,CN 102272183 B,158-152-995-861-610,2014-07-02,2014,CN 200980154183 A,2009-11-09,US 2009/0063725 W;;US 11319108 P,2008-11-10,"An isocyanate trimerisation catalyst system, a precursor formulation, a process for trimerising isocyanates, rigid polyisocyanurate/polyurethane foams made therefrom, and a process for making such foams",,DOW GLOBAL TECHNOLOGIES INC,ATHEY PHILLIP;;WILMOT NATHAN;;KEATON RICHARD;;BOYER CECILE;;MORLEY TIMOTHY,,https://lens.org/158-152-995-861-610,Granted Patent,no,0,0,9,9,0,C08G18/022;;C08G18/022;;C08G18/092;;C08G18/092;;C08G18/168;;C08G18/168;;C08G18/1858;;C08G18/1858;;C08G18/1883;;C08G18/1883;;C08G18/791;;C08G18/791;;C08G2110/0025;;C08G2110/0025;;C08G2115/02;;C08G2115/02,C08G18/02;;C08G18/09;;C08G18/16;;C08G18/18;;C08G18/79,,0,0,,,,INACTIVE
338,US,A1,US 2013/0136610 A1,160-143-103-051-311,2013-05-30,2013,US 201113304734 A,2011-11-28,US 201113304734 A,2011-11-28,TURBINE BUCKET AIRFOIL PROFILE,"A turbine bucket is provided including a bucket airfoil having an airfoil shape, the bucket airfoil having a nominal profile substantially in accordance with Cartesian coordinate values of X, Y and Z set forth in Table 1 wherein the Cartesian coordinate values of X, Y and Z are non-dimensional values from 0% to 100% convertible to dimensional distances in inches by multiplying the Cartesian coordinate values of X, Y and Z by a height of the airfoil in inches, and wherein X and Y are distances in inches which, when connected by smooth continuing arcs, define airfoil profile sections at each distance Z, the airfoil profile sections at Z distances being joined smoothly with one another to form a complete airfoil shape.",STEIN ALEXANDER;;BOYER BRADLEY TAYLOR;;FU XIAOYONG;;GOOD RANDALL RICHARD;;GEN ELECTRIC,STEIN ALEXANDER;;BOYER BRADLEY TAYLOR;;FU XIAOYONG;;GOOD RANDALL RICHARD,GE INFRASTRUCTURE TECHNOLOGY LLC (2023-11-10);;GENERAL ELECTRIC COMPANY (2012-02-01),https://lens.org/160-143-103-051-311,Patent Application,yes,3,5,2,2,0,F01D5/141;;F01D5/141;;F05D2250/74;;F05D2250/74,F01D5/14,416223 A,0,0,,,,ACTIVE
339,WO,A1,WO 2016/077765 A1,182-203-661-167-212,2016-05-19,2016,US 2015/0060697 W,2015-11-13,US 201462079367 P;;US 201514853504 A,2014-11-13,DEVICE AND METHOD FOR HEMORRHAGE DETECTION AND GUIDED RESUSCITATION AND APPLICATIONS OF SAME,"Aspects of the invention relates to systems and methods for detecting volume status, volume overload, dehydration, hemorrhage and real time assessment of resuscitation, as well as organ failure including but not limited cardiac, renal, and hepatic dysfunction, of a living subject using non-invasive vascular analysis (NIVA). In one embodiment, a non-invasive device, which includes at least one sensor, is used to acquire vascular signals from the living subject in real time. The vascular signals are sent to a controller, which processes the vascular signals to determine at least one hemodynamic parameter, such as the volume status of the living subject. In certain embodiments, the vascular signals are processed by a spectral fast Fourier transform (FFT) analysis to obtain the peripheral vascular signal frequency spectrum, and the volume status of the living subject may be determined by comparing amplitudes of the peaks of the peripheral vascular signal frequency spectrum.",UNIV VANDERBILT,EAGLE SUSAN;;BROPHY COLLEEN;;HOCKING KYLE;;BAUDENBACHER FRANZ;;BOYER RICHARD,,https://lens.org/182-203-661-167-212,Patent Application,yes,5,8,14,51,0,A61B5/02007;;A61B5/02028;;A61B5/02042;;A61B5/681;;A61B5/7257;;A61B5/0816;;A61B5/0002;;A61B5/02438;;A61B5/7221;;A61B5/4875;;A61B5/7221;;A61B5/0002;;A61B5/02007;;A61B5/02028;;A61B5/02042;;A61B5/02438;;A61B5/0816;;A61B5/4875;;A61B5/681;;A61B5/7257;;G16H40/63;;G16H40/63;;A61B5/0002;;A61B5/02007;;A61B5/02028;;A61B5/02042;;A61B5/02438;;A61B5/0816;;A61B5/4875;;A61B5/681;;A61B5/7221;;A61B5/7257;;G16H40/63,A61B5/02;;A61B5/00,,1,0,,,See also references of EP 3217863A4,PENDING
340,US,A,US 2913533 A,031-321-534-297-593,1959-11-17,1959,US 70448757 A,1957-12-23,US 70448757 A,1957-12-23,Broadcast paging system,,GEN DYNAMICS CORP,GATZERT ERNEST H;;PHARIS WILLIAM W;;BOYER JR RICHARD P,,https://lens.org/031-321-534-297-593,Granted Patent,no,5,3,1,1,0,H04M11/022;;H04M11/022,H04M11/02,,0,0,,,,EXPIRED
341,ES,T3,ES 2561042 T3,113-004-748-671-724,2016-02-24,2016,ES 09752074 T,2009-11-09,US 11319108 P;;US 2009/0063725 W,2008-11-10,"Un sistema catalítico de trimerización de isocianato, una formulación precursora, un procedimiento para trimerizar isocianatos, espumas rígidas de poliisocianurato/poliuretano preparadas a partir del mismo y un procedimiento para preparar dichas espumas","Un sistema catalítico de trimerización, que consiste en: (a) un catión que tiene la siguiente estructura:**Fórmula** en donde R1 se selecciona del grupo que consiste en H, C1-C18, N, Si y cualquier combinación de los mismos; en donde R2 se selecciona del grupo que consiste en H, C1-C18, N, Si y cualquier combinación de los mismos; y en donde R3 se selecciona del grupo que consiste en H, C1-C18, N, Si, y cualquier combinación de los mismos; y (b) un anión que induce el trímero de isocianato es carboxilato que tiene la siguiente estructura:**Fórmula** en donde X' se selecciona del grupo que consiste en H, C1-C18, alifático, aromático, cíclico, acíclico, acilo y derivados de los mismos. en donde dicho sistema catalítico de trimerización tiene una temperatura de activación de trimerización medida por Calorimetría de Barrido Diferencial (DSC) en el intervalo de igual a o menor que 73 ºC.",DOW GLOBAL TECHNOLOGIES LLC,ATHEY PHILLIP;;WILMOT NATHAN;;KEATON RICHARD;;BOYER CECILE;;MORLEY TIMOTHY,,https://lens.org/113-004-748-671-724,Granted Patent,no,0,0,9,9,0,C08G18/022;;C08G18/022;;C08G18/092;;C08G18/092;;C08G18/168;;C08G18/168;;C08G18/1858;;C08G18/1858;;C08G18/1883;;C08G18/1883;;C08G18/791;;C08G18/791;;C08G2110/0025;;C08G2110/0025;;C08G2115/02;;C08G2115/02,C08G18/02;;C08G18/09;;C08G18/16;;C08G18/18;;C08G18/79,,0,0,,,,ACTIVE
342,EP,A4,EP 3217863 A4,181-179-090-166-49X,2018-07-11,2018,EP 15859906 A,2015-11-13,US 201462079367 P;;US 201514853504 A;;US 2015/0060697 W,2014-11-13,DEVICE AND METHOD FOR HEMORRHAGE DETECTION AND GUIDED RESUSCITATION AND APPLICATIONS OF SAME,,UNIV VANDERBILT,EAGLE SUSAN;;BROPHY COLLEEN;;HOCKING KYLE;;BAUDENBACHER FRANZ;;BOYER RICHARD,,https://lens.org/181-179-090-166-49X,Search Report,no,3,0,14,51,0,A61B5/02007;;A61B5/02028;;A61B5/02042;;A61B5/681;;A61B5/7257;;A61B5/0816;;A61B5/0002;;A61B5/02438;;A61B5/7221;;A61B5/4875;;A61B5/7221;;A61B5/0002;;A61B5/02007;;A61B5/02028;;A61B5/02042;;A61B5/02438;;A61B5/0816;;A61B5/4875;;A61B5/681;;A61B5/7257;;G16H40/63;;G16H40/63;;A61B5/0002;;A61B5/02007;;A61B5/02028;;A61B5/02042;;A61B5/02438;;A61B5/0816;;A61B5/4875;;A61B5/681;;A61B5/7221;;A61B5/7257;;G16H40/63,A61B5/02;;A61B5/00,,1,0,,,See also references of WO 2016077765A1,PENDING
343,US,B2,US 11181646 B2,184-207-725-258-350,2021-11-23,2021,US 202016902858 A,2020-06-16,US 202016902858 A;;US 201815861961 A,2018-01-04,Systems and methods for providing anti-spoofing capability to a global navigation satellite system receiver,"Apparatus and methods provide anti-spoofing capability from a first global navigation satellite system (GNSS) receiver to a second GNSS receiver. These GNSS receivers can be, for example, global positioning satellite (GPS) receivers. Via an authentication technique, signals from authentic GNSS sources are distinguished from signals from spoofers. Timing information, such as numerically-controlled oscillator (NCO) settings, used for tracking authenticated signals are then used to generate replica GNSS signals, which are then provided to the second GNSS receiver. As a result, the second GNSS receiver can provide accurate positioning system information in the presence of GNSS spoofers.",INTERSTATE ELECTRONICS CORP,BOYER DEREK MICHAEL LOOMER;;ALEXANDER STEVEN B;;REDHEAD RICHARD F,L3HARRIS INTERSTATE ELECTRONICS CORPORATION (2021-10-18),https://lens.org/184-207-725-258-350,Granted Patent,yes,116,2,6,6,0,G01S19/215;;G01S19/36;;G01S19/03;;G01S19/24;;G01S19/215;;G01S19/36;;G01S19/03,G01S19/21;;G01S19/03;;G01S19/24;;G01S19/36,,7,0,,,"Chen, et al., “Off-the-Shelf Antennas for Controlled-Reception-Pattern Antenna Arrays”; GPS World; Innovation: Getting Control; Feb. 1, 2013, [retrieved on Feb. 26, 2014]. Retrieved from the Internet: URL: http://gpsworld.com/innovation-getting-control-off-the-shelf-antennas-for-controlled-reception-pattern-antenna-arrays/.;;Jackson Labs, “RSR GPS RF=Transcoder / 10-Channel GPS Simulator, 2.3×1.6 inches,” [online], Jan. 22, 2017, [retrieved on Jun. 1, 2017], retrieved from <URL: http://www.jackson-labs.com/assets/uploads/main/RSR_Transcoder_specsheet.pdf>.;;Office Action dated Aug. 28, 2017, from related U.S. Appl. No. 14/678,755, filed Apr. 3, 2015.;;PCT International Search Report and Written Opinion of the International Searching Authority regarding International Application No. PCT/US18/62115, dated Feb. 5, 2019, 19 Pages.;;Todd E. Humphreys, et al., “The GPS Assimilator: a Method for Upgrading Existing GPS User Equipment to Improve Accuracy, Robustness, and Resistance to Spoofing,” [online], Preprint of the 2010 ION GNSS Conference, Portland, Oregon, Sep. 21-24, 2010, [online], [retrieved on Apr. 26, 2017], retrieved from: <URL: https://radionavlab.ae.utexas.edu/images/stories/files/papers/assimilator_for_distribution.pdf>.;;Todd Humphreys, et al., “Assessing the Civil GPS Spoofing Threat,” [online], The University of Texas at Austin Radionavigation Laboratory, Powerpoint presentation, 2009, [retrieved on Apr. 26, 2017], retrieved from <URL: https://radionavlab.ae.utexas.edu/images/stories/files/presentations/assessingSpoofingThreat.pdf>.;;Wen, et al., “Countermeasures for GPS Signal Spoofing”; Proceedings of the 18th International Technical Meeting of the Satellite Division of The Institute of Navigation (ION GNSS 2005); Long Beach, CA, Sep. 2005, pp. 1285-1290, [retrieved on Sep. 24, 2013]. Retrieved from the Internet: URL: http://lens.ou.edu/Download/ION/ION%202005%20Wen_Spoof.doc.",ACTIVE
344,HU,T2,HU E041300 T2,030-535-085-175-482,2019-05-28,2019,HU E15191470 A,2007-06-26,US 81652206 P,2006-06-26,PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE,,AKEBIA THERAPEUTICS INC,KAWAMOTO RICHARD MASARU;;WARSHAKOON NAMAL;;WU SHENGDE;;BOYER ANGELIQUE;;GREIS KENNETH,,https://lens.org/030-535-085-175-482,Amended Patent,no,0,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,,,0,0,,,,PENDING
345,ES,T3,ES 2256493 T3,038-799-052-014-383,2006-07-16,2006,ES 02747330 T,2002-05-29,GB 0113232 A,2001-05-31,PROCEDIMIENTO PARA LA PREPARACION DE UN LIGANDO TIAZOL PPAR Y POLIMORFOS DEL MISMO.,Un procedimiento de preparación de un compuesto de fórmula (I). y sales y solvatos farmacéuticamente aceptables del mismo que comprende hacer reaccionar un compuesto de fórmula (II) en la que X es Me o H con un compuesto de fórmula (III) en la que X1 es cloro o imidazol.,SMITHKLINE BEECHAM CORP,BOYER THIERRY;;DAY CAROLINE JANE;;WHITEHEAD ANDREW JONATHAN;;HENSON RICHARD ANTHONY,,https://lens.org/038-799-052-014-383,Granted Patent,no,0,0,27,27,0,C07D277/56;;A61P1/14;;A61P29/00;;A61P3/00;;A61P3/10;;A61P3/04;;A61P3/06;;A61P9/04;;A61P9/10;;C07D277/56;;C07D277/56,A61K31/426;;A61P1/14;;A61P3/04;;C07D277/20;;A61P3/06;;A61P3/10;;A61P9/04;;A61P9/10;;A61P29/00;;C07D277/56,,0,0,,,,EXPIRED
346,WO,A3,WO 2005/075028 A3,048-988-526-249-172,2008-06-05,2008,US 2005/0002904 W,2005-01-31,US 77086204 A,2004-02-02,CHROMATIC ARCHITECTURE FOR SPORTS EQUIPMENT,"Sporting items such as soccer balls include a casing region and a graphic region that are defined by enhanced-visibility colors (EVCs) that are substantially complementary. Such EVCs can be selected to avoid colors associated with color confusion in color deficient individuals. In addition, such colors can be selected based on total reflectances to obtain a predetermined luminance contrast. EVCs can be selected based on separations of color coordinate locations using CIE chromaticity coordinates or CIE L-a-b coordinates or otherwise selected. Color selection can include consideration of anticipated viewing backgrounds in a general setting, or colors can be customized for a particular location and particular illumination conditions.",NIKE INTERNATIONAL LTD;;NIKE INC;;BOYER CLANCY G;;AVIS RICHARD G;;REICHOW ALAN W;;CITEK KARL,BOYER CLANCY G;;AVIS RICHARD G;;REICHOW ALAN W;;CITEK KARL,,https://lens.org/048-988-526-249-172,Search Report,yes,3,0,8,8,0,A63B43/008;;A63B71/00;;A63B2071/0027;;B44D3/003;;B44F1/08;;G01J3/46;;G01J3/462;;G01J3/463;;G01J3/465;;G01J3/46;;G01J3/463;;B44D3/003;;B44F1/08;;G01J3/465;;A63B43/008;;G01J3/462;;A63B2071/0027;;A63B71/00,A63B43/00;;A63B41/00;;A63B45/02;;A63B71/00;;B44D3/00;;B44F1/08;;G01J3/46;;G01J3/52,,0,0,,,,PENDING
347,CA,A1,CA 3061917 A1,079-830-903-723-584,2018-11-08,2018,CA 3061917 A,2018-05-01,US 201762492868 P;;US 201815968515 A;;US 2018/0030544 W,2017-05-01,SYSTEM FOR DOSING AND DISPENSING MEDICATION,"A system for medication delivery comprises a Package containing a medication and a Dosing mechanism for delivering a dose of a drug, formulated as multi-particulate, microspheres, powder or liquid. The Package comprises a bottle, a bottle insert that covers the bottle opening and includes a dispense nozzle. The dispense nozzle is sealed using a valve that opens when the Dosing device is engaged with the bottle. A closure covers the bottle insert and closes the bottle. The Dosing device, similar to an oral syringe, comprises a barrel with a valve at its distal end, a plunger and a dose control clip for attachment to the plunger. After the dosing device is connected to the bottle valve, withdrawal of the plunger causes the dosing device to receive a dose of drug, the user pushes the plunger which pushes the MP drug through the valve and into a patient's mouth.",QUINN MICHAEL V;;GORSHKOV ALEXANDER;;CRONENBERG RICHARD;;ALDEN TOR;;BOYER ROBERT,QUINN MICHAEL V;;BOYER ROBERT;;GORSHKOV ALEXANDER;;CRONENBERG RICHARD;;ALDEN TOR,,https://lens.org/079-830-903-723-584,Patent Application,no,0,0,7,7,0,A47G19/34;;A61M5/31501;;A61M5/3156;;A61M5/31563;;A61M39/26;;B65D83/06;;A61M2005/31508;;A61M2005/3154;;A61M2005/5033;;A61M2039/267;;A61J2200/76;;A61J7/0053;;A61J1/2096;;G01F11/027;;A61J7/0053;;A61J7/0076;;A61J1/00;;A61M5/31563;;B65D83/06;;A61M39/26;;A61M2039/267;;A61M5/31501;;A61M5/3156;;A61M2005/31508;;A61M2005/5033;;A61M2005/3154;;A61J2200/76,A61M39/26;;A47G19/34;;A47J31/40;;A61J1/20;;A61J7/00;;A61M5/315;;A61M5/50;;B65D83/06;;G01F11/46,,0,0,,,,PENDING
348,AT,T1,AT E315556 T1,130-325-453-920-66X,2006-02-15,2006,AT 02747330 T,2002-05-29,GB 0113232 A,2001-05-31,VERFAHREN ZUR HERSTELLUNG EINES THIAZOL-PPAR- LIGANDEN SOWIE DESSEN POLYMORPHE,,SMITHKLINE BEECHAM CORP,BOYER THIERRY;;DAY CAROLINE JANE;;WHITEHEAD ANDREW JONATHAN;;HENSON RICHARD ANTHONY,,https://lens.org/130-325-453-920-66X,Granted Patent,no,0,0,27,27,0,C07D277/56;;A61P1/14;;A61P29/00;;A61P3/00;;A61P3/10;;A61P3/04;;A61P3/06;;A61P9/04;;A61P9/10;;C07D277/56;;C07D277/56,C07D277/20;;A61K31/426;;A61P1/14;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/04;;A61P9/10;;A61P29/00;;C07D277/56,,0,0,,,,EXPIRED
349,US,B2,US 9587066 B2,080-725-239-248-068,2017-03-07,2017,US 200913125486 A,2009-11-09,US 200913125486 A;;US 11319308 P;;US 2009/0063728 W,2008-11-10,"Isocyanate trimerisation catalyst system, a precursor formulation, a process for trimerising isocyanates, rigid polyisocyanurate/polyurethane foams made therefrom, and a process for making such foams","The instant invention provides an isocyanate trimerisation catalyst system, a precursor formulation, a process for trimerising isocyanates, rigid foams made therefrom, and a process for making such foams. A trimerisation catalyst system comprising (a) a phosphonium cation; and (b) an isocyanate-trimer inducing carboxylate anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73° C. is provided.",ATHEY PHILLIP S;;WILMOT NATHAN;;KEATON RICHARD;;BOYER CECILE;;MORLEY TIMOTHY;;DOW GLOBAL TECHNOLOGIES LLC,ATHEY PHILLIP S;;WILMOT NATHAN;;KEATON RICHARD;;BOYER CECILE;;MORLEY TIMOTHY,DOW EUROPE GMBH (2009-07-17);;DOW GLOBAL TECHNOLOGIES LLC (2009-07-08);;THE DOW CHEMICAL COMPANY (2009-07-27),https://lens.org/080-725-239-248-068,Granted Patent,yes,12,0,10,10,0,C08G18/022;;C08G18/022;;C08G18/092;;C08G18/092;;C08G18/168;;C08G18/168;;C08G2110/0025;;C08G2110/0025;;C08G2115/02;;C08G2115/02,C08G18/02;;C08G18/09;;C08G18/16;;C08G101/00,,3,0,,,"Journal of American Chemical Society, vol. 49, p. 3181 (1927).;;PCT/US2009/063728 International Search Report and Written Opinion, (2009).;;PCT/US2009/063728 International Preliminary Report on Patentability, (2009).",INACTIVE
350,US,A1,US 2018/0311110 A1,084-337-077-040-934,2018-11-01,2018,US 201815968515 A,2018-05-01,US 201815968515 A;;US 201762492868 P,2017-05-01,System For Dosing And Dispensing Medication,"A system for medication delivery comprises a Package containing a medication and a Dosing mechanism for delivering a dose of a drug, formulated as multiparticulate, microspheres, powder or liquid. The Package comprises a bottle, a bottle insert that covers the bottle opening and includes a dispense nozzle. The dispense nozzle is sealed using a valve that opens when the Dosing device is engaged with the bottle. A closure covers the bottle insert and closes the bottle. The Dosing device, similar to an oral syringe, comprises a barrel with a valve at its distal end, a plunger and a dose control clip for attachment to the plunger. After the dosing device is connected to the bottle valve, withdrawal of the plunger causes the dosing device to receive a dose of drug, the user pushes the plunger which pushes the MP drug through the valve and into a patient's mouth.",QUINN MICHAEL VINCENT;;GORSHKOV ALEXANDER;;CRONENBERG RICHARD;;ALDEN TOR;;BOYER ROBERT,QUINN MICHAEL VINCENT;;GORSHKOV ALEXANDER;;CRONENBERG RICHARD;;ALDEN TOR;;BOYER ROBERT,SYMPFINY LLC (2020-12-10),https://lens.org/084-337-077-040-934,Patent Application,yes,6,5,7,7,0,A47G19/34;;A61M5/31501;;A61M5/3156;;A61M5/31563;;A61M39/26;;B65D83/06;;A61M2005/31508;;A61M2005/3154;;A61M2005/5033;;A61M2039/267;;A61J2200/76;;A61J7/0053;;A61J1/2096;;G01F11/027;;A61J7/0053;;A61J7/0076;;A61J1/00;;A61M5/31563;;B65D83/06;;A61M39/26;;A61M2039/267;;A61M5/31501;;A61M5/3156;;A61M2005/31508;;A61M2005/5033;;A61M2005/3154;;A61J2200/76,A61J7/00;;A61J1/00,,0,0,,,,ACTIVE
351,AT,T1,AT E485264 T1,048-859-705-443-391,2010-11-15,2010,AT 07835890 T,2007-06-26,US 81652206 P;;US 2007/0014832 W,2006-06-26,PROLYLHYDROXYLASE-HEMMER UND VERFAHREN ZU IHRER ANWENDUNG,,WARNER CHILCOTT CO LLC,KAWAMOTO RICHARD MASARU;;WARSHAKOON NAMAL;;WU SHENGDE;;BOYER ANGELIQUE;;GREIS KENNETH,,https://lens.org/048-859-705-443-391,Granted Patent,no,0,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,,,0,0,,,,ACTIVE
352,LT,T,LT 3357911 T,022-149-008-284-217,2022-08-10,2022,LT 18158907 T,2007-06-26,US 81652206 P,2006-06-26,PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE,,AKEBIA THERAPEUTICS INC,KAWAMOTO RICHARD MASARU;;WARSHAKOON NAMAL;;WU SHENGDE;;BOYER ANGELIQUE;;GREIS KENNETH,,https://lens.org/022-149-008-284-217,Unknown,no,0,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07D213/81;;A61K31/4418;;A61K31/4433;;A61P1/04;;A61P7/00;;A61P7/06;;A61P9/10;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;C07C235/60;;C07C237/42;;C07C255/57;;C07D213/65;;C07D295/192;;C07D401/04;;C07D401/10;;C07D405/04;;C07D405/10;;C07D417/04,,0,0,,,,PENDING
353,NZ,A,NZ 529486 A,103-651-983-477-137,2005-12-23,2005,NZ 52948602 A,2002-05-29,GB 0113232 A;;EP 0205884 W,2001-05-31,Process for preparing a thiazole PPAR-ligand and polymorphs thereof,"Disclosed is a method of preparing a compound of formula (I), comprising reacting a compound of formula (II), wherein X is Me or H, with a compound of formula (III), wherein X1 is chlorine or imidizole.",GLAXO GROUP LTD,BOYER THIERRY;;DAY CAROLINE JANE;;WHITEHEAD ANDREW JONATHAN;;HENSON RICHARD ANTHONY,,https://lens.org/103-651-983-477-137,Patent Application,no,0,0,27,27,0,C07D277/56;;A61P1/14;;A61P29/00;;A61P3/00;;A61P3/10;;A61P3/04;;A61P3/06;;A61P9/04;;A61P9/10;;C07D277/56;;C07D277/56,A61K31/426;;A61P1/14;;A61P3/04;;A61P3/06;;C07D277/20;;A61P3/10;;A61P9/04;;A61P9/10;;A61P29/00;;C07D277/56,,0,0,,,,PENDING
354,WO,A3,WO 2007/030678 A3,191-615-252-148-317,2007-06-28,2007,US 2006/0034962 W,2006-09-07,US 71536305 P;;US 79020906 P,2005-09-07,METHODS OF GENOME-WIDE LOCATION ANALYSIS IN STEM CELLS,"The invention relates to improved methods of identifying the genomic regions to which a protein of interest binds, and in particular, to methods that apply to stem cells such as but not limited to, embryonic stem cells and adult stem cells. The invention also provides methods of identifying agents which modulate differentiation of stem cells. The invention also provides methods of defining the differentiation potential of a cell and of designing array oligonucleotides.",WHITEHEAD BIOMEDICAL INST;;YOUNG RICHARD A;;LEE TONG IHN;;GUENTHER MATTHEW;;BOYER LAURIE A,YOUNG RICHARD A;;LEE TONG IHN;;GUENTHER MATTHEW;;BOYER LAURIE A,,https://lens.org/191-615-252-148-317,Search Report,yes,1,0,3,3,0,C12Q1/6809;;C12Q1/6809;;C12Q1/6837;;C12Q1/6837,C12Q1/68,,10,10,067-242-370-268-649;;029-251-310-758-845;;008-218-359-381-130;;030-586-745-640-31X;;024-275-371-019-135;;013-246-784-613-798;;006-537-838-063-709;;100-669-418-477-624;;024-703-708-159-749;;034-070-960-380-715,15988017;;10.1128/mcb.25.14.6031-6046.2005;;pmc1168830;;10.1073/pnas.1332764100;;pmc166200;;12808131;;pmc1142473;;15899964;;10.1101/gr.3430605;;10.1126/science.1075090;;12399584;;15231737;;10.1101/gad.1200204;;pmc443521;;pmc3006442;;10.1016/j.cell.2005.08.020;;16153702;;15461792;;10.1186/gb-2004-5-10-r73;;pmc545593;;10.1126/science.1103388;;15539566;;10.1007/s11103-005-6164-5;;16217608;;10.1016/j.tig.2005.06.007;;15979196;;pmc1855044,"CHEW JOON-LIN ET AL: ""Reciprocal transcriptional regulation of Pou5f1 and Sox2 via the Oct4/Sox2 complex in embryonic stem cells"", MOLECULAR AND CELLULAR BIOLOGY, vol. 25, no. 14, July 2005 (2005-07-01), pages 6031 - 6046, XP002412921, ISSN: 0270-7306;;LI ZIRONG ET AL: ""A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells."", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 100, no. 14, 8 July 2003 (2003-07-08), pages 8164 - 8169, XP002327641, ISSN: 0027-8424;;KIM TAE HOON ET AL: ""Direct isolation and identification of promoters in the human genome"", GENOME RESEARCH, vol. 15, no. 6, June 2005 (2005-06-01), pages 830 - 839, XP002412922, ISSN: 1088-9051;;LEE TONG IHN ET AL: ""Transcriptional regulatory networks in Saccharomyces cerevisiae."", SCIENCE. 25 OCT 2002, vol. 298, no. 5594, 25 October 2002 (2002-10-25), pages 799 - 804, XP002327643, ISSN: 1095-9203;;KIRMIZIS ANTONIS ET AL: ""Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27"", GENES & DEVELOPMENT, vol. 18, no. 13, 1 July 2004 (2004-07-01), pages 1592 - 1605, XP002412926, ISSN: 0890-9369;;BOYER LAURIE A ET AL: ""Core transcriptional regulatory circuitry in human embryonic stem cells"", CELL, vol. 122, no. 6, 23 September 2005 (2005-09-23), pages 947 - 956, XP002412923, ISSN: 0092-8674;;SCHADT ERIC E ET AL: ""A comprehensive transcript index of the human genome generated using microarrays and computational approaches"", GENOME BIOLOGY, BIOMED CENTRAL LTD., LONDON, GB, vol. 5, no. 10, 23 September 2004 (2004-09-23), pages R73, XP021012835, ISSN: 1465-6906;;BERTONE PAUL ET AL: ""Global identification of human transcribed sequences with genome tiling arrays"", SCIENCE (WASHINGTON D C), vol. 306, no. 5705, 24 December 2004 (2004-12-24), pages 2242 - 2246, XP002424376, ISSN: 0036-8075;;VIKTOR STOLC ET AL: ""A Pilot Study of Transcription Unit Analysis in Rice Using Oligonucleotide Tiling-path Microarray"", PLANT MOLECULAR BIOLOGY, KLUWER ACADEMIC PUBLISHERS, DO, vol. 59, no. 1, 1 September 2005 (2005-09-01), pages 137 - 149, XP019262760, ISSN: 1573-5028;;ROYCE ET AL: ""Issues in the analysis of oligonucleotide tiling microarrays for transcript mapping"", TRENDS IN GENETICS, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 21, no. 8, August 2005 (2005-08-01), pages 466 - 475, XP005065875, ISSN: 0168-9525",PENDING
355,CN,A,CN 110603071 A,032-136-635-554-191,2019-12-20,2019,CN 201880029343 A,2018-05-01,US 201762492868 P;;US 2018/0030544 W,2017-05-01,SYSTEM FOR DOSING AND DISPENSING MEDICATION,"A system for medication delivery comprises a package containing a medication and a dosing mechanism for delivering a dose of a drug, formulated as multiparticulate, microspheres, powder or liquid. Thepackage comprises a bottle, a bottle insert that covers the bottle opening and includes a dispense nozzle. The dispense nozzle is sealed using a valve that opens when the Dosing device is engaged with the bottle. A closure covers the bottle insert and closes the bottle. The dosing device, similar to an oral syringe, comprises a barrel with a valve at its distal end, a plunger and a dose control clip for attachment to the plunger. After the dosing device is connected to the bottle valve, withdrawal of the plunger causes the dosing device to receive a dose of drug, the user pushes the plunger which pushes the MP drug through the valve and into a patient's mouth.",HS DESIGN CO,QUINN MICHAEL V;;GORSHKOV ALEXANDER;;CRONENBERG RICHARD;;ALDEN TOR;;BOYER ROBERT,,https://lens.org/032-136-635-554-191,Patent Application,no,8,0,7,7,0,A47G19/34;;A61M5/31501;;A61M5/3156;;A61M5/31563;;A61M39/26;;B65D83/06;;A61M2005/31508;;A61M2005/3154;;A61M2005/5033;;A61M2039/267;;A61J2200/76;;A61J7/0053;;A61J1/2096;;G01F11/027;;A61J7/0053;;A61J7/0076;;A61J1/00;;A61M5/31563;;B65D83/06;;A61M39/26;;A61M2039/267;;A61M5/31501;;A61M5/3156;;A61M2005/31508;;A61M2005/5033;;A61M2005/3154;;A61J2200/76,A61M39/26;;A47G19/34;;A47J31/40;;A61J1/20;;A61J7/00;;A61M5/315;;A61M5/50;;B65D83/06;;G01F11/46,,0,0,,,,PENDING
356,EP,A1,EP 3628016 A1,039-681-521-620-355,2020-04-01,2020,EP 18726286 A,2018-05-01,US 201762492868 P;;US 2018/0030544 W,2017-05-01,SYSTEM FOR DOSING AND DISPENSING MEDICATION,,QUINN MICHAEL V;;GORSHKOV ALEXANDER;;CRONENBERG RICHARD;;ALDEN TOR;;BOYER ROBERT,QUINN MICHAEL V;;GORSHKOV ALEXANDER;;CRONENBERG RICHARD;;ALDEN TOR;;BOYER ROBERT,,https://lens.org/039-681-521-620-355,Patent Application,yes,0,0,7,7,0,A47G19/34;;A61M5/31501;;A61M5/3156;;A61M5/31563;;A61M39/26;;B65D83/06;;A61M2005/31508;;A61M2005/3154;;A61M2005/5033;;A61M2039/267;;A61J2200/76;;A61J7/0053;;A61J1/2096;;G01F11/027;;A61J7/0053;;A61J7/0076;;A61J1/00;;A61M5/31563;;B65D83/06;;A61M39/26;;A61M2039/267;;A61M5/31501;;A61M5/3156;;A61M2005/31508;;A61M2005/5033;;A61M2005/3154;;A61J2200/76,A61M39/26;;A47G19/34;;A47J31/40;;A61J1/20;;A61J7/00;;A61M5/315;;A61M5/50;;B65D83/06;;G01F11/46,,0,0,,,,PENDING
357,AU,B2,AU 2002/317764 B2,100-558-178-305-900,2005-01-06,2005,AU 2002/317764 A,2002-05-29,GB 0113232 A;;EP 0205884 W,2001-05-31,Process for preparing a thialzole PPAR-ligand and polymorphs thereof,,GLAXO GROUP LTD,BOYER THIERRY;;DAY CAROLINE JANE;;WHITEHEAD ANDREW JONATHAN;;HENSON RICHARD ANTHONY,,https://lens.org/100-558-178-305-900,Granted Patent,no,0,0,27,27,0,C07D277/56;;A61P1/14;;A61P29/00;;A61P3/00;;A61P3/10;;A61P3/04;;A61P3/06;;A61P9/04;;A61P9/10;;C07D277/56;;C07D277/56,C07D277/20;;A61K31/426;;A61P1/14;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/04;;A61P9/10;;A61P29/00;;C07D277/56,,0,0,,,,EXPIRED
358,EP,B1,EP 1395572 B1,187-845-615-615-885,2006-01-11,2006,EP 02747330 A,2002-05-29,EP 0205884 W;;GB 0113232 A,2001-05-31,PROCESS FOR PREPARING A THIAZOLE PPAR-LIGAND AND POLYMORPHS THEREOF,,SMITHKLINE BEECHAM CORP,BOYER THIERRY;;DAY CAROLINE JANE;;WHITEHEAD ANDREW JONATHAN;;HENSON RICHARD ANTHONY,SMITHKLINE BEECHAM CORPORATION (2005-04-20),https://lens.org/187-845-615-615-885,Granted Patent,yes,2,0,27,27,0,C07D277/56;;A61P1/14;;A61P29/00;;A61P3/00;;A61P3/10;;A61P3/04;;A61P3/06;;A61P9/04;;A61P9/10;;C07D277/56;;C07D277/56,C07D277/20;;A61K31/426;;C07D277/56;;A61P1/14;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/04;;A61P9/10;;A61P29/00,,1,0,,,"RANDAD R S ET AL: ""Allosteric modifiers of hemoglobin. 1. Design, synthesis, testing, and structure-allosteric activity relationship of novel hemoglobin oxygen affinity decreasing agents"" JOURNAL OF MEDICINAL CHEMISTRY, vol. 34, no. 2, February 1991 (1991-02), pages 752-757, XP002205822",EXPIRED
359,US,B2,US 11266573 B2,011-646-628-411-887,2022-03-08,2022,US 201815968515 A,2018-05-01,US 201815968515 A;;US 201762492868 P,2017-05-01,System for dosing and dispensing medication,"A system for medication delivery comprises a package containing a medication and a dosing device for delivering a dose of the medication, formulated as a multiparticulate, microspheres, a powder or a liquid. The package comprises a bottle, a bottle insert that covers a bottle opening and includes a dispense nozzle. The dispense nozzle is sealed using a valve that opens when the dosing device is engaged with the bottle. A closure covers the bottle insert and closes the bottle. The dosing device, similar to an oral syringe, comprises a barrel with a valve at a distal end of the barrel, a plunger and a dose control clip for attachment to the plunger. After the dosing device is connected to, the valve of the dispense nozzle, withdrawal of the plunger causes the dosing device to receive the dose of the medication, a user pushes the plunger which pushes the medication through the valve of the barrel and into a patient's mouth.",QUINN MICHAEL VINCENT;;GORSHKOV ALEXANDER;;CRONENBERG RICHARD;;ALDEN TOR;;BOYER ROBERT;;SYMPFINY LLC,QUINN MICHAEL VINCENT;;GORSHKOV ALEXANDER;;CRONENBERG RICHARD;;ALDEN TOR;;BOYER ROBERT,SYMPFINY LLC (2020-12-10),https://lens.org/011-646-628-411-887,Granted Patent,yes,14,1,7,7,0,A47G19/34;;A61M5/31501;;A61M5/3156;;A61M5/31563;;A61M39/26;;B65D83/06;;A61M2005/31508;;A61M2005/3154;;A61M2005/5033;;A61M2039/267;;A61J2200/76;;A61J7/0053;;A61J1/2096;;G01F11/027;;A61J7/0053;;A61J7/0076;;A61J1/00;;A61M5/31563;;B65D83/06;;A61M39/26;;A61M2039/267;;A61M5/31501;;A61M5/3156;;A61M2005/31508;;A61M2005/5033;;A61M2005/3154;;A61J2200/76,A61J7/00;;A61J1/00;;A61M5/315;;A61M5/50;;A61M39/26;;B65D83/06,,9,1,030-613-964-533-611,10.3390/scipharm87030020,"WIPO, International Bureau, International Preliminary Report on Patentability, for PCT/US2018/030544, PCT counterpart of US application, dated Nov. 14, 2019.;;WIPO International Searching Authority, International Search Report for PCT/US2018/030544, PCT counterpart of US application, dated Sep. 12, 2018.;;WIPO, International Searching Authority, Written Opinion of the International Searching Authority, for PCT/US2018/030544, PCT counterpart of US application, dated Sep. 12, 2018.;;Lengyel, M. et al. Multiparticules, Microspheres, and Microcapsules For Advanced Drug Delivery, Scientia Pharmaceutica, 2019 87:20 doi:10.3390/scipharm 87030020.;;13th Annual Conference European Paediatric Formulation Initiative EUPFI 2020-Virtual, 2021 downloaded from the Internet on Apr. 2, 2021, from http://eupfi.org/upcoming-conference/13th-eupfi-conference-virtual-.;;Bartlett, J.A. et al. Pediatric Formulation Development—Industry Perspective on Palatability Challenges and Opportunities, 2016, Presentation at CERSI Workshop in collaboration with EuPFI & IQ Consortium, Hyattsville, MD; downloaded from the Internet on Feb. 8, 2021, from https://www.pharmacy.umaryland.edu/media/SOP/wwwpharmacyumarylandedu/centers/cerseievents/pedsformulation/bartlett-presentation-notes.pdf.;;Pfizer Corp. Pfizer and The Institute of Pediatric Innovation Issue Open Innovation Challenge, May 24, 2016, downloaded from the Internet on Mar. 22, 2021, from https://pfizer.com/news/featured/featured_stories_detail/pfi . . . .;;Narsalay, R et al. Open Innovation at Pfizer, Accenture Co., 2017 downloaded from the Internet on Mar. 22, 2021, from www.ideaconnection.com.pdf.pfizer.;;PRWEB, Pediatric Open Innovation Challenge Grantees Awarded $50,000 by the Institute for Pediatric Innovation and Pfizer, Dec. 12, 2016, downloaded from the Internet on Mar. 22, 2021, from www.prweb.com.releases.2016/12.prweb13889068.",ACTIVE
360,WO,A2,WO 2007/030678 A2,048-094-282-152-653,2007-03-15,2007,US 2006/0034962 W,2006-09-07,US 71536305 P;;US 79020906 P,2005-09-07,METHODS OF GENOME-WIDE LOCATION ANALYSIS IN STEM CELLS,"The invention relates to improved methods of identifying the genomic regions to which a protein of interest binds, and in particular, to methods that apply to stem cells such as but not limited to, embryonic stem cells and adult stem cells. The invention also provides methods of identifying agents which modulate differentiation of stem cells. The invention also provides methods of defining the differentiation potential of a cell and of designing array oligonucleotides.",WHITEHEAD BIOMEDICAL INST;;YOUNG RICHARD A;;LEE TONG IHN;;GUENTHER MATTHEW;;BOYER LAURIE A,YOUNG RICHARD A;;LEE TONG IHN;;GUENTHER MATTHEW;;BOYER LAURIE A,,https://lens.org/048-094-282-152-653,Patent Application,yes,0,5,3,3,0,C12Q1/6809;;C12Q1/6809;;C12Q1/6837;;C12Q1/6837,C12Q1/68,,0,0,,,,PENDING
361,CZ,A3,CZ 20033256 A3,058-817-089-165-021,2004-04-14,2004,CZ 20033256 A,2002-05-29,GB 0113232 A,2001-05-31,CZ 20033256 A3,,GLAXO GROUP LTD,BOYER THIERRY;;DAY CAROLINE JANE;;WHITEHEAD ANDREW JONATHAN;;HENSON RICHARD ANTHONY,,https://lens.org/058-817-089-165-021,Patent Application,no,0,0,27,27,0,C07D277/56;;A61P1/14;;A61P29/00;;A61P3/00;;A61P3/10;;A61P3/04;;A61P3/06;;A61P9/04;;A61P9/10;;C07D277/56;;C07D277/56,A61K31/426;;A61P1/14;;A61P3/04;;C07D277/20;;A61P3/06;;A61P3/10;;A61P9/04;;A61P9/10;;A61P29/00;;C07D277/56,,0,0,,,,PENDING
362,CN,A,CN 1551871 A,089-397-629-954-256,2004-12-01,2004,CN 02810885 A,2002-05-29,GB 0113232 A,2001-05-31,Process for preparinga thiazole PPAR-ligand and polymorphs thereof,一种制备式(I)化合物及其可药用盐以及溶剂化物的方法。还公开了这种化合物的多晶型物以及其作为PPAR配体的应用。,GLAXO GROUP LTD,THIERRY BOYER;;JANE DAY CAROLINE;;JONATHAN WHITEHEAD ANDREW;;ANTHONY HENSON RICHARD,,https://lens.org/089-397-629-954-256,Patent Application,no,0,0,27,27,0,C07D277/56;;A61P1/14;;A61P29/00;;A61P3/00;;A61P3/10;;A61P3/04;;A61P3/06;;A61P9/04;;A61P9/10;;C07D277/56;;C07D277/56,C07D277/20;;A61K31/426;;A61P1/14;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/04;;A61P9/10;;A61P29/00;;C07D277/56,,0,0,,,,DISCONTINUED
363,NO,D0,NO 20035313 D0,158-153-201-272-297,2003-11-28,2003,NO 20035313 A,2003-11-28,EP 0205884 W;;GB 0113232 A,2001-05-31,Fremgangsmåte for fremstilling av tialzol PPAR-ligand og polymorfer derav,,GLAXO GROUP LTD,BOYER THIERRY;;DAY CAROLINE JANE;;WHITEHEAD ANDREW JONATHAN;;HENSON RICHARD ANTHONY,,https://lens.org/158-153-201-272-297,Patent Application,no,0,0,27,27,0,C07D277/56;;A61P1/14;;A61P29/00;;A61P3/00;;A61P3/10;;A61P3/04;;A61P3/06;;A61P9/04;;A61P9/10;;C07D277/56;;C07D277/56,A61K31/426;;C07D277/20;;A61P1/14;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/04;;A61P9/10;;A61P29/00;;C07D277/56,,0,0,,,,DISCONTINUED
364,US,B2,US 7244849 B2,077-938-109-863-709,2007-07-17,2007,US 47826004 A,2004-04-27,EP 0205884 W;;GB 0113232 A,2001-05-31,Process for preparing a thiazole PPAR-ligand and polymorphs thereof,"A method of preparing a compound of formula (I), and pharmaceutically acceptable salts and solvates thereof. Polymorphs of this compound and their use as PPAR ligands are also disclosed",GLAXO GROUP LTD,BOYER THIERRY;;DAY CAROLINE JANE;;WHITEHEAD ANDREW JONATHAN;;HENSON RICHARD ANTHONY,GLAXO GROUP LIMITED (2001-05-31),https://lens.org/077-938-109-863-709,Granted Patent,yes,6,0,27,27,0,C07D277/56;;A61P1/14;;A61P29/00;;A61P3/00;;A61P3/10;;A61P3/04;;A61P3/06;;A61P9/04;;A61P9/10;;C07D277/56;;C07D277/56,C07D277/20;;A61K31/426;;A61P1/14;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/04;;A61P9/10;;A61P29/00;;C07D277/56,548/200;;548/146,1,1,011-825-100-455-148,10.1021/jm00106a041;;1995897,"Randad, R.S., et al. ""Allosteric modifiers of hemoglobin. 1. Design, synthesis, testing, and structure-allosteric activity relationship of novel hemoglobin oxygen affinity decreasing agents."" Journal of Medicinal Chemistry, vol. 34, No. 2, Feb. 1991, pp. 752-757.",EXPIRED
365,EP,A1,EP 1395572 A1,070-212-993-991-287,2004-03-10,2004,EP 02747330 A,2002-05-29,EP 0205884 W;;GB 0113232 A,2001-05-31,PROCESS FOR PREPARING A THIAZOLE PPAR-LIGAND AND POLYMORPHS THEREOF,,GLAXO GROUP LTD,BOYER THIERRY;;DAY CAROLINE JANE;;WHITEHEAD ANDREW JONATHAN;;HENSON RICHARD ANTHONY,SMITHKLINE BEECHAM CORPORATION (2005-04-20),https://lens.org/070-212-993-991-287,Patent Application,yes,0,0,27,27,0,C07D277/56;;A61P1/14;;A61P29/00;;A61P3/00;;A61P3/10;;A61P3/04;;A61P3/06;;A61P9/04;;A61P9/10;;C07D277/56;;C07D277/56,A61K31/426;;A61P1/14;;A61P3/04;;C07D277/20;;A61P3/06;;A61P3/10;;A61P9/04;;A61P9/10;;A61P29/00;;C07D277/56,,0,0,,,,EXPIRED
366,HU,A2,HU P0400117 A2,148-431-422-750-285,2005-03-29,2005,HU P0400117 A,2002-05-29,EP 0205884 W;;GB 0113232 A,2001-05-31,"POLYMORPHS OF 2-METHYL-2-[4-({[-4METHYL-2-(4-TRIFLUOROMETHYL-PHENYL)-THIAZOL-5-CARBONYL]-AMINO}-METHYL)-PHENOXY]-PROPIONIC ACID, PROCESS FOR THEIR PREPARATION, THEIR USE AND PHARMACEURICAL COMPOSITIONS CONTAINING THEM","A találmány tárgya eljárás az (I) képletű vegyület, gyógyszerészetilegelfogadható sói és szolvátjai előállítására oly módon, hogy egy (II)általános képletű vegyületet - a képletben X jelentése metilcsoportvagy H - egy (III) általános képletű vegyülettel - a képletben X1jelentése klóratom vagy imidazolcsoport - reagáltatnak. A találmányvonatkozik továbbá az (I) képletű vegyület polimorf módosulataira, azezeket tartalmazó gyógyszerkészítményekre és alkalmazásukra hPPAR alfaáltal közvetített betegség vagy állapot kezelésére szolgáló gyógyszerelőállítására. Ó",GLAXO GROUP LTD,BOYER THIERRY;;DAY CAROLINE JANE;;WHITEHEAD ANDREW JONATHAN;;HENSON RICHARD ANTHONY,,https://lens.org/148-431-422-750-285,Patent Application,no,0,0,27,27,0,C07D277/56;;A61P1/14;;A61P29/00;;A61P3/00;;A61P3/10;;A61P3/04;;A61P3/06;;A61P9/04;;A61P9/10;;C07D277/56;;C07D277/56,A61K31/426;;C07D277/20;;A61P1/14;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/04;;A61P9/10;;A61P29/00;;C07D277/56,,0,0,,,,PENDING
367,US,B2,US 7963869 B2,148-154-422-830-098,2011-06-21,2011,US 71789407 A,2007-03-13,US 71789407 A;;US 77086204 A,2004-02-02,Chromatic architecture for sports equipment,"Sporting items such as soccer balls include a casing region and a graphic region that are defined by enhanced-visibility colors (EVCs) that are substantially complementary. Such EVCs can be selected to avoid colors associated with color confusion in color deficient individuals. In addition, such colors can be selected based on total reflectances to obtain a predetermined luminance contrast. EVCs can be selected based on separations of color coordinate locations using CIE chromaticity coordinates or CIE L-a-b coordinates or otherwise selected. Color selection can include consideration of anticipated viewing backgrounds in a general setting, or colors can be customized for a particular location and particular illumination conditions.",NIKE INC,BOYER CLANCY G;;AVIS RICHARD G;;REICHOW ALAN W;;CITEK KARL,NIKE INC (2004-06-15),https://lens.org/148-154-422-830-098,Granted Patent,yes,56,12,8,8,0,A63B43/008;;A63B71/00;;A63B2071/0027;;B44D3/003;;B44F1/08;;G01J3/46;;G01J3/462;;G01J3/463;;G01J3/465;;G01J3/46;;G01J3/463;;B44D3/003;;B44F1/08;;G01J3/465;;A63B43/008;;G01J3/462;;A63B2071/0027;;A63B71/00,A63B41/00;;A63B43/00;;A63B45/02;;A63B71/00;;G01J3/46,473/604;;40/327;;473/446,35,5,075-505-901-524-229;;003-640-002-574-046;;062-339-109-703-474;;172-136-737-968-965;;045-975-507-749-508,12472438;;10.1111/j.1444-0938.2000.tb05006.x;;9831156;;17073573;;10.1615/jlongtermeffmedimplants.v16.i4.50;;3209790;;10.1007/s002210000640;;11310166,"Advisory Action mailed Aug. 25, 2006 for U.S. Appl. No. 10/770,862, filed Feb. 2, 2004.;;Advisory Action mailed Mar. 27, 2008 for U.S. Appl. No. 10/770,862, filed Feb. 2, 2004.;;Final Office Action mailed May 10, 2006 for U.S. Appl. No. 10/770,862, filed Feb. 2, 2004.;;Final Office Actiion mailed Jan. 7, 2008 for U.S. Appl. No. 10/770,862, filed Feb. 2, 2004.;;Final Office Action mailed Apr. 3, 2009 for U.S. Appl. No. 10/770,862, filed Feb. 2, 2004.;;International Search Report mailed Sep. 7, 2006 for Appl. No. PCT/U05/04526, filed Feb. 9, 2005.;;International Search Report mailed Apr. 14, 2008 for PCT/US05/002904, filed Jan. 31, 2005.;;International Search Report mailed Aug. 29, 2008 for Appl. No. PCT/US08/63416, filed May 12, 2008.;;International Search Report mailed Sep. 5, 2008 for Appl. No. PCT/US08/634425, filed May 12, 2008.;;International Search Report mailed Nov. 26, 2009 for Appl. No. PCT/US08/63416, filed May 12, 2008.;;Non-Final Office Action mailed Jun. 8, 2005 for U.S. Appl. No. 10/770,862, filed Feb. 2, 2004.;;Non-Final Office Action mailed Oct. 19, 2005 for U.S. Appl. No. 10/770,862, filed Feb. 2, 2004.;;Non-Final Office Action mailed Jul. 24, 2007 for U.S. Appl. No. 10/770,862, filed Feb. 2, 2004.;;Non-Final Office Action mailed Jul. 1, 2008 for U.S. Appl. No. 10/770,862, filed Feb. 2, 2004.;;Non-Final Office Action mailed Jul. 28, 2009 for U.S. Appl. No. 11/942,520, filed Nov. 19, 2007.;;Non-Final Office Action mailed Oct. 8, 2009 for U.S. Appl. No. 11/801,931, filed May 11, 2007.;;Final Office Action mailed Dec. 9, 2009 for U.S. Appl. No. 11/942,520, filed Nov. 19, 2007.;;Non-Final Office Action mailed Dec. 15, 2009 for U.S. Appl. No. 11/717,894, filed Mar. 13, 2007.;;Notice of Allowance mailed Feb. 2, 2007 for U.S. Appl. No. 10/770,862, filed Feb. 2, 2004.;;Advisory Action mailed Feb. 19, 2010 for U.S. Appl. No. 11/942,520, filed Nov. 19, 2007.;;Final Office Action mailed Jun. 30, 2010 for U.S. Appl. No. 10/770,862, filed Feb. 2, 2004.;;Non Final Office Action mailed Oct. 7, 2010 for U.S. Appl. No. 11/942,520, filed Nov. 19, 2007.;;Non-Final Office Action mailed Dec. 15, 2009 for U.S. Appl. No. 10/770,862, filed Feb. 2, 2004.;;Cardall, ""Contact Lenses in Sport: a General Overview"", Optician, Jan. 13, 2006, pp. 22-25, vol. 231, No. 6034, United States.;;Coffey, et al., ""Optometric Evaluation of the Elite Athlete,"" Problems in Optometry, Mar. 1990, pp. 32-59, vol. 2, No. 1, United States.;;Coffey, et al., ""Visual Performance Enhancement in Sports Optometry"", Sports Vision 1995, pp. 158-177, Butterwork-Heinermann, Unted States.;;Farrow, et al., ""An Investigation of the Effectiveness of Bolle's Competivision Sport-Glasses on Tennis Performance"", Clinical and Experimental Optometry, Jul.-Aug. 2000, pp. 226-231, vol. 83, No. 4.;;Ferreira, ""An Overview of Research in Sports Vision: its History and an Optometric Perspective"", The South African Optometrist, Dec. 2003, pp. 142-149, vol. 62, No. 4, Auckland Park, South Africa.;;Herdman, et al., ""Computerized Dynamic Visual Acuity Test in the Assessment of Vestibular Deficits"", The American Journal of Otology, 1998, pp. 790-796, vol. 19, No. 6, United States.;;Koenig, ""Practicing Perception: Eyes Can Be Trained to be More Effective"", USA Today Baseball Weekly, 1996, 3 pages, United States.;;Reichow, et al., ""A Comparison of Contrast Sensitivity in Elite Athletes Versus a Normal Population"", American Journal of Optometry and Physiological Optics, Dec. 15, 1986, vol. 63, No. 82, United States.;;Reichow, et al., ""Introduction to Behavioral Optometry"", Sports Vision, 1993, 75 pages, Optometric Extension Program Foundation, United States.;;Reichow, et al., ""Ultraviolet and Short Wavelength Visible Light Exposure: Why Ultraviolet Protection Alone is Not Adequate"", Journal of Long-Term Effects of Medical Implants, 2006, pp. 315-325, vol. 16, No. 4, Begell House, Inc., United States.;;Rouse, et al., ""A Comparison Study of Dynamic Visual Acuity Between Athletes and Nonathletes"", Journal of the American Optometric Association, Dec. 1988, pp. 946-950, vol. 59, No. 12, United States.;;Tian, et al., ""Dynamic Visual Acuity Transient and Sinusoidal Yaw Rotation in Normal Ulilaterally Vestibulopathic Humans"", Experimental Brain Research, Feb. 8, 2001, pp. 12-25, vol. 137, Springer-Verlag, United States.",ACTIVE
368,PL,A1,PL 367114 A1,012-539-875-883-251,2005-02-21,2005,PL 36711402 A,2002-05-29,GB 0113232 A,2001-05-31,PROCESS FOR PREPARING A THIALZOLE PPAR-LIGAND AND POLYMORPHS THEREOF,,GLAXO GROUP LTD,BOYER THIERRY;;DAY CAROLINE JANE;;WHITEHEAD ANDREW JONATHAN;;HENSON RICHARD ANTHONY,,https://lens.org/012-539-875-883-251,Patent Application,no,0,0,27,27,0,C07D277/56;;A61P1/14;;A61P29/00;;A61P3/00;;A61P3/10;;A61P3/04;;A61P3/06;;A61P9/04;;A61P9/10;;C07D277/56;;C07D277/56,A61K31/426;;A61P1/14;;C07D277/20;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/04;;A61P9/10;;A61P29/00;;C07D277/56,,0,0,,,,DISCONTINUED
369,US,A1,US 2005/0170920 A1,014-364-297-452-61X,2005-08-04,2005,US 77086204 A,2004-02-02,US 77086204 A,2004-02-02,Chromatic architecture for sports equipment,"Sporting items such as soccer balls include a casing region and a graphic region that are defined by enhanced-visibility colors (EVCs) that are substantially complementary. Such EVCs can be selected to avoid colors associated with color confusion in color deficient individuals. In addition, such colors can be selected based on total reflectances to obtain a predetermined luminance contrast. EVCs can be selected based on separations of color coordinate locations using CIE chromaticity coordinates or CIE L-a-b coordinates or otherwise selected. Color selection can include consideration of anticipated viewing backgrounds in a general setting, or colors can be customized for a particular location and particular illumination conditions.",NIKE INC,BOYER CLANCY G;;AVIS RICHARD G;;REICHOW ALAN W;;CITEK KARL,NIKE INC (2004-06-28);;NIKE INTERNATIONAL LTD (2005-02-14),https://lens.org/014-364-297-452-61X,Patent Application,yes,51,30,8,8,0,A63B43/008;;A63B71/00;;A63B2071/0027;;B44D3/003;;B44F1/08;;G01J3/46;;G01J3/462;;G01J3/463;;G01J3/465;;G01J3/46;;G01J3/463;;B44D3/003;;B44F1/08;;G01J3/465;;A63B43/008;;G01J3/462;;A63B2071/0027;;A63B71/00,A63B41/00;;A63B43/00;;A63B45/02;;A63B71/00;;G01J3/46,473/570,0,0,,,,EXPIRED
370,US,B2,US 8661756 B2,158-227-272-598-541,2014-03-04,2014,US 201113043857 A,2011-03-09,US 201113043857 A;;US 32605910 P,2010-04-20,Insulated metal vertical joint insert,A composite panel assembly includes first and second panels. An edge of the first panel is positioned adjacent to an edge of the second panel to define a joint. The edge of the first panel and the edge of the second panel each define a recessed portion. An insert is positioned between the first and second panels at the joint. A portion of the insert is received within respective recessed portions of the first and second panels.,BOYER KEITH D;;WESCHE LARRY A;;GIANDOMENICO DARIO;;BROW RICHARD A;;CENTRIA,BOYER KEITH D;;WESCHE LARRY A;;GIANDOMENICO DARIO;;BROW RICHARD A,CENTRIA (2011-04-01);;NCI GROUP INC (2020-02-17);;NUCOR INSULATED PANEL GROUP LLC (2021-07-27),https://lens.org/158-227-272-598-541,Granted Patent,yes,11,1,2,2,0,E04F13/0846;;E04F13/0875;;E04F13/0894;;E04F13/0898;;E04C2/292;;E04F13/0898;;E04F13/0875;;E04F13/0846;;E04F13/0894;;E04C2/292,E04C3/00,52/459;;52/461;;52/782.1,0,0,,,,ACTIVE
371,US,A1,US 2011/0201708 A1,039-184-584-361-269,2011-08-18,2011,US 200913125486 A,2009-11-09,US 200913125486 A;;US 11319308 P;;US 2009/0063728 W,2008-11-10,"ISOCYANATE TRIMERISATION CATALYST SYSTEM, A PRECURSOR FORMULATION, A PROCESS FOR TRIMERISING ISOCYANATES, RIGID POLYISOCYANURATE/POLYURETHANE FOAMS MADE THEREFROM, AND A PROCESS FOR MAKING SUCH FOAMS","The instant invention provides an isocyanate trimerisation catalyst system, a precursor formulation, a process for trimerising isocyanates, rigid foams made therefrom, and a process for making such foams. The trimerisation catalyst system comprises: (a) a phosphonium cation; and (b) an isocyanate-trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73° C. The precursor formulation comprises (1) at least 25 percent by weight of polyol, based on the weight of the precursor formulation; (2) less than 15 percent by weight of a trimerisation catalyst system, based on the weight of the precursor formulation, comprising; (a) a phosphonium cation; and (c) an isocyanate-timer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73° C.; and (3) optionally one or more surfactants, one or more flame retardants, water, one or more antioxidants, one or more auxiliary blowing agents, one or more urethane catalysts, one or more auxiliary trimerisation catalysts, or combinations thereof. The process for trimerisation of isocyanates comprises the steps of: (1) providing one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture of any thereof; (2) providing a trimerisation catalyst system comprising; (a) an phosphonium cation; and (b) an isocyanate-trimer inducing anion; (c) wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73° C.; (3) trimerising said one or more monomers in the presence of said trimerisation catalyst; (4) thereby forming an isocyanurate trimer. The process for making the PIR foam comprises the steps of: (1) providing one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture of any thereof; (2) providing polyol; (3) providing a trimerisation catalyst system comprising; (a) a phosphonium cation; and (b) an isocyanate-trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73° C.; and (4) optionally providing one or more surfactants, one or more flame retardants, water, one or more antioxidants, one or more auxiliary blowing agents, one or more urethane catalysts, one or more auxiliary trimerisation catalysts, or combinations thereof; (5) contacting said one or more monomers, and said polyol, and optionally said one or more surfactants, and optionally said one or more flame retardants, and optionally said water, and optionally said one or more antioxidants, and optionally said one or more auxiliary blowing agents in the presence of said trimerisation catalyst system and optionally said one or more urethane catalysts, and optionally said one or more auxiliary trimerisation catalysts; (6) thereby forming said polyisocyanurate/polyurethane rigid foam. The PIR foam comprises the reaction product of one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture of any thereof with polyol in the presence of a trimerisation catalyst system comprising a phosphonium cation, and an isocyanate-trimer inducing anion, and optionally one or more surfactants, optionally one or more flame retardants, optionally water, optionally one or more antioxidants, optionally one or more auxiliary blowing agents, optionally one or more additional urethane catalysts, and optionally one or more auxiliary trimerisation catalysts, or optionally combinations thereof, wherein the trimerisation",DOW GLOBAL TECHNOLOGIES LLC,ATHEY PHILLIP S;;WILMOT NATHAN;;KEATON RICHARD;;BOYER CECILE;;MORLEY TIMOTHY,DOW EUROPE GMBH (2009-07-17);;DOW GLOBAL TECHNOLOGIES LLC (2009-07-08);;THE DOW CHEMICAL COMPANY (2009-07-27),https://lens.org/039-184-584-361-269,Patent Application,yes,12,6,10,10,0,C08G18/022;;C08G18/022;;C08G18/092;;C08G18/092;;C08G18/168;;C08G18/168;;C08G2110/0025;;C08G2110/0025;;C08G2115/02;;C08G2115/02,C08J9/00;;C07F9/54,521/108;;568/9;;562/579,0,0,,,,INACTIVE
372,US,B2,US 8360905 B2,035-798-354-182-928,2013-01-29,2013,US 77086204 A,2004-02-02,US 77086204 A,2004-02-02,Chromatic architecture for sports equipment,"Sporting items such as soccer balls include a casing region and a graphic region that are defined by enhanced-visibility colors (EVCs) that are substantially complementary. Such EVCs can be selected to avoid colors associated with color confusion in color deficient individuals. In addition, such colors can be selected based on total reflectances to obtain a predetermined luminance contrast. EVCs can be selected based on separations of color coordinate locations using CIE chromaticity coordinates or CIE L-a-b coordinates or otherwise selected. Color selection can include consideration of anticipated viewing backgrounds in a general setting, or colors can be customized for a particular location and particular illumination conditions.",NIKE INC;;BOYER CLANCY G;;AVIS RICHARD G;;REICHOW ALAN W;;CITEK KARL,BOYER CLANCY G;;AVIS RICHARD G;;REICHOW ALAN W;;CITEK KARL,NIKE INC (2004-06-28);;NIKE INTERNATIONAL LTD (2005-02-14),https://lens.org/035-798-354-182-928,Granted Patent,yes,54,7,8,8,0,A63B43/008;;A63B71/00;;A63B2071/0027;;B44D3/003;;B44F1/08;;G01J3/46;;G01J3/462;;G01J3/463;;G01J3/465;;G01J3/46;;G01J3/463;;B44D3/003;;B44F1/08;;G01J3/465;;A63B43/008;;G01J3/462;;A63B2071/0027;;A63B71/00,A63B41/08;;A63B41/00;;A63B43/00;;A63B45/02;;A63B71/00;;G01J3/46,473/604;;40/327,28,5,172-136-737-968-965;;075-505-901-524-229;;003-640-002-574-046;;045-975-507-749-508;;062-339-109-703-474,3209790;;12472438;;10.1111/j.1444-0938.2000.tb05006.x;;9831156;;10.1007/s002210000640;;11310166;;17073573;;10.1615/jlongtermeffmedimplants.v16.i4.50,"PCT/US2005/002904, Jan. 31, 2005, International Search Report, Applicant: Nike International Ltd.;;Reichow, et al., ""Introduction to Behavioral Optometry"", Sports Vision, 1993, 75 pages, Optometric Extension Program Foundation, United States.;;Ferreira, ""An Overview of Research in Sports Vision: its History and an Optometric Perspective"", The South African Optometrist, Dec. 2003, pp. 142-149, vol. 62, No. 4, Auckland Park, South Africa.;;Coffey, et al., ""Visual Performance Enhancement in Sports Optometry"", Sports Vision 1995, pp. 158-177, Butterworth-Heinermann, United States.;;Cardall, ""Contact Lenses in Sport: a General Overview"", Optician, Jan. 13, 2006, pp. 22-25, vol. 231, No. 6034, United States.;;Rouse, et al., ""A Comparison Study of Dynamic Visual Acuity Between Athletes and Nonathletes"", Journal of the American Optometric Association, Dec. 1988, pp. 946-950, vol. 59, No. 12, United States.;;Koenig, ""Practicing Perception: Eyes Can Be Trained to be More Effective"", USA Today Baseball Weekly, 1996, 3 pages, United States.;;Coffey, et al., ""Optometric Evaluation of the Elite Athlete,"" Problems in Optometry, Mar. 1990, pp. 32-59, vol. 2, No. 1, United States.;;Reichow, et al., ""A Comparison of Contrast Sensitivity in Elite Athletes Versus a Normal Population"", American Journal of Optometry and Physiological Optics, Dec. 15, 1986, vol. 63, No. 82, United States.;;Farrow, et al., ""An Investigation of the Effectiveness of Bolle's Competivision Sport-Glasses on Tennis Performance"", Clinical and Experimental Optometry, Jul.-Aug. 2000, pp. 226-231, vol. 83, No. 4.;;Herdman, et al., ""Computerized Dynamic Visual Acuity Test in the Assessment of Vestibular Deficits"", The American Journal of Otology, 1998, pp. 790-796, vol. 19, No. 6, United States.;;Tian, et al., ""Dynamic Visual Acuity During Transient and Sinusoidal Yaw Rotation in Normal Ulilaterally Vestibulopathic Humans"", Experimental Brain Research, Feb. 8, 2001, pp. 12-25, vol. 137, Springer-Verlag, United States.;;Reichow, et al., ""Ultraviolet and Short Wavelength Visible Light Exposure: Why Ultraviolet Protection Alone is Not Adequate"", Journal of Long-Term Effects of Medical Implants, 2006, pp. 315-325, vol. 16, No. 4, Begell House, Inc., United States.;;Advisory Action mailed Feb. 19, 2010 for U.S. Appl. No. 11/942,520, filed Nov. 19, 2007.;;International Search Report mailed Sep. 7, 2006 for Appl. No. PCT/U05/04526, filed Feb. 9, 2005.;;International Search Report mailed Sep. 5, 2008 for Appl. No. PCT/US08/634425, filed May 12, 2008.;;Non-Final Office Action mailed Jun. 4, 2009 for U.S. Appl. No. 11/801,931, filed May 11, 2007.;;Non-Final Office Action mailed Jul. 28, 2009 for U.S. Appl. No. 11/942,520, filed Nov. 19, 2007.;;Non-Final Office Action mailed Oct. 8, 2009 for U.S. Appl. No. 11/801,931, filed May 11, 2007.;;Non-Final Office Action mailed Dec. 15, 2009 for U.S. Appl. No. 11/717,894, filed Mar. 13, 2007.;;Final Office Action mailed Sep. 2, 2010 for U.S. Appl. No. 11/717,894, filed Mar. 13, 2007.;;Non Final Office Action mailed Mar. 25, 2010 for U.S. Appl. No. 11/717,894, filed Mar. 13, 2007.;;Non Final Office Action mailed Oct. 7, 2010 for U.S. Appl. No. 11/942,520, filed Nov. 19, 2007.;;Final Office Action mailed Apr. 22, 2010 for U.S. Appl. No. 11/801,931, filed May 11, 2007.;;Final Office Action mailed Mar. 11, 2011 for U.S. Appl. No. 11/942,520, filed Nov. 19, 2007.;;Notice of Allowance mailed Feb. 16, 2011 for U.S. Appl. No. 11/717,894, filed Mar. 13, 2007.;;Final Office Action of Sep. 22, 2011 for U.S. Appl. No. 11/801,931, filed May 11, 2007.;;Non Final Office Action mailed Apr. 6, 2011 for U.S. Appl. No. 11/801,931, filed May 11, 2007.",EXPIRED
373,ES,T3,ES 2354584 T3,001-404-496-215-045,2011-03-16,2011,ES 07835890 T,2007-06-26,US 81652206 P,2006-06-26,INHIBIDORES DE PROLILHIDROXILASA Y METODOS DE USO.,"Un compuesto que tiene la fórmula: en la que R es una unidad elegida entre: i) fenilo sustituido o sin sustituir; y ii) heteroarilo sustituido o sin sustituir; y R1 es hidrógeno; o en la que R es hidrógeno y R1 es fenilo sustituido o sin sustituir; eligiéndose dichas sustituciones entre: i) alquilo C1-C4 lineal, ramificado o cíclico; ii) alcoxi C1-C4 lineal, ramificado o cíclico; iii) haloalquilo C1-C4 lineal, ramificado o cíclico; iv) halógeno; v) -CN; vi) -NHC(O)R4 vii) -C(O)NR5aR5b; viii) heteroarilo; o ix) dos sustituciones pueden tomarse juntas para formar un anillo condensado que tiene de 5 a 7 átomos; R4 es alquilo C1-C4 lineal, ramificado o cíclico; cada uno de R5a y R5b es independientemente: i) hidrógeno; ii) alquilo C1-C4 lineal, ramificado o cíclico; o iii) R5a y R5b pueden tomarse juntos para formar un anillo de 3 a 7 átomos; R2 se elige entre: i) -OR6; o ii) -NR7aR7b; R6 es hidrógeno o alquilo C1-C4 lineal, ramificado o cíclico; cada uno de R7a y R7b es independientemente: i) hidrógeno; ii) alquilo C1-C4 lineal, ramificado o cíclico; o iii) R7a y R7b pueden tomarse juntos para formar un anillo que tiene de 3 a 7 átomos en el anillo; R3 es hidrógeno, metilo o etilo; L es una unidad de unión que tiene la fórmula: -[C(R8aR8b)]ncada uno de R8a y R8b es independientemente hidrógeno, metilo o etilo; el índice n es de 1 a 3; R9 es hidrógeno o metilo; o una sal farmacéuticamente aceptable del mismo.",WARNER CHILCOTT CO LLC,BOYER ANGELIQUE;;WU SHENGDE;;GREIS KENNETH;;WARSHAKOON NAMAL;;KAWAMOTO RICHARD MASARU,,https://lens.org/001-404-496-215-045,Granted Patent,no,0,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07C235/60;;C07C237/42;;C07C255/57;;C07D213/81,,0,0,,,,ACTIVE
374,ZA,B,ZA 200308570 B,117-914-299-037-418,2005-02-03,2005,ZA 200308570 A,2003-11-03,GB 0113232 A,2001-05-31,Process for preparing a thiazole PPAR-ligand and polymorphs thereof.,,GLAXO GROUP LTD,BOYER THIERRY;;WHITEHEAD ANDREW JONATHAN;;DAY CAROLINE JANE;;HENSON RICHARD ANTHONY,,https://lens.org/117-914-299-037-418,Granted Patent,no,0,0,27,27,0,C07D277/56;;A61P1/14;;A61P29/00;;A61P3/00;;A61P3/10;;A61P3/04;;A61P3/06;;A61P9/04;;A61P9/10;;C07D277/56;;C07D277/56,A61K31/426;;A61P1/14;;A61P3/04;;C07D277/20;;A61P3/06;;A61P3/10;;A61P9/04;;A61P9/10;;A61P29/00;;C07D277/56,,0,0,,,,EXPIRED
375,EP,A2,EP 1713549 A2,124-627-170-044-598,2006-10-25,2006,EP 05712366 A,2005-01-31,US 2005/0002904 W;;US 77086204 A,2004-02-02,CHROMATIC ARCHITECTURE FOR SPORTS EQUIPMENT,,NIKE INTERNATIONAL LTD,BOYER CLANCY G;;AVIS RICHARD G;;REICHOW ALAN W;;CITEK KARL,"NIKE INNOVATE C.V. (2014-08-06);;NIKE INNOVATE C.V., BEAVERTON, US (2019-06-12)",https://lens.org/124-627-170-044-598,Patent Application,yes,0,0,8,8,0,A63B43/008;;A63B71/00;;A63B2071/0027;;B44D3/003;;B44F1/08;;G01J3/46;;G01J3/462;;G01J3/463;;G01J3/465;;G01J3/46;;G01J3/463;;B44D3/003;;B44F1/08;;G01J3/465;;A63B43/008;;G01J3/462;;A63B2071/0027;;A63B71/00,A63B43/00;;A63B41/00;;A63B45/02;;A63B71/00;;B44D3/00;;B44F1/08;;G01J3/46;;G01J3/52,,0,0,,,,ACTIVE
376,US,B1,US 9899128 B1,192-822-216-646-413,2018-02-20,2018,US 201715413589 A,2017-01-24,US 201715413589 A,2017-01-24,Signal transmission cable assembly with ungrounded sheath containing electrically conductive particles,"A data transmission cable assembly includes an elongate first conductor, an elongate second conductor, and a sheath at least partially axially surrounding the first and second conductors. The sheath contains a plurality of electrically conductive particles interspersed within a matrix formed of an electrically insulative polymeric material. The conductive particles may be formed of a metallic material or and inherently conductive polymer material. The plurality conductive particles may be filaments that form a plurality of electrically interconnected networks. Each network is electrically isolated from every other network. Each network contains less than 125 filaments and/or has a length less than 13 millimeters. The bulk conductivity of the sheath is substantially equal to the conductivity of the electrically insulative polymeric material. The data transmission cable assembly does not include a terminal that is configured to connect the sheath to an electrical ground.",DELPHI TECH INC,BOYER RICHARD J;;HEFFRON JOHN F;;RUBINO EVANGELIA;;RICHMOND ZACHARY J,APTIV TECHNOLOGIES LIMITED (2018-01-01);;DELPHI TECHNOLOGIES INC (2017-01-17);;APTIV TECHNOLOGIES AG (2023-10-06),https://lens.org/192-822-216-646-413,Granted Patent,yes,5,10,2,2,0,H01B11/1058;;H01B1/22;;H01B1/24;;H01B7/187;;H01B13/24;;H01B11/10;;H01B7/18;;H01B1/22;;H01B1/24;;H01B7/187;;H01B13/24;;H01B13/26;;H01B11/002;;H01B11/1058,H01B11/10;;H01B1/22;;H01B1/24;;H01B7/18;;H01B11/00;;H01B13/24;;H01B13/26,,0,0,,,,ACTIVE
377,US,A1,US 2009/0221428 A1,190-010-544-629-982,2009-09-03,2009,US 6507606 A,2006-09-07,US 6507606 A;;US 71536305 P;;US 79020906 P;;US 2006/0034962 W,2005-09-07,Methods of Genome-Wide Location Analysis in Stem Cells,"The invention relates to improved methods of identifying the genomic regions to which a protein of interest binds, and in particular, to methods that apply to stem cells such as but not limited to; embryonic stem cells and adult stem cells. The invention also provides methods of identifying agents which modulate differentiation of stem cells. The invention also provides methods of defining the differentiation potential of a cell and of designing array oligonucleotides.",YOUNG RICHARD A;;LEE TONG IHN;;GUENTHER MATTHEW;;BOYER LAURIE A,YOUNG RICHARD A;;LEE TONG IHN;;GUENTHER MATTHEW;;BOYER LAURIE A,WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (2008-09-17),https://lens.org/190-010-544-629-982,Patent Application,yes,5,3,3,3,0,C12Q1/6809;;C12Q1/6809;;C12Q1/6837;;C12Q1/6837,C40B20/04;;C07H1/00;;C12Q1/68;;C40B50/14,506/4;;435/6;;536/55.3;;506/30,0,0,,,,DISCONTINUED
378,WO,A2,WO 2005/075028 A2,063-278-343-239-817,2005-08-18,2005,US 2005/0002904 W,2005-01-31,US 77086204 A,2004-02-02,CHROMATIC ARCHITECTURE FOR SPORTS EQUIPMENT,"Sporting items such as soccer balls include a casing region and a graphic region that are defined by enhanced-visibility colors (EVCs) that are substantially complementary. Such EVCs can be selected to avoid colors associated with color confusion in color deficient individuals. In addition, such colors can be selected based on total reflectances to obtain a predetermined luminance contrast. EVCs can be selected based on separations of color coordinate locations using CIE chromaticity coordinates or CIE L-a-b coordinates or otherwise selected. Color selection can include consideration of anticipated viewing backgrounds in a general setting, or colors can be customized for a particular location and particular illumination conditions.",NIKE INTERNATIONAL LTD;;NIKE INC;;BOYER CLANCY G;;AVIS RICHARD G;;REICHOW ALAN W;;CITEK KARL,BOYER CLANCY G;;AVIS RICHARD G;;REICHOW ALAN W;;CITEK KARL,,https://lens.org/063-278-343-239-817,Patent Application,yes,1,0,8,8,0,A63B43/008;;A63B71/00;;A63B2071/0027;;B44D3/003;;B44F1/08;;G01J3/46;;G01J3/462;;G01J3/463;;G01J3/465;;G01J3/46;;G01J3/463;;B44D3/003;;B44F1/08;;G01J3/465;;A63B43/008;;G01J3/462;;A63B2071/0027;;A63B71/00,A63B41/00;;A63B43/00;;A63B45/02;;A63B71/00;;G01J3/46,,0,0,,,,PENDING
379,US,A1,US 2011/0252737 A1,100-604-909-942-650,2011-10-20,2011,US 201113043857 A,2011-03-09,US 201113043857 A;;US 32605910 P,2010-04-20,Insulated Metal Vertical Joint Insert,A composite panel assembly includes first and second panels. An edge of the first panel is positioned adjacent to an edge of the second panel to define a joint. The edge of the first panel and the edge of the second panel each define a recessed portion. An insert is positioned between the first and second panels at the joint. A portion of the insert is received within respective recessed portions of the first and second panels.,CENTRIA,BOYER KEITH D;;WESCHE LARRY A;;GIANDOMENICO DARIO;;BROW RICHARD A,CENTRIA (2011-04-01);;NCI GROUP INC (2020-02-17);;NUCOR INSULATED PANEL GROUP LLC (2021-07-27),https://lens.org/100-604-909-942-650,Patent Application,yes,5,6,2,2,0,E04F13/0846;;E04F13/0875;;E04F13/0894;;E04F13/0898;;E04C2/292;;E04F13/0898;;E04F13/0875;;E04F13/0846;;E04F13/0894;;E04C2/292,E04C2/38;;E04B1/38;;E04C2/30,52/588.1;;52/782.1;;52/578,0,0,,,,ACTIVE
380,US,A1,US 2004/0242657 A1,096-298-795-817-572,2004-12-02,2004,US 47826004 A,2004-04-27,EP 0205884 W;;GB 0113232 A,2001-05-31,Process for preparinga thiazole ppar-ligand and polymorphs thereof,"
    A method of preparing a compound of formula (I), and pharmaceutically acceptable salts and solvates thereof. Polymorphs of this compound and their use as PPAR ligands are also disclosed. 
",BOYER THIERRY;;DAY CAROLINE JANE;;WHITEHEAD ANDREW JONATHAN;;HENSON RICHARD ANTHONY,BOYER THIERRY;;DAY CAROLINE JANE;;WHITEHEAD ANDREW JONATHAN;;HENSON RICHARD ANTHONY,GLAXO GROUP LIMITED (2001-05-31),https://lens.org/096-298-795-817-572,Patent Application,yes,4,3,27,27,0,C07D277/56;;A61P1/14;;A61P29/00;;A61P3/00;;A61P3/10;;A61P3/04;;A61P3/06;;A61P9/04;;A61P9/10;;C07D277/56;;C07D277/56,A61K31/426;;A61P1/14;;C07D277/20;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/04;;A61P9/10;;A61P29/00;;C07D277/56,514/365;;X5482,0,0,,,,EXPIRED
381,ES,T3,ES 2922078 T3,011-294-957-352-607,2022-09-07,2022,ES 18158907 T,2007-06-26,US 81652206 P,2006-06-26,Inhibidores de prolil hidroxilasa y métodos de uso,"La presente divulgación se relaciona con los inhibidores de HIF-1 ± prolil hidroxilasa, composiciones que comprenden los inhibidores de HIF-1 ± prolil hidroxilasa descritos en el presente documento y con los métodos para controlar, entre alas, enfermedad vascular periférica (PVD), enfermedad de la arteria coronaria (CAD),,, Heart Hearting fracaso, isquemia y anemia. (Traducción automática con Google Translate, sin valor legal)",AKEBIA THERAPEUTICS INC,KAWAMOTO RICHARD MASARU;;WARSHAKOON NAMAL;;WU SHENGDE;;BOYER ANGELIQUE;;GREIS KENNETH,,https://lens.org/011-294-957-352-607,Granted Patent,no,0,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07D213/81;;A61K31/4418;;A61P35/00,,0,0,,,,ACTIVE
382,EP,B1,EP 1713549 B1,058-051-107-399-90X,2019-07-03,2019,EP 05712366 A,2005-01-31,US 2005/0002904 W;;US 77086204 A,2004-02-02,CHROMATIC ARCHITECTURE FOR SPORTS EQUIPMENT,,NIKE INNOVATE CV,BOYER CLANCY G;;AVIS RICHARD G;;REICHOW ALAN W;;CITEK KARL,"NIKE INNOVATE C.V. (2014-08-06);;NIKE INNOVATE C.V., BEAVERTON, US (2019-06-12)",https://lens.org/058-051-107-399-90X,Granted Patent,yes,3,0,8,8,0,A63B43/008;;A63B71/00;;A63B2071/0027;;B44D3/003;;B44F1/08;;G01J3/46;;G01J3/462;;G01J3/463;;G01J3/465;;G01J3/46;;G01J3/463;;B44D3/003;;B44F1/08;;G01J3/465;;A63B43/008;;G01J3/462;;A63B2071/0027;;A63B71/00,A63B43/00;;A63B41/00;;A63B45/02;;A63B71/00;;B44D3/00;;B44F1/08;;G01J3/46;;G01J3/52,,0,0,,,,ACTIVE
383,NO,L,NO 20035313 L,133-314-534-048-717,2003-12-09,2003,NO 20035313 A,2003-11-28,EP 0205884 W;;GB 0113232 A,2001-05-31,Fremgangsmåte for fremstilling av tialzol PPAR-ligand og polymorfer derav,,GLAXO GROUP LTD,BOYER THIERRY;;DAY CAROLINE JANE;;WHITEHEAD ANDREW JONATHAN;;HENSON RICHARD ANTHONY,,https://lens.org/133-314-534-048-717,Abstract,no,0,0,27,27,0,C07D277/56;;A61P1/14;;A61P29/00;;A61P3/00;;A61P3/10;;A61P3/04;;A61P3/06;;A61P9/04;;A61P9/10;;C07D277/56;;C07D277/56,A61K31/426;;C07D277/20;;A61P1/14;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/04;;A61P9/10;;A61P29/00;;C07D277/56,,0,0,,,,DISCONTINUED
384,BR,A,BR 0209892 A,199-941-868-375-379,2004-06-08,2004,BR 0209892 A,2002-05-29,EP 0205884 W;;GB 0113232 A,2001-05-31,"Método de preparação de um composto, composto, composição farmacêutica, uso de um composto, e, método de tratamento de um paciente sofrendo de uma doença ou condição mediada por hppar alfa","""MéTODO DE PREPARAçãO DE UM COMPOSTO, COMPOSTO, COMPOSIçãO FARMACêUTICA, USO DE UM COMPOSTO, E, MéTODO DE TRATAMENTO DE UM PACIENTE SOFRENDO DE UMA DOENçA OU CONDIçãO MEDIADA POR HPPAR ALFA"". Um método de preparação de um composto da fórmula (I) e sais e solvatos farmaceuticamente aceitáveis do mesmo. Polimorfos deste composto e seu uso como ligantes PPAR são também expostos.",GLAXO GROUP LTD,BOYER THIERRY;;DAY CAROLINE JANE;;WHITEHEAD ANDREW JONATHAN;;HENSON RICHARD ANTHONY,,https://lens.org/199-941-868-375-379,Patent Application,no,0,0,27,27,0,C07D277/56;;A61P1/14;;A61P29/00;;A61P3/00;;A61P3/10;;A61P3/04;;A61P3/06;;A61P9/04;;A61P9/10;;C07D277/56;;C07D277/56,C07D277/20;;A61K31/426;;A61P1/14;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/04;;A61P9/10;;A61P29/00;;C07D277/56,,0,0,,,,DISCONTINUED
385,US,A1,US 2007/0285744 A1,033-306-407-970-359,2007-12-13,2007,US 71789407 A,2007-03-13,US 71789407 A;;US 77086204 A,2004-02-02,Chromatic architecture for sports equipment,"Sporting items such as soccer balls include a casing region and a graphic region that are defined by enhanced-visibility colors (EVCs) that are substantially complementary. Such EVCs can be selected to avoid colors associated with color confusion in color deficient individuals. In addition, such colors can be selected based on total reflectances to obtain a predetermined luminance contrast. EVCs can be selected based on separations of color coordinate locations using CIE chromaticity coordinates or CIE L-a-b coordinates or otherwise selected. Color selection can include consideration of anticipated viewing backgrounds in a general setting, or colors can be customized for a particular location and particular illumination conditions.",NIKE INC,BOYER CLANCY G;;AVIS RICHARD G;;REICHOW ALAN W;;CITEK KARL,NIKE INC (2004-06-15),https://lens.org/033-306-407-970-359,Patent Application,yes,53,12,8,8,0,A63B43/008;;A63B71/00;;A63B2071/0027;;B44D3/003;;B44F1/08;;G01J3/46;;G01J3/462;;G01J3/463;;G01J3/465;;G01J3/46;;G01J3/463;;B44D3/003;;B44F1/08;;G01J3/465;;A63B43/008;;G01J3/462;;A63B2071/0027;;A63B71/00,G03F3/08;;A63B41/00;;A63B43/00;;A63B45/02;;A63B71/00;;G01J3/46,358/518;;D3/223,0,0,,,,EXPIRED
386,DE,D1,DE 60208682 D1,095-911-501-763-238,2006-04-06,2006,DE 60208682 T,2002-05-29,GB 0113232 A;;EP 0205884 W,2001-05-31,VERFAHREN ZUR HERSTELLUNG EINES THIAZOL-PPAR-LIGANDEN SOWIE DESSEN POLYMORPHE,,SMITHKLINE BEECHAM CORP,BOYER THIERRY;;DAY CAROLINE JANE;;WHITEHEAD ANDREW JONATHAN;;HENSON RICHARD ANTHONY,,https://lens.org/095-911-501-763-238,Granted Patent,no,0,0,27,27,0,C07D277/56;;A61P1/14;;A61P29/00;;A61P3/00;;A61P3/10;;A61P3/04;;A61P3/06;;A61P9/04;;A61P9/10;;C07D277/56;;C07D277/56,A61K31/426;;C07D277/20;;A61P1/14;;C07D277/56;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/04;;A61P9/10;;A61P29/00,,0,0,,,,EXPIRED
387,WO,A1,WO 2018/204426 A1,127-640-335-181-693,2018-11-08,2018,US 2018/0030544 W,2018-05-01,US 201815968515 A;;US 201762492868 P,2017-05-01,SYSTEM FOR DOSING AND DISPENSING MEDICATION,"A system for medication delivery comprises a Package containing a medication and a Dosing mechanism for delivering a dose of a drug, formulated as multiparticulate, microspheres, powder or liquid. The Package comprises a bottle, a bottle insert that covers the bottle opening and includes a dispense nozzle. The dispense nozzle is sealed using a valve that opens when the Dosing device is engaged with the bottle. A closure covers the bottle insert and closes the bottle. The Dosing device, similar to an oral syringe, comprises a barrel with a valve at its distal end, a plunger and a dose control clip for attachment to the plunger. After the dosing device is connected to the bottle valve, withdrawal of the plunger causes the dosing device to receive a dose of drug, the user pushes the plunger which pushes the MP drug through the valve and into a patient's mouth.",QUINN MICHAEL V;;GORSHKOV ALEXANDER;;CRONENBERG RICHARD;;ALDEN TOR;;BOYER ROBERT,QUINN MICHAEL V;;GORSHKOV ALEXANDER;;CRONENBERG RICHARD;;ALDEN TOR;;BOYER ROBERT,,https://lens.org/127-640-335-181-693,Patent Application,yes,8,0,7,7,0,A47G19/34;;A61M5/31501;;A61M5/3156;;A61M5/31563;;A61M39/26;;B65D83/06;;A61M2005/31508;;A61M2005/3154;;A61M2005/5033;;A61M2039/267;;A61J2200/76;;A61J7/0053;;A61J1/2096;;G01F11/027;;A61J7/0053;;A61J7/0076;;A61J1/00;;A61M5/31563;;B65D83/06;;A61M39/26;;A61M2039/267;;A61M5/31501;;A61M5/3156;;A61M2005/31508;;A61M2005/5033;;A61M2005/3154;;A61J2200/76,A61M39/26;;A47G19/34;;A47J31/40;;A61J1/20;;A61J7/00;;A61M5/315;;A61M5/50;;B65D83/06;;G01F11/46,,0,0,,,,PENDING
388,HU,T2,HU E059557 T2,140-588-982-613-152,2022-11-28,2022,HU E18158907 A,2007-06-26,US 81652206 P,2006-06-26,PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE,,AKEBIA THERAPEUTICS INC,KAWAMOTO RICHARD MASARU;;WARSHAKOON NAMAL;;WU SHENGDE;;BOYER ANGELIQUE;;GREIS KENNETH,,https://lens.org/140-588-982-613-152,Amended Patent,no,0,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07D213/81;;A61P35/00,,0,0,,,,PENDING
389,CA,C,CA 3061917 C,187-373-541-347-060,2023-02-07,2023,CA 3061917 A,2018-05-01,US 201762492868 P;;US 201815968515 A;;US 2018/0030544 W,2017-05-01,SYSTEM FOR DOSING AND DISPENSING MEDICATION,"A system for medication delivery comprises a Package containing a medication and a Dosing mechanism for delivering a dose of a drug, formulated as multi-particulate, microspheres, powder or liquid. The Package comprises a bottle, a bottle insert that covers the bottle opening and includes a dispense nozzle. The dispense nozzle is sealed using a valve that opens when the Dosing device is engaged with the bottle. A closure covers the bottle insert and closes the bottle. The Dosing device, similar to an oral syringe, comprises a barrel with a valve at its distal end, a plunger and a dose control clip for attachment to the plunger. After the dosing device is connected to the bottle valve, withdrawal of the plunger causes the dosing device to receive a dose of drug, the user pushes the plunger which pushes the MP drug through the valve and into a patient's mouth.",QUINN MICHAEL V;;GORSHKOV ALEXANDER;;CRONENBERG RICHARD;;ALDEN TOR;;BOYER ROBERT,QUINN MICHAEL V;;GORSHKOV ALEXANDER;;CRONENBERG RICHARD;;ALDEN TOR;;BOYER ROBERT,,https://lens.org/187-373-541-347-060,Granted Patent,no,0,0,7,7,0,A47G19/34;;A61M5/31501;;A61M5/3156;;A61M5/31563;;A61M39/26;;B65D83/06;;A61M2005/31508;;A61M2005/3154;;A61M2005/5033;;A61M2039/267;;A61J2200/76;;A61J7/0053;;A61J1/2096;;G01F11/027;;A61J7/0053;;A61J7/0076;;A61J1/00;;A61M5/31563;;B65D83/06;;A61M39/26;;A61M2039/267;;A61M5/31501;;A61M5/3156;;A61M2005/31508;;A61M2005/5033;;A61M2005/3154;;A61J2200/76,A61M39/26;;A47G19/34;;A47J31/40;;A61J1/20;;A61J7/00;;A61M5/315;;A61M5/50;;B65D83/06;;G01F11/46,,0,0,,,,PENDING
390,US,A1,US 2021/0267468 A1,039-167-710-232-173,2021-09-02,2021,US 202117315651 A,2021-05-10,US 202117315651 A;;US 202016740888 A;;US 201715547935 A;;US 2016/0016420 W;;US 201514853504 A;;US 201562111337 P;;US 201462049829 P,2014-09-12,HYPOVOLEMIA/HYPERVOLEMIA AND INTRAVENOUS INFILTRATION DETECTION USING PERIPHERAL INTRAVENOUS WAVEFORM ANALYSIS (PIVA) AND APPLICATIONS OF SAME,"Peripheral intravenous (IV) waveform analysis (PIVA) systems and methods for determining an intravascular volume status of a living subject and monitoring an IV line functionality of a peripheral IV device are provided. The PIVA system includes a peripheral IV device and a processing device. The peripheral IV device includes a peripheral IV catheter inserted into a vein of the living subject, and a fluid controlling device to control fluid flow from a fluid source to the peripheral IV catheter. The processing device receives peripheral venous signals from the peripheral IV device, performs a spectral analysis on the peripheral venous signals to obtain a peripheral venous pressure frequency spectrum; and performs a statistical analysis on amplitudes of peaks of the peripheral venous pressure frequency spectrum to determine an intravascular volume status of the living subject and/or an IV line functionality of the peripheral IV catheter in real time.",UNIV VANDERBILT,EAGLE SUSAN S;;BROPHY COLLEEN;;HOCKING KYLE MITCHELL;;BAUDENBACHER FRANZ;;BOYER RICHARD,,https://lens.org/039-167-710-232-173,Patent Application,yes,8,0,4,51,0,A61B5/02152;;A61B5/7235;;A61B5/7257;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61B5/02152;;A61B5/7235;;A61B5/7257;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61B5/02152;;A61B5/7235;;A61M2005/1588;;A61M5/158;;A61B5/7257;;A61M5/16854,A61B5/0215;;A61B5/00;;A61M5/158;;A61M5/168,,1,1,059-259-977-142-971,24901895;;10.1088/0967-3334/35/7/1509,"Alian et al. ""Impact of lower body negative pressure induced hypovolemia on peripheral venous pressure waveform parameters in healthy volunteers."" Physiol Meas. 2014 Jul;35(7):1509-20. (Year: 2014)",PENDING
391,US,A1,US 2018/0020935 A1,134-090-917-069-300,2018-01-25,2018,US 201615547935 A,2016-02-03,US 201615547935 A;;US 201514853504 A;;US 201562111337 P;;US 201462049829 P;;US 2016/0016420 W,2014-09-12,INTRAVENOUS ACCESS DEVICE DETECTING INTRAVENOUS INFILTRATION AND IN-VEIN PLACEMENT,"Aspects of the invention relates to systems and methods for monitoring an intravenous (IV) line functionality of an IV device. In one embodiment, the system includes an IV catheter to be inserted into the vein of the living subject, at least one pressure sensor in fluid communication with the IV catheter to acquire peripheral venous signals; and a processing device. The processing device receives the peripheral venous signals from the pressure sensor, performs a spectral analysis on the peripheral venous signals to obtain a peripheral venous pressure frequency spectrum, and then performs a statistical analysis on amplitudes of peaks of the peripheral venous pressure frequency spectrum to determine an IV line functionality of the IV catheter in real time. When the IV line functionality indicates IV infiltration, the processing device may control the fluid controlling device to stop the fluid flow from the fluid source to the IV catheter.",UNIV VANDERBILT,EAGLE SUSAN S;;BROPHY COLLEEN;;HOCKING KYLE MITCHELL;;BAUDENBACHER FRANZ;;BOYER RICHARD,VANDERBILT UNIVERSITY (2017-10-23),https://lens.org/134-090-917-069-300,Patent Application,yes,13,3,4,51,0,A61B5/02152;;A61B5/02152;;A61B5/02152;;A61B5/7235;;A61B5/7235;;A61B5/7235;;A61B5/7257;;A61B5/7257;;A61B5/7257;;A61M5/158;;A61M5/158;;A61M5/158;;A61M5/16854;;A61M5/16854;;A61M5/16854;;A61M2005/1588;;A61M2005/1588;;A61M2005/1588,A61B5/0215;;A61B5/00;;A61M5/158;;A61M5/168,,0,0,,,,ACTIVE
392,WO,A3,WO 2010/054317 A3,154-907-030-577-434,2010-12-02,2010,US 2009/0063733 W,2009-11-09,US 11319608 P,2008-11-10,"ISOCYANATE TRIMERISATION CATALYST SYSTEM, A PRECURSOR FORMULATION, A PROCESS FOR TRIMERISING ISOCYANATES, RIGID POLYISOCYANURATE/POLYURETHANE FOAMS MADE THEREFROM, AND A PROCESS FOR MAKING SUCH FOAMS","The instant invention provides an isocyanate trimerisation catalyst system, a precursor formulation, a process for trimerising isocyanates, rigid foams made therefrom, and a process for making such foams. The trimerisation catalyst system comprises: (a) an imidazolium or imidazolinium cation; and (b) an isocyanate-trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73°C. The precursor formulation comprises: (1) at least 25 percent by weight of polyol, based on the weight of the precursor formulation; (2) less than 15 percent by weight of a trimerisation catalyst system, based on the weight of the precursor formulation, comprising; (a) an imidazolium or imidazolinium cation; and (c) an isocyanate-trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73°C; and (3) optionally one or more surfactants, one or more flame retardants, water, one or more antioxidants, one or more auxiliary blowing agents, one or more urethane catalysts, one or more auxiliary trimerisation catalysts, or combinations thereof. The process for trimerisation of isocyanates comprises the steps of: (1) providing one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanatetriisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture of any thereof; (2) providing a trimerisation catalyst system comprising; (a) an imidazolium or imidazolinium cation; and (b) an isocyanate-trimer inducing anion; (c) wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73°C; (3) trimerising said one or more monomers in the presence of said trimerisation catalyst; (4) thereby forming an isocyanurate trimer. The process for making the PIR foam comprises the steps of: (1) providing one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanatetriisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture any thereof; (2) providing polyol; (3) providing a trimerisation catalyst system comprising; (a) an imidazolium or imidazolinium cation; and (b) an isocyanate-trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73°C; and (4) optionally providing one or more surfactants, one or more flame retardants, water, one or more antioxidants, one or more auxiliary blowing agents, one or more urethane catalysts, one or more auxiliary trimerisation catalysts, or combinations thereof; (5) contacting said one or more monomers, and said polyol, and optionally said one or more surfactants, and optionally said one or more flame retardants, and optionally said water, and optionally said one or more antioxidants, and optionally said one or more auxiliary blowing agents in the presence of said trimerisation catalyst system and optionally said one or more urethane catalysts, and optionally said one or more auxiliary trimerisation catalysts; (6) thereby forming said polyisocyanurate/polyurethane rigid foam. The PIR foam comprises the reaction product of one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanatetriisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture any thereof with polyol in the presence of a trimerisation catalyst system comprising an imidazolium or imidazolinium cation, and an isocyanate-trimer inducing anion, and optionally one or more surfactants, optionally one or more flame retardants, optionally water, optionally one or more antioxidants, optionally one or more auxiliary blowing agents, optionally one or more additional urethane catalysts, and optionally one or more auxiliary trimerisation catalysts, or optionally combinations thereof, wherein the trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73°C. The PIR foam comprises the reaction product of one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanatetriisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture any thereof with polyol in the presence of a trimerisation catalyst system comprising an imidazolium or imidazolinium cation, and an isocyanate- trimer inducing anion, and optionally one or more surfactants, optionally one or more flame retardants, optionally water, optionally one or more antioxidants, optionally one or more auxiliary blowing agents, optionally one or more additional polyurethane catalysts, and optionally one or more auxiliary trimerisation catalysts, or optionally combinations thereof, wherein the PIR foam has a polyisocyanurate trimer ratio (Abs 1410 /Abs 1595 ) of at least 5 at a depth of 12 mm from the rising surface of the rigid foam, measured via ATR-FTIR spectroscopy.",DOW GLOBAL TECHNOLOGIES INC;;ATHEY PHILLIP;;WILMOT NATHAN;;KEATON RICHARD;;BABB DAVID;;BOYER CECILE;;MORLEY TIMOTHY,ATHEY PHILLIP;;WILMOT NATHAN;;KEATON RICHARD;;BABB DAVID;;BOYER CECILE;;MORLEY TIMOTHY,,https://lens.org/154-907-030-577-434,Search Report,yes,2,0,9,9,0,C08G18/022;;C08G18/092;;C08G18/1858;;C08G18/1875;;C08G18/2027;;C08G18/2063;;C08G18/4208;;C08G2120/00;;C08G2115/02;;C08G2110/0025;;C08G18/4208;;C08G18/022;;C08G18/092;;C08G18/1858;;C08G18/1875;;C08G18/2027;;C08G18/2063;;C08G2120/00;;C08G2110/0025;;C08G2115/02,C08G18/09;;C08G18/02;;C08G18/18;;C08G18/20,,0,0,,,,PENDING
393,BR,B1,BR 112017016723 B1,156-463-574-544-92X,2022-04-19,2022,BR 112017016723 A,2016-02-03,US 2016/0016420 W;;US 201562111337 P;;US 201514853504 A,2015-02-03,Sistema intravenoso (iv),"sistema intravenoso (iv), método para monitorar uma funcionalidade de linha intravenosa de um dispositivo iv e dispositivo de acesso intravenoso (iv). os aspectos da invenção se referem a sistemas e métodos para monitorar uma funcionalidade de linha intravenosa (iv) de um dispositivo iv. em uma modalidade, o sistema inclui um cateter iv para ser inserido na veia do indivíduo vivo, pelo menos um sensor de pressão em comunicação fluida com o cateter iv para adquirir sinais venosos periféricos e um dispositivo de processamento. o dispositivo de processamento recebe os sinais venosos periféricos a partir do sensor de pressão, realiza uma análise espectral nos sinais venosos periféricos para obter um espectro de frequência de pressão venosa periférica, e, então, realiza uma análise estatística em amplitudes de picos do espectro de frequência de pressão venosa periférica para determinar uma funcionalidade da linha iv do cateter iv em tempo real. quando a funcionalidade da linha iv indica infiltração iv, o dispositivo de processamento pode controlar o dispositivo de controle de fluido para interromper o fluxo de fluido a partir da fonte de fluido para o cateter iv.",UNIV VANDERBILT,BROPHY COLLEEN;;BAUDENBACHER FRANZ;;KYLE MITCHELL HOCKING;;BOYER RICHARD;;SUSAN S EAGLE,,https://lens.org/156-463-574-544-92X,Granted Patent,no,0,0,15,51,0,A61B5/02152;;A61B5/7235;;A61B5/7257;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61B5/7235;;A61B5/7257;;A61B5/02152;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61B5/7235;;A61B5/7257;;A61B5/02152,A61M5/158;;A61M5/165;;A61M5/172;;A61M25/01,,0,0,,,,ACTIVE
394,CN,B,CN 102272182 B,153-301-690-093-408,2014-02-12,2014,CN 200980153999 A,2009-11-09,US 2009/0063731 W;;US 11319508 P,2008-11-10,"Isocyanate trimerisation catalyst system, precursor formulation, process for trimerising isocyanates, rigid polyisocyanurate/polyurethane foams made therefrom, and process for making such foams",,DOW GLOBAL TECHNOLOGIES INC,ATHEY PHILLIP;;WILMOT NATHAN;;KEATON RICHARD;;BABB DAVID;;BOYER CECILE;;MORLEY TIMOTHY,,https://lens.org/153-301-690-093-408,Granted Patent,no,0,0,11,11,0,C08G18/022;;C08G18/022;;C08G18/092;;C08G18/092;;C08G18/166;;C08G18/168;;C08G18/168;;C08G18/1875;;C08G18/1875;;C08G2110/0025;;C08G2110/0025;;C08G2115/02;;C08G2115/02,C08G18/02;;C08G18/09;;C08G18/16;;C08G18/18,,0,0,,,,INACTIVE
395,EP,A4,EP 3253432 A4,106-162-224-284-336,2018-07-11,2018,EP 16747218 A,2016-02-03,US 201562111337 P;;US 201514853504 A;;US 2016/0016420 W,2015-02-03,INTRAVENOUS ACCESS DEVICE DETECTING INTRAVENOUS INFILTRATION AND IN-VEIN PLACEMENT,,UNIV VANDERBILT,EAGLE SUSAN S;;BROPHY COLLEEN;;HOCKING KYLE MITCHELL;;BAUDENBACHER FRANZ;;BOYER RICHARD,,https://lens.org/106-162-224-284-336,Search Report,no,3,0,15,51,0,A61B5/02152;;A61B5/7235;;A61B5/7257;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61B5/7235;;A61B5/7257;;A61B5/02152;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61B5/7235;;A61B5/7257;;A61B5/02152,A61B5/02;;A61B5/00,,1,0,,,See also references of WO 2016126856A1,ACTIVE
396,ES,T3,ES 2901790 T3,113-837-042-948-011,2022-03-23,2022,ES 16747218 T,2016-02-03,US 201562111337 P;;US 201514853504 A;;US 2016/0016420 W,2015-02-03,Dispositivo de acceso intravenoso que detecta infiltración intravenosa y colocación en la vena,"Un sistema intravenoso (IV), que comprende: un catéter IV (312), configurado para ser insertado en una vena de un sujeto vivo; un dispositivo de control de fluido (318) en comunicación fluida con el catéter IV, configurado para controlar el flujo de fluido desde una fuente de fluido hasta el catéter IV; al menos un sensor de presión en comunicación fluida con el catéter IV, configurado para adquirir, de la vena del sujeto vivo, señales venosas periféricas; y un dispositivo de procesamiento (320) conectado comunicativamente con el al menos un sensor de presión, configurado para: recibir las señales venosas periféricas desde el al menos un sensor de presión; realizar un análisis espectral sobre las señales venosas periféricas para obtener un espectro de frecuencia de presión venosa periférica; realizar un análisis estadístico sobre las amplitudes de los picos del espectro de frecuencia de presión venosa periférica para determinar una funcionalidad de la línea IV del catéter IV en tiempo real, en donde la funcionalidad de la línea IV del catéter IV indica infiltración IV cuando se detectan disminuciones de amplitud mayores que un primer umbral a partir de los picos del espectro de frecuencia de presión venosa periférica; y cuando la funcionalidad de la línea IV del catéter IV indica infiltración IV, controlar el dispositivo de control de fluido para detener el flujo de fluido desde la fuente de líquido hasta el catéter IV.",UNIV VANDERBILT,EAGLE SUSAN S;;BROPHY COLLEEN;;HOCKING KYLE MITCHELL;;BAUDENBACHER FRANZ;;BOYER RICHARD,,https://lens.org/113-837-042-948-011,Granted Patent,no,0,0,15,51,0,A61B5/02152;;A61B5/7235;;A61B5/7257;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61B5/7235;;A61B5/7257;;A61B5/02152;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61B5/7235;;A61B5/7257;;A61B5/02152,A61B5/02;;A61B5/00;;A61B5/0215;;A61M5/158;;A61M5/168,,0,0,,,,ACTIVE
397,EP,B1,EP 2346919 B1,130-737-322-747-765,2013-09-04,2013,EP 09752077 A,2009-11-09,US 2009/0063733 W;;US 11319608 P,2008-11-10,"ISOCYANATE TRIMERISATION CATALYST SYSTEM, A PRECURSOR FORMULATION, A PROCESS FOR TRIMERISING ISOCYANATES, RIGID POLYISOCYANURATE/POLYURETHANE FOAMS MADE THEREFROM, AND A PROCESS FOR MAKING SUCH FOAMS",,DOW GLOBAL TECHNOLOGIES LLC,ATHEY PHILLIP;;WILMOT NATHAN;;KEATON RICHARD;;BABB DAVID;;BOYER CECILE;;MORLEY TIMOTHY,,https://lens.org/130-737-322-747-765,Granted Patent,yes,2,0,9,9,0,C08G18/022;;C08G18/092;;C08G18/1858;;C08G18/1875;;C08G18/2027;;C08G18/2063;;C08G18/4208;;C08G2120/00;;C08G2115/02;;C08G2110/0025;;C08G18/4208;;C08G18/022;;C08G18/092;;C08G18/1858;;C08G18/1875;;C08G18/2027;;C08G18/2063;;C08G2120/00;;C08G2110/0025;;C08G2115/02,C08G18/20;;C08G18/02;;C08G18/09;;C08G18/18;;C08G18/42,,0,0,,,,ACTIVE
398,SG,A,SG 11202112086T A,166-987-190-237-920,2021-11-29,2021,SG 11202112086T A,2019-06-05,US 201962842824 P;;US 2019/0035543 W,2019-05-03,REACTION MIXER,,PHILADELPHIA MIXING SOLUTIONS LTD,HUTCHINSON TODD MICHAEL;;GRENVILLE RICHARD KENNETH;;GIACOMELLI JASON JON;;BOYER BENJAMIN AARON,,https://lens.org/166-987-190-237-920,Unknown,no,0,0,9,9,0,C01B25/222;;B01J19/20;;B01J2219/00189;;B01J19/0066;;B01J2219/0884;;B01F2215/0427;;B01F2215/0431;;B01D19/02;;B01J8/222;;B01J2208/0061;;B01J2219/00779;;B01F27/191;;B01F27/91;;B01F35/53;;B01J2219/185;;B01J2219/1923;;B01J19/1862;;B01F35/53;;B01F27/191;;B01F27/91;;B01F2215/0427;;B01F2215/0431;;B01J8/222;;B01J19/0066;;B01J19/02;;B01J19/20,B01J19/18;;C01B25/222,,0,0,,,,PENDING
399,US,A1,US 2020/0146566 A1,168-607-274-866-586,2020-05-14,2020,US 202016740888 A,2020-01-13,US 202016740888 A;;US 201715547935 A;;US 2016/0016420 W;;US 201514853504 A;;US 201562111337 P;;US 201462049829 P,2014-09-12,INTRAVENOUS ACCESS DEVICE DETECTING INTRAVENOUS INFILTRATION AND IN-VEIN PLACEMENT,"Aspects of the invention relates to systems and methods for monitoring an intravenous (IV) line functionality of an IV device. The system includes an IV catheter to be inserted into the vein of the living subject, at least one pressure sensor in fluid communication with the IV catheter to acquire peripheral venous signals; and a processing device. The processing device receives the peripheral venous signals from the pressure sensor, performs a spectral analysis on the peripheral venous signals to obtain a peripheral venous pressure frequency spectrum, and determines an IV line functionality of the IV catheter in real time, wherein the IV line functionality of the IV catheter indicates IV infiltration when amplitude decreases greater than a first threshold are detected from the peaks of the peripheral venous pressure frequency spectrum.",UNIV VANDERBILT,EAGLE SUSAN S;;BROPHY COLLEEN;;HOCKING KYLE MITCHELL;;BAUDENBACHER FRANZ;;BOYER RICHARD,VANDERBILT UNIVERSITY (2017-10-23),https://lens.org/168-607-274-866-586,Patent Application,yes,3,0,4,51,0,A61B5/02152;;A61B5/7235;;A61B5/7257;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61B5/02152;;A61B5/7235;;A61B5/7257;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61B5/02152;;A61B5/7235;;A61M2005/1588;;A61M5/158;;A61B5/7257;;A61M5/16854,A61B5/0215;;A61B5/00;;A61M5/158;;A61M5/168,,0,0,,,,DISCONTINUED
400,US,B2,US 10531799 B2,167-794-128-960-283,2020-01-14,2020,US 201615547935 A,2016-02-03,US 201615547935 A;;US 201514853504 A;;US 201562111337 P;;US 201462049829 P;;US 2016/0016420 W,2014-09-12,Intravenous access device detecting intravenous infiltration and in-vein placement,"Aspects of the invention relates to systems and methods for monitoring an intravenous (IV) line functionality of an IV device. In one embodiment, the system includes an IV catheter to be inserted into the vein of the living subject, at least one pressure sensor in fluid communication with the IV catheter to acquire peripheral venous signals; and a processing device. The processing device receives the peripheral venous signals from the pressure sensor, performs a spectral analysis on the peripheral venous signals to obtain a peripheral venous pressure frequency spectrum, and then performs a statistical analysis on amplitudes of peaks of the peripheral venous pressure frequency spectrum to determine an IV line functionality of the IV catheter in real time. When the IV line functionality indicates IV infiltration, the processing device may control the fluid controlling device to stop the fluid flow from the fluid source to the IV catheter.",UNIV VANDERBILT,EAGLE SUSAN S;;BROPHY COLLEEN;;HOCKING KYLE MITCHELL;;BAUDENBACHER FRANZ;;BOYER RICHARD,VANDERBILT UNIVERSITY (2017-10-23),https://lens.org/167-794-128-960-283,Granted Patent,yes,18,2,4,51,0,A61B5/02152;;A61B5/02152;;A61B5/02152;;A61B5/7235;;A61B5/7235;;A61B5/7235;;A61B5/7257;;A61B5/7257;;A61B5/7257;;A61M5/158;;A61M5/158;;A61M5/158;;A61M5/16854;;A61M5/16854;;A61M5/16854;;A61M2005/1588;;A61M2005/1588;;A61M2005/1588,A61B5/0215;;A61B5/00;;A61M5/158;;A61M5/168;;A61M5/172,,2,0,,,"Korean Intellectual Property Office (ISR/KR), “International Search Report for PCT/US2016/016420”, Korea, dated May 16, 2016.;;European Patent Office, “Extended European Search Report for 16747218.2”, The Hague, dated Jun. 11, 2018.",ACTIVE
401,WO,A8,WO 2010/054317 A8,182-016-236-170-601,2010-07-01,2010,US 2009/0063733 W,2009-11-09,US 11319608 P,2008-11-10,"ISOCYANATE TRIMERISATION CATALYST SYSTEM, A PRECURSOR FORMULATION, A PROCESS FOR TRIMERISING ISOCYANATES, RIGID POLYISOCYANURATE/POLYURETHANE FOAMS MADE THEREFROM, AND A PROCESS FOR MAKING SUCH FOAMS","The instant invention provides an isocyanate trimerisation catalyst system, a precursor formulation, a process for trimerising isocyanates, rigid foams made therefrom, and a process for making such foams. The trimerisation catalyst system comprises: (a) an imidazolium or imidazolinium cation; and (b) an isocyanate-trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73°C. The precursor formulation comprises: (1) at least 25 percent by weight of polyol, based on the weight of the precursor formulation; (2) less than 15 percent by weight of a trimerisation catalyst system, based on the weight of the precursor formulation, comprising; (a) an imidazolium or imidazolinium cation; and (c) an isocyanate-trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73°C; and (3) optionally one or more surfactants, one or more flame retardants, water, one or more antioxidants, one or more auxiliary blowing agents, one or more urethane catalysts, one or more auxiliary trimerisation catalysts, or combinations thereof. The process for trimerisation of isocyanates comprises the steps of: (1) providing one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanatetriisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture of any thereof; (2) providing a trimerisation catalyst system comprising; (a) an imidazolium or imidazolinium cation; and (b) an isocyanate-trimer inducing anion; (c) wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73°C; (3) trimerising said one or more monomers in the presence of said trimerisation catalyst; (4) thereby forming an isocyanurate trimer. The process for making the PIR foam comprises the steps of: (1) providing one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanatetriisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture any thereof; (2) providing polyol; (3) providing a trimerisation catalyst system comprising; (a) an imidazolium or imidazolinium cation; and (b) an isocyanate-trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73°C; and (4) optionally providing one or more surfactants, one or more flame retardants, water, one or more antioxidants, one or more auxiliary blowing agents, one or more urethane catalysts, one or more auxiliary trimerisation catalysts, or combinations thereof; (5) contacting said one or more monomers, and said polyol, and optionally said one or more surfactants, and optionally said one or more flame retardants, and optionally said water, and optionally said one or more antioxidants, and optionally said one or more auxiliary blowing agents in the presence of said trimerisation catalyst system and optionally said one or more urethane catalysts, and optionally said one or more auxiliary trimerisation catalysts; (6) thereby forming said polyisocyanurate/polyurethane rigid foam. The PIR foam comprises the reaction product of one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanatetriisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture any thereof with polyol in the presence of a trimerisation catalyst system comprising an imidazolium or imidazolinium cation, and an isocyanate-trimer inducing anion, and optionally one or more surfactants, optionally one or more flame retardants, optionally water, optionally one or more antioxidants, optionally one or more auxiliary blowing agents, optionally one or more additional urethane catalysts, and optionally one or more auxiliary trimerisation catalysts, or optionally combinations thereof, wherein the trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73°C. The PIR foam comprises the reaction product of one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanatetriisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture any thereof with polyol in the presence of a trimerisation catalyst system comprising an imidazolium or imidazolinium cation, and an isocyanate- trimer inducing anion, and optionally one or more surfactants, optionally one or more flame retardants, optionally water, optionally one or more antioxidants, optionally one or more auxiliary blowing agents, optionally one or more additional polyurethane catalysts, and optionally one or more auxiliary trimerisation catalysts, or optionally combinations thereof, wherein the PIR foam has a polyisocyanurate trimer ratio (Abs 1410 /Abs 1595 ) of at least 5 at a depth of 12 mm from the rising surface of the rigid foam, measured via ATR-FTIR spectroscopy.",DOW GLOBAL TECHNOLOGIES INC;;ATHEY PHILLIP;;WILMOT NATHAN;;KEATON RICHARD;;BABB DAVID;;BOYER CECILE;;MORLEY TIMOTHY,ATHEY PHILLIP;;WILMOT NATHAN;;KEATON RICHARD;;BABB DAVID;;BOYER CECILE;;MORLEY TIMOTHY,,https://lens.org/182-016-236-170-601,Amended Application,yes,0,0,9,9,0,C08G18/022;;C08G18/092;;C08G18/1858;;C08G18/1875;;C08G18/2027;;C08G18/2063;;C08G18/4208;;C08G2120/00;;C08G2115/02;;C08G2110/0025;;C08G18/4208;;C08G18/022;;C08G18/092;;C08G18/1858;;C08G18/1875;;C08G18/2027;;C08G18/2063;;C08G2120/00;;C08G2110/0025;;C08G2115/02,C08G18/18,,0,0,,,,PENDING
402,SG,A,SG 11201706298P A,187-599-162-522-625,2017-09-28,2017,SG 11201706298P A,2016-02-03,US 201562111337 P;;US 201514853504 A;;US 2016/0016420 W,2015-02-03,INTRAVENOUS ACCESS DEVICE DETECTING INTRAVENOUS INFILTRATION AND IN-VEIN PLACEMENT,,UNIV VANDERBILT,EAGLE SUSAN S;;BROPHY COLLEEN;;HOCKING KYLE MITCHELL;;BAUDENBACHER FRANZ;;BOYER RICHARD,,https://lens.org/187-599-162-522-625,Unknown,no,0,0,15,51,0,A61B5/02152;;A61B5/7235;;A61B5/7257;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61B5/7235;;A61B5/7257;;A61B5/02152;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61B5/7235;;A61B5/7257;;A61B5/02152,A61M5/172;;A61M5/158;;A61M5/165;;A61M25/01,,0,0,,,,PENDING
403,ES,T3,ES 2437604 T3,116-864-301-862-312,2014-01-13,2014,ES 09752076 T,2009-11-09,US 11319508 P;;US 2009/0063731 W,2008-11-10,"Un sistema catalítico de trimerización de isocianato, una formulación precursora, un procedimiento para trimerizar isocianatos, espumas rígidas de poliisocianurato/poliuretano hechas a partir de los mismos y un procedimiento para hacer dichas espumas","Un sistema catalítico de trimerización que comprende: un catión fosfatrano; y un anión que induce el trímero de isocianato; en donde dicho sistema catalítico de trimerización tiene una temperatura de activación de la trimerizaciónen el intervalo igual a, o menor que 73°C, como se determina mediante calorimetría diferencial de barrido(DSC) a una velocidad de 10°C/min, en donde dicho anión que induce el trímero de isocianato escarboxilato que tiene la siguiente estructura: en donde X' se selecciona del grupo que consiste en H, acilo C1-C18, alifático, aromático, cíclico, acíclico, yderivados de los mismos.",DOW GLOBAL TECHNOLOGIES LLC,ATHEY PHILLIP;;WILMOT NATHAN;;KEATON RICHARD;;BABB DAVID;;BOYER CECILE;;MORLEY TIMOTHY,,https://lens.org/116-864-301-862-312,Granted Patent,no,0,0,11,11,0,C08G18/022;;C08G18/022;;C08G18/092;;C08G18/092;;C08G18/166;;C08G18/168;;C08G18/168;;C08G18/1875;;C08G18/1875;;C08G2110/0025;;C08G2110/0025;;C08G2115/02;;C08G2115/02,C08G18/02;;C08G18/09;;C08G18/16;;C08G18/18,,0,0,,,,ACTIVE
404,US,A,US 6107067 A,122-043-300-892-076,2000-08-22,2000,US 11058298 A,1998-07-06,US 11058298 A,1998-07-06,"Porous, non-macroporous, inorganic oxide carrier body for immobilizing microorganisms for bioremediation","A porous inorganic oxide carrier body for immobilizing living cells is prepared from inorganic oxide particles such as clay particles. The particles have an average particle size of from 0.01 to 20 microns, and the carrier body has a total pore volume of 0.05 to 1.0 cc/g and an average pore diameter of 50 to 700 .ANG., and has substantially no pore volume in the range of 800 .ANG. or greater. The carrier is prepared by forming a mixture containing the particles, a liquid medium and optional ingredients including zeolite and activated carbon, and forming the mixture into a shaped carrier body which may be optionally dried and calcined. Typical shapes of the carrier include spheres, cylinders, rings, honeycombs and shaped monoliths. Bacteria and other microorganisms immobilized on the carrier are useful for treatment of contaminated waste streams or contaminated vapors, or for other uses for which microorganisms are used such as the synthesis of chemicals.",GRACE W R & CO,MILLER JAMES GEORGE;;BATES ROBERT HAYWOOD;;BOYER TIMOTHY ALLEN;;DURHAM DONALD RICHARD,W.R. GRACE & CO.-CONN (1998-07-06),https://lens.org/122-043-300-892-076,Granted Patent,yes,9,40,9,9,0,C02F3/10;;C12N11/14;;Y02W10/10;;C12N11/14;;C02F3/10;;Y02W10/10,C02F3/00;;C02F3/10;;C12N1/04;;C12N11/14,435/176;;435/41;;435/262.5;;435/395;;435/403;;210/615;;210/616,5,2,105-185-129-799-476;;007-129-266-679-711,10.1128/aem.60.11.4178-4181.1994;;16349446;;pmc201956;;16349386;;pmc201806;;10.1128/aem.60.9.3329-3335.1994,"Grace Technical Bulletin 928 1, Physical and Chemical Properties of Inorganic Oxide Biocarriers.;;Grace Technical Bulletin 928 2, Performance Properties of Inorganic Oxide Biocarriers Type Z.;;Grace Technical Bulletin 928 3, Performance Properties of Inorganic Oxide Biocarriers Type CZ.;;New Composite Biocarriers Engineered to Contain Adsorptive and Ion Exchange Properties Improved Immobilized Cell Biorector Process Dependability; Durham et al; vol. 60, No. 11, Applied and Environmental Microbiology, Nov. 1994, p. 4178 4181.;;Characteristics of Inorganic Biocarriers That Moderate System Upsets During Fixed Film Biotreatment Processes; Durham et al; vol. 60, No. 9, Applied and Environmental Microbiology, Sep. 1994, p. 3329 3335.",EXPIRED
405,EP,B1,EP 1093514 B1,183-491-273-430-168,2006-02-08,2006,EP 99930212 A,1999-06-10,US 9913207 W;;US 11058298 A,1998-07-06,NON-MACROPOROUS INORGANIC SUPPORT FOR BIOREMEDIATION,"A porous inorganic oxide carrier body for immobilizing living cells is prepared from inorganic oxide particles such as clay particles. The particles have an average particle size of from 0.01 to 20 microns, and the carrier body has a total pore volume of 0.05 to 1.0 cc/g and an average pore diameter of 50 to 700 ANGSTROM , and has substantially no pore volume in the range of 800 ANGSTROM or greater. The carrier is prepared by forming a mixture containing the particles, a liquid medium and optional ingredients including zeolite and activated carbon, and forming the mixture into a shaped carrier body which may be optionally dried and calcined. Typical shapes of the carrier include spheres, cylinders, rings, honeycombs and shaped monoliths. Bacteria and other microorganisms immobilized on the carrier are useful for treatment of contaminated waste streams or contaminated vapors, or for other uses for which microorganisms are used such as the synthesis of chemicals.",GRACE W R & CO,MILLER JAMES GEORGE;;BATES ROBERT HAYWOOD;;BOYER TIMOTHY ALLEN;;DURHAM DONALD RICHARD,,https://lens.org/183-491-273-430-168,Granted Patent,yes,1,0,9,9,0,C02F3/10;;C12N11/14;;Y02W10/10;;C12N11/14;;C02F3/10;;Y02W10/10,C12N11/14;;B01J35/10;;C02F3/00;;C02F3/10;;C12N1/04;;C12N5/00,,0,0,,,,EXPIRED
406,DE,T2,DE 69004109 T2,186-428-826-529-035,1994-05-11,1994,DE 69004109 T,1990-01-22,US 30242789 A,1989-01-26,"Mikrowellen-Absorbermaterial, das nadelförmige magnetische Metallfasern enthält.",,MINNESOTA MINING & MFG,BOYER CHARLES E;;BORCHERS ERIC J;;KUO RICHARD J;;HOYLE CHARLES D,,https://lens.org/186-428-826-529-035,Granted Patent,no,0,0,8,9,0,H01Q17/005,B32B7/02;;H01Q17/00;;H05K9/00,,0,0,,,,EXPIRED
407,WO,A3,WO 2010/054315 A3,059-874-039-447-239,2010-12-02,2010,US 2009/0063731 W,2009-11-09,US 11319508 P,2008-11-10,"AN ISOCYANATE TRIMERISATION CATALYST SYSTEM, A PRECURSOR FORMULATION, A PROCESS FOR TRIMERISING ISOCYANATES, RIGID POLYISOCYANURATE/POLYURETHANE FOAMS MADE THEREFROM, AND A PROCESS FOR MAKING SUCH FOAMS","The instant invention provides an isocyanate trimerisation catalyst system, a precursor formulation, a process for trimerising isocyanates, rigid foams made therefrom, and a process for making such foams. The trimerisation catalyst system comprises: (a) a phosphatrane cation; and (b) an isocyanate-trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73 C.",DOW GLOBAL TECHNOLOGIES INC;;ATHEY PHILLIP;;WILMOT NATHAN;;KEATON RICHARD;;BABB DAVID;;BOYER CECILE;;MORLEY TIMOTHY,ATHEY PHILLIP;;WILMOT NATHAN;;KEATON RICHARD;;BABB DAVID;;BOYER CECILE;;MORLEY TIMOTHY,,https://lens.org/059-874-039-447-239,Search Report,yes,1,0,11,11,0,C08G18/022;;C08G18/022;;C08G18/092;;C08G18/092;;C08G18/166;;C08G18/168;;C08G18/168;;C08G18/1875;;C08G18/1875;;C08G2110/0025;;C08G2110/0025;;C08G2115/02;;C08G2115/02,C08G18/02;;C08G18/09;;C08G18/16;;C08G18/18,,0,0,,,,PENDING
408,CA,A1,CA 2563996 A1,099-438-477-491-408,2005-11-10,2005,CA 2563996 A,2005-04-22,US 56474404 P;;US 2005/0013852 W,2004-04-23,AN AUTOMATED NON- INVASIVE REAL-TIME ACUTE RENAL FAILURE DETECTION SYSTEM,"[0111] A real-time, non-invasive system and method for determining the level of an analyze of interest in the urine of a patient is disclosed. The system and method uses the measured level of an analyze of interest to detect the onset of acute renal failure (ARF) as early as possible to prevent that patient from developing the disease or mitigating the effects of the disease . The system and method may be used to monitor the recovery of a patient after an ARF diagnosis. Preferably, the analyze of interest is creatinine or urea. The system may be placed in the urine drain line of a patient between a Fole y catheter or other urinary drain and a urine collection bag. The system makes substantially continuous measurements of the urine flow rate and the concentration of the analyze of interest to determine the mass excretion rat e of the analyze so it may be monitored to detect if the patient experiences a delta change in the mass excretion rate of an analyze that is indicative of the onset of ARF or a change in renal function.",RENAL DIAGNOSTIC INC,TOWNSEND SETH;;BOYER RICHARD;;KOMANSKI CHRISTOPHER;;FINE DEREK;;STAR ROBERT;;TEDFORD NATHAN,,https://lens.org/099-438-477-491-408,Patent Application,no,0,0,4,4,0,A61B5/14507;;A61B5/201;;A61B5/208;;A61B5/412;;A61B5/201;;A61B5/14507;;A61B5/208;;A61B5/412,G01N35/08;;G01N21/00,,0,0,,,,DISCONTINUED
409,JP,A,JP 2021090798 A,094-275-200-964-641,2021-06-17,2021,JP 2021023822 A,2021-02-18,US 201562111337 P;;US 201514853504 A,2015-02-03,INTRAVENOUS ACCESS DEVICE FOR DETECTING INTRAVENOUS LEAKING AND INSTALLATION IN VEIN,"To provide a system and a method for monitoring an intravenous (IV) line functionality of an IV device.SOLUTION: A system of the present invention includes an IV catheter to be inserted into the vein of a living body, at least one pressure sensor in fluid communication with the IV catheter to acquire peripheral venous signals, and a processing device. The processing device receives the peripheral venous signals from the pressure sensor, performs a spectral analysis on the peripheral venous signals to obtain a peripheral venous pressure frequency spectrum, and then performs a statistical analysis on amplitudes of peaks of the peripheral venous pressure frequency spectrum to determine an IV line functionality of the IV catheter in real time. When the IV line functionality indicates IV leaking, the processing device may control a fluid control device to stop the fluid flow from a fluid supply source to the IV catheter.SELECTED DRAWING: Figure 4",UNIV VANDERBILT,SUSAN S EAGLE;;COLLEEN BROPHY;;KYLE MITCHELL HOCKING;;FRANZ BAUDENBACHER;;RICHARD BOYER,,https://lens.org/094-275-200-964-641,Patent Application,no,2,0,15,51,0,A61B5/02152;;A61B5/7235;;A61B5/7257;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61B5/7235;;A61B5/7257;;A61B5/02152;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61B5/7235;;A61B5/7257;;A61B5/02152,A61M5/168;;A61B5/00,,0,0,,,,DISCONTINUED
410,EP,B1,EP 2634369 B1,117-018-143-732-304,2021-08-18,2021,EP 13157090 A,2013-02-27,US 201213409341 A,2012-03-01,TURBINE BUCKETS AND CORRESPONDING FORMING METHOD,,GEN ELECTRIC,ELLIS SCOTT EDMOND;;GOOD RANDALL RICHARD;;BOYER BRADLEY TAYLOR;;SMITH AARON EZEKIEL,"GENERAL ELECTRIC TECHNOLOGY GMBH, CH (2023-11-23)",https://lens.org/117-018-143-732-304,Granted Patent,yes,7,0,8,8,0,F05D2240/81;;F05D2250/185;;F01D5/187;;F05D2240/81;;F05D2250/185;;F01D5/187,F01D5/18,,1,0,,,None,ACTIVE
411,BR,A2,BR 112021022023 A2,117-754-516-694-933,2022-01-18,2022,BR 112021022023 A,2019-06-05,US 2019/0035543 W;;US 201962842824 P,2019-05-03,Misturador de reação,"misturador de reação. um agitador ou misturador instalado em um reator de sólido-líquido-gás/pasta, onde a remoção do gás da pasta e a destruição da espuma são promovidas. o misturador de reação inclui um recipiente e uma montagem de agitador. o recipiente serve para conter a mistura de sólido-líquido-gás e define duas zonas de mistura dentro de um determinado volume; uma primeira zona de mistura e uma segunda zona de mistura, localizada acima da primeira zona de mistura. a montagem de agitador é posicionada dentro do recipiente e compreende um eixo rotativo e um primeiro e um segundo propulsores acoplados ao eixo. o primeiro propulsor axial está localizado dentro da primeira zona de mistura e é configurado para bombear o líquido em uma direção descendente ao longo de um eixo geométrico vertical de rotação. o segundo propulsor está localizado dentro da segunda zona de mistura e é configurado para bombear o líquido em uma direção ascendente ao longo do eixo geométrico vertical de rotação.",PHILADELPHIA MIXING SOLUTIONS LTD,BENJAMIN AARON BOYER;;JASON JON GIACOMELLI;;RICHARD KENNETH GRENVILLE;;TODD MICHAEL HUTCHINSON,"PHILADELPHIA MIXING SOLUTIONS, LLC (US) (2022-05-17)",https://lens.org/117-754-516-694-933,Patent Application,no,0,0,9,9,0,C01B25/222;;B01J19/20;;B01J2219/00189;;B01J19/0066;;B01J2219/0884;;B01F2215/0427;;B01F2215/0431;;B01D19/02;;B01J8/222;;B01J2208/0061;;B01J2219/00779;;B01F27/191;;B01F27/91;;B01F35/53;;B01J2219/185;;B01J2219/1923;;B01J19/1862;;B01F35/53;;B01F27/191;;B01F27/91;;B01F2215/0427;;B01F2215/0431;;B01J8/222;;B01J19/0066;;B01J19/02;;B01J19/20,B01J19/18;;C01B25/222,,0,0,,,,PENDING
412,AU,A1,AU 2019/444631 A1,154-267-254-305-881,2021-11-25,2021,AU 2019/444631 A,2019-06-05,US 201962842824 P;;US 2019/0035543 W,2019-05-03,Reaction mixer,An agitator or mixer installed in a solid-liquid-gas/slurry reactor in which gas removal from the slurry and foam destruction is promoted. The reaction mixer includes a vessel and an agitator assembly. The vessel is for containing the solid-liquid-gas mixture and defines two mixing zones within a given volume; a first mixing zone and a second mixing zone located above the first mixing zone. The agitator assembly is positionable within the vessel and comprises a rotatable shaft and a first and second impeller coupled to the shaft. The first axial impeller is locatable within the first mixing zone and is configured to pump the liquid in a downward direction along a vertical axis of rotation. The second impeller is locatable within the second mixing zone and is configured to pump the liquid in an upward direction along the vertical axis of rotation.,PHILADELPHIA MIXING SOLUTIONS LLC,HUTCHINSON TODD MICHAEL;;GRENVILLE RICHARD KENNETH;;GIACOMELLI JASON JON;;BOYER BENJAMIN AARON,"PHILADELPHIA MIXING SOLUTIONS, LLC. (2022-02-17)",https://lens.org/154-267-254-305-881,Patent Application,no,0,0,9,9,0,C01B25/222;;B01J19/20;;B01J2219/00189;;B01J19/0066;;B01J2219/0884;;B01F2215/0427;;B01F2215/0431;;B01D19/02;;B01J8/222;;B01J2208/0061;;B01J2219/00779;;B01F27/191;;B01F27/91;;B01F35/53;;B01J2219/185;;B01J2219/1923;;B01J19/1862;;B01F35/53;;B01F27/191;;B01F27/91;;B01F2215/0427;;B01F2215/0431;;B01J8/222;;B01J19/0066;;B01J19/02;;B01J19/20,B01J19/18;;C01B25/222,,0,0,,,,PENDING
413,US,A1,US 2016/0176302 A1,061-310-199-756-274,2016-06-23,2016,US 201615046728 A,2016-02-18,US 201615046728 A;;US 201213562954 A;;US 201161515866 P,2011-08-06,INTERCONNECTED WIRELESS BATTERY CHARGING AND REGENERATIVE BRAKING SYSTEMS FOR AN ELECTRIC VEHICLE,"A wireless vehicle battery charging system includes an off-vehicle transducer connected to a power source and configured to wirelessly transmit and receive a first alternating current having a first frequency, an on-vehicle transducer configured to wirelessly transmit and receive the first alternating current, and a frequency converting circuit connected to the on-vehicle transducer. The frequency converting circuit is configured to change the first frequency of the first alternating current to a second alternating current having a second frequency. The system further includes a battery within the vehicle and a regenerative braking circuit connected to the frequency converting circuit and the battery. The regenerative braking circuit is configured to rectify the second alternating current to a direct current supplied to the battery and configured to convert the direct current from the battery to the second alternating current supplied to the frequency converting circuit.",DELPHI TECH INC,BOYER RICHARD J;;PASHA KERRY WHITE;;PASHA BRIAN D;;FUZO JOHN VICTOR,DELPHI TECHNOLOGIES INC (2016-02-18),https://lens.org/061-310-199-756-274,Patent Application,yes,6,6,1,3,0,Y02T10/7072;;Y02T90/14;;Y04S10/126;;H02J3/381;;H02J50/10;;H02J50/90;;B60L53/12;;B60L55/00;;B60L58/12;;B60L7/10;;H02J7/00036;;B60L58/16;;B60L53/62;;H02J2310/48;;H02J7/00047;;Y02E60/00;;Y02T10/70;;Y02T90/12;;B60L3/0046;;B60L7/10;;Y02T90/14;;H02J3/381;;Y02T10/7072;;Y04S10/126;;B60L53/12;;H02J50/10;;B60L55/00;;B60L58/12;;H02J50/90;;H02J7/00036;;B60L53/62;;Y02E60/00;;Y02T10/70;;Y02T90/12;;Y02T90/16;;H02J7/00047;;H02J2310/48,B60L11/18;;B60L3/00;;B60L7/10,,0,0,,,,DISCONTINUED
414,EP,A1,EP 3962638 A1,152-387-703-206-031,2022-03-09,2022,EP 19927694 A,2019-06-05,US 201962842824 P;;US 2019/0035543 W,2019-05-03,REACTION MIXER,,PHILADELPHIA MIXING SOLUTIONS LTD,HUTCHINSON TODD MICHAEL;;GRENVILLE RICHARD KENNETH;;GIACOMELLI JASON JON;;BOYER BENJAMIN AARON,"PHILADELPHIA MIXING SOLUTIONS, LLC (2022-03-23)",https://lens.org/152-387-703-206-031,Patent Application,yes,0,0,9,9,0,C01B25/222;;B01J19/20;;B01J2219/00189;;B01J19/0066;;B01J2219/0884;;B01F2215/0427;;B01F2215/0431;;B01D19/02;;B01J8/222;;B01J2208/0061;;B01J2219/00779;;B01F27/191;;B01F27/91;;B01F35/53;;B01J2219/185;;B01J2219/1923;;B01J19/1862;;B01F35/53;;B01F27/191;;B01F27/91;;B01F2215/0427;;B01F2215/0431;;B01J8/222;;B01J19/0066;;B01J19/02;;B01J19/20,B01J19/18;;C01B25/222,,0,0,,,,DISCONTINUED
415,CA,A1,CA 2975604 A1,164-554-270-507-496,2016-08-11,2016,CA 2975604 A,2016-02-03,US 201562111337 P;;US 201514853504 A;;US 2016/0016420 W,2015-02-03,INTRAVENOUS ACCESS DEVICE DETECTING INTRAVENOUS INFILTRATION AND IN-VEIN PLACEMENT,"Aspects of the invention relates to systems and methods for monitoring an intravenous (IV) line functionality of an IV device. In one embodiment, the system includes an IV catheter to be inserted into the vein of the living subject, at least one pressure sensor in fluid communication with the IV catheter to acquire peripheral venous signals; and a processing device. The processing device receives the peripheral venous signals from the pressure sensor, performs a spectral analysis on the peripheral venous signals to obtain a peripheral venous pressure frequency spectrum, and then performs a statistical analysis on amplitudes of peaks of the peripheral venous pressure frequency spectrum to determine an IV line functionality of the IV catheter in real time. When the IV line functionality indicates IV infiltration, the processing device may control the fluid controlling device to stop the fluid flow from the fluid source to the IV catheter.",UNIV VANDERBILT,EAGLE SUSAN S;;BROPHY COLLEEN;;HOCKING KYLE MITCHELL;;BAUDENBACHER FRANZ;;BOYER RICHARD,,https://lens.org/164-554-270-507-496,Patent Application,no,0,0,15,51,0,A61B5/02152;;A61B5/7235;;A61B5/7257;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61B5/7235;;A61B5/7257;;A61B5/02152;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61B5/7235;;A61B5/7257;;A61B5/02152,A61B5/02;;A61B5/0215;;A61M5/172;;A61M25/01,,0,0,,,,PENDING
416,WO,A1,WO 2020/226668 A1,169-036-801-671-239,2020-11-12,2020,US 2019/0035543 W,2019-06-05,US 201962842824 P,2019-05-03,REACTION MIXER,An agitator or mixer installed in a solid-liquid-gas/slurry reactor in which gas removal from the slurry and foam destruction is promoted. The reaction mixer includes a vessel and an agitator assembly. The vessel is for containing the solid-liquid-gas mixture and defines two mixing zones within a given volume; a first mixing zone and a second mixing zone located above the first mixing zone. The agitator assembly is positionable within the vessel and comprises a rotatable shaft and a first and second impeller coupled to the shaft. The first axial impeller is locatable within the first mixing zone and is configured to pump the liquid in a downward direction along a vertical axis of rotation. The second impeller is locatable within the second mixing zone and is configured to pump the liquid in an upward direction along the vertical axis of rotation.,PHILADELPHIA MIXING SOLUTIONS LTD,HUTCHINSON TODD MICHAEL;;GRENVILLE RICHARD KENNETH;;GIACOMELLI JASON JON;;BOYER BENJAMIN AARON,,https://lens.org/169-036-801-671-239,Patent Application,yes,7,0,9,9,0,C01B25/222;;B01J19/20;;B01J2219/00189;;B01J19/0066;;B01J2219/0884;;B01F2215/0427;;B01F2215/0431;;B01D19/02;;B01J8/222;;B01J2208/0061;;B01J2219/00779;;B01F27/191;;B01F27/91;;B01F35/53;;B01J2219/185;;B01J2219/1923;;B01J19/1862;;B01F35/53;;B01F27/191;;B01F27/91;;B01F2215/0427;;B01F2215/0431;;B01J8/222;;B01J19/0066;;B01J19/02;;B01J19/20,B01J19/18;;C01B25/222,,0,0,,,,PENDING
417,CO,A2,CO 2017007842 A2,189-850-982-658-798,2017-10-20,2017,CO 2017007842 A,2017-08-02,US 2016/0016420 W;;US 201562111337 P;;US 201514853504 A,2015-02-03,Dispositivo de acceso intravenoso que detecta infiltración intravenosa y colocación en vena,"Aspectos de la invención se refieren a sistemas y métodos para monitorizar una funcionalidad de línea intravenosa (IV) de un dispositivo IV. En una modalidad, el sistema incluye un catéter IV para que se inserte en la vena del sujeto vivo, al menos un sensor de presión en comunicación de fluidos con el catéter IV para adquirir señales venosas periféricas; y un dispositivo de procesamiento. El dispositivo de procesamiento recibe las señales venosas periféricas del sensor de presión, lleva a cabo un análisis espectral en las señales venosas periféricas para obtener un espectro de frecuencia de presión venosa periférica, y entonces lleva a cabo un análisis estadístico en amplitudes de picos del espectro de frecuencia de presión venosa periférica para determinar una funcionalidad de línea IV del catéter IV en tiempo real. Cuando la funcionalidad de línea IV indica infiltración IV, el dispositivo de procesamiento puede controlar el dispositivo de control de fluido para detener el flujo de fluido de la fuente de fluido al catéter IV.",UNIV VANDERBILT,BROPHY COLLEEN;;BAUDENBACHER FRANZ;;BOYER RICHARD;;EAGLE SUSAN S;;HOCKING KYLE MITCHELL,,https://lens.org/189-850-982-658-798,Patent Application,no,0,0,15,51,0,A61B5/02152;;A61B5/7235;;A61B5/7257;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61B5/7235;;A61B5/7257;;A61B5/02152;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61B5/7235;;A61B5/7257;;A61B5/02152,A61M5/172;;A61M5/158;;A61M5/165;;A61M25/01,,0,0,,,,PENDING
418,EP,A2,EP 2346918 A2,015-920-593-319-283,2011-07-27,2011,EP 09752076 A,2009-11-09,US 2009/0063731 W;;US 11319508 P,2008-11-10,"AN ISOCYANATE TRIMERISATION CATALYST SYSTEM, A PRECURSOR FORMULATION, A PROCESS FOR TRIMERISING ISOCYANATES, RIGID POLYISOCYANURATE/POLYURETHANE FOAMS MADE THEREFROM, AND A PROCESS FOR MAKING SUCH FOAMS",,DOW GLOBAL TECHNOLOGIES LLC,ATHEY PHILLIP;;WILMOT NATHAN;;KEATON RICHARD;;BABB DAVID;;BOYER CECILE;;MORLEY TIMOTHY,,https://lens.org/015-920-593-319-283,Patent Application,yes,0,0,11,11,0,C08G18/022;;C08G18/022;;C08G18/092;;C08G18/092;;C08G18/166;;C08G18/168;;C08G18/168;;C08G18/1875;;C08G18/1875;;C08G2110/0025;;C08G2110/0025;;C08G2115/02;;C08G2115/02,C08G18/02;;C08G18/09;;C08G18/16;;C08G18/18,,1,0,,,See references of WO 2010054315A2,ACTIVE
419,CA,A1,CA 2884397 A1,030-492-287-851-808,2014-03-13,2014,CA 2884397 A,2013-09-10,US 201261698790 P;;US 2013/0058992 W,2012-09-10,INTRAVENOUS ACCESS DEVICE HAVING INTEGRATED HEMODYNAMIC RESUSCITATION SYSTEM AND RELATED METHODS,"One aspect of the present disclosure is a system for hemodynamic resuscitation. The system includes an intravenous access device having a pressure sensor element configured to detect a peripheral venous pressure value in response to an occlusion of a peripheral vein. The system also includes a controller device that isconfigured to receive a signal from the pressure sensor comprising the peripheral venous pressure value, to process the signal to determine a hemodynamic parameter based on the peripheral venous pressue value, and to generate a resuscitation score based on the hemodynamic parameter.",UNIV VANDERBILT,SEXTON KEVIN;;EAGLE SUSAN;;HOCKING KYLE;;BAUDENBACHER FRANZ;;BROPHY COLLEEN;;BOYER RICHARD,,https://lens.org/030-492-287-851-808,Patent Application,no,0,0,8,8,0,A61B5/0002;;A61B5/0205;;A61M2005/14208;;A61M2205/3344;;A61M2205/3561;;A61M2205/3584;;A61M2205/3592;;A61M2205/50;;A61M2205/502;;A61M2230/30;;A61B17/1355;;A61M5/1723;;A61B5/02152;;A61M5/1723;;A61B5/02152;;A61B5/0205;;A61B5/0002;;A61M2205/502;;A61M2205/3584;;A61M2205/3561;;A61M2205/3344;;A61M2205/50;;A61M2230/30;;A61M2005/14208;;A61M2205/3592;;A61B17/1355,A61M1/10;;A61B5/021;;A61B5/026,,0,0,,,,ACTIVE
420,EP,A1,EP 2892582 A1,081-456-645-284-56X,2015-07-15,2015,EP 13835216 A,2013-09-10,US 201261698790 P;;US 2013/0058992 W,2012-09-10,INTRAVENOUS ACCESS DEVICE HAVING INTEGRATED HEMODYNAMIC RESUSCITATION SYSTEM.,,UNIV VANDERBILT,SEXTON KEVIN;;EAGLE SUSAN;;HOCKING KYLE;;BAUDENBACHER FRANZ;;BROPHY COLLEEN;;BOYER RICHARD,THE UNITED STATES AS REPRESENTED BY THE DEPARTMENT (2019-07-03);;VANDERBILT UNIVERSITY (2019-07-03),https://lens.org/081-456-645-284-56X,Patent Application,yes,0,2,8,8,0,A61B5/0002;;A61B5/0205;;A61M2005/14208;;A61M2205/3344;;A61M2205/3561;;A61M2205/3584;;A61M2205/3592;;A61M2205/50;;A61M2205/502;;A61M2230/30;;A61B17/1355;;A61M5/1723;;A61B5/02152;;A61M5/1723;;A61B5/02152;;A61B5/0205;;A61B5/0002;;A61M2205/502;;A61M2205/3584;;A61M2205/3561;;A61M2205/3344;;A61M2205/50;;A61M2230/30;;A61M2005/14208;;A61M2205/3592;;A61B17/1355,A61M1/10;;A61B5/021;;A61B5/026,,0,0,,,,ACTIVE
421,EP,B1,EP 3253432 B1,149-285-478-171-016,2021-10-27,2021,EP 16747218 A,2016-02-03,US 201562111337 P;;US 201514853504 A;;US 2016/0016420 W,2015-02-03,INTRAVENOUS ACCESS DEVICE DETECTING INTRAVENOUS INFILTRATION AND IN-VEIN PLACEMENT,,UNIV VANDERBILT,EAGLE SUSAN S;;BROPHY COLLEEN;;HOCKING KYLE MITCHELL;;BAUDENBACHER FRANZ;;BOYER RICHARD,,https://lens.org/149-285-478-171-016,Granted Patent,yes,8,0,15,51,0,A61B5/02152;;A61B5/7235;;A61B5/7257;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61B5/7235;;A61B5/7257;;A61B5/02152;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61B5/7235;;A61B5/7257;;A61B5/02152,A61B5/02;;A61B5/00;;A61B5/0215;;A61M5/158;;A61M5/168,,0,0,,,,ACTIVE
422,ES,T3,ES 2436013 T3,030-498-100-648-023,2013-12-26,2013,ES 09752077 T,2009-11-09,US 11319608 P;;US 2009/0063733 W,2008-11-10,"Sistema catalítico de trimerización de isocianato, una formulación precursora, un procedimiento para trimerizar isocianatos, espumas rígidas de poliisocianurato/poliuretano hechas a partir de los mismos y un procedimiento para hacer dichas espumas","Un sistema catalítico de trimerización que comprende: un catión imidazolio o imidazolinio; y un anión que induce el trímero de isocianato; en donde dicho sistema catalítico de trimerización tiene una temperatura de activación de trimerización en el intervalo de igual a o menor que 73°C como se determina por calorimetría por barrido diferencial (DSC) a una velocidad de 10°C/min. y en donde dicho catión de imidazolio o imidazolinio tiene la siguiente estructura en donde E es unión insaturada C2 o C6; en donde X se selecciona del grupo que consiste en H, C1-C18, P, Si, N y cualquier combinación de los mismos; en donde R1 se selecciona del grupo que consiste en H, C1-C18, Si y cualquier combinación de los mismos; en donde R2 se selecciona del grupo que consiste en H, C1-C18, Si y cualquier combinación de los mismos.",DOW GLOBAL TECHNOLOGIES LLC,ATHEY PHILLIP;;WILMOT NATHAN;;KEATON RICHARD;;BABB DAVID;;BOYER CECILE;;MORLEY TIMOTHY,,https://lens.org/030-498-100-648-023,Granted Patent,no,0,0,9,9,0,C08G18/022;;C08G18/092;;C08G18/1858;;C08G18/1875;;C08G18/2027;;C08G18/2063;;C08G18/4208;;C08G2120/00;;C08G2115/02;;C08G2110/0025;;C08G18/4208;;C08G18/022;;C08G18/092;;C08G18/1858;;C08G18/1875;;C08G18/2027;;C08G18/2063;;C08G2120/00;;C08G2110/0025;;C08G2115/02,C08G18/20;;C08G18/02;;C08G18/09;;C08G18/18;;C08G18/42,,0,0,,,,ACTIVE
423,EP,B1,EP 2892582 B1,039-556-494-530-131,2019-11-13,2019,EP 13835216 A,2013-09-10,US 201261698790 P;;US 2013/0058992 W,2012-09-10,INTRAVENOUS ACCESS DEVICE HAVING INTEGRATED HEMODYNAMIC RESUSCITATION SYSTEM.,,UNIV VANDERBILT;;THE UNITED STATES AS REPRESENTED BY THE DEPT OF VETERANS AFFAIRS,SEXTON KEVIN;;EAGLE SUSAN;;HOCKING KYLE;;BAUDENBACHER FRANZ;;BROPHY COLLEEN;;BOYER RICHARD,THE UNITED STATES AS REPRESENTED BY THE DEPARTMENT (2019-07-03);;VANDERBILT UNIVERSITY (2019-07-03),https://lens.org/039-556-494-530-131,Granted Patent,yes,8,0,8,8,0,A61B5/0002;;A61B5/0205;;A61M2005/14208;;A61M2205/3344;;A61M2205/3561;;A61M2205/3584;;A61M2205/3592;;A61M2205/50;;A61M2205/502;;A61M2230/30;;A61B17/1355;;A61M5/1723;;A61B5/02152;;A61M5/1723;;A61B5/02152;;A61B5/0205;;A61B5/0002;;A61M2205/502;;A61M2205/3584;;A61M2205/3561;;A61M2205/3344;;A61M2205/50;;A61M2230/30;;A61M2005/14208;;A61M2205/3592;;A61B17/1355,A61M1/10;;A61B5/021;;A61B5/026,,0,0,,,,ACTIVE
424,US,A1,US 2016/0264010 A1,070-951-463-496-747,2016-09-15,2016,US 201615159312 A,2016-05-19,US 201615159312 A;;US 201213450881 A;;US 201161506242 P,2011-07-11,WIRELESS ELECTRICAL CHARGING SYSTEM AND METHOD OF OPERATING SAME,"An electrical charging system configured to charge a battery includes a power transmitter, an energy coupling arrangement, an electrical signal shaping device including a controller, and an alignment means. The arrangement includes a first inductive coil disposed external to the vehicle and a second inductive coil attached with the vehicle. The alignment means communicates with the vehicle to ensure repeatable vehicle positioning so that the second inductive coil is positioned relative to the first inductive coil so that the second inductive coil receives the energy produced by the power transmitter wirelessly transmitted from the first inductive coil. The energy received by the second inductive coil is electrically shaped by the electrical signal shaping device and further transmitted through the electrical signal shaping device as controlled by the controller to charge the battery. Methods for transmitting energy through the electrical charging system to charge the battery are also presented.",DELPHI TECH INC,BOYER RICHARD J;;PASHA KERRY WHITE;;PASHA BRIAN D;;FUZO JOHN VICTOR,APTIV TECHNOLOGIES LIMITED (2018-01-01);;APTIV TECHNOLOGIES AG (2023-10-06),https://lens.org/070-951-463-496-747,Patent Application,yes,1,8,18,18,0,B60L2240/62;;Y02T90/16;;Y02T90/14;;Y04S30/14;;Y02T10/7072;;H02J50/10;;H02J50/80;;B60L53/35;;B60L53/38;;B60L53/665;;H02J50/90;;H02J7/00036;;B60L53/126;;B60L53/122;;H02J2310/48;;H02J7/00047;;Y02T10/70;;Y02T10/72;;Y02T90/12;;Y02T90/167;;H02J50/80;;H02J50/90;;H02J50/10;;B60L53/12;;B60L53/665;;B60L53/38;;B60L2240/62;;Y02T90/14;;Y04S30/14;;Y02T10/7072;;H02J7/00036;;B60Y2200/91;;B60Y2200/92;;H02J50/90;;H02J50/12;;B60L2240/62;;Y02T10/7072;;Y02T90/16;;Y02T90/14;;Y04S30/14;;H02J50/80;;H02J50/10;;H02J7/00;;B60L53/35;;B60L53/38;;B60L53/665;;H02J7/00036;;B60L53/122;;B60L53/126;;Y02T10/70;;Y02T10/72;;Y02T90/12;;Y02T90/167;;H02J7/00047;;H02J2310/48,B60L11/18,,0,0,,,,ACTIVE
425,EP,A4,EP 3962638 A4,153-483-184-530-863,2023-01-11,2023,EP 19927694 A,2019-06-05,US 201962842824 P;;US 2019/0035543 W,2019-05-03,REACTION MIXER,,PHILADELPHIA MIXING SOLUTIONS LLC,HUTCHINSON TODD MICHAEL;;GRENVILLE RICHARD KENNETH;;GIACOMELLI JASON JON;;BOYER BENJAMIN AARON,"PHILADELPHIA MIXING SOLUTIONS, LLC (2022-03-23)",https://lens.org/153-483-184-530-863,Search Report,no,4,0,9,9,0,C01B25/222;;B01J19/20;;B01J2219/00189;;B01J19/0066;;B01J2219/0884;;B01F2215/0427;;B01F2215/0431;;B01D19/02;;B01J8/222;;B01J2208/0061;;B01J2219/00779;;B01F27/191;;B01F27/91;;B01F35/53;;B01J2219/185;;B01J2219/1923;;B01J19/1862;;B01F35/53;;B01F27/191;;B01F27/91;;B01F2215/0427;;B01F2215/0431;;B01J8/222;;B01J19/0066;;B01J19/02;;B01J19/20,B01J19/18;;C01B25/222,,1,0,,,See also references of WO 2020226668A1,DISCONTINUED
426,US,B2,US 9707853 B2,073-415-342-675-626,2017-07-18,2017,US 201615159312 A,2016-05-19,US 201615159312 A;;US 201213450881 A;;US 201161506242 P,2011-07-11,Wireless electrical charging system and method of operating same,"An electrical charging system configured to charge a battery includes a power transmitter, an energy coupling arrangement, an electrical signal shaping device including a controller, and an alignment means. The arrangement includes a first inductive coil disposed external to the vehicle and a second inductive coil attached with the vehicle. The alignment means communicates with the vehicle to ensure repeatable vehicle positioning so that the second inductive coil is positioned relative to the first inductive coil so that the second inductive coil receives the energy produced by the power transmitter wirelessly transmitted from the first inductive coil. The energy received by the second inductive coil is electrically shaped by the electrical signal shaping device and further transmitted through the electrical signal shaping device as controlled by the controller to charge the battery. Methods for transmitting energy through the electrical charging system to charge the battery are also presented.",DELPHI TECH INC,BOYER RICHARD J;;PASHA KERRY WHITE;;PASHA BRIAN D;;FUZO JOHN VICTOR,APTIV TECHNOLOGIES LIMITED (2018-01-01);;APTIV TECHNOLOGIES AG (2023-10-06),https://lens.org/073-415-342-675-626,Granted Patent,yes,20,5,18,18,0,B60L2240/62;;Y02T90/16;;Y02T90/14;;Y04S30/14;;Y02T10/7072;;H02J50/10;;H02J50/80;;B60L53/35;;B60L53/38;;B60L53/665;;H02J50/90;;H02J7/00036;;B60L53/126;;B60L53/122;;H02J2310/48;;H02J7/00047;;Y02T10/70;;Y02T10/72;;Y02T90/12;;Y02T90/167;;H02J50/80;;H02J50/90;;H02J50/10;;B60L53/12;;B60L53/665;;B60L53/38;;B60L2240/62;;Y02T90/14;;Y04S30/14;;Y02T10/7072;;H02J7/00036;;B60Y2200/91;;B60Y2200/92;;H02J50/90;;H02J50/12;;B60L2240/62;;Y02T10/7072;;Y02T90/16;;Y02T90/14;;Y04S30/14;;H02J50/80;;H02J50/10;;H02J7/00;;B60L53/35;;B60L53/38;;B60L53/665;;H02J7/00036;;B60L53/122;;B60L53/126;;Y02T10/70;;Y02T10/72;;Y02T90/12;;Y02T90/167;;H02J7/00047;;H02J2310/48,H02J7/00;;B60L11/18;;H02J7/02,,0,0,,,,ACTIVE
427,DE,D1,DE 69004109 D1,092-007-346-487-258,1993-12-02,1993,DE 69004109 T,1990-01-22,US 30242789 A,1989-01-26,"Mikrowellen-Absorbermaterial, das nadelförmige magnetische Metallfasern enthält.",,MINNESOTA MINING & MFG,BOYER CHARLES E;;BORCHERS ERIC J;;KUO RICHARD J;;HOYLE CHARLES D,,https://lens.org/092-007-346-487-258,Granted Patent,no,0,0,8,9,0,H01Q17/005,B32B7/02;;H01Q17/00;;H05K9/00,,0,0,,,,EXPIRED
428,WO,A2,WO 2010/054315 A2,091-383-139-914-985,2010-05-14,2010,US 2009/0063731 W,2009-11-09,US 11319508 P,2008-11-10,"AN ISOCYANATE TRIMERISATION CATALYST SYSTEM, A PRECURSOR FORMULATION, A PROCESS FOR TRIMERISING ISOCYANATES, RIGID POLYISOCYANURATE/POLYURETHANE FOAMS MADE THEREFROM, AND A PROCESS FOR MAKING SUCH FOAMS","The instant invention provides an isocyanate trimerisation catalyst system, a precursor formulation, a process for trimerising isocyanates, rigid foams made therefrom, and a process for making such foams. The trimerisation catalyst system comprises: (a) a phosphatrane cation; and (b) an isocyanate-trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73 C.",DOW GLOBAL TECHNOLOGIES INC;;ATHEY PHILLIP;;WILMOT NATHAN;;KEATON RICHARD;;BABB DAVID;;BOYER CECILE;;MORLEY TIMOTHY,ATHEY PHILLIP;;WILMOT NATHAN;;KEATON RICHARD;;BABB DAVID;;BOYER CECILE;;MORLEY TIMOTHY,,https://lens.org/091-383-139-914-985,Patent Application,yes,1,1,11,11,0,C08G18/022;;C08G18/022;;C08G18/092;;C08G18/092;;C08G18/166;;C08G18/168;;C08G18/168;;C08G18/1875;;C08G18/1875;;C08G2110/0025;;C08G2110/0025;;C08G2115/02;;C08G2115/02,C08G18/18,,0,0,,,,PENDING
429,US,A1,US 2013/0230394 A1,103-791-920-426-708,2013-09-05,2013,US 201213409341 A,2012-03-01,US 201213409341 A,2012-03-01,Turbine Bucket with Pressure Side Cooling,"The present application provides a turbine bucket for use with a gas turbine engine. The turbine bucket may include a platform, an airfoil extending from the platform, and a number of cooling circuits extending through the platform and the airfoil. One of the cooling circuits may be a serpentine cooling channel positioned within the platform.",ELLIS SCOTT EDMOND;;GOOD RANDALL RICHARD;;BOYER BRADLEY TAYLOR;;SMITH AARON EZEKIEL;;GEN ELECTRIC,ELLIS SCOTT EDMOND;;GOOD RANDALL RICHARD;;BOYER BRADLEY TAYLOR;;SMITH AARON EZEKIEL,GE INFRASTRUCTURE TECHNOLOGY LLC (2023-11-10);;GENERAL ELECTRIC COMPANY (2012-03-01),https://lens.org/103-791-920-426-708,Patent Application,yes,2,11,8,8,0,F01D5/187;;F01D5/187;;F05D2240/81;;F05D2240/81;;F05D2250/185;;F05D2250/185,F01D5/18,416/1;;X416 97  R,0,0,,,,ACTIVE
430,US,A1,US 2002/0170384 A1,160-569-861-940-650,2002-11-21,2002,US 12418202 A,2002-04-17,US 12418202 A;;US 28434601 P;;US 28909801 P,2001-04-17,Hydrostatic transaxle,"
   A hydrostatic transaxle having a hydrostatic transmission module including a transmission housing, a rotating fluid pump and a rotatable fluid motor, the pump being of variable displacement, the motor being rotated at various speeds and in forward and reverse directions in response to changes in pump displacement; an axle drive unit including a housing and a speed reduction gear train having an input and an output disposed in the axle drive housing, the motor being operably coupled to the gear train input; a differential assembly having a rotating casing, the rotating casing being external to the transmission housing and axle drive unit housing; and a pair of axles extending from the differential assembly casing. 
",BOYER SCOTT G.;;JOHNSON KEVIN L.;;MCDONNER ORVILLE R.;;RUEBUSCH RICHARD T.,BOYER SCOTT G;;JOHNSON KEVIN L;;MCDONNER ORVILLE R;;RUEBUSCH RICHARD T,TECUMSEH PRODUCTS COMPANY (2002-06-10),https://lens.org/160-569-861-940-650,Patent Application,yes,0,16,3,3,0,B60K5/08;;B60K7/0015;;B60K17/04;;B60K17/043;;B60K17/105;;B60K17/16;;B60K2007/0046;;B60K2007/0069;;B60K2007/0076;;B60L2220/46;;B60W2300/156;;B60Y2200/223;;F16H47/02;;B60L2200/26;;Y10T74/2186;;Y10T74/19149;;Y10T74/2186;;Y10T74/19149;;B60K7/0015;;B60K17/04;;B60K2007/0069;;B60K17/105;;B60Y2200/223;;B60K5/08;;F16H47/02;;B60K17/16;;B60K2007/0046;;B60K2007/0076;;B60L2220/46;;B60W2300/156;;B60K17/043;;B60L2200/26,B60K5/08;;B60K7/00;;B60K17/04;;B60K17/10;;B60K17/16;;F16H47/02,74/730.1;;74/606;;180/305;;180/367,0,0,,,,DISCONTINUED
431,BR,A2,BR 112017016723 A2,001-470-738-706-660,2018-06-19,2018,BR 112017016723 A,2016-02-03,US 2016/0016420 W;;US 201562111337 P;;US 201514853504 A,2015-02-03,dispositivo de acesso intravenoso que detecta infiltração intravenosa e posicionamento na veia,,UNIV VANDERBILT,COLLEEN BROPHY;;FRANZ BAUDENBACHER;;KYLE MITCHELL HOCKING;;RICHARD BOYER;;SUSAN S EAGLE,,https://lens.org/001-470-738-706-660,Patent Application,no,0,0,15,51,0,A61B5/02152;;A61B5/7235;;A61B5/7257;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61B5/7235;;A61B5/7257;;A61B5/02152;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61B5/7235;;A61B5/7257;;A61B5/02152,A61M5/158;;A61M5/165;;A61M5/172;;A61M25/01,,0,0,,,,ACTIVE
432,EP,A4,EP 2892582 A4,054-072-917-290-225,2016-11-09,2016,EP 13835216 A,2013-09-10,US 201261698790 P;;US 2013/0058992 W,2012-09-10,INTRAVENOUS ACCESS DEVICE HAVING INTEGRATED HEMODYNAMIC RESUSCITATION SYSTEM AND RELATED METHODS,,UNIV VANDERBILT,SEXTON KEVIN;;EAGLE SUSAN;;HOCKING KYLE;;BAUDENBACHER FRANZ;;BROPHY COLLEEN;;BOYER RICHARD,THE UNITED STATES AS REPRESENTED BY THE DEPARTMENT (2019-07-03);;VANDERBILT UNIVERSITY (2019-07-03),https://lens.org/054-072-917-290-225,Search Report,no,3,0,8,8,0,A61B5/0002;;A61B5/0205;;A61M2005/14208;;A61M2205/3344;;A61M2205/3561;;A61M2205/3584;;A61M2205/3592;;A61M2205/50;;A61M2205/502;;A61M2230/30;;A61B17/1355;;A61M5/1723;;A61B5/02152;;A61M5/1723;;A61B5/02152;;A61B5/0205;;A61B5/0002;;A61M2205/502;;A61M2205/3584;;A61M2205/3561;;A61M2205/3344;;A61M2205/50;;A61M2230/30;;A61M2005/14208;;A61M2205/3592;;A61B17/1355,A61M1/10;;A61B5/021;;A61B5/026,,1,0,,,See also references of WO 2014040045A1,ACTIVE
433,US,B2,US 11898317 B2,094-202-009-234-811,2024-02-13,2024,US 202017065484 A,2020-10-07,US 202017065484 A;;US 201962973538 P;;US 201962974541 P;;US 202062995171 P;;US 202063102597 P;;US 202063204482 P,2019-10-07,Surface water management system including weir wall and detention pond,"An integrated system comprising a barrier, such as a weir with movable gates, controllably blocks water flow in a natural or concrete lined channel. Without substantially impeding flow in normal conditions, the barrier is configured to back up flood waters to spill into an upstream prepared detention basin. Water is thus kept from downstream areas until subsequently drained through a controlled spill. Multiple units installed in a watershed can store significant amounts of flood water, e.g., during a hurricane, protecting life and property downstream. The electromechanically-operated gates can be operated locally or from a remote control center. Gauges and sensors positioned near the weir and/or throughout the watershed can provide data used to control one or more barriers in the watershed, and the data may be used to train a machine learning model to control the system.",RSA PROTECTIVE TECH LLC,ADLER RICHARD S;;BOYER MARK L;;DOLAND GEORGE;;SALO RISTO;;AGHA MAJED,,https://lens.org/094-202-009-234-811,Granted Patent,yes,17,0,4,4,0,E02B3/02;;G06N20/00;;E02B7/28;;E02B3/10;;E02B7/16;;E02B7/20,E02B3/10;;E02B7/16;;E02B7/20,,2,0,,,"Amir Mosavi et al., “Flood Prediction Using Machine Learning Models: Literature Review,” Water, vol. 10, No. 11, Oct. 27, 2018 (Oct. 27, 2018), p. 1536, XP055695114.;;International Search Report and Written Opinion dated Jan. 15, 2021 in corresponding International Application No. PCT/US2020/054633.",ACTIVE
434,DE,A1,DE 1589938 A1,123-731-866-341-287,1970-05-27,1970,DE 1589938 A,1967-04-14,US 54263966 A,1966-04-14,Gehaeuse fuer ein Halbleiterplaettchen,,INT RECTIFIER CORP,A SCOTT ANGUS;;A HARTMAN RICHARD;;ESTATES PALOS VERDES;;L BOYER JOHN,,https://lens.org/123-731-866-341-287,Patent Application,no,0,0,5,6,0,H01L23/49562;;H01L23/49562;;H01L23/24;;H01L23/24;;H01L23/488;;H01L23/488;;H01L2924/0002;;H01L2924/0002,H01L23/24;;H01L23/488;;H01L23/495,,0,0,,,,DISCONTINUED
435,US,A1,US 2022/0212908 A1,185-054-597-420-414,2022-07-07,2022,US 202117505500 A,2021-10-19,US 202117505500 A;;US 202163133920 P,2021-01-05,ENGINE INSTALLATION SYSTEMS AND RELATED METHODS,"Engine installation systems and related methods. An engine installation system includes an adapter cradle and a transport dolly. The adapter cradle is configured to support the engine, and the transport dolly is configured to be selectively and operatively coupled to the adapter cradle to support the adapter cradle to facilitate transporting the adapter cradle and the engine across a ground surface. The adapter cradle is configured to be selectively coupled to each of the transport dolly and the vehicle. The adapter cradle is configured to pivot relative to the transport dolly or relative to the vehicle to transition between a transport configuration and an upright configuration. In examples, methods of installing an engine within an engine bay of a vehicle include positioning the engine beneath the engine bay, pivoting the engine relative to the vehicle, and lifting the engine into the engine bay.",BOEING CO,FRIZZELL MATTHEW JAMES;;FLACH JOSEPH EDWARD;;WAGNER RICHARD KURT;;BOYER LARRY PAUL,THE BOEING COMPANY (2020-12-30),https://lens.org/185-054-597-420-414,Patent Application,yes,10,2,2,2,0,B64F5/10;;B64F5/50;;B66F3/24;;B66F5/04;;B66F9/065;;B64F5/50;;B64F5/10,B66F9/065;;B64F5/10;;B64F5/50,,0,0,,,,ACTIVE
436,WO,A1,WO 2016/126856 A1,098-026-609-825-100,2016-08-11,2016,US 2016/0016420 W,2016-02-03,US 201562111337 P;;US 201514853504 A,2015-02-03,INTRAVENOUS ACCESS DEVICE DETECTING INTRAVENOUS INFILTRATION AND IN-VEIN PLACEMENT,"Aspects of the invention relates to systems and methods for monitoring an intravenous (IV) line functionality of an IV device. In one embodiment, the system includes an IV catheter to be inserted into the vein of the living subject, at least one pressure sensor in fluid communication with the IV catheter to acquire peripheral venous signals; and a processing device. The processing device receives the peripheral venous signals from the pressure sensor, performs a spectral analysis on the peripheral venous signals to obtain a peripheral venous pressure frequency spectrum, and then performs a statistical analysis on amplitudes of peaks of the peripheral venous pressure frequency spectrum to determine an IV line functionality of the IV catheter in real time. When the IV line functionality indicates IV infiltration, the processing device may control the fluid controlling device to stop the fluid flow from the fluid source to the IV catheter.",UNIV VANDERBILT,EAGLE SUSAN S;;BROPHY COLLEEN;;HOCKING KYLE MITCHELL;;BAUDENBACHER FRANZ;;BOYER RICHARD,,https://lens.org/098-026-609-825-100,Patent Application,yes,5,11,15,51,0,A61B5/02152;;A61B5/7235;;A61B5/7257;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61B5/7235;;A61B5/7257;;A61B5/02152;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61B5/7235;;A61B5/7257;;A61B5/02152,A61M5/172;;A61M5/158;;A61M5/165;;A61M25/01,,1,0,,,See also references of EP 3253432A4,PENDING
437,US,B2,US 11560298 B2,113-776-729-127-985,2023-01-24,2023,US 202117505500 A,2021-10-19,US 202117505500 A;;US 202163133920 P,2021-01-05,Engine installation systems and related methods,"Engine installation systems and related methods. An engine installation system includes an adapter cradle and a transport dolly. The adapter cradle is configured to support the engine, and the transport dolly is configured to be selectively and operatively coupled to the adapter cradle to support the adapter cradle to facilitate transporting the adapter cradle and the engine across a ground surface. The adapter cradle is configured to be selectively coupled to each of the transport dolly and the vehicle. The adapter cradle is configured to pivot relative to the transport dolly or relative to the vehicle to transition between a transport configuration and an upright configuration. In examples, methods of installing an engine within an engine bay of a vehicle include positioning the engine beneath the engine bay, pivoting the engine relative to the vehicle, and lifting the engine into the engine bay.",BOEING CO,FRIZZELL MATTHEW JAMES;;FLACH JOSEPH EDWARD;;WAGNER RICHARD KURT;;BOYER LARRY PAUL,THE BOEING COMPANY (2020-12-30),https://lens.org/113-776-729-127-985,Granted Patent,yes,10,1,2,2,0,B64F5/10;;B64F5/50;;B66F3/24;;B66F5/04;;B66F9/065;;B64F5/50;;B64F5/10,B66F9/065;;B64F5/10;;B64F5/50,,0,0,,,,ACTIVE
438,CA,A1,CA 3135763 A1,125-763-663-245-294,2020-11-12,2020,CA 3135763 A,2019-06-05,US 201962842824 P;;US 2019/0035543 W,2019-05-03,REACTION MIXER,An agitator or mixer installed in a solid-liquid-gas/slurry reactor in which gas removal from the slurry and foam destruction is promoted. The reaction mixer includes a vessel and an agitator assembly. The vessel is for containing the solid-liquid-gas mixture and defines two mixing zones within a given volume; a first mixing zone and a second mixing zone located above the first mixing zone. The agitator assembly is positionable within the vessel and comprises a rotatable shaft and a first and second impeller coupled to the shaft. The first axial impeller is locatable within the first mixing zone and is configured to pump the liquid in a downward direction along a vertical axis of rotation. The second impeller is locatable within the second mixing zone and is configured to pump the liquid in an upward direction along the vertical axis of rotation.,PHILADELPHIA MIXING SOLUTIONS LTD,HUTCHINSON TODD MICHAEL;;GRENVILLE RICHARD KENNETH;;GIACOMELLI JASON JON;;BOYER BENJAMIN AARON,,https://lens.org/125-763-663-245-294,Patent Application,no,0,0,9,9,0,C01B25/222;;B01J19/20;;B01J2219/00189;;B01J19/0066;;B01J2219/0884;;B01F2215/0427;;B01F2215/0431;;B01D19/02;;B01J8/222;;B01J2208/0061;;B01J2219/00779;;B01F27/191;;B01F27/91;;B01F35/53;;B01J2219/185;;B01J2219/1923;;B01J19/1862;;B01F35/53;;B01F27/191;;B01F27/91;;B01F2215/0427;;B01F2215/0431;;B01J8/222;;B01J19/0066;;B01J19/02;;B01J19/20,B01J19/18;;C01B25/222,,0,0,,,,PENDING
439,WO,A3,WO 2005/104702 A3,196-446-693-212-895,2006-02-09,2006,US 2005/0013852 W,2005-04-22,US 56474404 P,2004-04-23,AN AUTOMATED NON- INVASIVE REAL-TIME ACUTE RENAL FAILURE DETECTION SYSTEM,"⏧0111&rsqb; A real-time, non-invasive system and method for determining the level of an analyze of interest in the urine of a patient is disclosed. The system and method uses the measured level of an analyze of interest to detect the onset of acute renal failure (ARF) as early as possible to prevent that patient from developing the disease or mitigating the effects of the disease. The system and method may be used to monitor the recovery of a patient after an ARF diagnosis. Preferably, the analyze of interest is creatinine or urea. The system may be placed in the urine drain line of a patient between a Foley catheter or other urinary drain and a urine collection bag. The system makes substantially continuous measurements of the urine flow rate and the concentration of the analyze of interest to determine the mass excretion rate of the analyze so it may be monitored to detect if the patient experiences a delta change in the mass excretion rate of an analyze that is indicative of the onset of ARF or a change in renal function.",RENAL DIAGNOSTIC INC;;TOWNSEND SETH;;KOMANSKI CHRISTOPHER;;BOYER RICHARD;;TEDFORD NATHAN;;FINE DEREK;;STAR ROBERT,TOWNSEND SETH;;KOMANSKI CHRISTOPHER;;BOYER RICHARD;;TEDFORD NATHAN;;FINE DEREK;;STAR ROBERT,,https://lens.org/196-446-693-212-895,Search Report,yes,1,0,4,4,0,A61B5/14507;;A61B5/201;;A61B5/208;;A61B5/412;;A61B5/201;;A61B5/14507;;A61B5/208;;A61B5/412,G01N35/08;;G01N21/00,,0,0,,,,PENDING
440,MX,A,MX 2017010008 A,026-875-028-797-185,2017-11-22,2017,MX 2017010008 A,2016-02-03,US 201562111337 P;;US 201514853504 A;;US 2016/0016420 W,2015-02-03,INTRAVENOUS ACCESS DEVICE DETECTING INTRAVENOUS INFILTRATION AND IN-VEIN PLACEMENT.,"Aspects of the invention relates to systems and methods for monitoring an intravenous (IV) line functionality of an IV device. In one embodiment, the system includes an IV catheter to be inserted into the vein of the living subject, at least one pressure sensor in fluid communication with the IV catheter to acquire peripheral venous signals; and a processing device. The processing device receives the peripheral venous signals from the pressure sensor, performs a spectral analysis on the peripheral venous signals to obtain a peripheral venous pressure frequency spectrum, and then performs a statistical analysis on amplitudes of peaks of the peripheral venous pressure frequency spectrum to determine an IV line functionality of the IV catheter in real time. When the IV line functionality indicates IV infiltration, the processing device may control the fluid controlling device to stop the fluid flow from the fluid source to the IV catheter.",UNIV VANDERBILT,RICHARD BOYER;;FRANZ BAUDENBACHER;;COLLEEN BROPHY;;SUSAN S EAGLE;;KYLE MITCHELL HOCKING,,https://lens.org/026-875-028-797-185,Patent Application,no,0,0,15,51,0,A61B5/02152;;A61B5/7235;;A61B5/7257;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61B5/7235;;A61B5/7257;;A61B5/02152;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61B5/7235;;A61B5/7257;;A61B5/02152,A61M5/158;;A61M5/172;;A61M5/165;;A61M25/01,,0,0,,,,PENDING
441,WO,A1,WO 2022/128155 A1,103-962-115-845-612,2022-06-23,2022,EP 2021025497 W,2021-12-13,US 202017127846 A,2020-12-18,METHOD AND APPARATUS FOR TESTING DEVICES IN A NON-SECURED ENVIRONMENT,"Disclosed are methods, systems and devices for implementing built-in self-test (BIST) to be performed by an untrusted party and/or in an unsecure testing environment. In an embodiment, a test access port (TAP) on a device may enable a party to initiate execution of one or more BIST procedures on the device. Additionally, such a TAP may enable loading of encrypted instructions to be executed by one or more processors formed on a device under test.",ADVANCED RISC MACH LTD,PATERSON RICHARD;;HERBERHOLZ RAINER;;WILLIAMS PETER;;GOLOMBEK ODED;;LUKO EINAT;;BOYER JEFFREY,,https://lens.org/103-962-115-845-612,Patent Application,yes,6,0,3,3,0,G01R31/318533;;G01R31/31719;;G01R31/2815;;G01R31/31715;;G01R31/31724;;G01R31/3177;;G01R31/318533;;G01R31/318597;;G01R31/3187;;H04L9/0894,G01R31/3185;;G01R31/317,,0,0,,,,PENDING
442,US,A1,US 2022/0241748 A1,119-995-783-221-700,2022-08-04,2022,US 201917608561 A,2019-06-05,US 201917608561 A;;US 201962842824 P;;US 2019/0035543 W,2019-05-03,REACTION MIXER,An agitator or mixer installed in a solid-liquid-gas/slurry reactor in which gas removal from the slurry and foam destruction is promoted. The reaction mixer includes a vessel and an agitator assembly. The vessel is for containing the solid-liquid-gas mixture and defines two mixing zones within a given volume; a first mixing zone and a second mixing zone located above the first mixing zone. The agitator assembly is positionable within the vessel and comprises a rotatable shaft and a first and second impeller coupled to the shaft. The first axial impeller is locatable within the first mixing zone and is configured to pump the liquid in a downward direction along a vertical axis of rotation. The second impeller is locatable within the second fluxing zone and is configured to pump the liquid in an upward direction along the vertical axis of rotation.,PHILADELPHIA MIXING SOLUTIONS LTD,HUTCHINSON TODD MICHAEL;;GRENVILLE RICHARD KENNETH;;GIACOMELLI JASON JON;;BOYER BENJAMIN AARON,PHILADELPHIA MIXING SOLUTIONS LTD (2019-06-18),https://lens.org/119-995-783-221-700,Patent Application,yes,0,0,9,9,0,C01B25/222;;B01J19/20;;B01J2219/00189;;B01J19/0066;;B01J2219/0884;;B01F2215/0427;;B01F2215/0431;;B01D19/02;;B01J8/222;;B01J2208/0061;;B01J2219/00779;;B01F27/191;;B01F27/91;;B01F35/53;;B01J2219/185;;B01J2219/1923;;B01J19/1862;;B01F35/53;;B01F27/191;;B01F27/91;;B01F2215/0427;;B01F2215/0431;;B01J8/222;;B01J19/0066;;B01J19/02;;B01J19/20,B01J19/20;;B01F27/191;;B01F27/91;;B01F35/53;;B01J8/22;;B01J19/00;;B01J19/02,,0,0,,,,PENDING
443,US,A1,US 2006/0100743 A1,140-640-400-207-855,2006-05-11,2006,US 11321205 A,2005-04-22,US 11321205 A;;US 56474404 P,2004-04-23,Automated non-invasive real-time acute renal failure detection system,"A real-time, non-invasive system and method for determining the level of an analyte of interest in the urine of a patient is disclosed. The system and method uses the measured level of an analyte of interest to detect the onset of acute renal failure (ARF) as early as possible to prevent that patient from developing the disease or mitigating the effects of the disease. The system and method may be used to monitor the recovery of a patient after an ARF diagnosis. Preferably, the analyte of interest is creatinine or urea. The system may be placed in the urine drain line of a patient between a Foley catheter or other urinary drain and a urine collection bag. The system makes substantially continuous measurements of the urine flow rate and the concentration of the analyte of interest to determine the mass excretion rate of the analyte so it may be monitored to detect if the patient experiences a delta change in the mass excretion rate of an analyte that is indicative of the onset of ARF or a change in renal function.",RENAL DIAGNOSTIC INC,TOWNSEND SETH;;KOMANSKI CHRISTOPHER;;BOYER RICHARD;;TEDFORD NATHAN;;FINE DEREK;;STAR ROBERT,,https://lens.org/140-640-400-207-855,Patent Application,yes,10,73,4,4,0,A61B5/14507;;A61B5/201;;A61B5/208;;A61B5/412;;A61B5/201;;A61B5/14507;;A61B5/208;;A61B5/412,G05D21/00,700/266,0,0,,,,DISCONTINUED
444,EP,A2,EP 1251293 A2,134-754-942-843-109,2002-10-23,2002,EP 02008636 A,2002-04-17,US 28434601 P;;US 28909801 P,2001-04-17,Hydrostatic transaxle,"A hydrostatic transaxle having a hydrostatic transmission module (104) including a transmission housing (110), a rotating fluid pump and a rotatable fluid motor, the pump being of variable displacement, the motor being rotated at various speeds and in forward and reverse directions in response to changes in pump displacement; an axle drive unit (48) including a housing (80) and a speed reduction gear train having an input and an output disposed in the axle drive housing (80), the motor being operably coupled to the gear train input; a differential assembly (50) having a rotating casing (52), the rotating casing (52) being external to the transmission housing (110) and axle drive unit housing (80); and a pair of axles (44,46) extending from the differential assembly casing (52).",TECUMSEH PRODUCTS CO,BOYER SCOTT G;;JOHNSON KEVIN L;;MCDONNER ORVILLE R;;RUEBUSCH RICHARD T,,https://lens.org/134-754-942-843-109,Patent Application,yes,4,3,3,3,0,B60K5/08;;B60K7/0015;;B60K17/04;;B60K17/043;;B60K17/105;;B60K17/16;;B60K2007/0046;;B60K2007/0069;;B60K2007/0076;;B60L2220/46;;B60W2300/156;;B60Y2200/223;;F16H47/02;;B60L2200/26;;Y10T74/2186;;Y10T74/19149;;Y10T74/2186;;Y10T74/19149;;B60K7/0015;;B60K17/04;;B60K2007/0069;;B60K17/105;;B60Y2200/223;;B60K5/08;;F16H47/02;;B60K17/16;;B60K2007/0046;;B60K2007/0076;;B60L2220/46;;B60W2300/156;;B60K17/043;;B60L2200/26,B60K5/08;;B60K7/00;;B60K17/04;;B60K17/10;;B60K17/16;;F16H47/02,,0,0,,,,DISCONTINUED
445,AT,T1,AT E317430 T1,174-680-045-653-50X,2006-02-15,2006,AT 99930212 T,1999-06-10,US 11058298 A,1998-07-06,NICHT-MAKROPORÖSE INORGANISCHE VORRICHTUNG ZUR BIOLOGISCHEN ENTSORGUNG,"A porous inorganic oxide carrier body for immobilizing living cells is prepared from inorganic oxide particles such as clay particles. The particles have an average particle size of from 0.01 to 20 microns, and the carrier body has a total pore volume of 0.05 to 1.0 cc/g and an average pore diameter of 50 to 700 ANGSTROM , and has substantially no pore volume in the range of 800 ANGSTROM or greater. The carrier is prepared by forming a mixture containing the particles, a liquid medium and optional ingredients including zeolite and activated carbon, and forming the mixture into a shaped carrier body which may be optionally dried and calcined. Typical shapes of the carrier include spheres, cylinders, rings, honeycombs and shaped monoliths. Bacteria and other microorganisms immobilized on the carrier are useful for treatment of contaminated waste streams or contaminated vapors, or for other uses for which microorganisms are used such as the synthesis of chemicals.",GRACE W R & CO,MILLER JAMES GEORGE;;BATES ROBERT HAYWOOD;;BOYER TIMOTHY ALLEN;;DURHAM DONALD RICHARD,,https://lens.org/174-680-045-653-50X,Granted Patent,no,0,0,9,9,0,C02F3/10;;C12N11/14;;Y02W10/10;;C12N11/14;;C02F3/10;;Y02W10/10,C02F3/00;;C02F3/10;;C12N1/04;;C12N11/14,,0,0,,,,EXPIRED
446,CA,C,CA 2884397 C,002-952-594-601-12X,2019-10-08,2019,CA 2884397 A,2013-09-10,US 201261698790 P;;US 2013/0058992 W,2012-09-10,INTRAVENOUS ACCESS DEVICE HAVING INTEGRATED HEMODYNAMIC RESUSCITATION SYSTEM AND RELATED METHODS,"One aspect of the present disclosure is a system for hemodynamic resuscitation. The system includes an intravenous access device having a pressure sensor element configured to detect a peripheral venous pressure value in response to an occlusion of a peripheral vein. The system also includes a controller device that isconfigured to receive a signal from the pressure sensor comprising the peripheral venous pressure value, to process the signal to determine a hemodynamic parameter based on the peripheral venous pressue value, and to generate a resuscitation score based on the hemodynamic parameter.",UNIV VANDERBILT,SEXTON KEVIN;;EAGLE SUSAN;;HOCKING KYLE;;BAUDENBACHER FRANZ;;BROPHY COLLEEN;;BOYER RICHARD,,https://lens.org/002-952-594-601-12X,Granted Patent,no,0,0,8,8,0,A61B5/0002;;A61B5/0205;;A61M2005/14208;;A61M2205/3344;;A61M2205/3561;;A61M2205/3584;;A61M2205/3592;;A61M2205/50;;A61M2205/502;;A61M2230/30;;A61B17/1355;;A61M5/1723;;A61B5/02152;;A61M5/1723;;A61B5/02152;;A61B5/0205;;A61B5/0002;;A61M2205/502;;A61M2205/3584;;A61M2205/3561;;A61M2205/3344;;A61M2205/50;;A61M2230/30;;A61M2005/14208;;A61M2205/3592;;A61B17/1355,A61M1/10;;A61B5/021;;A61B5/026,,0,0,,,,ACTIVE
447,EP,B1,EP 2346918 B1,018-726-678-680-596,2013-09-18,2013,EP 09752076 A,2009-11-09,US 2009/0063731 W;;US 11319508 P,2008-11-10,"AN ISOCYANATE TRIMERISATION CATALYST SYSTEM, A PRECURSOR FORMULATION, A PROCESS FOR TRIMERISING ISOCYANATES, RIGID POLYISOCYANURATE/POLYURETHANE FOAMS MADE THEREFROM, AND A PROCESS FOR MAKING SUCH FOAMS",,DOW GLOBAL TECHNOLOGIES LLC,ATHEY PHILLIP;;WILMOT NATHAN;;KEATON RICHARD;;BABB DAVID;;BOYER CECILE;;MORLEY TIMOTHY,,https://lens.org/018-726-678-680-596,Granted Patent,yes,1,0,11,11,0,C08G18/022;;C08G18/022;;C08G18/092;;C08G18/092;;C08G18/166;;C08G18/168;;C08G18/168;;C08G18/1875;;C08G18/1875;;C08G2110/0025;;C08G2110/0025;;C08G2115/02;;C08G2115/02,C08G18/02;;C08G18/09;;C08G18/16;;C08G18/18,,0,0,,,,ACTIVE
448,WO,A2,WO 2005/104702 A2,075-505-124-096-580,2005-11-10,2005,US 2005/0013852 W,2005-04-22,US 56474404 P,2004-04-23,AN AUTOMATED NON- INVASIVE REAL-TIME ACUTE RENAL FAILURE DETECTION SYSTEM,"⏧0111&rsqb; A real-time, non-invasive system and method for determining the level of an analyze of interest in the urine of a patient is disclosed. The system and method uses the measured level of an analyze of interest to detect the onset of acute renal failure (ARF) as early as possible to prevent that patient from developing the disease or mitigating the effects of the disease. The system and method may be used to monitor the recovery of a patient after an ARF diagnosis. Preferably, the analyze of interest is creatinine or urea. The system may be placed in the urine drain line of a patient between a Foley catheter or other urinary drain and a urine collection bag. The system makes substantially continuous measurements of the urine flow rate and the concentration of the analyze of interest to determine the mass excretion rate of the analyze so it may be monitored to detect if the patient experiences a delta change in the mass excretion rate of an analyze that is indicative of the onset of ARF or a change in renal function.",RENAL DIAGNOSTIC INC;;TOWNSEND SETH;;KOMANSKI CHRISTOPHER;;BOYER RICHARD;;TEDFORD NATHAN;;FINE DEREK;;STAR ROBERT,TOWNSEND SETH;;KOMANSKI CHRISTOPHER;;BOYER RICHARD;;TEDFORD NATHAN;;FINE DEREK;;STAR ROBERT,,https://lens.org/075-505-124-096-580,Patent Application,yes,0,3,4,4,0,A61B5/14507;;A61B5/201;;A61B5/208;;A61B5/412;;A61B5/201;;A61B5/14507;;A61B5/208;;A61B5/412,G01N35/08;;G01N21/00,,0,0,,,,PENDING
449,US,A1,US 2011/0201706 A1,113-547-389-079-681,2011-08-18,2011,US 200913125476 A,2009-11-09,US 200913125476 A;;US 11319108 P;;US 2009/0063725 W,2008-11-10,"ISOCYANATE TRIMERISATION CATALYST SYSTEM, A PRECURSOR FORMULATION, A PROCESS FOR TRIMERISING ISOCYANATES, RIGID POLYISOCYANURATE/POLYURETHANE FOAMS MADE THEREFROM, AND A PROCESS FOR MAKING SUCH FOAMS","The instant invention provides an isocyanate trimerisation catalyst system, a precursor formulation, a process for trimerising isocyanates, rigid foams made therefrom, and a process for making such foams. The trimerisation catalyst system comprises: (a) a substituted iminium cation; and (b) an isocyanate-trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73° C. The precursor formulation comprises (1) at least 25 percent by weight of polyol, based on the weight of the precursor formulation; (2) less than 15 percent by weight of a trimerisation catalyst system, based on the weight of the precursor formulation, comprising; (a) a substituted iminium cation; and (c) an isocyanate-trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73° C.; and (4) optionally one or more surfactants, one or more flame retardants, water, one or more antioxidants, one or more auxiliary blowing agents, one or more urethane catalysts, one or more auxiliary trimerisation catalysts, or combinations thereof. The process for trimerisation of isocyanates comprises the steps of: (1) providing one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture of any thereof; (2) providing a trimerisation catalyst system comprising; (a) an substituted iminium cation; and (b) an isocyanate-trimer inducing anion; (c) wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73° C.; (3) trimerising said one or more monomers in the presence of said trimerisation catalyst; (4) thereby forming an isocyanurate ring. The process for making the PIR foam comprises the steps of: (1) providing one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture of any thereof; (2) providing polyol; (3) providing a trimerisation catalyst system comprising; (a) a substituted iminium cation; and (b) an isocyanate-trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73° C.; and (4) optionally providing one or more surfactants, one or more flame retardants, water, one or more antioxidants, one or more auxiliary blowing agents, one or more urethane catalysts, one or more auxiliary trimerisation catalysts, or combinations thereof; (5) contacting said one or more monomers, and said polyol, and optionally said one or more surfactants, and optionally said one or more flame retardants, and optionally said water, and optionally said one or more antioxidants, and optionally said one or more auxiliary blowing agents in the presence of said trimerisation catalyst system and optionally said one or more urethane catalysts, and optionally said one or more auxiliary trimerisation catalysts; (6) thereby forming said polyisocyanurate/polyurethane rigid foam. The PIR foam comprises the reaction product of one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture of any thereof with polyol in the presence of a trimerisation catalyst system comprising a substituted iminium cation, and an isocyanate-trimer inducing anion, and optionally one or more surfactants, optionally one or more flame retardants, optionally water, optionally one or more antioxidants, optionally one or more auxiliary blowing agents, optionally one or more additional urethane catalysts, and optionally one or more auxiliary trimerisation catalysts, or optionally combinations thereof, wherein the trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73° C. The PIR foam comprises the reaction product of one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture of any thereof with polyol in the presence of a trimerisation catalyst system comprising a substituted iminium cation, and an isocyanate-trimer inducing anion, and optionally one or more surfactants, optionally one or more flame retardants, optionally water, optionally one or more antioxidants, optionally one or more auxiliary blowing agents, optionally one or more additional polyurethane catalysts, and optionally one or more auxiliary trimerisation catalysts, or optionally combinations thereof, wherein the PIR foam has a polyisocyanurate trimer ratio (Abs1410/Abs1595) of at least 5 at a depth of 12 mm from the rising surface of the rigid foam, measured via ATR-FTIR spectroscopy.",DOW GLOBAL TECHNOLOGIES LLC,ATHEY PHILLIP S;;WILMOT NATHAN;;KEATON RICHARD;;BOYER CECILE;;MORLEY TIMOTHY A,DOW EUROPE GMBH (2009-07-17);;DOW GLOBAL TECHNOLOGIES LLC (2009-07-08);;THE DOW CHEMICAL COMPANY (2009-07-27),https://lens.org/113-547-389-079-681,Patent Application,yes,9,5,9,9,0,C08G18/022;;C08G18/022;;C08G18/092;;C08G18/092;;C08G18/168;;C08G18/168;;C08G18/1858;;C08G18/1858;;C08G18/1883;;C08G18/1883;;C08G18/791;;C08G18/791;;C08G2110/0025;;C08G2110/0025;;C08G2115/02;;C08G2115/02,C08J9/00;;C07C53/00,521/108;;562/512,0,0,,,,DISCONTINUED
450,WO,A2,WO 2010/054317 A2,176-837-676-829-722,2010-05-14,2010,US 2009/0063733 W,2009-11-09,US 11319608 P,2008-11-10,"AN ISOCYANATE TRIMERISATION CATALYST SYSTEM, A PRECURSOR FORMULATION, A PROCESS FOR TRIMERISING ISOCYANATES, RIGID POLYISOCYANURATE/POLYURETHANE FOAMS MADE THEREFROM, AND A PROCESS FOR MAKING SUCH FOAMS","The instant invention provides an isocyanate trimerisation catalyst system, a precursor formulation, a process for trimerising isocyanates, rigid foams made therefrom, and a process for making such foams. The trimerisation catalyst system comprises: (a) an imidazolium or imidazolinium cation; and (b) an isocyanate-trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73°C. The precursor formulation comprises: (1) at least 25 percent by weight of polyol, based on the weight of the precursor formulation; (2) less than 15 percent by weight of a trimerisation catalyst system, based on the weight of the precursor formulation, comprising; (a) an imidazolium or imidazolinium cation; and (c) an isocyanate-trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73°C; and (3) optionally one or more surfactants, one or more flame retardants, water, one or more antioxidants, one or more auxiliary blowing agents, one or more urethane catalysts, one or more auxiliary trimerisation catalysts, or combinations thereof. The process for trimerisation of isocyanates comprises the steps of: (1) providing one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanatetriisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture of any thereof; (2) providing a trimerisation catalyst system comprising; (a) an imidazolium or imidazolinium cation; and (b) an isocyanate-trimer inducing anion; (c) wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73°C; (3) trimerising said one or more monomers in the presence of said trimerisation catalyst; (4) thereby forming an isocyanurate trimer. The process for making the PIR foam comprises the steps of: (1) providing one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanatetriisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture any thereof; (2) providing polyol; (3) providing a trimerisation catalyst system comprising; (a) an imidazolium or imidazolinium cation; and (b) an isocyanate-trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73°C; and (4) optionally providing one or more surfactants, one or more flame retardants, water, one or more antioxidants, one or more auxiliary blowing agents, one or more urethane catalysts, one or more auxiliary trimerisation catalysts, or combinations thereof; (5) contacting said one or more monomers, and said polyol, and optionally said one or more surfactants, and optionally said one or more flame retardants, and optionally said water, and optionally said one or more antioxidants, and optionally said one or more auxiliary blowing agents in the presence of said trimerisation catalyst system and optionally said one or more urethane catalysts, and optionally said one or more auxiliary trimerisation catalysts; (6) thereby forming said polyisocyanurate/polyurethane rigid foam. The PIR foam comprises the reaction product of one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanatetriisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture any thereof with polyol in the presence of a trimerisation catalyst system comprising an imidazolium or imidazolinium cation, and an isocyanate-trimer inducing anion, and optionally one or more surfactants, optionally one or more flame retardants, optionally water, optionally one or more antioxidants, optionally one or more auxiliary blowing agents, optionally one or more additional urethane catalysts, and optionally one or more auxiliary trimerisation catalysts, or optionally combinations thereof, wherein the trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73°C. The PIR foam comprises the reaction product of one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanatetriisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture any thereof with polyol in the presence of a trimerisation catalyst system comprising an imidazolium or imidazolinium cation, and an isocyanate- trimer inducing anion, and optionally one or more surfactants, optionally one or more flame retardants, optionally water, optionally one or more antioxidants, optionally one or more auxiliary blowing agents, optionally one or more additional polyurethane catalysts, and optionally one or more auxiliary trimerisation catalysts, or optionally combinations thereof, wherein the PIR foam has a polyisocyanurate trimer ratio (Abs 1410 /Abs 1595 ) of at least 5 at a depth of 12 mm from the rising surface of the rigid foam, measured via ATR-FTIR spectroscopy.",DOW GLOBAL TECHNOLOGIES INC;;ATHEY PHILLIP;;WILMOT NATHAN;;KEATON RICHARD;;BABB DAVID;;BOYER CECILE;;MORLEY TIMOTHY,ATHEY PHILLIP;;WILMOT NATHAN;;KEATON RICHARD;;BABB DAVID;;BOYER CECILE;;MORLEY TIMOTHY,,https://lens.org/176-837-676-829-722,Patent Application,yes,1,12,9,9,0,C08G18/022;;C08G18/092;;C08G18/1858;;C08G18/1875;;C08G18/2027;;C08G18/2063;;C08G18/4208;;C08G2120/00;;C08G2115/02;;C08G2110/0025;;C08G18/4208;;C08G18/022;;C08G18/092;;C08G18/1858;;C08G18/1875;;C08G18/2027;;C08G18/2063;;C08G2120/00;;C08G2110/0025;;C08G2115/02,C08G18/18,,0,0,,,,PENDING
451,CN,A,CN 107257652 A,198-683-065-773-773,2017-10-17,2017,CN 201680008685 A,2016-02-03,US 201562111337 P;;US 201514853504 A;;US 2016/0016420 W,2015-02-03,Intravenous access device detecting intravenous infiltration and in-vein placement,"Aspects of the invention relates to systems and methods for monitoring an intravenous (IV) line functionality of an IV device. In one embodiment, the system includes an IV catheter to be inserted into the vein of the living subject, at least one pressure sensor in fluid communication with the IV catheter to acquire peripheral venous signals; and a processing device. The processing device receives the peripheral venous signals from the pressure sensor, performs a spectral analysis on the peripheral venous signals to obtain a peripheral venous pressure frequency spectrum, and then performs a statistical analysis on amplitudes of peaks of the peripheral venous pressure frequency spectrum to determine an IV line functionality of the IV catheter in real time. When the IV line functionality indicates IV infiltration, the processing device may control the fluid controlling device to stop the fluid flow from the fluid source to the IV catheter.",UNIV VANDERBILT,EAGLE SUSAN S;;BROPHY COLLEEN;;HOCKING KYLE MITCHELL;;BAUDENBACHER FRANZ;;BOYER RICHARD,,https://lens.org/198-683-065-773-773,Patent Application,no,7,0,15,51,0,A61B5/02152;;A61B5/7235;;A61B5/7257;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61B5/7235;;A61B5/7257;;A61B5/02152;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61B5/7235;;A61B5/7257;;A61B5/02152,A61B5/0215;;A61B5/00;;A61M5/158;;A61M5/168,,0,0,,,,DISCONTINUED
452,CA,A1,CA 2381873 A1,040-828-530-506-908,2002-10-17,2002,CA 2381873 A,2002-04-17,US 28434601 P;;US 28909801 P,2001-04-17,HYDROSTATIC TRANSAXLE,"A hydrostatic transaxle having a hydrostatic transmission module including a transmission housing, a rotating fluid pump and a rotatable flui d motor, the pump being of variable displacement, the motor being rotated at various speeds and in forward and reverse directions in response to changes in pump displacement; an axle drive unit including a housing and a speed reduction gear train having an input and an output disposed in the axle driv e housing, the motor being operably coupled to the gear train input; a differential assembly having a rotating casing, the rotating casing being external to the transmission housing and axle drive unit housing; and a pair of axles extending from the differential assembly casing.",TECUMSEH PRODUCTS CO,JOHNSON KEVIN L;;MCDONNER ORVILLE R;;BOYER SCOTT G;;RUEBUSCH RICHARD T,,https://lens.org/040-828-530-506-908,Patent Application,no,0,0,3,3,0,B60K5/08;;B60K7/0015;;B60K17/04;;B60K17/043;;B60K17/105;;B60K17/16;;B60K2007/0046;;B60K2007/0069;;B60K2007/0076;;B60L2220/46;;B60W2300/156;;B60Y2200/223;;F16H47/02;;B60L2200/26;;Y10T74/2186;;Y10T74/19149;;Y10T74/2186;;Y10T74/19149;;B60K7/0015;;B60K17/04;;B60K2007/0069;;B60K17/105;;B60Y2200/223;;B60K5/08;;F16H47/02;;B60K17/16;;B60K2007/0046;;B60K2007/0076;;B60L2220/46;;B60W2300/156;;B60K17/043;;B60L2200/26,B60K5/08;;B60K7/00;;B60K17/04;;B60K17/10;;B60K17/16;;F16H47/02,,0,0,,,,DISCONTINUED
453,EP,A2,EP 2346919 A2,063-248-822-132-390,2011-07-27,2011,EP 09752077 A,2009-11-09,US 2009/0063733 W;;US 11319608 P,2008-11-10,"ISOCYANATE TRIMERISATION CATALYST SYSTEM, A PRECURSOR FORMULATION, A PROCESS FOR TRIMERISING ISOCYANATES, RIGID POLYISOCYANURATE/POLYURETHANE FOAMS MADE THEREFROM, AND A PROCESS FOR MAKING SUCH FOAMS",,DOW GLOBAL TECHNOLOGIES LLC,ATHEY PHILLIP;;WILMOT NATHAN;;KEATON RICHARD;;BABB DAVID;;BOYER CECILE;;MORLEY TIMOTHY,,https://lens.org/063-248-822-132-390,Patent Application,yes,0,0,9,9,0,C08G18/022;;C08G18/092;;C08G18/1858;;C08G18/1875;;C08G18/2027;;C08G18/2063;;C08G18/4208;;C08G2120/00;;C08G2115/02;;C08G2110/0025;;C08G18/4208;;C08G18/022;;C08G18/092;;C08G18/1858;;C08G18/1875;;C08G18/2027;;C08G18/2063;;C08G2120/00;;C08G2110/0025;;C08G2115/02,C08G18/20;;C08G18/02;;C08G18/09;;C08G18/18;;C08G18/42,,0,0,,,,ACTIVE
454,RU,C2,RU 2636645 C2,135-757-766-106-205,2017-11-24,2017,RU 2013108924 A,2013-02-28,US 201213409341 A,2012-03-01,PRESSURE TURBINE BLADE (VERSIONS) AND METHOD OF COOLING TURBINE PRESSURE BLADE PLATFORM,"FIELD: engines and pumps.SUBSTANCE: turbine pressure blade for use with the gas turbine engine comprises of a platform, an aerodynamic portion extending from the platform, and cooling circuits passing through the platform and the aerodynamic part of the blade. One of the cooling circuits comprises of a serpentine cooling channel disposed in the platform and comprising of one or more straight sections and one or more bends and several internal connecting passages in the serpentine cooling channel for inspection and access for repair purposes. Internal connecting passages are soldered.EFFECT: cooling of the platform and other components without unnecessary production and operating costs and without excessive losses of the cooling medium, for efficient operation and extended component life.18 cl, 5 dwg",GEN ELECTRIC,ELLIS SCOTT EDMOND;;GOOD RANDALL RICHARD;;BOYER BRADLEY TAYLOR;;SMITH AARON EZEKIEL,,https://lens.org/135-757-766-106-205,Granted Patent,no,6,0,8,8,0,F01D5/187;;F01D5/187;;F05D2240/81;;F05D2240/81;;F05D2250/185;;F05D2250/185,F01D5/18,,0,0,,,,INACTIVE
455,US,S,US D0895145 S,192-394-610-105-676,2020-09-01,2020,US 201829666354 F,2018-10-11,US 201829666354 F,2018-10-11,Package for medical device,,MILLENNIUM PHARM INC,SMITH CARSON;;GALAS JR RICHARD A;;TRUONG NOBEL;;RUAN TIEMING;;BOYER SCOTT,TAKEDA PHARMACEUTICALS U.S.A. INC (2019-04-05);;MILLENNIUM PHARMACEUTICALS INC (2019-04-05),https://lens.org/192-394-610-105-676,Design Right,no,41,13,2,2,0,,,2402;;D24/229,0,0,,,,ACTIVE
456,EP,A1,EP 1093514 A1,010-113-614-443-898,2001-04-25,2001,EP 99930212 A,1999-06-10,US 9913207 W;;US 11058298 A,1998-07-06,NON-MACROPOROUS INORGANIC SUPPORT FOR BIOREMEDIATION,"A porous inorganic oxide carrier body for immobilizing living cells is prepared from inorganic oxide particles such as clay particles. The particles have an average particle size of from 0.01 to 20 microns, and the carrier body has a total pore volume of 0.05 to 1.0 cc/g and an average pore diameter of 50 to 700 ANGSTROM , and has substantially no pore volume in the range of 800 ANGSTROM or greater. The carrier is prepared by forming a mixture containing the particles, a liquid medium and optional ingredients including zeolite and activated carbon, and forming the mixture into a shaped carrier body which may be optionally dried and calcined. Typical shapes of the carrier include spheres, cylinders, rings, honeycombs and shaped monoliths. Bacteria and other microorganisms immobilized on the carrier are useful for treatment of contaminated waste streams or contaminated vapors, or for other uses for which microorganisms are used such as the synthesis of chemicals.",GRACE W R & CO,MILLER JAMES GEORGE;;BATES ROBERT HAYWOOD;;BOYER TIMOTHY ALLEN;;DURHAM DONALD RICHARD,,https://lens.org/010-113-614-443-898,Patent Application,yes,0,1,9,9,0,C02F3/10;;C12N11/14;;Y02W10/10;;C12N11/14;;C02F3/10;;Y02W10/10,C02F3/00;;C02F3/10;;C12N1/04;;C12N11/14,,0,0,,,,EXPIRED
457,US,B2,US 9109454 B2,027-578-972-702-64X,2015-08-18,2015,US 201213409341 A,2012-03-01,US 201213409341 A,2012-03-01,Turbine bucket with pressure side cooling,"A turbine bucket for use with a gas turbine engine, as described herein, may include a platform, an airfoil extending from the platform, and a number of cooling circuits extending through the platform and the airfoil. One of the cooling circuits may be a serpentine cooling channel positioned within the platform.",ELLIS SCOTT EDMOND;;GOOD RANDALL RICHARD;;BOYER BRADLEY TAYLOR;;SMITH AARON EZEKIEL;;GEN ELECTRIC,ELLIS SCOTT EDMOND;;GOOD RANDALL RICHARD;;BOYER BRADLEY TAYLOR;;SMITH AARON EZEKIEL,GE INFRASTRUCTURE TECHNOLOGY LLC (2023-11-10);;GENERAL ELECTRIC COMPANY (2012-03-01),https://lens.org/027-578-972-702-64X,Granted Patent,yes,29,7,8,8,0,F01D5/187;;F01D5/187;;F05D2240/81;;F05D2240/81;;F05D2250/185;;F05D2250/185,F01D5/18,,3,0,,,"U.S. Appl. No. 12/878,075, filed Sep. 9, 2010, Boyer.;;U.S. Appl. No. 12/972,835, filed Dec. 20, 2010, Harris, Jr., et al.;;Search Report and Written Opinion from EP Application No. 13157090.5 dated May 16, 2013.",ACTIVE
458,US,A1,US 2020/0179601 A1,049-898-343-785-690,2020-06-11,2020,US 201916685042 A,2019-11-15,US 201916685042 A;;US 201314022902 A;;US 201261698790 P,2012-09-10,INTRAVENOUS ACCESS DEVICE HAVING INTEGRATED HEMODYNAMIC RESUSCITATION SYSTEM AND RELATED METHODS,"One aspect of the present disclosure is a system for hemodynamic resuscitation. The system includes an intravenous access device having a pressure sensor element configured to detect a peripheral venous pressure value in response to an occlusion of a peripheral vein. The system also includes a controller device that is configured to receive a signal from the pressure sensor comprising the peripheral venous pressure value, to process the signal to determine a hemodynamic parameter based on the peripheral venous pressure value, and to generate a resuscitation score based on the hemodynamic parameter.",UNIV VANDERBILT;;THE UNITED STATES AS REPRESENTED BY THE DEPT OF VETRANS AFFAIRS,SEXTON KEVIN;;EAGLE SUSAN;;HOCKING KYLE;;BAUDENBACHER FRANZ;;BROPHY COLLEEN;;BOYER RICHARD,,https://lens.org/049-898-343-785-690,Patent Application,yes,0,0,8,8,0,A61B5/0002;;A61B5/0205;;A61M2005/14208;;A61M2205/3344;;A61M2205/3561;;A61M2205/3584;;A61M2205/3592;;A61M2205/50;;A61M2205/502;;A61M2230/30;;A61B17/1355;;A61M5/1723;;A61B5/02152;;A61M5/1723;;A61B5/02152;;A61B5/0205;;A61B5/0002;;A61M2205/502;;A61M2205/3584;;A61M2205/3561;;A61M2205/3344;;A61M2205/50;;A61M2230/30;;A61M2005/14208;;A61M2205/3592;;A61B17/1355,A61M5/172;;A61B5/0215,,0,0,,,,DISCONTINUED
459,US,A,US 5711992 A,070-761-918-768-933,1998-01-27,1998,US 57376695 A,1995-12-18,US 57376695 A;;US 21097894 A,1994-03-21,Environmentally safer process of manufacturing honeycomb products for use in composite materials using a water-based phenolic thermosetting resin and the products made thereby,The substitution of a water-based phenolic thermosetting resin for a phenolic thermosetting resin in an organic solvent provides a safer and environmentally improved method for making honeycomb core. Improved processing characteristics in components manufactured from such honeycomb core are observed.,HEXCEL CORP,HEITKAMP RICHARD R;;ILER THOMAS H;;DANVER DALE;;CAO LIQUN;;BOYER RONALD,CIBA-GEIGY CORPORATION (1995-12-08);;HEXCEL CORPORATION (1996-04-16),https://lens.org/070-761-918-768-933,Granted Patent,yes,8,6,7,7,0,B29D99/0089;;B29L2031/608;;C09D161/06;;B29D99/0089;;C09D161/06;;B29L2031/608,B29B15/12;;B32B3/12;;B29D99/00;;B32B27/42;;C09D161/06,427/243;;427/385.3;;427/380.4;;427/349.8;;427/391;;427/393.5;;427/395,2,0,,,"S. P. Qureshi et al., 38th Int. Sampe Symposium 5/10 13 (1993) pp. 16 27 (no mo.).;;Derw. Abst. 94 097849/12 of JP Sho 60 49158 (no date).",EXPIRED
460,EP,A4,EP 1093514 A4,177-595-144-525-581,2002-01-16,2002,EP 99930212 A,1999-06-10,US 9913207 W;;US 11058298 A,1998-07-06,NON-MACROPOROUS INORGANIC SUPPORT FOR BIOREMEDIATION,"A porous inorganic oxide carrier body for immobilizing living cells is prepared from inorganic oxide particles such as clay particles. The particles have an average particle size of from 0.01 to 20 microns, and the carrier body has a total pore volume of 0.05 to 1.0 cc/g and an average pore diameter of 50 to 700 ANGSTROM , and has substantially no pore volume in the range of 800 ANGSTROM or greater. The carrier is prepared by forming a mixture containing the particles, a liquid medium and optional ingredients including zeolite and activated carbon, and forming the mixture into a shaped carrier body which may be optionally dried and calcined. Typical shapes of the carrier include spheres, cylinders, rings, honeycombs and shaped monoliths. Bacteria and other microorganisms immobilized on the carrier are useful for treatment of contaminated waste streams or contaminated vapors, or for other uses for which microorganisms are used such as the synthesis of chemicals.",GRACE W R & CO,MILLER JAMES GEORGE;;BATES ROBERT HAYWOOD;;BOYER TIMOTHY ALLEN;;DURHAM DONALD RICHARD,,https://lens.org/177-595-144-525-581,Search Report,no,6,0,9,9,0,C02F3/10;;C12N11/14;;Y02W10/10;;C12N11/14;;C02F3/10;;Y02W10/10,C02F3/00;;C02F3/10;;C12N1/04;;C12N11/14,,0,0,,,,EXPIRED
461,CA,A1,CA 3157384 A1,010-959-021-314-504,2021-04-15,2021,CA 3157384 A,2020-10-07,US 201962973538 P;;US 201962974541 P;;US 202062995171 P;;US 202063102597 P;;US 202063204482 P;;US 2020/0054633 W,2019-10-07,SURFACE WATER MANAGEMENT SYSTEM INCLUDING WEIR WALL AND DETENTION POND,"An integrated system comprising a barrier, such as a weir with movable gates, controllably blocks water flow in a natural or concrete lined channel. Without substantially impeding flow in normal conditions, the barrier is configured to back up flood waters to spill into an upstream prepared detention basin. Water is thus kept from downstream areas until subsequently drained through a controlled spill. Multiple units installed in a watershed can store significant amounts of flood water, e.g., during a hurricane, protecting life and property downstream. The electromechanically-operated gates can be operated locally or from a remote control center. Gauges and sensors positioned near the weir and/ or throughout the watershed can provide data used to control one or more barriers in the watershed, and the data may be used to train a machine learning model to control the system.",RSA PROTECTIVE TECH LLC,ADLER RICHARD S;;BOYER MARK L;;DOLAND GEORGE;;SALO RISTO;;AGHA MAJED,,https://lens.org/010-959-021-314-504,Patent Application,no,0,0,4,4,0,E02B3/02;;G06N20/00;;E02B7/28;;E02B3/10;;E02B7/16;;E02B7/20,E02B3/02;;E02B3/04;;G06N3/02,,0,0,,,,PENDING
462,CN,A,CN 103291374 A,031-830-865-991-737,2013-09-11,2013,CN 201310065323 A,2013-03-01,US 201213409341 A,2012-03-01,Turbine bucket with pressure side cooling,"The present application provides a turbine bucket for use with a gas turbine engine. The turbine bucket may include a platform, an airfoil extending from the platform, and a number of cooling circuits extending through the platform and the airfoil. One of the cooling circuits may be a serpentine cooling channel positioned within the platform.",GEN ELECTRIC,ELLIS SCOTT EDMOND;;GOOD RANDALL RICHARD;;BOYER BRADLEY TAYLOR;;SMITH AARON EZEKIEL,,https://lens.org/031-830-865-991-737,Patent Application,no,7,4,8,8,0,F01D5/187;;F01D5/187;;F05D2240/81;;F05D2240/81;;F05D2250/185;;F05D2250/185,F01D5/18,,0,0,,,,ACTIVE
463,EP,A1,EP 3253432 A1,138-188-404-920-658,2017-12-13,2017,EP 16747218 A,2016-02-03,US 201562111337 P;;US 201514853504 A;;US 2016/0016420 W,2015-02-03,INTRAVENOUS ACCESS DEVICE DETECTING INTRAVENOUS INFILTRATION AND IN-VEIN PLACEMENT,,UNIV VANDERBILT,EAGLE SUSAN S;;BROPHY COLLEEN;;HOCKING KYLE MITCHELL;;BAUDENBACHER FRANZ;;BOYER RICHARD,,https://lens.org/138-188-404-920-658,Patent Application,yes,0,0,15,51,0,A61B5/02152;;A61B5/7235;;A61B5/7257;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61B5/7235;;A61B5/7257;;A61B5/02152;;A61M5/158;;A61M5/16854;;A61M2005/1588;;A61B5/7235;;A61B5/7257;;A61B5/02152,A61M5/172;;A61M5/158;;A61M5/165;;A61M25/01,,0,0,,,,ACTIVE
464,EP,A1,EP 2634369 A1,142-307-365-521-059,2013-09-04,2013,EP 13157090 A,2013-02-27,US 201213409341 A,2012-03-01,Turbine buckets and corresponding cooling method,"The present application provides a turbine bucket 100 for use with a gas turbine engine 10. The turbine bucket 100 may include a platform 130, an airfoil 100 extending from the platform 130, and a number of cooling circuits 96 extending through the platform and the airfoil. One of the cooling circuits 96 may be a serpentine cooling channel positioned within the platform 130.
",GEN ELECTRIC,ELLIS SCOTT EDMOND;;GOOD RANDALL RICHARD;;BOYER BRADLEY TAYLOR;;SMITH AARON EZEKIEL,"GENERAL ELECTRIC TECHNOLOGY GMBH, CH (2023-11-23)",https://lens.org/142-307-365-521-059,Patent Application,yes,7,1,8,8,0,F01D5/187;;F01D5/187;;F05D2240/81;;F05D2240/81;;F05D2250/185;;F05D2250/185,F01D5/18,,0,0,,,,ACTIVE
465,US,A1,US 2021/0262185 A1,148-956-482-462-834,2021-08-26,2021,US 202017065484 A,2020-10-07,US 202017065484 A;;US 201962973538 P;;US 201962974541 P;;US 202062995171 P;;US 202063102597 P;;US 202063204482 P,2019-10-07,SURFACE WATER MANAGEMENT SYSTEM INCLUDING WEIR WALL AND DETENTION POND,"An integrated system comprising a barrier, such as a weir with movable gates, controllably blocks water flow in a natural or concrete lined channel. Without substantially impeding flow in normal conditions, the barrier is configured to back up flood waters to spill into an upstream prepared detention basin. Water is thus kept from downstream areas until subsequently drained through a controlled spill. Multiple units installed in a watershed can store significant amounts of flood water, e.g., during a hurricane, protecting life and property downstream. The electromechanically-operated gates can be operated locally or from a remote control center. Gauges and sensors positioned near the weir and/or throughout the watershed can provide data used to control one or more barriers in the watershed, and the data may be used to train a machine learning model to control the system.",RSA PROTECTIVE TECH LLC,ADLER RICHARD S;;BOYER MARK L;;DOLAND GEORGE;;SALO RISTO;;AGHA MAJED,RSA PROTECTIVE TECHNOLOGIES LLC (2020-11-24),https://lens.org/148-956-482-462-834,Patent Application,yes,15,1,4,4,0,E02B3/02;;G06N20/00;;E02B7/28;;E02B3/10;;E02B7/16;;E02B7/20,E02B7/16;;E02B3/10;;E02B7/20,,0,0,,,,ACTIVE
466,US,A,US 5085931 A,199-842-890-441-754,1992-02-04,1992,US 54739790 A,1990-07-03,US 54739790 A;;US 30242789 A,1989-01-26,Microwave absorber employing acicular magnetic metallic filaments,"An electromagnetic radiation absorber is formed by dispersing into a dielectric binder acicular magnetic metallic filaments with an average length of about 10 micron or less, diameters of 0.1 micron or more, and aspect (length/diameter) ratios between 10:1 and 50:1. Preferably the average length is about 5 micron, the aspect ratios are between 10:1 and 25:1, and the dielectric binder is polymeric. The volume fraction of the filaments may be lower than 35% of the total and still provide satisfactory absorption. An absorbing paint is formed by dissolving the absorber in a base liquid. The absorber or absorbing paint may be applied to a conductive surface, such as a metallic wire, plate or foil. Impedance matching materials are preferred but not required.",MINNESOTA MINING & MFG,BOYER III CHARLES E;;BORCHERS ERIC J;;KUO RICHARD J;;HOYLE CHARLES D,,https://lens.org/199-842-890-441-754,Granted Patent,yes,31,35,1,9,0,H01Q17/005;;H01Q17/005;;Y10T428/256;;Y10T428/256;;Y10T428/268;;Y10T428/268,H01Q17/00,428/328;;428/338;;252/513;;342/1;;342/4;;342/5,4,0,,,"Ram Maintenance Procedures (Interim), U.S. Navy, Oct. 1985.;;Ruck et al., Radar Cross Section Handbook, vol. 2, pp. 617 622, Section 8.3.2.1.1.3, Plenum Press 1970.;;David L. Dye et al., Theoretical Investigation of Fibers, Boeing Aerospace Company, Seattle, Washington, draft report for Department of Defense Contract DAAK11 82 C 0152, 1983.;;Dye et al., Theoretical Investigation of Fibers, Boeing Aerospace Co., Seattle, Washington, draft report for DOD Contract DAAK11 82 C 0152, 1983.",EXPIRED
467,DE,A1,DE 1594261 A1,193-067-573-239-744,1970-10-01,1970,DE 1594261 A,1966-02-28,US 43876765 A;;US 44217465 A;;US 44219565 A;;US 45349365 A;;US 45351365 A,1965-03-10,Heissschmelzklebstoff,,SUN OIL CO,ELLIS PETERKIN MELVIN;;ELWOOD WARE RICHARD;;WENDELL HALL JUN LEWIS;;SCHELL BOYER JACKSON,,https://lens.org/193-067-573-239-744,Patent Application,no,0,1,8,18,0,C09J123/12;;C09J123/12;;C08L2666/02;;C08L2666/02;;Y10T428/31902;;Y10T428/31902,C09J123/12,,0,0,,,,DISCONTINUED
468,US,A,US 5854308 A,117-230-256-668-220,1998-12-29,1998,US 60892196 A,1996-02-29,US 60892196 A,1996-02-29,Water-based pigmented inks having silicone-containing polymer incorporated therein,"Water-based pigmented ink formulations are disclosed including a water soluble or water dispersible silicone-containing polymer additive comprising a vinyl silicone polymer. The additive significantly reduces kogation, mudcracking, and banding in some or all of the pigmented ink formulations.",MINNESOTA MINING & MFG,KUO RICHARD J;;MITRA SMARAJIT;;BOYER III CHARLES E;;PENDERGRASS JR DANIEL B,MINNESOTA MINING AND MANUFACTURING COMPANY (1996-04-01),https://lens.org/117-230-256-668-220,Granted Patent,yes,13,21,9,9,0,C08G77/442;;C09D11/322;;Y10S260/38;;C09D11/30;;B41J2/01;;C09D11/322;;C08G77/442;;Y10S260/38,B41M5/00;;B41J2/01;;C08G77/442;;C09D11/00;;C09D11/10,523/161;;524/261;;524/265;;524/267;;524/502;;524/504;;524/505;;524/506;;X260DIG  38;;106/31.13,2,0,,,Derwent Abstract for JP 7 041 712 (1995).;;Derwent Abstract for JP 6 256 661 (1994).,EXPIRED
469,US,B2,US 8740570 B2,050-143-351-263-200,2014-06-03,2014,US 201113304734 A,2011-11-28,US 201113304734 A,2011-11-28,Turbine bucket airfoil profile,"A turbine bucket is provided including a bucket airfoil having an airfoil shape, the bucket airfoil having a nominal profile substantially in accordance with Cartesian coordinate values of X, Y and Z set forth in Table 1 wherein the Cartesian coordinate values of X, Y and Z are non-dimensional values from 0% to 100% convertible to dimensional distances in inches by multiplying the Cartesian coordinate values of X, Y and Z by a height of the airfoil in inches, and wherein X and Y are distances in inches which, when connected by smooth continuing arcs, define airfoil profile sections at each distance Z, the airfoil profile sections at Z distances being joined smoothly with one another to form a complete airfoil shape.",STEIN ALEXANDER;;BOYER BRADLEY TAYLOR;;FU XIAOYONG;;GOOD RANDALL RICHARD;;ZEMITIS WILLIAM SCOTT;;GEN ELECTRIC,STEIN ALEXANDER;;BOYER BRADLEY TAYLOR;;FU XIAOYONG;;GOOD RANDALL RICHARD;;ZEMITIS WILLIAM SCOTT,GE INFRASTRUCTURE TECHNOLOGY LLC (2023-11-10);;GENERAL ELECTRIC COMPANY (2012-02-01),https://lens.org/050-143-351-263-200,Granted Patent,yes,20,4,2,2,0,F01D5/141;;F01D5/141;;F05D2250/74;;F05D2250/74,F01D5/14,416223A;;416/243,0,0,,,,ACTIVE
470,US,A1,US 2011/0201709 A1,183-327-741-682-952,2011-08-18,2011,US 200913125465 A,2009-11-09,US 200913125465 A;;US 11319608 P;;US 2009/0063733 W,2008-11-10,"ISOCYANATE TRIMERISATION CATALYST SYSTEM, A PRECURSOR FORMULATION, A PROCESS FOR TRIMERISING ISOCYANATES, RIGID POLYISOCYANURATE/POLYURETHANE FOAMS MADE THEREFROM, AND A PROCESS FOR MAKING SUCH FOAMS","The instant invention provides an isocyanate trimerisation catalyst system, a precursor formulation, a process for trimerising isocyanates, rigid foams made therefrom, and a process for making such foams. The trimerisation catalyst system comprises: (a) an imidazolium or imidazolinium cation; and (b) an isocyanate-trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73° C. The precursor formulation comprises: (1) at least 25 percent by weight of polyol, based on the weight of the precursor formulation; (2) less than 15 percent by weight of a trimerisation catalyst system, based on the weight of the precursor formulation, comprising; (a) an imidazolium or imidazolinium cation; and (c) an isocyanate-trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73° C.; and (3) optionally one or more surfactants, one or more flame retardants, water, one or more antioxidants, one or more auxiliary blowing agents, one or more urethane catalysts, one or more auxiliary trimerisation catalysts, or combinations thereof. The process for trimerisation of isocyanates comprises the steps of: (1) providing one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanatetriisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture of any thereof; (2) providing a trimerisation catalyst system comprising; (a) an imidazolium or imidazolinium cation; and (b) an isocyanate-trimer inducing anion; (c) wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73° C.; (3) trimerising said one or more monomers in the presence of said trimerisation catalyst; (4) thereby forming an isocyanurate trimer. The process for making the PIR foam comprises the steps of: (1) providing one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanatetriisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture any thereof; (2) providing polyol; (3) providing a trimerisation catalyst system comprising; (a) an imidazolium or imidazolinium cation; and (b) an isocyanate-timer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73° C.; and (4) optionally providing one or more surfactants, one or more flame retardants, water, one or more antioxidants, one or more auxiliary blowing agents, one or more urethane catalysts, one or more auxiliary trimerisation catalysts, or combinations thereof; (5) contacting said one or more monomers, and said polyol, and optionally said one or more surfactants, and optionally said one or more flame retardants, and optionally said water, and optionally said one or more antioxidants, and optionally said one or more auxiliary blowing agents in the presence of said trimerisation catalyst system and optionally said one or more urethane catalysts, and optionally said one or more auxiliary trimerisation catalysts; (6) thereby forming said polyisocyanurate/polyurethane rigid foam. The PIR foam comprises the reaction product of one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanatetriisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture any thereof with polyol in the presence of a trimerisation catalyst system comprising an imidazolium or imidazolinium cation, and an isocyanate-trimer inducing anion, and optionally one or more surfactants, optionally one or more flame retardants, optionally water, optionally one or more antioxidants, optionally one or more auxiliary blowing agents, optionally one or more additional urethane catalysts, and optionally one or more auxiliary trimerisation catalysts, or optionally combinations thereof, wherein the trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73° C. The PIR foam comprises the reaction product of one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanatetriisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture any thereof with polyol in the presence of a trimerisation catalyst system comprising an imidazolium or imidazolinium cation, and an isocyanate-trimer inducing anion, and optionally one or more surfactants, optionally one or more flame retardants, optionally water, optionally one or more antioxidants, optionally one or more auxiliary blowing agents, optionally one or more additional polyurethane catalysts, and optionally one or more auxiliary trimerisation catalysts, or optionally combinations thereof, wherein the PIR foam has a polyisocyanurate trimer ratio (Abs 1410 /Abs 1595 ) of at least 5 at a depth of 12 mm from the rising surface of the rigid foam, measured via ATR-FTIR spectroscopy.",DOW GLOBAL TECHNOLOGIES LLC,ATHEY PHILLIP;;WILMOT NATHAN;;KEATON RICHARD;;BABB DAVID A;;BOYER CECILE;;MORLEY TIMOTHY,DOW EUROPE GMBH (2009-07-17);;DOW GLOBAL TECHNOLOGIES LLC (2009-07-08);;THE DOW CHEMICAL COMPANY (2009-07-27),https://lens.org/183-327-741-682-952,Patent Application,yes,14,19,9,9,0,C08G18/022;;C08G18/092;;C08G18/1858;;C08G18/1875;;C08G18/2027;;C08G18/2063;;C08G18/4208;;C08G2120/00;;C08G2115/02;;C08G2110/0025;;C08G18/4208;;C08G18/022;;C08G18/092;;C08G18/1858;;C08G18/1875;;C08G18/2027;;C08G18/2063;;C08G2120/00;;C08G2110/0025;;C08G2115/02,C08J9/00;;C07D233/58;;C07D251/30;;C08G18/74,521/128;;548/335.1;;548/345.1;;544/193,0,0,,,,DISCONTINUED
471,CO,A2,CO 6170355 A2,193-081-449-775-591,2010-06-18,2010,CO 09006711 A,2009-01-26,US 81652206 P,2006-06-26,INHIBIDORES PROLIL HIDROXILASA Y METODOS DE USO,"1.- Un compuesto que tiene la Fórmula:en donde X es N o CH;R y R1 son cada uno independientemente una unidad seleccionada de:i) hidrógeno;ii) fenilo sustituido o no sustituido; y iii) heteroarilo sustituido o no sustituido; dichas sustituciones seleccionadas de:i) Cicloalquilo cíclico, lineal o ramificado C1-C4;ii) Alcoxi cíclico, lineal o ramificado C1-C4; iii) Haloalquilo cíclico, lineal o ramificado C1-C4;iv) halógeno;v) -CN; vi) -NHC(O)R4 vii) -C(O)NR5aR5b; viii) heteroarilo ; oix) dos sustituciones se pueden tomar juntas para formar un anillo fusionado que tiene de 5 a 7 átomos;R4 es alquilo cíclico, lineal o ramificado C1-C4;R5a y R5b son cada uno independientemente:i) hidrógeno;ii) Cicloalquilo cíclico, lineal o ramificado C1-C4; oiii) R5a y R5b se pueden tomar juntos para formar un anillo que tiene de 3 a 7 átomos; R2 se selecciona de: i) -OR6; oii) -NR7aR7b;R6 es hidrógeno o cicloalquilo cíclico, lineal o ramificado C1-C4;R7a y R7b son cada uno independientemente:i) hidrógeno;ii) Cicloalquilo cíclico, lineal o ramificado C1-C4; oiii) R7a y R7b se pueden tomar juntos para formar un anillo que tiene de 3 a 7 átomos del anillo;Y se selecciona de:i) hidrógeno;ii) -OR3;es hidrógeno, metilo, o etilo;L es una unidad de ligado que tiene la Fórmula: R8a y R8b son cada uno independientemente hidrógeno, metilo, o etilo; el índice n es de 1 a 3; R9 es hidrógeno o metilo.",PROCTER & GAMBLE,KAWAMOTO RICHARD MASARU;;EDOKIMOV ARTEM G;;GREIS KENNETH DONALD;;BOYER ANGELIQUE;;WU SHENGDE,,https://lens.org/193-081-449-775-591,Patent Application,no,0,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07C235/60;;C07C237/42;;C07C255/57;;C07D213/81,,0,0,,,,ACTIVE
472,AU,A,AU 1996/061072 A,018-343-015-937-102,1997-09-16,1997,AU 1996/061072 A,1996-06-10,US 60892196 A;;US 9609733 W,1996-02-29,Water-based pigmented inks having silicone-containing polymer incorporated therein,,MINNESOTA MINING & MFG,KUO RICHARD J;;MITRA SMARAJIT;;BOYER CHARLES E III;;PENDERGRASS DANIEL B JR,,https://lens.org/018-343-015-937-102,Patent Application,no,0,0,9,9,0,C08G77/442;;C09D11/322;;Y10S260/38;;C09D11/30;;B41J2/01;;C09D11/322;;C08G77/442;;Y10S260/38,B41J2/01;;B41M5/00;;C08G77/442;;C09D11/00;;C09D11/10,,0,0,,,,DISCONTINUED
473,CA,A1,CA 2005198 A1,046-922-684-495-008,1990-07-26,1990,CA 2005198 A,1989-12-12,US 30242789 A,1989-01-26,MICROWAVE ABSORBER EMPLOYING ACICULAR MAGNETIC METALLIC FILAMENTS,"MICROWAVE ABSORBER EMPLOYING ACICULAR MAGNETIC METALLIC FILAMENTS An electromagnetic radiation absorber is formed by dispersing into a dielectric binder acicular magnetic metallic filaments with an average length of about 10 micron or less, diameters of 0.1 micron or more, and aspect (length/diameter) ratios between 10:1 and 50:1. Preferably the average length is about 5 micron, the aspect ratios are between 10:1 and 25:1, and the dielectric binder is polymeric. The volume fraction of the filaments may be lower than 35% of the total and still provide satisfactory absorption. An absorbing paint is formed by dissolving the absorber in a base liquid. The absorber or absorbing paint may be applied to a conductive surface, such as a metallic wire, plate or foil. Impedance matching materials are preferred but not required. PFAPP5.5",MINNESOTA MINING & MFG,BOYER CHARLES E III;;BORCHERS ERIC J;;KUO RICHARD J;;HOYLE CHARLES D,,https://lens.org/046-922-684-495-008,Patent Application,no,0,0,8,9,0,H01Q17/005,B32B7/02;;H01Q17/00;;H05K9/00,D10310106    M,0,0,,,,DISCONTINUED
474,AU,A,AU 1989/047088 A,077-878-302-525-478,1990-08-02,1990,AU 1989/047088 A,1989-12-21,US 30242789 A,1989-01-26,MICROWAVE ABSORBER EMPLOYING ACICULAR MAGNETIC METALLIC FILAMENTS,,MINNESOTA MINING & MFG,BOYER CHARLES EDWARD III;;BORCHERS ERIC JOHN;;KUO RICHARD JENTEN;;HOYLE CHARLES DAVID,,https://lens.org/077-878-302-525-478,Patent Application,no,0,0,8,9,0,H01Q17/005,B32B7/02;;H01Q17/00;;H05K9/00,,0,0,,,,EXPIRED
475,WO,A1,WO 1997/031984 A1,168-079-579-559-935,1997-09-04,1997,US 9609733 W,1996-06-10,US 60892196 A,1996-02-29,WATER-BASED PIGMENTED INKS HAVING SILICONE-CONTAINING POLYMER INCORPORATED THEREIN,"Water-based pigmented ink formulations are disclosed including a water soluble or water dispersible silicone-containing polymer additive comprising a vinyl silicone polymer. The additive significantly reduces kogation, mudcracking, and banding in some or all of the pigmented ink formulations.",MINNESOTA MINING & MFG,KUO RICHARD J;;MITRA SMARAJIT;;BOYER CHARLES E III;;PENDERGRASS DANIEL B JR,,https://lens.org/168-079-579-559-935,Patent Application,yes,2,8,9,9,0,C08G77/442;;C09D11/322;;Y10S260/38;;C09D11/30;;B41J2/01;;C09D11/322;;C08G77/442;;Y10S260/38,B41M5/00;;C08G77/442;;B41J2/01;;C09D11/00;;C09D11/10,,2,0,,,"DATABASE WPI Section Ch Week 9516, Derwent World Patents Index; Class A97, AN 95-118887, XP002019966;;DATABASE WPI Section Ch Week 9441, Derwent World Patents Index; Class A26, AN 94-330292, XP002019967",PENDING
476,WO,A1,WO 2000/001803 A1,198-426-569-297-347,2000-01-13,2000,US 9913207 W,1999-06-10,US 11058298 A,1998-07-06,NON-MACROPOROUS INORGANIC SUPPORT FOR BIOREMEDIATION,"A method of using a porous, non-macroporous inorganic oxide material as a carrier to immobilize a microorganism in a bioreactor is disclosed. Also disclosed is a composite body comprising a microorganism fixed on said porous carriers. A bioreactor system comprising a bioreactor vessel and the carrier-microorganism is also disclosed. The porous non-macroporous carrier is useful for the biotreatment of aqueous waste water contaminants. The porous carrier of the invention contains substantially no pore volume in the macropore range, i.e. 800 Å or greater.",GRACE W R & CO,MILLER JAMES GEORGE;;BATES ROBERT HAYWOOD DI;;BOYER TIMOTHY ALLEN;;DURHAM DONALD RICHARD,,https://lens.org/198-426-569-297-347,Patent Application,yes,4,12,9,9,0,C02F3/10;;C12N11/14;;Y02W10/10;;C12N11/14;;C02F3/10;;Y02W10/10,C02F3/00;;C02F3/10;;C12N1/04;;C12N11/14,,1,1,105-185-129-799-476,10.1128/aem.60.11.4178-4181.1994;;16349446;;pmc201956,"DURHAM D R, ET AL.: ""NEW COMPOSITE BIOCARRIERS ENGINEERED TO CONTAIN ADSORPTIVE AND ION-EXCHANGE PROPERTIES IMPROVE IMMOBILIZED-CELL BIOREACTOR PROCESSDEPENDABILITY"", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 60, no. 11, 1 November 1994 (1994-11-01), US, pages 4178 - 4181, XP002924414, ISSN: 0099-2240",PATENTED
477,EP,A1,EP 0883655 A1,064-322-889-699-534,1998-12-16,1998,EP 96918396 A,1996-06-10,US 9609733 W;;US 60892196 A,1996-02-29,WATER-BASED PIGMENTED INKS HAVING SILICONE-CONTAINING POLYMER INCORPORATED THEREIN,,MINNESOTA MINING & MFG,KUO RICHARD J;;MITRA SMARAJIT;;BOYER CHARLES E III;;PENDERGRASS DANIEL B JR,,https://lens.org/064-322-889-699-534,Patent Application,yes,0,0,9,9,0,C08G77/442;;C09D11/322;;Y10S260/38;;C09D11/30;;B41J2/01;;C09D11/322;;C08G77/442;;Y10S260/38,B41J2/01;;B41M5/00;;C08G77/442;;C09D11/00;;C09D11/10,,0,0,,,,DISCONTINUED
478,AU,B2,AU 615817 B2,079-072-551-204-421,1991-10-10,1991,AU 1989/047088 A,1989-12-21,US 30242789 A,1989-01-26,MICROWAVE ABSORBER,,MINNESOTA MINING & MFG,BOYER CHARLES EDWARD III;;BORCHERS ERIC JOHN;;KUO RICHARD JENTEN;;HOYLE CHARLES DAVID,,https://lens.org/079-072-551-204-421,Granted Patent,no,3,0,8,9,0,H01Q17/005,B32B7/02;;H01Q17/00;;H05K9/00,,0,0,,,,EXPIRED
479,CA,A1,CA 2244896 A1,129-533-831-200-75X,1997-09-04,1997,CA 2244896 A,1996-06-10,US 60892196 A,1996-02-29,WATER-BASED PIGMENTED INKS HAVING SILICONE-CONTAINING POLYMER INCORPORATED THEREIN,"Water-based pigmented ink formulations are disclosed including a water soluble or water dispersible silicone-containing polymer additive comprising a vinyl silicone polymer. The additive significantly reduces kogation, mudcracking, and banding in some or all of the pigmented ink formulations.",MINNESOTA MINING & MFG,PENDERGRASS DANIEL B III;;KUO RICHARD J;;MITRA SMARAJIT;;BOYER CHARLES E III,,https://lens.org/129-533-831-200-75X,Patent Application,no,0,0,9,9,0,C08G77/442;;C09D11/322;;Y10S260/38;;C09D11/30;;B41J2/01;;C09D11/322;;C08G77/442;;Y10S260/38,B41J2/01;;B41M5/00;;C08G77/442;;C09D11/00;;C09D11/10,,0,0,,,,DISCONTINUED
480,BR,A,BR 9612550 A,162-255-584-937-525,1999-07-20,1999,BR 9612550 A,1996-06-10,US 60892196 A;;US 9609733 W,1996-02-29,Formulação de tinta pigmentada à base de água tinta e processo para utilizar a tinta,,MINNESOTA MINING & MFG,KUO RICHARD J;;MITRA SMARAJIT;;BOYER CHARLES E III;;PENDERGRASS DANIEL B JR,,https://lens.org/162-255-584-937-525,Patent Application,no,0,0,9,9,0,C08G77/442;;C09D11/322;;Y10S260/38;;C09D11/30;;B41J2/01;;C09D11/322;;C08G77/442;;Y10S260/38,B41J2/01;;B41M5/00;;C08G77/442;;C09D11/00;;C09D11/10,,0,0,,,,DISCONTINUED
481,US,A1,US 2008/0124740 A1,010-914-825-208-265,2008-05-29,2008,US 71394107 A,2007-03-05,US 71394107 A;;US 77989806 P,2006-03-07,Three dimensional coordinates of hypoxia inducible factor 1 alpha (HIF-1 alpha)-prolyl hydroxylase (EGLN1) and uses thereof,The crystal structure of ligand-bound EGLN1 catalytic domain of prolyl hydroxylase is disclosed. These coordinates are useful in computer aided drug design for identifying compounds that regulate EGLN1 prolyl hydroxylase and thereby regulate HIF-regulated disorders.,PROCTER & GAMBLE,EVDOKIMOV ARTEM GENNADY;;KAWAMOTO RICHARD MASARU;;BOYER ANGELIQUE SUN;;MEKEL MARLENE JAN;;POKROSS MATTHEW EUGENE;;WALTER RICHARD LEE,AKEBIA THERAPEUTICS INC (2011-12-15);;PROCTER & GAMBLE COMPANY THE (2006-04-30);;WARNER CHILCOTT COMPANY LLC (2009-10-30),https://lens.org/010-914-825-208-265,Patent Application,yes,2,49,6,6,14,C07K2299/00;;C12N9/0071;;C12Q1/26;;G01N2500/00;;C12Q1/26;;C07K2299/00;;C12N9/0071;;G01N2500/00,G01N33/566,435/7.8,0,0,,,,ACTIVE
482,US,A1,US 2009/0240475 A1,034-720-588-343-652,2009-09-24,2009,US 47353609 A,2009-05-28,US 47353609 A;;US 71394107 A;;US 77989806 P,2006-03-07,THREE DIMENSIONAL COORDINATES OF HYPOXIA INDUCIBLE FACTOR 1 ALPHA (HIF-1 ALPHA) PROLYL HYDROXYLASE (EGLN1) AND USES THEREOF,The crystal structure of ligand-bound EGLN1 catalytic domain of prolyl hydroxylase is disclosed. These coordinates are useful in computer aided drug design for identifying compounds that regulate EGLN1 prolyl hydroxylase and thereby regulate HIF-regulated disorders.,EVDOKIMOV ARTEM GENNADY;;KAWAMOTO RICHARD MASARU;;BOYER SUN;;MEKEL MERLENE JAN;;POKROSS METTHEW EUGENE;;WALTER JR RICHARD LEE,EVDOKIMOV ARTEM GENNADY;;KAWAMOTO RICHARD MASARU;;BOYER SUN;;MEKEL MERLENE JAN;;POKROSS METTHEW EUGENE;;WALTER JR RICHARD LEE,AKEBIA THERAPEUTICS INC (2011-12-15);;WARNER CHILCOTT COMPANY LLC (2009-10-30),https://lens.org/034-720-588-343-652,Patent Application,yes,18,4,6,6,14,C07K2299/00;;C12N9/0071;;C12Q1/26;;G01N2500/00;;C12Q1/26;;C07K2299/00;;C12N9/0071;;G01N2500/00,G06F17/50,703/1,0,0,,,,ACTIVE
483,WO,A2,WO 2014/036445 A2,058-173-763-906-741,2014-03-06,2014,US 2013/0057588 W,2013-08-30,US 201261695686 P,2012-08-31,NOVEL MUCOLYTIC AGENTS,Provided is a method of liquefying mucus from mucosal surfaces by administering compounds containing a phosphine group.,JOHNSON MICHAEL R;;THELIN WILLIAM R;;BOUCHER RICHARD C;;VILLALON DIANE;;BOYER JOSE L,JOHNSON MICHAEL R;;THELIN WILLIAM R;;BOUCHER RICHARD C;;VILLALON DIANE;;BOYER JOSE L,,https://lens.org/058-173-763-906-741,Patent Application,yes,0,2,3,3,0,A61K31/66;;A61K31/663;;A61K9/0073;;A61P11/12;;Y02A50/30;;A61K31/66;;A61K9/0073;;A61K31/663;;C07F9/5004;;C07F9/5022,A61K31/66,,0,0,,,,PENDING
484,US,B2,US 11039754 B2,145-315-363-041-405,2021-06-22,2021,US 201816109252 A,2018-08-22,US 201816109252 A;;US 201862671108 P,2018-05-14,System and method for monitoring and determining patient parameters from sensed venous waveform,"Devices, systems, and methods for monitoring patient hemodynamic status, systemic vascular resistance, reversal of cardiac and respiratory rates, and patient respiratory volume or effort are disclosed. A peripheral venous pressure is measured and used to detect levels, changes, or problems relating to patient blood volume. The peripheral venous pressure measurement is transformed from the time domain to the frequency domain for analysis. A heart rate frequency is identified, and harmonics of the heart rate frequency are detected and evaluated to determine, among other things, hypovolemia or hypervolemia, systemic vascular resistance, and of cardiac and respiratory rates, and patient respiratory volume or effort.",BAXTER INT;;BAXTER HEALTHCARE SA,HANDLER JONATHAN;;MARTUCCI JAMES;;HOCKING KYLE;;EAGLE SUSAN;;BROPHY COLLEEN;;BOYER RICHARD;;BAUDENBACHER FRANZ,BAXTER HEALTHCARE SA (2019-08-05);;BAXTER INTERNATIONAL INC (2019-08-05),https://lens.org/145-315-363-041-405,Granted Patent,yes,214,0,3,26,0,A61B5/02152;;A61B5/02152;;A61B5/0205;;A61B5/024;;A61B5/029;;A61B5/029;;A61B5/0816;;A61B5/486;;A61B5/4875;;A61B5/4875;;A61B5/6852;;A61B5/6865;;A61B5/7235;;A61B5/7257;;A61B5/7257;;A61B5/7278;;A61B5/746;;A61B2562/0247;;A61M2025/0003,A61B5/0215;;A61B5/00;;A61B5/029;;A61M25/00,,9,1,059-259-977-142-971,24901895;;10.1088/0967-3334/35/7/1509,"European Search Report for related European Application No. PCT/US2018/065637; dated Mar. 14, 2019; (17 pages).;;International Search Report for PCT/US2017/066689; dated Apr. 6, 2018; (19 pages).;;International Search Report and Written Opinion for related International Application No. PCT/US2018/040389; dated Sep. 17, 2018; (16 pages).;;Aymen A Alian, et al.; “Impact of lower body negative pressure induced hypovolemia on peripheral venous pressure waveform parameters in healthy volunteers”; Institute of Physics and Engineering in Medicine; Physiol. Meas. 35; 2014; pp. 1509-1520; (13 pages).;;International Preliminary Report on Patentability for related international Application No. PCT/US2017/066689; dated Jun. 18, 2019; (11 pages).;;Preliminary Report on Patentability for related International Application No. PCT/US2018/040389; dated Jan. 9, 2020; (9 pages).;;International Preliminary Report on Patentability for related International Application No. PCT/US2018065637; dated Jun. 16, 2020; (9 pages).;;Singapore Written Opinion for related Singapore Application No. 11201905459X; dated Jun. 22, 2020; (5 pages).;;Japanese Office Action for related Japanese Application No. 2019-531946; dated Sep. 25, 2020; (10 pages).",ACTIVE
485,WO,A1,WO 2019/006362 A1,170-505-946-506-933,2019-01-03,2019,US 2018/0040389 W,2018-06-29,US 201762527944 P;;US 201762528570 P;;US 201762599421 P;;US 201862671108 P;;US 201816023945 A,2017-06-30,SYSTEMS AND METHODS FOR FILTERING NOISE AND ANALYZING VENOUS WAVEFORM SIGNALS,"Devices, systems, and methods for filtering medical device noise artifacts from venous waveform signals are disclosed. A peripheral venous pressure (PVP) is measured and transformed from the time domain to the frequency domain for analysis to determine patient status. To avoid artifacts of the pumping, the time-domain PVP measurements are filtered to generate a filtered time-domain PVP signal by removing active pumping periods. The filtered time-domain PVP signal is transformed into a frequency-domain PVP signal, which is analyzed based upon peaks indicating respiratory rate, heart rate, or harmonics thereof. A metric of patient status is then determined from the peaks or corresponding frequencies. The patient status may be related to blood volume of the patient and may be used to control pump operation.",BAXTER INT;;BAXTER HEALTHCARE SA,HANDLER JONATHAN;;MARTUCCI JAMES;;HOCKING KYLE;;EAGLE SUSAN;;BROPHY COLLEEN;;BOYER RICHARD;;BAUDENBACHER FRANZ,,https://lens.org/170-505-946-506-933,Patent Application,yes,4,3,11,26,0,A61B5/6866;;A61B5/7217;;A61B5/02152;;A61B5/7278;;A61M2205/3576;;A61M2205/502;;A61M2205/52;;A61B5/7246;;A61B5/02405;;A61B5/02444;;A61B5/0816;;A61B5/112;;A61B5/4094;;A61B5/6824;;A61B5/7257;;G16H40/63;;G16H50/30;;G16H50/70;;G16H20/40;;A61B5/4839;;A61B5/725;;A61B5/7282;;A61B2562/0247;;A61M5/14232;;A61M5/1723;;A61M2205/3331;;A61M2230/30;;A61B5/7217;;A61B5/02152;;A61B5/02444;;A61B5/0816;;A61B5/112;;A61B5/6824;;A61B5/7257;;A61B5/7278;;A61M5/14232;;A61M5/1723;;G16H20/40;;G16H40/63;;G16H50/70;;A61B2562/0247;;A61B5/6866;;A61M2205/502;;A61M2205/52;;A61B5/02405;;A61B5/7246;;A61B5/02152;;A61M2205/3576;;A61B5/7278;;A61B5/0816;;A61B5/6824;;G16H20/40;;A61B5/7257;;A61B5/112;;A61B5/02444;;A61B5/7217;;G16H50/70;;A61B5/4094;;G16H50/30;;G16H40/63;;A61B5/0215;;A61B5/4839;;A61B5/7203;;A61B5/725;;A61B5/7282;;A61B2562/0247;;A61M5/14232;;A61M5/1723;;A61M2205/3331;;A61M2230/30,A61B5/00;;A61B5/0215,,0,0,,,,PENDING
486,CN,A,CN 116489979 A,184-497-879-386-644,2023-07-25,2023,CN 202310107275 A,2023-01-19,US 202318097400 A,2023-01-16,Internal EMC protection for shields of plastic high voltage distribution centers,"A power distribution center (100) includes: a housing (104) formed of a non-conductive material; an electromagnetic housing shield (110) formed of an electrically conductive material, the electromagnetic housing shield disposed within the cavity (112) in the housing (104); a cover (116) enclosing the cavity (112), the cover having an electromagnetic cover shield (118) formed of an electrically conductive material and in electrical contact with the housing shield (110); and a plurality of shielded electrical connectors (102) interconnected to each other by an electrical component (126) housed within the cavity (112). The electrical components (126) are mounted on a plurality of legs (128) defined by an inner surface of the housing (104). The plurality of legs (128) extend through a plurality of apertures (130) defined in the housing shield (110).",APTIV TECH LTD,FERRUCCIO MICHAEL;;SILVA FRANCIS J;;BOYER RICHARD J;;SPADONI SIMONE;;BIZON DAVID;;BRANDON CHRISTOPHER,,https://lens.org/184-497-879-386-644,Patent Application,no,0,0,1,4,0,H02B1/26;;H05K9/0007;;H01R13/6581;;H01R13/6473,H05K9/00;;H01R13/6473;;H01R13/6581;;H02B1/26,,0,0,,,,PENDING
487,US,A1,US 2010/0217052 A1,117-007-332-858-869,2010-08-26,2010,US 60198508 A,2008-05-30,DE 102007025315 A;;EP 2008004327 W,2007-05-31,Catalyst For The Selective Hydrogenation Of Acetylenic Hydrocarbons And Method For Producing Said Catalyst,"A method for producing a catalyst, in particular for the selective reduction of acetylenic compounds in hydrocarbon streams. An impregnation solution is provided, which contains a mixture of water and at least one water-miscible organic solvent as solvent in which at least one active metal compound and also preferably at least one promoter metal compound is dissolved. A support is provided, the support is impregnated with the impregnation solution, and the impregnated support is calcined. Palladium is preferably used as active metal and silver is preferably used as promoter metal. Also, a catalyst as is obtained by the method and also its preferred use for the selective hydrogenation of acetylenic compounds.",SUED CHEMIE AG,UNGAR SYBILLE;;FISCHER RICHARD;;TRAUTWEIN ANDREAS;;BLANKENSHIP STEVE;;BOYER JENNIFER;;URBANCIC MICHAEL;;ROKICKI ANDRZEJ,SUD-CHEMIE AG (2009-12-28);;SUED-CHEMIE IP GMBH & CO. KG (2012-06-18),https://lens.org/117-007-332-858-869,Patent Application,yes,99,32,11,11,0,B01J23/40;;B01J23/44;;B01J23/48;;B01J23/50;;B01J23/74;;B01J37/0203;;B01J37/0221;;B01J37/16;;C07C7/167;;C07C2521/04;;C07C2523/44;;C07C2523/56;;C10G45/40;;Y02P20/52;;B01J35/397;;B01J35/393;;B01J35/30;;B01J35/613;;B01J37/02;;B01J23/40;;B01J23/74;;C10G45/40;;B01J23/44;;C07C2521/04;;C10G45/40;;B01J23/48;;B01J37/16;;B01J37/0203;;B01J23/50;;B01J23/40;;B01J23/74;;C07C2523/56;;B01J37/0221;;C07C7/167;;C07C2523/44;;Y02P20/52;;B01J35/30;;B01J35/393;;B01J35/397;;B01J35/613,C07C5/08;;B01J31/12,585/250;;502/154,0,0,,,,DISCONTINUED
488,SG,A,SG 10202112770T A,181-193-392-291-561,2021-12-30,2021,SG 10202112770T A,2017-12-15,US 201662434796 P;;US 201662434849 P;;US 201662434768 P;;US 201762528794 P,2016-12-15,SYSTEM AND METHOD FOR MONITORING AND DETERMINING PATIENT PARAMETERS FROM SENSED VENOUS WAVEFORM,,BAXTER INT;;BAXTER HEALTHCARE SA,HANDLER JONATHAN;;MARTUCCI JAMES;;HOCKING KYLE;;EAGLE SUSAN;;BROPHY COLLEEN;;BOYER RICHARD;;BAUDENBACHER FRANZ,,https://lens.org/181-193-392-291-561,Unknown,no,0,0,19,19,0,A61B5/6865;;A61B5/726;;A61B5/02007;;A61B5/024;;A61M1/3639;;A61M1/3666;;A61B5/0816;;A61B5/091;;A61M16/00;;A61B5/4839;;A61M2230/30;;A61B5/02152;;A61B5/7257;;A61M2205/3344;;A61M2230/06;;A61B5/02152;;A61B5/02007;;A61B5/024;;A61B5/0295;;A61B5/0816;;A61B5/091;;A61B5/4839;;A61B5/486;;A61B5/6876;;A61B5/7225;;A61B5/7257;;A61B5/7278;;A61B5/746;;A61M25/00;;A61M5/1723;;A61B2562/0247;;A61B5/0816;;A61B5/726;;A61B5/02007;;A61B5/024;;A61M1/3666;;A61B5/6865;;A61B5/4839;;A61B5/091;;A61M2230/30;;A61M16/00;;A61M1/3639;;A61B5/02152;;A61B5/0295;;A61B5/486;;A61B5/6876;;A61B5/7225;;A61B5/7257;;A61B5/7278;;A61B5/746;;A61B2562/0247;;A61M5/1723;;A61M25/00;;A61M2025/0003;;A61M2205/3344;;A61M2230/06,,,0,0,,,,PENDING
489,CA,C,CA 2298294 C,038-209-601-595-924,2008-07-22,2008,CA 2298294 A,2000-02-09,US 39753499 A,1999-09-16,BACK-LIT FASCIA WITH SPRING LOADED FASCIA TENSIONER,"A sign frame assembly for supporting a flexible fascia. In one embodiment, a frame member extends in a first direction and has first and second bracket-mounting sections spaced apart from each other in the first direction. First and second brackets have inner and outer opposite ends. The inner end of the first bracket is attached to the first bracket-mounti ng section of the first frame member. The inner end of the second bracket are pivotally mounted to the second bracket-mounting section of the frame member. First and second elongated fascia attachment members are affixed respectively to the outer ends of the first and second brackets. A flexible fascia having oppositely disposed edges is connected to the first and second elongated members. A bias member is operatively disposed between the frame member and the second bracket such that the bias member exerts a rotational force on the second bracket in a direction tending to spread apart the elongated fascia attachment members and tension the flexible fascia therebetween. Additional embodiments utilizing biased pivotal fascia tension members are disclosed.",LSI INDUSTRIES INC,WEDDING WILLIAM R;;GESSNER S FRANK;;GRIMES RICHARD SCOTT;;MAKSTALLER RONALD W;;BOYER JOHN,,https://lens.org/038-209-601-595-924,Granted Patent,no,0,0,6,6,0,G09F17/00;;G09F17/00;;G09F13/04;;G09F13/04;;G09F15/0025;;G09F15/0025;;Y10T29/49716;;Y10T29/49716;;Y10T29/4984;;Y10T29/4984;;Y10T29/49863;;Y10T29/49863;;Y10T29/49867;;Y10T29/49867;;Y10T29/4987;;Y10T29/4987,G09F7/18;;G09F13/04;;G09F15/00;;G09F17/00,,0,0,,,,EXPIRED
490,CN,A,CN 110248596 A,111-579-617-089-317,2019-09-17,2019,CN 201780085234 A,2017-12-15,US 201662434796 P;;US 201662434849 P;;US 201662434768 P;;US 201762528794 P;;US 2017/0066689 W,2016-12-15,SYSTEM AND METHOD FOR MONITORING AND DETERMINING PATIENT PARAMETERS FROM SENSED VENOUS WAVEFORM,"Devices, systems, and methods for monitoring patient hemodynamic status, systemic vascular resistance, reversal of cardiac and respiratory rates, and patient respiratory volume or effort are disclosed. A peripheral venous pressure is measured and used to detect levels, changes, or problems relating to patient blood volume. The peripheral venous pressure measurement is transformed from the time domain to the frequency domain for analysis. A heart rate frequency is identified, and harmonics of the heart rate frequency are detected and evaluated to determine, among other things, hypovolemia or hypervolemia, systemic vascular resistance, and cardiac and respiratory rates, and patient respiratory volume or effort.",BAXTER INT;;BAXTER HEALTHCARE SA,HANDLER JONATHAN;;MARTUCCI JAMES;;HOCKING KYLE;;EAGLE SUSAN;;BROPHY COLLEEN;;BOYER RICHARD;;BAUDENBACHER FRANZ,,https://lens.org/111-579-617-089-317,Patent Application,no,6,0,19,19,0,A61B5/6865;;A61B5/726;;A61B5/02007;;A61B5/024;;A61M1/3639;;A61M1/3666;;A61B5/0816;;A61B5/091;;A61M16/00;;A61B5/4839;;A61M2230/30;;A61B5/02152;;A61B5/7257;;A61M2205/3344;;A61M2230/06;;A61B5/02152;;A61B5/02007;;A61B5/024;;A61B5/0295;;A61B5/0816;;A61B5/091;;A61B5/4839;;A61B5/486;;A61B5/6876;;A61B5/7225;;A61B5/7257;;A61B5/7278;;A61B5/746;;A61M25/00;;A61M5/1723;;A61B2562/0247;;A61B5/0816;;A61B5/726;;A61B5/02007;;A61B5/024;;A61M1/3666;;A61B5/6865;;A61B5/4839;;A61B5/091;;A61M2230/30;;A61M16/00;;A61M1/3639;;A61B5/02152;;A61B5/0295;;A61B5/486;;A61B5/6876;;A61B5/7225;;A61B5/7257;;A61B5/7278;;A61B5/746;;A61B2562/0247;;A61M5/1723;;A61M25/00;;A61M2025/0003;;A61M2205/3344;;A61M2230/06,A61B5/0215;;A61B5/00;;A61B5/02;;A61B5/024;;A61B5/08;;A61B5/091;;A61M16/00,,0,0,,,,ACTIVE
491,MX,A,MX 2019007125 A,113-476-078-235-557,2019-09-16,2019,MX 2019007125 A,2017-12-15,US 201662434768 P;;US 201662434796 P;;US 201662434849 P;;US 201762528794 P;;US 2017/0066689 W,2016-12-15,SYSTEM AND METHOD FOR MONITORING AND DETERMINING PATIENT PARAMETERS FROM SENSED VENOUS WAVEFORM.,"Devices, systems, and methods for monitoring patient hemodynamic status, systemic vascular resistance, reversal of cardiac and respiratory rates, and patient respiratory volume or effort are disclosed. A peripheral venous pressure is measured and used to detect levels, changes, or problems relating to patient blood volume. The peripheral venous pressure measurement is transformed from the time domain to the frequency domain for analysis. A heart rate frequency is identified, and harmonics of the heart rate frequency are detected and evaluated to determine, among other things, hypovolemia or hypervolemia, systemic vascular resistance, and cardiac and respiratory rates, and patient respiratory volume or effort.",BAXTER INT,COLLEEN BROPHY;;KYLE HOCKING;;RICHARD BOYER;;FRANZ BAUDENBACHER;;SUSAN EAGLE;;JONATHAN HANDLER;;JAMES MARTUCCI,,https://lens.org/113-476-078-235-557,Patent Application,no,0,0,19,19,0,A61B5/6865;;A61B5/726;;A61B5/02007;;A61B5/024;;A61M1/3639;;A61M1/3666;;A61B5/0816;;A61B5/091;;A61M16/00;;A61B5/4839;;A61M2230/30;;A61B5/02152;;A61B5/7257;;A61M2205/3344;;A61M2230/06;;A61B5/02152;;A61B5/02007;;A61B5/024;;A61B5/0295;;A61B5/0816;;A61B5/091;;A61B5/4839;;A61B5/486;;A61B5/6876;;A61B5/7225;;A61B5/7257;;A61B5/7278;;A61B5/746;;A61M25/00;;A61M5/1723;;A61B2562/0247;;A61B5/0816;;A61B5/726;;A61B5/02007;;A61B5/024;;A61M1/3666;;A61B5/6865;;A61B5/4839;;A61B5/091;;A61M2230/30;;A61M16/00;;A61M1/3639;;A61B5/02152;;A61B5/0295;;A61B5/486;;A61B5/6876;;A61B5/7225;;A61B5/7257;;A61B5/7278;;A61B5/746;;A61B2562/0247;;A61M5/1723;;A61M25/00;;A61M2025/0003;;A61M2205/3344;;A61M2230/06,A61B5/0215;;A61B5/00;;A61B5/02;;A61B5/024;;A61B5/08;;A61B5/091;;A61M16/00,,0,0,,,,PENDING
492,US,B2,US 11039753 B2,176-021-404-740-896,2021-06-22,2021,US 201715843935 A,2017-12-15,US 201715843935 A;;US 201662434796 P;;US 201662434849 P;;US 201662434768 P;;US 201762528794 P,2016-12-15,System and method for monitoring and determining patient parameters from sensed venous waveform,"Devices, systems, and methods for monitoring patient hemodynamic status, systemic vascular resistance, reversal of cardiac and respiratory rates, and patient respiratory volume or effort are disclosed. A peripheral venous pressure is measured and used to detect levels, changes, or problems relating to patient blood volume. The peripheral venous pressure measurement is transformed from the time domain to the frequency domain for analysis. A heart rate frequency is identified, and harmonics of the heart rate frequency are detected and evaluated to determine, among other things, hypovolemia or hypervolemia, systemic vascular resistance, and of cardiac and respiratory rates, and patient respiratory volume or effort.",BAXTER INT;;BAXTER HEALTHCARE SA,HANDLER JONATHAN;;MARTUCCI JAMES;;HOCKING KYLE;;EAGLE SUSAN;;BROPHY COLLEEN;;BOYER RICHARD;;BAUDENBACHER FRANZ,BAXTER HEALTHCARE SA (2018-07-03);;BAXTER INTERNATIONAL INC (2018-07-03),https://lens.org/176-021-404-740-896,Granted Patent,yes,211,1,19,19,0,A61B5/6865;;A61B5/726;;A61B5/02007;;A61B5/024;;A61M1/3639;;A61M1/3666;;A61B5/0816;;A61B5/091;;A61M16/00;;A61B5/4839;;A61M2230/30;;A61B5/02152;;A61B5/7257;;A61M2205/3344;;A61M2230/06;;A61B5/02152;;A61B5/02007;;A61B5/024;;A61B5/0295;;A61B5/0816;;A61B5/091;;A61B5/4839;;A61B5/486;;A61B5/6876;;A61B5/7225;;A61B5/7257;;A61B5/7278;;A61B5/746;;A61M25/00;;A61M5/1723;;A61B2562/0247;;A61B5/0816;;A61B5/726;;A61B5/02007;;A61B5/024;;A61M1/3666;;A61B5/6865;;A61B5/4839;;A61B5/091;;A61M2230/30;;A61M16/00;;A61M1/3639;;A61B5/02152;;A61B5/0295;;A61B5/486;;A61B5/6876;;A61B5/7225;;A61B5/7257;;A61B5/7278;;A61B5/746;;A61B2562/0247;;A61M5/1723;;A61M25/00;;A61M2025/0003;;A61M2205/3344;;A61M2230/06,A61B5/02;;A61B5/00;;A61B5/0215;;A61B5/024;;A61B5/0295;;A61B5/08;;A61B5/091;;A61M1/36;;A61M5/172;;A61M16/00;;A61M25/00,,10,1,059-259-977-142-971,24901895;;10.1088/0967-3334/35/7/1509,"European Search Report for related European Application No. PCT/US2018/065637; report dated Mar. 14, 2019; (17 pages).;;International Search Report for PCT/US2017/066689; mailed Apr. 06, 2018; (19 pp.).;;International Search Report and Written Opinion for related International Application No. PCT/US2018/040389; report dated Sep. 17, 2018; (16 pages).;;Aymen A Alian, et al.; “Impact of lower body negative pressure induced hypovolemia on peripheral venous pressure waveform parameters in healthy volunteers”; Institute of Physics and Engineering in Medicine; Physiol. Meas. 35; 2014; pp. 1509-1520; (13 pages).;;International Search Report for PCT/US2017/066689; dated Apr. 6, 2018; (19 pages).;;Preliminary Report on Patentability for related International Application No. PCT/US2018/040389; report dated Jan. 9, 2020; (9 pages).;;International Preliminary Report on Patentability for related international Application No. PCT/US2017/066689; action dated Jun. 18, 2019; (11 pages).;;International Preliminary Report on Patentability for related International Application No. PCT/US2018065637; report dated Jun. 16, 2020; (9 pages).;;Singapore Written Opinion for related Singapore Application No. 11201905459X; action dated Jun. 22, 2020; (5 pages).;;Japanese Office Action for related Japanese Application No. 2019-531946; action dated Sep. 25, 2020; (10 pages).",ACTIVE
493,BR,A2,BR 112019027925 A2,172-685-418-056-290,2020-07-14,2020,BR 112019027925 A,2018-06-29,US 2018/0040389 W;;US 201762527944 P;;US 201762528570 P;;US 201762599421 P;;US 201862671108 P;;US 201816023945 A,2017-06-30,sistemas a métodos para filtrar ruídos e analisar sinais de forma de onda venosa,"a presente invenção refere-se a dispositivos, sistemas e métodos para filtragem de artefatos de ruído de dispositivo médico a partir de sinais de forma de onda venosa. uma pressão venosa periférica (pvp) é medida e transformada do domínio de tempo para o domínio de frequência para análise que determina o status de paciente. para evitar artefatos do bombeamento, as medições de pvp em domínio de tempo são filtradas para gerar um sinal filtrado de pvp em domínio de tempo removendo-se os períodos de bombeamento ativo. o sinal filtrado de pvp em domínio de tempo é transformado em um sinal de pvp em domínio de frequência, o qual é analisado com base nos picos que indicam a taxa respiratória, o ritmo cardíaco ou a harmônica do mesmo. a métrica de status de paciente é então determinada a partir dos picos ou frequências correspondentes. o status de paciente pode ser relacionado com o volume de sangue do paciente e pode ser usado para controlar a operação da bomba.",BAXTER HEALTHCARE SA;;BAXTER INT,COLLEEN BROPHY;;FRANZ BAUDENBACHER;;JAMES MARTUCCI;;JONATHAN HANDLER;;KYLE HOCKING;;RICHARD BOYER;;SUSAN EAGLE,,https://lens.org/172-685-418-056-290,Patent Application,no,0,0,11,26,0,A61B5/6866;;A61B5/7217;;A61B5/02152;;A61B5/7278;;A61M2205/3576;;A61M2205/502;;A61M2205/52;;A61B5/7246;;A61B5/02405;;A61B5/02444;;A61B5/0816;;A61B5/112;;A61B5/4094;;A61B5/6824;;A61B5/7257;;G16H40/63;;G16H50/30;;G16H50/70;;G16H20/40;;A61B5/4839;;A61B5/725;;A61B5/7282;;A61B2562/0247;;A61M5/14232;;A61M5/1723;;A61M2205/3331;;A61M2230/30;;A61B5/7217;;A61B5/02152;;A61B5/02444;;A61B5/0816;;A61B5/112;;A61B5/6824;;A61B5/7257;;A61B5/7278;;A61M5/14232;;A61M5/1723;;G16H20/40;;G16H40/63;;G16H50/70;;A61B2562/0247;;A61B5/6866;;A61M2205/502;;A61M2205/52;;A61B5/02405;;A61B5/7246;;A61B5/02152;;A61M2205/3576;;A61B5/7278;;A61B5/0816;;A61B5/6824;;G16H20/40;;A61B5/7257;;A61B5/112;;A61B5/02444;;A61B5/7217;;G16H50/70;;A61B5/4094;;G16H50/30;;G16H40/63;;A61B5/0215;;A61B5/4839;;A61B5/7203;;A61B5/725;;A61B5/7282;;A61B2562/0247;;A61M5/14232;;A61M5/1723;;A61M2205/3331;;A61M2230/30,A61B5/0215;;A61B5/00,,0,0,,,,PENDING
494,EP,A1,EP 3357911 A1,152-321-108-353-342,2018-08-08,2018,EP 18158907 A,2007-06-26,US 81652206 P;;EP 15191470 A;;EP 11000872 A;;EP 10009965 A;;EP 07835890 A;;US 2007/0014832 W,2006-06-26,PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE,"The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.",AKEBIA THERAPEUTICS INC,KAWAMOTO RICHARD MASARU;;WARSHAKOON NAMAL CHITHRANGA;;WU SHENGDE;;BOYER ANGELIQUE SUN;;GREIS KENNETH DONALD,,https://lens.org/152-321-108-353-342,Patent Application,yes,2,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07D213/81;;A61K31/4418;;A61P35/00,,11,5,056-436-730-631-840;;034-760-425-242-511;;077-106-322-076-470;;011-101-678-202-709;;015-199-257-732-502,7852211;;10.1016/s0889-8588(18)30134-5;;10.1016/s0021-9258(17)31580-6;;8089148;;10.1182/blood.v77.3.419.bloodjournal773419;;10.1182/blood.v77.3.419.419;;1991159;;10.1016/s0074-7696(01)04002-5;;11243594;;10.1016/s0968-0004(97)01074-8;;9255066,"SEMENZA, G.L.: ""Regulation of erythropoietin production: New insights into molecular mechanisms of oxygen homeostasis"", HEMATOL. ONCOL. CLIN. NORTH AM., vol. 8, 1994, pages 863 - 884;;SEMENZA, G. L. ET AL.: ""Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1"", J. BIOL. CHEM., vol. 269, 1994, pages 23757 - 63, XP000578184;;KRANTZ, S. B.: ""Erythropoietin"", BLOOD, vol. 77, 1991, pages 419 - 434;;NGUYEN, L.L., INT. REV. CYTOL., vol. 204, 2001, pages 1 - 48;;BUSSOLINO, F., TRENDS BIOCHEM. SCI., vol. 22, 1997, pages 251 - 256;;FOLKMAN ET AL.: ""Tumor Angiogenesis"", pages: 206 - 32;;""The Molecular Basis of Cancer"", 1995;;WEIDNER, NEW ENG. J. MED., vol. 324, no. 1, 1991, pages 1 - 8;;O'REILLY ET AL., CELL, vol. 79, 1994, pages 315 - 28;;O'REILLY ET AL., CELL, vol. 88, 1997, pages 277 - 85;;TEISCHER ET AL., INT. J. CANCER, vol. 57, 1994, pages 920 - 25",ACTIVE
495,BR,A8,BR 112019012214 A8,174-365-817-964-819,2023-03-28,2023,BR 112019012214 A,2017-12-15,US 2017/0066689 W;;US 201662434768 P;;US 201662434796 P;;US 201662434849 P;;US 201762528794 P,2016-12-15,SISTEMA E MÉTODO PARA MONITORAR E DETERMINAR PARÂMETROS DO PACIENTE A PARTIR DE FORMA DE ONDA VENOSA DETECTADA,"A presente invenção refere-se a dispositivos, sistemas e métodos para monitorar estado hemodinâmico do paciente, resistência vascular sistêmica, reversão das taxas cardíacas e respiratórias, e volume respiratório do paciente ou esforço. Uma pressão venosa periférica é medida e usada para detectar níveis, mudanças, ou problemas referentes ao volume sanguíneo do paciente. A medição de pressão venosa periférica é transformada do domínio de tempo em domínio de frequência para análise. Uma frequência cardíaca é identificada, e harmônicas da frequência cardíaca são detectadas e avaliadas para determinar, entre outras coisas, hipovolemia ou hipervolemia, resistência vascular sistêmica, e de taxas cardíacas e respiratórias, e volume ou esforço respiratório do paciente.",BAXTER INT;;BAXTER HEALTHCARE SA,JONATHAN HANDLE;;JAMES MARTUCCI;;KYLE HOCKING;;SUSAN EAGLE;;COLLEEN BROPHY;;RICHARD BOYER;;FRANZ BAUDENBACHER,,https://lens.org/174-365-817-964-819,Patent Application,no,0,0,19,19,0,A61B5/6865;;A61B5/726;;A61B5/02007;;A61B5/024;;A61M1/3639;;A61M1/3666;;A61B5/0816;;A61B5/091;;A61M16/00;;A61B5/4839;;A61M2230/30;;A61B5/02152;;A61B5/7257;;A61M2205/3344;;A61M2230/06;;A61B5/02152;;A61B5/02007;;A61B5/024;;A61B5/0295;;A61B5/0816;;A61B5/091;;A61B5/4839;;A61B5/486;;A61B5/6876;;A61B5/7225;;A61B5/7257;;A61B5/7278;;A61B5/746;;A61M25/00;;A61M5/1723;;A61B2562/0247;;A61B5/0816;;A61B5/726;;A61B5/02007;;A61B5/024;;A61M1/3666;;A61B5/6865;;A61B5/4839;;A61B5/091;;A61M2230/30;;A61M16/00;;A61M1/3639;;A61B5/02152;;A61B5/0295;;A61B5/486;;A61B5/6876;;A61B5/7225;;A61B5/7257;;A61B5/7278;;A61B5/746;;A61B2562/0247;;A61M5/1723;;A61M25/00;;A61M2025/0003;;A61M2205/3344;;A61M2230/06,A61B5/0215;;A61B5/024;;A61B5/08;;A61B5/091,,0,0,,,,DISCONTINUED
496,US,A1,US 2015/0307530 A1,186-502-159-247-933,2015-10-29,2015,US 201314440043 A,2013-08-30,US 201314440043 A;;US 201261695686 P;;US 2013/0057588 W,2012-08-31,NOVEL MUCOLYTIC AGENTS,Provided is a method of liquefying mucus from mucosal surfaces by administering compounds containing a phosphine group.,JOHNSON MICHAEL R;;THELIN WILLIAM R;;BOUCHER RICHARD C;;VILLALON DIANE;;BOYER JOSE L;;PARION SCIENCES INC,JOHNSON MICHAEL R;;THELIN WILLIAM R;;BOUCHER RICHARD C;;VILLALON DIANE;;BOYER JONE L,PARION SCIENCES INC (2015-06-08),https://lens.org/186-502-159-247-933,Patent Application,yes,4,18,3,3,0,A61K31/66;;A61K31/663;;A61K9/0073;;A61P11/12;;Y02A50/30;;A61K31/66;;A61K9/0073;;A61K31/663;;C07F9/5004;;C07F9/5022,C07F9/50,,4,2,054-356-268-729-465;;026-763-542-671-036,10.1002/14651858.cd007168.pub3;;10.1002/14651858.cd007168.pub2;;19160327;;23852992;;pmc8078644;;10841796;;10.1021/jm9909600,"Burns et al, J. Org. Chem. 191, 56, 2648-2650.;;Jayaraman et al, The Journal of Clinical Investigations, February 2001, volume 107, Number 3.;;Nash et al, Cochrane Database Syst Rev. 2009;21(1):CD007168.;;Noszal et al, J. Med. Chem. 2000, 43, 2176-2182.",DISCONTINUED
497,AU,A1,AU 2017/377044 A1,116-196-999-411-757,2019-07-04,2019,AU 2017/377044 A,2017-12-15,US 201762528794 P;;US 201662434768 P;;US 201662434849 P;;US 201662434796 P;;US 2017/0066689 W,2016-12-15,System and method for monitoring and determining patient parameters from sensed venous waveform,"Devices, systems, and methods for monitoring patient hemodynamic status, systemic vascular resistance, reversal of cardiac and respiratory rates, and patient respiratory volume or effort are disclosed. A peripheral venous pressure is measured and used to detect levels, changes, or problems relating to patient blood volume. The peripheral venous pressure measurement is transformed from the time domain to the frequency domain for analysis. A heart rate frequency is identified, and harmonics of the heart rate frequency are detected and evaluated to determine, among other things, hypovolemia or hypervolemia, systemic vascular resistance, and cardiac and respiratory rates, and patient respiratory volume or effort.",BAXTER HEALTHCARE SA;;BAXTER INT,HANDLER JONATHAN;;MARTUCCI JAMES;;HOCKING KYLE;;EAGLE SUSAN;;BROPHY COLLEEN;;BOYER RICHARD;;BAUDENBACHER FRANZ,,https://lens.org/116-196-999-411-757,Patent Application,no,0,0,19,19,0,A61B5/6865;;A61B5/726;;A61B5/02007;;A61B5/024;;A61M1/3639;;A61M1/3666;;A61B5/0816;;A61B5/091;;A61M16/00;;A61B5/4839;;A61M2230/30;;A61B5/02152;;A61B5/7257;;A61M2205/3344;;A61M2230/06;;A61B5/02152;;A61B5/02007;;A61B5/024;;A61B5/0295;;A61B5/0816;;A61B5/091;;A61B5/4839;;A61B5/486;;A61B5/6876;;A61B5/7225;;A61B5/7257;;A61B5/7278;;A61B5/746;;A61M25/00;;A61M5/1723;;A61B2562/0247;;A61B5/0816;;A61B5/726;;A61B5/02007;;A61B5/024;;A61M1/3666;;A61B5/6865;;A61B5/4839;;A61B5/091;;A61M2230/30;;A61M16/00;;A61M1/3639;;A61B5/02152;;A61B5/0295;;A61B5/486;;A61B5/6876;;A61B5/7225;;A61B5/7257;;A61B5/7278;;A61B5/746;;A61B2562/0247;;A61M5/1723;;A61M25/00;;A61M2025/0003;;A61M2205/3344;;A61M2230/06,A61B5/0215;;A61B5/00;;A61B5/02;;A61B5/024;;A61B5/08;;A61B5/091;;A61M16/00,,0,0,,,,ACTIVE
498,CA,A1,CA 3068151 A1,131-236-026-794-955,2019-01-03,2019,CA 3068151 A,2018-06-29,US 201762527944 P;;US 201762599421 P;;US 201816023945 A;;US 2018/0040389 W,2017-06-30,SYSTEMS AND METHODS FOR FILTERING NOISE AND ANALYZING VENOUS WAVEFORM SIGNALS,"Devices, systems, and methods for filtering medical device noise artifacts from venous waveform signals are disclosed. A peripheral venous pressure (PVP) is measured and transformed from the time domain to the frequency domain for analysis to determine patient status. To avoid artifacts of the pumping, the time-domain PVP measurements are filtered to generate a filtered time-domain PVP signal by removing active pumping periods. The filtered time-domain PVP signal is transformed into a frequency-domain PVP signal, which is analyzed based upon peaks indicating respiratory rate, heart rate, or harmonics thereof. A metric of patient status is then determined from the peaks or corresponding frequencies. The patient status may be related to blood volume of the patient and may be used to control pump operation.",BAXTER INT;;BAXTER HEALTHCARE SA,HANDLER JONATHAN;;MARTUCCI JAMES;;HOCKING KYLE;;EAGLE SUSAN;;BROPHY COLLEEN;;BOYER RICHARD;;BAUDENBACHER FRANZ,,https://lens.org/131-236-026-794-955,Patent Application,no,0,0,1,26,0,,A61B5/00;;A61B5/0215,,0,0,,,,PENDING
499,WO,A3,WO 2008/145387 A3,143-826-152-597-544,2009-03-12,2009,EP 2008004327 W,2008-05-30,DE 102007025315 A,2007-05-31,CATALYST FOR THE SELECTIVE HYDROGENATION OF ACETYLENIC HYDROCARBONS AND METHOD FOR PRODUCING SAID CATALYST,"The invention relates to a method for producing a catalyst, in particular for the selective reduction of acetylenic compounds in hydrocarbon streams. According to said method: an impregnating solution is provided, said solution containing a mixture of water and at least one organic solvent that is miscible with water as the solvent, in which at least one active metal compound and preferably at least one promoter metal compound is dissolved; a support is provided; the support is impregnated with the impregnating solution; the impregnated support is calcined. Palladium is preferred as the active metal and silver as the promoter metal. The invention also relates to a catalyst obtained according to the method and to the preferred use of said catalyst for the selective hydrogenation of acetylenic compounds.",SUED CHEMIE AG;;UNGAR SYBILLE;;FISCHER RICHARD;;TRAUTWEIN ANDREAS;;BLANKENSHIP STEVE;;BOYER JENNIFER;;URBANCIC MICHAEL;;ROKICKI ANDRZEJ,UNGAR SYBILLE;;FISCHER RICHARD;;TRAUTWEIN ANDREAS;;BLANKENSHIP STEVE;;BOYER JENNIFER;;URBANCIC MICHAEL;;ROKICKI ANDRZEJ,,https://lens.org/143-826-152-597-544,Search Report,yes,6,0,11,11,0,B01J23/40;;B01J23/44;;B01J23/48;;B01J23/50;;B01J23/74;;B01J37/0203;;B01J37/0221;;B01J37/16;;C07C7/167;;C07C2521/04;;C07C2523/44;;C07C2523/56;;C10G45/40;;Y02P20/52;;B01J35/397;;B01J35/393;;B01J35/30;;B01J35/613;;B01J37/02;;B01J23/40;;B01J23/74;;C10G45/40;;B01J23/44;;C07C2521/04;;C10G45/40;;B01J23/48;;B01J37/16;;B01J37/0203;;B01J23/50;;B01J23/40;;B01J23/74;;C07C2523/56;;B01J37/0221;;C07C7/167;;C07C2523/44;;Y02P20/52;;B01J35/30;;B01J35/393;;B01J35/397;;B01J35/613,B01J37/02;;B01J23/40;;B01J23/48;;B01J23/74;;C10G45/40,,0,0,,,,PENDING
500,WO,A2,WO 2008/145387 A2,174-101-139-693-423,2008-12-04,2008,EP 2008004327 W,2008-05-30,DE 102007025315 A,2007-05-31,CATALYST FOR THE SELECTIVE HYDROGENATION OF ACETYLENIC HYDROCARBONS AND METHOD FOR PRODUCING SAID CATALYST,"The invention relates to a method for producing a catalyst, in particular for the selective reduction of acetylenic compounds in hydrocarbon streams. According to said method: an impregnating solution is provided, said solution containing a mixture of water and at least one organic solvent that is miscible with water as the solvent, in which at least one active metal compound and preferably at least one promoter metal compound is dissolved; a support is provided; the support is impregnated with the impregnating solution; the impregnated support is calcined. Palladium is preferred as the active metal and silver as the promoter metal. The invention also relates to a catalyst obtained according to the method and to the preferred use of said catalyst for the selective hydrogenation of acetylenic compounds.",SUED CHEMIE AG;;UNGAR SYBILLE;;FISCHER RICHARD;;TRAUTWEIN ANDREAS;;BLANKENSHIP STEVE;;BOYER JENNIFER;;URBANCIC MICHAEL;;ROKICKI ANDRZEJ,UNGAR SYBILLE;;FISCHER RICHARD;;TRAUTWEIN ANDREAS;;BLANKENSHIP STEVE;;BOYER JENNIFER;;URBANCIC MICHAEL;;ROKICKI ANDRZEJ,,https://lens.org/174-101-139-693-423,Patent Application,yes,0,4,11,11,0,B01J23/40;;B01J23/44;;B01J23/48;;B01J23/50;;B01J23/74;;B01J37/0203;;B01J37/0221;;B01J37/16;;C07C7/167;;C07C2521/04;;C07C2523/44;;C07C2523/56;;C10G45/40;;Y02P20/52;;B01J35/397;;B01J35/393;;B01J35/30;;B01J35/613;;B01J37/02;;B01J23/40;;B01J23/74;;C10G45/40;;B01J23/44;;C07C2521/04;;C10G45/40;;B01J23/48;;B01J37/16;;B01J37/0203;;B01J23/50;;B01J23/40;;B01J23/74;;C07C2523/56;;B01J37/0221;;C07C7/167;;C07C2523/44;;Y02P20/52;;B01J35/30;;B01J35/393;;B01J35/397;;B01J35/613,B01J37/02;;B01J23/40;;B01J23/44;;B01J23/48;;B01J23/50;;B01J23/74;;B01J35/00;;C07C7/167;;C10G45/40,,0,0,,,,PENDING
501,US,A1,US 2021/0267469 A1,184-315-249-592-013,2021-09-02,2021,US 202117325599 A,2021-05-20,US 202117325599 A;;US 201816109252 A;;US 201862671108 P,2018-05-14,SYSTEM AND METHOD FOR MONITORING AND DETERMINING PATIENT PARAMETERS FROM SENSED VENOUS WAVEFORM,"Devices, systems, and methods for monitoring patient hemodynamic status, systemic vascular resistance, reversal of cardiac and respiratory rates, and patient respiratory volume or effort are disclosed. A peripheral venous pressure is measured and used to detect levels, changes, or problems relating to patient blood volume. The peripheral venous pressure measurement is transformed from the time domain to the frequency domain for analysis. A heart rate frequency is identified, and harmonics of the heart rate frequency are detected and evaluated to determine, among other things, hypovolemia or hypervolemia, systemic vascular resistance, and of cardiac and respiratory rates, and patient respiratory volume or effort.",BAXTER INT;;BAXTER HEALTHCARE SA,HANDLER JONATHAN;;MARTUCCI JAMES;;HOCKING KYLE;;EAGLE SUSAN;;BROPHY COLLEEN;;BOYER RICHARD;;BAUDENBACHER FRANZ,BAXTER HEALTHCARE SA (2019-08-05);;BAXTER INTERNATIONAL INC (2019-08-05),https://lens.org/184-315-249-592-013,Patent Application,yes,0,0,3,26,0,A61B5/02152;;A61B5/02152;;A61B5/0205;;A61B5/024;;A61B5/029;;A61B5/029;;A61B5/0816;;A61B5/486;;A61B5/4875;;A61B5/4875;;A61B5/6852;;A61B5/6865;;A61B5/7235;;A61B5/7257;;A61B5/7257;;A61B5/7278;;A61B5/746;;A61B2562/0247;;A61M2025/0003,A61B5/0215;;A61B5/00;;A61B5/029,,0,0,,,,DISCONTINUED
502,EP,A1,EP 3026044 A1,009-054-918-259-798,2016-06-01,2016,EP 15191470 A,2007-06-26,US 81652206 P;;EP 11000872 A;;EP 10009965 A;;EP 07835890 A;;US 2007/0014832 W,2006-06-26,PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE,"The present invention provides a compound having the formula (I):
  
wherein R is selected from 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl; R 6  is hydrogen, methyl, or ethyl; or a pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the compound of formula (I) and one or more excipients. The compound is for use in methods for treating or preventing anemia, for treating anemia associated with kidney failure, for treating anemia associated with chemotherapy, for treating wounds, for regulating angiogenesis in a human, for vascularizing ischemic tissue in a human, for promoting the growth of skin graft replacements in a human, for promoting tissue repair in the context of guided tissue regeneration, and for treating or preventing cancer.",AKEBIA THERAPEUTICS INC,KAWAMOTO RICHARD MASARU;;WARSHAKOON NAMAL CHITHRANGA;;WU SHENGDE;;BOYER ANGELIQUE SUN;;GREIS KENNETH DONALD,"AKEBIA THERAPEUTICS, INC. (2018-01-24)",https://lens.org/009-054-918-259-798,Patent Application,yes,8,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07D213/81,,11,6,056-436-730-631-840;;034-760-425-242-511;;077-106-322-076-470;;011-101-678-202-709;;015-199-257-732-502;;003-330-211-576-597,7852211;;10.1016/s0889-8588(18)30134-5;;10.1016/s0021-9258(17)31580-6;;8089148;;10.1182/blood.v77.3.419.bloodjournal773419;;10.1182/blood.v77.3.419.419;;1991159;;10.1016/s0074-7696(01)04002-5;;11243594;;10.1016/s0968-0004(97)01074-8;;9255066;;16908149;;10.1016/j.bmcl.2006.08.026,"SEMENZA, G.L.: ""Regulation of erythropoietin production: New insights into molecular mechanisms of oxygen homeostasis"", HEMATOL. ONCOL. CLIN NORTH AM., vol. 8, 1994, pages 863 - 884;;SEMENZA, G. L. ET AL.: ""Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1"", J. BIOL. CHEM., vol. 269, 1994, pages 23757 - 63;;KRANTZ, S. B.: ""Erythropoietin"", BLOOD, vol. 77, 1991, pages 419 - 434;;NGUYEN, L.L., , INT. REV. CYTOL., vol. 204, 2001, pages 1 - 48;;BUSSOLINO, F., TRENDS BIOCHEM. SCI., vol. 22, 1997, pages 251 - 256;;FOLKMAN ET AL.: ""The Molecular Basis of Cancer"", 1995, W. B. SAUNDERS, article ""Tumor Angiogenesis"", pages: 206 - 32;;WEIDNER, NEW ENG. J. MED., vol. 324, no. 1, 1991, pages 1 - 8;;O'REILLY ET AL., CELL, vol. 79, 1994, pages 315 - 28;;O'REILLY ET AL., CELL, vol. 88, 1997, pages 277 - 85;;TEISCHER ET AL., INT. J. CANCER, vol. 57, 1994, pages 920 - 25;;WARSHAKOON ET AL.: ""Design and synthesis of substituted pyridine derivatives as HIF-lrt prolyl hydroxylase inhibitors"", BIOORG MED CHEM LETT., vol. 16, no. 21, 1 November 2006 (2006-11-01), pages 5616 - 5620, XP027966145",ACTIVE
503,EP,A2,EP 2155392 A2,066-401-029-462-420,2010-02-24,2010,EP 08758898 A,2008-05-30,EP 2008004327 W;;DE 102007025315 A,2007-05-31,METHOD FOR PRODUCING A CATALYST FOR THE SELECTIVE HYDROGENATION OF ACETYLENIC HYDROCARBONS,,SUED CHEMIE AG,UNGAR SYBILLE;;FISCHER RICHARD;;TRAUTWEIN ANDREAS;;BLANKENSHIP STEVE;;BOYER JENNIFER;;URBANCIC MICHAEL;;ROKICKI ANDRZEJ,SUED-CHEMIE IP GMBH & CO. KG (2012-08-15),https://lens.org/066-401-029-462-420,Patent Application,yes,0,0,11,11,0,B01J23/40;;B01J23/44;;B01J23/48;;B01J23/50;;B01J23/74;;B01J37/0203;;B01J37/0221;;B01J37/16;;C07C7/167;;C07C2521/04;;C07C2523/44;;C07C2523/56;;C10G45/40;;Y02P20/52;;B01J35/397;;B01J35/393;;B01J35/30;;B01J35/613;;B01J37/02;;B01J23/40;;B01J23/74;;C10G45/40;;B01J23/44;;C07C2521/04;;C10G45/40;;B01J23/48;;B01J37/16;;B01J37/0203;;B01J23/50;;B01J23/40;;B01J23/74;;C07C2523/56;;B01J37/0221;;C07C7/167;;C07C2523/44;;Y02P20/52;;B01J35/30;;B01J35/393;;B01J35/397;;B01J35/613,B01J37/02;;B01J23/40;;B01J23/44;;B01J23/48;;B01J23/50;;B01J23/74;;B01J35/00;;C07C7/167;;C10G45/40,,0,0,,,,DISCONTINUED
504,DK,T3,DK 3026044 T3,060-678-054-664-861,2019-02-18,2019,DK 15191470 T,2007-06-26,US 81652206 P;;EP 11000872 A,2006-06-26,PROLYLHYDROXYLASEINHIBITORER OG FREMGANGSMÅDER TIL BRUG,,AKEBIA THERAPEUTICS INC,KAWAMOTO RICHARD MASARU;;WU SHENGDE;;WARSHAKOON NAMAL CHITHRANGA;;BOYER ANGELIQUE SUN;;GREIS KENNETH DONALD,,https://lens.org/060-678-054-664-861,Granted Patent,no,0,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07D213/81,,0,0,,,,ACTIVE
505,CN,A,CN 110809429 A,095-341-176-523-799,2020-02-18,2020,CN 201880043655 A,2018-06-29,US 201762527944 P;;US 201762528570 P;;US 201762599421 P;;US 201862671108 P;;US 2018/0040389 W,2017-06-30,SYSTEMS AND METHODS FOR FILTERING NOISE AND ANALYZING VENOUS WAVEFORM SIGNALS,"Devices, systems, and methods for filtering medical device noise artifacts from venous waveform signals are disclosed. A peripheral venous pressure (PVP) is measured and transformed from the time domain to the frequency domain for analysis to determine patient status. To avoid artifacts of the pumping, the time-domain PVP measurements are filtered to generate a filtered time-domain PVP signal by removing active pumping periods. The filtered time-domain PVP signal is transformed into a frequency-domain PVP signal, which is analyzed based upon peaks indicating respiratory rate, heart rate, or harmonics thereof. A metric of patient status is then determined from the peaks or corresponding frequencies. The patient status may be related to blood volume of the patient and may be used to controlpump operation.",BAXTER INT;;BAXTER HEALTHCARE SA,HANDLER JONATHAN;;MARTUCCI JAMES;;HOCKING KYLE;;EAGLE SUSAN;;BROPHY COLLEEN;;BOYER RICHARD;;BAUDENBACHER FRANZ,,https://lens.org/095-341-176-523-799,Patent Application,no,4,0,11,26,0,A61B5/6866;;A61B5/7217;;A61B5/02152;;A61B5/7278;;A61M2205/3576;;A61M2205/502;;A61M2205/52;;A61B5/7246;;A61B5/02405;;A61B5/02444;;A61B5/0816;;A61B5/112;;A61B5/4094;;A61B5/6824;;A61B5/7257;;G16H40/63;;G16H50/30;;G16H50/70;;G16H20/40;;A61B5/4839;;A61B5/725;;A61B5/7282;;A61B2562/0247;;A61M5/14232;;A61M5/1723;;A61M2205/3331;;A61M2230/30;;A61B5/7217;;A61B5/02152;;A61B5/02444;;A61B5/0816;;A61B5/112;;A61B5/6824;;A61B5/7257;;A61B5/7278;;A61M5/14232;;A61M5/1723;;G16H20/40;;G16H40/63;;G16H50/70;;A61B2562/0247;;A61B5/6866;;A61M2205/502;;A61M2205/52;;A61B5/02405;;A61B5/7246;;A61B5/02152;;A61M2205/3576;;A61B5/7278;;A61B5/0816;;A61B5/6824;;G16H20/40;;A61B5/7257;;A61B5/112;;A61B5/02444;;A61B5/7217;;G16H50/70;;A61B5/4094;;G16H50/30;;G16H40/63;;A61B5/0215;;A61B5/4839;;A61B5/7203;;A61B5/725;;A61B5/7282;;A61B2562/0247;;A61M5/14232;;A61M5/1723;;A61M2205/3331;;A61M2230/30,A61B5/00;;A61B5/0215,,0,0,,,,DISCONTINUED
506,US,A,US 5157736 A,108-847-173-098-115,1992-10-20,1992,US 68817391 A,1991-04-19,US 68817391 A,1991-04-19,Apparatus and method for optical recognition of chemical graphics,"An apparatus and method for optical recognition of chemical graphics allows documents containing chemical structures to be optically scanned so that both the text and the chemical structures are recognized. The structures are converted directly into molecular structure files suitable for direct input into chemical databases, molecular modeling programs, image rendering programs and programs that perform real time manipulation of structures.",IBM,BOYER STEPHEN K;;CASEY RICHARD G;;MILLER ALEX M;;OUDOT BERNADETTE;;ZILLES KARL S,INTERNATIONAL BUSINESS MACHINES CORPORATION A CORP. OF NEW YORK (1991-07-20),https://lens.org/108-847-173-098-115,Granted Patent,yes,15,73,1,1,0,G16C20/70;;G16C20/80;;G06V30/422;;G16C20/80;;G16C20/70;;G06V30/422,G06K9/00,382/10;;382/21;;382/1;;364/496,3,1,153-550-196-630-439,10.1021/ci00037a009,"Article entitled Computational Perception and Recognition of Digitized Molecular Structures M. Leonor Contreras, et al., J. Chem. Inf. Comput. Sci., vol. 30, No. 3, 1990, pp. 302 307.;;Article entitled Syntactic definition and parsing of molecular formulae by P. G. Barker, The Computer Journal, (vol. 18, No. 4), 1974, pp. 355 359.;;Article entitled Chemical Symbol String Parser by J. Figueras from 1983 Chemical Society pp. 48 52.",EXPIRED
507,TR,T4,TR 201900548 T4,154-034-526-180-713,2019-02-21,2019,TR 201900548 T,2007-06-26,US 81652206 P,2006-06-26,Prolil hidroksilaz inhibitörleri ve kullanım yöntemleri.,"Mevcut buluş, formül (I) 'e sahip bir bileşik sunmakta olup: özelliği; R'nin, 2-florofenil, 3-florofenil, 4-florofenilden seçilmesi; R6'nın, hidrojen, metil veya etil olması; veya bunun farmasötik olarak kabul edilebilir bir tuzu olması, ve farmasötik bileşimlerinin formül (I) bileşiğini ve bir veya daha fazla yardımcı maddeyi içermesidir. Bileşik, anemiyi tedavi etme veya önleme için, böbrek yetmezliği ile ilişkili anemiyi tedavi etmek için, kemoterapi ile ilişkili anemiyi tedavi etmek için, yaraların tedavisi için, bir insandaki anjiyogenezin düzenlenmesi için, bir insandaki iskemik dokunun vaskülerize edilmesi için, bir insandaki cilt grefti replasmanlarının büyümesinin teşvik edilmesi için, güdümlü doku rejenerasyonu bağlamında doku onarımının teşvik edilmesi için ve kanser tedavisi için yöntemlerde kullanım için olmasıdır.",AKEBIA THERAPEUTICS INC,RICHARD MASARU KAWAMOTO;;NAMAL CHITHRANGA WARSHAKOON;;SHENGDE WU;;ANGELIQUE SUN BOYER;;KENNETH DONALD GREIS,,https://lens.org/154-034-526-180-713,Granted Patent,no,0,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07D213/81,,0,0,,,,ACTIVE
508,DK,T3,DK 3357911 T3,171-350-094-944-046,2022-07-04,2022,DK 18158907 T,2007-06-26,US 81652206 P;;EP 15191470 A,2006-06-26,PROLYLHYDROXYLASEINHIBITORER OG FREMGANGSMÅDER TIL ANVENDELSE,,AKEBIA THERAPEUTICS INC,KAWAMOTO RICHARD MASARU;;WARSHAKOON NAMAL CHITHRANGA;;WU SHENGDE;;BOYER ANGELIQUE SUN;;GREIS KENNETH DONALD,,https://lens.org/171-350-094-944-046,Granted Patent,no,0,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07D213/81;;A61K31/4418;;A61P35/00,,0,0,,,,ACTIVE
509,EP,B8,EP 3026044 B8,195-173-300-630-141,2018-12-19,2018,EP 15191470 A,2007-06-26,US 81652206 P;;EP 11000872 A;;EP 10009965 A;;EP 07835890 A;;US 2007/0014832 W,2006-06-26,PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE,,AKEBIA THERAPEUTICS INC,KAWAMOTO RICHARD MASARU;;WARSHAKOON NAMAL CHITHRANGA;;WU SHENGDE;;BOYER ANGELIQUE SUN;;GREIS KENNETH DONALD,"AKEBIA THERAPEUTICS, INC. (2018-01-24)",https://lens.org/195-173-300-630-141,Amended Patent,yes,2,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07D213/81,,0,0,,,,ACTIVE
510,US,A1,US 2019/0000326 A1,014-079-377-389-494,2019-01-03,2019,US 201816023945 A,2018-06-29,US 201816023945 A;;US 201762527944 P;;US 201762528570 P;;US 201762599421 P;;US 201862671108 P,2017-06-30,SYSTEMS AND METHODS FOR FILTERING NOISE AND ANALYZING VENOUS WAVEFORM SIGNALS,"Devices, systems, and methods for filtering medical device noise artifacts from venous waveform signals are disclosed. A peripheral venous pressure (PVP) is measured and transformed from the time domain to the frequency domain for analysis to determine patient status. To avoid artifacts of the pumping, the time-domain PVP measurements are filtered to generate a filtered time-domain PVP signal by removing active pumping periods. The filtered time-domain PVP signal is transformed into a frequency-domain PVP signal, which is analyzed based upon peaks indicating respiratory rate, heart rate, or harmonics thereof. A metric of patient status is then determined from the peaks or corresponding frequencies. The patient status may be related to blood volume of the patient and may be used to control pump operation.",BAXTER INT;;BAXTER HEALTHCARE SA,HANDLER JONATHAN;;MARTUCCI JAMES;;HOCKING KYLE;;EAGLE SUSAN;;BROPHY COLLEEN;;BOYER RICHARD;;BAUDENBACHER FRANZ,BAXTER HEALTHCARE SA (2017-12-14);;BAXTER INTERNATIONAL INC (2017-12-14),https://lens.org/014-079-377-389-494,Patent Application,yes,1,6,11,26,0,A61B5/6866;;A61B5/7217;;A61B5/02152;;A61B5/7278;;A61M2205/3576;;A61M2205/502;;A61M2205/52;;A61B5/7246;;A61B5/02405;;A61B5/02444;;A61B5/0816;;A61B5/112;;A61B5/4094;;A61B5/6824;;A61B5/7257;;G16H40/63;;G16H50/30;;G16H50/70;;G16H20/40;;A61B5/4839;;A61B5/725;;A61B5/7282;;A61B2562/0247;;A61M5/14232;;A61M5/1723;;A61M2205/3331;;A61M2230/30;;A61B5/7217;;A61B5/02152;;A61B5/02444;;A61B5/0816;;A61B5/112;;A61B5/6824;;A61B5/7257;;A61B5/7278;;A61M5/14232;;A61M5/1723;;G16H20/40;;G16H40/63;;G16H50/70;;A61B2562/0247;;A61B5/6866;;A61M2205/502;;A61M2205/52;;A61B5/02405;;A61B5/7246;;A61B5/02152;;A61M2205/3576;;A61B5/7278;;A61B5/0816;;A61B5/6824;;G16H20/40;;A61B5/7257;;A61B5/112;;A61B5/02444;;A61B5/7217;;G16H50/70;;A61B5/4094;;G16H50/30;;G16H40/63;;A61B5/0215;;A61B5/4839;;A61B5/7203;;A61B5/725;;A61B5/7282;;A61B2562/0247;;A61M5/14232;;A61M5/1723;;A61M2205/3331;;A61M2230/30,A61B5/0215;;A61B5/00;;A61M5/142;;A61M5/172,,0,0,,,,DISCONTINUED
511,TW,A,TW 200916189 A,080-433-112-042-877,2009-04-16,2009,TW 97119794 A,2008-05-29,DE 102007025315 A,2007-05-31,Catalyst for the selective hydrogenation of acetylenic hydrocarbons and process for producing it,"The invention relates to a process for producing a catalyst, in particular for the selective reduction of acetylenic compounds in hydrocarbon streams, wherein: an impregnation solution which contains a mixture of water and at least one water-miscible organic solvent as solvent in which at least one active metal compound and also preferably at least one promoter metal compound is dissolved is provided; a support is provided; the support is impregnated with the impregnation solution; the impregnated support is calcined. Palladium is preferably used as active metal and silver is preferably used as promoter metal. Furthermore, the invention relates to a catalyst as is obtained by the process and also its preferred use for the selective hydrogenation of acetylenic compounds.",SUED CHEMIE AG,UNGAR SYBILLE;;FISCHER RICHARD;;TRAUTWEIN ANDREAS;;BLANKENSHIP STEVE;;BOYER JENNIFER;;URBANCIC MICHAEL;;ROKICKI ANDRZEJ,,https://lens.org/080-433-112-042-877,Patent of Addition,no,0,0,11,11,0,B01J23/40;;B01J23/44;;B01J23/48;;B01J23/50;;B01J23/74;;B01J37/0203;;B01J37/0221;;B01J37/16;;C07C7/167;;C07C2521/04;;C07C2523/44;;C07C2523/56;;C10G45/40;;Y02P20/52;;B01J35/397;;B01J35/393;;B01J35/30;;B01J35/613;;B01J37/02;;B01J23/40;;B01J23/74;;C10G45/40;;B01J23/44;;C07C2521/04;;C10G45/40;;B01J23/48;;B01J37/16;;B01J37/0203;;B01J23/50;;B01J23/40;;B01J23/74;;C07C2523/56;;B01J37/0221;;C07C7/167;;C07C2523/44;;Y02P20/52;;B01J35/30;;B01J35/393;;B01J35/397;;B01J35/613,B01J23/44;;B01J23/48;;B01J35/10;;B01J37/02,,0,0,,,,PENDING
512,SI,T1,SI 3357911 T1,100-723-890-207-577,2022-10-28,2022,SI 200732190 T,2007-06-26,US 81652206 P;;EP 18158907 A,2006-06-26,PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE,,AKEBIA THERAPEUTICS INC,KAWAMOTO RICHARD MASARU;;WARSHAKOON NAMAL CHITHRANGA;;WU SHENGDE;;BOYER ANGELIQUE SUN;;GREIS KENNETH DONALD,,https://lens.org/100-723-890-207-577,Granted Patent,no,0,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07D213/00;;A61K31/00;;A61P35/00,,0,0,,,,ACTIVE
513,PT,E,PT 2044005 E,126-176-866-442-140,2010-12-17,2010,PT 07835890 T,2007-06-26,US 81652206 P,2006-06-26,PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE,,WARNER CHILCOTT CO LLC,WARSHAKOON NAMAL CHITHRANGA;;KAWAMOTO RICHARD MASARU;;WU SHENGDE;;BOYER ANGELIQUE SUN;;GREIS KENNETH DONALD,,https://lens.org/126-176-866-442-140,Granted Patent,no,0,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07C235/60;;C07C237/42;;C07C255/57;;C07D213/81,,0,0,,,,ACTIVE
514,MX,A,MX 2019015734 A,181-806-091-529-782,2020-11-06,2020,MX 2019015734 A,2018-06-29,US 201762527944 P;;US 201762528570 P;;US 201762599421 P;;US 201862671108 P;;US 201816023945 A;;US 2018/0040389 W,2017-06-30,SYSTEMS AND METHODS FOR FILTERING NOISE AND ANALYZING VENOUS WAVEFORM SIGNALS.,"Devices, systems, and methods for filtering medical device noise artifacts from venous waveform signals are disclosed. A peripheral venous pressure (PVP) is measured and transformed from the time domain to the frequency domain for analysis to determine patient status. To avoid artifacts of the pumping, the time-domain PVP measurements are filtered to generate a filtered time-domain PVP signal by removing active pumping periods. The filtered time-domain PVP signal is transformed into a frequency-domain PVP signal, which is analyzed based upon peaks indicating respiratory rate, heart rate, or harmonics thereof. A metric of patient status is then determined from the peaks or corresponding frequencies. The patient status may be related to blood volume of the patient and may be used to control pump operation.",BAXTER INT,BROPHY COLLEEN;;BOYER RICHARD;;BAUDENBACHER FRANZ;;EAGLE SUSAN;;HANDLER JONATHAN;;MARTUCCI JAMES;;HOCKING KYLE,,https://lens.org/181-806-091-529-782,Patent Application,no,0,0,11,26,0,A61B5/6866;;A61B5/7217;;A61B5/02152;;A61B5/7278;;A61M2205/3576;;A61M2205/502;;A61M2205/52;;A61B5/7246;;A61B5/02405;;A61B5/02444;;A61B5/0816;;A61B5/112;;A61B5/4094;;A61B5/6824;;A61B5/7257;;G16H40/63;;G16H50/30;;G16H50/70;;G16H20/40;;A61B5/4839;;A61B5/725;;A61B5/7282;;A61B2562/0247;;A61M5/14232;;A61M5/1723;;A61M2205/3331;;A61M2230/30;;A61B5/7217;;A61B5/02152;;A61B5/02444;;A61B5/0816;;A61B5/112;;A61B5/6824;;A61B5/7257;;A61B5/7278;;A61M5/14232;;A61M5/1723;;G16H20/40;;G16H40/63;;G16H50/70;;A61B2562/0247;;A61B5/6866;;A61M2205/502;;A61M2205/52;;A61B5/02405;;A61B5/7246;;A61B5/02152;;A61M2205/3576;;A61B5/7278;;A61B5/0816;;A61B5/6824;;G16H20/40;;A61B5/7257;;A61B5/112;;A61B5/02444;;A61B5/7217;;G16H50/70;;A61B5/4094;;G16H50/30;;G16H40/63;;A61B5/0215;;A61B5/4839;;A61B5/7203;;A61B5/725;;A61B5/7282;;A61B2562/0247;;A61M5/14232;;A61M5/1723;;A61M2205/3331;;A61M2230/30,A61B5/00;;A61B5/0215,,0,0,,,,PENDING
515,HK,A1,HK 1258159 A1,012-232-574-357-69X,2019-11-08,2019,HK 19100514 A,2019-01-14,US 81652206 P,2006-06-26,PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE,,AKEBIA THERAPEUTICS INC,KAWAMOTO RICHARD MASARU;;WARSHAKOON NAMAL CHITHRANGA;;WU SHENGDE;;BOYER ANGELIQUE SUN;;GREIS KENNETH DONALD,,https://lens.org/012-232-574-357-69X,Patent Application,no,0,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07D/;;A61K/;;A61P/,,0,0,,,,PENDING
516,MX,A,MX 2020006205 A,019-075-533-418-28X,2020-08-27,2020,MX 2020006205 A,2018-12-14,US 201762599421 P;;US 201862671108 P;;US 2018/0065637 W,2017-12-15,SYSTEMS AND METHODS FOR FILTERING MEDICAL DEVICE NOISE ARTIFACTS FROM VENOUS WAVEFORM SIGNALS.,"Devices, systems, and methods for filtering medical device noise artifacts from circulatory waveform signals are disclosed. A circulatory pressure is measured and transformed from the time domain to the frequency domain for analysis to determine patient status. To avoid artifacts of the pumping, the time-domain measurements are filtered to generate a filtered time-domain signal, by removing active pumping periods. The filtered time-domain signal is transformed into a frequency-domain signal, which is analyzed based upon peaks indicating respiratory rate, heart rate, or harmonics thereof. Peaks may be adjusted based on a ratio that considers removed signals. A metric of patient status is then determined from the peaks or corresponding frequencies. The patient status may be related to blood volume of the patient and may be used to control pump operation.",BAXTER INT,BOYER RICHARD;;BAUDENBACHER FRANZ;;BROPHY COLLEEN;;EAGLE SUSAN;;HANDLER JONATHAN;;MARTUCCI JAMES;;HOCKING KYLE,,https://lens.org/019-075-533-418-28X,Patent Application,no,0,0,11,26,0,A61B5/7217;;A61B5/7282;;A61B5/7278;;A61B5/02152;;A61B5/6866;;A61B5/02152;;A61B5/7217;;A61B5/02156;;A61B5/6866;;A61B5/725;;A61B5/7278;;A61M1/3639;;A61M1/3656;;A61M5/16854;;A61M5/1723;;A61M2205/3331;;A61M2230/30;;A61B5/02108;;A61B5/7275;;F04B43/12;;G16H20/17;;G16H40/60;;A61B5/02152;;A61B5/7203;;A61B5/725;;A61M2205/3331;;A61B2562/0247;;A61M5/14212;;A61M2230/30;;A61B5/6866;;A61B5/7278;;A61B5/7282;;A61B5/7217;;A61M5/142;;G16H40/63;;A61M5/16854;;A61B5/02141;;G16H40/60;;A61B5/7275;;G16H20/17;;G16H20/10;;A61M2005/16863;;A61B5/021;;F04B43/12;;A61M5/14232;;A61B5/02108,A61B5/00;;A61B5/0215;;A61M1/14,,0,0,,,,PENDING
517,KR,A,KR 20190094214 A,026-915-575-593-433,2019-08-12,2019,KR 20197019905 A,2017-12-15,US 201662434796 P;;US 201662434849 P;;US 201662434768 P;;US 201762528794 P;;US 2017/0066689 W,2016-12-15,감지된 정맥 파형으로부터 환자 파라미터들을 모니터링하고 결정하기 위한 시스템 및 방법,"환자의 혈류역학적 상태, 전신 혈관 저항, 심장박동수 및 호흡수의 역전, 및 환자의 호흡량 또는 호흡 노력을 모니터링하기 위한 디바이스들, 시스템들 및 방법들이 개시되어 있다. 말초 정맥압이 측정되어 환자 혈량에 관련된 레벨들, 변화들 또는 문제들을 검출하는데 이용된다. 말초 정맥압 측정치는 분석을 위해 시간 도메인으로부터 주파수 도메인으로 변환된다. 심박수 주파수가 식별되고, 심박수 주파수의 고조파들이 검출되고 평가되어, 특히 저혈량증 또는 고혈량증, 전신 혈관 저항, 및 심장박동수 및 호흡수, 및 환자의 호흡량 또는 호흡 노력을 결정한다.",BAXTER INT;;BAXTER HEALTHCARE SA,HANDLER JONATHAN;;MARTUCCI JAMES;;HOCKING KYLE;;EAGLE SUSAN;;BROPHY COLLEEN;;BOYER RICHARD;;BAUDENBACHER FRANZ,,https://lens.org/026-915-575-593-433,Patent Application,no,0,1,19,19,0,A61B5/6865;;A61B5/726;;A61B5/02007;;A61B5/024;;A61M1/3639;;A61M1/3666;;A61B5/0816;;A61B5/091;;A61M16/00;;A61B5/4839;;A61M2230/30;;A61B5/02152;;A61B5/7257;;A61M2205/3344;;A61M2230/06;;A61B5/02152;;A61B5/02007;;A61B5/024;;A61B5/0295;;A61B5/0816;;A61B5/091;;A61B5/4839;;A61B5/486;;A61B5/6876;;A61B5/7225;;A61B5/7257;;A61B5/7278;;A61B5/746;;A61M25/00;;A61M5/1723;;A61B2562/0247;;A61B5/0816;;A61B5/726;;A61B5/02007;;A61B5/024;;A61M1/3666;;A61B5/6865;;A61B5/4839;;A61B5/091;;A61M2230/30;;A61M16/00;;A61M1/3639;;A61B5/02152;;A61B5/0295;;A61B5/486;;A61B5/6876;;A61B5/7225;;A61B5/7257;;A61B5/7278;;A61B5/746;;A61B2562/0247;;A61M5/1723;;A61M25/00;;A61M2025/0003;;A61M2205/3344;;A61M2230/06,A61B5/0215;;A61B5/00;;A61B5/02;;A61B5/024;;A61B5/0295;;A61B5/08;;A61B5/091;;A61M5/172;;A61M25/00,,0,0,,,,ACTIVE
518,SG,A,SG 11201913638P A,062-759-066-198-279,2020-01-30,2020,SG 11201913638P A,2018-06-29,US 201762527944 P;;US 201762528570 P;;US 201762599421 P;;US 201862671108 P;;US 201816023945 A;;US 2018/0040389 W,2017-06-30,SYSTEMS AND METHODS FOR FILTERING NOISE AND ANALYZING VENOUS WAVEFORM SIGNALS,,BAXTER INT;;BAXTER HEALTHCARE SA,HANDLER JONATHAN;;MARTUCCI JAMES;;HOCKING KYLE;;EAGLE SUSAN;;BROPHY COLLEEN;;BOYER RICHARD;;BAUDENBACHER FRANZ,,https://lens.org/062-759-066-198-279,Unknown,no,0,0,11,26,0,A61B5/6866;;A61B5/7217;;A61B5/02152;;A61B5/7278;;A61M2205/3576;;A61M2205/502;;A61M2205/52;;A61B5/7246;;A61B5/02405;;A61B5/02444;;A61B5/0816;;A61B5/112;;A61B5/4094;;A61B5/6824;;A61B5/7257;;G16H40/63;;G16H50/30;;G16H50/70;;G16H20/40;;A61B5/4839;;A61B5/725;;A61B5/7282;;A61B2562/0247;;A61M5/14232;;A61M5/1723;;A61M2205/3331;;A61M2230/30;;A61B5/7217;;A61B5/02152;;A61B5/02444;;A61B5/0816;;A61B5/112;;A61B5/6824;;A61B5/7257;;A61B5/7278;;A61M5/14232;;A61M5/1723;;G16H20/40;;G16H40/63;;G16H50/70;;A61B2562/0247;;A61B5/6866;;A61M2205/502;;A61M2205/52;;A61B5/02405;;A61B5/7246;;A61B5/02152;;A61M2205/3576;;A61B5/7278;;A61B5/0816;;A61B5/6824;;G16H20/40;;A61B5/7257;;A61B5/112;;A61B5/02444;;A61B5/7217;;G16H50/70;;A61B5/4094;;G16H50/30;;G16H40/63;;A61B5/0215;;A61B5/4839;;A61B5/7203;;A61B5/725;;A61B5/7282;;A61B2562/0247;;A61M5/14232;;A61M5/1723;;A61M2205/3331;;A61M2230/30,A61B5/00;;A61B5/0215,,0,0,,,,PENDING
519,WO,A1,WO 2019/118822 A1,006-676-224-046-517,2019-06-20,2019,US 2018/0065637 W,2018-12-14,US 201762599421 P;;US 201862671108 P,2017-12-15,SYSTEMS AND METHODS FOR FILTERING MEDICAL DEVICE NOISE ARTIFACTS FROM VENOUS WAVEFORM SIGNALS,"Devices, systems, and methods for filtering medical device noise artifacts from circulatory waveform signals are disclosed. A circulatory pressure is measured and transformed from the time domain to the frequency domain for analysis to determine patient status. To avoid artifacts of the pumping, the time-domain measurements are filtered to generate a filtered time-domain signal, by removing active pumping periods. The filtered time-domain signal is transformed into a frequency-domain signal, which is analyzed based upon peaks indicating respiratory rate, heart rate, or harmonics thereof. Peaks may be adjusted based on a ratio that considers removed signals. A metric of patient status is then determined from the peaks or corresponding frequencies. The patient status may be related to blood volume of the patient and may be used to control pump operation.",BAXTER INT;;BAXTER HEALTHCARE SA,HANDLER JONATHAN;;MARTUCCI JAMES;;HOCKING KYLE;;EAGLE SUSAN;;BROPHY COLLEEN;;BOYER RICHARD;;BAUDENBACHER FRANZ,,https://lens.org/006-676-224-046-517,Patent Application,yes,7,0,11,26,0,A61B5/7217;;A61B5/7282;;A61B5/7278;;A61B5/02152;;A61B5/6866;;A61B5/02152;;A61B5/7217;;A61B5/02156;;A61B5/6866;;A61B5/725;;A61B5/7278;;A61M1/3639;;A61M1/3656;;A61M5/16854;;A61M5/1723;;A61M2205/3331;;A61M2230/30;;A61B5/02108;;A61B5/7275;;F04B43/12;;G16H20/17;;G16H40/60;;A61B5/02152;;A61B5/7203;;A61B5/725;;A61M2205/3331;;A61B2562/0247;;A61M5/14212;;A61M2230/30;;A61B5/6866;;A61B5/7278;;A61B5/7282;;A61B5/7217;;A61M5/142;;G16H40/63;;A61M5/16854;;A61B5/02141;;G16H40/60;;A61B5/7275;;G16H20/17;;G16H20/10;;A61M2005/16863;;A61B5/021;;F04B43/12;;A61M5/14232;;A61B5/02108,A61B5/0215;;A61B5/00;;A61M1/14,,0,0,,,,PENDING
520,EP,A1,EP 3554355 A1,039-219-310-772-076,2019-10-23,2019,EP 17826090 A,2017-12-15,US 201662434796 P;;US 201662434849 P;;US 201662434768 P;;US 201762528794 P;;US 2017/0066689 W,2016-12-15,SYSTEM AND METHOD FOR MONITORING AND DETERMINING PATIENT PARAMETERS FROM SENSED VENOUS WAVEFORM,,BAXTER INT;;BAXTER HEALTHCARE SA,HANDLER JONATHAN;;MARTUCCI JAMES;;HOCKING KYLE;;EAGLE SUSAN;;BROPHY COLLEEN;;BOYER RICHARD;;BAUDENBACHER FRANZ,,https://lens.org/039-219-310-772-076,Patent Application,yes,0,0,19,19,0,A61B5/6865;;A61B5/726;;A61B5/02007;;A61B5/024;;A61M1/3639;;A61M1/3666;;A61B5/0816;;A61B5/091;;A61M16/00;;A61B5/4839;;A61M2230/30;;A61B5/02152;;A61B5/7257;;A61M2205/3344;;A61M2230/06;;A61B5/02152;;A61B5/02007;;A61B5/024;;A61B5/0295;;A61B5/0816;;A61B5/091;;A61B5/4839;;A61B5/486;;A61B5/6876;;A61B5/7225;;A61B5/7257;;A61B5/7278;;A61B5/746;;A61M25/00;;A61M5/1723;;A61B2562/0247;;A61B5/0816;;A61B5/726;;A61B5/02007;;A61B5/024;;A61M1/3666;;A61B5/6865;;A61B5/4839;;A61B5/091;;A61M2230/30;;A61M16/00;;A61M1/3639;;A61B5/02152;;A61B5/0295;;A61B5/486;;A61B5/6876;;A61B5/7225;;A61B5/7257;;A61B5/7278;;A61B5/746;;A61B2562/0247;;A61M5/1723;;A61M25/00;;A61M2025/0003;;A61M2205/3344;;A61M2230/06,A61B5/0215;;A61B5/00;;A61B5/02;;A61B5/024;;A61B5/08;;A61B5/091;;A61M16/00,,0,0,,,,PENDING
521,WO,A3,WO 2014/036445 A3,046-857-220-086-208,2015-07-16,2015,US 2013/0057588 W,2013-08-30,US 201261695686 P,2012-08-31,NOVEL MUCOLYTIC AGENTS,"The present invention relates to mucolytic agents. The present invention also includes a variety of methods of treatment using these inventive mucolytic agents. Provided is a method of liquefying mucus from mucosal surfaces in a patient with excessive mucus or mucus with increased viscoelastic, cohesive, or adhesive properties by administering to said patient, a mucolytic compound containing a phosphine group to decrease mucus viscoelasticity through the reduction of mucin disulfide bonds.",PARION SCIENCES INC,JOHNSON MICHAEL R;;THELIN WILLIAM R;;BOUCHER RICHARD C;;VILLALON DIANE;;BOYER JOSE L,,https://lens.org/046-857-220-086-208,Search Report,yes,6,0,3,3,0,A61K31/66;;A61K31/663;;A61K9/0073;;A61P11/12;;Y02A50/30;;A61K31/66;;A61K9/0073;;A61K31/663;;C07F9/5004;;C07F9/5022,A61P11/12;;A61K31/66,,0,0,,,,PENDING
522,HK,A1,HK 1129369 A1,053-215-476-621-090,2009-11-27,2009,HK 09108318 A,2009-09-10,US 2007/0014832 W;;US 81652206 P,2006-06-26,PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE,,WARNER CHILCOTT CO LLC,KAWAMOTO RICHARD MASARU;;WARSHAKOON NAMAL CHITHRANGA;;WU SHENGDE;;BOYER ANGELIQUE SUN;;GREIS KENNETH DONALD,,https://lens.org/053-215-476-621-090,Patent Application,no,0,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07C/;;C07D/,,0,0,,,,DISCONTINUED
523,EP,A1,EP 3644837 A1,110-088-050-794-716,2020-05-06,2020,EP 18743344 A,2018-06-29,US 201762527944 P;;US 201762528570 P;;US 201762599421 P;;US 201862671108 P;;US 2018/0040389 W,2017-06-30,SYSTEMS AND METHODS FOR FILTERING NOISE AND ANALYZING VENOUS WAVEFORM SIGNALS,,BAXTER INT;;BAXTER HEALTHCARE SA,HANDLER JONATHAN;;MARTUCCI JAMES;;HOCKING KYLE;;EAGLE SUSAN;;BROPHY COLLEEN;;BOYER RICHARD;;BAUDENBACHER FRANZ,,https://lens.org/110-088-050-794-716,Patent Application,yes,0,0,11,26,0,A61B5/6866;;A61B5/7217;;A61B5/02152;;A61B5/7278;;A61M2205/3576;;A61M2205/502;;A61M2205/52;;A61B5/7246;;A61B5/02405;;A61B5/02444;;A61B5/0816;;A61B5/112;;A61B5/4094;;A61B5/6824;;A61B5/7257;;G16H40/63;;G16H50/30;;G16H50/70;;G16H20/40;;A61B5/4839;;A61B5/725;;A61B5/7282;;A61B2562/0247;;A61M5/14232;;A61M5/1723;;A61M2205/3331;;A61M2230/30;;A61B5/7217;;A61B5/02152;;A61B5/02444;;A61B5/0816;;A61B5/112;;A61B5/6824;;A61B5/7257;;A61B5/7278;;A61M5/14232;;A61M5/1723;;G16H20/40;;G16H40/63;;G16H50/70;;A61B2562/0247;;A61B5/6866;;A61M2205/502;;A61M2205/52;;A61B5/02405;;A61B5/7246;;A61B5/02152;;A61M2205/3576;;A61B5/7278;;A61B5/0816;;A61B5/6824;;G16H20/40;;A61B5/7257;;A61B5/112;;A61B5/02444;;A61B5/7217;;G16H50/70;;A61B5/4094;;G16H50/30;;G16H40/63;;A61B5/0215;;A61B5/4839;;A61B5/7203;;A61B5/725;;A61B5/7282;;A61B2562/0247;;A61M5/14232;;A61M5/1723;;A61M2205/3331;;A61M2230/30,A61B5/00;;A61B5/0215,,0,0,,,,PENDING
524,WO,A1,WO 2018/112354 A1,135-952-557-119-003,2018-06-21,2018,US 2017/0066689 W,2017-12-15,US 201662434796 P;;US 201662434849 P;;US 201662434768 P;;US 201762528794 P,2016-12-15,SYSTEM AND METHOD FOR MONITORING AND DETERMINING PATIENT PARAMETERS FROM SENSED VENOUS WAVEFORM,"Devices, systems, and methods for monitoring patient hemodynamic status, systemic vascular resistance, reversal of cardiac and respiratory rates, and patient respiratory volume or effort are disclosed. A peripheral venous pressure is measured and used to detect levels, changes, or problems relating to patient blood volume. The peripheral venous pressure measurement is transformed from the time domain to the frequency domain for analysis. A heart rate frequency is identified, and harmonics of the heart rate frequency are detected and evaluated to determine, among other things, hypovolemia or hypervolemia, systemic vascular resistance, and cardiac and respiratory rates, and patient respiratory volume or effort.",BAXTER INT;;BAXTER HEALTHCARE SA,HANDLER JONATHAN;;MARTUCCI JAMES;;HOCKING KYLE;;EAGLE SUSAN;;BROPHY COLLEEN;;BOYER RICHARD;;BAUDENBACHER FRANZ,,https://lens.org/135-952-557-119-003,Patent Application,yes,3,5,19,19,0,A61B5/6865;;A61B5/726;;A61B5/02007;;A61B5/024;;A61M1/3639;;A61M1/3666;;A61B5/0816;;A61B5/091;;A61M16/00;;A61B5/4839;;A61M2230/30;;A61B5/02152;;A61B5/7257;;A61M2205/3344;;A61M2230/06;;A61B5/02152;;A61B5/02007;;A61B5/024;;A61B5/0295;;A61B5/0816;;A61B5/091;;A61B5/4839;;A61B5/486;;A61B5/6876;;A61B5/7225;;A61B5/7257;;A61B5/7278;;A61B5/746;;A61M25/00;;A61M5/1723;;A61B2562/0247;;A61B5/0816;;A61B5/726;;A61B5/02007;;A61B5/024;;A61M1/3666;;A61B5/6865;;A61B5/4839;;A61B5/091;;A61M2230/30;;A61M16/00;;A61M1/3639;;A61B5/02152;;A61B5/0295;;A61B5/486;;A61B5/6876;;A61B5/7225;;A61B5/7257;;A61B5/7278;;A61B5/746;;A61B2562/0247;;A61M5/1723;;A61M25/00;;A61M2025/0003;;A61M2205/3344;;A61M2230/06,A61B5/0215;;A61B5/00;;A61B5/02;;A61B5/024;;A61B5/08;;A61B5/091;;A61M16/00,,0,0,,,,PENDING
525,US,B1,US 9991620 B1,129-987-185-182-820,2018-06-05,2018,US 201715604812 A,2017-05-25,US 201715604812 A,2017-05-25,Electrical cable connector,"An electrical connector assembly is presented herein. The electrical connector includes a pair of connector blocks each defining a groove in an end surface that is configured to have an electrical conductor of an electrical cable partially disposed within it, e.g. a carbon nanotube conductor. The electrical connector also includes a housing configured to receive connector blocks, align the groove of one connector block with the groove of the other connector block, and hold the connector blocks together such that the electrical conductors within the grooves are in direct physical and electrical contact with the one another and are compressed. An electrical cable assembly incorporating such as connector and an method of manufacturing a cable assembly using such a connector is also presented.",DELPHI TECH INC,BOYER RICHARD J;;HEFFRON JOHN F;;RUBINO EVANGELIA;;BRANTINGHAM DUANE L;;RICHMOND ZACHARY J,APTIV TECHNOLOGIES LIMITED (2018-01-01);;DELPHI TECHNOLOGIES INC (2017-05-22);;APTIV TECHNOLOGIES AG (2023-10-06),https://lens.org/129-987-185-182-820,Granted Patent,yes,4,5,2,2,0,H01R13/28;;H01R13/28;;H01R13/025;;H01R13/025;;H01R13/6272;;H01R13/6272,H01R13/64;;H01R13/28;;H01R13/627;;H01R43/20;;H01R43/26,,0,0,,,,ACTIVE
526,DK,T3,DK 2044005 T3,169-811-915-231-906,2011-01-24,2011,DK 07835890 T,2007-06-26,US 81652206 P;;US 2007/0014832 W,2006-06-26,Prolylhydroxylasehæmmere og fremgangsmåder til anvendelse af disse,,WARNER CHILCOTT CO LLC,WARSHAKOON NAMAL CHITHRANGA;;WU SHENGDE;;BOYER ANGELIQUE SUN;;GREIS KENNETH DONALD;;KAWAMOTO RICHARD MASARU,,https://lens.org/169-811-915-231-906,Granted Patent,no,0,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07C235/60;;C07C237/42;;C07C255/57;;C07D213/81,,0,0,,,,ACTIVE
527,CN,A,CN 101506149 A,030-009-456-294-086,2009-08-12,2009,CN 200780030720 A,2007-06-26,US 2007/0014832 W;;US 81652206 P,2006-06-26,Prolyl hydroxylase inhibitors and methods of use,"The present disclosure relates to HIF-1a prolyl hydroxylase inhibitors, compositions which comprise the HIF-1a prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.",PROCTER & GAMBLE,CHITHRANGA WARSHAKOON NAMAL;;MASARU KAWAMOTO RICHARD;;SHENGDE WU;;DONALD GREIS KENNETH;;SUN BOYER ANGELIQUE,"AKEBIA THERAPEUTICS INC. (2013-08-07);;WARNER CHILCOTT CO., LTD. (2010-11-01)",https://lens.org/030-009-456-294-086,Patent Application,no,0,31,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07C235/60;;C07C237/42;;C07C255/57;;C07D213/81,,0,0,,,,ACTIVE
528,BR,A2,BR 112019012214 A2,051-988-591-056-340,2019-11-12,2019,BR 112019012214 A,2017-12-15,US 2017/0066689 W;;US 201662434768 P;;US 201662434796 P;;US 201662434849 P;;US 201762528794 P,2016-12-15,sistema e método para monitorar e determinar parâmetros do paciente a partir de forma de onda venosa detectada,"a presente invenção refere-se a dispositivos, sistemas e métodos para monitorar estado hemodinâmico do paciente, resistência vascular sistêmica, reversão das taxas cardíacas e respiratórias, e volume respiratório do paciente ou esforço. uma pressão venosa periférica é medida e usada para detectar níveis, mudanças, ou problemas referentes ao volume sanguíneo do paciente. a medição de pressão venosa periférica é transformada do domínio de tempo em domínio de frequência para análise. uma frequência cardíaca é identificada, e harmônicas da frequência cardíaca são detectadas e avaliadas para determinar, entre outras coisas, hipovolemia ou hipervolemia, resistência vascular sistêmica, e de taxas cardíacas e respiratórias, e volume ou esforço respiratório do paciente.",BAXTER HEALTHCARE SA;;BAXTER INT,COLLEEN BROPHY;;FRANZ BAUDENBACHER;;JAMES MARTUCCI;;JONATHAN HANDLE;;KYLE HOCKING;;RICHARD BOYER;;SUSAN EAGLE,,https://lens.org/051-988-591-056-340,Patent Application,no,0,0,19,19,0,A61B5/6865;;A61B5/726;;A61B5/02007;;A61B5/024;;A61M1/3639;;A61M1/3666;;A61B5/0816;;A61B5/091;;A61M16/00;;A61B5/4839;;A61M2230/30;;A61B5/02152;;A61B5/7257;;A61M2205/3344;;A61M2230/06;;A61B5/02152;;A61B5/02007;;A61B5/024;;A61B5/0295;;A61B5/0816;;A61B5/091;;A61B5/4839;;A61B5/486;;A61B5/6876;;A61B5/7225;;A61B5/7257;;A61B5/7278;;A61B5/746;;A61M25/00;;A61M5/1723;;A61B2562/0247;;A61B5/0816;;A61B5/726;;A61B5/02007;;A61B5/024;;A61M1/3666;;A61B5/6865;;A61B5/4839;;A61B5/091;;A61M2230/30;;A61M16/00;;A61M1/3639;;A61B5/02152;;A61B5/0295;;A61B5/486;;A61B5/6876;;A61B5/7225;;A61B5/7257;;A61B5/7278;;A61B5/746;;A61B2562/0247;;A61M5/1723;;A61M25/00;;A61M2025/0003;;A61M2205/3344;;A61M2230/06,A61B5/02;;A61B5/00;;A61B5/0215;;A61B5/024;;A61B5/08;;A61B5/091;;A61M16/00,,0,0,,,,DISCONTINUED
529,CA,A1,CA 2298294 A1,134-783-776-075-10X,2001-03-16,2001,CA 2298294 A,2000-02-09,US 39753499 A,1999-09-16,BACK LIT FASCIA WITH SPRING LOADED FASCIA TENSIONER,"A sign frame assembly for supporting a flexible fascia. In one embodiment, a frame member extends in a first direction and has first and second bracket-mounting sections spaced apart from each other in the first direction. First and second brackets have inner and outer opposite ends. The inner end of the first bracket is attached to the first bracket-mounti ng section of the first frame member. The inner end of the second bracket are pivotally mounted to the second bracket-mounting section of the frame member. First and second elongated fascia attachment members are affixed respectively to the outer ends of the first and second brackets. A flexible fascia having oppositely disposed edges is connected to the first and second elongated members. A bias member is operatively disposed between the frame member and the second bracket such that the bias member exerts a rotational force on the second bracket in a direction tending to spread apart the elongated fascia attachment members and tension the flexible fascia therebetween. Additional embodiments utilizing biased pivotal fascia tension members are disclosed.",LSI INDUSTRIES INC,GRIMES RICHARD SCOTT;;WEDDING WILLIAM R;;GESSNER S FRANK;;BOYER JOHN;;MAKSTALLER RONALD W,,https://lens.org/134-783-776-075-10X,Patent Application,no,0,0,6,6,0,G09F17/00;;G09F17/00;;G09F13/04;;G09F13/04;;G09F15/0025;;G09F15/0025;;Y10T29/49716;;Y10T29/49716;;Y10T29/4984;;Y10T29/4984;;Y10T29/49863;;Y10T29/49863;;Y10T29/49867;;Y10T29/49867;;Y10T29/4987;;Y10T29/4987,G09F13/04;;G09F15/00;;G09F17/00,,0,0,,,,EXPIRED
530,BR,A2,BR 112020011612 A2,143-066-865-910-714,2020-12-08,2020,BR 112020011612 A,2018-12-14,US 2018/0065637 W;;US 201762599421 P;;US 201862671108 P,2017-12-15,sistemas e métodos para filtrar artefatos de ruído de um dispositivo médico de sinais de forma de onda venosa,"a presente invenção refere-se a dispositivos, sistemas e métodos para filtrar artefato de ruído de um dispositivo médico de sinais de forma de onda circulatória. uma pressão circulatória é medida e transformada do domínio de tempo ao domínio da frequência para que a análise determine a condição do paciente. para evitar artefatos do bombeamento, as medições do domínio do tempo são filtradas para gerar um sinal filtrado do domínio do tempo, mediante a remoção dos períodos de bombeamento ativos. o sinal filtrado do domínio do tempo é transformado em um sinal do domínio da frequência, o qual é analisado com base nos picos que indicam a taxa de respiração, a taxa de batimentos cardíacos, ou os seus harmônicos. os picos podem ser ajustados com base em uma razão que considera os sinais removidos. uma métrica da condição do paciente é determinada então a partir dos picos ou das frequências correspondentes. a condição do paciente pode ser relacionada ao volume do sangue do paciente e pode ser usada para controlar a operação da bomba.",BAXTER HEALTHCARE SA;;BAXTER INT,COLLEEN BROPHY;;FRANZ BAUDENBACHER;;JAMES MARTUCCI;;JONATHAN HANDLER;;KYLE HOCKING;;RICHARD BOYER;;SUSAN EAGLE,,https://lens.org/143-066-865-910-714,Patent Application,no,0,0,11,26,0,A61B5/7217;;A61B5/7282;;A61B5/7278;;A61B5/02152;;A61B5/6866;;A61B5/02152;;A61B5/7217;;A61B5/02156;;A61B5/6866;;A61B5/725;;A61B5/7278;;A61M1/3639;;A61M1/3656;;A61M5/16854;;A61M5/1723;;A61M2205/3331;;A61M2230/30;;A61B5/02108;;A61B5/7275;;F04B43/12;;G16H20/17;;G16H40/60;;A61B5/02152;;A61B5/7203;;A61B5/725;;A61M2205/3331;;A61B2562/0247;;A61M5/14212;;A61M2230/30;;A61B5/6866;;A61B5/7278;;A61B5/7282;;A61B5/7217;;A61M5/142;;G16H40/63;;A61M5/16854;;A61B5/02141;;G16H40/60;;A61B5/7275;;G16H20/17;;G16H20/10;;A61M2005/16863;;A61B5/021;;F04B43/12;;A61M5/14232;;A61B5/02108,A61B5/0215;;A61B5/00;;A61M1/14,,0,0,,,,DISCONTINUED
531,EP,A1,EP 2327696 A1,193-496-930-498-935,2011-06-01,2011,EP 11000872 A,2007-06-26,EP 10009965 A;;EP 07835890 A;;US 81652206 P,2006-06-26,Prolyl hydroxylase inhibitors and methods of use,"The present invention relates to compounds having formula I and a medicament containing them
  
",WARNER CHILCOTT CO LLC,KAWAMOTO RICHARD MASARU;;WARSHAKOON NAMAL CHITHRANGA;;WU SHENGDE;;BOYER ANGELIQUE SUN;;GREIS KENNETH DONALD,AKEBIA THERAPEUTICS INC. (2014-08-13),https://lens.org/193-496-930-498-935,Patent Application,yes,8,1,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07D213/81,,16,11,056-436-730-631-840;;034-760-425-242-511;;077-106-322-076-470;;011-101-678-202-709;;015-199-257-732-502;;003-330-211-576-597;;042-987-854-927-099;;007-834-259-097-311;;098-888-990-357-930;;018-052-265-551-042;;019-130-789-993-789,7852211;;10.1016/s0889-8588(18)30134-5;;10.1016/s0021-9258(17)31580-6;;8089148;;10.1182/blood.v77.3.419.bloodjournal773419;;10.1182/blood.v77.3.419.419;;1991159;;10.1016/s0074-7696(01)04002-5;;11243594;;10.1016/s0968-0004(97)01074-8;;9255066;;16908149;;10.1016/j.bmcl.2006.08.026;;10.1021/jm050444b;;16302822;;10.1021/jm050444b.s001;;10.1002/chem.200902455;;20397153;;10.1021/ja00383a030;;pmc1502536;;16782814;;10.1073/pnas.0601283103;;10.2210/pdb2g1m/pdb;;10.1351/pac199567081307,"SEMENZA, G.L.: ""Regulation of erythropoietin production: New insights into molecular mechanisms of oxygen homeostasis"", HEMATOL. ONCOL. CLILI. NORTH AM., vol. 8, 1994, pages 863 - 884;;SEMENZA, G. L. ET AL.: ""Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1"", J. BIOL. CHEM., vol. 269, 1994, pages 23757 - 63;;KRANTZ, S. B.: ""Erythropoietin"", BLOOD, vol. 77, 1991, pages 419 - 434;;NGUYEN, L.L., INT. REV. CYTOL., vol. 204, 2001, pages 1 - 48;;BUSSOLINO, F., TRENDS BIOCHEM. SCI., vol. 22, 1997, pages 251 - 256;;FOLKMAN ET AL.: ""The Molecular Basis of Cancer"", 1995, W. B. SAUNDERS, article ""Tumor Angiogenesis"", pages: 206 - 32;;WEIDNER, NEW ENG. J. MED., vol. 324, no. 1, 1991, pages 1 - 8;;O'REILLY ET AL., CELL, vol. 79, 1994, pages 315 - 28;;O'REILLY ET AL., CELL, vol. 88, 1997, pages 277 - 85;;TEISCHER ET AL., INT. J. CANCER, vol. 57, 1994, pages 920 - 25;;WARSHAKOON N C ET AL: ""DESIGN AND SYNTHESIS OF SUBSTITUTED PYRIDINE DERIVATIVES AS H IF-1ALPHA PROLYL HYDROXYLASEINHIBITORS"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 16, no. 21, 1 January 2006 (2006-01-01), pages 5616 - 5620;;IAN R HARDCASTLE ET AL: ""DISCOVERY OF POTENT CHROMEN-4-ONE INHIBITORS OF THE DNA-DEPENDENT PROTEIN KINASE(DNA-PK) USING A SMALL-MOLECULE LIBRARY APPROACH"", JOURNAL OF MEDICINAL CHEMISTRY, vol. 48, no. 24, December 2005 (2005-12-01), pages 7829 - 7846, XP055029942;;PIYAMONGKOL SIRIVIPA ET AL: ""AMIDO-3-HYDROXYPYRIDIN-4-ONES AS IRON(III)LIGANDS"", CHEMISTRY- AN EUROPEAN JOURNAL, vol. 16, no. 21, 1 June 2010 (2010-06-01), pages 6374 - 6381, XP055175031, DOI: 10.1002/CHEM.200902455;;HOEKSEMA H. ET AL: ""STRUCTURE OF RUBRADIRIN"", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 104, no. 19, September 1982 (1982-09-01), pages 5173 - 5181, XP055175033, DOI: 10.1021/JA00383A030;;MCDONOUGH MICHAEL A ET AL: ""CELLULAR OXYGEN SENSING: CRYSTAL STRUCTURE OF HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE (PHD2)"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES,, vol. 103, no. 26, 16 June 2006 (2006-06-16), pages 9814 - 9819, XP002432975;;MOSS G P ET AL: ""GLOSSARY OF CLASS NAMES OF ORGANIC COMPOUNDS AND REACTIVITY INTERMEDIATES BASED ON STRUCTURE (IUPAC RECOMMENDATIONS 1995)"", PURE & APPLIED CHEMISTRY, vol. 67, no. 8/9, 1 January 1995 (1995-01-01), PERGAMON PRESS, OXFORD, GB, pages 1307 - 1375, XP007914773, DOI: 10.1351/PAC199567081307",DISCONTINUED
532,KR,A,KR 20100041714 A,039-858-075-589-722,2010-04-22,2010,KR 20097027581 A,2008-05-30,DE 102007025315 A,2007-05-31,CATALYST FOR THE SELECTIVE HYDROGENATION OF ACETYLENIC HYDROCARBONS AND METHOD FOR PRODUCING SAID CATALYST,"The invention relates to a method for producing a catalyst, in particular for the selective reduction of acetylenic compounds in hydrocarbon streams. According to said method: an impregnating solution is provided, said solution containing a mixture of water and at least one organic solvent that is miscible with water as the solvent, in which at least one active metal compound and preferably at least one promoter metal compound is dissolved; a support is provided; the support is impregnated with the impregnating solution; the impregnated support is calcined. Palladium is preferred as the active metal and silver as the promoter metal. The invention also relates to a catalyst obtained according to the method and to the preferred use of said catalyst for the selective hydrogenation of acetylenic compounds.",SUED CHEMIE AG,UNGAR SYBILLE;;FISCHER RICHARD;;TRAUTWEIN ANDREAS;;BLANKENSHIP STEVE;;BOYER JENNIFER;;URBANCIC MICHAEL;;ROKICKI ANDRZEJ,,https://lens.org/039-858-075-589-722,Patent Application,no,0,1,11,11,0,B01J23/40;;B01J23/44;;B01J23/48;;B01J23/50;;B01J23/74;;B01J37/0203;;B01J37/0221;;B01J37/16;;C07C7/167;;C07C2521/04;;C07C2523/44;;C07C2523/56;;C10G45/40;;Y02P20/52;;B01J35/397;;B01J35/393;;B01J35/30;;B01J35/613;;B01J37/02;;B01J23/40;;B01J23/74;;C10G45/40;;B01J23/44;;C07C2521/04;;C10G45/40;;B01J23/48;;B01J37/16;;B01J37/0203;;B01J23/50;;B01J23/40;;B01J23/74;;C07C2523/56;;B01J37/0221;;C07C7/167;;C07C2523/44;;Y02P20/52;;B01J35/30;;B01J35/393;;B01J35/397;;B01J35/613,B01J37/02;;B01J23/40;;B01J23/74;;C10G45/40,,0,0,,,,DISCONTINUED
533,US,A,US 5345516 A,070-036-886-500-913,1994-09-06,1994,US 68900491 A,1991-04-19,US 68900491 A,1991-04-19,Apparatus and method for parsing a chemical string,"An apparatus and method for optical recognition of chemical graphics allows documents containing chemical structures to be optically scanned so that both the text and the chemical structures are recognized. The structures are converted directly into molecular structure files suitable for direct input into chemical databases, molecular modeling programs, image rendering programs and programs that perform real time manipulation of structures.",IBM,BOYER STEVEN K;;CASEY RICHARD G;;MILLER ALEX M;;OUDOT BERNADETTE;;ZILLES KARL S,INTERNATIONAL BUSINESS MACHINES CORPORATION A CORP. OF NEW YORK (1991-07-20),https://lens.org/070-036-886-500-913,Granted Patent,yes,17,36,1,1,0,G16C20/80;;G06V30/422;;G16C20/80;;G06V30/422,G06K9/00,382/10;;382/1;;382/36;;364/496,3,1,153-550-196-630-439,10.1021/ci00037a009,"Contreras, et al., Computational Perception and Recognition of Digitized Molecular Structures , J. Chem. Inf. Comput. Sci. , vol. 30, No. 3, 1990, pp. 302 307.;;Barker, Syntactic Definition and Parsing of Molecular Formulae , The Computer Journal , vol. 18, No. 4, 1974, pp. 355 359.;;Figueras, Chemical Symbol String Parser , J. Chemical Inf. Comput. Sci. , vol. 23, No. 1, 1983, pp. 48 52.",EXPIRED
534,PL,T3,PL 3026044 T3,081-861-051-325-853,2019-04-30,2019,PL 15191470 T,2007-06-26,US 81652206 P;;EP 15191470 A;;EP 11000872 A;;EP 10009965 A;;EP 07835890 A;;US 2007/0014832 W,2006-06-26,PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE,,AKEBIA THERAPEUTICS INC,KAWAMOTO RICHARD MASARU;;WARSHAKOON NAMAL CHITHRANGA;;WU SHENGDE;;BOYER ANGELIQUE SUN;;GREIS KENNETH DONALD,,https://lens.org/081-861-051-325-853,Patent Application,no,0,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07D213/81,,0,0,,,,PENDING
535,CO,A2,CO 2019007422 A2,097-416-809-982-634,2019-10-21,2019,CO 2019007422 A,2019-07-12,US 2017/0066689 W;;US 201662434796 P;;US 201662434849 P;;US 201662434768 P;;US 201762528794 P,2016-12-15,Sistema y método para monitorear y determinar los parámetros de los pacientes a partir de la forma de onda venosa detectada,"RESUMEN Se divulgan dispositivos, sistemas y métodos para el monitoreo del estado hemodinámico del paciente, la resistencia vascular sistémica, la reversión de la frecuencia cardíaca y respiratoria y el esfuerzo o volumen respiratorio del paciente. Se mide una presión venosa periférica y se usa para detectar niveles, cambios o problemas relacionados con el volumen sanguíneo del paciente. La medición de la presión venosa periférica se transforma del dominio del tiempo al dominio de la frecuencia para su análisis. Se identifica una frecuencia de ritmo cardíaco y se detectan y evalúan armónicos para determinar, entre otras cosas, hipovolemia o hipervolemia, resistencia vascular sistémica y frecuencias cardíacas y respiratorias y volumen o esfuerzo respiratorio del paciente.",BAXTER HEALTHCARE SA;;BAXTER INT,EAGLE SUSAN;;HANDLER JONATHAN;;MARTUCCI JAMES;;HOCKING KYLE;;BROPHY COLLEEN;;BOYER RICHARD;;BAUDENBACHER FRANZ,,https://lens.org/097-416-809-982-634,Patent Application,no,0,0,19,19,0,A61B5/6865;;A61B5/726;;A61B5/02007;;A61B5/024;;A61M1/3639;;A61M1/3666;;A61B5/0816;;A61B5/091;;A61M16/00;;A61B5/4839;;A61M2230/30;;A61B5/02152;;A61B5/7257;;A61M2205/3344;;A61M2230/06;;A61B5/02152;;A61B5/02007;;A61B5/024;;A61B5/0295;;A61B5/0816;;A61B5/091;;A61B5/4839;;A61B5/486;;A61B5/6876;;A61B5/7225;;A61B5/7257;;A61B5/7278;;A61B5/746;;A61M25/00;;A61M5/1723;;A61B2562/0247;;A61B5/0816;;A61B5/726;;A61B5/02007;;A61B5/024;;A61M1/3666;;A61B5/6865;;A61B5/4839;;A61B5/091;;A61M2230/30;;A61M16/00;;A61M1/3639;;A61B5/02152;;A61B5/0295;;A61B5/486;;A61B5/6876;;A61B5/7225;;A61B5/7257;;A61B5/7278;;A61B5/746;;A61B2562/0247;;A61M5/1723;;A61M25/00;;A61M2025/0003;;A61M2205/3344;;A61M2230/06,A61B5/0215;;A61B5/00;;A61B5/02;;A61B5/024;;A61B5/08;;A61B5/091;;A61M16/00,,0,0,,,,PENDING
536,US,A1,US 2019/0343408 A1,110-816-593-835-900,2019-11-14,2019,US 201816109252 A,2018-08-22,US 201816109252 A;;US 201862671108 P,2018-05-14,SYSTEM AND METHOD FOR MONITORING AND DETERMINING PATIENT PARAMETERS FROM SENSED VENOUS WAVEFORM,"Devices, systems, and methods for monitoring patient hemodynamic status, systemic vascular resistance, reversal of cardiac and respiratory rates, and patient respiratory volume or effort are disclosed. A peripheral venous pressure is measured and used to detect levels, changes, or problems relating to patient blood volume. The peripheral venous pressure measurement is transformed from the time domain to the frequency domain for analysis. A heart rate frequency is identified, and harmonics of the heart rate frequency are detected and evaluated to determine, among other things, hypovolemia or hypervolemia, systemic vascular resistance, and of cardiac and respiratory rates, and patient respiratory volume or effort.",BAXTER INT;;BAXTER HEALTHCARE SA,HANDLER JONATHAN;;MARTUCCI JAMES;;HOCKING KYLE;;EAGLE SUSAN;;BROPHY COLLEEN;;BOYER RICHARD;;BAUDENBACHER FRANZ,BAXTER HEALTHCARE SA (2019-08-05);;BAXTER INTERNATIONAL INC (2019-08-05),https://lens.org/110-816-593-835-900,Patent Application,yes,3,1,3,26,0,A61B5/02152;;A61B5/02152;;A61B5/0205;;A61B5/024;;A61B5/029;;A61B5/029;;A61B5/0816;;A61B5/486;;A61B5/4875;;A61B5/4875;;A61B5/6852;;A61B5/6865;;A61B5/7235;;A61B5/7257;;A61B5/7257;;A61B5/7278;;A61B5/746;;A61B2562/0247;;A61M2025/0003,A61B5/0215;;A61B5/00;;A61B5/029,,0,0,,,,ACTIVE
537,US,A1,US 2014/0156339 A1,109-095-892-441-546,2014-06-05,2014,US 201213692297 A,2012-12-03,US 201213692297 A,2012-12-03,OPERATIONAL RISK AND CONTROL ANALYSIS OF AN ORGANIZATION,"Systems and methods that facilitate operational risk and control analysis of an organization may include receiving a plurality of key risks and the plurality of key risks identify operational risks of an organization. A plurality of sets of data is received from a plurality of data providers, and the plurality of the sets of data comprise information associated with a plurality of business units in the organization. Each set of data is associated with a key risk, and the plurality of the sets of data is compiled based on the key risk. The compiled data is quantified, and quantifying the integrated data comprises weighting the compiled data according to the key risk. The quantified data is stored to facilitate risk analysis.",BANK OF AMERICA,BOYER CAROL A;;CORRADO STEPHEN A;;POTTLE PAULA E;;RAHIMI NOORUDDIN;;SIMPSON RICHARD WARREN,BANK OF AMERICA CORPORATION (2012-11-30),https://lens.org/109-095-892-441-546,Patent Application,yes,23,3,1,1,0,G06Q10/0635;;G06Q10/0635;;G06Q10/067;;G06Q10/067,G06Q10/06,705/7.28,0,0,,,,DISCONTINUED
538,KR,A,KR 20200101385 A,116-807-087-431-253,2020-08-27,2020,KR 20207019992 A,2018-12-14,US 201762599421 P;;US 201862671108 P;;US 2018/0065637 W,2017-12-15,정맥 파형 신호들로부터 의료 디바이스 노이즈 아티팩트들을 필터링하기 위한 시스템들 및 방법들,"순환 파형 신호들로부터의 의료 디바이스 노이즈 아티팩트들을 필터링하기 위한 디바이스들, 시스템들 및 방법들이 개시된다. 순환 압력이 측정되고 분석을 위해 시간 도메인으로부터 주파수 도메인으로 변환되어 환자 상태를 결정한다. 펌핑의 아티팩트들을 회피하기 위해, 시간-도메인 측정들은 필터링되어 활성 펌핑 기간을 제거하는 것에 의해, 필터링된 시간-도메인 신호를 생성한다. 필터링된 시간-도메인 신호는 주파수-도메인 신호로 변환되고, 이는 그 호흡수, 심박수, 또는 고조파들을 표시하는 피크들에 기초하여 분석된다. 피크들은 제거된 신호들을 고려하는 비율에 기초하여 조정될 수 있다. 그 후, 환자 상태의 메트릭은 피크들 또는 대응하는 주파수들로부터 결정된다. 환자 상태는 환자의 혈액량과 관련될 수 있고, 펌프 동작을 제어하기 위해 사용될 수 있다.",BAXTER INT;;BAXTER HEALTHCARE SA,HANDLER JONATHAN;;MARTUCCI JAMES;;HOCKING KYLE;;EAGLE SUSAN;;BROPHY COLLEEN;;BOYER RICHARD;;BAUDENBACHER FRANZ,,https://lens.org/116-807-087-431-253,Patent Application,no,0,0,11,26,0,A61B5/7217;;A61B5/7282;;A61B5/7278;;A61B5/02152;;A61B5/6866;;A61B5/02152;;A61B5/7217;;A61B5/02156;;A61B5/6866;;A61B5/725;;A61B5/7278;;A61M1/3639;;A61M1/3656;;A61M5/16854;;A61M5/1723;;A61M2205/3331;;A61M2230/30;;A61B5/02108;;A61B5/7275;;F04B43/12;;G16H20/17;;G16H40/60;;A61B5/02152;;A61B5/7203;;A61B5/725;;A61M2205/3331;;A61B2562/0247;;A61M5/14212;;A61M2230/30;;A61B5/6866;;A61B5/7278;;A61B5/7282;;A61B5/7217;;A61M5/142;;G16H40/63;;A61M5/16854;;A61B5/02141;;G16H40/60;;A61B5/7275;;G16H20/17;;G16H20/10;;A61M2005/16863;;A61B5/021;;F04B43/12;;A61M5/14232;;A61B5/02108,A61B5/0215;;A61B5/00;;A61M1/36;;A61M5/168;;A61M5/172,,0,0,,,,DISCONTINUED
539,US,A1,US 2019/0183362 A1,134-472-816-461-489,2019-06-20,2019,US 201816220618 A,2018-12-14,US 201816220618 A;;US 201762599421 P;;US 201862671108 P,2017-12-15,SYSTEMS AND METHODS FOR FILTERING MEDICAL DEVICE NOISE ARTIFACTS FROM VENOUS WAVEFORM SIGNALS,"Devices, systems, and methods for filtering medical device noise artifacts from circulatory waveform signals are disclosed. A circulatory pressure is measured and transformed from the time domain to the frequency domain for analysis to determine patient status. To avoid artifacts of the pumping, the time-domain measurements are filtered to generate a filtered time-domain signal, by removing active pumping periods. The filtered time-domain signal is transformed into a frequency-domain signal, which is analyzed based upon peaks indicating respiratory rate, heart rate, or harmonics thereof. Peaks may be adjusted based on a ratio that considers removed signals. A metric of patient status is then determined from the peaks or corresponding frequencies. The patient status may be related to blood volume of the patient and may be used to control pump operation.",BAXTER INT;;BAXTER HEALTHCARE SA,HANDLER JONATHAN;;MARTUCCI JAMES;;HOCKING KYLE;;EAGLE SUSAN;;BROPHY COLLEEN;;BOYER RICHARD;;BAUDENBACHER FRANZ,BAXTER HEALTHCARE SA (2018-07-03);;BAXTER INTERNATIONAL INC (2018-07-03),https://lens.org/134-472-816-461-489,Patent Application,yes,1,3,11,26,0,A61B5/7217;;A61B5/7282;;A61B5/7278;;A61B5/02152;;A61B5/6866;;A61B5/02152;;A61B5/7217;;A61B5/02156;;A61B5/6866;;A61B5/725;;A61B5/7278;;A61M1/3639;;A61M1/3656;;A61M5/16854;;A61M5/1723;;A61M2205/3331;;A61M2230/30;;A61B5/02108;;A61B5/7275;;F04B43/12;;G16H20/17;;G16H40/60;;A61B5/02152;;A61B5/7203;;A61B5/725;;A61M2205/3331;;A61B2562/0247;;A61M5/14212;;A61M2230/30;;A61B5/6866;;A61B5/7278;;A61B5/7282;;A61B5/7217;;A61M5/142;;G16H40/63;;A61M5/16854;;A61B5/02141;;G16H40/60;;A61B5/7275;;G16H20/17;;G16H20/10;;A61M2005/16863;;A61B5/021;;F04B43/12;;A61M5/14232;;A61B5/02108,A61B5/0215;;A61B5/00,,0,0,,,,DISCONTINUED
540,CA,A1,CA 3084143 A1,135-212-403-199-799,2019-06-20,2019,CA 3084143 A,2018-12-14,US 201762599421 P;;US 201862671108 P;;US 2018/0065637 W,2017-12-15,SYSTEMS AND METHODS FOR FILTERING MEDICAL DEVICE NOISE ARTIFACTS FROM VENOUS WAVEFORM SIGNALS,"Devices, systems, and methods for filtering medical device noise artifacts from circulatory waveform signals are disclosed. A circulatory pressure is measured and transformed from the time domain to the frequency domain for analysis to determine patient status. To avoid artifacts of the pumping, the time-domain measurements are filtered to generate a filtered time-domain signal, by removing active pumping periods. The filtered time-domain signal is transformed into a frequency-domain signal, which is analyzed based upon peaks indicating respiratory rate, heart rate, or harmonics thereof. Peaks may be adjusted based on a ratio that considers removed signals. A metric of patient status is then determined from the peaks or corresponding frequencies. The patient status may be related to blood volume of the patient and may be used to control pump operation.",BAXTER INT;;BAXTER HEALTHCARE SA,HANDLER JONATHAN;;MARTUCCI JAMES;;HOCKING KYLE;;EAGLE SUSAN;;BROPHY COLLEEN;;BOYER RICHARD;;BAUDENBACHER FRANZ,,https://lens.org/135-212-403-199-799,Patent Application,no,0,0,11,26,0,A61B5/7217;;A61B5/7282;;A61B5/7278;;A61B5/02152;;A61B5/6866;;A61B5/02152;;A61B5/7217;;A61B5/02156;;A61B5/6866;;A61B5/725;;A61B5/7278;;A61M1/3639;;A61M1/3656;;A61M5/16854;;A61M5/1723;;A61M2205/3331;;A61M2230/30;;A61B5/02108;;A61B5/7275;;F04B43/12;;G16H20/17;;G16H40/60;;A61B5/02152;;A61B5/7203;;A61B5/725;;A61M2205/3331;;A61B2562/0247;;A61M5/14212;;A61M2230/30;;A61B5/6866;;A61B5/7278;;A61B5/7282;;A61B5/7217;;A61M5/142;;G16H40/63;;A61M5/16854;;A61B5/02141;;G16H40/60;;A61B5/7275;;G16H20/17;;G16H20/10;;A61M2005/16863;;A61B5/021;;F04B43/12;;A61M5/14232;;A61B5/02108,A61B5/00;;A61B5/0215;;A61M1/14,,0,0,,,,PENDING
541,PL,T3,PL 2044005 T3,149-162-698-024-843,2011-04-29,2011,PL 07835890 T,2007-06-26,US 81652206 P;;EP 07835890 A;;US 2007/0014832 W,2006-06-26,PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE,,AKEBIA THERAPEUTICS INC,KAWAMOTO RICHARD MASARU;;WARSHAKOON NAMAL CHITHRANGA;;WU SHENGDE;;BOYER ANGELIQUE SUN;;GREIS KENNETH DONALD,,https://lens.org/149-162-698-024-843,Patent Application,no,0,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07C235/60;;C07C237/42;;C07C255/57;;C07D213/81,,0,0,,,,PENDING
542,EP,A1,EP 3323807 A1,008-674-646-070-908,2018-05-23,2018,EP 17201327 A,2007-06-26,US 81652206 P;;EP 15191470 A;;EP 11000872 A;;EP 10009965 A;;EP 07835890 A,2006-06-26,PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE,"The present invention provides a compound having the formula (I):
  
wherein R is selected from 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl; R 6  is hydrogen, methyl, or ethyl; or a pharmaceutically acceptable salt thereof. The compound is for use in methods for treating,  inter alia,  peripheral vascular disease, coronary artery disease or heart failure, for increasing blood flow, oxygen delivery or energy utilization in ischemic tissues, for controlling the proliferation and differentiation of erythroid progenitor cells into red blood cells, for alleviating the adverse consequences of hypertension or diabetes or for increasing stimulus of vasodilation, vascular permeability, or endothelial cell migration and proliferation.",AKEBIA THERAPEUTICS INC,KAWAMOTO RICHARD MASARU;;WARSHAKOON NAMAL CHITHRANGA;;WU SHENGDE;;BOYER ANGELIQUE SUN;;GREIS KENNETH DONALD,,https://lens.org/008-674-646-070-908,Patent Application,yes,2,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07D213/81;;A61K31/4418;;A61P35/00,,11,5,056-436-730-631-840;;034-760-425-242-511;;077-106-322-076-470;;011-101-678-202-709;;015-199-257-732-502,7852211;;10.1016/s0889-8588(18)30134-5;;10.1016/s0021-9258(17)31580-6;;8089148;;10.1182/blood.v77.3.419.bloodjournal773419;;10.1182/blood.v77.3.419.419;;1991159;;10.1016/s0074-7696(01)04002-5;;11243594;;10.1016/s0968-0004(97)01074-8;;9255066,"SEMENZA, G.L.: ""Regulation of erythropoietin production: New insights into molecular mechanisms of oxygen homeostasis"", HEMATOL. ONCOL. CLIN. NORTH AM., vol. 8, 1994, pages 863 - 884;;SEMENZA, G. L. ET AL.: ""Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1"", J. BIOL. CHEM., vol. 269, 1994, pages 23757 - 63, XP000578184;;KRANTZ, S. B.: ""Erythropoietin"", BLOOD, vol. 77, 1991, pages 419 - 434;;NGUYEN, L.L., INT. REV. CYTOL., vol. 204, 2001, pages 1 - 48;;BUSSOLINO, F., TRENDS BIOCHEM. SCI., vol. 22, 1997, pages 251 - 256;;FOLKMAN ET AL.: ""Tumor Angiogenesis"", pages: 206 - 32;;""The Molecular Basis of Cancer"", 1995, W. B. SAUNDERS;;WEIDNER, NEW ENG. J. MED., vol. 324, no. 1, 1991, pages 1 - 8;;O'REILLY ET AL., CELL, vol. 79, 1994, pages 315 - 28;;O'REILLY ET AL., CELL, vol. 88, 1997, pages 277 - 85;;TEISCHER ET AL., INT. J. CANCER, vol. 57, 1994, pages 920 - 25",DISCONTINUED
543,CN,A,CN 111479500 A,027-691-743-100-690,2020-07-31,2020,CN 201880080372 A,2018-12-14,US 201762599421 P;;US 201862671108 P;;US 2018/0065637 W,2017-12-15,Systems and methods for filtering medical device noise artifacts from venous waveform signals,"Devices, systems, and methods for filtering medical device noise artifacts from circulatory waveform signals are disclosed. A circulatory pressure is measured and transformed from the time domain to the frequency domain for analysis to determine patient status. To avoid artifacts of the pumping, the time-domain measurements are filtered to generate a filtered time-domain signal, by removing activepumping periods. The filtered time-domain signal is transformed into a frequency-domain signal, which is analyzed based upon peaks indicating respiratory rate, heart rate, or harmonics thereof. Peaksmay be adjusted based on a ratio that considers removed signals. A metric of patient status is then determined from the peaks or corresponding frequencies. The patient status may be related to bloodvolume of the patient and may be used to control pump operation.",BAXTER INT;;BAXTER HEALTHCARE SA,HANDLER JONATHAN;;MARTUCCI JAMES;;HOCKING KYLE;;EAGLE SUSAN;;BROPHY COLLEEN;;BOYER RICHARD;;BAUDENBACHER FRANZ,,https://lens.org/027-691-743-100-690,Patent Application,no,9,0,11,26,0,A61B5/7217;;A61B5/7282;;A61B5/7278;;A61B5/02152;;A61B5/6866;;A61B5/02152;;A61B5/7217;;A61B5/02156;;A61B5/6866;;A61B5/725;;A61B5/7278;;A61M1/3639;;A61M1/3656;;A61M5/16854;;A61M5/1723;;A61M2205/3331;;A61M2230/30;;A61B5/02108;;A61B5/7275;;F04B43/12;;G16H20/17;;G16H40/60;;A61B5/02152;;A61B5/7203;;A61B5/725;;A61M2205/3331;;A61B2562/0247;;A61M5/14212;;A61M2230/30;;A61B5/6866;;A61B5/7278;;A61B5/7282;;A61B5/7217;;A61M5/142;;G16H40/63;;A61M5/16854;;A61B5/02141;;G16H40/60;;A61B5/7275;;G16H20/17;;G16H20/10;;A61M2005/16863;;A61B5/021;;F04B43/12;;A61M5/14232;;A61B5/02108,A61B5/00;;A61B5/0215;;A61M1/14,,0,0,,,,DISCONTINUED
544,KR,A,KR 20200024855 A,039-088-510-128-894,2020-03-09,2020,KR 20207002412 A,2018-06-29,US 201762527944 P;;US 201762528570 P;;US 201762599421 P;;US 201862671108 P;;US 201816023945 A;;US 2018/0040389 W,2017-06-30,잡음을 필터링하고 정맥 파형 신호들을 분석하기 위한 시스템들 및 방법들,"정맥 파형 신호들로부터 의료 기기 잡음 아티팩트들을 필터링하는 기기, 시스템, 및 방법이 개시된다. 환자 상태를 결정하기 위한 분석을 위해 말초 정맥 압력(PVP)이 측정되고 시간 도메인으로부터 주파수 도메인으로 변환된다. 펌핑의 아티팩트들을 피하기 위해, 시간 도메인 PVP 측정들은 활성 펌핑 기간들을 제거함으로써 필터링된 시간 도메인 PVP 신호를 생성하도록 필터링된다. 필터링된 시간 도메인 PVP 신호는 주파수 도메인 PVP 신호로 변환되는데, 이는 호흡수, 심박수, 또는 그 고조파들을 나타내는 피크들에 기초하여 분석된다. 그 다음, 피크들 또는 대응하는 주파수들로부터 환자 상태의 메트릭이 결정된다. 환자 상태는 환자의 혈액량과 관련될 수 있고, 펌프 동작을 제어하기 위해 사용될 수 있다.",BAXTER INT;;BAXTER HEALTHCARE SA,HANDLER JONATHAN;;MARTUCCI JAMES;;HOCKING KYLE;;EAGLE SUSAN;;BROPHY COLLEEN;;BOYER RICHARD;;BAUDENBACHER FRANZ,,https://lens.org/039-088-510-128-894,Patent Application,no,0,0,11,26,0,A61B5/6866;;A61B5/7217;;A61B5/02152;;A61B5/7278;;A61M2205/3576;;A61M2205/502;;A61M2205/52;;A61B5/7246;;A61B5/02405;;A61B5/02444;;A61B5/0816;;A61B5/112;;A61B5/4094;;A61B5/6824;;A61B5/7257;;G16H40/63;;G16H50/30;;G16H50/70;;G16H20/40;;A61B5/4839;;A61B5/725;;A61B5/7282;;A61B2562/0247;;A61M5/14232;;A61M5/1723;;A61M2205/3331;;A61M2230/30;;A61B5/7217;;A61B5/02152;;A61B5/02444;;A61B5/0816;;A61B5/112;;A61B5/6824;;A61B5/7257;;A61B5/7278;;A61M5/14232;;A61M5/1723;;G16H20/40;;G16H40/63;;G16H50/70;;A61B2562/0247;;A61B5/6866;;A61M2205/502;;A61M2205/52;;A61B5/02405;;A61B5/7246;;A61B5/02152;;A61M2205/3576;;A61B5/7278;;A61B5/0816;;A61B5/6824;;G16H20/40;;A61B5/7257;;A61B5/112;;A61B5/02444;;A61B5/7217;;G16H50/70;;A61B5/4094;;G16H50/30;;G16H40/63;;A61B5/0215;;A61B5/4839;;A61B5/7203;;A61B5/725;;A61B5/7282;;A61B2562/0247;;A61M5/14232;;A61M5/1723;;A61M2205/3331;;A61M2230/30,A61B5/00;;A61B5/0215;;A61B5/024;;A61B5/08;;A61B5/11;;A61M5/142;;A61M5/172;;G16H20/40;;G16H40/63;;G16H50/70,,0,0,,,,ACTIVE
545,US,A1,US 2021/0267470 A1,057-031-043-930-399,2021-09-02,2021,US 202117325637 A,2021-05-20,US 202117325637 A;;US 201715843935 A;;US 201662434796 P;;US 201662434849 P;;US 201662434768 P;;US 201762528794 P,2016-12-15,SYSTEM AND METHOD FOR MONITORING AND DETERMINING PATIENT PARAMETERS FROM SENSED VENOUS WAVEFORM,"Devices, systems, and methods for monitoring patient hemodynamic status, systemic vascular resistance, reversal of cardiac and respiratory rates, and patient respiratory volume or effort are disclosed. A peripheral venous pressure is measured and used to detect levels, changes, or problems relating to patient blood volume. The peripheral venous pressure measurement is transformed from the time domain to the frequency domain for analysis. A heart rate frequency is identified, and harmonics of the heart rate frequency are detected and evaluated to determine, among other things, hypovolemia or hypervolemia, systemic vascular resistance, and of cardiac and respiratory rates, and patient respiratory volume or effort.",BAXTER INT;;BAXTER HEALTHCARE SA,HANDLER JONATHAN;;MARTUCCI JAMES;;HOCKING KYLE;;EAGLE SUSAN;;BROPHY COLLEEN;;BOYER RICHARD;;BAUDENBACHER FRANZ,BAXTER HEALTHCARE SA (2018-07-03);;BAXTER INTERNATIONAL INC (2018-07-03),https://lens.org/057-031-043-930-399,Patent Application,yes,0,0,19,19,0,A61B5/6865;;A61B5/726;;A61B5/02007;;A61B5/024;;A61M1/3639;;A61M1/3666;;A61B5/0816;;A61B5/091;;A61M16/00;;A61B5/4839;;A61M2230/30;;A61B5/02152;;A61B5/7257;;A61M2205/3344;;A61M2230/06;;A61B5/02152;;A61B5/02007;;A61B5/024;;A61B5/0295;;A61B5/0816;;A61B5/091;;A61B5/4839;;A61B5/486;;A61B5/6876;;A61B5/7225;;A61B5/7257;;A61B5/7278;;A61B5/746;;A61M25/00;;A61M5/1723;;A61B2562/0247;;A61B5/0816;;A61B5/726;;A61B5/02007;;A61B5/024;;A61M1/3666;;A61B5/6865;;A61B5/4839;;A61B5/091;;A61M2230/30;;A61M16/00;;A61M1/3639;;A61B5/02152;;A61B5/0295;;A61B5/486;;A61B5/6876;;A61B5/7225;;A61B5/7257;;A61B5/7278;;A61B5/746;;A61B2562/0247;;A61M5/1723;;A61M25/00;;A61M2025/0003;;A61M2205/3344;;A61M2230/06,A61B5/0215;;A61B5/00;;A61B5/02;;A61B5/024;;A61B5/0295;;A61B5/08;;A61B5/091;;A61M5/172;;A61M25/00,,0,0,,,,PENDING
546,SI,T1,SI 2044005 T1,114-262-975-681-138,2011-01-31,2011,SI 200730449 T,2007-06-26,US 81652206 P;;US 2007/0014832 W;;EP 07835890 A,2006-06-26,PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE,,WARNER CHILCOTT CO LLC,KAWAMOTO RICHARD MASARU;;WARSHAKOON NAMAL CHITHRANGA;;WU SHENGDE;;BOYER ANGELIQUE SUN;;GREIS KENNETH DONALD,,https://lens.org/114-262-975-681-138,Granted Patent,no,0,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07C235/00;;C07C237/00;;C07C255/00;;C07D213/00,,0,0,,,,ACTIVE
547,EP,B1,EP 3026044 B1,126-360-435-835-188,2018-11-07,2018,EP 15191470 A,2007-06-26,US 81652206 P;;EP 11000872 A;;EP 10009965 A;;EP 07835890 A;;US 2007/0014832 W,2006-06-26,PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE,,AKEBIA THERAPEUTICS INC,KAWAMOTO RICHARD MASARU;;WARSHAKOON NAMAL CHITHRANGA;;WU SHENGDE;;BOYER ANGELIQUE SUN;;GREIS KENNETH DONALD,"AKEBIA THERAPEUTICS, INC. (2018-01-24)",https://lens.org/126-360-435-835-188,Granted Patent,yes,2,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07D213/81,,0,0,,,,ACTIVE
548,CA,A1,CA 3047120 A1,154-809-625-391-728,2018-06-21,2018,CA 3047120 A,2017-12-15,US 201662434796 P;;US 201662434849 P;;US 201662434768 P;;US 201762528794 P;;US 2017/0066689 W,2016-12-15,SYSTEM AND METHOD FOR MONITORING AND DETERMINING PATIENT PARAMETERS FROM SENSED VENOUS WAVEFORM,"Devices, systems, and methods for monitoring patient hemodynamic status, systemic vascular resistance, reversal of cardiac and respiratory rates, and patient respiratory volume or effort are disclosed. A peripheral venous pressure is measured and used to detect levels, changes, or problems relating to patient blood volume. The peripheral venous pressure measurement is transformed from the time domain to the frequency domain for analysis. A heart rate frequency is identified, and harmonics of the heart rate frequency are detected and evaluated to determine, among other things, hypovolemia or hypervolemia, systemic vascular resistance, and cardiac and respiratory rates, and patient respiratory volume or effort.",BAXTER INT;;BAXTER HEALTHCARE SA,HANDLER JONATHAN;;MARTUCCI JAMES;;HOCKING KYLE;;EAGLE SUSAN;;BROPHY COLLEEN;;BOYER RICHARD;;BAUDENBACHER FRANZ,,https://lens.org/154-809-625-391-728,Patent Application,no,0,0,19,19,0,A61B5/6865;;A61B5/726;;A61B5/02007;;A61B5/024;;A61M1/3639;;A61M1/3666;;A61B5/0816;;A61B5/091;;A61M16/00;;A61B5/4839;;A61M2230/30;;A61B5/02152;;A61B5/7257;;A61M2205/3344;;A61M2230/06;;A61B5/02152;;A61B5/02007;;A61B5/024;;A61B5/0295;;A61B5/0816;;A61B5/091;;A61B5/4839;;A61B5/486;;A61B5/6876;;A61B5/7225;;A61B5/7257;;A61B5/7278;;A61B5/746;;A61M25/00;;A61M5/1723;;A61B2562/0247;;A61B5/0816;;A61B5/726;;A61B5/02007;;A61B5/024;;A61M1/3666;;A61B5/6865;;A61B5/4839;;A61B5/091;;A61M2230/30;;A61M16/00;;A61M1/3639;;A61B5/02152;;A61B5/0295;;A61B5/486;;A61B5/6876;;A61B5/7225;;A61B5/7257;;A61B5/7278;;A61B5/746;;A61B2562/0247;;A61M5/1723;;A61M25/00;;A61M2025/0003;;A61M2205/3344;;A61M2230/06,A61B5/0215;;A61B5/00;;A61B5/02;;A61B5/024;;A61B5/08;;A61B5/091;;A61M16/00,,0,0,,,,PENDING
549,PL,T3,PL 3357911 T3,019-720-357-136-361,2022-09-05,2022,PL 18158907 T,2007-06-26,US 81652206 P,2006-06-26,PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE,,AKEBIA THERAPEUTICS INC,KAWAMOTO RICHARD MASARU;;WARSHAKOON NAMAL CHITHRANGA;;WU SHENGDE;;BOYER ANGELIQUE SUN;;GREIS KENNETH DONALD,,https://lens.org/019-720-357-136-361,Patent Application,no,0,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07D213/81;;A61K31/4418;;A61P35/00,,0,0,,,,PENDING
550,CO,A2,CO 2020000673 A2,097-714-296-541-539,2020-04-24,2020,CO 2020000673 A,2020-01-22,US 2018/0040389 W;;US 201762527944 P;;US 201762528570 P;;US 201762599421 P;;US 201862671108 P;;US 201816023945 A,2017-06-30,Sistemas y métodos para filtrar el ruido y analizar señales de forma de onda venosa,"RESUMEN Se describen dispositivos, sistemas y métodos para filtrar artefactos de ruido de dispositivos médicos a partir de señales de forma de onda venosa. Se mide la presión venosa periférica (PVP) y se transforma del dominio del tiempo al dominio de la frecuencia para el análisis y determinar el estado del paciente. Para evitar artefactos del bombeo, las mediciones de PVP en el dominio del tiempo se filtran para generar una señal de PVP en el dominio del tiempo filtrada al eliminar los períodos de bombeo activos. La señal de PVP de dominio de tiempo filtrada se transforma en una señal de PVP de dominio de frecuencia, que se analiza con base en picos que indican frecuencia respiratoria, frecuencia cardíaca o armónicos de los mismos. Luego se determina una métrica del estado del paciente a partir de los picos o las frecuencias correspondientes. El estado del paciente puede estar relacionado con el volumen sanguíneo del paciente y puede usarse para controlar el funcionamiento de la bomba.",BAXTER INT;;BAXTER HEALTHCARE SA,EAGLE SUSAN;;HANDLER JONATHAN;;MARTUCCI JAMES;;HOCKING KYLE;;BROPHY COLLEEN;;BOYER RICHARD;;BAUDENBACHER FRANZ,,https://lens.org/097-714-296-541-539,Patent Application,no,0,0,11,26,0,A61B5/6866;;A61B5/7217;;A61B5/02152;;A61B5/7278;;A61M2205/3576;;A61M2205/502;;A61M2205/52;;A61B5/7246;;A61B5/02405;;A61B5/02444;;A61B5/0816;;A61B5/112;;A61B5/4094;;A61B5/6824;;A61B5/7257;;G16H40/63;;G16H50/30;;G16H50/70;;G16H20/40;;A61B5/4839;;A61B5/725;;A61B5/7282;;A61B2562/0247;;A61M5/14232;;A61M5/1723;;A61M2205/3331;;A61M2230/30;;A61B5/7217;;A61B5/02152;;A61B5/02444;;A61B5/0816;;A61B5/112;;A61B5/6824;;A61B5/7257;;A61B5/7278;;A61M5/14232;;A61M5/1723;;G16H20/40;;G16H40/63;;G16H50/70;;A61B2562/0247;;A61B5/6866;;A61M2205/502;;A61M2205/52;;A61B5/02405;;A61B5/7246;;A61B5/02152;;A61M2205/3576;;A61B5/7278;;A61B5/0816;;A61B5/6824;;G16H20/40;;A61B5/7257;;A61B5/112;;A61B5/02444;;A61B5/7217;;G16H50/70;;A61B5/4094;;G16H50/30;;G16H40/63;;A61B5/0215;;A61B5/4839;;A61B5/7203;;A61B5/725;;A61B5/7282;;A61B2562/0247;;A61M5/14232;;A61M5/1723;;A61M2205/3331;;A61M2230/30,A61B5/00;;A61B5/0215,,0,0,,,,PENDING
551,AU,A1,AU 2018/385617 A1,148-127-122-390-058,2020-07-16,2020,AU 2018/385617 A,2018-12-14,US 201862671108 P;;US 201762599421 P;;US 2018/0065637 W,2017-12-15,Systems and methods for filtering medical device noise artifacts from venous waveform signals,"Devices, systems, and methods for filtering medical device noise artifacts from circulatory waveform signals are disclosed. A circulatory pressure is measured and transformed from the time domain to the frequency domain for analysis to determine patient status. To avoid artifacts of the pumping, the time-domain measurements are filtered to generate a filtered time-domain signal, by removing active pumping periods. The filtered time-domain signal is transformed into a frequency-domain signal, which is analyzed based upon peaks indicating respiratory rate, heart rate, or harmonics thereof. Peaks may be adjusted based on a ratio that considers removed signals. A metric of patient status is then determined from the peaks or corresponding frequencies. The patient status may be related to blood volume of the patient and may be used to control pump operation.",BAXTER HEALTHCARE SA;;BAXTER INT,HANDLER JONATHAN;;MARTUCCI JAMES;;HOCKING KYLE;;EAGLE SUSAN;;BROPHY COLLEEN;;BOYER RICHARD;;BAUDENBACHER FRANZ,,https://lens.org/148-127-122-390-058,Patent Application,no,0,0,11,26,0,A61B5/7217;;A61B5/7282;;A61B5/7278;;A61B5/02152;;A61B5/6866;;A61B5/02152;;A61B5/7217;;A61B5/02156;;A61B5/6866;;A61B5/725;;A61B5/7278;;A61M1/3639;;A61M1/3656;;A61M5/16854;;A61M5/1723;;A61M2205/3331;;A61M2230/30;;A61B5/02108;;A61B5/7275;;F04B43/12;;G16H20/17;;G16H40/60;;A61B5/02152;;A61B5/7203;;A61B5/725;;A61M2205/3331;;A61B2562/0247;;A61M5/14212;;A61M2230/30;;A61B5/6866;;A61B5/7278;;A61B5/7282;;A61B5/7217;;A61M5/142;;G16H40/63;;A61M5/16854;;A61B5/02141;;G16H40/60;;A61B5/7275;;G16H20/17;;G16H20/10;;A61M2005/16863;;A61B5/021;;F04B43/12;;A61M5/14232;;A61B5/02108,A61B5/00;;A61B5/0215;;A61M1/14,,0,0,,,,DISCONTINUED
552,PT,T,PT 3026044 T,195-480-470-831-456,2019-01-23,2019,PT 15191470 T,2007-06-26,US 81652206 P,2006-06-26,PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE,,AKEBIA THERAPEUTICS INC,RICHARD MASARU KAWAMOTO;;NAMAL CHITHRANGA WARSHAKOON;;SHENGDE WU;;ANGELIQUE SUN BOYER;;KENNETH DONALD GREIS,,https://lens.org/195-480-470-831-456,Patent Application,no,0,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07D213/81,,0,0,,,,PENDING
553,US,A1,US 2018/0168467 A1,050-600-634-961-958,2018-06-21,2018,US 201715843935 A,2017-12-15,US 201715843935 A;;US 201662434796 P;;US 201662434849 P;;US 201662434768 P;;US 201762528794 P,2016-12-15,SYSTEM AND METHOD FOR MONITORING AND DETERMINING PATIENT PARAMETERS FROM SENSED VENOUS WAVEFORM,"Devices, systems, and methods for monitoring patient hemodynamic status, systemic vascular resistance, reversal of cardiac and respiratory rates, and patient respiratory volume or effort are disclosed. A peripheral venous pressure is measured and used to detect levels, changes, or problems relating to patient blood volume. The peripheral venous pressure measurement is transformed from the time domain to the frequency domain for analysis. A heart rate frequency is identified, and harmonics of the heart rate frequency are detected and evaluated to determine, among other things, hypovolemia or hypervolemia, systemic vascular resistance, and of cardiac and respiratory rates, and patient respiratory volume or effort.",BAXTER INT;;BAXTER HEALTHCARE SA,HANDLER JONATHAN;;MARTUCCI JAMES;;HOCKING KYLE;;EAGLE SUSAN;;BROPHY COLLEEN;;BOYER RICHARD;;BAUDENBACHER FRANZ,BAXTER HEALTHCARE SA (2018-07-03);;BAXTER INTERNATIONAL INC (2018-07-03),https://lens.org/050-600-634-961-958,Patent Application,yes,1,2,19,19,0,A61B5/6865;;A61B5/726;;A61B5/02007;;A61B5/024;;A61M1/3639;;A61M1/3666;;A61B5/0816;;A61B5/091;;A61M16/00;;A61B5/4839;;A61M2230/30;;A61B5/02152;;A61B5/7257;;A61M2205/3344;;A61M2230/06;;A61B5/02152;;A61B5/02007;;A61B5/024;;A61B5/0295;;A61B5/0816;;A61B5/091;;A61B5/4839;;A61B5/486;;A61B5/6876;;A61B5/7225;;A61B5/7257;;A61B5/7278;;A61B5/746;;A61M25/00;;A61M5/1723;;A61B2562/0247;;A61B5/0816;;A61B5/726;;A61B5/02007;;A61B5/024;;A61M1/3666;;A61B5/6865;;A61B5/4839;;A61B5/091;;A61M2230/30;;A61M16/00;;A61M1/3639;;A61B5/02152;;A61B5/0295;;A61B5/486;;A61B5/6876;;A61B5/7225;;A61B5/7257;;A61B5/7278;;A61B5/746;;A61B2562/0247;;A61M5/1723;;A61M25/00;;A61M2025/0003;;A61M2205/3344;;A61M2230/06,A61B5/0215;;A61B5/00;;A61B5/0295;;A61M5/172;;A61M25/00,,0,0,,,,ACTIVE
554,US,A1,US 2011/0201707 A1,049-423-280-892-747,2011-08-18,2011,US 200913125481 A,2009-11-09,US 200913125481 A;;US 11319508 P;;US 2009/0063731 W,2008-11-10,"ISOCYANATE TRIMERISATION CATALYST SYSTEM, A PRECURSOR FORMULATION, A PROCESS FOR TRIMERISING ISOCYANATES, RIGID POLYISOCYANURATE/POLYURETHANE FOAMS MADE THEREFROM, AND A PROCESS FOR MAKING SUCH FOAMS","The instant invention provides an isocyanate trimerisation catalyst system, a precursor formulation, a process for trimerising isocyanates, rigid foams made therefrom, and a process for making such foams. The trimerisation catalyst system comprises: (a) a phosphatrane cation; and (b) an isocyanate-trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73 C.",DOW GLOBAL TECHNOLOGIES LLC,ATHEY PHILLIP S;;WILMOT NATHAN;;KEATON RICHARD;;BABB DAVID A;;BOYER CECILE;;MORLEY TIMOTHY,DOW EURIPE GMBH (2011-11-22);;DOW GLOBAL TECHNOLOGIES LLC (2007-07-17);;THE DOW CHEMICAL COMPANY (2011-11-28),https://lens.org/049-423-280-892-747,Patent Application,yes,17,7,11,11,0,C08G18/022;;C08G18/022;;C08G18/092;;C08G18/092;;C08G18/166;;C08G18/168;;C08G18/168;;C08G18/1875;;C08G18/1875;;C08G2110/0025;;C08G2110/0025;;C08G2115/02;;C08G2115/02,C08J9/00;;C07F9/02,521/108;;568/12;;562/579,0,0,,,,DISCONTINUED
555,US,A1,US 2023/0238747 A1,070-744-778-914-681,2023-07-27,2023,US 202318097400 A,2023-01-16,US 202318097400 A;;US 202263301822 P;;US 202263343646 P,2022-01-21,INTERNAL EMC PROTECTION FOR SHIELD FOR PLASTIC HIGH VOLTAGE DISTRIBUTION CENTERS,"An electrical distribution center includes a housing formed of an electrically nonconductive material, an electromagnetic housing shield formed of an electrically conductive material disposed within a cavity in the housing, a cover enclosing the cavity having an electromagnetic cover shield formed of the electrically conductive material and in electrical contact with the housing shield, and a plurality of shielded electrical connectors interconnected to one another through electrical components contained within the cavity. The electrical components are mounted on a plurality of standoffs defined by an inner surface of the housing. The plurality of standoffs extends through a plurality of apertures defined in the housing shield.",APTIV TECH LTD,FERRUCIO MARCIO;;SILVA FERNANDO JOSE;;BOYER RICHARD J;;SPADONI STEVE;;BIZON DON;;BRANDON CHRISTOPHER,APTIV TECHNOLOGIES LIMITED (2023-01-06);;APTIV TECHNOLOGIES AG (2023-10-06),https://lens.org/070-744-778-914-681,Patent Application,yes,0,0,3,4,0,H05K9/0045;;H01R13/6588;;H01R13/659,H01R13/6588;;H01R13/659,,0,0,,,,PENDING
556,AU,B2,AU 2017/377044 B2,133-694-848-380-699,2023-01-05,2023,AU 2017/377044 A,2017-12-15,US 201762528794 P;;US 201662434768 P;;US 201662434849 P;;US 201662434796 P;;US 2017/0066689 W,2016-12-15,System and method for monitoring and determining patient parameters from sensed venous waveform,"Devices, systems, and methods for monitoring patient hemodynamic status, systemic vascular resistance, reversal of cardiac and respiratory rates, and patient respiratory volume or effort are disclosed. A peripheral venous pressure is measured and used to detect levels, changes, or problems relating to patient blood volume. The peripheral venous pressure measurement is transformed from the time domain to the frequency domain for analysis. A heart rate frequency is identified, and harmonics of the heart rate frequency are detected and evaluated to determine, among other things, hypovolemia or hypervolemia, systemic vascular resistance, and cardiac and respiratory rates, and patient respiratory volume or effort.",BAXTER HEALTHCARE SA;;BAXTER INT,HANDLER JONATHAN;;MARTUCCI JAMES;;HOCKING KYLE;;EAGLE SUSAN;;BROPHY COLLEEN;;BOYER RICHARD;;BAUDENBACHER FRANZ,,https://lens.org/133-694-848-380-699,Granted Patent,no,1,0,19,19,0,A61B5/6865;;A61B5/726;;A61B5/02007;;A61B5/024;;A61M1/3639;;A61M1/3666;;A61B5/0816;;A61B5/091;;A61M16/00;;A61B5/4839;;A61M2230/30;;A61B5/02152;;A61B5/7257;;A61M2205/3344;;A61M2230/06;;A61B5/02152;;A61B5/02007;;A61B5/024;;A61B5/0295;;A61B5/0816;;A61B5/091;;A61B5/4839;;A61B5/486;;A61B5/6876;;A61B5/7225;;A61B5/7257;;A61B5/7278;;A61B5/746;;A61M25/00;;A61M5/1723;;A61B2562/0247;;A61B5/0816;;A61B5/726;;A61B5/02007;;A61B5/024;;A61M1/3666;;A61B5/6865;;A61B5/4839;;A61B5/091;;A61M2230/30;;A61M16/00;;A61M1/3639;;A61B5/02152;;A61B5/0295;;A61B5/486;;A61B5/6876;;A61B5/7225;;A61B5/7257;;A61B5/7278;;A61B5/746;;A61B2562/0247;;A61M5/1723;;A61M25/00;;A61M2025/0003;;A61M2205/3344;;A61M2230/06,A61B5/0215;;A61B5/00;;A61B5/02;;A61B5/024;;A61B5/08;;A61B5/091;;A61M16/00,,0,0,,,,ACTIVE
557,ES,T3,ES 2705587 T3,144-869-423-027-102,2019-03-26,2019,ES 15191470 T,2007-06-26,US 81652206 P,2006-06-26,Inhibidores de prolil hidroxilasa y métodos de uso,"Un compuesto que tiene la fórmula (I):**Fórmula** en donde R se selecciona entre 2-fluorofenilo, 3-fluorofenilo, 4-fluorofenilo; R6 es hidrógeno, metilo o etilo; o una sal farmacéuticamente aceptable del mismo.",AKEBIA THERAPEUTICS INC,KAWAMOTO RICHARD MASARU;;WARSHAKOON NAMAL CHITHRANGA;;WU SHENGDE;;BOYER ANGELIQUE SUN;;GREIS KENNETH DONALD,,https://lens.org/144-869-423-027-102,Granted Patent,no,0,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07D213/81,,0,0,,,,ACTIVE
558,HK,A1,HK 1218548 A1,154-878-798-087-168,2017-02-24,2017,HK 16106587 A,2016-06-08,US 81652206 P,2006-06-26,PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE,,AKEBIA THERAPEUTICS INC,KAWAMOTO RICHARD MASARU;;WARSHAKOON NAMAL CHITHRANGA;;WU SHENGDE;;BOYER ANGELIQUE SUN;;GREIS KENNETH DONALD,,https://lens.org/154-878-798-087-168,Patent Application,no,0,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07D/,,0,0,,,,PENDING
559,CN,A,CN 101730588 A,166-001-515-799-38X,2010-06-09,2010,CN 200880018334 A,2008-05-30,EP 2008004327 W;;DE 102007025315 A,2007-05-31,Catalyst for the selective hydrogenation of acetylenic hydrocarbons and method for producing said catalyst,"The invention relates to a method for producing a catalyst, in particular for the selective reduction of acetylenic compounds in hydrocarbon streams. According to said method: an impregnating solution is provided, said solution containing a mixture of water and at least one organic solvent that is miscible with water as the solvent, in which at least one active metal compound and preferably at least one promoter metal compound is dissolved; a support is provided; the support is impregnated with the impregnating solution; the impregnated support is calcined. Palladium is preferred as the active metal and silver as the promoter metal. The invention also relates to a catalyst obtained according to the method and to the preferred use of said catalyst for the selective hydrogenation of acetylenic compounds.",SUED CHEMIE AG,SYBILLE UNGAR;;RICHARD FISCHER;;ANDREAS TRAUTWEIN;;STEVE BLANKENSHIP;;JENNIFER BOYER;;MICHAEL URBANCIC;;ANDRZEJ ROKICKI,SC INTELLECTUAL PROPERTY JOINT LTD. (2013-01-10),https://lens.org/166-001-515-799-38X,Patent Application,no,0,4,11,11,0,B01J23/40;;B01J23/44;;B01J23/48;;B01J23/50;;B01J23/74;;B01J37/0203;;B01J37/0221;;B01J37/16;;C07C7/167;;C07C2521/04;;C07C2523/44;;C07C2523/56;;C10G45/40;;Y02P20/52;;B01J35/397;;B01J35/393;;B01J35/30;;B01J35/613;;B01J37/02;;B01J23/40;;B01J23/74;;C10G45/40;;B01J23/44;;C07C2521/04;;C10G45/40;;B01J23/48;;B01J37/16;;B01J37/0203;;B01J23/50;;B01J23/40;;B01J23/74;;C07C2523/56;;B01J37/0221;;C07C7/167;;C07C2523/44;;Y02P20/52;;B01J35/30;;B01J35/393;;B01J35/397;;B01J35/613,B01J37/02;;B01J23/40;;B01J23/48;;B01J23/74,,0,0,,,,DISCONTINUED
560,DE,D1,DE 602007009992 D1,161-632-162-684-825,2010-12-02,2010,DE 602007009992 T,2007-06-26,US 81652206 P;;US 2007/0014832 W,2006-06-26,PROLYLHYDROXYLASE-HEMMER UND VERFAHREN ZU IHRER ANWENDUNG,,WARNER CHILCOTT CO LLC,KAWAMOTO RICHARD MASARU;;WARSHAKOON NAMAL CHITHRANGA;;WU SHENGDE;;BOYER ANGELIQUE SUN;;GREIS KENNETH DONALD,,https://lens.org/161-632-162-684-825,Granted Patent,no,0,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07C235/60;;C07C237/42;;C07C255/57;;C07D213/81,,0,0,,,,ACTIVE
561,JP,A,JP 2021112633 A,042-723-640-192-825,2021-08-05,2021,JP 2021075879 A,2021-04-28,JP 2019531946 A;;US 201662434796 P;;US 201662434849 P;;US 201662434768 P;;US 201762528794 P,2016-12-15,SYSTEM AND METHOD FOR MONITORING AND DETERMINING PATIENT PARAMETERS FROM SENSED VENOUS WAVEFORM,"To provide a system and method suitable for monitoring and determining patient parameters from a sensed venous waveform.SOLUTION: Devices, systems, and methods for monitoring a patient hemodynamic status, systemic vascular resistance, reversal of cardiac and respiratory rates, and patient respiratory volume or effort are disclosed. A peripheral venous pressure is measured and used to detect levels, changes, or problems relating to patient blood volume. The peripheral venous pressure measurement is transformed from the time domain to the frequency domain for analysis. A heart rate frequency is identified, and harmonics of the heart rate frequency are detected and evaluated to determine, among other things, hypovolemia or hypervolemia, systemic vascular resistance, and cardiac and respiratory rates, and patient respiratory volume or effort.SELECTED DRAWING: Figure 1",BAXTER INT;;BAXTER HEALTHCARE SA,JONATHAN HANDLER;;JAMES MARTUCCI;;KYLE HOCKING;;SUSAN EAGLE;;COLLEEN BROPHY;;RICHARD BOYER;;FRANZ BAUDENBACHER,,https://lens.org/042-723-640-192-825,Patent Application,no,5,0,19,19,0,A61B5/6865;;A61B5/726;;A61B5/02007;;A61B5/024;;A61M1/3639;;A61M1/3666;;A61B5/0816;;A61B5/091;;A61M16/00;;A61B5/4839;;A61M2230/30;;A61B5/02152;;A61B5/7257;;A61M2205/3344;;A61M2230/06;;A61B5/02152;;A61B5/02007;;A61B5/024;;A61B5/0295;;A61B5/0816;;A61B5/091;;A61B5/4839;;A61B5/486;;A61B5/6876;;A61B5/7225;;A61B5/7257;;A61B5/7278;;A61B5/746;;A61M25/00;;A61M5/1723;;A61B2562/0247;;A61B5/0816;;A61B5/726;;A61B5/02007;;A61B5/024;;A61M1/3666;;A61B5/6865;;A61B5/4839;;A61B5/091;;A61M2230/30;;A61M16/00;;A61M1/3639;;A61B5/02152;;A61B5/0295;;A61B5/486;;A61B5/6876;;A61B5/7225;;A61B5/7257;;A61B5/7278;;A61B5/746;;A61B2562/0247;;A61M5/1723;;A61M25/00;;A61M2025/0003;;A61M2205/3344;;A61M2230/06,A61B5/0245;;A61B5/027;;A61B5/08,,0,0,,,,PENDING
562,DE,A1,DE 102007025315 A1,171-341-214-919-917,2008-12-11,2008,DE 102007025315 A,2007-05-31,DE 102007025315 A,2007-05-31,Katalysator zur selektiven Hydrierung acetylenischer Kohlenwasserstoffe und Verfahren zu seiner Herstellung,"Die Erfindung betrifft ein Verfahren zur Herstellung eines Katalysators, insbesondere für die selektive Reduktion acetylenischer Verbindungen in Kohlenwasserstoffströmen, wobei: - eine Imprägnierlösung bereitgestellt wird, welche als Lösungsmittel ein Gemisch aus Wasser und zumindest einem mit Wasser mischbaren organischen Lösungsmittel enthält, in welchem zumindest eine Aktivmetallverbindung sowie vorzugsweise zumindest eine Promotormetallverbindung gelöst ist; - ein Träger bereitgestellt wird; - der Träger mit der Imprägnierlösung imprägniert wird; - der imprägnierte Träger kalziniert wird. Als Aktivmetall wird bevorzugt Palladium und als Promotormetall bevorzugt Silber verwendet. Ferner betrifft die Erfindung einen Katalysator, wie er mit dem Verfahren erhalten wird, sowie dessen bevorzugte Verwendung zur selektiven Hydrierung acetylenischer Verbindungen.",SUED CHEMIE AG,UNGAR SYBILLE;;FISCHER RICHARD;;TRAUTWEIN ANDREAS;;BLANKENSHIP STEVE;;BOYER JENNIFER;;URBANCIC MICHAEL;;ROKICKI ANDRZEJ,"SUED-CHEMIE IP GMBH & CO. KG, DE (2012-10-25)",https://lens.org/171-341-214-919-917,Patent Application,no,4,0,11,11,0,B01J23/40;;B01J23/44;;B01J23/48;;B01J23/50;;B01J23/74;;B01J37/0203;;B01J37/0221;;B01J37/16;;C07C7/167;;C07C2521/04;;C07C2523/44;;C07C2523/56;;C10G45/40;;Y02P20/52;;B01J35/397;;B01J35/393;;B01J35/30;;B01J35/613;;B01J37/02;;B01J23/40;;B01J23/74;;C10G45/40;;B01J23/44;;C07C2521/04;;C10G45/40;;B01J23/48;;B01J37/16;;B01J37/0203;;B01J23/50;;B01J23/40;;B01J23/74;;C07C2523/56;;B01J37/0221;;C07C7/167;;C07C2523/44;;Y02P20/52;;B01J35/30;;B01J35/393;;B01J35/397;;B01J35/613,B01J23/38;;B01J35/10;;B01J37/02,,2,0,,,"DIN 66131;;J. Am. Chem. Soc. 60, 309 (1938)",DISCONTINUED
563,SG,A,SG 11202005111Y A,021-430-399-379-069,2020-06-29,2020,SG 11202005111Y A,2018-12-14,US 201762599421 P;;US 201862671108 P;;US 2018/0065637 W,2017-12-15,SYSTEMS AND METHODS FOR FILTERING MEDICAL DEVICE NOISE ARTIFACTS FROM VENOUS WAVEFORM SIGNALS,,BAXTER INT;;BAXTER HEALTHCARE SA,HANDLER JONATHAN;;MARTUCCI JAMES;;HOCKING KYLE;;EAGLE SUSAN;;BROPHY COLLEEN;;BOYER RICHARD;;BAUDENBACHER FRANZ,,https://lens.org/021-430-399-379-069,Unknown,no,0,0,11,26,0,A61B5/7217;;A61B5/7282;;A61B5/7278;;A61B5/02152;;A61B5/6866;;A61B5/02152;;A61B5/7217;;A61B5/02156;;A61B5/6866;;A61B5/725;;A61B5/7278;;A61M1/3639;;A61M1/3656;;A61M5/16854;;A61M5/1723;;A61M2205/3331;;A61M2230/30;;A61B5/02108;;A61B5/7275;;F04B43/12;;G16H20/17;;G16H40/60;;A61B5/02152;;A61B5/7203;;A61B5/725;;A61M2205/3331;;A61B2562/0247;;A61M5/14212;;A61M2230/30;;A61B5/6866;;A61B5/7278;;A61B5/7282;;A61B5/7217;;A61M5/142;;G16H40/63;;A61M5/16854;;A61B5/02141;;G16H40/60;;A61B5/7275;;G16H20/17;;G16H20/10;;A61M2005/16863;;A61B5/021;;F04B43/12;;A61M5/14232;;A61B5/02108,A61B5/00;;A61B5/0215;;A61M1/14,,0,0,,,,PENDING
564,EP,A1,EP 4095127 A1,044-815-456-086-513,2022-11-30,2022,EP 22172062 A,2007-06-26,US 81652206 P;;EP 18158907 A;;EP 15191470 A;;EP 11000872 A;;EP 10009965 A;;EP 07835890 A;;US 2007/0014832 W,2006-06-26,PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE,"The present disclosure relates to HIF-lα prolyl hydroxylase inhibitors, compositions which comprise the HIF-lα prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.",AKEBIA THERAPEUTICS INC,KAWAMOTO RICHARD MASARU;;WARSHAKOON NAMAL CHITHRANGA;;WU SHENGDE;;BOYER ANGELIQUE SUN;;GREIS KENNETH DONALD,,https://lens.org/044-815-456-086-513,Patent Application,yes,2,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07D213/81,,10,5,056-436-730-631-840;;034-760-425-242-511;;077-106-322-076-470;;011-101-678-202-709;;015-199-257-732-502,7852211;;10.1016/s0889-8588(18)30134-5;;10.1016/s0021-9258(17)31580-6;;8089148;;10.1182/blood.v77.3.419.bloodjournal773419;;10.1182/blood.v77.3.419.419;;1991159;;10.1016/s0074-7696(01)04002-5;;11243594;;10.1016/s0968-0004(97)01074-8;;9255066,"SEMENZA, G.L.: ""Regulation of erythropoietin production: New insights into molecular mechanisms of oxygen homeostasis"", HEMATOL. ONCOL. CLIN. NORTH AM., vol. 8, 1994, pages 863 - 884;;SEMENZA, G. L. ET AL.: ""Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1"", J. BIOL. CHEM., vol. 269, 1994, pages 23757 - 63, XP000578184;;KRANTZ, S. B.: ""Erythropoietin"", BLOOD, vol. 77, 1991, pages 419 - 434;;NGUYEN, L.L., INT. REV. CYTOL., vol. 204, 2001, pages 1 - 48;;BUSSOLINO, F., TRENDS BIOCHEM. SCI., vol. 22, 1997, pages 251 - 256;;FOLKMAN ET AL.: ""The Molecular Basis of Cancer"", 1995, article ""Tumor Angiogenesis"", pages: 206 - 32;;WEIDNER, NEW ENG. J. MED., vol. 324, no. 1, 1991, pages 1 - 8;;O'REILLY ET AL., CELL, vol. 79, 1994, pages 315 - 28;;O'REILLY ET AL., CELL, vol. 88, 1997, pages 277 - 85;;TEISCHER ET AL., INT. J. CANCER, vol. 57, 1994, pages 920 - 25",PENDING
565,EP,B1,EP 3357911 B1,061-268-338-900-613,2022-05-11,2022,EP 18158907 A,2007-06-26,US 81652206 P;;EP 15191470 A;;EP 11000872 A;;EP 10009965 A;;EP 07835890 A;;US 2007/0014832 W,2006-06-26,PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE,,AKEBIA THERAPEUTICS INC,KAWAMOTO RICHARD MASARU;;WARSHAKOON NAMAL CHITHRANGA;;WU SHENGDE;;BOYER ANGELIQUE SUN;;GREIS KENNETH DONALD,,https://lens.org/061-268-338-900-613,Granted Patent,yes,14,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07D213/81;;A61K31/4418;;A61P35/00,,5,3,074-536-164-121-774;;066-519-812-638-153;;003-330-211-576-597,10.1007/978-1-4615-4141-7_70;;pmc129695;;12351678;;10.1073/pnas.192342099;;16908149;;10.1016/j.bmcl.2006.08.026,"""Prolyl 4-hydroxylase inhibitors, Chapter"", 1 January 1998, article DEKKER MARCEL: ""Prolyl hydroxylase, protein disulfide isomerase, and other structurally related proteins"", pages: 96 - 95, XP093028314;;""Molecular Modeling and Prediction of Bioactivity, Chapter 23"", 1 January 2000, SPRINGER, BOSTON, article BARINGHAUS K.-H, GUENZLER-PUKALL V, SCHUBERT G, WEIDMANN K, MARION ROUSSEL HOECHST: ""3D QSAR OF PROLYL 4-HYDROXYLASE INHIBITORS"", pages: 345 - 346, XP093028320;;WARD SIMON: ""Exhibit SW2 to the first report of Simon Ward, filed on behalf of the Claimants in Claim No. HP-2018-000036 and the First and Second Defendants in IL-2019- 000031, and the Claimants in Claim No. HP-2018-000038 and the First and Second Defendants in Claim No. IL-2019-000032"", THE HIGH COURT OF JUSTICE BUSINESS AND PROPERTY COURTS OF ENGLAND AND WALES INTELLECTUAL PROPERTY LIST, (CHD) PATENTS COUR, 3 January 2020 (2020-01-03), pages 1 - 23, XP093028335;;IVAN M,ET AL: ""Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor."", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 99, no. 21, 15 October 2002 (2002-10-15), pages 13459 - 13464, XP002232952, ISSN: 0027-8424, DOI: 10.1073/pnas.192342099;;WARSHAKOON, N.C. ET AL: ""Design and synthesis of substituted pyridine derivatives as HIF-1@a prolyl hydroxylase inhibitors"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM NL, vol. 16, no. 21, 1 November 2006 (2006-11-01), Amsterdam NL , pages 5616 - 5620, XP005663504, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2006.08.026",ACTIVE
566,EP,A1,EP 3723590 A1,150-263-540-408-79X,2020-10-21,2020,EP 18839644 A,2018-12-14,US 201762599421 P;;US 201862671108 P;;US 2018/0065637 W,2017-12-15,SYSTEMS AND METHODS FOR FILTERING MEDICAL DEVICE NOISE ARTIFACTS FROM VENOUS WAVEFORM SIGNALS,,BAXTER INT;;BAXTER HEALTHCARE SA,HANDLER JONATHAN;;MARTUCCI JAMES;;HOCKING KYLE;;EAGLE SUSAN;;BROPHY COLLEEN;;BOYER RICHARD;;BAUDENBACHER FRANZ,,https://lens.org/150-263-540-408-79X,Patent Application,yes,0,0,11,26,0,A61B5/7217;;A61B5/7282;;A61B5/7278;;A61B5/02152;;A61B5/6866;;A61B5/02152;;A61B5/7217;;A61B5/02156;;A61B5/6866;;A61B5/725;;A61B5/7278;;A61M1/3639;;A61M1/3656;;A61M5/16854;;A61M5/1723;;A61M2205/3331;;A61M2230/30;;A61B5/02108;;A61B5/7275;;F04B43/12;;G16H20/17;;G16H40/60;;A61B5/02152;;A61B5/7203;;A61B5/725;;A61M2205/3331;;A61B2562/0247;;A61M5/14212;;A61M2230/30;;A61B5/6866;;A61B5/7278;;A61B5/7282;;A61B5/7217;;A61M5/142;;G16H40/63;;A61M5/16854;;A61B5/02141;;G16H40/60;;A61B5/7275;;G16H20/17;;G16H20/10;;A61M2005/16863;;A61B5/021;;F04B43/12;;A61M5/14232;;A61B5/02108,A61B5/0215;;A61B5/00;;A61M1/14,,0,0,,,,PENDING
567,AU,A1,AU 2018/294354 A1,163-205-872-426-43X,2020-02-13,2020,AU 2018/294354 A,2018-06-29,US 201862671108 P;;US 201816023945 A;;US 201762528570 P;;US 201762599421 P;;US 201762527944 P;;US 2018/0040389 W,2017-06-30,Systems and methods for filtering noise and analyzing venous waveform signals,"Devices, systems, and methods for filtering medical device noise artifacts from venous waveform signals are disclosed. A peripheral venous pressure (PVP) is measured and transformed from the time domain to the frequency domain for analysis to determine patient status. To avoid artifacts of the pumping, the time-domain PVP measurements are filtered to generate a filtered time-domain PVP signal by removing active pumping periods. The filtered time-domain PVP signal is transformed into a frequency-domain PVP signal, which is analyzed based upon peaks indicating respiratory rate, heart rate, or harmonics thereof. A metric of patient status is then determined from the peaks or corresponding frequencies. The patient status may be related to blood volume of the patient and may be used to control pump operation.",BAXTER HEALTHCARE SA;;BAXTER INT,HANDLER JONATHAN;;MARTUCCI JAMES;;HOCKING KYLE;;EAGLE SUSAN;;BROPHY COLLEEN;;BOYER RICHARD;;BAUDENBACHER FRANZ,,https://lens.org/163-205-872-426-43X,Patent Application,no,0,0,11,26,0,A61B5/6866;;A61B5/7217;;A61B5/02152;;A61B5/7278;;A61M2205/3576;;A61M2205/502;;A61M2205/52;;A61B5/7246;;A61B5/02405;;A61B5/02444;;A61B5/0816;;A61B5/112;;A61B5/4094;;A61B5/6824;;A61B5/7257;;G16H40/63;;G16H50/30;;G16H50/70;;G16H20/40;;A61B5/4839;;A61B5/725;;A61B5/7282;;A61B2562/0247;;A61M5/14232;;A61M5/1723;;A61M2205/3331;;A61M2230/30;;A61B5/7217;;A61B5/02152;;A61B5/02444;;A61B5/0816;;A61B5/112;;A61B5/6824;;A61B5/7257;;A61B5/7278;;A61M5/14232;;A61M5/1723;;G16H20/40;;G16H40/63;;G16H50/70;;A61B2562/0247;;A61B5/6866;;A61M2205/502;;A61M2205/52;;A61B5/02405;;A61B5/7246;;A61B5/02152;;A61M2205/3576;;A61B5/7278;;A61B5/0816;;A61B5/6824;;G16H20/40;;A61B5/7257;;A61B5/112;;A61B5/02444;;A61B5/7217;;G16H50/70;;A61B5/4094;;G16H50/30;;G16H40/63;;A61B5/0215;;A61B5/4839;;A61B5/7203;;A61B5/725;;A61B5/7282;;A61B2562/0247;;A61M5/14232;;A61M5/1723;;A61M2205/3331;;A61M2230/30,A61B5/00;;A61B5/0215,,0,0,,,,DISCONTINUED
568,US,A1,US 2012/0282627 A1,031-246-478-009-309,2012-11-08,2012,US 201113230548 A,2011-09-12,US 201113230548 A;;US 47353609 A;;US 71394107 A;;US 77989806 P,2006-03-07,CRYSTAL OF HYPOXIA INDUCIBLE FACTOR 1 ALPHA PROLYL HYDROXYLASE,The crystal structure of ligand-bound EGLN1 catalytic domain of prolyl hydroxylase is disclosed. These coordinates are useful in computer aided drug design for identifying compounds that regulate EGLN1 prolyl hydroxylase and thereby regulate HIF-regulated disorders.,EVDOKIMOV ARTEM GENNADY;;KAWAMOTO RICHARD MASARU;;BOYER ANGELIQUE SUN;;MEKEL MARLENE JAN;;POKROSS MATTHEW EUGENE;;WALTER JR RICHARD LEE,EVDOKIMOV ARTEM GENNADY;;KAWAMOTO RICHARD MASARU;;BOYER ANGELIQUE SUN;;MEKEL MARLENE JAN;;POKROSS MATTHEW EUGENE;;WALTER JR RICHARD LEE,AKEBIA THERAPEUTICS INC (2011-12-15),https://lens.org/031-246-478-009-309,Patent Application,yes,0,23,6,6,14,C07K2299/00;;C12N9/0071;;C12Q1/26;;G01N2500/00;;C12Q1/26;;C07K2299/00;;C12N9/0071;;G01N2500/00,G01N33/573;;C12Q1/34;;G06F19/10,435/7.4;;435/18;;703/2,9,7,045-208-478-295-57X;;046-795-305-707-439;;090-890-626-525-186;;051-798-597-480-575;;028-010-000-589-990;;087-667-912-261-011;;018-774-223-791-149,11403880;;10.1016/s0301-4622(01)00157-0;;10.1146/annurev.bioeng.1.1.505;;11701498;;10.1107/s0907444905017038;;16041081;;10.1007/s00018-003-3260-z;;15004692;;10.1016/s0076-6879(97)76048-8;;27799088;;2185018;;10.1111/j.1432-1033.1990.tb15454.x;;10.1107/s0907444905034281;;16369099,"Drenth et al., ""Principles of X-ray Crystallography,"" Springer, New York, 1999, p. 1;;Kierzek et al., Biophys Chem 91:1-20, 2001;;Wiencek, Ann Rev Biomed Eng 1:505-534, 1999;;Buts et al., Acta Cryst D61:1149-1159, 2005;;Kundrot et al., Cell. Mol. Life Sci. 2004, 61: 525-536;;Weber, Methods in Enzymology, 1997, Vol. 276, pp. 13-22;;Cudney, Rigaku Journal, 1999, Vol. 16, No. 1, pp. 1-7;;McPherson et al., Eur. J. Biochem. 189:1-23, 1990;;Skarzynski et al., Acta Cryst D62:102-107, 2006",ACTIVE
569,US,B2,US 8050873 B2,050-092-565-851-780,2011-11-01,2011,US 47353609 A,2009-05-28,US 47353609 A;;US 71394107 A;;US 77989806 P,2006-03-07,Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase,The crystal structure of ligand-bound EGLN1 catalytic domain of prolyl hydroxylase is disclosed. These coordinates are useful in computer aided drug design for identifying compounds that regulate EGLN1 prolyl hydroxylase and thereby regulate HIF-regulated disorders.,WARNER CHILCOTT COMPANY,EVDOKIMOV ARTEM GENNADY;;KAWAMOTO RICHARD MASARU;;BOYER ANGELIQUE SUN;;MEKEL MARLENE JAN;;POKROSS MATTHEW EUGENE;;WALTER JR RICHARD LEE,AKEBIA THERAPEUTICS INC (2011-12-15);;WARNER CHILCOTT COMPANY LLC (2009-10-30),https://lens.org/050-092-565-851-780,Granted Patent,yes,51,26,6,6,15,C07K2299/00;;C12N9/0071;;C12Q1/26;;G01N2500/00;;C12Q1/26;;C07K2299/00;;C12N9/0071;;G01N2500/00,G01N31/00;;C12Q1/26;;G01N33/567;;G06G7/58,702/27;;703/11;;435/25;;435/7.21,39,34,102-345-845-395-203;;015-199-257-732-502;;009-081-622-113-208;;052-512-054-021-225;;022-156-141-942-093;;081-136-747-247-898;;030-042-017-746-591;;131-046-096-401-339;;092-475-988-464-223;;135-654-547-079-284;;077-106-322-076-470;;069-450-943-413-364;;025-178-564-355-938;;048-830-824-939-083;;102-949-159-342-256;;018-052-265-551-042;;064-406-626-054-484;;011-101-678-202-709;;129-297-815-048-32X;;023-017-724-234-140;;074-344-536-692-994;;091-474-773-070-883;;016-533-076-557-079;;034-760-425-242-511;;056-436-730-631-840;;149-920-492-418-396;;074-156-318-814-764;;064-242-953-339-024;;062-826-287-074-090;;065-169-875-352-44X;;045-408-622-411-245;;096-459-000-284-800;;040-667-645-789-907;;017-183-541-402-013,1583540;;10.1007/bf00124387;;10.1016/s0968-0004(97)01074-8;;9255066;;10.1021/jm00092a016;;1321909;;pmc312791;;10.1101/gad.914801;;11581158;;10.1016/s0304-4157(99)00006-4;;10548717;;1665444;;10.1042/bst0190812;;10.1021/jm00145a002;;3892003;;10.1002/prot.340080302;;2281083;;7823319;;10.1016/s0022-2836(95)80037-9;;15952883;;10.1146/annurev.biochem.74.082803.133142;;10.1182/blood.v77.3.419.bloodjournal773419;;10.1182/blood.v77.3.419.419;;1991159;;7154081;;10.1016/0022-2836(82)90153-x;;12482756;;10.1074/jbc.m210385200;;10613823;;10.1038/71527;;10.1161/01.cir.0000044914.42696.6a;;12538431;;pmc1502536;;16782814;;10.1073/pnas.0601283103;;10.2210/pdb2g1m/pdb;;10.1002/prot.340110104;;1961699;;10.1016/s0074-7696(01)04002-5;;11243594;;10.1016/s0040-4020(01)86503-0;;7525077;;10.1016/0092-8674(94)90200-3;;10.1016/s0092-8674(00)81848-6;;9008168;;10.1172/jci23865;;16007254;;pmc1159132;;10.1016/s0303-7207(99)00017-9;;10411333;;10.1016/s0021-9258(17)31580-6;;8089148;;7852211;;10.1016/s0889-8588(18)30134-5;;10.1016/s0006-2952(02)01168-1;;12213597;;19649971;;10.1021/jo01340a533;;5902481;;7515861;;10.1002/ijc.2910570624;;11056102;;10.1161/01.cir.102.18.2255;;10.1096/fj.02-1062fje;;12709400;;8606489;;10.1056/nejm199101033240101;;1701519;;12649278;;10.1074/jbc.m301391200,"Flower, ""Drug Design, Cutting Edge Approaches,"" Royal Society of Chemistry, Cambridge, UK, 2002.;;Brucz, K., ""HIF Prolyl 4-Hydroxylase (PHD) Activity and Structure Analysis: Blueprints For Development of Specific Substrate Inhibitors"", Dissertation, University of New York at Buffalo, 2005.;;Bartlett et al., ""Molecular Recognition in Chemical and Biological Problems,""Special Pub., Royal Chem. Soc., 78, 182-196 Caveat: A Program to Facilitate the Structure-derived Design of Biologically Active Molecules (Apr. 1989).;;Böhm, ""The Computer Program LUDI: A New Method for the Novo Design of Enzyme Inhibitors,"" J. Computer-Aided Molecular Design,6:61-78 (1992).;;Bussolino, ""Molecular Mechanisms of Blood Vessel Formation,"" Trends Biochem. Sci.,22(7):251-256 (1997).;;Cunliffe et al., ""Novel Inhibitors of Prolyl 4-Hydroxylase 3 Inhibition by the Substrate Analogue N-Oxaloglycine and Its Derivatives,"" J. Med. Chem.35:2652-2658 (1992).;;Elson et al., ""Induction of Hypervascularity Without Leakage or Inflammation in Transgenic Mice Overexpressing Hypoxia-Indicible Factor-1alpha,"" Genes & Dev., 15:2520-2532 (2001).;;Flower, ""Modelling G-protein-coupled receptors for drug design,"" Biochimica et Biophysica Acta, 1422:207-234 (1999).;;Folkman et al., ""Tumor Angiogenesis,"" The Molecular Basis of Cancer, Mendelsohn et al., eds., W. B. Saunders, Chapter 10, pp. 206-232 (1995).;;Franklin et al., ""Approaches to the Design of Anti-Fibrotic Drugs,"" Biochem Soc Trans., 19(4):812-5 (Nov. 1991).;;Goodford, ""A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules,"" J. Med. Chem., 28(7):849-857 (1985).;;Goodsell et al., ""Automated Docking of Substrates to Proteins by Simulated Annealing,"" Proteins: Structure, Function, and Genetics, 8:195-202 (1990).;;Jones et al., ""Molecular Recognition of Receptor Sites Using a Genetic Algorithm with a Description of Desolvation,"" J. Mol. Biol., 245:43-53 (1995).;;Kaelin, ""Proline Hydroxylation and Gene Expression,"" Annu. Rev. Biochem., 74:115-125 (2005).;;Krantz, ""Erythropoietin,"" Blood, 77:419-434 (1991).;;Kuntz et al., ""A Geometric Approach to Macromolecule-Ligand Interactions,"" J. Mol. Biol., 161:269-288 (1982).;;Lee et al., ""Structure of Human FIH-1 Reveals a Unique Active Site Pocket and Interaction Sites for HIF-1 and von Hippel Lindau,"" JBC, 278:7558-7563 (2003).;;Li et al., ""PR39, A Peptide Regulator of Angiogenesis,"" Nat Med., 6(1):49-55 (2000).;;Mancini et al., ""Effect of Erythropoietin on Exercise Capacity in Patients with Moderate to Severe Chronic Heart Failure,"" Circulation, 107:294-299 (2003).;;McDonough et al., ""Cellular Oxygen Sensing: Crystal Structure of Hypoxia-Inducible Factor Prolyl Hydroxylase (PHD2),"" PNAS, 103(26):9814-9819 (2006).;;Miranker et al., ""Functionality Maps of Binding Sites: A Multiple Copy Simultaneous Search Method,"" Proteins: Structure, Function and Genetics, 11:29-34 (1991).;;Nguyen et al., ""Cellular Interactions in Vascular Growth and Differentiation,"" Int. Review of Cytology, 204:1-48 (2001).;;Nishibata et al., ""Automatic Creation of Drug Candidate Structures Based on Receptor Structure. Starting Point for Artificial Lead Generation,"" Tetrahedron, 47(43):8985-8990 (1991).;;O'Reilly et al., ""Angiostatin: A Novel Angiogenesis Inhibitor that Mediates the Suppression of Metastases by a Lewis Lung Carcinoma,"" Cell, 79:315-328 (1994).;;O'Reilly et al., ""Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth,"" Cell, 88:277-285 (1997).;;Peyssonnaux et al.,""HIF-1alpha Expression Regulates the Bactericidal Capacity of Phagocytes,"" J. Clinical Invest., 115(7):1806-1815 (Jul. 2005).;;Schoneberg et al., ""Structural Basis of G Protein-Coupled Receptor Function,"" Molecular and Cellular Endocrinology, 151:181-193 (1999).;;Semenza et al., ""Transcriptional Regulation of Genes Encoding Glycolytic Enzymes by Hypoxia-Inducible Factor 1,"" J. Biol. Chem., 269:23757-23763 (1994).;;Semenza, ""Regulation of Erythropoietin Production: New Insights into Molecular Mechanisms of Oxygen Homeostasis,"" Hematol. Oncol. Clin. North Am., 8:863-884 (1994).;;Semenza, ""Signal Transduction to Hypoxia-inducible Factor 1,"" Biocehm Pharmacol, 64:993-998 (2002).;;Sexton, ""Recent advances in our understanding of peptide hormone receptors and RAMPS,"" Current Opinion in Drug Discovery and Development, 2(5):440-448 (1999).;;Sheehan, ""3-Hydroxypicolinic Acid and Some of its Derivatives,"" J. Organic Chemistry 31(3):636-638 (1996).;;Teicher et al., ""Potentiation of Cytotoxic Cancer Therapies by TNP-470 Alone and with Other Anti-Angiogenic Agents,"" Int. J. Cancer, 57:920-925 (1994).;;Vincent et al., ""Angiogenesis is Induced in a Rabbit Model of Hindlimb Ischemia by Naked DNA Encoding an HIF-1alpha/VP16 Hybrid Transcription Factor,"" Circulation, 102:2255-2261 (2000).;;Warnecke et al., ""Activation of the Hypoxia-Inducible Factor Pathway and Stimulation of Angiogenesis by Application of Prolyl Hydroxylase Inhibitors,"" FASEB Journal, 17:1186-1188 (2003).;;Wax et al., ""SM-20 is a Novel 20-kd Protein Whose Expression in the Arterial Wall is Restricted to Smooth Muscle,"" Lab. Invest., 74(4):797-808 (1996).;;Weidner et al., ""Tumor Angiogenesis and Metastasis-Correlation in Invasive Breast Carcinoma,"" New Eng. J. Med., 324(1):1-8 (1991).;;Wright et al., ""Activation of the Prolyl Hydroxylase Oxygen-Sensor Results in Induction of GLUT1, Heme Oxygenase-1, and Nitric-Oxide Synthase Proteins and Confers Protection from Metabolic Inhibition to Cardiomyocytes,"" J. Bio. Chem., 278(22):20235-20239 (2003).;;U.S. Appl. No. 11/821,936, filed Jun. 26, 2007, Kawamoto.",ACTIVE
570,US,B2,US 7588924 B2,134-931-561-928-971,2009-09-15,2009,US 71394107 A,2007-03-05,US 71394107 A;;US 77989806 P,2006-03-07,Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase,The crystal structure of ligand-bound EGLN1 catalytic domain of prolyl hydroxylase is disclosed. These coordinates are useful in computer aided drug design for identifying compounds that regulate EGLN1 prolyl hydroxylase and thereby regulate HIF-regulated disorders.,PROCTER & GAMBLE,EVDOKIMOV ARTEM GENNADY;;KAWAMOTO RICHARD MASARU;;BOYER ANGELIQUE SUN;;MEKEL MARLENE JAN;;POKROSS MATTHEW EUGENE;;WALTER JR RICHARD LEE,AKEBIA THERAPEUTICS INC (2011-12-15);;PROCTER & GAMBLE COMPANY THE (2006-04-30);;WARNER CHILCOTT COMPANY LLC (2009-10-30),https://lens.org/134-931-561-928-971,Granted Patent,yes,7,61,6,6,14,C07K2299/00;;C12N9/0071;;C12Q1/26;;G01N2500/00;;C12Q1/26;;C07K2299/00;;C12N9/0071;;G01N2500/00,C12N9/02,435/189,32,28,045-208-478-295-57X;;046-795-305-707-439;;090-890-626-525-186;;018-774-223-791-149;;051-798-597-480-575;;028-010-000-589-990;;087-667-912-261-011;;022-156-141-942-093;;135-654-547-079-284;;025-178-564-355-938;;016-533-076-557-079;;074-156-318-814-764;;096-459-000-284-800;;102-345-845-395-203;;052-512-054-021-225;;030-042-017-746-591;;131-046-096-401-339;;092-475-988-464-223;;069-450-943-413-364;;048-830-824-939-083;;102-949-159-342-256;;018-052-265-551-042;;064-406-626-054-484;;129-297-815-048-32X;;149-920-492-418-396;;065-169-875-352-44X;;045-408-622-411-245;;017-183-541-402-013,11403880;;10.1016/s0301-4622(01)00157-0;;10.1146/annurev.bioeng.1.1.505;;11701498;;10.1107/s0907444905017038;;16041081;;10.1107/s0907444905034281;;16369099;;10.1007/s00018-003-3260-z;;15004692;;10.1016/s0076-6879(97)76048-8;;27799088;;2185018;;10.1111/j.1432-1033.1990.tb15454.x;;10.1016/s0304-4157(99)00006-4;;10548717;;15952883;;10.1146/annurev.biochem.74.082803.133142;;12482756;;10.1074/jbc.m210385200;;10.1016/s0303-7207(99)00017-9;;10411333;;19649971;;8606489;;1583540;;10.1007/bf00124387;;pmc312791;;10.1101/gad.914801;;11581158;;10.1021/jm00145a002;;3892003;;10.1002/prot.340080302;;2281083;;7823319;;10.1016/s0022-2836(95)80037-9;;7154081;;10.1016/0022-2836(82)90153-x;;10613823;;10.1038/71527;;10.1161/01.cir.0000044914.42696.6a;;12538431;;pmc1502536;;16782814;;10.1073/pnas.0601283103;;10.2210/pdb2g1m/pdb;;10.1002/prot.340110104;;1961699;;10.1016/s0040-4020(01)86503-0;;10.1016/s0006-2952(02)01168-1;;12213597;;11056102;;10.1161/01.cir.102.18.2255;;10.1096/fj.02-1062fje;;12709400;;12649278;;10.1074/jbc.m301391200,"Branden et al., ""Introduction to Protein Structure Second Edition"", Garland Publishing Inc., New York, 1999, pp. 374-375.;;Drenth et al., ""Principles of X-ray Crystallography,"" Springer, New York, 1999, p. 1.;;Kierzek et al., Biophys Chem 91:1-20, 2001.;;Wiencek, Ann Rev Biomed Eng 1:505-534, 1999.;;Buts et al., Acta Cryst D61:1149-1159, 2005.;;Skarzynski et al., Acta Cryst D62:102-107, 2006.;;Kundrot et al., Cell. Mol. Life Sci. 2004, 61: 525-536.;;Weber, Methods in Enzymology, 1997, vol. 276, pp. 13-22.;;Cudney, Rigaku Journal, 1999, vol. 16, No. 1, pp. 1-7.;;McPherson et al., Eur. J. Biochem. 189:1-23, 1990.;;Flower, D., ""Modelling G-Protein-Coupled Receptors For Drug Design,"" Biochim Biophys Acta, 1422, pp. 207-234, 1999.;;Kaelin, WG, ""Proline Hydroxylation and Gene Expression, ""Annu. Rev. Biochem. 2005, 74: 115-28.;;Lee, Cheolju et al., Structure of Human FIH-1 Reveals a Unique Active Site Pocket and Interaction Sites for HIF-1 and von Hippel Lindau, JBC, vol. 278, Feb. 28, pp. 7558-7563, 2003.;;Schoneberg, T., et al., Molecular and Cellular Endocrinology, 151:181-193, 1999.;;Sexton, P.M., curr. Opin. Drug Discovery and Development, 2, pp. 440-448, 1999.;;Wax, S.D. et al., ""SM-20 is a Novel 40-kd Protein Whose Expression in the Arterial Wall is Restricted to Smooth Muscle,"" Lab. Invest. 74(4), 797-808, 1996.;;Bartlett et al., ""Molecular Recognition in Chemical and Biological Problems,"" Special Pub., Royal Chem. Soc., 78, 182-196 Caveat: A Program to Facilitate the Structure-derived Design of Biologically Active Molecules (Apr. 1989).;;Böhm, ""The Computer Program LUDI: A New Method for the Novo Design of Enzyme Inhibitors,"" J. Computer-Aided Molecular Design,6:61-78 (1992).;;Elson et al., ""Induction of Hypervascularity Without Leakage or Inflammation in Transgenic Mice Overexpressing Hypoxia-Indicible Factor-1alpha,,"" Genes & Dev., 15:2520-2532 (2001).;;Goodford, ""A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules,"" J. Med. Chem., 28(7):849-857 (1985).;;Goodsell et al., ""Automated Docking of Substrates to Proteins by Simulated Annealing,"" Proteins: Structure, Function, and Genetics, 8:195-202 (1990).;;Jones et al., ""Molecular Recognition of Receptor Sites Using a Genetic Algorithm with a Description of Desolvation,"" J. Mol. Biol., 245:43-53 (1995).;;Kuntz et al., ""A Geometric Approach to Macromolecule-Ligand Interactions,"" J. Mol. Biol., 161:269-288 (1982).;;LI et al., ""PR39, A Peptide Regulator of Angiogenesis,"" Nat Med., 6(1):49-55 (2000).;;Mancini et al., ""Effect of Erythropoietin on Exercise Capacity in Patients with Moderate to Severe Chronic Heart Failure,"" Circulation, 107:294-299 (2003).;;McDonough et al., ""Cellular Oxygen Sensing: Crystal Structure of Hypoxia-Inducible Factor Prolyl Hydroxylase (PHD2),"" PNAS, 103(26):9814-9819 (2006).;;Miranker et al., ""Functionality Maps of Binding Sites: A Multiple Copy Simultaneous Search Method,"" Proteins: Structure, Function and Genetics, 11:29-34 (1991).;;Nishibata et al., ""Automatic Creation of Drug Candidate Structures Based on Receptor Structure. Starting Point for Artificial Lead Generation,"" Tetrahedron, 47(43):8985-8990 (1991).;;Semenza, ""Signal Transduction to Hypoxia-inducible Factor 1,"" Biocehm Pharmacol, 64:993-998 (2002).;;Vincent et al., ""Angiogenesis is Induced in a Rabbit Model of Hindlimb Ischemia by Naked DNA Encoding an HIF-1alpha/VP16 Hybrid Transcription Factor,"" Circulation, 102:2255-2261 (2000).;;Warnecke et al., ""Activation of the Hypoxia-Inducible Factor Pathway and Stimulation of Angiogenesis by Application of Prolyl Hydroxylase Inhibitors,"" FASEB Journal, 17:1186-1188(2003).;;Wright et al,, ""Activation of the Prolyl Hydroxylase Oxygen-Sensor Results in Induction of GLUT1, Heme Oxygenase-1, and Nitric-Oxide Synthase Proteins and Confers Protection from Metabolic Inhibition to Cardiomyocytes,"" J. Bio. Chem., 278(22):20235-20239 (2003).",ACTIVE
571,US,B2,US 8512972 B2,024-871-563-566-601,2013-08-20,2013,US 201113230548 A,2011-09-12,US 201113230548 A;;US 47353609 A;;US 71394107 A;;US 77989806 P,2006-03-07,Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase,The crystal structure of ligand-bound EGLN1 catalytic domain of prolyl hydroxylase is disclosed. These coordinates are useful in computer aided drug design for identifying compounds that regulate EGLN1 prolyl hydroxylase and thereby regulate HIF-regulated disorders.,EVDOKIMOV ARTEM GENNADY;;KAWAMOTO RICHARD MASARU;;BOYER ANGELIQUE SUN;;MEKEL MARLENE JAN;;POKROSS MATTHEW EUGENE;;WALTER JR RICHARD LEE;;AKEBIA THERAPEUTICS INC,EVDOKIMOV ARTEM GENNADY;;KAWAMOTO RICHARD MASARU;;BOYER ANGELIQUE SUN;;MEKEL MARLENE JAN;;POKROSS MATTHEW EUGENE;;WALTER JR RICHARD LEE,AKEBIA THERAPEUTICS INC (2011-12-15),https://lens.org/024-871-563-566-601,Granted Patent,yes,56,17,6,6,14,C07K2299/00;;C12N9/0071;;C12Q1/26;;G01N2500/00;;C12Q1/26;;C07K2299/00;;C12N9/0071;;G01N2500/00,C12Q1/26;;G01N31/00;;G06G7/58,435/25;;702/27;;703/11;;703/12,88,43,045-208-478-295-57X;;046-795-305-707-439;;090-890-626-525-186;;051-798-597-480-575;;028-010-000-589-990;;087-667-912-261-011;;018-774-223-791-149;;102-345-845-395-203;;015-199-257-732-502;;009-081-622-113-208;;052-512-054-021-225;;022-156-141-942-093;;081-136-747-247-898;;030-042-017-746-591;;131-046-096-401-339;;092-475-988-464-223;;135-654-547-079-284;;077-106-322-076-470;;069-450-943-413-364;;025-178-564-355-938;;048-830-824-939-083;;102-949-159-342-256;;018-052-265-551-042;;064-406-626-054-484;;011-101-678-202-709;;129-297-815-048-32X;;023-017-724-234-140;;074-344-536-692-994;;091-474-773-070-883;;016-533-076-557-079;;149-920-492-418-396;;056-436-730-631-840;;034-760-425-242-511;;074-156-318-814-764;;064-242-953-339-024;;062-826-287-074-090;;065-169-875-352-44X;;045-408-622-411-245;;096-459-000-284-800;;040-667-645-789-907;;017-183-541-402-013;;019-130-789-993-789;;003-330-211-576-597,11403880;;10.1016/s0301-4622(01)00157-0;;10.1146/annurev.bioeng.1.1.505;;11701498;;10.1107/s0907444905017038;;16041081;;10.1007/s00018-003-3260-z;;15004692;;10.1016/s0076-6879(97)76048-8;;27799088;;2185018;;10.1111/j.1432-1033.1990.tb15454.x;;10.1107/s0907444905034281;;16369099;;1583540;;10.1007/bf00124387;;10.1016/s0968-0004(97)01074-8;;9255066;;10.1021/jm00092a016;;1321909;;pmc312791;;10.1101/gad.914801;;11581158;;10.1016/s0304-4157(99)00006-4;;10548717;;1665444;;10.1042/bst0190812;;10.1021/jm00145a002;;3892003;;10.1002/prot.340080302;;2281083;;7823319;;10.1016/s0022-2836(95)80037-9;;15952883;;10.1146/annurev.biochem.74.082803.133142;;10.1182/blood.v77.3.419.bloodjournal773419;;10.1182/blood.v77.3.419.419;;1991159;;7154081;;10.1016/0022-2836(82)90153-x;;12482756;;10.1074/jbc.m210385200;;10613823;;10.1038/71527;;10.1161/01.cir.0000044914.42696.6a;;12538431;;pmc1502536;;16782814;;10.1073/pnas.0601283103;;10.2210/pdb2g1m/pdb;;10.1002/prot.340110104;;1961699;;10.1016/s0074-7696(01)04002-5;;11243594;;10.1016/s0040-4020(01)86503-0;;7525077;;10.1016/0092-8674(94)90200-3;;10.1016/s0092-8674(00)81848-6;;9008168;;10.1172/jci23865;;16007254;;pmc1159132;;10.1016/s0303-7207(99)00017-9;;10411333;;10.1016/s0006-2952(02)01168-1;;12213597;;7852211;;10.1016/s0889-8588(18)30134-5;;10.1016/s0021-9258(17)31580-6;;8089148;;19649971;;10.1021/jo01340a533;;5902481;;7515861;;10.1002/ijc.2910570624;;11056102;;10.1161/01.cir.102.18.2255;;10.1096/fj.02-1062fje;;12709400;;8606489;;10.1056/nejm199101033240101;;1701519;;12649278;;10.1074/jbc.m301391200;;10.1351/pac199567081307;;16908149;;10.1016/j.bmcl.2006.08.026,"Drenth et al., ""Principles of X-ray Crystallography,"" Springer, New York, 1999, p. 1.;;Kierzek et al., Biophys Chem 91:1-20, 2001.;;Wiencek, Ann Rev Biomed Eng 1:505-534, 1999.;;Buts et al., Acta Cryst D61:1149-1159, 2005.;;Kundrot et al., Cell. Mol. Life Sci. 2004, 61: 525-536.;;Weber, Methods in Enzymology, 1997, vol. 276, pp. 13-22.;;Cudney, Rigaku Journal, 1999, vol. 16, No. 1, pp. 1-7.;;McPherson et al., Eur. J. Biochem. 189:1-23, 1990.;;Skarzynski et al., Acta Cryst D62:102-107, 2006.;;Bartlett et al., ""Molecular Recognition in Chemical and Biological Problems,"" Special Pub., Royal Chem. Soc., 78, 182-196 Caveat: A Program to Facilitate the Structure-derived Design of Biologically Active Molecules (Apr. 1989).;;Böhm, ""The Computer Program LUDI: A New Method for the Novo Design of Enzyme Inhibitors,"" J. Computer-Aided Molecular Design,6:61-78 (1992).;;Branden et al., ""Introduction to Protein Structure Second Edition,"" Garland Publishing Inc., New York, 1999, pp. 374-375.;;Bussolino, ""Molecular Mechanisms of Blood Vessel Formation,"" Trends Biochem. Sci.,22(7):251-256 (1997).;;Cunliffe et al., ""Novel Inhibitors of Prolyl 4-Hydroxylase. 3. Inhibition by the Substrate Analogue N-Oxaloglycine and Its Derivatives,"" J. Med.Chem. 35:2652-2658 (1992).;;Elson et al., ""Introduction of Hypervascularity Without Leakage or Inflammation in Transgenic Mice Overexpressing Hypoxia-Indicible Factor-1alpha,"" Genes & Dev., 15:2520-2532 (2001).;;Flower, ""Modelling G-protein-coupled receptors for drug design,"" Biochimica et Biophysica Acta, 1422:207-234 (1999).;;Folkman et al., ""Tumor Angiogenesis,"" The Molecular Basis of Cancer, Mendelsohn et al., eds., W. B. Saunders, Chapter 10, pp. 206-232 (1995).;;Franklin et al., ""Approaches to the Design of Anti-Fibrotic Drugs,"" Biochem. Soc. Trans., 19(4):812-5 (Nov. 1991).;;Goodford, ""A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules,"" J. Med. Chem., 28(7):849-857 (1985).;;Goodsell et al., ""Automated Docking of Substrates to Proteins by Simulated Annealing,"" Proteins: Structure, Function, and Genetics, 8:195-202 (1990).;;Jones et al., ""Molecular Recognition of Receptor Sites Using a Genetic Algorithm with a Description of Desolvation,"" J. Mol. Biol., 245:43-53 (1995).;;Kaelin, ""Proline Hydroxylation and Gene Expression,"" Annu. Rev. Biochem., 74:115-125 (2005).;;Krantz, ""Erythropoietin,"" Blood, 77:419-434 (1991).;;Kuntz et al., ""A Geometric Approach to Macromolecule-Ligand Interactions,"" J. Mol. Biol., 161:269-288 (1982).;;Lee et al., ""Structure of Human FIH-1 Reveals a Unique Active Site Pocket and Interaction Sites for HIF-1 and von Hippel Lindau,"" JBC, 278:7558-7563 (2003).;;Li et al., ""PR39, A Peptide Regulator of Angiogenesis,"" Nat Med., 6(1):49-55 (2000).;;Mancini et al., ""Effect of Erythropoietin on Exercise Capacity in Patients with Moderate to Severe Chronic Heart Failure,"" Circulation, 107:294-299 (2003).;;McDonough et al., ""Cellular Oxygen Sensing: Crystal Structure of Hypoxia-Inducible Factor Prolyl Hydroxylase (PHD2),"" PNAS, 103(26):9814-9819 (2006).;;Miranker et al., ""Functionality Maps of Binding Sites: A Multiple Copy Simultaneous Search Method,"" Proteins: Structure, Function and Genetics, 11:29-34 (1991).;;Nguyen et al., ""Cellular Interactions in Vascular Growth and Differentiation,"" Int. Review of Cytology, 204:1-48 (2001).;;Nishibata et al., ""Automatic Creation of Drug Candidate Structures Based on Receptor Structure. Starting Point for Artificial Lead Generation,"" Tetrahedron, 47(43):8985-8990 (1991).;;O'Reilly et al., ""Angiostatin: A Novel Angiogenesis Inhibitor that Mediates the Suppression of Metastases by a Lewis Lung Carcinoma,"" Cell, 79:315-328 (1994).;;O'Reilly et al., ""Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth,"" Cell, 88:277-285 (1997).;;Peyssonnaux et al., ""HIF-1alpha Expression Regulates the Bactericidal Capacity of Phagocytes,"" J. Clinical Invest., 115(7):1806-1815, (2005).;;Schoneberg et al., ""Structural Basis of G Protein-Coupled Receptor Function,"" Molecular and Cellular Endocrinology, 151:181-193 (1999).;;Semenza, ""Signal Transduction to Hypoxia-inducible Factor 1,"" Biochem. Pharmacol, 64:993-998 (2002).;;Semenza, ""Regulation of Erythropoietin Production: New Insights into Molecular Mechanisms of Oxygen Homeostasis,"" Hematol. Oncol. Clin. North Am., 8:863-884 (1994).;;Semenza et al., ""Transcriptional Regulation of Genes Encoding Glycolytic Enzymes by Hypoxia-Inducible Factor 1,"" J. Biol. Chem., 269:23757-23763 (1994).;;Sexton, ""Recent advances in our understanding of peptide hormone receptors and RAMPS,"" Current Opinion in Drug Discovery and Development, 2(5):440-448 (1999).;;Sheehan, ""3-Hydroxypicolinic Acid and Some of its Derivatives,"" J. Organic Chemistry 31(3):636-638 (1996).;;Teicher et al., ""Potentiation of Cytotoxic Cancer Therapies by TNP-470 Alone and with Other Anti-Angiogenic Agents,"" Int. J. Cancer, 57:920-925 (1994).;;Vincent et al., ""Angiogenesis is Induced in a Rabbit Model of Hindlimb Ischemia by Naked DNA Encoding an HIF-1alpha/VP16 Hybrid Transcription Factor,"" Circulation, 102:2255-2261 (2000).;;Warnecke et al., ""Activation of the Hypoxia-Inducible Factor Pathway and Stimulation of Angiogenesis by Application of Prolyl Hydroxylase Inhibitors,"" FASEB Journal, 17:1186-1188 (2003).;;Wax et al., ""SM-20 is a Novel 20-kd Protein Whose Expression in the Arterial Wall is Restricted to Smooth Muscle,"" Lab. Invest., 74(4):797-808 (1996).;;Weidner et al., ""Tumor Angiogenesis and Metastasis-Correlation in Invasive Breast Carcinoma,"" New Eng. J. Med., 324(1):1-8 (1991).;;Wright et al., ""Activation of the Prolyl Hydroxylase Oxygen-Sensor Results in Induction of GLUT1, Heme Oxygenase-1, and Nitric-Oxide Synthase Proteins and Confers Protection from Metabolic Inhibition to Cardiomyocytes,"" J. Bio. Chem., 278(22):20235-20239 (2003).;;Australian Patent Application No. 2007265460; Preliminary Amendment, Apr. 28, 2010.;;Australian Patent Application No. 2007265460; First Examination Report, Jul. 19, 2010.;;Australian Patent Application No. 2007265460; Response to First Examination Report, Nov. 18, 2010.;;Canadian Patent Application No. 2,659,682; Preliminary Amendment, Mar. 29, 2010.;;New Zealand Patent Application No. 574408; Office Action, Nov. 10, 2011.;;New Zealand Patent Application No. 574408; Response to Office Action, Jul. 24, 2012.;;Philippine Patent Application No. 1-2009-500030; Response to Office Action, May 20, 2010.;;Russian Patent Application No. 2009102220; Office Action, Dec. 29, 2010.;;Russian Patent Application No. 2009102220; Response to Office Action, Jan. 5, 2011.;;Singapore Patent Application No. 200809595-2; Office Action, Feb. 5, 2010.;;Singapore Patent Application No. 200809595-2; Response to Office Action, Mar. 4, 2010.;;Singapore Patent Application No. 200809595-2; Response to Office Action, Feb. 15, 2011.;;Singapore Patent Application No. 200809595-2; Notice of Allowance, Jul. 15, 2011.;;Canadian Patent Application No. 2,659,682; Office Action, May 18, 2010.;;Canadian Patent Application No. 2,659,682; Response Office Action, Jun. 11, 2010.;;Chinese Patent Application No. 200780030720.0; Preliminary Amendments, May 10, 2010.;;Chinese Patent Application No. 200780030720.0; Office Action, Aug. 19, 2011.;;Chinese Patent Application No. 200780030720.0; Response to Office Action, Aug. 22, 2011.;;Chinese Patent Application No. 200780030720.0; Response to Office Action, Mar. 15, 2012.;;Colombian Patent Application No. 09006711; Preliminary Amendment, Apr. 29, 2010.;;Colombian Patent Application No. 09006711; Office Action, Aug. 23, 2012.;;Colombian Patent Application No. 09006711; Response to Office Action, Sep. 18, 2012.;;European Patent Application No. 07 835 890.0; Office Action, Mar. 3, 2010.;;European Patent Application No. 07 835 890.0; Response to Office Action, Mar. 28, 2010.;;European Patent Application No. 07 835 890.0; Notice of Allowance, Jun. 24, 2010.;;European Patent Application No. 07 835 890.0; Opposition Filed, Jul. 20, 2011.;;European Patent Application No. 07 835 890.0; Document Cited in Opposition: International Union of Pure and Applied Chemistry; Glossary of Class Names of Organic Compounds and Reactive Intermediates Based on Structure; Pure & Appl. Chem., vol. 67, Nos. 8/9, pp. 1307-1375, (1995).;;European Patent Application No. 07 835 890.0; Document Cited in Opposition: Certified U.S. Appl. No. 60/816,522, Priority Document of European Patent Application No. 07 835 890.0, Sep. 27, 2007.;;Warshakoon et al., ""Design and synthesis of substituted pyridine derivatives as HIF-1alpha prolyl hydroxylase inhibitors,"" Bioorganic & Medicinal Chemistry Letters, 16 (2006) 5616-5620.;;European Patent Application No. 07 835 890.0; Response to Opposition, Dec. 28, 2011.;;European Patent Application No. 11 000 872.9; European Search Report, Apr. 28, 2011.;;Israeli Patent Application No. 196127; Preliminary Amendments, Apr. 12, 2010.;;Israeli Patent Application No. 196127; Office Action Feb. 15, 2012.;;Israeli Patent Application No. 196127; Response to Office Action Feb. 20, 2012.;;Japanese Patent Application No. 2009-518232; Office Action, Nov. 11, 2011.;;Japanese Patent Application No. 2009-518232; Response to Office Action, Feb. 10, 2012.;;Japanese Patent Application No. 2009-518232; Office Action, May 24, 2012.;;Japanese Patent Application No. 2009-518232; Response to Office Action, Jul. 25, 2012.;;Japanese Patent Application No. 2009-518232; Notice of Allowance, Oct. 4, 2012.;;Korean Patent Application No. 2009-7001697; Office Action, May 4, 2011.;;Korean Patent Application No. 2009-7001697; Response to Office Action, Jun. 8, 2011.;;Korean Patent Application No. 2009-7001697; Decision to Grant, Dec. 28, 2011.",ACTIVE
572,US,B2,US 9666391 B2,160-013-559-162-284,2017-05-30,2017,US 201414520101 A,2014-10-21,US 201414520101 A;;US 201361894324 P,2013-10-22,Retractable snap domes,"A retractable snap dome in a keyboard, serving as a force resistor for a key in a conventional manner, includes an additional collapsed state wherein the key can be retracted by an electromechanical polymer (EMP) actuator to a persistent down position. In one embodiment, the EMP actuator is a bimorph EMP actuator that can be actuated to bring the key from down position to up position, ready for conventional keyboard operation, and vice versa. Such operations allow the keyboard to have a desirable decreased thickness relative to conventional keyboards. Thus, a keyboard of the present invention finds application in ultra-slim electronic devices. When provided in a notebook computer wherein the keyboard is folded against a video or graphic display, the keyboard keys may be placed in the retracted down position, thereby preventing the keys from pressing against the video or graphical display with a force that may damage the display.",NOVASENTIS INC,LEVATICH MARK;;ZELLERS BRIAN C;;FOSTER EDWARD;;BOYER MADELINE;;THALER BRIAN;;PATHAK RAJ;;DUCHARME RICHARD,NOVASENTIS INC (2013-10-18);;KEMET ELECTRONICS CORPORATION (2021-10-01),https://lens.org/160-013-559-162-284,Granted Patent,yes,71,0,2,2,0,H01H13/85;;H01H13/85;;H01H2215/016;;H01H2215/016,H01H13/85,,16,4,028-579-544-599-333;;094-469-853-004-192;;044-426-781-244-15X;;108-010-564-784-716,10.1117/12.879438;;18687960;;10.1126/science.1159655;;10.1126/science.280.5372.2101;;9641912;;0009641912;;10.1002/1521-4095(20021104)14:21<1574::aid-adma1574>3.0.co;2-#,"Matysek, Marc et al., “Combined Driving and Sensing Circuitry for Dielectric Elastomer Actuators in mobile applications”, Electroactive Polymer Actuators and Devices (EAPAD) 2011, Proc. of SPIE vol. 7976, 797612, 11 pages.;;Neese, Bret et al., “Large Electrocaloric Effect in Ferroelectric Polymers Near Room Temperature”, Science vol. 321, Aug. 8, 2008, pp. 821-823.;;Zhang Q. M. et al., “Giant Electrostriction and Relaxor Ferroelectric Behavior in Electron-Irradiated Poly(vinylidene fluoride-trifluoroethylene) Copolymer”, Science vol. 280, Jun. 26, 1998, pp. 2101-2104.;;Xia F. et al., “High Electromechanical Responses in a Poly(vinylidene fluoride-trifluoroethylene-chlorofluoroethylene) Terpolymer”, Advanced Materials, vol. 14, issue 21, Nov. 2002, pp. 1574-1577.;;PCT International Search Report and Written Opinion date of mailing Dec. 23, 2013, International Patent Application No. PCT/US2013/053594, 9 pages.;;PCT International Search Report and Written Opinion date of mailing Mar. 17, 2014, International Patent Application No. PCT/US2013/071085, 10 pages.;;PCT International Search Report and Written Opinion date of mailing Mar. 13, 2014, International Patent Application No. PCT/US2013/071072, 15 pages.;;PCT International Search Report and Written Opinion date of mailing Mar. 20, 2014, International Patent Application No. PCT/US2013/071075, 12 pages.;;PCT International Search Report and Written Opinion date of mailing Mar. 28, 2014, International Patent Application No. PCT/US2013/071078, 13 pages.;;PCT International Search Report and Written Opinion date of mailing Apr. 28, 2014, International Patent Application No. PCT/US2013/071062, 11 pages.;;PCT International Preliminary Report on Patentability dated May 26, 2015, International Patent Application No. PCT/US2013/071072, 9 pages.;;PCT International Preliminary Report on Patentability dated May 26, 2015, International Patent Application No. PCT/US2013/071075, 9 pages.;;PCT International Preliminary Report on Patentability dated May 26, 2015, International Patent Application No. PCT/US2013/071078, 10 pages.;;PCT International Preliminary Report on Patentability dated May 26, 2015, International Patent Application No. PCT/US2013/071085, 7 pages.;;PCT International Preliminary Report on Patentability dated Jul. 7, 2015, International Patent Application No. PCT/IB2013/003212, 15 pages.;;PCT International Written Opinion date of mailing Oct. 15, 2014, International Patent Application No. PCT/IB2013/003212, 20 pages.",ACTIVE
573,EP,A2,EP 4227147 A2,054-455-018-580-542,2023-08-16,2023,EP 23152001 A,2023-01-17,US 202263301822 P;;US 202263343646 P;;US 202318097400 A,2022-01-21,INTERNAL EMC PROTECTION FOR SHIELD FOR PLASTIC HIGH VOLTAGE DISTRIBUTION CENTERS,"An electrical distribution center (100) includes a housing (104) formed of an electrically nonconductive material, an electromagnetic housing shield (110) formed of an electrically conductive material disposed within a cavity (112) in the housing (104), a cover (116) enclosing the cavity (112) having an electromagnetic cover shield (118) formed of the electrically conductive material and in electrical contact with the housing shield (110), and a plurality of shielded electrical connectors (102) interconnected to one another through electrical components (126) contained within the cavity (112). The electrical components (126) are mounted on a plurality of standoffs (128) defined by an inner surface of the housing (104). The plurality of standoffs (128) extends through a plurality of apertures (130) defined in the housing shield (110).
",APTIV TECH LTD,FERRUCIO MARCIO;;SILVA FERNANDO JOSE;;BOYER RICHARD J;;SPADONI STEVE;;BIZON DON E;;BRANDON CHRISTOPHER,,https://lens.org/054-455-018-580-542,Patent Application,yes,0,0,3,4,0,H05K9/0045;;H01R13/6588;;H01R13/659,B60L50/00;;H05K9/00,,0,0,,,,PENDING
574,SG,A1,SG 115805 A1,138-666-293-236-653,2005-10-28,2005,SG 200501874 A,2005-03-29,US 55865004 P,2004-04-01,TEMPLATE FOR EVALUATING PARTS AND METHOD OF USING SAME,,UNITED TECHNOLOGIES CORP,RICHARD W VARSELL;;JESSE R BOYER;;DOREL M MOISEI;;JAMES M KOONANKEIL;;LUKAS A RUBINO,,https://lens.org/138-666-293-236-653,Patent Application,no,3,0,6,6,0,G01B3/14;;B33Y80/00;;B33Y80/00;;G01B3/14,B23P15/00;;F01D5/00;;G01B3/14,,0,0,,,,PENDING
575,KR,A,KR 20190051826 A,177-448-973-144-823,2019-05-15,2019,KR 20180132768 A,2018-11-01,US 201715804444 A,2017-11-06,ELECTRICAL CONNECTION SYSTEM FOR SHIELDED WIRE CABLE,"The present invention relates to an electrical connection system configured to terminate electrical conductors (102, 104) and transmit a digital electrical signal having a data transfer rate of 5 gigabit per second (Gb/s). The system comprises: a pair of first parallel specular symmetric terminals (160, 162) having planar connection portions (164, 166); and a pair of second parallel specular symmetric terminals (132, 134) having contact points (138, 142) configured to be in contact with the cantlevercantilever portions (136, 140) and the first terminals (160, 162). The cantilever portions (136, 140) are perpendicular to the planar connection portions (164, 166) in general. The terminals (132, 134, 160, 162) cooperate to provide a constant characteristic impedance. The connection system further comprises electromagnetic shielding portions (172, 174) surrounding the terminals (132, 134, 160, 162) in a longitudinal direction. The connection system is suitable for a termination wire cable (100) for transmitting a digital signal using a data transport protocol such as a universal serial bus (USB) 3.0 and a high-definition multimedia interface (HDMI) 1.4.",APTIV TECH LTD,BOYER RICHARD J;;CARBONE KLARA P;;JONES LESLIE L;;LIPTAK NICOLE L;;MESSURI DOMINIC ANTHONY,,https://lens.org/177-448-973-144-823,Patent Application,no,2,1,7,39,0,H01R13/2442;;H01R13/6593;;H01B7/1875;;H01B11/002;;H01B11/1091;;H01R13/6474;;H01R13/6581;;H01R13/6591;;H01R24/62;;H01R2107/00,H01R13/24;;H01B7/18;;H01B11/00;;H01B11/10;;H01R13/6581,,0,0,,,,ACTIVE
576,EP,A2,EP 1252809 A2,018-196-239-396-141,2002-10-30,2002,EP 02009122 A,2002-04-24,US 28641401 P,2001-04-25,Walk-behind implement having forward and reverse drives and a method of operation therefor,"A walk-behind self-propelled implement (20a, 20b, 20c), such as a snow thrower (20a, 20b) or lawnmower (20c), for example, is provided. The implement includes first and second transmission modules (128, 130) associated with a common single axle (142) to which a pair of drive wheels (24a, 24b, 24c) is attached. The first and second transmission modules are operable exclusively with respect to one another to drive the axle and the wheels in a forward and reverse direction, respectively. A control member (262) mounted to the handle (30) of the implement includes a forward bail member (264) pivotable to rotate the control member in a first direction to urge the wheel to rotate in a forward direction, and a reverse bail member (266) pivotable to rotate the control member in a second direction opposite the first direction to urge the wheel to rotate in a reverse direction.",TECUMSEH PRODUCTS CO,COX PAUL C;;JOHNSON KEVIN L;;BOYER SCOTT G;;RUEBUSCH RICHARD T;;HERRICK TODD W,,https://lens.org/018-196-239-396-141,Patent Application,yes,0,5,6,6,0,A01D34/6812;;A01D34/6812;;A01D34/69;;A01D34/69;;A01D2034/6843;;A01D2034/6843;;A01D2101/00;;A01D2101/00;;E01H5/04;;E01H5/04;;F16D23/12;;F16D23/12,A01D34/47;;A01D34/56;;A01D34/69;;E01H5/04;;E01H5/09;;F16D23/12,,0,0,,,,DISCONTINUED
577,US,B2,US 9234428 B2,175-279-299-679-916,2016-01-12,2016,US 201213613922 A,2012-09-13,US 201213613922 A,2012-09-13,Turbine bucket internal core profile,"Turbine bucket nominal internal core profiles and core insert external profiles are provided. In one embodiment, a turbine bucket includes an airfoil, platform, shank and dovetail. The bucket has a nominal internal core profile substantially in accordance with Cartesian coordinate values of X, Y and Z set forth in Table 1 wherein the Z values are non-dimensional values from 0 to 1 convertible to Z distances in inches by multiplying the Z values by a height of the bucket in inches, and wherein X and Y are non-dimensional values which, when connected by smooth continuing arcs, define internal core profile sections at each distance Z along the bucket, the profile sections at the Z distances being joined smoothly with one another to form said bucket internal core profile.",GOOD RANDALL RICHARD;;BOYER BRADLEY TAYLOR;;FU XIAOYONG;;SMITH AARON EZEKIEL;;PERRY II JACOB C;;GEN ELECTRIC,GOOD RANDALL RICHARD;;BOYER BRADLEY TAYLOR;;FU XIAOYONG;;SMITH AARON EZEKIEL;;PERRY II JACOB C,GE INFRASTRUCTURE TECHNOLOGY LLC (2023-11-10);;GENERAL ELECTRIC COMPANY (2012-09-13),https://lens.org/175-279-299-679-916,Granted Patent,yes,7,0,2,2,0,F01D5/14;;F01D5/14;;F01D5/187;;F01D5/187,F01D5/14;;F01D5/18,,1,0,,,"U.S. Appl. No. 13/304,734, filed Nov. 28, 2011.",ACTIVE
578,US,B2,US 10211546 B2,024-979-521-006-205,2019-02-19,2019,US 201715804444 A,2017-11-06,US 201715804444 A;;US 201615369973 A;;US 201314101472 A,2013-12-10,Electrical connection system for shielded wire cable,An electrical connection system configured to terminate electrical connectors and to transmit digital electrical signals having a data transfer rate of 5 Gigabits per second (Gb/s) or higher. The system includes a first parallel mirrored pair of terminals having a planar connection portion and a second pair of parallel mirrored terminals having a cantilever beam portion and a contact points configured to contact the first terminals. The cantilever beam portions are generally perpendicular to the planar connection portions. The terminals cooperate to provide consistent characteristic impedance. The connection system further includes an electromagnetic shield that longitudinally surrounds the terminals. The connection system is suited for terminating wire cables transmitting digital signals using data transfer protocols such as Universal Serial Bus (USB) 3.0 and High Definition Multimedia Interface (HDMI) 1.4.,APTIV TECH LTD,BOYER RICHARD J;;CARBONE KLARA P;;JONES LESLIE L;;LIPTAK NICOLE L;;MESSURI DOMINIC ANTHONY,APTIV TECHNOLOGIES LIMITED (2018-01-01);;DELPHI TECHNOLOGIES INC (2017-09-27);;APTIV TECHNOLOGIES AG (2023-10-06),https://lens.org/024-979-521-006-205,Granted Patent,yes,28,0,2,39,0,H01B1/026;;H01B7/1875;;H01B11/002;;H01B11/1091;;H01R9/0518;;H01R13/6582;;H01R13/6593;;H01R13/65912;;H01R9/03;;H01B1/026;;H01B7/1875;;H01B11/002;;H01B11/1091;;H01R9/0518;;H01R13/6582;;H01R13/6593;;H01R13/65912,H01R9/03;;H01B1/02;;H01B7/18;;H01B11/00;;H01B11/10;;H01R9/05;;H01R13/6582;;H01R13/6593,,0,0,,,,ACTIVE
579,EP,A3,EP 4227147 A3,162-006-041-845-950,2023-10-18,2023,EP 23152001 A,2023-01-17,US 202263301822 P;;US 202263343646 P;;US 202318097400 A,2022-01-21,INTERNAL EMC PROTECTION FOR SHIELD FOR PLASTIC HIGH VOLTAGE DISTRIBUTION CENTERS,"An electrical distribution center (100) includes a housing (104) formed of an electrically nonconductive material, an electromagnetic housing shield (110) formed of an electrically conductive material disposed within a cavity (112) in the housing (104), a cover (116) enclosing the cavity (112) having an electromagnetic cover shield (118) formed of the electrically conductive material and in electrical contact with the housing shield (110), and a plurality of shielded electrical connectors (102) interconnected to one another through electrical components (126) contained within the cavity (112). The electrical components (126) are mounted on a plurality of standoffs (128) defined by an inner surface of the housing (104). The plurality of standoffs (128) extends through a plurality of apertures (130) defined in the housing shield (110).
",APTIV TECH LTD,FERRUCIO MARCIO;;SILVA FERNANDO JOSE;;BOYER RICHARD J;;SPADONI STEVE;;BIZON DON E;;BRANDON CHRISTOPHER,,https://lens.org/162-006-041-845-950,Search Report,yes,4,0,3,4,0,H05K9/0045;;H01R13/6588;;H01R13/659,B60L50/00;;H05K9/00,,0,0,,,,PENDING
580,CA,A1,CA 2500683 A1,014-449-118-715-22X,2005-10-01,2005,CA 2500683 A,2005-03-14,US 55865004 P,2004-04-01,TEMPLATE FOR EVALUATING PARTS AND METHOD OF USING SAME,"A template for evaluating a part, comprising: a surface having a shape corresponding to the part; and at least one element on the surface corresponding to a desired location of a feature on the part. A method of evaluating a part, comprising the steps of: providing a template having a shape corresponding to the part and at least o ne element thereon corresponding to a desired location of a feature on the part associating the template with the part; and using the element to determine whether the feature is at the desir ed location.",UNITED TECHNOLOGIES CORP,VARSELL RICHARD W;;KOONANKEIL JAMES M;;RUBINO LUKAS A;;BOYER JESSE R;;MOISEI DOREL M,,https://lens.org/014-449-118-715-22X,Patent Application,no,0,0,6,6,0,G01B3/14;;B33Y80/00;;B33Y80/00;;G01B3/14,B23P15/00;;F01D5/00;;G01B3/14,,0,0,,,,DISCONTINUED
581,US,A,US 5850806 A,188-638-344-603-405,1998-12-22,1998,US 76619296 A,1996-12-12,US 76619296 A,1996-12-12,Controllable strobe light system and method for directing the movements of fish,"A system for directing fish away from danger points at an underwater structure includes multiple submersible flash heads operatively connected to a flash head control unit. The flash sequence, rate and intensity are adjustable by the system operator in real time using a system control unit which can be remotely located. The flash heads are strobed in a manner intended to alter the behavior of the fish. The system may include means to generate an air curtain near the flash heads to improve light dispersion and water jet means to clean the lenses on the flash heads.",FLASH TECHNOLOGY CORP OF AMERI,MARK FRED;;NORTHRUP RICHARD;;OUELLETTE LARRY;;SCHIPP ROBERTO;;IHRIE RONALD;;BOYER EDWARD;;SOMERS WILLIAM F,SPX CORPORATION (2003-01-17);;GS DEVELOPMENT CORPORATION (2004-12-30);;FLASH TECHNOLOGY CORPORATION OF AMERICA (1998-10-18);;GSLE SUBCO L.L.C (2004-12-31),https://lens.org/188-638-344-603-405,Granted Patent,yes,6,15,2,16,0,A01K79/02;;A01K79/02,A01K79/02,119/219,18,0,,,"Innovators with EPRI Technology Jul. 1992.;;Cost Effective Approaches for Protecting Fish at Hydroelectric Projects HCI Publications 1992.;;Evaluation of Study Technologies to Asses the Effectiveness the Strobe Lights . . . Mar. 1999.;;A Demonstration of Strobe Lights to Repel Fish .;;Species of Fish Showing Avoidance Response to Strobe Lights.;;Met Ed. News Shad Project at York Haven Show Results.;;Behavioral Barriers.;;Guiding American Shad w/Strobe Lights.;;Response of Juvenile Coho & Chinook Salmon to Strobe & Mercury Vapor Lights.;;Innovators with Epritechnology Jul. 1992.;;Cost Effective Approaches for Protecting Fish at Hydroelectric Projects HCI Publications 1992.;;Evaluation of Study Techniques to Assiss . . . .;;A Demonstration of Strobe Lights to Repel Fish Water Power 91.;;Species of Fish Showing Avoidance Response to Strobe Lights EPRI May 1994 .;;Shad Project at York Havin Shows Results Met Ed New. Oct. 22, 1991.;;Guiding American Shad w/Strobe Lights Hydro Review Jul. 1992.;;Response of Juvenile Coho and Chinook Salmon . . . NAJM 1992.;;Fishing Behavior Fishing Behaviors.",EXPIRED
582,US,A1,US 2002/0189137 A1,195-509-770-431-805,2002-12-19,2002,US 12818402 A,2002-04-23,US 12818402 A;;US 28641401 P,2001-04-25,Walk-behind implement having forward and reverse drives and a method of operation therefor,"
   A walk-behind self-propelled implement, such as a snow thrower or lawnmower, for example, is provided. The implement includes first and second transmission modules associated with a common single axle to which a pair of drive wheels is attached. The first and second transmission modules are operable exclusively with respect to one another to drive the axle and the wheels in a forward and reverse direction, respectively. A control member mounted to the handle of the implement includes a forward bail member pivotable to rotate the control member in a first direction to urge the wheel to rotate in a forward direction, and a reverse bail member pivotable to rotate the control member in a second direction opposite the first direction to urge the wheel to rotate in a reverse direction. 
",COX C. PAUL;;JOHNSON KEVIN L.;;BOYER SCOTT G.;;RUEBUSCH RICHARD T.;;HERRICK TODD W.,COX C PAUL;;JOHNSON KEVIN L;;BOYER SCOTT G;;RUEBUSCH RICHARD T;;HERRICK TODD W,TECUMSEH PRODUCTS COMPANY (2001-08-05),https://lens.org/195-509-770-431-805,Patent Application,yes,7,28,6,6,0,A01D34/6812;;A01D34/6812;;A01D34/69;;A01D34/69;;A01D2034/6843;;A01D2034/6843;;A01D2101/00;;A01D2101/00;;E01H5/04;;E01H5/04;;F16D23/12;;F16D23/12,A01D34/47;;A01D34/56;;A01D34/69;;E01H5/04;;E01H5/09;;F16D23/12,37/242,0,0,,,,DISCONTINUED
583,JP,A,JP 2019106356 A,090-818-703-775-562,2019-06-27,2019,JP 2018177085 A,2018-09-21,US 201715804444 A,2017-11-06,ELECTRICAL CONNECTION SYSTEM FOR SHIELDED WIRE CABLE,To provide an electrical connection system configured to terminate electrical conductors and to transmit digital electrical signals having a data transfer rate of 5 Gigabits per second (Gb/s) or higher.SOLUTION: A system includes a first pair of parallel mirrored terminals having a planar connection portion and a second pair of parallel mirrored terminals. The second pair of parallel mirrored terminals has a cantilever beam portion and contact points configured to contact the first terminals. The cantilever beam portions are substantially perpendicular to the planar connection portions. The terminals cooperate to provide constant characteristic impedance. The connection system further includes an electromagnetic shield that longitudinally surrounds the terminals. The connection system is suited for terminating wire cables transmitting digital signals using data transfer protocol such as Universal Serial Bus (USB) 3.0 and High Definition Multimedia Interface (HDMI:R).SELECTED DRAWING: Figure 8,APTIV TECHNOLOFIES LTD,RICHARD J BOYER;;KLARA P CARBONE;;JONES LESLIE L;;NICOLE L LIPTAK;;DOMINIC ANTHONY MESSURI,,https://lens.org/090-818-703-775-562,Patent Application,no,6,0,7,39,0,H01R13/2442;;H01R13/6593;;H01B7/1875;;H01B11/002;;H01B11/1091;;H01R13/6474;;H01R13/6581;;H01R13/6591;;H01R24/62;;H01R2107/00,H01R24/28;;H01R13/04;;H01R13/11;;H01R13/6581;;H01R24/20,,0,0,,,,ACTIVE
584,US,B1,US 6370802 B1,136-086-120-504-599,2002-04-16,2002,US 39753499 A,1999-09-16,US 39753499 A,1999-09-16,Back-lit fascia with spring loaded fascia tensioner,"
    A sign frame assembly for supporting a flexible fascia. In one embodiment, a frame member extends in a first direction and has first and second bracket-mounting sections spaced apart from each other in the first direction. First and second brackets have inner and outer opposite ends. The inner end of the first bracket is attached to the first bracket-mounting section of the first frame member. The inner end of the second bracket are pivotally mounted to the second bracket-mounting section of the frame member. First and second elongated fascia attachment members are affixed respectively to the outer ends of the first and second brackets. A flexible fascia having oppositely disposed edges is connected to the first and second elongated members. A bias member is operatively disposed between the frame member and the second bracket such that the bias member exerts a rotational force on the second bracket in a direction tending to spread apart the elongated fascia attachment members and tension the flexible fascia therebetween. Additional embodiments utilizing biased pivotal fascia tension members are disclosed. 
",LSI INDUSTRIES INC,BOYER JOHN D;;MAKSTALLER RONALD W;;GESSNER S FRANK;;GRIMES RICHARD SCOTT;;WEDDING WILLIAM R,LSI INDUSTRIES INC (1999-09-10),https://lens.org/136-086-120-504-599,Granted Patent,yes,19,3,6,6,0,G09F17/00;;G09F17/00;;G09F13/04;;G09F13/04;;G09F15/0025;;G09F15/0025;;Y10T29/49716;;Y10T29/49716;;Y10T29/4984;;Y10T29/4984;;Y10T29/49863;;Y10T29/49863;;Y10T29/49867;;Y10T29/49867;;Y10T29/4987;;Y10T29/4987,G09F13/04;;G09F15/00;;G09F17/00,40/603;;40/564;;160/378,0,0,,,,EXPIRED
585,JP,A,JP 2002339329 A,190-065-737-003-79X,2002-11-27,2002,JP 2002122186 A,2002-04-24,US 28641401 P,2001-04-25,WALK-BEHIND TYPE MACHINE HAVING FORWARD AND REARWARD DRIVE AND ITS OPERATION METHOD,"PROBLEM TO BE SOLVED: To provide a walk-behind type self-propelled implement (20a, 20b, 20c) such as a pushing type snow plower (20a, 20b) or lawn mower (20c) for example. SOLUTION: This machine contains first and second transmission modules (128, 130) coupled to a common single axle (142). The first and second transmission modules respectively drive and wheel in forward and reverse directions and thus they can act exclusively to each other. A control member (262) mounted to a handle (30) of the machine includes a forward bail member (264) which is rotatable to urge the wheel to rotate in forward direction by turning the control member in the first direction and to rotate the wheel in reverse direction and also includes a reverse bail member (266) which is pivotable to rotate the control member in a second direction opposite the first direction to urge the wheel to rotate in a retreat direction.",TECUMSEH PRODUCTS CO,COX PAUL C;;JOHNSON KEVIN L;;BOYER SCOTT G;;RUEBUSCH RICHARD T;;HERRICK TODD W,,https://lens.org/190-065-737-003-79X,Patent Application,no,0,0,6,6,0,A01D34/6812;;A01D34/6812;;A01D34/69;;A01D34/69;;A01D2034/6843;;A01D2034/6843;;A01D2101/00;;A01D2101/00;;E01H5/04;;E01H5/04;;F16D23/12;;F16D23/12,A01D34/47;;A01D34/56;;A01D34/69;;E01H5/04;;E01H5/09;;F16D23/12,,0,0,,,,PENDING
586,EP,A1,EP 3480900 A1,086-213-077-724-306,2019-05-08,2019,EP 18201302 A,2018-10-18,US 201715804444 A,2017-11-06,ELECTRICAL CONNECTION SYSTEM FOR SHIELDED WIRE CABLE,"An electrical connection system configured to terminate electrical conductors (102, 104) and to transmit digital electrical signals having a data transfer rate of 5 Gigabits per second (Gb/s) or higher. The system includes a first parallel mirrored pair of terminals (160, 162) having a planar connection portion (164, 166) and a second pair of parallel mirrored terminals (132, 134) having a cantilever beam portion (136, 140) and a contact points (138, 142) configured to contact the first terminals (160, 162). The cantilever beam portions (136, 140) are generally perpendicular to the planar connection portions (164, 166). The terminals (132, 134, 160, 162) cooperate to provide consistent characteristic impedance. The connection system further includes an electromagnetic shield (172, 174) that longitudinally surrounds the terminals (132, 134, 160, 162). The connection system is suited for terminating wire cables (100) transmitting digital signals using data transfer protocols such as Universal Serial Bus (USB) 3.0 and High Definition Multimedia Interface (HDMI) 1.4.
",APTIV TECH LTD,BOYER RICHARD J;;CARBONE KLARA P;;JONES LESLIE L;;LIPTAK NICOLE L;;MESSURI DOMINIC A,,https://lens.org/086-213-077-724-306,Patent Application,yes,3,1,7,39,0,H01R13/6474;;H01R13/6591;;H01R13/6593;;H01R24/62;;H01R2107/00;;H01R13/2442;;H01R13/6581;;H01B11/1091;;H01B11/002;;H01B7/1875,H01R13/6593;;H01R13/6474;;H01R13/6591;;H01R24/62;;H01R107/00,,0,0,,,,DISCONTINUED
587,EP,A3,EP 1252809 A3,146-592-874-021-192,2003-10-29,2003,EP 02009122 A,2002-04-24,US 28641401 P,2001-04-25,Walk-behind implement having forward and reverse drives and a method of operation therefor,"A walk-behind self-propelled implement (20a, 20b, 20c), such as a snow thrower (20a, 20b) or lawnmower (20c), for example, is provided. The implement includes first and second transmission modules (128, 130) associated with a common single axle (142) to which a pair of drive wheels (24a, 24b, 24c) is attached. The first and second transmission modules are operable exclusively with respect to one another to drive the axle and the wheels in a forward and reverse direction, respectively. A control member (262) mounted to the handle (30) of the implement includes a forward bail member (264) pivotable to rotate the control member in a first direction to urge the wheel to rotate in a forward direction, and a reverse bail member (266) pivotable to rotate the control member in a second direction opposite the first direction to urge the wheel to rotate in a reverse direction.",TECUMSEH PRODUCTS CO,COX PAUL C;;JOHNSON KEVIN L;;BOYER SCOTT G;;RUEBUSCH RICHARD T;;HERRICK TODD W,,https://lens.org/146-592-874-021-192,Search Report,yes,4,0,6,6,0,A01D34/69;;A01D2101/00;;E01H5/04;;F16D23/12;;A01D34/6812;;A01D2034/6843;;F16D23/12;;E01H5/04;;A01D2101/00;;A01D34/69;;A01D2034/6843;;A01D34/6812,A01D34/56;;A01D34/69;;A01D34/47;;E01H5/04;;E01H5/09;;F16D23/12,,0,0,,,,DISCONTINUED
588,CN,A,CN 109755816 A,186-888-961-760-878,2019-05-14,2019,CN 201811294285 A,2018-11-01,US 201715804444 A,2017-11-06,Electrical connection system for shielded wire cable,"An electrical connection system configured to terminate electrical conductors (102, 104) and to transmit digital electrical signals having a data transfer rate of 5 Gigabits per second (Gb/s) or higher. The system includes a first parallel mirrored pair of terminals (160, 162) having a planar connection portion (164, 166) and a second pair of parallel mirrored terminals (132, 134) having a cantilever beam portion (136, 140) and a contact points (138, 142) configured to contact the first terminals (160, 162). The cantilever beam portions (136, 140) are generally perpendicular to the planar connection portions (164, 166). The terminals (132, 134, 160, 162) cooperate to provide consistent characteristic impedance. The connection system further includes an electromagnetic shield (172, 174) that longitudinally surrounds the terminals (132, 134, 160, 162). The connection system is suited for terminating wire cables (100) transmitting digital signals using data transfer protocols such as Universal Serial Bus (USB) 3.0 and High Definition Multimedia Interface (HDMI) 1.4.",DELPHI TECH INC,BOYER RICHARD J;;CARBONE KLARA P;;JONES LESLIE L;;LIPTAK NICOLE L;;MESSURI DOMINIC ANTHONY,,https://lens.org/186-888-961-760-878,Patent Application,no,5,1,7,39,0,H01R13/2442;;H01R13/6593;;H01B7/1875;;H01B11/002;;H01B11/1091;;H01R13/6474;;H01R13/6581;;H01R13/6591;;H01R24/62;;H01R2107/00,H01R13/6592;;H01B7/02;;H01B11/00;;H01B11/10;;H01R13/22;;H01R13/24;;H01R13/6581,,0,0,,,,ACTIVE
589,US,A1,US 2005/0217131 A1,078-210-137-259-298,2005-10-06,2005,US 89869404 A,2004-07-23,US 89869404 A;;US 55865004 P,2004-04-01,Template for evaluating parts and method of using same,"A template for evaluating a part, comprising: a surface having a shape corresponding to the part; and at least one element on the surface corresponding to a desired location of a feature on the part. A method of evaluating a part, comprising the steps of: providing a template having a shape corresponding to the part and at least one element thereon corresponding to a desired location on the part; associating the template with the part; and using the element to determine whether the feature is at the desired location.",VARSELL RICHARD W;;BOYER JESSE R;;MOISEI DOREL M;;KOONANKEIL JAMES M;;RUBINO LUKAS A,VARSELL RICHARD W;;BOYER JESSE R;;MOISEI DOREL M;;KOONANKEIL JAMES M;;RUBINO LUKAS A,RTX CORPORATION (2004-05-24),https://lens.org/078-210-137-259-298,Patent Application,yes,14,23,6,6,0,G01B3/14;;B33Y80/00;;B33Y80/00;;G01B3/14,B23P15/00;;F01D5/00;;G01B3/14,33/562,0,0,,,,ACTIVE
590,EP,A1,EP 1582838 A1,074-191-310-094-399,2005-10-05,2005,EP 05251995 A,2005-03-30,US 55865004 P,2004-04-01,Template for evaluating turbine blades,"A template (11) for evaluating a part (50), preferably a turbine blade, comprises a surface (17) having shape corresponding to the part (50) and at least one element (21) on the surface (17) corresponding to a desired location of a feature on the part (50). A method of evaluating a part comprises the steps of: providing a template (11) having a shape corresponding to the part (50) and at least one element thereon corresponding to a desired location of a feature on the part (50), associating the template (11) with the part (50); and using the element to determine whether the feature is at the desired location.",UNITED TECHNOLOGIES CORP,VARSELL RICHARD W;;BOYER JESSE R;;MOISEI DOREL M;;KOONANKEIL JAMES M;;RUBINO LUKAS A,,https://lens.org/074-191-310-094-399,Patent Application,yes,8,7,6,6,0,G01B3/14;;B33Y80/00;;B33Y80/00;;G01B3/14,B23P15/00;;F01D5/00;;G01B3/14,,0,0,,,,DISCONTINUED
591,US,A1,US 2018/0062280 A1,126-227-117-216-231,2018-03-01,2018,US 201715804444 A,2017-11-06,US 201715804444 A;;US 201615369973 A;;US 201314101472 A,2013-12-10,ELECTRICAL CONNECTION SYSTEM FOR SHIELDED WIRE CABLE,An electrical connection system configured to terminate electrical connectors and to transmit digital electrical signals having a data transfer rate of 5 Gigabits per second (Gb/s) or higher. The system includes a first parallel mirrored pair of terminals having a planar connection portion and a second pair of parallel mirrored terminals having a cantilever beam portion and a contact points configured to contact the first terminals. The cantilever beam portions are generally perpendicular to the planar connection portions. The terminals cooperate to provide consistent characteristic impedance. The connection system further includes an electromagnetic shield that longitudinally surrounds the terminals. The connection system is suited for terminating wire cables transmitting digital signals using data transfer protocols such as Universal Serial Bus (USB) 3.0 and High Definition Multimedia Interface (HDMI) 1.4.,DELPHI TECH INC,BOYER RICHARD J;;CARBONE KLARA P;;JONES LESLIE L;;LIPTAK NICOLE L;;MESSURI DOMINIC ANTHONY,APTIV TECHNOLOGIES LIMITED (2018-01-01);;DELPHI TECHNOLOGIES INC (2017-09-27);;APTIV TECHNOLOGIES AG (2023-10-06),https://lens.org/126-227-117-216-231,Patent Application,yes,11,3,2,39,0,H01B1/026;;H01B7/1875;;H01B11/002;;H01B11/1091;;H01R9/0518;;H01R13/6582;;H01R13/6593;;H01R13/65912;;H01R9/03;;H01B1/026;;H01B7/1875;;H01B11/002;;H01B11/1091;;H01R9/0518;;H01R13/6582;;H01R13/6593;;H01R13/65912,H01R9/03;;H01B11/00;;H01R13/506;;H04L25/02,,0,0,,,,ACTIVE
592,US,A1,US 2014/0069110 A1,059-033-176-961-086,2014-03-13,2014,US 201213613922 A,2012-09-13,US 201213613922 A,2012-09-13,TURBINE BUCKET INTERNAL CORE PROFILE,"Turbine bucket nominal internal core profiles and core insert external profiles are provided. In one embodiment, a turbine bucket includes an airfoil, platform, shank and dovetail. The bucket has a nominal internal core profile substantially in accordance with Cartesian coordinate values of X, Y and Z set forth in Table 1 wherein the Z values are non-dimensional values from 0 to 1 convertible to Z distances in inches by multiplying the Z values by a height of the bucket in inches, and wherein X and Y are non-dimensional values which, when connected by smooth continuing arcs, define internal core profile sections at each distance Z along the bucket, the profile sections at the Z distances being joined smoothly with one another to form said bucket internal core profile.",GOOD RANDALL RICHARD;;BOYER BRADLEY TAYLOR;;FU XIAOYONG;;SMITH AARON EZEKIEL;;PERRY II JACOB C;;GEN ELECTRIC,GOOD RANDALL RICHARD;;BOYER BRADLEY TAYLOR;;FU XIAOYONG;;SMITH AARON EZEKIEL;;PERRY II JACOB C,GE INFRASTRUCTURE TECHNOLOGY LLC (2023-11-10);;GENERAL ELECTRIC COMPANY (2012-09-13),https://lens.org/059-033-176-961-086,Patent Application,yes,3,1,2,2,0,F01D5/14;;F01D5/14;;F01D5/187;;F01D5/187,F01D5/14,60/805;;X416223  A,0,0,,,,ACTIVE
593,CN,A,CN 1677045 A,048-840-220-852-613,2005-10-05,2005,CN 200510062963 A,2005-03-31,US 55865004 P,2004-04-01,Template for evaluating parts and method of using same,,UNITED TECHNOLOGIES CORP,VARSELL RICHARD W;;BOYER JESSE R;;MOISEI DOREL M;;KOONANKEIL JAMES M;;RUBINO LUKAS A,,https://lens.org/048-840-220-852-613,Patent Application,no,0,2,6,6,0,G01B3/14;;B33Y80/00;;B33Y80/00;;G01B3/14,B23P15/00;;F01D5/00;;G01B3/14,,0,0,,,,DISCONTINUED
594,AU,A,AU 2002/035656 A,056-437-304-772-493,2002-11-07,2002,AU 2002/035656 A,2002-04-24,US 28641401 P,2001-04-25,Walk-behind implement having forward and reverse drives and a method of operation therefor,,TECUMSEH PRODUCTS CO,COX C PAUL;;HERRICK TODD W;;RUEBUSCH RICHARD T;;BOYER SCOTT G;;JOHNSON KEVIN L,,https://lens.org/056-437-304-772-493,Patent Application,no,0,0,6,6,0,A01D34/6812;;A01D34/6812;;A01D34/69;;A01D34/69;;A01D2034/6843;;A01D2034/6843;;A01D2101/00;;A01D2101/00;;E01H5/04;;E01H5/04;;F16D23/12;;F16D23/12,A01D34/47;;A01D34/56;;A01D34/69;;E01H5/04;;E01H5/09;;F16D23/12,,0,0,,,,DISCONTINUED
595,CA,A1,CA 2383671 A1,117-995-118-837-940,2002-10-25,2002,CA 2383671 A,2002-04-24,US 28641401 P,2001-04-25,WALK-BEHIND IMPLEMENT HAVING FORWARD AND REVERSE DRIVES AND A METHOD OF OPERATION THEREFOR,"A walk-behind self-propelled implement, such as a snow thrower or lawnmower, for example, is provided. The implement includes first and second transmission modules associated with a common single axle to which a pair of drive wheels is attached. The first and second transmission modules are operable exclusively with respect to one another to drive the axle and the wheels in a forward and reverse direction, respectively. A control member mounted to the handle of the implement includes a forward bail member pivotable to rotate the control member in a first direction to urge the wheel to rotate in a forward direction, and a reverse bail member pivotable to rotate the control member in a second direction opposite the first direction to urge the wheel to rotate in a reverse direction.",TECUMSEH PRODUCTS CO,RUEBUSCH RICHARD T;;BOYER SCOTT G;;HERRICK TODD W;;COX C PAUL;;JOHNSON KEVIN L,,https://lens.org/117-995-118-837-940,Patent Application,no,0,0,6,6,0,A01D34/6812;;A01D34/6812;;A01D34/69;;A01D34/69;;A01D2034/6843;;A01D2034/6843;;A01D2101/00;;A01D2101/00;;E01H5/04;;E01H5/04;;F16D23/12;;F16D23/12,A01D34/47;;A01D34/56;;A01D34/69;;E01H5/04;;E01H5/09;;F16D23/12,,0,0,,,,DISCONTINUED
596,US,B2,US 7024787 B2,014-888-729-992-335,2006-04-11,2006,US 89869404 A,2004-07-23,US 89869404 A;;US 55865004 P,2004-04-01,Template for evaluating parts and method of using same,"A template for evaluating a part, comprising: a surface having a shape corresponding to the part; and at least one element on the surface corresponding to a desired location of a feature on the part. A method of evaluating a part, comprising the steps of: providing a template having a shape corresponding to the part and at least one element thereon corresponding to a desired location on the part; associating the template with the part; and using the element to determine whether the feature is at the desired location.",UNITED TECHNOLOGIES CORP,VARSELL RICHARD W;;BOYER JESSE R;;MOISEI DOREL M;;KOONANKEIL JAMES M;;RUBINO LUKAS A,RTX CORPORATION (2004-05-24),https://lens.org/014-888-729-992-335,Granted Patent,yes,14,30,6,6,0,G01B3/14;;B33Y80/00;;B33Y80/00;;G01B3/14,G01B3/14;;B23P15/00;;F01D5/00,33/562;;33/547,0,0,,,,ACTIVE
597,US,A1,US 2015/0107976 A1,173-776-540-446-591,2015-04-23,2015,US 201414520101 A,2014-10-21,US 201414520101 A;;US 201361894324 P,2013-10-22,RETRACTABLE SNAP DOMES,"A retractable snap dome in a keyboard, serving as a force resistor for a key in a conventional manner, includes an additional collapsed state wherein the key can be retracted by an electromechanical polymer (EMP) actuator to a persistent down position. In one embodiment, the EMP actuator is a bimorph EMP actuator that can be actuated to bring the key from down position to up position, ready for conventional keyboard operation, and vice versa. Such operations allow the keyboard to have a desirable decreased thickness relative to conventional keyboards. Thus, a keyboard of the present invention finds application in ultra-slim electronic devices. When provided in a notebook computer wherein the keyboard is folded against a video or graphic display, the keyboard keys may be placed in the retracted down position, thereby preventing the keys from pressing against the video or graphical display with a force that may damage the display.",NOVASENTIS INC,LEVATICH MARK;;ZELLERS BRIAN C;;FOSTER EDWARD;;BOYER MADELINE;;THALER BRIAN;;PATHAK RAJ;;DUCHARME RICHARD,NOVASENTIS INC (2013-10-18);;KEMET ELECTRONICS CORPORATION (2021-10-01),https://lens.org/173-776-540-446-591,Patent Application,yes,7,0,2,2,0,H01H13/85;;H01H13/85;;H01H2215/016;;H01H2215/016,H01H13/85,200  5 A,0,0,,,,ACTIVE
598,US,A1,US 2017/0283541 A1,160-860-509-162-128,2017-10-05,2017,US 201715621171 A,2017-06-13,US 201715621171 A;;US 201113125481 A;;US 2009/0063731 W;;US 11319508 P,2008-11-10,"ISOCYANATE TRIMERISATION CATALYST SYSTEM, A PRECURSOR FORMULATION, A PROCESS FOR TRIMERISING ISOCYANATES, RIGID POLYISOCYANURATE/POLYURETHANE FOAMS MADE THEREFROM, AND A PROCESS FOR MAKING SUCH FOAMS","The instant invention provides an isocyanate trimerisation catalyst system, a precursor formulation, a process for trimerising isocyanates, rigid foams made therefrom, and a process for making such foams. The trimerisation catalyst system comprises: (a) a phosphatrane cation; and (b) an isocyanate-trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73° C. The precursor formulation comprises (1) at least 25 percent by weight of polyol, based on the weight of the precursor formulation; (2) less than 15 percent by weight of a trimerisation catalyst system, based on the weight of the precursor formulation, comprising; (a) a phosphatrane cation; and (c) an isocyanate-trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73° C.; and (4) optionally one or more surfactants, one or more flame retardants, water, one or more antioxidants, one or more auxiliary blowing agents, one or more urethane catalysts, one or more auxiliary trimerisation catalysts, or combinations thereof. The process for trimerisation of isocyanates comprises the steps of: (1) providing one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture of any thereof; (2) providing a trimerisation catalyst system comprising; (a) an phosphatrane cation; and (b) an isocyanate-trimer inducing anion; (c) wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73° C.; (3) trimerising said one or more monomers in the presence of said trimerisation catalyst; (4) thereby forming an isocyanurate ring. The process for making the PIR foam comprises the steps of: (1) providing one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture of any thereof; (2) providing polyol; (3) providing a trimerisation catalyst system comprising; (a) a phosphatrane cation; and (b) an isocyanate-trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73° C.; and (4) optionally providing one or more surfactants, one or more flame retardants, water, one or more antioxidants, one or more auxiliary blowing agents, one or more urethane catalysts, one or more auxiliary trimerisation catalysts, or combinations thereof; (5) contacting said one or more monomers, and said polyol, and optionally said one or more surfactants, and optionally said one or more flame retardants, and optionally said water, and optionally said one or more antioxidants, and optionally said one or more auxiliary blowing agents in the presence of said trimerisation catalyst system and optionally said one or more urethane catalysts, and optionally said one or more auxiliary trimerisation catalysts; (6) thereby forming said polyisocyanurate/polyurethane rigid foam. The PIR foam comprises the reaction product of one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture of any thereof with polyol in the presence of a trimerisation catalyst system comprising a phosphatrane cation, and an isocyanate-trimer inducing anion, and optionally one or more surfactants, optionally one or more flame retardants, optionally water, optionally one or more antioxidants, optionally one or more auxiliary blowing agents, optionally one or more additional urethane catalysts, and optionally one or more auxiliary trimerisation catalysts, or optionally combinations thereof, wherein the trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73° C. The PIR foam comprises the reaction product of one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture of any thereof with polyol in the presence of a trimerisation catalyst system comprising a phosphatrane cation, and an isocyanate-trimer inducing anion, and optionally one or more surfactants, optionally one or more flame retardants, optionally water, optionally one or more antioxidants, optionally one or more auxiliary blowing agents, optionally one or more additional polyurethane catalysts, and optionally one or more auxiliary trimerisation catalysts, or optionally combinations thereof, wherein the PIR foam has a polyisocyanurate trimer ratio (Abs 1410 /Abs 1595 ) of at least 5 at a depth of 12 mm from the rising surface of the rigid foam, measured via ATR-FTIR spectroscopy.",ATHEY PHILLIP S;;WILMOT NATHAN;;KEATON RICHARD J;;BABB DAVID A;;BOYER CECILE;;MORLEY TIMOTHY A;;DOW GLOBAL TECHNOLOGIES LLC,ATHEY PHILLIP S;;WILMOT NATHAN;;KEATON RICHARD J;;BABB DAVID A;;BOYER CECILE;;MORLEY TIMOTHY A,DOW EUROPE GMBH (2011-11-22);;DOW GLOBAL TECHNOLOGIES LLC (2011-11-28);;THE DOW CHEMICAL COMPANY (2011-11-28);;DOW GLOBAL TECHNOLOGIES INC (2009-07-08),https://lens.org/160-860-509-162-128,Patent Application,yes,0,0,11,11,0,C08G18/022;;C08G18/022;;C08G18/092;;C08G18/092;;C08G18/166;;C08G18/168;;C08G18/168;;C08G18/1875;;C08G18/1875;;C08G2110/0025;;C08G2110/0025;;C08G2115/02;;C08G2115/02,C08G18/02;;C08G18/09;;C08G18/18,,0,0,,,,INACTIVE
599,US,B2,US 11480613 B2,116-229-458-573-436,2022-10-25,2022,US 202017127846 A,2020-12-18,US 202017127846 A,2020-12-18,Method and/or system for testing devices in non-secured environment,"Disclosed are methods, systems and devices for implementing built-in self-test (BIST) to be performed by an untrusted party and/or in an unsecure testing environment. In an embodiment, a test access port (TAP) on a device may enable a party to initiate execution of one or more BIST procedures on the device. Additionally, such a TAP may enable loading of encrypted instructions to be executed by one or more processors formed on a device under test.",ADVANCED RISC MACH LTD,PATERSON RICHARD ANDREW;;HERBERHOLZ RAINER;;WILLIAMS PETER ANDREW REES;;GOLOMBEK ODED;;LUKO EINAT;;BOYER JEFFREY SCOTT,ARM LIMITED (2021-02-14),https://lens.org/116-229-458-573-436,Granted Patent,yes,19,0,3,3,0,G01R31/318533;;G01R31/31719;;G01R31/2815;;G01R31/31715;;G01R31/31724;;G01R31/3177;;G01R31/318533;;G01R31/318597;;G01R31/3187;;H04L9/0894,G01R31/3177;;G01R31/28;;G01R31/317;;G01R31/3185;;G01R31/3187;;H04L9/08,,1,0,,,"Notification of Transmittal of the International Search Report the Written Opinion of the International Searching Authority, of the Declaration, App. No. PCT/EP2021/025497, dated Apr. 19, 2022, 17 pages.",ACTIVE
600,US,B2,US 10294322 B2,182-236-410-465-646,2019-05-21,2019,US 201715621171 A,2017-06-13,US 201715621171 A;;US 201113125481 A;;US 2009/0063731 W;;US 11319508 P,2008-11-10,"Isocyanate trimerisation catalyst system, a precursor formulation, a process for trimerising isocyanates, rigid polyisocyanurate/polyurethane foams made therefrom, and a process for making such foams","The instant invention provides an isocyanate trimerization catalyst system, a precursor formulation, a process for trimerizing isocyanates, rigid foams made therefrom, and a process for making such foams. The trimerization catalyst system comprises: (a) a phosphatrane cation; and (b) an isocyanate-trimer inducing anion; wherein said trimerization catalyst system has a trimerization activation temperature in the range of equal to or less than 73° C. The precursor formulation comprises (1) at least 25 percent by weight of polyol, based on the weight of the precursor formulation; (2) less than 15 percent by weight of a trimerization catalyst system, based on the weight of the precursor formulation, comprising; (a) a phosphatrane cation; and (c) an isocyanate-trimer inducing anion; wherein said trimerization catalyst system has a trimerization activation temperature in the range of equal to or less than 73° C.; and (4) optionally one or more surfactants, one or more flame retardants, water, one or more antioxidants, one or more auxiliary blowing agents, one or more urethane catalysts, one or more auxiliary trimerization catalysts, or combinations thereof. The process for trimerization of isocyanates comprises the steps of: (1) providing one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture of any thereof; (2) providing a trimerization catalyst system comprising; (a) an phosphatrane cation; and (b) an isocyanate-trimer inducing anion; (c) wherein said trimerization catalyst system has a trimerization activation temperature in the range of equal to or less than 73° C.; (3) trimerizing said one or more monomers in the presence of said trimerization catalyst; (4) thereby forming an isocyanurate ring. The process for making the PIR foam comprises the steps of: (1) providing one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture of any thereof; (2) providing polyol; (3) providing a trimerization catalyst system comprising; (a) a phosphatrane cation; and (b) an isocyanate-trimer inducing anion; wherein said trimerization catalyst system has a trimerization activation temperature in the range of equal to or less than 73° C.; and (4) optionally providing one or more surfactants, one or more flame retardants, water, one or more antioxidants, one or more auxiliary blowing agents, one or more urethane catalysts, one or more auxiliary trimerization catalysts, or combinations thereof; (5) contacting said one or more monomers, and said polyol, and optionally said one or more surfactants, and optionally said one or more flame retardants, and optionally said water, and optionally said one or more antioxidants, and optionally said one or more auxiliary blowing agents in the presence of said trimerization catalyst system and optionally said one or more urethane catalysts, and optionally said one or more auxiliary trimerization catalysts; (6) thereby forming said polyisocyanurate/polyurethane rigid foam. The PIR foam comprises the reaction product of one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture of any thereof with polyol in the presence of a trimerization catalyst system comprising a phosphatrane cation, and an isocyanate-trimer inducing anion, and optionally one or more surfactants, optionally one or more flame retardants, optionally water, optionally one or more antioxidants, optionally one or more auxiliary blowing agents, optionally one or more additional urethane catalysts, and optionally one or more auxiliary trimerization catalysts, or optionally combinations thereof, wherein the trimerization catalyst system has a trimerization activation temperature in the range of equal to or less than 73° C. The PIR foam comprises the reaction product of one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture of any thereof with polyol in the presence of a trimerization catalyst system comprising a phosphatrane cation, and an isocyanate-trimer inducing anion, and optionally one or more surfactants, optionally one or more flame retardants, optionally water, optionally one or more antioxidants, optionally one or more auxiliary blowing agents, optionally one or more additional polyurethane catalysts, and optionally one or more auxiliary trimerization catalysts, or optionally combinations thereof, wherein the PIR foam has a polyisocyanurate trimer ratio (Abs 1410 /Abs 1595 ) of at least 5 at a depth of 12 mm from the rising surface of the rigid foam, measured via ATR-FTIR spectroscopy.",ATHEY PHILLIP S;;WILMOT NATHAN;;KEATON RICHARD J;;BABB DAVID A;;BOYER CECILE;;MORLEY TIMOTHY A;;DOW GLOBAL TECHNOLOGIES LLC,ATHEY PHILLIP S;;WILMOT NATHAN;;KEATON RICHARD J;;BABB DAVID A;;BOYER CECILE;;MORLEY TIMOTHY A,DOW EUROPE GMBH (2011-11-22);;DOW GLOBAL TECHNOLOGIES LLC (2011-11-28);;THE DOW CHEMICAL COMPANY (2011-11-28);;DOW GLOBAL TECHNOLOGIES INC (2009-07-08),https://lens.org/182-236-410-465-646,Granted Patent,yes,14,0,11,11,0,C08G18/022;;C08G18/022;;C08G18/092;;C08G18/092;;C08G18/166;;C08G18/168;;C08G18/168;;C08G18/1875;;C08G18/1875;;C08G2110/0025;;C08G2110/0025;;C08G2115/02;;C08G2115/02,C08G18/02;;C08G18/09;;C08G18/16;;C08G18/18;;C08G101/00,,8,5,150-188-795-861-767;;007-994-457-079-811;;017-002-866-188-160;;044-157-396-209-881;;182-804-283-426-814,10.1021/ja01411a033;;10.1021/ja00191a081;;10.1002/zaac.19916050120;;10.1016/s0040-4039(00)60476-8;;10.1021/jo00104a041,"Polyurethane (from Wikipedia).;;E. P. Kohler, et al., An Apparatus for Determining Both the Quantity of Gas Evolved and the Amount of Reagent Consumed in Reactions with Methyl Magnesium Iodide, Journal of the American Chemical Society, 1927, pp. 3181-3188, vol. 49, Issue 12.;;C. Lensink, et al., The Unusually Robust P—H Bond in the Novel Cation, Journal of the American Chemical Society, 1989, pp. 3478-3479, vol. 111, Issue 9.;;M. Laramay, et al., Unusually Lewis Basic Pro-azaphosphatranes, Z. anorg. allg. Chem., 1991, pp. 163-174, vol. 505.;;J. Tang, et al., An Improved Synthesis of the Strong base P (MeNCH2Ch2)3N, Tetrahedron Letters, 1993, pp. 2903-2904, vol. 34, No. 18.;;J. Tang, et al., Nonionic Superbase-Promoted Synthesis of Oxazoles and Pyrroles: Facile Synthesis of Porphyrins and a-C-Acyl Amino Acid Esters, Journal of Organic Chemistry, 1994, pp. 7793-7802, vol. 59, Issue 25.;;International Search Report and Written Opinion for PCT/US2009/063731 dated Oct. 14, 2010.;;International Preliminary Report on Patentability for PCT/US2009/063731 dated May 19, 2011.",INACTIVE
601,US,A1,US 2022/0196734 A1,059-726-195-722-39X,2022-06-23,2022,US 202017127846 A,2020-12-18,US 202017127846 A,2020-12-18,METHOD AND/OR SYSTEM FOR TESTING DEVICES IN NON-SECURED ENVIRONMENT,"Disclosed are methods, systems and devices for implementing built-in self-test (BIST) to be performed by an untrusted party and/or in an unsecure testing environment. In an embodiment, a test access port (TAP) on a device may enable a party to initiate execution of one or more BIST procedures on the device. Additionally, such a TAP may enable loading of encrypted instructions to be executed by one or more processors formed on a device under test.",ADVANCED RISC MACH LTD,PATERSON RICHARD ANDREW;;HERBERHOLZ RAINER;;WILLIAMS PETER ANDREW REES;;GOLOMBEK ODED;;LUKO EINAT;;BOYER JEFFREY SCOTT,ARM LIMITED (2021-02-14),https://lens.org/059-726-195-722-39X,Patent Application,yes,13,1,3,3,0,G01R31/318533;;G01R31/31719;;G01R31/2815;;G01R31/31715;;G01R31/31724;;G01R31/3177;;G01R31/318533;;G01R31/318597;;G01R31/3187;;H04L9/0894,G01R31/3177;;G01R31/317,,0,0,,,,ACTIVE
602,DE,B2,DE 1585423 B2,101-955-453-523-538,1974-01-10,1974,DE 1585423 A,1965-12-15,US 41846064 A,1964-12-15,DE 1585423 B2,,"NORTH AMERICAN ROCKWELL CORP., PITTSBURGH, PA. (V.ST.A.)","IMBODEN, WALTER HAROLD, MIDVALE MANOR;;JANDA, RICHARD MARTIN, CHRESTWOOD, READING;;BOYER JUN., JAMES HEILIG, MT. PENN",,https://lens.org/101-955-453-523-538,Patent Application,no,0,0,4,5,0,D04B9/20;;D04B9/56;;D04B15/82;;D04B9/56;;D04B9/20;;D04B15/82,D04B9/20;;D04B9/46;;D04B15/82,,0,0,,,,EXPIRED
603,US,B1,US 10295749 B1,050-807-142-418-842,2019-05-21,2019,US 201815897563 A,2018-02-15,US 201815897563 A,2018-02-15,Optical interconnect attach to photonic device with partitioning adhesive function,A photonic assembly includes an optical die including a suspended membrane structure arranged thereon. A cavity is arranged beneath the suspended membrane structure. An optical interconnect structure is arranged on the optical die. The photonic assembly also includes an optical adhesive arranged on the optical die in contact with the optical interconnect structure. The optical adhesive is arranged beneath the suspended membrane structure to at least partially fill the cavity beneath the suspended membrane structure. The photonic assembly also includes a structural adhesive arranged on the optical die adjacent to the optical adhesive.,IBM,JANTA-POLCZYNSKI BARNIM ALEXANDER;;CYR ELAINE;;BARWICZ TYMON;;BOYER NICOLAS;;LANGLOIS RICHARD D;;FORTIER PAUL FRANCIS,INTERNATIONAL BUSINESS MACHINES CORPORATION (2018-02-15),https://lens.org/050-807-142-418-842,Granted Patent,yes,13,9,2,2,0,G02B6/30;;G02B6/30;;G02B6/02209;;G02B6/305;;G02B6/305;;G02B6/3636;;G02B6/3636;;G02B6/3861;;G02B6/4239;;G02B6/4239,G02B6/30;;G02B6/02;;G02B6/36;;G02B6/38,,10,4,058-970-286-695-233;;140-244-880-815-66X;;149-088-638-038-925;;004-662-687-118-564,10.1109/ectc.2017.185;;10.1109/ectc.2015.7159680;;10.1109/jstqe.2011.2113171;;10.1002/lpor.200900033,"Alexander Janta-Polczynski et al., “Towards Co-packaging of Photonics and Microelectronics in Existing Manufacturing Facilities”, Proceedings of SPIE vol. 10538-105380B, 11 pps.;;Boyer et al., “Novel, High-Throughput, Fiber-to-Chip Assembly Employing Only Off-the-Shelf Components”, 2017 IEEE 67th Electronic Components and Technology Conference, pp. 1632-1639.;;N.B. Feilchenfeld et al., Silicon Photonics and Challenges for Fabrication, Proceedings of SPIE, vol. 10149, 101490D 2017, 10 pps.;;Tymon Barwicz et al., “A Metamaterial Converter Centered at 1490nm for Interfacing Standard Fibers to Nanophotonic Waveguides”, OFC 2016 Optical Society of America, 3 pps.;;Tymon Barwicz et al., “An O-band Metamaterial Converter Interfacing Standard Optical Fibers to Silicon Nanophotonic Waveguides”, OFC 2015 Optical Society of America, 3 pps.;;Tymon Barwicz et al., “Automated, Self-Aligned Assembly of 12 Fibers per Nanophotonic Chip With Standard Microelectronics Assembly Tooling”, IEEE 2015 Electronic Components & Technology Conference, pp. 775-782.;;Tolga Tekin, “Review of Packaging of Optoelectronic, Photonic, and MEMS Components”; IEEE Journal of Selected Topics in Quantum Electronics; vol. 17, Issue: 3, May-Jun. 2011. (Abstract Only).;;G. Roelkens et al., “III-V/silicon photonics for on-chip and intra-chip optical interconnects”, http://onlinelibrary.wiley.com/doi/10.1002/lpor.200900033/full, vol. 4, Issue 6, Nov. 2010, pp. 751-779. (Abstract Only).;;Janta-Polczynski, et al., “Optical Interconnect Attach to Photonic Device With Partitioning Adhesive Function”, U.S. Appl. No. 16/143,609, filed Sep. 27, 2018.;;List of IBM Patents or Patent Applications Treated as Related; (Appendix P), Filed Sep. 27, 2018, 2 pages.",INACTIVE
604,US,B1,US 10302869 B1,128-193-804-654-09X,2019-05-28,2019,US 201816143609 A,2018-09-27,US 201816143609 A;;US 201815897563 A,2018-02-15,Optical interconnect attach to photonic device with partitioning adhesive function,A photonic assembly includes an optical die including a suspended membrane structure arranged thereon. A cavity is arranged beneath the suspended membrane structure. An optical interconnect structure is arranged on the optical die. The photonic assembly also includes an optical adhesive arranged on the optical die in contact with the optical interconnect structure. The optical adhesive is arranged beneath the suspended membrane structure to at least partially fill the cavity beneath the suspended membrane structure. The photonic assembly also includes a structural adhesive arranged on the optical die adjacent to the optical adhesive.,IBM,JANTA-POLCZYNSKI BARNIM ALEXANDER;;CYR ELAINE;;BARWICZ TYMON;;BOYER NICOLAS;;LANGLOIS RICHARD D;;FORTIER PAUL FRANCIS,INTERNATIONAL BUSINESS MACHINES CORPORATION (2018-02-15),https://lens.org/128-193-804-654-09X,Granted Patent,yes,11,0,2,2,0,G02B6/30;;G02B6/30;;G02B6/02209;;G02B6/305;;G02B6/305;;G02B6/3636;;G02B6/3636;;G02B6/3861;;G02B6/4239;;G02B6/4239,G02B6/30;;G02B6/02;;G02B6/36;;G02B6/38,,2,0,,,"Janta-Polczynski, et al., “Optical Interconnect Attach to Photonic Device With Partitioning Adhesive Function”, U.S. Appl. No. 15/897,563, filed Feb. 15, 2018.;;List of IBM Patents or Patent Applications Treated as Related; (Appendix P), Filed Sep. 27, 2018, 2 pages.",ACTIVE
605,ZA,B,ZA 936070 B,006-170-415-307-857,1995-02-20,1995,ZA 936070 A,1993-08-18,US 9208162 W,1992-09-24,Oil-tolerant reinforcement strip,,MINNESOTA MINING & MFG,MIDGLEY ROLAND RICHARD;;UREY RUBEN EMILIO VELASQUEY;;BOYER CHARLES EDWARD III;;KINNEY ROBERT JAMES;;GOBRAN RAMSIS,,https://lens.org/006-170-415-307-857,Granted Patent,no,0,0,27,27,0,A61F13/5633;;A61F13/58;;A61L15/42;;A61L15/58;;A61L15/585;;C08L2666/02;;C09J153/02;;A61F13/58,A61F13/49;;A61F5/44;;A61F13/15;;A61F13/472;;A61F13/56;;A61F13/58;;A61L15/00;;A61L15/42;;A61L15/58;;C09J7/02;;C09J153/00;;C09J153/02,,0,0,,,,EXPIRED
606,DE,C3,DE 1585423 C3,194-713-450-178-742,1974-08-01,1974,DE 1585423 A,1965-12-15,US 41846064 A,1964-12-15,DE 1585423 C3,,"NORTH AMERICAN ROCKWELL CORP., PITTSBURGH, PA. (V.ST.A.)","IMBODEN, WALTER HAROLD, MIDVALE MANOR;;JANDA, RICHARD MARTIN, CHRESTWOOD, READING;;BOYER JUN., JAMES HEILIG, MT. PENN",,https://lens.org/194-713-450-178-742,Granted Patent,no,0,0,4,5,0,D04B9/20;;D04B9/56;;D04B15/82;;D04B9/56;;D04B9/20;;D04B15/82,D04B9/20;;D04B9/46;;D04B15/82,,0,0,,,,EXPIRED
607,US,B2,US 8323671 B2,029-843-955-462-784,2012-12-04,2012,US 86013610 A,2010-08-20,US 86013610 A;;US 82193607 A;;US 81652206 P,2006-06-26,Prolyl hydroxylase inhibitors and methods of use,"The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.",WU SHENGDE;;WARSHAKOON NAMAL C;;EVDOKIMOV ARTEM G;;GREIS KENNETH D;;BOYER ANGELIQUE SUN;;KAWAMOTO RICHARD MASARU;;AKEBIA THERAPEUTICS INC,WU SHENGDE;;WARSHAKOON NAMAL C;;EVDOKIMOV ARTEM G;;GREIS KENNETH D;;BOYER ANGELIQUE SUN;;KAWAMOTO RICHARD MASARU,THE PROCTER & GAMBLE COMPANY (2008-12-19);;AKEBIA THERAPEUTICS INC (2011-12-15);;WARNER CHILCOTT COMPANY LLC (2009-10-30),https://lens.org/029-843-955-462-784,Granted Patent,yes,79,34,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,A61K8/02;;A61K31/44;;C07D213/65;;C07D213/89,424/401;;514/346;;546/296;;546/298,67,43,017-669-075-762-985;;010-824-042-186-283;;125-424-943-194-608;;026-655-568-834-966;;103-335-591-460-884;;028-862-168-091-90X;;063-746-538-402-770;;093-087-601-151-305;;006-143-986-832-256;;064-865-149-673-057;;102-345-845-395-203;;015-199-257-732-502;;009-081-622-113-208;;052-512-054-021-225;;022-156-141-942-093;;081-136-747-247-898;;030-042-017-746-591;;131-046-096-401-339;;092-475-988-464-223;;135-654-547-079-284;;077-106-322-076-470;;069-450-943-413-364;;025-178-564-355-938;;048-830-824-939-083;;102-949-159-342-256;;018-052-265-551-042;;064-406-626-054-484;;011-101-678-202-709;;129-297-815-048-32X;;023-017-724-234-140;;074-344-536-692-994;;016-533-076-557-079;;149-920-492-418-396;;056-436-730-631-840;;034-760-425-242-511;;074-156-318-814-764;;064-242-953-339-024;;062-826-287-074-090;;065-169-875-352-44X;;045-408-622-411-245;;096-459-000-284-800;;040-667-645-789-907;;017-183-541-402-013,10.1016/s0040-4020(03)01100-1;;490542;;10.1021/jm00194a018;;10.1007/978-1-4684-5445-1_9;;2965848;;15132592;;10.1021/cc049977g;;10.1002/hlca.200490260;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;15664391;;10.1016/j.cardiores.2004.09.004;;15637314;;10.1161/01.str.0000153795.38388.72;;10.1373/49.1.32;;12507958;;3326854;;10.1111/j.1399-3011.1987.tb03385.x;;1583540;;10.1007/bf00124387;;10.1016/s0968-0004(97)01074-8;;9255066;;10.1021/jm00092a016;;1321909;;pmc312791;;10.1101/gad.914801;;11581158;;10.1016/s0304-4157(99)00006-4;;10548717;;1665444;;10.1042/bst0190812;;10.1021/jm00145a002;;3892003;;10.1002/prot.340080302;;2281083;;7823319;;10.1016/s0022-2836(95)80037-9;;15952883;;10.1146/annurev.biochem.74.082803.133142;;10.1182/blood.v77.3.419.bloodjournal773419;;10.1182/blood.v77.3.419.419;;1991159;;7154081;;10.1016/0022-2836(82)90153-x;;12482756;;10.1074/jbc.m210385200;;10613823;;10.1038/71527;;10.1161/01.cir.0000044914.42696.6a;;12538431;;pmc1502536;;16782814;;10.1073/pnas.0601283103;;10.2210/pdb2g1m/pdb;;10.1002/prot.340110104;;1961699;;10.1016/s0074-7696(01)04002-5;;11243594;;10.1016/s0040-4020(01)86503-0;;7525077;;10.1016/0092-8674(94)90200-3;;10.1016/s0092-8674(00)81848-6;;9008168;;10.1016/s0303-7207(99)00017-9;;10411333;;10.1016/s0006-2952(02)01168-1;;12213597;;7852211;;10.1016/s0889-8588(18)30134-5;;10.1016/s0021-9258(17)31580-6;;8089148;;19649971;;10.1021/jo01340a533;;5902481;;7515861;;10.1002/ijc.2910570624;;11056102;;10.1161/01.cir.102.18.2255;;10.1096/fj.02-1062fje;;12709400;;8606489;;10.1056/nejm199101033240101;;1701519;;12649278;;10.1074/jbc.m301391200,"U.S. Appl. No. 11/821,936, filed Jun. 26, 2007, Kawamoto, Restriction Requirement, Nov. 13, 2009.;;U.S. Appl. No. 11/821,936, filed Jun. 26, 2007, Kawamoto, Response to Restriction Requirement, Nov. 20, 2009.;;U.S. Appl. No. 11/821,936, filed Jun. 26, 2007, Kawamoto, Non-Final Office Action, Mar. 16, 2010.;;U.S. Appl. No. 11/821,936, filed Jun. 26, 2007, Kawamoto, Draft Response to Office Action, Apr. 4, 2010.;;U.S. Appl. No. 11/821,936, filed Jun. 26, 2007, Kawamoto, Examiner's Interview Summary, Apr. 19, 2010.;;U.S. Appl. No. 11/821,936, filed Jun. 26, 2007, Kawamoto, Response to Office Action, Apr. 20, 2010.;;U.S. Appl. No. 11/821,936, filed Jun. 26, 2007, Kawamoto, Notice of Allowance, Aug. 12, 2010.;;U.S. Appl. No. 11/821,936, filed Jun. 26, 2007, Kawamoto, Issue Notification, Sep. 22, 2010.;;U.S. Appl. No. 11/713,941, filed Mar. 5, 2007, Evdokimov, Restriction Requirement, May 29, 2008.;;U.S. Appl. No. 11/713,941, filed Mar. 5, 2007, Evdokimov, Response to Restriction Requirement, Jul. 22, 2008.;;U.S. Appl. No. 11/713,941, filed Mar. 5, 2007, Evdokimov, Non-Final Office Action, Nov. 18, 2008.;;U.S. Appl. No. 11/713,941, filed Mar. 5, 2007, Evdokimov, Response to Office Action, Mar. 16, 2009.;;U.S. Appl. No. 11/713,941, filed Mar. 5, 2007, Evdokimov, Final Rejection, May 15, 2009.;;U.S. Appl. No. 11/713,941, filed Mar. 5, 2007, Evdokimov, Response to Final Office Action, May 28, 2009.;;U.S. Appl. No. 11/713,941, filed Mar. 5, 2007, Evdokimov, Response to Final Office Action, Jun. 3, 2009.;;U.S. Appl. No. 11/713,941, filed Mar. 5, 2007, Evdokimov, Notice of Allowance, Jun. 17, 2009.;;U.S. Appl. No. 11/713,941, filed Mar. 5, 2007, Evdokimov, Issue Notification, Aug. 26, 2009.;;U.S. Appl. No. 12/473,536, filed May 28, 2009, Evdokimov, Restriction Requirement, Jun. 21, 2010.;;U.S. Appl. No. 12/473,536, filed May 28, 2009, Evdokimov, Response to Restriction Requirement, Jun. 23, 2010.;;U.S. Appl. No. 12/473,536, filed May 28, 2009, Evdokimov, Non-Final Office Action, Aug. 16, 2010.;;U.S. Appl. No. 12/473,536, filed May 28, 2009, Evdokimov, Response to Office Action.;;Alesso et al., ""Improving resins for solid phase synthesis: incorporation of 1-[2-(2-methoxyethoxy)ethoxy]4-vinyl-benzene"" Tetrahedron: 59, 7163-7169 (2003).;;Anderson et al., ""Antileukemic Activity of Derivatives of 1,2-Dimethy1-3,4-bis(hydroxymethyl)-5-phenylpyrrole Bis(N-methylcarbamate)"" J Med. Chem.: vol. 22(8), 977-980 (1979).;;Kawashima et al., ""Suppressive effect of quinolinic acid an hippuric acid on bone marrow erythroid growth and lymphocyte blast formation in uremia,"" Advances in Experimental Medicine and Biology, (1987), vol. 223, p. 69-72.;;Vickerstaffe et al., ""Fully Automated Polymer-Assisted Synthesis of 1,5-Biaryl Pyrazoles,"" J. Comb. Chem., 2004, 6, 332-33.;;Tzschucke et al., ""Fluorous-Silica-Supported Perfluoro-Tagged Palladium Complexes Catalyze Suzuki Coupling in Water"" Helvetica Chimica Acta; vol. 87 2882-2889 (2004).;;Altschul et al., ""Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs,"" Nucleic Acids Res., 25(27):3389-3402 (1997).;;Annex et al., ""Growth Factor-Induced Therapeutic Angiogenesis in the Heart: Protein Therapy,"" Cardiovascular Research, 65(3):649-655 (2005).;;Ardelt et al., ""Estradiol Regulates Angiopoietin-1 mRNA Expression Through Estrogen Receptor-alpha in a Rodent Experimental Stroke Model,"" Stroke, 36:337-341 (2005).;;Auerbach et al., ""Angiogenesis Assays: A Critical Overview,"" Clinical Chemistry, 49:32-40 (2003).;;Barany et al., ""Solid-phase Peptide Synthesis: A Silver Anniversary Report, ""Int. J. Peptide Protein Res., 30(6):705-739 (1987).;;Bartlett et al., ""Molecular Recognition in Chemical and Biological Problems, "" Special Pub., Royal Chem. Soc., 78, 182-196 Caveat: A Program to Facilitate the Structure-derived Design of Biologically Active Molecules (Apr. 1989).;;Böhm, ""The Computer Program LUDI: A New Method for the Novo Design of Enzyme Inhibitors,"" J. Computer-Aided Molecular Design,6:61-78 (1992).;;Branden et al., ""Introduction to Protein Structure Second Edition,"" Garland Publising Inc., New York, 1999, pp. 374-375.;;Bussolino, ""Molecular Mechanisms of Blood Vessel Formation,"" Trends Biochem. Sci.,22(7):251-256 (1997).;;Cunliffe et al., ""Novel Inhibitors of Prolyl 4-Hydroxylase. 3. Inhibition by the Substrate Analogue N-Oxaloglycine and Its Derivatives,"" J. Med.Chem. 35:2652-2658 (1992).;;Elson et al., ""Induction of Hypervascularity Without Leakage or Inflammation in Transgenic Mice Overexpressing Hypoxia-Indicible Factor-1alpha,"" Genes & Dev.,15:2520-2532 (2001).;;Flower, ""Modelling G-protein-coupled receptors for drug design,"" Biochimica et Biophysica Acta, 1422:207-234 (1999).;;Folkman et al., ""Tumor Angiogenesis,"" The Molecular Basis of Cancer, Mendelsohn et al., eds., W. B. Saunders, Chapter 10, pp. 206-232 (1995).;;Franklin et al., ""Approaches to the Design of Anti-Fibrotic Drugs,"" Biochem. Soc. Trans., 19(4):812-5 (Nov. 1991).;;Goodford, ""A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules,"" J. Med. Chem., 28(7):849-857 (1985).;;Goodsell et al., ""Automated Docking of Substrates to Proteins by Simulated Annealing,"" Proteins: Structure, Function, and Genetics, 8:195-202 (1990).;;Jones et al., ""Molecular Recognition of Receptor Sites Using a Genetic Algorithm with a Description of Desolvation,"" J. Mol. Biol., 245:43-53 (1995).;;Kaelin, ""Proline Hydroxylation and Gene Expression,"" Annu. Rev. Biochem., 74:115-125 (2005).;;Krantz, ""Erythropoietin,"" Blood, 77:419-434 (1991).;;Kuntz et al., ""A Geometric Approach to Macromolecule-Ligand Interactions,"" J. Mol. Biol., 161:269-288 (1982).;;Lee et al., ""Structure of Human FIH-1 Reveals a Unique Active Site Pocket and Interaction Sites for HIF-1 and von Hippel Lindau,"" JBC, 278:7558-7563 (2003).;;Li et al., ""PR39, A Peptide Regulator of Angiogenesis,"" Nat Med., 6(1):49-55 (2000).;;Mancini et al., ""Effect of Erythropoietin on Exercise Capacity in Patients with Moderate to Severe Chronic Heart Failure,"" Circulation, 107:294-299 (2003).;;McDonough et al., ""Cellular Oxygen Sensing: Crystal Structure of Hypoxia-Inducible Factor Prolyl Hydroxylase (PHD2),"" PNAS, 103(26):9814-9819 (2006).;;Miranker et al., ""Functionality Maps of Binding Sites: A Multiple Copy Simultaneous Search Method,"" Proteins: Structure, Function and Genetics, 11:29-34 (1991).;;Nguyen et al., ""Cellular Interactions in Vascular Growth and Differentiation,"" Int. Review of Cytology, 204:1-48 (2001).;;Nishibata et al., ""Automatic Creation of Drug Candidate Structures Based on Receptor Structure. Starting Point for Artificial Lead Generation,"" Tetrahedron, 47(43):8985-8990 (1991).;;O'Reilly et al., ""Angiostatin: A Novel Angiogenesis Inhibitor that Mediates the Suppression of Metastases by a Lewis Lung Carcinoma,"" Cell, 79:315-328 (1994).;;O'Reilly et al., ""Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth,"" Cell, 88:277-285 (1997).;;Schoneberg et al., ""Structural Basis of G Protein-Coupled Receptor Function,"" Molecular and Cellular Endocrinology, 151:181-193 (1999).;;Semenza, ""Signal Transduction to Hypoxia-inducible Factor 1,"" Biochem. Pharmacol, 64:993-998 (2002).;;Semenza, ""Regulation of Erythropoietin Porduction: New Insights into Molecular Mechanisms of Oxygen Homeostasis,"" Hematol. Oncol. Clin. North Am., 8:863-884 (1994).;;Semenza et al., ""Transcriptional Regulation of Genes Encoding Glycolytic Enzymes by Hypoxia-Inducible Factor 1,"" J. Biol. Chem., 269:23757-23763 (1994).;;Sexton, ""Recent advances in our understanding of peptide hormone receptors and RAMPS,"" Current Opinion in Drug Discovery and Development, 2(5):440-448 (1999).;;Sheehan, ""3-Hydroxypicolinic Acid and Some of its Derivatives,"" J. Organic Chemistry 31(3):636-638 (1996).;;Teicher et al., ""Potentiation of Cytotoxic Cancer Therapies by TNP-470 Alone and with Other Anti-Angiogenic Agents,"" Int. J. Cancer, 57:920-925 (1994).;;Vincent et al., ""Angiogenesis is Induced in a Rabbit Model of Hindlimb Ischemia by Naked DNA Encoding an HIF-1alpha/VP16 Hybrid Transcription Factor,"" Circulation, 102:2255-2261 (2000).;;Warnecke et al., ""Activation of the Hypoxia-Inducible Factor Pathway and Stimulation of Angiogenesis by Application of Prolyl Hydroxylase Inhibitors,"" FASEB Journal, 17:1186-1188 (2003).;;Wax et al., ""SM-20 is a Novel 20-kd Protein Whose Expression in the Arterial Wall is Restricted to Smooth Muscle,"" Lab. Invest., 74(4):797-808 (1996).;;Weidner et al., ""Tumor Angiogenesis and Metastasis-Correlation in Invasive Breast Carcinoma,"" New Eng. J. Med., 324(1):1-8 (1991).;;Wright et al., ""Activation of the Prolyl Hydroxylase Oxygen-Sensor Results in Induction of GLUT1, Heme Oxygenase-1, and Nitric-Oxide Synthase Proteins and Confers Protection from Metabolic Inhibition to Cardiomyocytes,"" J. Bio. Chem., 278(22):20235-20239 (2003).",ACTIVE
608,NZ,A,NZ 623002 A,052-545-081-842-345,2015-08-28,2015,NZ 62300207 A,2007-06-26,US 81652206 P;;NZ 60173007 A,2006-06-26,Prolyl hydroxylase inhibitors and methods of use,"Disclosed is a compound selected from: [(3-hydroxypyridine-2-carbonyl)methylamino]acetic acid ethyl ester; and [(3-hydroxypyridine-2-carbonyl)methylamino]acetic acid; or a pharmaceutically acceptable salt thereof. Further disclosed is a composition comprising: A) one or more compounds as defined above or a pharmaceutically acceptable salt thereof; and B) one or more excipients or carriers; for for treating a disease selected from diabetic retinopathy, macular degeneration, sickle cell anemia, sarcoid, syphilis, pseudoxanthoma elasticum, Paget’s disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis/vitritis, mycobacterial infections, Lyme’s disease, systemic lupus erythematosis, retinopathy of prematurity, Eales’ disease, Behcet’s disease, infections causing a retinitis or choroiditis, presumed ocular histoplasmosis, Best’s disease, myopia, optic pits, Stargardt’s disease, pars planitis, chronic retinal detachment, hyperviscosity syndrome, toxoplasmosis, trauma post-laser complications, diseases associated with rubeosis, and proliferative vitroeretinopathy, Crohn’s disease and ulcerative colitis, psoriasis, sarcoidosis, rheumatoid arthritis, hemangiomas, Osler-Weber-Rendu disease, or hereditary hemorrhagic telangiectasia, solid or blood borne tumors, acquired immune deficiency syndrome, skeletal muscle and myocardial ischemia, stroke, coronary artery disease, peripheral vascular disease, and coronary artery disease. Also disclosed is the use of a compound as defined above or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating wounds, for promoting wound healing, for regulating angiogenesis in a human, vascularizing ischemic tissue in a human, for promoting the growth of skin graft replacements in a human, for treating a cancer or for treating anaemia (particularly anemia associated with kidney failure or chemotherapy).",AKEBIA THERAPEUTICS INC,WU SHENGDE;;KAWAMOTO RICHARD MASARU;;GREIS KENNETH DONALD;;WARSHAKOON NAMAL CHITHRANGA;;EDOKIMOV ARTEM G;;BOYER ANGELIQUE SUN,,https://lens.org/052-545-081-842-345,Patent Application,no,0,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07C255/57;;A61K31/44;;A61K31/4418;;A61P7/06;;C07C235/60;;C07C237/42;;C07D213/65;;C07D213/81,,0,0,,,,PENDING
609,US,A1,US 2013/0346614 A1,108-022-239-230-128,2013-12-26,2013,US 201213533164 A,2012-06-26,US 201213533164 A,2012-06-26,WORKLOAD ADAPTIVE CLOUD COMPUTING RESOURCE ALLOCATION,"A workload associated with a task is assessed with respect to each of a plurality of computing paradigms offered by a cloud computing environment. Adaptive learning is employed by maintaining a table of Q-values corresponding to the computing paradigms and the workload is distributed according to a ratio of Q-values. The Q-values may be adjusted responsive to a performance metric and/or a value, reward, and/or decay function. The workload is then assigned to available computing paradigms to be performed with improved utilization of resources.",BAUGHMAN AARON K;;BOYER LINDA M;;CODELLA CHRISTOPHER F;;DARDEN RICHARD L;;DUBYAK WILLIAM G;;GREENLAND ARNOLD;;IBM,BAUGHMAN AARON K;;BOYER LINDA M;;CODELLA CHRISTOPHER F;;DARDEN RICHARD L;;DUBYAK WILLIAM G;;GREENLAND ARNOLD,INTERNATIONAL BUSINESS MACHINES CORPORATION (2012-05-31),https://lens.org/108-022-239-230-128,Patent Application,yes,17,118,2,2,0,G06F9/5083;;G06F9/5083,G06F15/173,709/226,0,0,,,,INACTIVE
610,EP,B8,EP 2044005 B8,185-759-906-405-761,2012-12-05,2012,EP 07835890 A,2007-06-26,US 2007/0014832 W;;US 81652206 P,2006-06-26,PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE,,WARNER CHILCOTT CO LLC,KAWAMOTO RICHARD MASARU;;WARSHAKOON NAMAL CHITHRANGA;;EVDOKIMOV ARTEM G;;WU SHENGDE;;BOYER ANGELIQUE SUN;;GREIS KENNETH DONALD,"GREIS KENNETH DONALD, FORT THOMAS, KY, US (2013-02-26);;AKEBIA THERAPEUTICS INC., US (2015-01-12);;WARNER CHILCOTT COMPANY, LLC (2010-09-22);;WARSHAKOON NAMAL CHITHRANGA, MASON, OH, US (2013-02-26);;AKEBIA THERAPEUTICS INC.; US (2013-12-03);;AKEBIA THERAPEUTICS INC. (2014-12-17);;EVDOKIMOV ARTEM, G., NIANTIC, CT, US (2013-02-26);;AKEBIA THERAPEUTICS INC., CINCINNATI, OH, US (2014-10-13);;BOYER ANGELIQUE SUN, WEST CH ESTER, OH, US (2013-02-26);;AKEBIA THERAPEUTICS INC., CAMBRIDGE, MA, US (2014-12-12);;AKEBIA THERAPEUTICS INC., CAMBRIDGE, US (2014-05-22);;KAWAMOTO RICHARD MASARU, DIVIDE, CO, US (2013-02-26);;WU SHENGDE, WEST CHESTER, OH, US (2013-02-26)",https://lens.org/185-759-906-405-761,Amended Patent,yes,1,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07C235/60;;C07C237/42;;C07C255/57;;C07D213/81,,0,0,,,,INACTIVE
611,US,A1,US 2023/0201178 A1,064-196-412-373-364,2023-06-29,2023,US 202217815391 A,2022-07-27,US 202217815391 A;;US 202016908092 A;;US 201816119146 A;;US 201715420617 A;;US 201514854080 A;;US 201414568200 A;;US 201314062011 A;;US 201213681876 A;;US 86007310 A;;US 82193607 A;;US 81652206 P,2006-06-26,PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE,"The present disclosure relates to HIF- 1 α prolyl hydroxylase inhibitors, compositions which comprise the HIF- 1 α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.",AKEBIA THERAPEUTICS INC,KAWAMOTO RICHARD MASARU;;WU SHENGDE;;EVDOKIMOV ARTEM G;;GREIS KENNETH D;;BOYER ANGELIQUE SUN;;WARSHAKOON NAMAL C,THE PROCTER & GAMBLE COMPANY (2007-07-27);;AKEBIA THERAPEUTICS INC (2011-12-15);;WARNER CHILCOTT COMPANY LLC (2009-10-30),https://lens.org/064-196-412-373-364,Patent Application,yes,1,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,A61K31/4418;;A61K31/4433;;C07C235/60;;C07C237/42;;C07C255/57;;C07D213/65;;C07D213/81;;C07D295/192;;C07D401/04;;C07D401/10;;C07D405/04;;C07D405/10;;C07D417/04,,0,0,,,,ACTIVE
612,EP,B1,EP 2044005 B1,192-194-554-629-70X,2010-10-20,2010,EP 07835890 A,2007-06-26,US 2007/0014832 W;;US 81652206 P,2006-06-26,PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE,,WARNER CHILCOTT CO LLC,KAWAMOTO RICHARD MASARU;;WARSHAKOON NAMAL CHITHRANGA;;EVDOKIMOV ARTEM G;;WU SHENGDE;;BOYER ANGELIQUE SUN;;GREIS KENNETH DONALD,"GREIS KENNETH DONALD, FORT THOMAS, KY, US (2013-02-26);;AKEBIA THERAPEUTICS INC., US (2015-01-12);;WARNER CHILCOTT COMPANY, LLC (2010-09-22);;WARSHAKOON NAMAL CHITHRANGA, MASON, OH, US (2013-02-26);;AKEBIA THERAPEUTICS INC.; US (2013-12-03);;AKEBIA THERAPEUTICS INC. (2014-12-17);;EVDOKIMOV ARTEM, G., NIANTIC, CT, US (2013-02-26);;AKEBIA THERAPEUTICS INC., CINCINNATI, OH, US (2014-10-13);;BOYER ANGELIQUE SUN, WEST CH ESTER, OH, US (2013-02-26);;AKEBIA THERAPEUTICS INC., CAMBRIDGE, MA, US (2014-12-12);;AKEBIA THERAPEUTICS INC., CAMBRIDGE, US (2014-05-22);;KAWAMOTO RICHARD MASARU, DIVIDE, CO, US (2013-02-26);;WU SHENGDE, WEST CHESTER, OH, US (2013-02-26)",https://lens.org/192-194-554-629-70X,Granted Patent,yes,1,9,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07C235/60;;C07C237/42;;C07C255/57;;C07D213/81,,0,0,,,,INACTIVE
613,NZ,A,NZ 601730 A,011-164-216-147-045,2014-04-30,2014,NZ 60173007 A,2007-06-26,US 81652206 P;;NZ 57440807 A,2006-06-26,Prolyl hydroxylase inhibitors and methods of use,"601730 Disclosed are { [5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} -acetic acid derivatives as represented by the general formula, as inhibitors of human protein prolyl hydroxylase for stimulating an angiogenic response for increasing blood flow, oxygen delivery and energy utilization in ischemic tissues; wherein R and R1 are each independently: i) hydrogen; ii) substituted or unsubstituted phenyl; or iii) substituted or unsubstituted heteroaryl; provided that R and R1 are not both hydrogen; R2 is OR6 or NR7aR7b; R6 is hydrogen or linear, branched, or cyclic alkyl; R7a and R7b are each independently: hydrogen, linear, branched, or cyclic alkyl; or R7a and R7b can be taken together to form a ring having from 3 to 7 atoms; R3 is hydrogen, methyl, or ethyl; L is an C1-C3 optionally substituted alkylene moiety; R9 is hydrogen or methyl; or a pharmaceutically acceptable salt thereof; and wherein the remaining substituents are as defined herein. Representative compounds include { [5-(4-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid methyl ester, [(3-hydroxy-5-(4-methylphenyl)pyridine-2-carbonyl)amino]acetic acid methyl ester, { [3-hydroxy-5-(3-trifluoromethylphenyl)-pyridine-2-carbonyl]amino} acetic acid methyl ester, [(3-hydroxy-5-isoquinolin-4-yl-pyridine-2-carbonyl)amino]acetic acid methyl ester, ({ 5-[3-(cyclopropanecarbonylamino)phenyl]-3-hydroxypyridine-2-carbonyl} amino)acetic acid methyl ester, 5-(3-chlorophenyl)-N-(2-dimethylamino-2-oxoethyl)-3-hydroxypyridin-2-yl amide, 5-(3-chlorophenyl)-N-(2-isopropylamino-2-oxoethyl)-3-hydroxypyridin-2-yl amide, 2-{ [5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} -2-methyl-propionic acid methyl ester and 5-(3-chlorophenyl)-N-(2-methylamino-2-oxo-1,1-dimethylethyl)-3-hydroxylpyridin-2-yl amide. Further disclosed is a composition comprising one or more compounds as defined above, or a pharmaceutically acceptable salt thereof; and one or more excipients or carriers; for treating a disease selected from diabetic retinopathy, macular degeneration, sickle cell anemia, sarcoid, syphilis, pseudoxanthoma elasticum, Paget’s disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis/vitritis, mycobacterial infections, Lyme’s disease, systemic lupus erythematosis, retinopathy of prematurity, Eales’ disease, Behcet’s disease, infections causing a retinitis or choroiditis, presumed ocular histoplasmosis, Best’s disease, myopia, optic pits, Stargardt’s disease, pars planitis, chronic retinal detachment, hyperviscosity syndrome, toxoplasmosis, trauma post-laser complications, diseases associated with rubeosis, and proliferative vitroeretinopathy, Crohn’s disease and ulcerative colitis, psoriasis, sarcoidosis, rheumatoid arthritis, hemangiomas, Osler-Weber-Rendu disease, or hereditary hemorrhagic telangiectasia, solid or blood borne tumors, acquired immune deficiency syndrome, skeletal muscle and myocardial ischemia, stroke, coronary artery disease, peripheral vascular disease, and coronary artery disease.",AKEBIA THERAPEUTICS INC,KAWAMOTO RICHARD MASARU;;WARSHAKOON NAMAL CHITHRANGA;;GREIS KENNETH DONALD;;BOYER ANGELIQUE SUN;;WU SHENGDE;;EDOKIMOV ARTEM G,"AKEBIA THERAPEUTICS INC., NZ (2013-09-26)",https://lens.org/011-164-216-147-045,Patent Application,no,0,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07C255/57;;A61K31/4418;;A61P7/06;;C07C235/60;;C07C237/42;;C07D213/65;;C07D213/81,,0,0,,,,PENDING
614,US,A1,US 2014/0057892 A1,060-838-178-646-999,2014-02-27,2014,US 201314071088 A,2013-11-04,US 201314071088 A;;US 201213681876 A;;US 86007310 A;;US 82193607 A;;US 81652206 P,2006-06-26,PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE,"The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD) heart failure, ischemia, and anemia.",AKEBIA THERAPEUTICS INC,KAWAMOTO RICHARD MASARU;;WU SHENGDE;;EVDOKIMOV ARTEM G;;GREIS KENNETH D;;BOYER ANGELIQUE SUN;;WARSHAKOON NAMAL C,THE PROCTER & GAMBLE COMPANY (2008-12-19);;AKEBIA THERAPEUTICS INC (2011-12-15);;WARNER CHILCOTT COMPANY LLC (2009-10-30),https://lens.org/060-838-178-646-999,Patent Application,yes,1,22,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07D417/04;;C07D213/81;;C07D295/192;;C07D401/04;;C07D401/10,514/210.18;;514/350;;514/343;;514/340;;514/334;;514/256;;514/307;;514/342,1,0,,,"Gavhane; International Journal of Pharma Sciences and Research, 2011, 2 , 1-12",DISCONTINUED
615,US,A1,US 2017/0189387 A1,146-921-792-600-697,2017-07-06,2017,US 201715420617 A,2017-01-31,US 201715420617 A;;US 201514854080 A;;US 201414568200 A;;US 201314062011 A;;US 201213681876 A;;US 86007310 A;;US 82193607 A;;US 81652206 P,2006-06-26,PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE,"The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.",AKEBIA THERAPEUTICS INC,KAWAMOTO RICHARD MASARU;;WU SHENGDE;;EVDOKIMOV ARTEM G;;GREIS KENNETH D;;BOYER ANGELIQUE SUN;;WARSHAKOON NAMAL C,THE PROCTER & GAMBLE COMPANY (2008-12-19);;AKEBIA THERAPEUTICS INC (2011-12-15);;WARNER CHILCOTT COMPANY LLC (2009-10-30),https://lens.org/146-921-792-600-697,Patent Application,yes,0,14,83,83,1,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,A61K31/4418;;A61K31/4433,,0,0,,,,DISCONTINUED
616,US,A1,US 2010/0331374 A1,170-922-805-085-837,2010-12-30,2010,US 86013610 A,2010-08-20,US 86013610 A;;US 82193607 A;;US 81652206 P,2006-06-26,PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE,"The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.",WU SHENGDE;;WARSHAKOON NAMAL C;;EVDOKIMOV ARTEM G;;GREIS KENNETH D;;BOYER ANGELIQUE SUN;;KAWAMOTO RICHARD MASARU,WU SHENGDE;;WARSHAKOON NAMAL C;;EVDOKIMOV ARTEM G;;GREIS KENNETH D;;BOYER ANGELIQUE SUN;;KAWAMOTO RICHARD MASARU,THE PROCTER & GAMBLE COMPANY (2008-12-19);;AKEBIA THERAPEUTICS INC (2011-12-15);;WARNER CHILCOTT COMPANY LLC (2009-10-30),https://lens.org/170-922-805-085-837,Patent Application,yes,26,21,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,A61K31/4439;;A61K31/4418;;A61P7/06;;A61P17/02,514/343;;514/350;;514/340,0,0,,,,ACTIVE
617,CA,A1,CA 2659682 A1,025-995-181-818-472,2008-01-03,2008,CA 2659682 A,2007-06-26,US 81652206 P;;US 2007/0014832 W,2006-06-26,PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE,"The present disclosure relates to HIF-1.alpha. prolyl hydroxylase inhibit ors, compositions which comprise the HIF-1.alpha. prolyl hydroxylase inhibit ors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischem ia, and anemia.",PROCTER & GAMBLE,KAWAMOTO RICHARD MASARU;;BOYER ANGELIQUE SUN;;EDOKIMOV ARTEM G;;GREIS KENNETH DONALD;;WARSHAKOON NAMAL CHITHRANGA;;WU SHENGDE,,https://lens.org/025-995-181-818-472,Patent Application,no,0,5,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07C235/60;;C07C237/42;;C07C255/57;;C07D213/81,,0,0,,,,ACTIVE
618,US,B2,US 8343952 B2,006-563-087-477-538,2013-01-01,2013,US 86007310 A,2010-08-20,US 86007310 A;;US 82193607 A;;US 81652206 P,2006-06-26,Prolyl hydroxylase inhibitors and methods of use,"The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.",AKEBIA THERAPEUTICS INC;;WU SHENGDE;;WARSHAKOON NAMAL C;;EVDOKIMOV ARTEM G;;GREIS KENNETH D;;BOYER ANGELIQUE SUN;;KAWAMOTO RICHARD MASARU,WU SHENGDE;;WARSHAKOON NAMAL C;;EVDOKIMOV ARTEM G;;GREIS KENNETH D;;BOYER ANGELIQUE SUN;;KAWAMOTO RICHARD MASARU,THE PROCTER & GAMBLE COMPANY (2008-12-19);;AKEBIA THERAPEUTICS INC (2011-12-15);;WARNER CHILCOTT COMPANY LLC (2009-10-30),https://lens.org/006-563-087-477-538,Granted Patent,yes,75,32,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,A61K31/4418;;A61K31/4427;;A61K31/4433;;A61K31/4439;;A61K31/444;;A61K31/4725;;A61K31/506;;A61P7/06;;A61P17/02;;C07D213/81;;C07D401/04;;C07D401/10;;C07D405/10,514/210.18;;514/346;;514/343;;514/340;;514/334;;514/256;;514/307;;514/342;;514/338;;546/291;;546/279.1;;546/268.4;;546/257;;546/144;;546/270.4;;546/282.4,80,45,028-862-168-091-90X;;063-746-538-402-770;;093-087-601-151-305;;006-143-986-832-256;;064-865-149-673-057;;102-345-845-395-203;;015-199-257-732-502;;009-081-622-113-208;;052-512-054-021-225;;022-156-141-942-093;;081-136-747-247-898;;030-042-017-746-591;;131-046-096-401-339;;092-475-988-464-223;;135-654-547-079-284;;077-106-322-076-470;;069-450-943-413-364;;025-178-564-355-938;;048-830-824-939-083;;102-949-159-342-256;;018-052-265-551-042;;064-406-626-054-484;;011-101-678-202-709;;129-297-815-048-32X;;023-017-724-234-140;;074-344-536-692-994;;091-474-773-070-883;;016-533-076-557-079;;149-920-492-418-396;;056-436-730-631-840;;034-760-425-242-511;;074-156-318-814-764;;064-242-953-339-024;;062-826-287-074-090;;065-169-875-352-44X;;045-408-622-411-245;;096-459-000-284-800;;040-667-645-789-907;;017-183-541-402-013;;017-669-075-762-985;;010-824-042-186-283;;066-519-812-638-153;;125-424-943-194-608;;026-655-568-834-966;;103-335-591-460-884,10.1093/nar/25.17.3389;;9254694;;pmc146917;;15664391;;10.1016/j.cardiores.2004.09.004;;15637314;;10.1161/01.str.0000153795.38388.72;;10.1373/49.1.32;;12507958;;3326854;;10.1111/j.1399-3011.1987.tb03385.x;;1583540;;10.1007/bf00124387;;10.1016/s0968-0004(97)01074-8;;9255066;;10.1021/jm00092a016;;1321909;;pmc312791;;10.1101/gad.914801;;11581158;;10.1016/s0304-4157(99)00006-4;;10548717;;1665444;;10.1042/bst0190812;;10.1021/jm00145a002;;3892003;;10.1002/prot.340080302;;2281083;;7823319;;10.1016/s0022-2836(95)80037-9;;15952883;;10.1146/annurev.biochem.74.082803.133142;;10.1182/blood.v77.3.419.bloodjournal773419;;10.1182/blood.v77.3.419.419;;1991159;;7154081;;10.1016/0022-2836(82)90153-x;;12482756;;10.1074/jbc.m210385200;;10613823;;10.1038/71527;;10.1161/01.cir.0000044914.42696.6a;;12538431;;pmc1502536;;16782814;;10.1073/pnas.0601283103;;10.2210/pdb2g1m/pdb;;10.1002/prot.340110104;;1961699;;10.1016/s0074-7696(01)04002-5;;11243594;;10.1016/s0040-4020(01)86503-0;;7525077;;10.1016/0092-8674(94)90200-3;;10.1016/s0092-8674(00)81848-6;;9008168;;10.1172/jci23865;;16007254;;pmc1159132;;10.1016/s0303-7207(99)00017-9;;10411333;;10.1016/s0006-2952(02)01168-1;;12213597;;7852211;;10.1016/s0889-8588(18)30134-5;;10.1016/s0021-9258(17)31580-6;;8089148;;19649971;;10.1021/jo01340a533;;5902481;;7515861;;10.1002/ijc.2910570624;;11056102;;10.1161/01.cir.102.18.2255;;10.1096/fj.02-1062fje;;12709400;;8606489;;10.1056/nejm199101033240101;;1701519;;12649278;;10.1074/jbc.m301391200;;10.1016/s0040-4020(03)01100-1;;490542;;10.1021/jm00194a018;;pmc129695;;12351678;;10.1073/pnas.192342099;;10.1007/978-1-4684-5445-1_9;;2965848;;15132592;;10.1021/cc049977g;;10.1002/hlca.200490260,"U.S. Appl. No. 11/821,936, Kawamoto, filed Jun. 26, 2007, Restriction Requirement, Nov. 13, 2009.;;U.S. Appl. No. 11/821,936, Kawamoto, filed Jun. 26, 2007, Response to Restriction Requirement, Nov. 20, 2009.;;U.S. Appl. No. 11/821,936, Kawamoto, filed Jun. 26, 2007, Non-Final Office Action, Mar. 16, 2010.;;U.S. Appl. No. 11/821,936, Kawamoto, filed Jun. 26, 2007, Draft Response to Office Action, Apr. 4, 2010.;;U.S. Appl. No. 11/821,936, Kawamoto, filed Jun. 26, 2007, Examiner's Interview Summary, Apr. 19, 2010.;;U.S. Appl. No. 11/821,936, Kawamoto, filed Jun. 26, 2007, Response to Office Action, Apr. 20, 2010.;;U.S. Appl. No. 11/821,936, Kawamoto, filed Jun. 26, 2007, Notice of Allowance, Aug. 12, 2010.;;U.S. Appl. No. 11/821,936, Kawamoto, filed Jun. 26, 2007, Issue Notification, Sep. 22, 2010.;;U.S. Appl. No. 11/713,941, Evdokimov, filed Mar. 5, 2007, Restriction Requirement, May 29, 2008.;;U.S. Appl. No. 11/713,941, Evdokimov, filed Mar. 5, 2007, Response to Restriction Requirement, Jul. 22, 2008.;;U.S. Appl. No. 11/713,941, Evdokimov, filed Mar. 5, 2007, Non-Final Office Action, Nov. 18, 2008.;;U.S. Appl. No. 11/713,941, Evdokimov, filed Mar. 5, 2007, Response to Office Action, Mar. 16, 2009.;;U.S. Appl. No. 11/713,941, Evdokimov, filed Mar. 5, 2007, Final Rejection, May 15, 2009.;;U.S. Appl. No. 11/713,941, Evdokimov, filed Mar. 5, 2007, Response to Final Office Action, May 28, 2009.;;U.S. Appl. No. 11/713,941, Evdokimov, filed Mar. 5, 2007, Response to Final Office Action, Jun. 3, 2009.;;U.S. Appl. No. 11/713,941, Evdokimov, filed Mar. 5, 2007, Notice of Allowance, Jun. 17, 2009.;;U.S. Appl. No. 11/713,941, Evdokimov, filed Mar. 5, 2007, Issue Notification, Aug. 26, 2009.;;U.S. Appl. No. 12/473,536, Evdokimov, filed May 28, 2009, Restriction Requirement, Jun. 21, 2010.;;U.S. Appl. No. 12/473,536, Evdokimov, filed May 28, 2009, Response to Restriction Requirement, Jun. 23, 2010.;;U.S. Appl. No. 12/473,536, Evdokimov, filed May 28, 2009, Non-Final Office Action, Aug. 16, 2010.;;U.S. Appl. No. 12/473,536, Evdokimov, filed May 28, 2009, Response to Office Action.;;AU, 2007265460, Jan. 22, 2009, Akebia Pharmaceuticals, Office Action, Jul. 19, 2010.;;AU, 2007265460, Jan. 22, 2009, Akebia Pharmaceuticals, Response to Office Action, Nov. 18, 2010.;;CA, 2,659,682, Dec. 23, 2008, Akebia Pharmaceuticals, Office Action, May 18, 2010.;;CA, 2,659,682, Dec. 23, 2008, Akebia Pharmaceuticals, Response to Office Action, Jun. 22, 2010.;;CA, 2,659,682, Dec. 23, 2008, Akebia Pharmaceuticals, Notice of Allowance, Aug. 30, 2010.;;EP, 07835890.0, Jun. 26, 2007, Akebia Pharmaceuticals, Office Action, Mar. 3, 2010.;;EP, 07835890.0, Jun. 26, 2007, Akebia Pharmaceuticals, Response to Office Action, Apr. 9, 2010.;;EP, 07835890.0, Jun. 26, 2007, Akebia Pharmaceuticals, Rule 71(3) EPC, Jun. 24, 2010.;;EP, 07835890.0, Jun. 26, 2007, Akebia Pharmaceuticals, Decision to Grant, Sep. 23, 2010.;;SG, 200809595-2, Jun. 27, 2007, Akebia Pharmaceuticals, Office Action, Jan. 13, 2010.;;SG, 200809595-2, Jun. 27, 2007, Akebia Pharmaceuticals, Response to Office Action, Jun. 10, 2010.;;Altschul et al., ""Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs,"" Nucleic Acids Res., 25(27):3389-3402 (1997).;;Annex et al., ""Growth Factor-Induced Therapeutic Angiogenesis in the Heart: Protein Therapy,"" Cardiovascular Research, 65(3):649-655 (2005).;;Ardelt et al., ""Estradiol Regulates Angiopoietin-1 mRNA Expression Through Estrogen Receptor-alpha in a Rodent Experimental Stroke Model,"" Stroke, 36:337-341 (2005).;;Auerbach et al., ""Angiogenesis Assays: A Critical Overview,"" Clinical Chemistry, 49:32-40 (2003).;;Barany et al., ""Solid-phase Peptide Synthesis: A Silver Anniversary Report,"" Int. J. Peptide Protein Res., 30(6):705-739 (1987).;;Bartlett et al., ""Molecular Recognition in Chemical and Biological Problems,"" Special Pub., Royal Chem. Soc., 78, 182-196 Caveat: A Program to Facilitate the Structure-derived Design of Biologically Active Molecules (Apr. 1989).;;Böhm, ""The Computer Program LUDI: A New Method for the Novo Design of Enzyme Inhibitors,"" J. Computer-Aided Molecular Design, 6:61-78 (1992).;;Branden et al., ""Introduction to Protein Structure Second Edition,"" Garland Publising Inc., New York, 1999, pp. 374-375.;;Bussolino, ""Molecular Mechanisms of Blood Vessel Formation,"" Trends Biochem. Sci.,22(7):251-256 (1997).;;Cunliffe et al., ""Novel Inhibitors of Prolyl 4-Hydroxylase. 3. Inhibition by the Substrate Analogue N-Oxaloglycine and Its Derivatives,"" J. Med. Chem. 35:2652-2658 (1992).;;Elson et al., ""Induction of Hypervascularity Without Leakage or Inflammation in Transgenic Mice Overexpressing Hypoxia-Indicible Factor-1alpha,"" Genes & Dev.,15:2520-2532 (2001).;;Flower, ""Modelling G-protein-coupled receptors for drug design,"" Biochimica et Biophysica Acta, 1422:207-234 (1999).;;Folkman et al., ""Tumor Angiogenesis,"" The Molecular Basis of Cancer, Mendelsohn et al., eds., W. B. Saunders, Chapter 10, pp. 206-232 (1995).;;Franklin et al., ""Approaches to the Design of Anti-Fibrotic Drugs,"" Biochem. Soc. Trans., 19(4):812-5 (Nov. 1991).;;Goodford, ""A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules,"" J. Med. Chem., 28(7):849-857 (1985).;;Goodsell et al., ""Automated Docking of Substrates to Proteins by Simulated Annealing,"" Proteins: Structure, Function, and Genetics, 8:195-202 (1990).;;Jones et al., ""Molecular Recognition of Receptor Sites Using a Genetic Algorithm with a Description of Desolvation,"" J. Mol. Biol., 245:43-53 (1995).;;Kaelin, ""Proline Hydroxylation and Gene Expression,"" Annu. Rev. Biochem., 74:115-125 (2005).;;Krantz, ""Erythropoietin,"" Blood, 77:419-434 (1991).;;Kuntz et al., ""A Geometric Approach to Macromolecule-Ligand Interactions,"" J. Mol. Biol., 161:269-288 (1982).;;Lee et al., ""Structure of Human FIH-1 Reveals a Unique Active Site Pocket and Interaction Sites for HIF-1 and von Hippel Lindau,"" JBC, 278:7558-7563 (2003).;;Li et al., ""PR39, A Peptide Regulator of Angiogenesis,"" Nat Med., 6(1):49-55 (2000).;;Mancini et al., ""Effect of Erythropoietin on Exercise Capacity in Patients with Moderate to Severe Chronic Heart Failure,"" Circulation, 107:294-299 (2003).;;McDonough et al., ""Cellular Oxygen Sensing: Crystal Structure of Hypoxia-Inducible Factor Prolyl Hydroxylase (PHD2),"" PNAS, 103(26):9814-9819 (2006).;;Miranker et al., ""Functionality Maps of Binding Sites: A Multiple Copy Simultaneous Search Method,"" Proteins: Structure, Function and Genetics, 11:29-34 (1991).;;Nguyen et al., ""Cellular Interactions in Vascular Growth and Differentiation,"" Int. Review of Cytology, 204:1-48 (2001).;;Nishibata et al., ""Automatic Creation of Drug Candidate Structures Based on Receptor Structure. Starting Point for Artificial Lead Generation,"" Tetrahedron, 47(43):8985-8990 (1991).;;O'Reilly et al., ""Angiostatin: A Novel Angiogenesis Inhibitor that Mediates the Suppression of Metastases by a Lewis Lung Carcinoma,"" Cell, 79:315-328 (1994).;;O'Reilly et al., ""Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth,"" Cell, 88:277-285 (1997).;;Peyssonnaux et al., ""HIF-1alpha Expression Regulates the Bactericidal Capacity of Phagocytes,"" J. Clinical Invest., 115(7):1806-1815, Jul. 1, 2005.;;Schoneberg et al., ""Structural Basis of G Protein-Coupled Receptor Function,"" Molecular and Cellular Endocrinology, 151:181-193 (1999).;;Semenza, ""Signal Transduction to Hypoxia-inducible Factor 1,"" Biochem. Pharmacol, 64:993-998 (2002).;;Semenza, ""Regulation of Erythropoietin Porduction: New Insights into Molecular Mechanisms of Oxygen Homeostasis,"" Hematol. Oncol. Clin. North Am., 8:863-884 (1994).;;Semenza et al., ""Transcriptional Regulation of Genes Encoding Glycolytic Enzymes by Hypoxia-Inducible Factor 1,"" J. Biol. Chem., 269:23757-23763 (1994).;;Sexton, ""Recent advances in our understanding of peptide hormone receptors and Ramps,"" Current Opinion in Drug Discovery and Development, 2(5):440-448 (1999).;;Sheehan, ""3-Hydroxypicolinic Acid and Some of its Derivatives,"" J. Organic Chemistry 31(3):636-638 (1996).;;Teicher et al., ""Potentiation of Cytotoxic Cancer Therapies by TNP-470 Alone and with Other Anti-Angiogenic Agents,"" Int. J. Cancer, 57:920-925 (1994).;;Vincent et al., ""Angiogenesis is Induced in a Rabbit Model of Hindlimb Ischemia by Naked DNA Encoding an HIF-1alpha/VP16 Hybrid Transcription Factor,"" Circulation, 102:2255-2261 (2000).;;Warnecke et al., ""Activation of the Hypoxia-Inducible Factor Pathway and Stimulation of Angiogenesis by Application of Prolyl Hydroxylase Inhibitors,"" FASEB Journal, 17:1186-1188 (2003).;;Wax et al., ""SM-20 is a Novel 20-kd Protein Whose Expression in the Arterial Wall is Restricted to Smooth Muscle,"" Lab. Invest., 74(4):797-808 (1996).;;Weidner et al., ""Tumor Angiogenesis and Metastasis-Correlation in Invasive Breast Carcinoma,"" New Eng. J Med., 324(1):1-8 (1991).;;Wright et al., ""Activation of the Prolyl Hydroxylase Oxygen-Sensor Results in Induction of GLUT1, Heme Oxygenase-1, and Nitric-Oxide Synthase Proteins and Confers Protection from Metabolic Inhibition to Cardiomyocytes,"" J. Bio. Chem., 278(22):20235-20239 (2003).;;Alesso et al., ""Improving resins for solid phase synthesis: incorporation of 1-[2-(2-methoxyethoxy)ethoxy]4-vinyl-benzene"" Tetrahedron: 59, 7163-7169 (2003).;;Anderson et al., ""Antileukemic Activity of Derivatives of 1,2-Dimethyl-3,4-bis(hydroxymethyl)-5-phenylpyrrole Bis(N-methylcarbamate)"" J. Med. Chem.: vol. 22(8), 977-980 (1979).;;Ivan et al., ""Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor,"" Proceedings of the National Academy of Science; 99(21) 13459-13464.;;Kawashima et al., ""Suppressive effect of quinolinic acid an hippuric acid on bone marrow erythroid growth and lymphocyte blast formation in uremia,"" Advances in Experimental Medicine and Biology, (1987), vol. 223, p. 69-72.;;Vickerstaffe et al., ""Fully Automated Polymer-Assisted Synthesis of 1,5-Biaryl Pyrazoles,"" J. Comb. Chem., 2004, 6, 332-33.;;Tzschucke et al., ""Fluorous-Silica-Supported Perfluoro-Tagged Palladium Complexes Catalyze Suzuki Coupling in Water"" Helvetica Chimica Acta; vol. 87 2882-2889 (2004).",ACTIVE
619,NZ,A,NZ 601731 A,027-246-132-786-253,2014-04-30,2014,NZ 60173107 A,2007-06-26,US 81652206 P;;NZ 57440807 A,2006-06-26,Prolyl hydroxylase inhibitors and methods for use,"601731 Disclosed are { [5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} -acetic acid derivatives as represented by the general formula, as inhibitors of human protein prolyl hydroxylase for stimulating an angiogenic response for increasing blood flow, oxygen delivery and energy utilization in ischemic tissues; wherein the specific compounds of formula (I) are chosen from { [5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid methyl ester, [(3-hydroxy-5-(4-methylphenyl)pyridine-2-carbonyl)amino]acetic acid, { [5-(2-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid methyl ester, { [5-(4-cyanophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid, { [5-(4-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid, { [5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid, { [5-(2-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid and 5-(3-chlorophenyl)-N-(2-methylamino-2-oxoethyl)-3-hydroxylpyridin-2-yl amide; or a pharmaceutically acceptable salt thereof. Further disclosed is a composition comprising one or more compounds as defined above, or a pharmaceutically acceptable salt thereof; and one or more excipients or carriers; for treating a disease selected from diabetic retinopathy, macular degeneration, sickle cell anemia, sarcoid, syphilis, pseudoxanthoma elasticum, Paget’s disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis/vitritis, mycobacterial infections, Lyme’s disease, systemic lupus erythematosis, retinopathy of prematurity, Eales’ disease, Behcet’s disease, infections causing a retinitis or choroiditis, presumed ocular histoplasmosis, Best’s disease, myopia, optic pits, Stargardt’s disease, pars planitis, chronic retinal detachment, hyperviscosity syndrome, toxoplasmosis, trauma post-laser complications, diseases associated with rubeosis, and proliferative vitroeretinopathy, Crohn’s disease and ulcerative colitis, psoriasis, sarcoidosis, rheumatoid arthritis, hemangiomas, Osler-Weber-Rendu disease, or hereditary hemorrhagic telangiectasia, solid or blood borne tumors, acquired immune deficiency syndrome, skeletal muscle and myocardial ischemia, stroke, coronary artery disease, peripheral vascular disease, and coronary artery disease.",AKEBIA THERAPEUTICS INC,KAWAMOTO RICHARD MASARU;;WARSHAKOON NAMAL CHITHRANGA;;GREIS KENNETH DONALD;;BOYER ANGELIQUE SUN;;WU SHENGDE;;EDOKIMOV ARTEM G,"AKEBIA THERAPEUTICS INC., NZ (2013-09-26)",https://lens.org/027-246-132-786-253,Patent Application,no,0,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07C255/57;;A61K31/4418;;A61P7/06;;C07C235/60;;C07C237/42;;C07D213/65;;C07D213/81,,0,0,,,,PENDING
620,MX,A,MX 2009000286 A,155-416-467-797-392,2009-03-20,2009,MX 2009000286 A,2007-06-26,US 81652206 P;;US 2007/0014832 W,2006-06-26,PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE.,"The present disclosure relates to HIF-1alpha prolyl hydroxylase inhibitors, compositions which comprise the HIF-1alpha prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.",PROCTER & GAMBLE,WARSHAKOON NAMAL CHITHRANGA;;KAWAMOTO RICHARD MASARU;;WU SHENGDE;;EDOKIMOV ARTEM G;;GREIS KENNETH DONALD;;BOYER ANGELIQUE SUN,AKEBIA THERAPEUTICS INC. (2013-12-13),https://lens.org/155-416-467-797-392,Patent Application,no,0,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07C235/60;;C07C237/42;;C07C255/57;;C07D213/81,,0,0,,,,ACTIVE
621,US,A1,US 2016/0009648 A1,163-110-894-350-534,2016-01-14,2016,US 201514854080 A,2015-09-15,US 201514854080 A;;US 201414568200 A;;US 201314062011 A;;US 201213681876 A;;US 86007310 A;;US 82193607 A;;US 81652206 P,2006-06-26,PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE,"The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.",AKEBIA THERAPEUTICS INC,KAWAMOTO RICHARD MASARU;;WU SHENGDE;;EVDOKIMOV ARTEM G;;GREIS KENNETH D;;BOYER ANGELIQUE SUN;;WARSHAKOON NAMAL C,THE PROCTER & GAMBLE COMPANY (2008-12-19);;AKEBIA THERAPEUTICS INC (2011-12-15);;WARNER CHILCOTT COMPANY LLC (2009-10-30),https://lens.org/163-110-894-350-534,Patent Application,yes,14,17,83,83,1,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07D213/81;;C07D401/04;;C07D401/10;;C07D405/04;;C07D417/04,,0,0,,,,ACTIVE
622,CN,B,CN 101506149 B,082-378-069-358-422,2012-11-14,2012,CN 200780030720 A,2007-06-26,US 2007/0014832 W;;US 81652206 P,2006-06-26,Prolyl hydroxylase inhibitors and methods of use,"The present disclosure relates to HIF-1a prolyl hydroxylase inhibitors, compositions which comprise the HIF-1a prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.",PROCTER & GAMBLE,SHENGDE WU;;CHITHRANGA WARSHAKOON NAMAL;;MASARU KAWAMOTO RICHARD;;SUN BOYER ANGELIQUE;;EDOKIMOV ARTEM G;;DONALD GREIS KENNETH,"AKEBIA THERAPEUTICS INC. (2013-08-07);;WARNER CHILCOTT CO., LTD. (2010-11-01)",https://lens.org/082-378-069-358-422,Granted Patent,no,0,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07C235/60;;C07C237/42;;C07C255/57;;C07D213/81,,0,0,,,,ACTIVE
623,US,B2,US 11426393 B2,094-352-591-371-646,2022-08-30,2022,US 202016908092 A,2020-06-22,US 202016908092 A;;US 201816119146 A;;US 201715420617 A;;US 201514854080 A;;US 201414568200 A;;US 201314062011 A;;US 201213681876 A;;US 86007310 A;;US 82193607 A;;US 81652206 P,2006-06-26,Prolyl hydroxylase inhibitors and methods of use,"The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.",AKEBIA THERAPEUTICS INC,KAWAMOTO RICHARD MASARU;;WU SHENGDE;;EVDOKIMOV ARTEM G;;GREIS KENNETH D;;BOYER ANGELIQUE SUN;;WARSHAKOON NAMAL C,THE PROCTER & GAMBLE COMPANY (2008-12-19);;AKEBIA THERAPEUTICS INC (2011-12-15);;WARNER CHILCOTT COMPANY LLC (2009-10-30),https://lens.org/094-352-591-371-646,Granted Patent,yes,140,2,83,83,1,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07D213/81;;A61K31/4418;;A61K31/4433;;C07C235/60;;C07C237/42;;C07C255/57;;C07D213/65;;C07D295/192;;C07D401/04;;C07D401/10;;C07D405/04;;C07D405/10;;C07D417/04,,102,70,000-203-740-034-24X;;017-669-075-762-985;;028-862-168-091-90X;;010-824-042-186-283;;063-746-538-402-770;;093-087-601-151-305;;006-143-986-832-256;;064-865-149-673-057;;102-345-845-395-203;;000-457-771-937-337;;015-199-257-732-502;;105-391-605-288-229;;009-081-622-113-208;;052-512-054-021-225;;095-605-097-751-343;;022-156-141-942-093;;081-136-747-247-898;;087-705-105-313-369;;030-042-017-746-591;;131-046-096-401-339;;007-397-822-838-463;;042-987-854-927-099;;046-414-927-085-724;;098-888-990-357-930;;102-347-048-244-655;;019-130-789-993-789;;066-519-812-638-153;;022-950-342-458-554;;083-737-080-066-103;;092-475-988-464-223;;135-654-547-079-284;;125-424-943-194-608;;129-372-774-596-270;;015-285-296-623-617;;077-106-322-076-470;;069-450-943-413-364;;025-178-564-355-938;;048-830-824-939-083;;056-311-147-347-640;;102-949-159-342-256;;018-052-265-551-042;;064-406-626-054-484;;011-101-678-202-709;;129-297-815-048-32X;;023-017-724-234-140;;074-344-536-692-994;;032-766-102-934-139;;091-474-773-070-883;;007-834-259-097-311;;019-005-723-569-798;;104-310-480-694-456;;016-533-076-557-079;;018-490-208-246-068;;034-760-425-242-511;;056-436-730-631-840;;149-920-492-418-396;;074-156-318-814-764;;064-242-953-339-024;;046-494-590-295-402;;141-317-043-329-438;;062-826-287-074-090;;117-587-550-537-020;;103-335-591-460-884;;026-655-568-834-966;;065-169-875-352-44X;;045-408-622-411-245;;003-330-211-576-597;;096-459-000-284-800;;040-667-645-789-907;;017-183-541-402-013,10.1093/ndt/14.5.1171;;10344357;;10.1016/s0040-4020(03)01100-1;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;490542;;10.1021/jm00194a018;;15664391;;10.1016/j.cardiores.2004.09.004;;15637314;;10.1161/01.str.0000153795.38388.72;;10.1373/49.1.32;;12507958;;3326854;;10.1111/j.1399-3011.1987.tb03385.x;;1583540;;10.1007/bf00124387;;1763185;;10.1007/978-3-0348-7139-6_7;;10.1016/s0968-0004(97)01074-8;;9255066;;10.2337/diabetes.53.12.3226;;15561954;;10.1021/jm00092a016;;1321909;;pmc312791;;10.1101/gad.914801;;11581158;;pmc1440619;;10.1136/bmj.332.7546.900;;16613966;;10.1016/s0304-4157(99)00006-4;;10548717;;1665444;;10.1042/bst0190812;;10.1021/jo980823v;;10.1021/jm00145a002;;3892003;;10.1002/prot.340080302;;2281083;;28532635;;10.1053/j.ajkd.2016.12.011;;10.1053/j.ajkd.2017.04.001;;28242135;;10.1021/jm050444b;;16302822;;10.1021/jm050444b.s001;;10.1074/jbc.m304982200;;12788921;;10.1021/ja00383a030;;10.1016/j.bmc.2006.01.059;;16481176;;10.1351/pac199567081307;;pmc129695;;12351678;;10.1073/pnas.192342099;;10.1126/science.1059817;;11292862;;10.1126/science.1059796;;11292861;;011292861;;7823319;;10.1016/s0022-2836(95)80037-9;;15952883;;10.1146/annurev.biochem.74.082803.133142;;10.1007/978-1-4684-5445-1_9;;2965848;;10.1124/mol.106.027029;;16887934;;26610437;;pmc6332328;;10.3390/molecules201119717;;10.1182/blood.v77.3.419.bloodjournal773419;;10.1182/blood.v77.3.419.419;;1991159;;7154081;;10.1016/0022-2836(82)90153-x;;12482756;;10.1074/jbc.m210385200;;10613823;;10.1038/71527;;10.2174/0929867053363540;;15638729;;10.1161/01.cir.0000044914.42696.6a;;12538431;;pmc1502536;;16782814;;10.1073/pnas.0601283103;;10.2210/pdb2g1m/pdb;;10.1002/prot.340110104;;1961699;;10.1016/s0074-7696(01)04002-5;;11243594;;10.1016/s0040-4020(01)86503-0;;7525077;;10.1016/0092-8674(94)90200-3;;10.1016/s0092-8674(00)81848-6;;9008168;;27650732;;10.1016/j.kint.2016.07.019;;10.1172/jci23865;;16007254;;pmc1159132;;10.1002/chem.200902455;;20397153;;10.2337/db14-0472;;24789921;;10.1002/anie.199620561;;10.1016/s0303-7207(99)00017-9;;10411333;;10.1101/gad.14.16.1983;;10950862;;10.1016/s0021-9258(17)31580-6;;8089148;;7852211;;10.1016/s0889-8588(18)30134-5;;10.1016/s0006-2952(02)01168-1;;12213597;;19649971;;10.1021/jo01340a533;;5902481;;16227210;;10.1074/jbc.m504963200;;pmc2586128;;16373931;;10.2337/diacare.29.s1.06.s4;;7515861;;10.1002/ijc.2910570624;;10.1039/cs9790800563;;10.1002/hlca.200490260;;15132592;;10.1021/cc049977g;;11056102;;10.1161/01.cir.102.18.2255;;10.1096/fj.02-1062fje;;12709400;;16908149;;10.1016/j.bmcl.2006.08.026;;8606489;;10.1056/nejm199101033240101;;1701519;;12649278;;10.1074/jbc.m301391200,"Aucella et al. “Synergistic effect of desferrioxamine and recombinant erythropoietin on erythroid precursor proliferation in chronic renal failure” Nephrol Dial Transplant. May 1999;14(5):1171-5.;;Alesso et al., Improving resins for solid phase synthesis: incorporation of I-[2-(2-methoxyethoxy) ethoxy]4-vinyl-benzene, Tetrahedron, vol. 59, 7163-7169, 2003.;;Altschul et al., Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs, Nucleic Acids Res., vol. 25, No. 27, 3389-3402, 1997.;;Anderson et al., Antileukemic Activity of Derivatives of I ,2-Dimethyl-3,4-bis(hydroxymethyl)-5-phenylpyrrole Bis(N-methylcarbamate), J. Med. Chem.: vol. 22, No. 8, 977-980, 1979.;;Annex et al., Growth Factor-Induced Therapeutic Angiogenesis in the Heart: Protein Therapy, Cardiovascular Research, vol. 65, No. 3, 649-655, 2005.;;Ardelt et al., Estradiol Regulates Angiopoietin-1 mRNA Expression Through Estrogen Receptor-a in a Rodent Experimental Stroke Model, Stroke, vol. 36, 337-341, 2005.;;Auerbach et al., Angiogenesis Assays: A Critical Overview, Clinical Chemistry, vol. 49, 32-40, 2003.;;Barany et al., Solid-phase Peptide Synthesis: A Silver Anniversary Report, Int. J. Peptide Protein Res., vol. 30, No. 6, 705-739, 1987.;;Bartlett et al., Molecular Recognition in Chemical and Biological Problems, Special Pub., Royal Chem. Soc., vol. 78, 182-196 Caveat: A Program to Facilitate the Structure-derived Design of Biologically Active Molecules, Apr. 1989.;;Bohm, The Computer Program LUDI: A New Method for the Novo Design ofEnzyme Inhibitors, J. Computer-Aided Molecular Design, vol. 6, 61-78, 1992.;;Branden et al., Introduction to Protein Structure Second Edition, Garland Publishing, Inc., New York, DD.374-375, 1999.;;Burger, Isosterism and bioisosterism in drug design, Progress in Drug Research, vol. 37, 287-371, 1991.;;Bussolino, Molecular Mechanisms of Blood Vessel Formation, Trends Biochem. Sci., vol. 22, No. 7, 251-256, 1997.;;Catrina et al., Hyperglycemia Regulates Hypoxia-Inducible Factor-la Protein Stability and Function, Diabetes, vol. 53, 3226-3232, 2004.;;Cheeseright, The identification of bioisosteres as drug development candidates, Innovations in Pharmeceutical Technology, 22-26, 2009.;;Cunliffe et al., Novel Inhibitors of Prolyl4-Hydroxylase. 3. Inhibition by the Substrate Analogue N-Oxaloglycine and Its Derivatives, J. Med. Chem. vol. 35, 2652-2658, 1992.;;Elson et al., Induction of Hypervascularity Without Leakage or Inflammation in Transgenic Mice Overexpressing Hypoxia-Indicible Factor-la, Genes & Dev., vol. 15, 2520-2532, 2001.;;Enoch et al., ABC of wound healing: non-surgical and drug treatments, BMJ, vol. 332, 900-903, 2006.;;Flower, Modelling G-protein-coupled receptors for drug design, Biochimica et Biophysica Acta, vol. 1422, 207-234, 1999.;;Folkman et al., Tumor Angiogenesis, The Molecular Basis of Cancer, Mendelsohn et al., eds., W. B. Saunders, Chapter 10, DD. 206-232, 1995.;;Franklin et al., Approaches to the Design of Anti-Fibrotic Drugs, Biochem. Soc. Trans., vol. 19, No. 4, :812-5, Nov. 1991.;;Gavhane et al., Solid tumors: facts, challenges and solutions, International Journal of Pharma Sciences and Research, vol. 2, No. 1, 1-12, 2011.;;Gaunt et al., Rational design of benzyl-type protecting groups allows sequential deprotection of hydroxyl groups by catalytic hydrogenolysis, J. Org. Chem., vol. 63, 4172-4173, 1998.;;Goodford, A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules, J. Med. Chem., vol. 28, No. 7, 840-857, 1985.;;Goodsell et al., Automated Docking of Substrates to Proteins by Simulated Annealing, Proteins: Structure, Function, and Genetics, vol. 195-202, 1990.;;Gupta; Am J Kidney Dis. 2017, 69, 815-826. DOI: 10.1053/j.ajkd.2016.12.011 (Year: 2017).;;Hardcastle et al., Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small molecule library approach, J. Med. Chem., vol. 48, 7829-7846, 2005.;;Hippuric acid sodium salt. Science Lab.com: Chemicals & Laboratory Equipment. (http://web.archive.org/web/20041107121553/http://www.sciencelab.com/page/S/PVAR/10415/SLH2620, accessed Mar. 11, 2010).;;Hirsila et al., Characterization of the Human Prolyl 4-Hyrdoxylases That Modify the Hypoxia-inducible Factor, The Journal of Biological Chemistry, vol. 278, No. 33, 30772-30780, Aug. 2003.;;Hoeksema et al., Structure of Rubradirin, Journal of American Chemical Society, vol. 104, 5173-5181, 1982.;;Ikura; Bioorganic & Medicinal Chemistry 14 (2006) 4241-4252. doi: 10.1016/j.bmc.2006.01.059 (Year: 2006).;;Ingersoll et al., Organic Syntheses, CV 2, 328, “Hippuric acid”. (http://web.archive.org/web/20020724135719/http://www.orgsyn.org/orgsyn/orgysn/prepContent.asp?prep=cv2p0328, accessed Mar. 11, 2010).;;International Search Report dated May 8, 2008 for PCT/US2007/014832.;;International Union of Pure and Applied Chemistry; Glossary of Class Names of Organic Compounds and Reactive Intermediates Based on Structure; Pure & D Appl. Chem., vol. 67, Nos. 8/9, 1307-1375, 1995.;;Ivan et al., Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor, Proceedings of the National Academy of Science; vol. 99, No. 21, 13459-13464, 2002.;;Ivan et al., HIFa Targeted for VHL-Mediated Destruction by Praline Hydroxylation: Implications for 02 Sensing, Science vol. 292, 464-468, 2001.;;Jaakkola et al., Targeting of HIF-a to the von Rippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation, Science, vol. 292, 468-472, 2001.;;Jones et al., Molecular Recognition ofReceptor Sites Using a Genetic Algorithm with a Description of Desolvation, J. Mol. Biol., vol. 245, 43-53, 1995.;;Kaelin, Praline Hydroxylation and Gene Expression, Annu. Rev. Biochem., vol. 74, 115-125, 2005.;;Kawashima et al., Suppressive effect of quinolinic acid and hippuric acid on bone marrow erythroid growth and lymphocyte blast formation in uremia, Advances in Experimental Medicine and Biology, vol. 223, 69-72, 1987.;;Ke et al., Hypoxia-Inducible Factor-1 (HIF-1), Molecular Pharmacology, vol. 70, No. 5, 1469-1480, Aug. 2006.;;Kim et al., Recent Advances in Developing Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylases and Their Therapeutic Implications, Molecules, vol. 20, No. 11, 20551-20568, Nov. 2015.;;Krantz, “Erythropoietin,” Blood, vol. 77, 419-434, 1991.;;Kuntz et al., A Geometric Approach to Macromolecule-Ligand Interactions, J. Mol. Biol., vol. 161, 269-288, 1982.;;Langsetmo, Inhibition of HIF-Prolyl Hydroxylases with FG-4539 Is Neuroprotective in a Mouse Model of Permanent Focal Ischemia, International Stroke Conference, Kissimmee, Florida, Presentation No. 427, 2006.;;Lee et al., Structure of Human FIH-1 Reveals a Unique Active Site Pocket and Interaction Sites for HIF-1 and von Hinnel Lindau, JBC, vol. 278, 7558-7563, 2003.;;Li et al., PR39, A Peptide Regulator of Angiogenesis, Nat Med., vol. 6, No. 1, 49-55, 2000.;;Lima et al., Bioisosterism: a useful strategy for molecular modification and drug design, Current Medicinal Chemistry, vol. 12, 23-49, 2005.;;Mancini et al., Effect of Erythropoietin on Exercise Capacity in Patients with Moderate to Severe Chronic Heart Failure, Circulation, vol. 107, 294-299, 2003.;;McDonough et al., Cellular Oxygen Sensing: Crystal Structure of Hypoxia-Inducible Factor Prolyl Hydroxylase (PHD2), PNAS, vol. 103 No. 26, 9814-9819, 2006.;;Miranker et al., Functionality Maps of Binding Sites: A Multiple Copy Simultaneous Search Method, Proteins: Structure, Function and Genetics, vol. 11, 29-34, 1991.;;Nguyen et al., Cellular Interactions in Vascular Growth and Differentiation, Int. Review of Cytology, vol. 204, 1-48, 2001.;;Nishihata et al., Automatic Creation of Drug Candidate Structures Based on Receptor Structure. Starting Point for Artificial Lead Generation, Tetrahedron, vol. 47, No. 43, 8985-8990, 1991.;;O'Reilly et al., Angiostatin: A Novel Angiogenesis Inhibitor that Mediates the Suppression of Metastases bv a Lewis Lung Carcinoma, Cell, vol. 79, 315-328, 1994.;;O'Reilly et al., “Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth,” Cell, 88:277-285 (1997).;;Pergola et al., Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease, Kidney International, vol. 90, No. 5, 1115-1122, Sep. 2016.;;Peyssonnaux et al., HIF-la Expression Regulates the Bactericidal Capacity of Phagocytes, J. Clinical Invest., vol. 115, No. 7, 1806-1815, 2005.;;Piyamongkol et al., Amido-3-hydroxypyridin-4-ones as iron(III) ligands, Chemistry, A European Journal, vol. 16, 6374-6381, 2010.;;Qian et al., A Randomized, Double-Blind, Placebo Controlled Trial ofFG-4592 for Correction of Anemia in Subjects with Chronic Kidney Disease in China, Oral Abstract FR-ORO11, J. Am. Soc. Nephrol., vol. 24:38A, 2013.;;Rahtu-Korpela, HIF Prolyl 4-Hydroxylase-2 Inhibition Improves Glucose and Lipid Metabolism and Protects Against Obesity and Metabolic Dysfunction, Diabetes, vol. 63, 3324-3333, 2014.;;Schelhaas et al., Protecting group strategies in organic synthesis, Angew, Chem. Int. Ed. Engl., vol. 35, 2056-2083, 1996.;;Schoneberg et al., Structural Basis of G Protein-Coupled Receptor Function, Molecular and Cellular Endocrinology, vol. 151, 181-193, 1999.;;Search Report dated Apr. 28, 2011 for European Pat. App. No. 11000872.9.;;Semenza, HIF-1 and human disease: one highly involved factor, Genes and Development, vol. 14, No. 16, 1983-1991, Aug. 2000.;;Semenza et al., Transcriptional Regulation of Genes Encoding Glycolytic Enzymes by Hypoxia-Inducible Factor I, J. Biol. Chem., vol. 269, 23757-23763, 1994.;;Semenza, Regulation of Erythropoietin Porduction: New Insights into Molecular Mechanisms of Oxygen Homeostasis, Hematol. Oncol. Clin. North Am., vol. 8, 863-884, 1994.;;Semenza, Signal Transduction to Hypoxia-inducible Factor I, Biochem. Pharmacol, vol. 64, 993-998, 2002.;;Sexton, Recent advances in our understanding of peptide hormone receptors and RAMPS, Current Opinion in Drug Discovery and Development, vol. 2, No. 5. 440-448, 1999.;;Sheehan, 3-Hydroxypicolinic Acid and Some of its Derivatives, J. Organic Chemistry, vol. 31, No. 3, 636-638, 1996.;;Siddiq et al., Hypoxia-inducible Factor Prolyl 4-Hydroxylase Inhibition, The Journal of Biological Chemistry, vol. 280, No. 50, 41732-41743, Dec. 2005.;;Silverman, The Organic Chemistry of Drug Design and Drug Action, 2nd Edition, 2004, Elsevier, Section 2.2, E.4, pp. 29-34.;;Standards of Medical Care in Diabetes—2006, Diabetes Care, vol. 29. 4-s42, 2006.;;Sutter et al., Hypoxia-inducible factor 1α protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations, PNAS, vol. 97, No. 9, 4748-4753, 2000.;;Teicher et al., Potentiation of Cytotoxic Cancer Therapies by TNP-470 Alone and with Other Anti-Angiogenic Agents, Int. J. Cancer, vol. 57, 920-925, 1994.;;Thornber, Isosterism and molecular modification in drug design, Chem Soc. Rev., vol. 8, 563-580, 1979.;;Tzschucke et al., Fluorous-Silica-Supported Perfluoro-Tagged Palladium Complexes Catalyze Suzuki Coupling in Water, Helvetica Chimica Acta; vol. 87, 2882-2889, 2004.;;Vickerstaffe et al., Fully Automated Polymer-Assisted Synthesis of 1,5-Biaryl Pyrazoles, J. Comb. Chem., vol. 6, 332-33, 2004.;;Vincent et al., Angiogenesis is Induced in a Rabbit Model of Hindlimb Ischemia by Naked DNA Encoding an HIF-I aNP16 Hybrid Transcription Factor, Circulation, vol. 102, 2255-2261, 2000.;;Warnecke et al., Activation of the Hypoxia-Inducible Factor Pathway and Stimulation of Angiogenesis by Application of Prolyl Hydroxylase Inhibitors, FASEB Journal, vol. 17, 1186-1188, 2003.;;Warshakoon et al., Design and synthesis of substituted pyridine derivatives as HIF-1alpha prolyl hydroxylase inhibitors, Bioorganic & Medicinal Chemistry Letters, vol. 16, 5616-5620, 2006.;;Wax et al., SM-20 is a Novel20-kd Protein Whose Expression in the Arterial Wall is Restricted to Smooth Muscle, Lab. Invest., vol. 74, No. 4, 797-808, 1996.;;Weidner et al., Tumor Angiogenesis and Metastasis—Correlation in Invasive Breast Carcinoma, New Eng. J. Med., vol. 324, No. 1, 1-8, 1991.;;Wright et al., Activation of the Prolyl Hydroxylase Oxygen-Sensor Results in Induction of GLUTI, Heme Oxygenase-1, and Nitric-Oxide Synthase Proteins and Confers Protection from Metabolic Inhibition to Cardiomyocytes, J. Bio. Chem., vol. 278, No. 22, 20235-20239, 2003.;;European Patent No. 2044005, Opposition Filed, Jul. 20, 2011.;;European Patent No. 2044005, Response to Opposition, dated Dec. 28, 2011.;;European Patent No. 2044005, Summons to Attend Oral Proceedings and Preliminary Opinion of the Opposition Division, dated Oct. 31, 2012.;;European Patent No. 2044005, Decision of the Opposition Division, Instruction, and Grounds for the Decision, dated May 3, 2013.;;European Patent No. 2044005, Patent Owner Statement of Grounds of Appeal, dated Sep. 13, 2013.;;European Patent Office, Interlocutory Decision in Opposition Proceedings, dated May 3, 2013, 76 pages.;;European Patent Office, Minutes of the Oral Proceedings Before the Opposition Division, dated May 3, 2013, 6 pages.;;European Patent No. 2044005, Opponent Statement of Grounds of Appeal, dated Sep. 13, 2013.;;European Patent No. 2044005, Opponent Reply to Appeal, dated Jan. 29, 2014.;;European Patent No. 2044005, Patent Owner Reply to Appeal, dated Jan. 29, 2014.;;European Patent No. 2044005, Patent Owner Response to the Opponent's Communication, dated Aug. 28, 2014.;;European Patent No. 2044005, Communication of the Board of Appeal, dated Aug. 29, 2017.;;European Patent No. 2044005, Response of Opponent to Communication of the Board of Appeal, dated Nov. 8, 2017.;;Withdrawal of an Appeal by Proprietor in the Opposition Against European Patent No. 2044005, dated Feb. 27, 2018.;;Decision of the Board of Appeal of the European Patent Office in the Opposition Against European Patent No. 2044005, dated Mar. 6, 2018.;;Termination of Opposition Proceedings of European Patent No. 2044005, dated Apr. 18, 2018.;;Notice of Opposition u/s 25(2) filed on Sep. 25, 2018 by Dr. Reddy's Laboratories Limited against Indian Patent No. 287720.;;Reply Statement of Patentee, filed Jan. 15, 2019, in the Post Grant Opposition against Indian Patent No. 287720 (39 pages).;;Reply on Behalf of Opponent to the Counterstatement by the Patentee and Reply Evidence, submitted Feb. 14, 2019, in the Post Grant Opposition against Indian Patent No. 287720 (237 pages).",ACTIVE
624,US,A1,US 2013/0203816 A1,120-524-105-450-234,2013-08-08,2013,US 201213681876 A,2012-11-20,US 201213681876 A;;US 86007310 A;;US 82193607 A;;US 81652206 P,2006-06-26,PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE,"The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.",KAWAMOTO RICHARD MASARU;;WU SHENGDE;;WARSHAKOON NAMAL C;;EVDOKIMOV ARTEM G;;GREIS KENNETH D;;BOYER ANGELIQUE SUN;;AKEBIA THERAPEUTICS INC,KAWAMOTO RICHARD MASARU;;WU SHENGDE;;WARSHAKOON NAMAL C;;EVDOKIMOV ARTEM G;;GREIS KENNETH D;;BOYER ANGELIQUE SUN,THE PROCTER & GAMBLE COMPANY (2008-12-19);;AKEBIA THERAPEUTICS INC (2011-12-15);;WARNER CHILCOTT COMPANY LLC (2009-10-30),https://lens.org/120-524-105-450-234,Patent Application,yes,4,23,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07D405/10;;C07D213/65,514/338;;546/298;;514/350;;546/282.4,2,2,095-605-097-751-343;;095-605-097-751-343,pmc1440619;;10.1136/bmj.332.7546.900;;16613966;;pmc1440619;;10.1136/bmj.332.7546.900;;16613966,"Stuart Enoch, Joseph E Grey, Keith G Harding; BMJ 2006;332:900-3;;Stuart Enoch, Joseph E Grey, Keith G Harding; BMJ 2006;332:900-3",ACTIVE
625,US,A1,US 2014/0045899 A1,050-252-303-147-187,2014-02-13,2014,US 201314062011 A,2013-10-24,US 201314062011 A;;US 201213681876 A;;US 86007310 A;;US 82193607 A;;US 81652206 P,2006-06-26,PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE,"The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.",AKEBIA THERAPEUTICS INC,KAWAMOTO RICHARD MASARU;;WU SHENGDE;;EVDOKIMOV ARTEM G;;GREIS KENNETH D;;BOYER ANGELIQUE SUN;;WARSHAKOON NAMAL C,THE PROCTER & GAMBLE COMPANY (2008-12-19);;AKEBIA THERAPEUTICS INC (2011-12-15);;WARNER CHILCOTT COMPANY LLC (2009-10-30),https://lens.org/050-252-303-147-187,Patent Application,yes,0,18,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07D213/81;;C07D405/04,514/338;;514/346,0,0,,,,ACTIVE
626,EP,A2,EP 2044005 A2,094-871-599-181-614,2009-04-08,2009,EP 07835890 A,2007-06-26,US 2007/0014832 W;;US 81652206 P,2006-06-26,PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE,,PROCTER & GAMBLE,KAWAMOTO RICHARD MASARU;;WARSHAKOON NAMAL CHITHRANGA;;EVDOKIMOV ARTEM G;;WU SHENGDE;;BOYER ANGELIQUE SUN;;GREIS KENNETH DONALD,"GREIS KENNETH DONALD, FORT THOMAS, KY, US (2013-02-26);;AKEBIA THERAPEUTICS INC., US (2015-01-12);;WARNER CHILCOTT COMPANY, LLC (2010-09-22);;WARSHAKOON NAMAL CHITHRANGA, MASON, OH, US (2013-02-26);;AKEBIA THERAPEUTICS INC.; US (2013-12-03);;AKEBIA THERAPEUTICS INC. (2014-12-17);;EVDOKIMOV ARTEM, G., NIANTIC, CT, US (2013-02-26);;AKEBIA THERAPEUTICS INC., CINCINNATI, OH, US (2014-10-13);;BOYER ANGELIQUE SUN, WEST CH ESTER, OH, US (2013-02-26);;AKEBIA THERAPEUTICS INC., CAMBRIDGE, MA, US (2014-12-12);;AKEBIA THERAPEUTICS INC., CAMBRIDGE, US (2014-05-22);;KAWAMOTO RICHARD MASARU, DIVIDE, CO, US (2013-02-26);;WU SHENGDE, WEST CHESTER, OH, US (2013-02-26)",https://lens.org/094-871-599-181-614,Patent Application,yes,0,7,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07C235/60;;C07C237/42;;C07C255/57;;C07D213/81,,0,0,,,,INACTIVE
627,US,E,US RE047437 E,144-299-912-405-766,2019-06-18,2019,US 201815875495 A,2018-01-19,US 201815875495 A;;US 201514854080 A;;US 81652206 P,2006-06-26,Prolyl hydroxylase inhibitors and methods of use,"The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.",AKEBIA THERAPEUTICS INC,KAWAMOTO RICHARD MASARU;;WU SHENGDE;;EVDOKIMOV ARTEM G;;GREIS KENNETH D;;BOYER ANGELIQUE SUN;;WARSHAKOON NAMAL C,,https://lens.org/144-299-912-405-766,Amended Patent,yes,120,4,83,83,1,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07D417/04;;A61K31/4418;;A61K31/4433;;C07C235/60;;C07C237/42;;C07C255/57;;C07D213/65;;C07D213/81;;C07D295/192;;C07D401/04;;C07D401/10;;C07D405/04;;C07D405/10,,103,62,000-457-771-937-337;;095-605-097-751-343;;087-705-105-313-369;;042-987-854-927-099;;098-888-990-357-930;;129-372-774-596-270;;015-285-296-623-617;;056-311-147-347-640;;032-766-102-934-139;;007-834-259-097-311;;104-310-480-694-456;;018-490-208-246-068;;046-494-590-295-402;;117-587-550-537-020;;046-414-927-085-724;;017-669-075-762-985;;028-862-168-091-90X;;010-824-042-186-283;;063-746-538-402-770;;006-143-986-832-256;;064-865-149-673-057;;102-345-845-395-203;;015-199-257-732-502;;009-081-622-113-208;;022-156-141-942-093;;081-136-747-247-898;;030-042-017-746-591;;131-046-096-401-339;;019-130-789-993-789;;066-519-812-638-153;;092-475-988-464-223;;135-654-547-079-284;;125-424-943-194-608;;077-106-322-076-470;;069-450-943-413-364;;025-178-564-355-938;;048-830-824-939-083;;102-949-159-342-256;;018-052-265-551-042;;064-406-626-054-484;;011-101-678-202-709;;129-297-815-048-32X;;023-017-724-234-140;;074-344-536-692-994;;016-533-076-557-079;;034-760-425-242-511;;056-436-730-631-840;;149-920-492-418-396;;074-156-318-814-764;;064-242-953-339-024;;062-826-287-074-090;;103-335-591-460-884;;026-655-568-834-966;;065-169-875-352-44X;;045-408-622-411-245;;003-330-211-576-597;;096-459-000-284-800;;040-667-645-789-907;;017-183-541-402-013;;141-317-043-329-438;;019-005-723-569-798;;105-391-605-288-229,1763185;;10.1007/978-3-0348-7139-6_7;;pmc1440619;;10.1136/bmj.332.7546.900;;16613966;;10.1021/jo980823v;;10.1021/jm050444b;;16302822;;10.1021/jm050444b.s001;;10.1021/ja00383a030;;10.1124/mol.106.027029;;16887934;;26610437;;pmc6332328;;10.3390/molecules201119717;;10.2174/0929867053363540;;15638729;;27650732;;10.1016/j.kint.2016.07.019;;10.1002/chem.200902455;;20397153;;10.1002/anie.199620561;;10.1101/gad.14.16.1983;;10950862;;16227210;;10.1074/jbc.m504963200;;pmc2586128;;10.1039/cs9790800563;;10.1074/jbc.m304982200;;12788921;;10.1016/s0040-4020(03)01100-1;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;490542;;10.1021/jm00194a018;;15664391;;10.1016/j.cardiores.2004.09.004;;10.1373/49.1.32;;12507958;;3326854;;10.1111/j.1399-3011.1987.tb03385.x;;1583540;;10.1007/bf00124387;;10.1016/s0968-0004(97)01074-8;;9255066;;10.1021/jm00092a016;;1321909;;10.1016/s0304-4157(99)00006-4;;10548717;;1665444;;10.1042/bst0190812;;10.1021/jm00145a002;;3892003;;10.1002/prot.340080302;;2281083;;10.1351/pac199567081307;;pmc129695;;12351678;;10.1073/pnas.192342099;;7823319;;10.1016/s0022-2836(95)80037-9;;15952883;;10.1146/annurev.biochem.74.082803.133142;;10.1007/978-1-4684-5445-1_9;;2965848;;10.1182/blood.v77.3.419.bloodjournal773419;;10.1182/blood.v77.3.419.419;;1991159;;7154081;;10.1016/0022-2836(82)90153-x;;12482756;;10.1074/jbc.m210385200;;10613823;;10.1038/71527;;10.1161/01.cir.0000044914.42696.6a;;12538431;;pmc1502536;;16782814;;10.1073/pnas.0601283103;;10.2210/pdb2g1m/pdb;;10.1002/prot.340110104;;1961699;;10.1016/s0074-7696(01)04002-5;;11243594;;10.1016/s0040-4020(01)86503-0;;7525077;;10.1016/0092-8674(94)90200-3;;10.1016/s0092-8674(00)81848-6;;9008168;;10.1016/s0303-7207(99)00017-9;;10411333;;10.1016/s0021-9258(17)31580-6;;8089148;;7852211;;10.1016/s0889-8588(18)30134-5;;10.1016/s0006-2952(02)01168-1;;12213597;;19649971;;10.1021/jo01340a533;;5902481;;7515861;;10.1002/ijc.2910570624;;10.1002/hlca.200490260;;15132592;;10.1021/cc049977g;;11056102;;10.1161/01.cir.102.18.2255;;10.1096/fj.02-1062fje;;12709400;;16908149;;10.1016/j.bmcl.2006.08.026;;8606489;;10.1056/nejm199101033240101;;1701519;;12649278;;10.1074/jbc.m301391200;;16373931;;10.2337/diacare.29.s1.06.s4;;10.2337/db14-0472;;24789921;;10.2337/diabetes.53.12.3226;;15561954,"U.S. Appl. No. 60/816,522, filed Jun. 26, 2006, Kawamoto et al.;;U.S. Appl. No. 15/559,200, filed Sep. 18, 2017, Hanselmann et al.;;U.S. Appl. No. 15/563,169, filed Sep. 29, 2017, Smith et al.;;Alfred Burger, “Isosterism and bioisosterism in drug design,” Progress in Drug Research (Ed. J.A. Salmon et al), pp. 287-371, 1991.;;Tim Cheeseright, “The identification of bioisosteres as drug development candidates,” Innovations in Pharmaceutical Technology, 22-26, 2009.;;Stuart Enoch et al., “ABC of wound healing: non-surgical and drug treatments” BMJ: 332:900-903, 2006.;;Y.N. Gavhane et al., “Solid tumors: facts, challenges and solutions,” International Journal of Pharma Sciences and Research, 2(1):1-12, 2011.;;Matthew J. Gaunt et al., “Rational design of benzyl-type protecting groups allows sequential deprotection of hydroxyl groups by catalytic hydrogenolysis,” J. Org. Chem., 63:4172-4173, 1998.;;Ian R. Hardcastle et al., “Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach,” J. Med. Chem., 48:7829-7846, 2005.;;Hippuric acid sodium salt. Science Lab.com: Chemicals & Laboratory Equipment. (“http://web.archive.org/web/20041107121553/http://www.sciencelab.com/pag-e/S/PVAR/10415/SLH2620”, accessed Mar. 11, 2010).;;H. Hoeksema et al., “Structure of Rubradirin,” Journal of the American Chemical Society, 104:5173-5181, 1982.;;Ingersoll et al. Organic Syntheses, CV 2, 328, “Hippuric acid”. (http://web.archive.org/web/20020724135719/http://www.orgsyn.org/orgsyn/o-rgsyn/prepContent.asp?prep=cv2p0328, accessed Mar. 11, 2010).;;Qingdong Ke et al., “Hypoxia-inducible factor-1 (HIF-1),” Molecular Pharmacology, 70(5):1469-1480, 2006.;;So Yeon Kim et al., “Recent advances in developing inhibitors for hypoxia-inducible factor prolyl hydroxylases and their therapeutic implications,” Molecules, 20(11), 20551-20568, 2015.;;Lída Moreira Lima et al., “Bioisosterism: a useful strategy for molecular modification and drug design,” Current Medicinal Chemistry, 12:23-49, 2005.;;Pablo E. Pergola et al., “Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease,” Kidney International, 90(5):1115-1122, 2016.;;Sirivipa Piyamongkol et al., “Amido-3-hydroxypyridin-4-ones as iron(III) ligands,” Chemistry, A European Journal, 16:6374-6381, 2010.;;Michael Schelhaas et al., “Protecting group strategies in organic synthesis,” Angew. Chem. Int. Ed. Engl., 35:2056-2083, 1996.;;Gregg L. Semenza, “HIF-1 and human disease: one highly involved factor,” Genes & Dev., 14:1983-1991, 2000.;;Ambreena Siddiq et al., “Hypoxia-inducible factor prolyl 4-hydroxylase inhibition: a target for neuroprotection in the central nervous system,” Journal of Biological Chemistry, 280:41732-41743, 2005.;;Silverman; The Organic Chemistry of Drug Design and Drug Action, 2nd Edition, 2004, Elsevier, Section 2.2, E.4, pp. 29-34.;;Carrie Hayes Sutter et al., “Hypoxia-inducible factor lαprotein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations,” PNAS, 97(9)4748-4753, 2000.;;C.W. Thornber, “Isosterism and molecular modification in drug design,” Chem. Soc. Rev., 8:563-580, 1979.;;European Patent No. 2044005, Opposition Filed, Jul. 20, 2011.;;European Patent No. 2044005, Response to Opposition, Dec. 28, 2011.;;European Patent No. 2044005, Summons to Attend Oral Proceedings and Preliminary Opinion of the Opposition Division, Oct. 31, 2012.;;European Patent No. 2044005, Decision of the Opposition Division, Instruction, and Grounds for the Decision, May 3, 2013.;;European Patent No. 2044005, Patent Owner Statement of Grounds of Appeal, Sep. 13, 2013.;;European Patent No. 2044005, Opponent Statement of Grounds of Appeal, Sep. 13, 2013.;;European Patent No. 2044005, Opponent Reply to Appeal, Jan. 29, 2014.;;European Patent No. 2044005, Patent Owner Reply to Appeal, Jan. 29, 2014.;;European Patent No. 2044005, Patent Owner Response to the Opponent's Communication, Aug. 28, 2014.;;European Patent No. 2044005, Communication of the Board of Appeal, Aug. 29, 2017.;;European Patent No. 2044005, Response of Opponent to Communication of the Board of Appeal, Nov. 8, 2017.;;Withdrawal of an appeal by proprietor in the Opposition against EP2044005 (07835890.0) submitted to the European Patent Office on Feb. 27, 2018.;;Decision of the Board of Appeal of the European Patent Office in the Opposition against EP2044005 (07835890.0) issued on Mar. 6, 2018.;;Termination of Opposition Proceedings of Patent No. EP2044005 (07835890.0) issued on Apr. 18, 2018.;;“Notice of Opposition u/s 25(2)” filed on Sep. 25, 2018 by Dr. Reddy's Laboratories Limited against Indian Patent No. 287720.;;Hirsila et al., “Characterization of the Human Prolyl 4-Hydroxylases That Modify the Hypoxia-inducible Factor”, The Journal of Biological Chemistry, 278(33): 30772-30780 (Aug. 15, 2003).;;Alesso et al., “Improving resins for solid phase synthesis: incorporation of 1-[2-(2-methoxyethoxy) ethoxy]4-vinyl-benzene” Tetrahedron: 59,7163-7169 (2003).;;Altschul et al., “Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs,” Nucleic Acids Res., 25(27):3389-3402 (1997).;;Anderson et al., “Antileukemic Activity of Derivatives of 1,2-Dimethy1-3,4-bis(hydroxymethyl)-5-phenylpyrrole Bis(N-methylcarbamate)” J. Med. Chem.: vol. 22(8), 977-980 (1979).;;Annex et al., “Growth Factor-Induced Therapeutic Angiogenesis in the Heart: Protein Therapy,” Cardiovascular Research, 65(3):649-655 (2005).;;Ardelt et al., “Estradiol Regulates Angiopoietin-1 mRNA Expression Through Estrogen Receptor-α in a Rodent Experimental Stroke Model,” Stroke, 36:337-341 (2005).;;Auerbach et al., “Angiogenesis Assays: A Critical Overview,” Clinical Chemistry, 49:32-40 (2003).;;Barany et al., “Solid-phase Peptide Synthesis: A Silver Anniversary Report,” Int. J. Peptide Protein Res., 30( 6):705-739 (1987).;;Bartlett et al., “Molecular Recognition in Chemical and Biological Problems,” Special Pub., Royal Chem. Soc., 78, 182-196 Caveat: A Program to Facilitate the Structure-derived Design of Biologically Active Molecules (Apr. 1989).;;Böhm, “The Computer Program LUDI: A New Method for the Novo Design of Enzyme Inhibitors,” J. Computer-Aided Molecular Design, 6:61-78 (1992).;;Branden et al., “Introduction to Protein Structure Second Edition,” Garland Publishing, Inc., New York, 1999, pp. 374-375.;;Bussolino, “Molecular Mechanisms of Blood Vessel Formation,” Trends Biochem. Sci., 22(7):251-256 (1997).;;Cunliffe et al., “Novel Inhibitors of Prolyl4-Hydroxylase 3 Inhibition by the Substrate Analogue N-Oxaloglycine and Its Derivatives,” J. Med. Chem. 35:2652-2658 (1992).;;Elson et al., “Induction of Hypervascularity Without Leakage or Inflammation in Transgenic Mice Overexpressing Hypoxia-Indicible Factor-1α,” Genes & Dev., 15:2520-2532 (2001).;;European Patent Application No. 11 000 872.9; European Search Report, Apr. 28, 2011.;;European Patent Office, Interlocutory Decision in Opposition Proccedings, mailed May 3, 2013, 76 pages.;;European Patent Office, Minutes of the Oral Proceedings Before the Opposition Division, mailed May 3, 2013, 6 pages.;;Flower, “Modelling G-protein-coupled receptors for drug design,” Biochimica et Biophysica Acta, 1422:207-234 (1999).;;Folkman et al., “Tumor Angiogenesis,” The Molecular Basis of Cancer, Mendelsohn et al., eds., W. B. Saunders, Chapter 10, pp. 206-232 (1995).;;Franklin et al., “Approaches to the Design of Anti-Fibrotic Drugs,” Biochem. Soc. Trans., 19(4):812-5 (Nov. 1991).;;Goodford, “A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules,” J. Med. Chem., 28(7):849-857 (1985).;;Goodsell et al., “Automated Docking of Substrates to Proteins by Simulated Annealing,” Proteins: Structure, Function, and Genetics, 8:195-202 (1990).;;International Union of Pure and Applied Chemistry; Glossary of Class Names of Organic Compounds and Reactive Intermediates Based on Structure; Pure & D Appl. Chem., vol. 67, Nos. 8/9, pp. 1307-1375, (1995).;;Ivan et al., “HIFαTargeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing,” Science 292, 464-468 (2001).;;Ivan et al., “Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor,” Proceedings of the National Academy of Science; 99(21) 13459-13464 (2002).;;Jaakkola et al., “Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2 Regulated Prolyl Hydroxylation,” Science 292, 468-472 (2001).;;Jones et al., “Molecular Recognition of Receptor Sites Using a Genetic Algorithm with a Description of Desolvation,” J. Mol. Biol., 245:43-53 (1995).;;Kaelin, “Proline Hydroxylation and Gene Expression,” Annu. Rev. Biochem., 74:115-125 (2005).;;Kawashima et al., “Suppressive effect of quinolinic acid and hippuric acid on bone marrow erythroid growth and lymphocyte blast formation in uremia,” Advances in Experimental Medicine and Biology, (1987), vol. 223, p. 69-72.;;Krantz, “Erythropoietin,” Blood, 77:419-434 (1991).;;Kuntz et al., “A Geometric Approach to Macromolecule-Ligand Interactions,” J. Mol. Biol., 161:269-288 (1982).;;Lee et al., “Structure of Human FIH-1 Reveals a Unique Active Site Pocket and Interaction Sites for HIF-1 and von Hippel Lindau,” JBC, 278:7558-7563 (2003).;;Li et al., “PR39, A Peptide Regulator of Angiogenesis,” Nat Med., 6(1):49-55 (2000).;;Mancini et al., “Effect of Erythropoietin on Exercise Capacity in Patients with Moderate to Severe Chronic Heart Failure,” Circulation, 107:294-299 (2003).;;McDonough et al., “Cellular Oxygen Sensing: Crystal Structure of Hypoxia-Inducible Factor Prolyl Hydroxylase (PHD2),” PNAS, 103(26):9814-9819 (2006).;;Miranker et al., “Functionality Maps of Binding Sites: A Multiple Copy Simultaneous Search Method,” Proteins: Structure, Function and Genetics, 11:29-34 (1991).;;Nguyen et al., “Cellular Interactions in Vascular Growth and Differentiation,” Int. Review of Cytology, 204:1-48 (2001).;;Nishibata et al., “Automatic Creation of Drug Candidate Structures Based on Receptor Structure. Starting Point for Artificial Lead Generation,” Tetrahedron, 47( 43):8985-8990 (1991).;;O'Reilly et al., “Angiostatin: A Novel Angiogenesis Inhibitor that Mediates the Suppression of Metastases by a Lewis Lung Carcinoma,”, Cell, 79:315-328 (1994).;;O'Reilly et al., “Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth,” Cell, 88:277-285 (1997).;;Peyssonnaux et al., “HIF-1αExpression Regulates the Bactericidal Capacity of Phagocytes,” J. Clinical Invest., 115(7):1806-1815 (2005).;;Qian, Oral abstract FR-OR011, J. Am. Soc. Nephrol., 24:38A (2013).;;Schoneberg et al., “Structural Basis of G Protein-Coupled Receptor Function,” Molecular and Cellular Endocrinology, 151:181-193 (1999).;;Semenza et al., “Transcriptional Regulation of Genes Encoding Glycolytic Enzymes by Hypoxia-Inducible Factor 1,” J. Biol. Chem., 269:23757-23763 (1994).;;Semenza, “Regulation of Erythropoietin Porduction: New Insights into Molecular Mechanisms of Oxygen Homeostasis,” Hematol. Oncol. Clin. North Am., 8:863-884 (1994).;;Semenza, “Signal Transduction to Hypoxia-inducible Factor 1,” Biochem. Pharmacol, 64:993-998 (2002).;;Sexton, “Recent advances in our understanding of peptide hormone receptors and RAMPS,” Current Opinion in Drug Discovery and Development, 2(5):440-448 (1999).;;Sheehan, “3-Hydroxypicolinic Acid and Some of its Derivatives,” J. Organic Chemistry 31(3):636-638 (1996).;;Teicher et al., “Potentiation of Cytotoxic Cancer Therapies by TNP-470 Alone and with Other Anti-Angiogenic Agents,” Int. J. Cancer, 57:920-925 (1994).;;Tzschucke et al., “Fluorous-Silica-Supported Perfluoro-Tagged Palladium Complexes Catalyze Suzuki Coupling in Water” Helvetica Chimica Acta; vol. 87 2882-2889 (2004).;;Vickerstaffe et al., “Fully Automated Polymer-Assisted Synthesis of 1,5-Biaryl Pyrazoles,” J. Comb. Chem., 2004,6,332-33.;;Vincent et al., “Angiogenesis is Induced in a Rabbit Model of Hindlimb Ischemia by Naked DNA Encoding an HIF-1a/VP16 Hybrid Transcription Factor,” Circulation, 102:2255-2261 (2000).;;Warnecke et al., “Activation of the Hypoxia-Inducible Factor Pathway and Stimulation of Angiogenesis by Application of Prolyl Hydroxylase Inhibitors,” FASEB Journal, 17: 1186-1188 (2003).;;Warshakoon et al., “Design and synthesis of substituted pyridine derivatives as HIF-1alpha prolyl hydroxylase inhibitors,” Bioorganic & Medicinal Chemistry Letters, 16 (2006) 5616-5620.;;Wax et al., “SM-20 is a Nove120-kd Protein Whose Expression in the Arterial Wall is Restricted to Smooth Muscle,” Lab. Invest., 74(4):797-808 (1996).;;Weidner et al., “Tumor Angiogenesis and Metastasis--Correlation in Invasive Breast Carcinoma,” New Eng. J. Med., 324(1):1-8 (1991).;;Wright et al., “Activation of the Prolyl Hydroxylase Oxygen-Sensor Results in Induction of GLUT1, Heme Oxygenase-1, and Nitric-Oxide Synthase Proteins and Confers Protection from Metabolic Inhibition to Cardiomyocytes,” J. Bio. Chem., 278(22):20235-20239 (2003).;;Office action mailed Oct. 7, 2013 in connection with U.S. Appl. No. 13/489,400.;;Office action mailed Jan. 30, 2014 in connection with U.S. Appl. No. 13/489,400.;;Office action mailed Dec. 12, 2013 in connection with U.S. Appl. No. 14/071,088.;;“Standards of Medical Care in Diabetes-2006,” Diabetes Care, 29:s4-s42 (2006).;;Qian et al., “A Randomized, Double-Blind, Placebo Controlled Trial of FG-4592 for Correction of Anemia in Subjects with Chronic Kidney Disease in China,” Oral Abstract FR-OR011, J. Am. Soc. Nephrol. 24:38A (2013).;;Langsetmo, “Inhibition of HIF-Prolyl Hydroxylases with FG-4539 Is Neuroprotective in a Mouse Model of Permanent Focal Ischemia,” International Stroke Conference, Kissimmee Florida, Presentation No. 427 (2006).;;Rahtu-Korpela, “HIF Prolyl 4-Hydroxylase-2 Inhibition Improves Glucose and Lipid Metabolism and Protects Against Obesity and Metabolic Dysfunction,” Diabetes 63:3324-3333 (2014).;;Catrina et al., 2004, “Hyperglycemia Regulates Hypoxia-Inducible Factor-1 Protein Stability and Function,” Diabetes 53:3226-3232.",PENDING
628,US,B2,US 9598370 B2,080-933-454-513-043,2017-03-21,2017,US 201514854080 A,2015-09-15,US 201514854080 A;;US 201414568200 A;;US 201314062011 A;;US 201213681876 A;;US 86007310 A;;US 82193607 A;;US 81652206 P,2006-06-26,Prolyl hydroxylase inhibitors and methods of use,"The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.",AKEBIA THERAPEUTICS INC,KAWAMOTO RICHARD MASARU;;WU SHENGDE;;EVDOKIMOV ARTEM G;;GREIS KENNETH D;;BOYER ANGELIQUE SUN;;WARSHAKOON NAMAL C,THE PROCTER & GAMBLE COMPANY (2008-12-19);;AKEBIA THERAPEUTICS INC (2011-12-15);;WARNER CHILCOTT COMPANY LLC (2009-10-30),https://lens.org/080-933-454-513-043,Granted Patent,yes,87,21,83,83,1,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07D417/04;;C07C235/60;;C07C237/42;;C07C255/57;;C07D213/65;;C07D213/81;;C07D295/192;;C07D401/04;;C07D401/10;;C07D405/04;;C07D405/10,,64,52,017-669-075-762-985;;028-862-168-091-90X;;010-824-042-186-283;;063-746-538-402-770;;093-087-601-151-305;;006-143-986-832-256;;064-865-149-673-057;;102-345-845-395-203;;015-199-257-732-502;;009-081-622-113-208;;052-512-054-021-225;;022-156-141-942-093;;081-136-747-247-898;;030-042-017-746-591;;131-046-096-401-339;;019-130-789-993-789;;022-950-342-458-554;;066-519-812-638-153;;083-737-080-066-103;;092-475-988-464-223;;135-654-547-079-284;;125-424-943-194-608;;077-106-322-076-470;;069-450-943-413-364;;025-178-564-355-938;;048-830-824-939-083;;102-949-159-342-256;;018-052-265-551-042;;064-406-626-054-484;;011-101-678-202-709;;129-297-815-048-32X;;023-017-724-234-140;;074-344-536-692-994;;091-474-773-070-883;;016-533-076-557-079;;034-760-425-242-511;;056-436-730-631-840;;149-920-492-418-396;;074-156-318-814-764;;064-242-953-339-024;;062-826-287-074-090;;103-335-591-460-884;;026-655-568-834-966;;065-169-875-352-44X;;045-408-622-411-245;;003-330-211-576-597;;096-459-000-284-800;;040-667-645-789-907;;017-183-541-402-013;;141-317-043-329-438;;019-005-723-569-798;;105-391-605-288-229,10.1016/s0040-4020(03)01100-1;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;490542;;10.1021/jm00194a018;;15664391;;10.1016/j.cardiores.2004.09.004;;15637314;;10.1161/01.str.0000153795.38388.72;;10.1373/49.1.32;;12507958;;3326854;;10.1111/j.1399-3011.1987.tb03385.x;;1583540;;10.1007/bf00124387;;10.1016/s0968-0004(97)01074-8;;9255066;;10.1021/jm00092a016;;1321909;;pmc312791;;10.1101/gad.914801;;11581158;;10.1016/s0304-4157(99)00006-4;;10548717;;1665444;;10.1042/bst0190812;;10.1021/jm00145a002;;3892003;;10.1002/prot.340080302;;2281083;;10.1351/pac199567081307;;10.1126/science.1059817;;11292862;;pmc129695;;12351678;;10.1073/pnas.192342099;;10.1126/science.1059796;;11292861;;011292861;;7823319;;10.1016/s0022-2836(95)80037-9;;15952883;;10.1146/annurev.biochem.74.082803.133142;;10.1007/978-1-4684-5445-1_9;;2965848;;10.1182/blood.v77.3.419.bloodjournal773419;;10.1182/blood.v77.3.419.419;;1991159;;7154081;;10.1016/0022-2836(82)90153-x;;12482756;;10.1074/jbc.m210385200;;10613823;;10.1038/71527;;10.1161/01.cir.0000044914.42696.6a;;12538431;;pmc1502536;;16782814;;10.1073/pnas.0601283103;;10.2210/pdb2g1m/pdb;;10.1002/prot.340110104;;1961699;;10.1016/s0074-7696(01)04002-5;;11243594;;10.1016/s0040-4020(01)86503-0;;7525077;;10.1016/0092-8674(94)90200-3;;10.1016/s0092-8674(00)81848-6;;9008168;;10.1172/jci23865;;16007254;;pmc1159132;;10.1016/s0303-7207(99)00017-9;;10411333;;10.1016/s0021-9258(17)31580-6;;8089148;;7852211;;10.1016/s0889-8588(18)30134-5;;10.1016/s0006-2952(02)01168-1;;12213597;;19649971;;10.1021/jo01340a533;;5902481;;7515861;;10.1002/ijc.2910570624;;10.1002/hlca.200490260;;15132592;;10.1021/cc049977g;;11056102;;10.1161/01.cir.102.18.2255;;10.1096/fj.02-1062fje;;12709400;;16908149;;10.1016/j.bmcl.2006.08.026;;8606489;;10.1056/nejm199101033240101;;1701519;;12649278;;10.1074/jbc.m301391200;;16373931;;10.2337/diacare.29.s1.06.s4;;10.2337/db14-0472;;24789921;;10.2337/diabetes.53.12.3226;;15561954,"Alesso et al., ""Improving resins for solid phase synthesis: incorporation of 1-[2-(2-methoxyethoxy) ethoxy]4-vinyl-benzene"" Tetrahedron: 59,7163-7169 (2003).;;Altschul et al., ""Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs,"" Nucleic Acids Res., 25(27):3389-3402 (1997).;;Anderson et al., ""Antileukemic Activity of Derivatives of 1,2-Dimethy1-3,4-bis(hydroxymethyl)-5-phenylpyrrole Bis(N-methylcarbamate)"" J. Med. Chem.: vol. 22(8), 977-980 (1979).;;Annex et al., ""Growth Factor-Induced Therapeutic Angiogenesis in the Heart: Protein Therapy,"" Cardiovascular Research, 65(3):649-655 (2005).;;Ardelt et al., ""Estradiol Regulates Angiopoietin-1 mRNA Expression Through Estrogen Receptor-alpha in a Rodent Experimental Stroke Model,"" Stroke, 36:337-341 (2005).;;Auerbach et al., ""Angiogenesis Assays: A Critical Overview,"" Clinical Chemistry, 49:32-40 (2003).;;Barany et al., ""Solid-phase Peptide Synthesis: A Silver Anniversary Report,"" Int. J. Peptide Protein Res., 30( 6):705-739 (1987).;;Bartlett et al., ""Molecular Recognition in Chemical and Biological Problems,"" Special Pub., Royal Chem. Soc., 78, 182-196 Caveat: A Program to Facilitate the Structure-derived Design of Biologically Active Molecules (Apr. 1989).;;Böhm, ""The Computer Program LUDI: A New Method for the Novo Design of Enzyme Inhibitors,"" J. Computer-Aided Molecular Design, 6:61-78 (1992).;;Branden et al., ""Introduction to Protein Structure Second Edition,"" Garland Publishing, Inc., New York, 1999, pp. 374-375.;;Bussolino, ""Molecular Mechanisms of Blood Vessel Formation,"" Trends Biochem. Sci., 22(7):251-256 (1997).;;Cunliffe et al., ""Novel Inhibitors of Prolyl4-Hydroxylase 3 Inhibition by the Substrate Analogue N-Oxaloglycine and Its Derivatives,"" J. Med. Chem. 35:2652-2658 (1992).;;Elson et al., ""Induction of Hypervascularity Without Leakage or Inflammation in Transgenic Mice Overexpressing Hypoxia-Indicible Factor-1alpha,"" Genes & Dev., 15:2520-2532 (2001).;;European Patent Application No. 11 000 872.9; European Search Report, Apr. 28, 2011.;;European Patent Office, Interlocutory Decision in Opposition Proccedings, mailed May 3, 2013, 76 pages.;;European Patent Office, Minutes of the Oral Proceedings Before the Opposition Division, mailed May 3, 2013, 6 pages.;;Flower, ""Modelling G-protein-coupled receptors for drug design,"" Biochimica et Biophysica Acta, 1422:207-234 (1999).;;Folkman et al., ""Tumor Angiogenesis,"" The Molecular Basis of Cancer, Mendelsohn et al., eds., W. B. Saunders, Chapter 10, pp. 206-232 (1995).;;Franklin et al., ""Approaches to the Design of Anti-Fibrotic Drugs,"" Biochem. Soc. Trans., 19(4):812-5 (Nov. 1991).;;Goodford, ""A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules,"" J. Med. Chem., 28(7):849-857 (1985).;;Goodsell et al., ""Automated Docking of Substrates to Proteins by Simulated Annealing,"" Proteins: Structure, Function, and Genetics, 8:195-202 (1990).;;International Union of Pure and Applied Chemistry; Glossary of Class Names of Organic Compounds and Reactive Intermediates Based on Structure; Pure & D Appl. Chem., vol. 67, Nos. 8/9, pp. 1307-1375, (1995).;;Ivan et al., ""HIFalphaTargeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing,"" Science 292, 464-468 (2001).;;Ivan et al., ""Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor,"" Proceedings of the National Academy of Science; 99(21) 13459-13464 (2002).;;Jaakkola et al., ""Targeting of HIF-alpha to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation,"" Science 292, 468-472 (2001).;;Jones et al., ""Molecular Recognition of Receptor Sites Using a Genetic Algorithm with a Description of Desolvation,"" J. Mol. Biol., 245:43-53 (1995).;;Kaelin, ""Proline Hydroxylation and Gene Expression,"" Annu. Rev. Biochem., 74:115-125 (2005).;;Kawashima et al., ""Suppressive effect of quinolinic acid and hippuric acid on bone marrow erythroid growth and lymphocyte blast formation in uremia,"" Advances in Experimental Medicine and Biology, (1987), vol. 223, p. 69-72.;;Krantz, ""Erythropoietin,"" Blood, 77:419-434 (1991).;;Kuntz et al., ""A Geometric Approach to Macromolecule-Ligand Interactions,"" J. Mol. Biol., 161:269-288 (1982).;;Lee et al., ""Structure of Human FIH-1 Reveals a Unique Active Site Pocket and Interaction Sites for HIF-1 and von Hippel Lindau,"" JBC, 278:7558-7563 (2003).;;Li et al., ""PR39, A Peptide Regulator of Angiogenesis,"" Nat Med., 6(1):49-55 (2000).;;Mancini et al., ""Effect of Erythropoietin on Exercise Capacity in Patients with Moderate to Severe Chronic Heart Failure,"" Circulation, 107:294-299 (2003).;;McDonough et al., ""Cellular Oxygen Sensing: Crystal Structure of Hypoxia-Inducible Factor Prolyl Hydroxylase (PHD2),"" PNAS, 103(26):9814-9819 (2006).;;Miranker et al., ""Functionality Maps of Binding Sites: A Multiple Copy Simultaneous Search Method,"" Proteins: Structure, Function and Genetics, 11:29-34 (1991).;;Nguyen et al., ""Cellular Interactions in Vascular Growth and Differentiation,"" Int. Review of Cytology, 204:1-48 (2001).;;Nishibata et al., ""Automatic Creation of Drug Candidate Structures Based on Receptor Structure. Starting Point for Artificial Lead Generation,"" Tetrahedron, 47( 43):8985-8990 (1991).;;O'Reilly et al., ""Angiostatin: A Novel Angiogenesis Inhibitor that Mediates the Suppression of Metastases by a Lewis Lung Carcinoma,"", Cell, 79:315-328 (1994).;;O'Reilly et al., ""Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth,"" Cell, 88:277-285 (1997).;;Peyssonnaux et al., ""HIF-1alpha Expression Regulates the Bactericidal Capacity of Phagocytes,"" J. Clinical Invest., 115(7):1806-1815 (2005).;;Qian, Oral abstract FR-OR011, J. Am. Soc. Nephrol., 24:38A (2013).;;Schoneberg et al., ""Structural Basis of G Protein-Coupled Receptor Function,"" Molecular and Cellular Endocrinology, 151:181-193 (1999).;;Semenza et al., ""Transcriptional Regulation of Genes Encoding Glycolytic Enzymes by Hypoxia-Inducible Factor 1,"" J. Biol. Chem., 269:23757-23763 (1994).;;Semenza, ""Regulation of Erythropoietin Porduction: New Insights into Molecular Mechanisms of Oxygen Homeostasis,"" Hematol. Oncol. Clin. North Am., 8:863-884 (1994).;;Semenza, ""Signal Transduction to Hypoxia-inducible Factor 1,"" Biochem. Pharmacol, 64:993-998 (2002).;;Sexton, ""Recent advances in our understanding of peptide hormone receptors and RAMPS,"" Current Opinion in Drug Discovery and Development, 2(5):440-448 (1999).;;Sheehan, ""3-Hydroxypicolinic Acid and Some of its Derivatives,"" J. Organic Chemistry 31(3):636-638 (1996).;;Teicher et al., ""Potentiation of Cytotoxic Cancer Therapies by TNP-470 Alone and with Other Anti-Angiogenic Agents,"" Int. J. Cancer, 57:920-925 (1994).;;Tzschucke et al., ""Fluorous-Silica-Supported Perfluoro-Tagged Palladium Complexes Catalyze Suzuki Coupling in Water"" Helvetica Chimica Acta; vol. 87 2882-2889 (2004).;;Vickerstaffe et al., ""Fully Automated Polymer-Assisted Synthesis of 1,5-Biaryl Pyrazoles,"" J. Comb. Chem., 2004,6,332-33.;;Vincent et al., ""Angiogenesis is Induced in a Rabbit Model of Hindlimb Ischemia by Naked DNA Encoding an HIF-1a/VP16 Hybrid Transcription Factor,"" Circulation, 102:2255-2261 (2000).;;Warnecke et al., ""Activation of the Hypoxia-Inducible Factor Pathway and Stimulation of Angiogenesis by Application of Prolyl Hydroxylase Inhibitors,"" FASEB Journal, 17: 1186-1188 (2003).;;Warshakoon et al., ""Design and synthesis of substituted pyridine derivatives as HIF-1alpha prolyl hydroxylase inhibitors,"" Bioorganic & Medicinal Chemistry Letters, 16 (2006) 5616-5620.;;Wax et al., ""SM-20 is a Nove120-kd Protein Whose Expression in the Arterial Wall is Restricted to Smooth Muscle,"" Lab. Invest., 74(4):797-808 (1996).;;Weidner et al., ""Tumor Angiogenesis and Metastasis-Correlation in Invasive Breast Carcinoma,"" New Eng. J. Med., 324(1):1-8 (1991).;;Wright et al., ""Activation of the Prolyl Hydroxylase Oxygen-Sensor Results in Induction of GLUT1, Heme Oxygenase-1, and Nitric-Oxide Synthase Proteins and Confers Protection from Metabolic Inhibition to Cardiomyocytes,"" J. Bio. Chem., 278(22):20235-20239 (2003).;;Office action mailed Oct. 7, 2013 in connection with U.S. Appl. No. 13/489,400.;;Office action mailed Jan. 30, 2014 in connection with U.S. Appl. No. 13/489,400.;;Office action mailed Dec. 12, 2013 in connection with U.S. Appl. No. 14/071,088.;;""Standards of Medical Care in Diabetes-2006,"" Diabetes Care, 29:s4-s42 (2006).;;Qian et al., ""A Randomized, Double-Blind, Placebo Controlled Trial of FG-4592 for Correction of Anemia in Subjects with Chronic Kidney Disease in China,"" Oral Abstract FR-OR011, J. Am. Soc. Nephrol. 24:38A (2013).;;Langsetmo, ""Inhibition of HIF-Prolyl Hydroxylases with FG-4539 Is Neuroprotective in a Mouse Model of Permanent Focal Ischemia,"" International Stroke Conference, Kissimmee Florida, Presentation No. 427 (2006).;;Rahtu-Korpela, ""HIF Prolyl 4-Hydroxylase-2 Inhibition Improves Glucose and Lipid Metabolism and Protects Against Obesity and Metabolic Dysfunction,"" Diabetes 63:3324-3333 (2014).;;Catrina et al., 2004, ""Hyperglycemia Regulates Hypoxia-Inducible Factor-1 Protein Stability and Function,"" Diabetes 53:3226-3232.",ACTIVE
629,US,B2,US 7811595 B2,111-152-052-516-015,2010-10-12,2010,US 82193607 A,2007-06-26,US 82193607 A;;US 81652206 P,2006-06-26,Prolyl hydroxylase inhibitors and methods of use,"The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.",WARNER CHILCOTT CO LLC,KAWAMOTO RICHARD MASARU;;WU SHENGDE;;WARSHAKOON NAMAL C;;EVDOKIMOV ARTEM G;;GREIS KENNETH D;;BOYER ANGELIQUE SUN,THE PROCTER & GAMBLE COMPANY (2008-12-04);;AKEBIA THERAPEUTICS INC (2011-12-15);;PROCTER & GAMBLE COMPANY THE (2007-07-27);;WARNER CHILCOTT COMPANY LLC (2009-10-30),https://lens.org/111-152-052-516-015,Granted Patent,yes,51,60,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,A61K8/02;;A61K31/44;;C07D213/65;;C07D213/89,424/401;;514/346;;546/296;;546/298,43,34,009-081-622-113-208;;081-136-747-247-898;;091-474-773-070-883;;064-242-953-339-024;;015-199-257-732-502;;077-106-322-076-470;;011-101-678-202-709;;023-017-724-234-140;;074-344-536-692-994;;056-436-730-631-840;;034-760-425-242-511;;062-826-287-074-090;;040-667-645-789-907;;102-345-845-395-203;;052-512-054-021-225;;022-156-141-942-093;;030-042-017-746-591;;131-046-096-401-339;;092-475-988-464-223;;135-654-547-079-284;;069-450-943-413-364;;025-178-564-355-938;;048-830-824-939-083;;102-949-159-342-256;;018-052-265-551-042;;064-406-626-054-484;;129-297-815-048-32X;;016-533-076-557-079;;149-920-492-418-396;;074-156-318-814-764;;065-169-875-352-44X;;045-408-622-411-245;;096-459-000-284-800;;017-183-541-402-013,10.1021/jm00092a016;;1321909;;1665444;;10.1042/bst0190812;;10.1172/jci23865;;16007254;;pmc1159132;;10.1021/jo01340a533;;5902481;;10.1016/s0968-0004(97)01074-8;;9255066;;10.1182/blood.v77.3.419.bloodjournal773419;;10.1182/blood.v77.3.419.419;;1991159;;10.1016/s0074-7696(01)04002-5;;11243594;;7525077;;10.1016/0092-8674(94)90200-3;;10.1016/s0092-8674(00)81848-6;;9008168;;7852211;;10.1016/s0889-8588(18)30134-5;;10.1016/s0021-9258(17)31580-6;;8089148;;7515861;;10.1002/ijc.2910570624;;10.1056/nejm199101033240101;;1701519;;1583540;;10.1007/bf00124387;;pmc312791;;10.1101/gad.914801;;11581158;;10.1016/s0304-4157(99)00006-4;;10548717;;10.1021/jm00145a002;;3892003;;10.1002/prot.340080302;;2281083;;7823319;;10.1016/s0022-2836(95)80037-9;;15952883;;10.1146/annurev.biochem.74.082803.133142;;7154081;;10.1016/0022-2836(82)90153-x;;12482756;;10.1074/jbc.m210385200;;10613823;;10.1038/71527;;10.1161/01.cir.0000044914.42696.6a;;12538431;;pmc1502536;;16782814;;10.1073/pnas.0601283103;;10.2210/pdb2g1m/pdb;;10.1002/prot.340110104;;1961699;;10.1016/s0040-4020(01)86503-0;;10.1016/s0303-7207(99)00017-9;;10411333;;10.1016/s0006-2952(02)01168-1;;12213597;;19649971;;11056102;;10.1161/01.cir.102.18.2255;;10.1096/fj.02-1062fje;;12709400;;8606489;;12649278;;10.1074/jbc.m301391200,"Ingersoll et al. Organic Syntheses, CV 2, 328, ""Hippuric acid"". (http://web.archive.org/web/20020724135719/http://www.orgsyn.org/orgsyn/orgsyn/prepContent.asp?prep=cv2p0328, accessed Mar. 11, 2010).;;""Hippuric acid sodium salt"". Science Lab.com: Chemicals & Laboratory Equipment. (""http://web.archive.org/web/20041107121553/http://www.sciencelab.com/page/S/PVAR/10415/SLH2620"", accessed Mar. 11, 2010).;;Cunliffe et al., ""Novel Inhibitors of Prolyl 4-Hydroxylase. 3. Inhibition by the Substrate Analogue N-Oxaloglycine and Its Derivatives,"" J Med. Chem. 35:2652-2658 (1992).;;Franklin et al., ""Approaches to the Design of Anti-Fibrotic Drugs,"" Biochem Soc Trans., 19(4):812-5 (Nov. 1991).;;Peyssonnaux et al.,""HIF-1alpha Expression Regulates the Bactericidal Capacity of Phagocytes,"" J. Clinical Invest. , 115(7):1806-1815 (Jul. 2005).;;Sheehan, ""3-Hydroxypicolinic Acid and Some of its Derivatives,"" J. Organic Chemistry 31(3):636-638 (1996).;;Bussolino, ""Molecular Mechanisms of Blood Vessel Formation,"" Trends Biochem. Sci.,22(7):251-256 (1997).;;Folkman et al., ""Tumor Angiogenesis,"" The Molecular Basis of Cancer, Mendelsohn et al., eds., W. B. Saunders, Chapter 10, pp. 206-232 (1995).;;Krantz, ""Erythropoietin,"" Blood, 77:419-434 (1991).;;Nguyen et al., ""Cellular Interactions in Vascular Growth and Differentiation,"" Int. Review of Cytology, 204:1-48 (2001).;;O'Reilly et al., ""Angiostatin: A Novel Angiogenesis Inhibitor that Mediates the Suppression of Metastases by a Lewis Lung Carcinoma,"" Cell, 79:315-328 (1994).;;O'Reilly et al., ""Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth,"" Cell, 88:277-285(1997).;;Semenza, ""Regulation of Erythropoietin Porduction: New Insights into Molecular Mechanisms of Oxygen Homeostasis,"" Hematol. Oncol. Clin. North Am., 8:863-884 (1994).;;Semenza et al., ""Transcriptional Regulation of Genes Encoding Glycolytic Enzymes by Hypoxia-Inducible Factor 1,"" J. Biol. Chem., 269:23757-23763 (1994).;;Teicher et al., ""Potentiation of Cytotoxic Cancer Therapies by TNP-470 Alone and with Other Anti-Angiogenic Agents,"" Int. J. Cancer, 57:920-925 (1994).;;Weidner et al., ""Tumor Angiogenesis and Metastasis-Correlation in Invasive Breast Carcinoma,"" New Eng. J. Med., 324(1):1-8 (1991).;;Bartlett et al., ""Molecular Recognition in Chemical and Biological Problems,"" Special Pub., Royal Chem. Soc., 78, 182-196 Caveat: A Program to Facilitate the Structure-derived Design of Biologically Active Molecules (Apr. 1989).;;Böhm, ""The Computer Program LUDI: A New Method for the Novo Design of Enzyme Inhibitors,"" J. Computer-Aided Molecular Design,6:61-78 (1992).;;Elson et al., ""Induction of Hypervascularity Without Leakage or Inflammation in Transgenic Mice Overexpressing Hypoxia-Indicible Factor-1alpha,"" Genes & Dev., 15:2520-2532 (2001).;;Flower, ""Modelling G-protein-coupled receptors for drug design,"" Biochimica et Biophysica Acta, 1422:207-234 (1999).;;Goodford, ""A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules,"" J Med. Chem., 28(7):849-857 (1985).;;Goodsell et al., ""Automated Docking of Substrates to Proteins by Simulated Annealing,"" Proteins: Structure, Function, and Genetics, 8:195-202 (1990).;;Jones et al., ""Molecular Recognition of Receptor Sites Using a Genetic Algorithm with a Description of Desolvation,"" J. Mol. Biol., 245:43-53 (1995).;;Kaelin, ""Proline Hydroxylation and Gene Expression,"" Annu. Rev. Biochem., 74:115-125 (2005).;;Kuntz et al., ""A Geometric Approach to Macromolecule-Ligand Interactions,"" J. Mol. Biol., 161:269-288 (1982).;;Lee et al., ""Structure of Human FIH-1 Reveals a Unique Active Site Pocket and Interaction Sites for HIF-1 and von Hippel Lindau,"" JBC, 278:7558-7563 (2003).;;Li et al., ""PR39, A Peptide Regulator of Angiogenesis,"" Nat Med., 6(1):49-55 (2000).;;Mancini et al., ""Effect of Erythropoietin on Exercise Capacity in Patients with Moderate to Severe Chronic Heart Failure,"" Circulation, 107:294-299 (2003).;;McDonough et al., ""Cellular Oxygen Sensing: Crystal Structure of Hypoxia-Inducible Factor Prolyl Hydroxylase (PHD2),"" PNAS, 103(26):9814-9819 (2006).;;Miranker et al., ""Functionality Maps of Binding Sites: A Multiple Copy Simultaneous Search Method,"" Proteins: Structure, Function and Genetics, 11:29-34 (1991).;;Nishibata et al., ""Automatic Creation of Drug Candidate Structures Based on Receptor Structure. Starting Point for Artificial Lead Generation,"" Tetrahedron, 47(43):8985-8990 (1991).;;Schoneberg et al., ""Structural Basis of G Protein-Coupled Receptor Function,"" Molecular and Cellular Endocrinology, 151:181-193 (1999).;;Semenza, ""Signal Transduction to Hypoxia-inducible Factor 1,"" Biocehm Pharmacol, 64:993-998 (2002).;;Sexton, ""Recent advances in our understanding of peptide hormone receptors and RAMPS,"" Current Opinion in Drug Discovery and Development, 2(5):440-448 (1999).;;Vincent et al., ""Angiogenesis is Induced in a Rabbit Model of Hindlimb Ischemia by Naked DNA Encoding an HIF-1alpha/VP16 Hybrid Transcription Factor,"" Circulation, 102:2255-2261 (2000).;;Warnecke et al., ""Activation of the Hypoxia-Inducible Factor Pathway and Stimulation of Angiogenesis by Application of Prolyl Hydroxylase Inhibitors,"" FASEB Journal, 17:1186-1188 (2003).;;Wax et al., ""SM-20 is a Novel 20-kd Protein Whose Expression in the Arterial Wall is Restricted to Smooth Muscle,"" Lab. Invest., 74(4):797-808 (1996).;;Wright et al., ""Activation of the Prolyl Hydroxylase Oxygen-Sensor Results in Induction of GLUT1, Heme Oxygenase-1, and Nitric-Oxide Synthase Proteins and Confers Protection from Metabolic Inhibition to Cardiomyocytes,"" J. Bio. Chem., 278(22):20235-20239 (2003).;;Singapore, 200809595-2, Jun. 27, 2007, Akebia Pharmaceuticals, Office Action, Dec. 28, 2009.;;Singapore, 200809595-2, Jun. 27, 2007, Akebia Pharmaceuticals, Response to Office Action, Mar. 4, 2010.;;Canada, 2,659,682, Jun. 27, 2007, Akebia Pharmaceuticals, Office Action, May 18, 2010.;;Canada, 2,659,682, Jun. 27, 2007, Akebia Pharmaceuticals, Response to Office Action, Jun. 11, 2010.;;Europe, 07835890.0, Jun. 27, 2007, Akebia Pharmaceuticals, Form 71(3) Notice of Allowance, Jun. 24, 2010.",ACTIVE
630,US,B2,US 11883386 B2,007-747-614-570-13X,2024-01-30,2024,US 202217815391 A,2022-07-27,US 202217815391 A;;US 202016908092 A;;US 201816119146 A;;US 201715420617 A;;US 201514854080 A;;US 201414568200 A;;US 201314062011 A;;US 201213681876 A;;US 86007310 A;;US 82193607 A;;US 81652206 P,2006-06-26,Prolyl hydroxylase inhibitors and methods of use,"The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.",AKEBIA THERAPEUTICS INC,KAWAMOTO RICHARD MASARU;;WU SHENGDE;;EVDOKIMOV ARTEM G;;GREIS KENNETH D;;BOYER ANGELIQUE SUN;;WARSHAKOON NAMAL C,THE PROCTER & GAMBLE COMPANY (2007-07-27);;AKEBIA THERAPEUTICS INC (2011-12-15);;WARNER CHILCOTT COMPANY LLC (2009-10-30),https://lens.org/007-747-614-570-13X,Granted Patent,yes,150,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07D213/81;;A61K31/4418;;A61K31/4433;;C07C235/60;;C07C237/42;;C07C255/57;;C07D213/65;;C07D295/192;;C07D401/04;;C07D401/10;;C07D405/04;;C07D405/10;;C07D417/04,,107,72,017-669-075-762-985;;028-862-168-091-90X;;010-824-042-186-283;;063-746-538-402-770;;093-087-601-151-305;;129-926-400-245-400;;006-143-986-832-256;;000-203-740-034-24X;;064-865-149-673-057;;074-536-164-121-774;;102-345-845-395-203;;000-457-771-937-337;;015-199-257-732-502;;105-391-605-288-229;;009-081-622-113-208;;052-512-054-021-225;;095-605-097-751-343;;022-156-141-942-093;;081-136-747-247-898;;087-705-105-313-369;;030-042-017-746-591;;131-046-096-401-339;;007-397-822-838-463;;042-987-854-927-099;;046-414-927-085-724;;098-888-990-357-930;;102-347-048-244-655;;019-130-789-993-789;;066-519-812-638-153;;022-950-342-458-554;;083-737-080-066-103;;092-475-988-464-223;;135-654-547-079-284;;125-424-943-194-608;;129-372-774-596-270;;015-285-296-623-617;;077-106-322-076-470;;069-450-943-413-364;;025-178-564-355-938;;048-830-824-939-083;;056-311-147-347-640;;102-949-159-342-256;;018-052-265-551-042;;064-406-626-054-484;;011-101-678-202-709;;129-297-815-048-32X;;023-017-724-234-140;;074-344-536-692-994;;032-766-102-934-139;;091-474-773-070-883;;007-834-259-097-311;;019-005-723-569-798;;104-310-480-694-456;;016-533-076-557-079;;018-490-208-246-068;;034-760-425-242-511;;056-436-730-631-840;;149-920-492-418-396;;074-156-318-814-764;;064-242-953-339-024;;046-494-590-295-402;;141-317-043-329-438;;062-826-287-074-090;;117-587-550-537-020;;103-335-591-460-884;;026-655-568-834-966;;065-169-875-352-44X;;045-408-622-411-245;;003-330-211-576-597;;096-459-000-284-800;;040-667-645-789-907;;017-183-541-402-013,10.1016/s0040-4020(03)01100-1;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;490542;;10.1021/jm00194a018;;15664391;;10.1016/j.cardiores.2004.09.004;;15637314;;10.1161/01.str.0000153795.38388.72;;10.1021/jo000315x;;10956494;;10.1373/49.1.32;;12507958;;10.1093/ndt/14.5.1171;;10344357;;3326854;;10.1111/j.1399-3011.1987.tb03385.x;;10.1007/978-1-4615-4141-7_70;;1583540;;10.1007/bf00124387;;1763185;;10.1007/978-3-0348-7139-6_7;;10.1016/s0968-0004(97)01074-8;;9255066;;10.2337/diabetes.53.12.3226;;15561954;;10.1021/jm00092a016;;1321909;;pmc312791;;10.1101/gad.914801;;11581158;;pmc1440619;;10.1136/bmj.332.7546.900;;16613966;;10.1016/s0304-4157(99)00006-4;;10548717;;1665444;;10.1042/bst0190812;;10.1021/jo980823v;;10.1021/jm00145a002;;3892003;;10.1002/prot.340080302;;2281083;;28532635;;10.1053/j.ajkd.2016.12.011;;10.1053/j.ajkd.2017.04.001;;28242135;;10.1021/jm050444b;;16302822;;10.1021/jm050444b.s001;;10.1074/jbc.m304982200;;12788921;;10.1021/ja00383a030;;10.1016/j.bmc.2006.01.059;;16481176;;10.1351/pac199567081307;;pmc129695;;12351678;;10.1073/pnas.192342099;;10.1126/science.1059817;;11292862;;10.1126/science.1059796;;11292861;;011292861;;7823319;;10.1016/s0022-2836(95)80037-9;;15952883;;10.1146/annurev.biochem.74.082803.133142;;10.1007/978-1-4684-5445-1_9;;2965848;;10.1124/mol.106.027029;;16887934;;26610437;;pmc6332328;;10.3390/molecules201119717;;10.1182/blood.v77.3.419.bloodjournal773419;;10.1182/blood.v77.3.419.419;;1991159;;7154081;;10.1016/0022-2836(82)90153-x;;12482756;;10.1074/jbc.m210385200;;10613823;;10.1038/71527;;10.2174/0929867053363540;;15638729;;10.1161/01.cir.0000044914.42696.6a;;12538431;;pmc1502536;;16782814;;10.1073/pnas.0601283103;;10.2210/pdb2g1m/pdb;;10.1002/prot.340110104;;1961699;;10.1016/s0074-7696(01)04002-5;;11243594;;10.1016/s0040-4020(01)86503-0;;7525077;;10.1016/0092-8674(94)90200-3;;10.1016/s0092-8674(00)81848-6;;9008168;;27650732;;10.1016/j.kint.2016.07.019;;10.1172/jci23865;;16007254;;pmc1159132;;10.1002/chem.200902455;;20397153;;10.2337/db14-0472;;24789921;;10.1002/anie.199620561;;10.1016/s0303-7207(99)00017-9;;10411333;;10.1101/gad.14.16.1983;;10950862;;10.1016/s0021-9258(17)31580-6;;8089148;;7852211;;10.1016/s0889-8588(18)30134-5;;10.1016/s0006-2952(02)01168-1;;12213597;;19649971;;10.1021/jo01340a533;;5902481;;16227210;;10.1074/jbc.m504963200;;pmc2586128;;16373931;;10.2337/diacare.29.s1.06.s4;;7515861;;10.1002/ijc.2910570624;;10.1039/cs9790800563;;10.1002/hlca.200490260;;15132592;;10.1021/cc049977g;;11056102;;10.1161/01.cir.102.18.2255;;10.1096/fj.02-1062fje;;12709400;;16908149;;10.1016/j.bmcl.2006.08.026;;8606489;;10.1056/nejm199101033240101;;1701519;;12649278;;10.1074/jbc.m301391200,"Alesso et al., Improving resins for solid phase synthesis: incorporation of I-[2-(2-methoxyethoxy) ethoxy]4-vinyl-benzene, Tetrahedron, vol. 59, 7163-7169, 2003.;;Altschul et al., Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs, Nucleic Acids Res., vol. 25, No. 27, 3389-3402, 1997.;;Anderson et al., Antileukemic Activity of Derivatives of I ,2-Dimethyl-3,4-bis(hydroxymethyl)-5-phenylpyrrole Bis(N-methylcarbamate), J. Med. Chem.: vol. 22, No. 8, 977-980, 1979.;;Annex et al., Growth Factor-Induced Therapeutic Angiogenesis in the Heart: Protein Therapy, Cardiovascular Research, vol. 65, No. 3, 649-655, 2005.;;Ardelt et al., Estradiol Regulates Angiopoietin-1 mRNA Expression Through Estrogen Receptor-a in a Rodent Experimental Stroke Model, Stroke, vol. 36, 337-341, 2005.;;Atkinson, G. E. et al., A Versatile Polymer-Supported 4-(4Methylphenyl(chloro)methyl)phenoxy Linker for Solid-Phase Synthesis of Pseudopeptides, Journal of Organic Chemistry, 2000, vol. 65, No. 16, p. 5048-5056.;;Auerbach et al., Angiogenesis Assays: A Critical Overview, Clinical Chemistry, vol. 49, 32-40, 2003.;;Aucella et al., Synergistic effect of desferrioxamine and recombinant erythropeoietin on erythroid precursor proliferation in chronic renal failure, Nephrol. Dial Transplant. May 1999; 14(5):1171-1175.;;Barany et al., Solid-phase Peptide Synthesis: A Silver Anniversary Report, Int. J. Peptide Protein Res., vol. 30, No. 6, 705-739, 1987.;;Baringhaus et al., 3D QSAR of prolyl 4-hydroxylase inhibitors, Chapter 23 in “Molecular Modeling and Prediction of Bioactivity” (Springer, Boston, MA), 2000, 345-346.;;Bartlett et al., Molecular Recognition in Chemical and Biological Problems, Special Pub., Royal Chem. Soc., vol. 78, 182-196 Caveat: A Program to Facilitate the Structure-derived Design of Biologically Active Molecules, Apr. 1989.;;Bohm, The Computer Program LUDI: A New Method for the Novo Design of Enzyme Inhibitors, J. Computer-Aided Molecular Design, vol. 6, 61-78, 1992.;;Branden et al., Introduction to Protein Structure Second Edition, Garland Publishing, Inc., New York, pp. 374-375, 1999.;;Burger, Isosterism and bioisosterism in drug design, Progress in Drug Research, vol. 37, 287-371,1991.;;Bussolino, Molecular Mechanisms of Blood Vessel Formation, Trends Biochem. Sci., vol. 22, No. 7, 251-256, 1997.;;Catrina et al., Hyperglycemia Regulates Hypoxia-Inducible Factor-Ia Protein Stability and Function, Diabetes, vol. 53, 3226-3232, 2004.;;Cheeseright, The identification of bioisosteres as drug development candidates, Innovations in Pharmeceutical Technology, 22-26, 2009.;;Cunliffe et al., Novel Inhibitors of Prolyl4-Hydroxylase. 3. Inhibition by the Substrate Analogue N-Oxaloglycine and Its Derivatives, J. Med. Chem. vol. 35, 2652-2658, 1992.;;Elson et al., Induction of Hypervascularity Without Leakage or Inflammation in Transgenic Mice Overexpressing Hypoxia-Indicible Factor-la, Genes & Dev., vol. 15, 2520-2532, 2001.;;Enoch et al., ABC of wound healing: non-surgical and drug treatments, BMJ, vol. 332, 900-903, 2006.;;Exhibit SW2 to the first report of Simon Ward, filed on behalf of the Claimants in Claim No. HP-2018-000036 and the First and Second Defendants in IL-2019-000031, and the Claimants in Claim No. HP-2018-000032, in the High Court of Justice Business and Property Courts of England and Wales Intellectual Property List (ChD) Patent Court, Jan. 3, 2020 (23 pages).;;Flower, Modelling G-protein-coupled receptors for drug design, Biochimica et Biophysica Acta, vol. 1422, 207-234, 1999.;;Folkman et al., Tumor Angiogenesis, The Molecular Basis of Cancer, Mendelsohn et al., eds., W. B. Saunders, Chapter 10, pp. 206-232, 1995.;;Franklin et al., Approaches to the Design of Anti-Fibrotic Drugs, Biochem. Soc. Trans., vol. 19, No. 4, :812-5, Nov. 1991.;;Gavhane et al., Solid tumors: facts, challenges and solutions, International Journal of Pharma Sciences and Research, vol. 2, No. 1, 1-12, 2011.;;Gaunt et al., Rational design of benzyl-type protecting groups allows sequential deprotection of hydroxyl groups by catalytic hydrogenolysis, J. Org. Chem., vol. 63, 4172-4173, 1998.;;Goodford, A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules, J. Med. Chem., vol. 28, No. 7, 849-857, 1985.;;Gunzler et al., Prolyl 4-hydroxylase inhibitors, Chapter 2 in Prolyl hydroxylase, protein disulfide isomerase, and other structurally related proteins (Marcel Dekker), 1998, 65-95.;;Goodsell et al., Automated Docking of Substrates to Proteins by Simulated Annealing, Proteins: Structure, Function, and Genetics, vol. 8, 195-202, 1990.;;Gupta et al., Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD, Am J Kidney Dis. 2017, vol. 69, issue 6, pp. 815-826. DOI: 10.1053/j.ajkd.2016.12.011 (Year: 2017).;;Hardcastle et al., Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small molecule library approach, J. Med. Chem., vol. 48, 7829-7846, 2005.;;Hippuric acid sodium salt. Science Lab.com: Chemicals & Laboratory Equipment. (http://web.archive.org/web/20041107121553/http://www.sciencelab.com/page/S/PVAR/10415/SLH2620, accessed Mar. 11, 2010). 1 page.;;Hirsila et al., Characterization of the Human Prolyl 4-Hyrdoxylases That Modify the Hypoxia-inducible Factor, The Journal of Biological Chemistry, vol. 278, No. 33, 30772-30780, Aug. 2003.;;Hoeksema et al., Structure of Rubradirin, Journal of American Chemical Society, vol. 104, 5173-5181, 1982.;;Ikura; Bioorganic & Medicinal Chemistry 14 (2006) 4241-4252. doi: 10.1016/j.bmc.2006.01.059 (Year: 2006).;;Ingersoll et al., Organic Syntheses, CV 2, 328, “Hippuric acid”. (http://web.archive.org/web/20020724135719/http://www.orgsyn.org/orgsyn/orgysn/prepContent.asp?prep=cv2p0328, accessed Mar. 11, 2010). 4 pages.;;International Search Report dated May 8, 2008 for PCT/US2007/014832. 3 pages.;;International Union of Pure and Applied Chemistry; Glossary of Class Names of Organic Compounds and Reactive Intermediates Based on Structure; Pure & D Appl. Chem., vol. 67, Nos. 8/9, 1307-1375, 1995.;;Ivan et al., Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor, Proceedings of the National Academy of Science; vol. 99, No. 21, 13459-13464, 2002.;;Ivan et al., HIFa Targeted for VHL-Mediated Destruction by Praline Hydroxylation: Implications for 02 Sensing, Science vol. 292, 464-468, 2001.;;Jaakkola et al., Targeting of HIF-a to the von Rippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation, Science, vol. 292, 468-472, 2001.;;Jones et al., Molecular Recognition of Receptor Sites Using a Genetic Algorithm with a Description of Desolvation, J. Mol. Biol., vol. 245, 43-53, 1995.;;Kaelin, Praline Hydroxylation and Gene Expression, Annu. Rev. Biochem., vol. 74, 115-125, 2005.;;Kawashima et al., Suppressive effect of quinolinic acid and hippuric acid on bone marrow erythroid growth and lymphocyte blast formation in uremia, Advances in Experimental Medicine and Biology, vol. 223, 69-72, 1987.;;Ke et al., Hypoxia-Inducible Factor-1 (HIF-1), Molecular Pharmacology, vol. 70, No. 5, 1469-1480, Aug. 2006.;;Kim et al., Recent Advances in Developing Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylases and Their Therapeutic Implications, Molecules, vol. 20, No. 11, 20551-20568, Nov. 2015.;;Krantz, “Erythropoietin,” Blood, vol. 77, 419-434, 1991.;;Kuntz et al., A Geometric Approach to Macromolecule-Ligand Interactions, J. Mol. Biol., vol. 161,269-288, 1982.;;Langsetmo, Inhibition of HIF-Prolyl Hydroxylases with FG-4539 Is Neuroprotective in a Mouse Model of Permanent Focal Ischemia, International Stroke Conference, Kissimmee, Florida, Presentation No. 427, 2006. 1 page.;;Lee et al., Structure of Human FIH-1 Reveals a Unique Active Site Pocket and Interaction Sites for HIF-1 and von Hinnel Lindau, JBC, vol. 278, 7558-7563, 2003.;;Li et al., PR39, A Peptide Regulator of Angiogenesis, Nat Med., vol. 6, No. 1, 49-55, 2000.;;Lima et al., Bioisosterism: a useful strategy for molecular modification and drug design, Current Medicinal Chemistry, vol. 12, 23-49, 2005.;;Mancini et al., Effect of Erythropoietin on Exercise Capacity in Patients with Moderate to Severe Chronic Heart Failure, Circulation, vol. 107, 294-299, 2003.;;McDonough et al., Cellular Oxygen Sensing: Crystal Structure of Hypoxia-Inducible Factor Prolyl Hydroxylase (PHD2), Pnas, vol. 103 No. 26, 9814-9819, 2006.;;Miranker et al., Functionality Maps of Binding Sites: A Multiple Copy Simultaneous Search Method, Proteins: Structure, Function and Genetics, vol. 11, 29-34, 1991.;;Nguyen et al., Cellular Interactions in Vascular Growth and Differentiation, Int. Review of Cytology, vol. 204, 1-48, 2001.;;Nishibata et al., Automatic Creation of Drug Candidate Structures Based on Receptor Structure. Starting Point for Artificial Lead Generation, Tetrahedron, vol. 47, No. 43, 8985-8990, 1991.;;Notice of Opposition communication for European Patent No. 3357911, dated Feb. 23, 2023. 26 pages.;;O'Reilly et al., Angiostatin: A Novel Angiogenesis Inhibitor that Mediates the Suppression of Metastases bv a Lewis Lung Carcinoma, Cell, vol. 79, 315-328, 1994.;;O'Reilly et al., “Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth,” Cell, 88:277-285 (1997).;;Pergola et al., Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease, Kidney International, vol. 90, No. 5, 1115-1122, Sep. 2016.;;Peyssonnaux et al., HIF-Ia Expression Regulates the Bactericidal Capacity of Phagocytes, J. Clinical Invest., vol. 115, No. 7, 1806-1815, 2005.;;Piyamongkol et al., Amido-3-hydroxypyridin-4-ones as iron(III) ligands, Chemistry, A European Journal, vol. 16, 6374-6381, 2010.;;Qian et al., A Randomized, Double-Blind, Placebo Controlled Trial ofFG-4592 for Correction of Anemia in Subjects with Chronic Kidney Disease in China, Oral Abstract FR-ORO11, J. Am. Soc. Nephrol., vol. 24:38A, 2013. 1 page.;;Rahtu-Korpela, HIF Prolyl 4-Hydroxylase-2 Inhibition Improves Glucose and Lipid Metabolism and Protects Against Obesity and etabolic Dysfunction, Diabetes, vol. 63, 3324-3333, 2014.;;Schelhaas et al., Protecting group strategies in organic synthesis, Angew, Chem. Int. Ed. Engl., vol. 35, 2056-2083, 1996.;;Schoneberg et al., Structural Basis of G Protein-Coupled Receptor Function, Molecular and Cellular Endocrinology, vol. 151, 181-193, 1999.;;Search Report dated Apr. 28, 2011 for European Pat. App. No. 11000872.9. 3 pages.;;Semenza, HIF-1 and human disease: one highly involved factor, Genes and Development, vol. 14, No. 16, 1983-1991, Aug. 2000.;;Semenza et al., Transcriptional Regulation of Genes Encoding Glycolytic Enzymes by Hypoxia-Inducible Factor I , J. Biol. Chem., vol. 269, 23757-23763, 1994.;;Semenza, Regulation of Erythropoietin Porduction: New Insights into Molecular Mechanisms of Oxygen Homeostasis, Hematol. Oncol. Clin. North Am., vol. 8, 863-884, 1994.;;Semenza, Signal Transduction to Hypoxia-inducible Factor I , Biochem. Pharmacol, vol. 64, 993-998, 2002.;;Sexton, Recent advances in our understanding of peptide hormone receptors and RAMPS, Current Opinion in Drug Discovery and Development, vol. 2, No. 5. 440-448, 1999.;;Sheehan, 3-Hydroxypicolinic Acid and Some of its Derivatives, J. Organic Chemistry, vol. 31, No. 3, 636-638, 1996.;;Siddiq et al., Hypoxia-inducible Factor Prolyl 4-Hydroxylase Inhibition, The Journal of Biological Chemistry, vol. 280, No. 50, 41732-41743, Dec. 2005.;;Silverman, The Organic Chemistry of Drug Design and Drug Action, 2nd Edition, 2004, Elsevier, Section 2.2, E.4, pp. 29-34.;;Standards of Medical Care in Diabetes-2006, Diabetes Care, vol. 29. 4-s42, 2006. 39 pages.;;Sutter et al., Hypoxia-inducible factor 1α protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations, PNAS, vol. 97, No. 9, 4748-4753, 2000.;;Teicher et al., Potentiation of Cytotoxic Cancer Therapies by TNP-470 Alone and with Other Anti-Angiogenic Agents, Int. J. Cancer, vol. 57, 920-925, 1994.;;Thornber, Isosterism and molecular modification in drug design, Chem Soc. Rev., vol. 8, 563-580, 1979.;;Tzschucke et al., Fluorous-Silica-Supported Perfluoro-Tagged Palladium Complexes Catalyze Suzuki Coupling in Water, Helvetica Chimica Acta; vol. 87, 2882-2889, 2004.;;Vickerstaffe et al., Fully Automated Polymer-Assisted Synthesis of 1,5-Biaryl Pyrazoles, J. Comb. Chem., vol. 6, 332-33, 2004.;;Vincent et al., Angiogenesis is Induced in a Rabbit Model of Hindlimb Ischemia by Naked DNA Encoding an HIF-I aNP16 Hybrid Transcription Factor, Circulation, vol. 102, 2255-2261, 2000.;;Warnecke et al., Activation of the Hypoxia-Inducible Factor Pathway and Stimulation of Angiogenesis by Application of Prolyl Hydroxylase Inhibitors, FASEB Journal, vol. 17, 1186-1188, 2003.;;Warshakoon et al., Design and synthesis of substituted pyridine derivatives as HIF-1alpha prolyl hydroxylase inhibitors, Bioorganic & Medicinal Chemistry Letters, vol. 16, 5616-5620, 2006.;;Wax et al., SM-20 is a Novel20-kd Protein Whose Expression in the Arterial Wall is Restricted to Smooth Muscle, Lab. Invest., vol. 74, No. 4, 797-808, 1996.;;Weidner et al., Tumor Angiogenesis and Metastasis—Correlation in Invasive Breast Carcinoma, New Eng. J. Med., vol. 324, No. 1, 1-8, 1991.;;Wright et al., Activation of the Prolyl Hydroxylase Oxygen-Sensor Results in Induction of GLUTI, Heme Oxygenase-1, and Nitric-Oxide Synthase Proteins and Confers Protection from Metabolic Inhibition to Cardiomyocytes, J. Bio. Chem., vol. 278, No. 22, 20235-20239, 2003.;;European Patent No. 2044005, Opposition Filed, Jul. 20, 2011. 51 pages.;;European Patent No. 2044005, Response to Opposition, Dec. 28, 2011. 9 pages.;;European Patent No. 2044005, Summons to Attend Oral Proceedings and Preliminary Opinion of the Opposition Division, Oct. 31, 2012. 5 pages.;;European Patent No. 2044005, Decision of the Opposition Division, Instruction, and Grounds for the Decision, May 3, 2013. 21 pages.;;European Patent No. 2044005, Patent Owner Statement of Grounds of Appeal, Sep. 13, 2013. 14 pages.;;European Patent Office, Interlocutory Decision in Opposition Proceedings, mailed May 3, 2013, 76 pages.;;European Patent Office, Minutes of the Oral Proceedings Before the Opposition Division, mailed May 3, 2013, 6 pages.;;European Patent No. 2044005, Opponent Statement of Grounds of Appeal, Sep. 13, 2013. 16 pages.;;European Patent No. 2044005, Opponent Reply to Appeal, Jan. 29, 2014. 30 pages.;;European Patent No. 2044005, Patent Owner Reply to Appeal, Jan. 29, 2014. 26 pages.;;European Patent No. 2044005, Patent Owner Response to the Opponent's Communication, Aug. 28, 2014. 50 pages.;;European Patent No. 2044005, Communication of the Board of Appeal, Aug. 29, 2017. 12 pages.;;European Patent No. 2044005, Response of Opponent to Communication of the Board of Appeal, Nov. 8, 2017. 30 pages.;;Withdrawal of an Appeal by Proprietor in the Opposition Against European Patent No. 2044005, Feb. 27, 2018. 3 pages.;;Decision of the Board of Appeal of the European Patent Office in the Opposition Against European Patent No. 2044005, Mar. 6, 2018. 6 pages.;;Termination of Opposition Proceedings of European Patent No. 2044005, Apr. 18, 2018. 1 page.;;Notice of Opposition u/s 25(2) filed on Sep. 25, 2018 by Dr. Reddy's Laboratories Limited against Indian Patent No. 287720. 237 pages.;;Reply Statement of Patentee, filed Jan. 15, 2019, in the Post Grant Opposition against Indian Patent No. 287720 (39 pages).;;Reply on Behalf of Opponent to the Counterstatement by the Patentee and Reply Evidence, submitted Feb. 14, 2019, in the Post Grant Opposition against Indian Patent No. 287720 (237 pages).",ACTIVE
631,AU,B2,AU 2007/265460 B2,018-831-414-388-289,2011-03-03,2011,AU 2007/265460 A,2007-06-26,US 81652206 P;;US 2007/0014832 W,2006-06-26,Prolyl hydroxylase inhibitors and methods of use,,AKEBIA THERAPEUTICS INC,BOYER ANGELIQUE SUN;;GREIS KENNETH DONALD;;EDOKIMOV ARTEM G;;WU SHENGDE;;KAWAMOTO RICHARD MASARU;;WARSHAKOON NAMAL CHITHRANGA,"WARNER CHILCOTT, LLC (2010-12-09)",https://lens.org/018-831-414-388-289,Granted Patent,no,4,4,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07C235/60;;A61K31/44;;A61P9/10;;C07C235/52;;C07C237/42;;C07C255/57;;C07D213/81,,0,0,,,,ACTIVE
632,KR,A,KR 20090060264 A,121-161-633-174-612,2009-06-11,2009,KR 20097001697 A,2007-06-26,US 2007/0014832 W;;US 81652206 P,2006-06-26,PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE,"The present disclosure relates to HIF-1alpha prolyl hydroxylase inhibitors, compositions which comprise the HIF-1alpha prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.",PROCTER & GAMBLE,KAWAMOTO RICHARD MASARU;;WU SHENGDE;;WARSHAKOON NAMAL CHITHRANGA;;EVDOKIMOV ARTEM G;;GREIS KENNETH DONALD;;BOYER ANGELIQUE SUN,,https://lens.org/121-161-633-174-612,Patent Application,no,0,4,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57,,0,0,,,,ACTIVE
633,US,A1,US 2021/0137901 A1,038-860-042-243-756,2021-05-13,2021,US 202016908092 A,2020-06-22,US 202016908092 A;;US 201816119146 A;;US 201715420617 A;;US 201514854080 A;;US 201414568200 A;;US 201314062011 A;;US 201213681876 A;;US 86007310 A;;US 82193607 A;;US 81652206 P,2006-06-26,PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE,"The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.",AKEBIA THERAPEUTICS INC,KAWAMOTO RICHARD MASARU;;WU SHENGDE;;EVDOKIMOV ARTEM G;;GREIS KENNETH D;;BOYER ANGELIQUE SUN;;WARSHAKOON NAMAL C,THE PROCTER & GAMBLE COMPANY (2008-12-19);;AKEBIA THERAPEUTICS INC (2011-12-15);;WARNER CHILCOTT COMPANY LLC (2009-10-30),https://lens.org/038-860-042-243-756,Patent Application,yes,0,2,83,83,1,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,A61K31/4418;;A61K31/4433;;C07C235/60;;C07C237/42;;C07C255/57;;C07D213/65;;C07D213/81;;C07D295/192;;C07D401/04;;C07D401/10;;C07D405/04;;C07D405/10;;C07D417/04,,0,0,,,,ACTIVE
634,US,B2,US 10729681 B2,133-042-573-070-363,2020-08-04,2020,US 201816119146 A,2018-08-31,US 201816119146 A;;US 201715420617 A;;US 201514854080 A;;US 201414568200 A;;US 201314062011 A;;US 201213681876 A;;US 86007310 A;;US 82193607 A;;US 81652206 P,2006-06-26,Prolyl hydroxylase inhibitors and methods of use,"The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.",AKEBIA THERAPEUTICS INC,KAWAMOTO RICHARD MASARU;;WU SHENGDE;;EVDOKIMOV ARTEM G;;GREIS KENNETH D;;BOYER ANGELIQUE SUN;;WARSHAKOON NAMAL C,THE PROCTER & GAMBLE COMPANY (2008-12-19);;AKEBIA THERAPEUTICS INC (2011-12-15);;WARNER CHILCOTT COMPANY LLC (2009-10-30),https://lens.org/133-042-573-070-363,Granted Patent,yes,120,7,83,83,1,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,A61K31/4418;;A61K31/4433;;C07C235/60;;C07C237/42;;C07C255/57;;C07D213/65;;C07D213/81;;C07D295/192;;C07D401/04;;C07D401/10;;C07D405/04;;C07D405/10;;C07D417/04,,75,63,102-347-048-244-655;;007-397-822-838-463;;141-317-043-329-438;;017-669-075-762-985;;028-862-168-091-90X;;010-824-042-186-283;;063-746-538-402-770;;093-087-601-151-305;;006-143-986-832-256;;064-865-149-673-057;;102-345-845-395-203;;000-457-771-937-337;;015-199-257-732-502;;105-391-605-288-229;;009-081-622-113-208;;052-512-054-021-225;;022-156-141-942-093;;081-136-747-247-898;;087-705-105-313-369;;030-042-017-746-591;;131-046-096-401-339;;042-987-854-927-099;;098-888-990-357-930;;019-130-789-993-789;;066-519-812-638-153;;022-950-342-458-554;;083-737-080-066-103;;092-475-988-464-223;;135-654-547-079-284;;125-424-943-194-608;;077-106-322-076-470;;069-450-943-413-364;;025-178-564-355-938;;048-830-824-939-083;;056-311-147-347-640;;102-949-159-342-256;;018-052-265-551-042;;064-406-626-054-484;;011-101-678-202-709;;129-297-815-048-32X;;023-017-724-234-140;;074-344-536-692-994;;091-474-773-070-883;;007-834-259-097-311;;019-005-723-569-798;;104-310-480-694-456;;016-533-076-557-079;;034-760-425-242-511;;056-436-730-631-840;;149-920-492-418-396;;074-156-318-814-764;;064-242-953-339-024;;062-826-287-074-090;;117-587-550-537-020;;103-335-591-460-884;;026-655-568-834-966;;065-169-875-352-44X;;045-408-622-411-245;;003-330-211-576-597;;096-459-000-284-800;;040-667-645-789-907;;017-183-541-402-013;;012-293-487-994-251,10.1016/j.bmc.2006.01.059;;16481176;;28532635;;10.1053/j.ajkd.2016.12.011;;10.1053/j.ajkd.2017.04.001;;28242135;;16373931;;10.2337/diacare.29.s1.06.s4;;10.1016/s0040-4020(03)01100-1;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;490542;;10.1021/jm00194a018;;15664391;;10.1016/j.cardiores.2004.09.004;;15637314;;10.1161/01.str.0000153795.38388.72;;10.1373/49.1.32;;12507958;;3326854;;10.1111/j.1399-3011.1987.tb03385.x;;1583540;;10.1007/bf00124387;;1763185;;10.1007/978-3-0348-7139-6_7;;10.1016/s0968-0004(97)01074-8;;9255066;;10.2337/diabetes.53.12.3226;;15561954;;10.1021/jm00092a016;;1321909;;pmc312791;;10.1101/gad.914801;;11581158;;10.1016/s0304-4157(99)00006-4;;10548717;;1665444;;10.1042/bst0190812;;10.1021/jo980823v;;10.1021/jm00145a002;;3892003;;10.1002/prot.340080302;;2281083;;10.1021/jm050444b;;16302822;;10.1021/jm050444b.s001;;10.1021/ja00383a030;;10.1351/pac199567081307;;pmc129695;;12351678;;10.1073/pnas.192342099;;10.1126/science.1059817;;11292862;;10.1126/science.1059796;;11292861;;011292861;;7823319;;10.1016/s0022-2836(95)80037-9;;15952883;;10.1146/annurev.biochem.74.082803.133142;;10.1007/978-1-4684-5445-1_9;;2965848;;10.1182/blood.v77.3.419.bloodjournal773419;;10.1182/blood.v77.3.419.419;;1991159;;7154081;;10.1016/0022-2836(82)90153-x;;12482756;;10.1074/jbc.m210385200;;10613823;;10.1038/71527;;10.2174/0929867053363540;;15638729;;10.1161/01.cir.0000044914.42696.6a;;12538431;;pmc1502536;;16782814;;10.1073/pnas.0601283103;;10.2210/pdb2g1m/pdb;;10.1002/prot.340110104;;1961699;;10.1016/s0074-7696(01)04002-5;;11243594;;10.1016/s0040-4020(01)86503-0;;7525077;;10.1016/0092-8674(94)90200-3;;10.1016/s0092-8674(00)81848-6;;9008168;;10.1172/jci23865;;16007254;;pmc1159132;;10.1002/chem.200902455;;20397153;;10.2337/db14-0472;;24789921;;10.1002/anie.199620561;;10.1016/s0303-7207(99)00017-9;;10411333;;10.1016/s0021-9258(17)31580-6;;8089148;;7852211;;10.1016/s0889-8588(18)30134-5;;10.1016/s0006-2952(02)01168-1;;12213597;;19649971;;10.1021/jo01340a533;;5902481;;7515861;;10.1002/ijc.2910570624;;10.1039/cs9790800563;;10.1002/hlca.200490260;;15132592;;10.1021/cc049977g;;11056102;;10.1161/01.cir.102.18.2255;;10.1096/fj.02-1062fje;;12709400;;16908149;;10.1016/j.bmcl.2006.08.026;;8606489;;10.1056/nejm199101033240101;;1701519;;12649278;;10.1074/jbc.m301391200;;10.1073/pnas.080072497;;pmc18304;;10758161,"Ikura; Bioorganic & Medicinal Chemistry 14 (2006) 4241-4252. doi:10.1016/j.bmc.2006.01.059 (Year: 2006).;;Gupta; Am J Kidney Dis. 2017, 69, 815-826. DOI: 10.1053/j.ajkd.2016.12.011 (Year: 2017).;;U.S. Appl. No. 16/352,705, Lanthier et al.;;U.S. Appl. No. 16/178,191, Copp et al.;;“Standards of Medical Care in Diabetes—2006,” Diabetes Care, 29:s4-s42 (2006).;;Alesso et al., “Improving resins for solid phase synthesis: incorporation of I-[2-(2-methoxyethoxy) ethoxy]4-vinyl-benzene” Tetrahedron: 59,7163-7169 (2003).;;Altschul et al., “Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs,” Nucleic Acids Res., 25(27):3389-3402 (1997).;;Anderson et al., “Antileukemic Activity of Derivatives of I ,2-Dimethyl-3,4-bis(hydroxymethyl)-5-phenylpyrrole Bis(N-methylcarbamate)” J. Med. Chem.: vol. 22(8), 977-980 (1979).;;Annex et al., “Growth Factor-Induced Therapeutic Angiogenesis in the Heart: Protein Therapy,” Cardiovascular Research, 65(3):649-655 (2005).;;Ardelt et al., “Estradiol Regulates Angiopoietin-1 mRNA Expression Through Estrogen Receptor-a in a Rodent Experimental Stroke Model,” Stroke, 36:337-341 (2005).;;Auerbach et al., “Angiogenesis Assays: A Critical Overview,” Clinical Chemistry, 49:32-40 (2003).;;Barany et al., “Solid-phase Peptide Synthesis: A Silver Anniversary Report,” Int. J. Peptide Protein Res., 30( 6):705-739 (1987).;;Bartlett et al., “Molecular Recognition in Chemical and Biological Problems,” Special Pub., Royal Chem. Soc., 78, 182-196 Caveat: A Program to Facilitate the Structure-derived Design of Biologically Active Molecules (Apr. 1989).;;Bohm, “The Computer Program LUDI: A New Method for the Novo Design ofEnzyme Inhibitors,” J. Computer-Aided Molecular Design, 6:61-78 (1992).;;Branden et al., “Introduction to Protein Structure Second Edition,” Garland Publishing, Inc., New York, DD:374-375 (1999).;;Burger, “Isosterism and biososterism in drug design”, Progress in Drug Research, Birkhauser Verlag (1991).;;Bussolino, “Molecular Mechanisms of Blood Vessel Formation,” Trends Biochem. Sci., 22(7):251-256 (1997).;;Catrina et al., “Hyperglycemia Regulates Hypoxia-Inducible Factor-Ia Protein Stability and Function,” Diabetes 53:3226-3232 (2004).;;Cheeseright, “The Identifiction of Bioisosteres as Drug Development Candidates”, Innovations in Pharmaceutical Technology, issue 28 (2009).;;Cunliffe et al., “Novel Inhibitors of Prolyl4-Hydroxylase. 3. Inhibition by the Substrate Analogue N-Oxaloglycine and Its Derivatives,” J. Med. Chem. 35:2652-2658 (1992).;;Elson et al., “Induction ofHypervascularity Without Leakage or Inflammation in Transgenic Mice Overexpressing Hypoxia-Indicible Factor-Ia,” Genes & Dev., 15:2520-2532 (2001).;;European Patent Office, Interlocutory Decision in Opposition Proceedings, dated May 3, 2013, 76 pages.;;European Patent Office, Minutes of the Oral Proceedings Before the Opposition Division, dated May 3, 2013, 6 pages.;;Flower, “Modelling G-protein-coupled receptors for drug design,” Biochimica et Biophysica Acta, 1422:207-234 (1999).;;Folkman et al., “Tumor Angiogenesis,” The Molecular Basis of Cancer, Mendelsohn et al., eds., W. B. Saunders, Chapter 10, DD. 206-232 (1995).;;Franklin et al., “Approaches to the Design of Anti-Fibrotic Drugs,” Biochem. Soc. Trans., 19(4):812-5 (Nov. 1991).;;Gaunt, 1998, “Rational Design of Benzyl-Type Protecting Groups Allows Sequential Deprotection of Hydroxyl Groups by Catalytic Hydrogenolysis”, 63(13): 4172-4173.;;Goodford, “A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules,” J. Med. Chem., 28(7):849-857 (1985).;;Goodsell et al., “Automated Docking of Substrates to Proteins by Simulated Annealing,” Proteins: Structure, Function, and Genetics, 8:195-202 (1990).;;Hardcastle et al., “Discovery of Potent Chromen-4-one Inhibitors of the DNA-Dependent Protein Kinase (DNA-PK) Using a Small-Molecule Library Approach”, J. of Medicinal Chem., 48(24): 7829-7846 (2005).;;Hoesksema et al., “Structure of Rubradirin”, J. of American Chem. Society, 104(19): 5173-5181 (1982).;;International Search Report dated May 8, 2008 for PCT/US2007/014832.;;International Union of Pure and Applied Chemistry; Glossary of Class Names of Organic Compounds and Reactive Intermediates Based on Structure; Pure & D Appl. Chem., vol. 67, Nos. 8/9, pp. 1307-1375, (1995).;;Ivan et al., “Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor,” Proceedings of the National Academy of Science; 99(21) 13459-13464 (2002).;;Ivan et al., “HIFa Targeted for VHL-Mediated Destruction by Praline Hydroxylation: Implications for 02 Sensing,” Science 292, 464-468 (2001).;;Jaakkola et al., “Targeting of HIF-a to the von Rippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation,” Science 292, 468-472 (2001).;;Jones et al., “Molecular Recognition ofReceptor Sites Using a Genetic Algorithm with a Description of Desolvation,” J. Mol. Biol., 245:43-53 (1995).;;Kaelin, “Praline Hydroxylation and Gene Expression,” Annu. Rev. Biochem., 74:115-125 (2005).;;Kawashima et al., “Suppressive effect of quinolinic acid and hippuric acid on bone marrow erythroid growth and lymphocyte blast formation in uremia,” Advances in Experimental Medicine and Biology, vol. 223, p. 69-72 (1987).;;Krantz, “Erythropoietin,” Blood, 77:419-434 (1991).;;Kuntz et al., “A Geometric Approach to Macromolecule-Ligand Interactions,” J. Mol. Biol., 161:269-288 (1982).;;Langsetmo, “Inhibition of HIF-Prolyl Hydroxylases with FG-4539 Is Neuroprotective in a Mouse Model of Permanent Focal Ischemia,” International Stroke Conference, Kissimmee, Florida, Presentation No. 427 (2006).;;Lee et al., “Structure of Human FIH-1 Reveals a Unique Active Site Pocket and Interaction Sites for HIF-1 and von Hinnel Lindau,” JBC, 278:7558-7563 (2003).;;Li et al., “PR39, A Peptide Regulator of Angiogenesis,” Nat Med., 6(1):49-55 (2000).;;Lima and Barreiro, “Bioisosterism: A Useful Strategy for Molecular Modification and Drug Design”, Current Medicinal Chemistry, 12:23-49 (2005).;;Mancini et al., “Effect of Erythropoietin on Exercise Capacity in Patients with Moderate to Severe Chronic Heart Failure,” Circulation, 107:294-299 (2003).;;McDonough et al., “Cellular Oxygen Sensing: Crystal Structure of Hypoxia-Inducible Factor Prolyl Hydroxylase (PHD2),” PNAS, 103(26):9814-9819 (2006).;;Miranker et al., “Functionality Maps of Binding Sites: A Multiple Copy Simultaneous Search Method,” Proteins: Structure, Function and Genetics, 11:29-34 (1991).;;Nguyen et al., “Cellular Interactions in Vascular Growth and Differentiation,” Int. Review of Cytology, 204:1-48 (2001).;;Nishibata et al., “Automatic Creation of Drug Candidate Structures Based on Receptor Structure. Starting Point for Artificial Lead Generation,” Tetrahedron, 47( 43):8985-8990 (1991).;;O'Reilly et al., “Angiostatin: A Novel Angiogenesis Inhibitor that Mediates the Suppression of Metastases by a Lewis Lung Carcinoma,” Cell, 79:315-328 (1994).;;O'Reilly et al., “Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth,” Cell, 88:277-285 (1997).;;Peyssonnaux et al., “HIF—Ia Expression Regulates the Bactericidal Capacity of Phagocytes,” J. Clinical Invest., 115(7):1806-1815 (2005).;;Piyamongkol et al., “Amido-3-hydroxypyridin-4-ones as Iron (III) Ligands”, Chemistry A European Journal, vol. 16: 6374-6381 (2010).;;Qian et al., “A Randomized, Double-Blind, Placebo Controlled Trial ofFG-4592 for Correction of Anemia in Subjects with Chronic Kidney Disease in China,” Oral Abstract FR-ORO11, J. Am. Soc. Nephrol. 24:38A (2013).;;Rahtu-Korpela, “HIF Prolyl 4-Hydroxylase-2 Inhibition Improves Glucose and Lipid Metabolism and Protects Against Obesity and Metabolic Dysfunction,” Diabetes 63:3324-3333 (2014).;;Schelhass and Waldmann, “Protecting Group Strategies in Organic Synthesis”, Chem. Int Ed. Engl., 36:2056-2083 (1996).;;Schoneberg et al., “Structural Basis of G Protein-Coupled Receptor Function,” Molecular and Cellular Endocrinology, 151:181-193 (1999).;;Search Report dated Apr. 28, 2011 for European Pat. App. No. 11000872.9.;;Semenza et al., “Transcriptional Regulation of Genes Encoding Glycolytic Enzymes by Hypoxia-Inducible Factor I ,” J. Biol. Chem., 269:23757-23763 (1994).;;Semenza, “Regulation of Erythropoietin Porduction: New Insights into Molecular Mechanisms of Oxygen Homeostasis,” Hematol. Oncol. Clin. North Am., 8:863-884 (1994).;;Semenza, “Signal Transduction to Hypoxia-inducible Factor I ,” Biochem. Pharmacol, 64:993-998 (2002).;;Sexton, “Recent advances in our understanding of peptide hormone receptors and RAMPS,” Current Opinion in Drug Discovery and Development, 2(5):440-448 (1999).;;Sheehan, “3-Hydroxypicolinic Acid and Some of its Derivatives,” J. Organic Chemistry 31(3):636-638 (1996).;;Teicher et al., “Potentiation of Cytotoxic Cancer Therapies by TNP-470 Alone and with Other Anti-Angiogenic Agents,” Int. J. Cancer, 57:920-925 (1994).;;Thornber, “Isosterism and Molecular Modification in Drug Design”, Progress Drug Res., vol. 37: 563-580 (1979).;;Tzschucke et al., “Fluorous-Silica-Supported Perfluoro-Tagged Palladium Complexes Catalyze Suzuki Coupling in Water” Helvetica Chimica Acta; vol. 87 2882-2889 (2004).;;Vickerstaffe et al., “Fully Automated Polymer-Assisted Synthesis of 1,5-Biaryl Pyrazoles,”J. Comb. Chem., 6:332-33 (2004).;;Vincent et al., “Angiogenesis is Induced in a Rabbit Model of Hindlimb Ischemia by Naked DNA Encoding an HIF-I aNP16 Hybrid Transcription Factor,” Circulation, 102:2255-2261 (2000).;;Warnecke et al., “Activation of the Hypoxia-Inducible Factor Pathway and Stimulation of Angiogenesis by Application of Prolyl Hydroxylase Inhibitors,” FASEB Journal, 17: 1186-1188 (2003).;;Warshakoon et al., “Design and synthesis of substituted pyridine derivatives as HIF-1alpha prolyl hydroxylase inhibitors,” Bioorganic & Medicinal Chemistry Letters, 16:5616-5620, (2006).;;Wax et al., “SM-20 is a Novel20-kd Protein Whose Expression in the Arterial Wall is Restricted to Smooth Muscle,” Lab. Invest., 74(4):797-808 (1996).;;Weidner et al., “Tumor Angiogenesis and Metastasis—Correlation in Invasive Breast Carcinoma,” New Eng. J. Med., 324(1):1-8 (1991).;;Wright et al., “Activation of the Prolyl Hydroxylase Oxygen-Sensor Results in Induction of GLUTI, Heme Oxygenase-1, and Nitric-Oxide Synthase Proteins and Confers Protection from Metabolic Inhibition to Cardiomyocytes,” J. Bio. Chem., 278(22):20235-20239 (2003).;;Sutter, “Hypoxia-inducible factor 1 alpha protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations”, PNAS vol. 97, No. 9, pp. 4748-4753 (2000).",ACTIVE
635,US,A1,US 2013/0245076 A1,154-527-301-424-591,2013-09-19,2013,US 201313859574 A,2013-04-09,US 201313859574 A;;US 201213681876 A;;US 86007310 A;;US 82193607 A;;US 81652206 P,2006-06-26,PROLYL HYDROXYLASE INHIBITORS AND METHOD OF USE,"The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.",AKEBIA THERAPEUTICS INC;;AERPIO THERAPEUTICS INC,KAWAMOTO RICHARD MASARU;;WU SHENGDE;;EVDOKIMOV ARTEM G;;GREIS KENNETH D;;BOYER ANGELIQUE SUN;;WARSHAKOON NAMAL C,THE PROCTER & GAMBLE COMPANY (2008-12-19);;AKEBIA THERAPEUTICS INC (2011-12-15);;WARNER CHILCOTT COMPANY LLC (2009-10-30),https://lens.org/154-527-301-424-591,Patent Application,yes,0,15,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07D213/81,514/350;;546/298,0,0,,,,ACTIVE
636,US,A1,US 2019/0192494 A1,044-505-949-214-022,2019-06-27,2019,US 201816119146 A,2018-08-31,US 201816119146 A;;US 201715420617 A;;US 201514854080 A;;US 201414568200 A;;US 201314062011 A;;US 201213681876 A;;US 86007310 A;;US 82193607 A;;US 81652206 P,2006-06-26,PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE,"The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.",AKEBIA THERAPEUTICS INC,KAWAMOTO RICHARD MASARU;;WU SHENGDE;;EVDOKIMOV ARTEM G;;GREIS KENNETH D;;BOYER ANGELIQUE SUN;;WARSHAKOON NAMAL C,THE PROCTER & GAMBLE COMPANY (2008-12-19);;AKEBIA THERAPEUTICS INC (2011-12-15);;WARNER CHILCOTT COMPANY LLC (2009-10-30),https://lens.org/044-505-949-214-022,Patent Application,yes,0,6,83,83,1,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,A61K31/4418;;A61K31/4433;;C07C235/60;;C07C237/42;;C07C255/57;;C07D213/65;;C07D213/81;;C07D295/192;;C07D401/04;;C07D401/10;;C07D405/04;;C07D405/10;;C07D417/04,,0,0,,,,ACTIVE
637,US,A1,US 2010/0331303 A1,083-046-204-797-010,2010-12-30,2010,US 86007310 A,2010-08-20,US 86007310 A;;US 82193607 A;;US 81652206 P,2006-06-26,PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE,"The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.",KAWAMOTO RICHARD MASARU;;WU SHENGDE;;WARSHAKOON NAMAL C;;EVDOKIMOV ARTEM G;;GREIS KENNETH D;;BOYER ANGELIQUE SUN,KAWAMOTO RICHARD MASARU;;WU SHENGDE;;WARSHAKOON NAMAL C;;EVDOKIMOV ARTEM G;;GREIS KENNETH D;;BOYER ANGELIQUE SUN,THE PROCTER & GAMBLE COMPANY (2008-12-19);;AKEBIA THERAPEUTICS INC (2011-12-15);;WARNER CHILCOTT COMPANY LLC (2009-10-30),https://lens.org/083-046-204-797-010,Patent Application,yes,26,22,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,A61K31/4418;;A61K31/4427;;A61K31/4433;;A61K31/4439;;A61K31/444;;A61K31/4725;;A61K31/506;;A61P7/06;;A61P17/02;;C07D213/81;;C07D401/04;;C07D401/10;;C07D405/10,514/210.18;;546/291;;546/279.1;;546/268.4;;546/257;;544/333;;546/144;;546/270.4;;546/282.4;;514/346;;514/343;;514/340;;514/334;;514/256;;514/307;;514/342;;514/338,0,0,,,,ACTIVE
638,US,B2,US 8940773 B2,082-074-500-140-680,2015-01-27,2015,US 201314062011 A,2013-10-24,US 201314062011 A;;US 201213681876 A;;US 86007310 A;;US 82193607 A;;US 81652206 P,2006-06-26,Prolyl hydroxylase inhibitors and methods of use,"The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.",AKEBIA THERAPEUTICS INC,KAWAMOTO RICHARD MASARU;;WU SHENGDE;;EVDOKIMOV ARTEM G;;GREIS KENNETH D;;BOYER ANGELIQUE SUN;;WARSHAKOON NAMAL C,THE PROCTER & GAMBLE COMPANY (2008-12-19);;AKEBIA THERAPEUTICS INC (2011-12-15);;WARNER CHILCOTT COMPANY LLC (2009-10-30),https://lens.org/082-074-500-140-680,Granted Patent,yes,83,22,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07D405/04;;A61K31/44;;C07C235/60;;C07C237/42;;C07C255/57;;C07D213/65;;C07D213/81;;C07D295/192;;C07D401/04;;C07D401/10;;C07D405/10;;C07D417/04,514/350;;514/338;;514/346,59,49,017-669-075-762-985;;028-862-168-091-90X;;010-824-042-186-283;;063-746-538-402-770;;093-087-601-151-305;;006-143-986-832-256;;064-865-149-673-057;;102-345-845-395-203;;015-199-257-732-502;;009-081-622-113-208;;052-512-054-021-225;;022-156-141-942-093;;081-136-747-247-898;;030-042-017-746-591;;131-046-096-401-339;;019-130-789-993-789;;022-950-342-458-554;;066-519-812-638-153;;083-737-080-066-103;;092-475-988-464-223;;135-654-547-079-284;;125-424-943-194-608;;077-106-322-076-470;;069-450-943-413-364;;025-178-564-355-938;;048-830-824-939-083;;102-949-159-342-256;;018-052-265-551-042;;064-406-626-054-484;;011-101-678-202-709;;129-297-815-048-32X;;023-017-724-234-140;;074-344-536-692-994;;091-474-773-070-883;;016-533-076-557-079;;034-760-425-242-511;;056-436-730-631-840;;149-920-492-418-396;;074-156-318-814-764;;064-242-953-339-024;;062-826-287-074-090;;103-335-591-460-884;;026-655-568-834-966;;065-169-875-352-44X;;045-408-622-411-245;;003-330-211-576-597;;096-459-000-284-800;;040-667-645-789-907;;017-183-541-402-013,10.1016/s0040-4020(03)01100-1;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;490542;;10.1021/jm00194a018;;15664391;;10.1016/j.cardiores.2004.09.004;;15637314;;10.1161/01.str.0000153795.38388.72;;10.1373/49.1.32;;12507958;;3326854;;10.1111/j.1399-3011.1987.tb03385.x;;1583540;;10.1007/bf00124387;;10.1016/s0968-0004(97)01074-8;;9255066;;10.1021/jm00092a016;;1321909;;pmc312791;;10.1101/gad.914801;;11581158;;10.1016/s0304-4157(99)00006-4;;10548717;;1665444;;10.1042/bst0190812;;10.1021/jm00145a002;;3892003;;10.1002/prot.340080302;;2281083;;10.1351/pac199567081307;;10.1126/science.1059817;;11292862;;pmc129695;;12351678;;10.1073/pnas.192342099;;10.1126/science.1059796;;11292861;;011292861;;7823319;;10.1016/s0022-2836(95)80037-9;;15952883;;10.1146/annurev.biochem.74.082803.133142;;10.1007/978-1-4684-5445-1_9;;2965848;;10.1182/blood.v77.3.419.bloodjournal773419;;10.1182/blood.v77.3.419.419;;1991159;;7154081;;10.1016/0022-2836(82)90153-x;;12482756;;10.1074/jbc.m210385200;;10613823;;10.1038/71527;;10.1161/01.cir.0000044914.42696.6a;;12538431;;pmc1502536;;16782814;;10.1073/pnas.0601283103;;10.2210/pdb2g1m/pdb;;10.1002/prot.340110104;;1961699;;10.1016/s0074-7696(01)04002-5;;11243594;;10.1016/s0040-4020(01)86503-0;;7525077;;10.1016/0092-8674(94)90200-3;;10.1016/s0092-8674(00)81848-6;;9008168;;10.1172/jci23865;;16007254;;pmc1159132;;10.1016/s0303-7207(99)00017-9;;10411333;;10.1016/s0021-9258(17)31580-6;;8089148;;7852211;;10.1016/s0889-8588(18)30134-5;;10.1016/s0006-2952(02)01168-1;;12213597;;19649971;;10.1021/jo01340a533;;5902481;;7515861;;10.1002/ijc.2910570624;;10.1002/hlca.200490260;;15132592;;10.1021/cc049977g;;11056102;;10.1161/01.cir.102.18.2255;;10.1096/fj.02-1062fje;;12709400;;16908149;;10.1016/j.bmcl.2006.08.026;;8606489;;10.1056/nejm199101033240101;;1701519;;12649278;;10.1074/jbc.m301391200,"Qian; Oral abstract FR-OR011 in J Am Soc Nephrol, 2013, 24, 38A.;;Alesso et al., ""Improving resins for solid phase synthesis: incorporation of 1-[2-(2-methoxyethoxy) ethoxy]4-vinyl-benzene"" Tetrahedron: 59,7163-7169 (2003).;;Altschul et al., ""Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs,"" Nucleic Acids Res., 25(27):3389-3402 (1997).;;Anderson et al., ""Antileukemic Activity of Derivatives of 1,2-Dimethy1-3,4-bis(hydroxymethyl)-5-phenylpyrrole Bis(N-methylcarbamate)"" J. Med. Chem.: vol. 22(8), 977-980 (1979).;;Annex et al., ""Growth Factor-Induced Therapeutic Angiogenesis in the Heart: Protein Therapy,"" Cardiovascular Research, 65(3):649-655 (2005).;;Ardelt et al., ""Estradiol Regulates Angiopoietin-1 mRNA Expression Through Estrogen Receptor-alpha in a Rodent Experimental Stroke Model,"" Stroke, 36:337-341 (2005).;;Auerbach et al., ""Angiogenesis Assays: A Critical Overview,"" Clinical Chemistry, 49:32-40 (2003).;;Barany et al., ""Solid-phase Peptide Synthesis: A Silver Anniversary Report,"" Int. J. Peptide Protein Res., 30( 6):705-739 (1987).;;Bartlett et al., ""Molecular Recognition in Chemical and Biological Problems,"" Special Pub., Royal Chem. Soc., 78, 182-196 Caveat: A Program to Facilitate the Structure-derived Design of Biologically Active Molecules (Apr. 1989).;;Böhm, ""The Computer Program LUDI: A New Method for the Novo Design of Enzyme Inhibitors,"" J. Computer-Aided Molecular Design, 6:61-78 (1992).;;Branden et al., ""Introduction to Protein Structure Second Edition,"" Garland Publishing, Inc., New York, 1999, pp. 374-375.;;Bussolino, ""Molecular Mechanisms of Blood Vessel Formation,"" Trends Biochem. Sci., 22(7):251-256 (1997).;;Cunliffe et al., ""Novel Inhibitors of Prolyl4-Hydroxylase 3. Inhibition by the Substrate Analogue N-Oxaloglycine and Its Derivatives,"" J. Med. Chem. 35:2652-2658 (1992).;;Elson et al., ""Induction of Hypervascularity Without Leakage or Inflammation in Transgenic Mice Overexpressing Hypoxia-Indicible Factor-1alpha,"" Genes & Dev., 15:2520-2532 (2001).;;European Patent Application No. 11 000 872.9; European Search Report, Apr. 28, 2011.;;European Patent Office, Interlocutory Decision in Opposition Proccedings, mailed May 3, 2013, 76 pages.;;European Patent Office, Minutes of the Oral Proceedings Before the Opposition Division, mailed May 3, 2013, 6 pages.;;Flower, ""Modelling G-protein-coupled receptors for drug design,"" Biochimica et Biophysica Acta, 1422:207-234 (1999).;;Folkman et al., ""Tumor Angiogenesis,"" The Molecular Basis of Cancer, Mendelsohn et al., eds., W. B. Saunders, Chapter 10, pp. 206-232 (1995).;;Franklin et al., ""Approaches to the Design of Anti-Fibrotic Drugs,"" Biochem. Soc. Trans., 19(4):812-5 (Nov. 1991).;;Goodford, ""A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules,"" J. Med. Chem. 28(7):849-857 (1985).;;Goodsell et al., ""Automated Docking of Substrates to Proteins by Simulated Annealing,"" Proteins: Structure, Function, and Genetics, 8:195-202 (1990).;;International Union of Pure and Applied Chemistry; Glossary of Class Names of Organic Compounds and Reactive Intermediates Based on Structure; Pure & D Appl. Chern., vol. 67, Nos. 8/9, pp. 1307-1375, (1995).;;Ivan et al., ""HIFalpha Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing,"" Science 292, 464-468 (2001).;;Ivan et al., ""Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor,"" Proceedings of the National Academy of Science; 99(21) 13459-13464 (2002).;;Jaakkola et al., ""Targeting of HIF-alpha to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation,"" Science 292, 468-472 (2001).;;Jones et al., ""Molecular Recognition of Receptor Sites Using a Genetic Algorithm with a Description of Desolvation,"" J. Mol. Biol., 245:43-53 (1995).;;Kaelin, ""Proline Hydroxylation and Gene Expression,"" Annu. Rev. Biochem., 74:115-125 (2005).;;Kawashima et al., ""Suppressive effect of quinolinic acid and hippuric acid on bone marrow erythroid growth and lymphocyte blast formation in uremia"" Advances in Experimental Medicine and Biology, (1987), vol. 223, p. 69-72.;;Krantz, ""Erythropoietin,"" Blood, 77:419-434 (1991).;;Kuntz et al., ""A Geometric Approach to Macromolecule-Ligand Interactions,"" J. Mol. Biol., 161:269-288 (1982).;;Lee et al., ""Structure of Human FIH-1 Reveals a Unique Active Site Pocket and Interaction Sites for HIF-1 and von Hippel Lindau,"" JBC, 278:7558-7563 (2003).;;Li et al., ""PR39, A Peptide Regulator of Angiogenesis,"" Nat Med., 6(1):49-55 (2000).;;Mancini et al., ""Effect of Erythropoietin on Exercis Capacity in Patients with Moderate to Severe Chronic Heart Failure,"" Circulation, 107:294-299 (2003).;;McDonough et al., ""Cellular Oxygen Sensing: Crystal Structure of Hypoxia-Inducible Factor Prolyl Hydroxylase (PHD2),"" PNAS, 103(26):9814-9819 (2006).;;Miranker et al., ""Functionally Maps of Binding Sites: A Multiple Copy Simultaneous Search Method,"" Proteins: Structure, Function and Genetics, 11:29-34 (1991).;;Nguyen et al., ""Cellular Interactions in Vascular Growth and Differentiation,"" Int. Review of Cytology, 204:1-48 (2001).;;Nishibata et al., ""Automatic Creation of Drug Candidate Structures Based on Receptor Structure. Starting Point for Artificial Lead Generation,"" Tetrahedron, 47(43):8985-8990 (1991).;;O'Reilly et al., ""Angiostatin: A Novel Angiogenesis Inhibitor that Mediates the Suppresion of Metastases by a Lewis Lung Carcinoma,"" Cell, 79:315-328 (1994).;;O'Reilly et al., ""Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth,"" Cell, 88:277-285 (1997).;;Peyssonnaux et al., ""HIF-1alpha Expression Regulates the Bactericidal Capacity of Phagocytes,"" J. Clinical Invest., 115(7):1806-1815 (2005).;;Schoneberg et al., ""Structural Basis of G Protein-Coupled Receptor Function,"" Molecular and Cellular Endocrinology, 151:181-193 (1999).;;Semenza et al., ""Transcriptional Regulation of Genes Encoding Glycolytic Enzymes by Hypoxia-Inducible Factor 1,"" J. Biol. Chem., 269:23757-23763 (1994).;;Semenza, ""Regulation of Erythropoietin Porduction: New Insights into Molecular Mechanisms of Oxygen Homeostasis,"" Hematol. Oncol. Clin. North Am., 8:863-884 (1994).;;Semenza, ""Signal Transduction to Hypoxia-inducible Factor 1,"" Biochem. Pharmacol, 64:993-998 (2002).;;Sexton, ""Recent advances in our understanding of peptide hormone receptors and RAMPS,"" Current Opinon in Drug Discovery and Development, 2(5):440-448 (1999).;;Sheehan, ""3-Hydroxypicolinic Acid and Some of its Derivatives,"" J. Organic Chemistry 31(3):636-638 (1996).;;Teicher et al., ""Potentiation of Cytotoxic Cancer Therapies by TNP-470 Alone and with Other Anti-Angiogenic Agents,"" Int. J. Cancer, 57:920-925 (1994).;;Tzschucke et al., ""Fluorous-Silica-Supported Perfluoro-Tagged Palladium Complexes Catalyze Suzuki Coupling in Water"" Helvetica Chimica Acta; vol. 87 2882-2889 (2004).;;Vickerstaffe et al., ""Fully Automated Polymer-Assisted Synthesis of 1,5-Biaryl Pyrazoles,"" J. Comb. Chem., 2004,6,332-33.;;Vincent et al., ""Angiogenesis is Induced in a Rabbit Model of Hindlimb Ischemia by Naked DNA Encoding an HIF-1a/VP16 Hydrid Transcription Factor,"" Circulation, 102:2255-2261 (2000).;;Warnecke et al., ""Activation of the Hypoxia-Inducible Factor Pathway and Stimulation of Angiogenesis by Application of Prolyl Hydroxylase Inhibitors,"" FASEB Journal, 17: 1186-1188 (2003).;;Warshakoon et al., ""Design and synthesis of substituted pyridine derivatives as HIF-1alpha prolyl hydroxylase inhibitors,"" Bioorganic & Medicinal Chemistry Letters, 16 (2006) 5616-5620.;;Wax et al., ""SM-20 is a Novel20-kd Protein Whose Expression in the Arterial Wall is Restricted to Smooth Muscle,"" Lab. Invest., 74(4):797-808 (1996).;;Weidner et al., ""Tumor Angiogenesis and Metastasis-Correlation in Invasive Breast Carcinoma,"" New Eng. J. Med., 324(1):1-8 (1991).;;Wright et al., ""Activation of the Prolyl Hydroxylase Oxygen-Sensor Results in Induction of GLUTI, Heme Oxygenase-1, and Nitric-Oxide Synthase Proteins and Confers Protection from Metabolic Inhibition to Cardiomyocytes,"" J. Bio. Chem., 278(22):20235-20239 (2003).;;Office action mailed Oct. 7, 2013 in connection with U.S. Appl. No. 13/489,400.;;Office action mailed Jan. 30, 2014 in connection with U.S. Appl. No. 13/489,387.;;Office action mailed Dec. 12, 2013 in connection with U.S. Appl. No. 14/071,088.",ACTIVE
639,CA,C,CA 2659682 C,175-067-140-378-922,2010-12-21,2010,CA 2659682 A,2007-06-26,US 81652206 P;;US 2007/0014832 W,2006-06-26,PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE,"The present disclosure relates to HIF-1.alpha. prolyl hydroxylase inhibitors of Formula I (see formula I) wherein R, R1, R2, R3, R a and I, are as defined in the description, compositions which comprise the HIF-1.alpha. prolyl hydroxylase inhibitors of Formula I and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia using the compounds of Formula I.",PROCTER & GAMBLE,KAWAMOTO RICHARD MASARU;;GREIS KENNETH DONALD;;EDOKIMOV ARTEM G;;BOYER ANGELIQUE SUN;;WU SHENGDE;;WARSHAKOON NAMAL CHITHRANGA,,https://lens.org/175-067-140-378-922,Granted Patent,no,0,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07D213/81;;A61K31/4418;;A61K31/4427;;A61K31/4725;;A61K31/506;;C07D401/04;;C07D401/10;;C07D405/04;;C07D417/04,,0,0,,,,ACTIVE
640,US,B2,US 8598210 B2,071-468-431-458-638,2013-12-03,2013,US 201213681876 A,2012-11-20,US 201213681876 A;;US 86007310 A;;US 82193607 A;;US 81652206 P,2006-06-26,Prolyl hydroxylase inhibitors and methods of use,"The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.",AKEBIA THERAPEUTICS INC;;AKEBIA THERAPEUTICS INC,KAWAMOTO RICHARD MASARU;;WU SHENGDE;;WARSHAKOON NAMAL C;;EVDOKIMOV ARTEM G;;GREIS KENNETH D;;BOYER ANGELIQUE SUN,THE PROCTER & GAMBLE COMPANY (2008-12-19);;AKEBIA THERAPEUTICS INC (2011-12-15);;WARNER CHILCOTT COMPANY LLC (2009-10-30),https://lens.org/071-468-431-458-638,Granted Patent,yes,84,26,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,A01N43/40;;A61K31/44;;C07D213/62;;C07D213/78;;C07D405/00,514/338;;514/350;;546/298;;546/282.4,100,20,095-605-097-751-343;;028-862-168-091-90X;;063-746-538-402-770;;093-087-601-151-305;;064-865-149-673-057;;102-345-845-395-203;;015-199-257-732-502;;009-081-622-113-208;;052-512-054-021-225;;069-450-943-413-364;;129-297-815-048-32X;;091-474-773-070-883;;056-436-730-631-840;;045-408-622-411-245;;096-459-000-284-800;;040-667-645-789-907;;019-130-789-993-789;;003-330-211-576-597;;017-669-075-762-985;;010-824-042-186-283,pmc1440619;;10.1136/bmj.332.7546.900;;16613966;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;15664391;;10.1016/j.cardiores.2004.09.004;;15637314;;10.1161/01.str.0000153795.38388.72;;3326854;;10.1111/j.1399-3011.1987.tb03385.x;;1583540;;10.1007/bf00124387;;10.1016/s0968-0004(97)01074-8;;9255066;;10.1021/jm00092a016;;1321909;;pmc312791;;10.1101/gad.914801;;11581158;;7154081;;10.1016/0022-2836(82)90153-x;;10.1016/s0040-4020(01)86503-0;;10.1172/jci23865;;16007254;;pmc1159132;;7852211;;10.1016/s0889-8588(18)30134-5;;10.1096/fj.02-1062fje;;12709400;;8606489;;10.1056/nejm199101033240101;;1701519;;10.1351/pac199567081307;;16908149;;10.1016/j.bmcl.2006.08.026;;10.1016/s0040-4020(03)01100-1;;490542;;10.1021/jm00194a018,"Stuart Enoch, Joseph E Grey, Keith G Harding; BMJ 2006;332:900-3.;;Altschul et al., ""Gapped BLAST and PSI-BLAST:A New Generation of Protein Database Search Programs,"" Nucleic Acids Res., 25(27):3389-3402 (1997).;;Annex et al., ""Growth Factor-Induced Therapeutic Angiogenesis in the Heart: Protein Therapy,"" Cardiovascular Research, 65(3):649-655 (2005).;;Ardelt et al., ""Estradiol Regulates Angiopoietin-1 mRNA Expression Through Estrogen Receptor-alpha in a Rodent Experimental Stroke Model,"" Stroke, 36:337-341 (2005).;;Barany et al., ""Solid-phase Peptide Synthesis: A Silver Anniversary Report,"" Int. J. Peptide Protein Res., 30 (6):705-739 (1987).;;Böhm, ""The Computer Program LUDI: A New Method for the Novo Design of Enzyme Inhibitors,"" J. Computer-Aided Molecular Design,6:61-78 (1992).;;Branden et al., ""Introduction to Protein Structure Second Edition,"" Garland Publising Inc., New York, 1999, pp. 374-375.;;Bussolino, ""Molecular Mechanisms of Blood Vessel Formation,"" Trends Biochem. Sci.,22(7):251-256 (1997).;;Cunliffe et al., ""Novel Inhibitors of Prolyl 4-Hydroxylase. 3. Inhibition by the Substrate Analogue N-Oxaloglycine and Its Derivatives,"" J. Med.Chem. 35:2652-2658 (1992).;;Elson et al., ""Induction of Hypervascularity Without Leakage or Inflammation in Transgenic Mice Overexpressing Hypoxia-Indicible Factor-1alpha,"" Genes & Dev.,15:2520-2532 (2001).;;Kuntz et al., ""A Geometric Approach to Macromolecule-Ligand Interactions,"" J. Mol. Biol., 161:269-288 (1982).;;Nishibata et al., ""Automatic Creation of Drug Candidate Structures Based on Receptor Structure. Starting Point for Artificial Lead Generation,"" Tetrahedron, 47(43):8985-8990 (1991).;;Peyssonnaux et al., ""HIF-1alpha Expression Regulates the Bactericidal Capacity of Phagocytes,"" J. Clinical Invest., 115(7):1806-1815, 2005.;;Semenza, ""Regulation of Erythropoietin Production: New Insights into Molecular Mechanisms of Oxygen Homeostasis,"" Hematol. Oncol. Clin. North Am., 8:863-884 (1994).;;Warnecke et al., ""Activation of the Hypoxia-Inducible Factor Pathway and Stimulation of Angiogenesis by Application of Prolyl Hydroxylase Inhibitors,"" FASEB Journal, 17:1186-1188 (2003).;;Wax et al., ""SM-20 is a Novel 20-kd Protein Whose Expression in the Arterial Wall is Restricted to Smooth Muscle,"" Lab. Invest., 74(4):797-808 (1996).;;Weidner et al., ""Tumor Angiogenesis and Metastasis-Correlation in Invasive Breast Carcinoma,"" New Eng. J. Med., 324(1):1-8 (1991).;;Australian Patent Application No. 2007265460, Prolyl Hydroxylase Inhibitors and Methods of Use, National Stage Entry of PCT/US2007/014832, claiming priority to U.S. Appl. No. 60/816,522, filed Jun. 26, 2006, now AU 2007265460 B2.;;Australian Patent Application No. 2007265460; Preliminary Amendment, Apr. 28, 2010.;;Australian Patent Application No. 2007265460; First Examination Report, Jul. 19, 2010.;;Australian Patent Application No. 2007265460; Response to First Examination Report, Nov. 18, 2010.;;Australian Patent Application No. 2007265460; Notice of Acceptance, Mar. 17, 2011.;;Brazilian Patent Application No. PI 071.3350-2, Prolyl Hydroxylase Inhibitors and Methods of Use, National Stage Entry of PCT/US2007/014832, claiming priority to U.S. Appl. No. 60/816,522, filed Jun. 26, 2006.;;Canadian Patent Application No. 2,659,682, Prolyl Hydroxylase Inhibitors and Methods of Use, National Stage Entry of PCT/US2007/014832, claiming priority to U.S. Appl. No. 60/816,522, filed Jun. 26, 2006; now CA 2,659,682.;;Canadian Patent Application No. 2,659,682; Preliminary Amendment, Mar. 29, 2010.;;New Zealand Patent Application No. 574408; Response to Examination Report, Apr. 13, 2011.;;New Zealand Patent Application No. 574408; Office Action, Nov. 10, 2011.;;New Zealand Patent Application No. 574408; Response to Office Action, Jan. 20, 2012.;;New Zealand Patent Application No. 574408; Office Action, Feb. 15, 2012.;;New Zealand Patent Application No. 574408; Response to Office Action, Jul. 24, 2012.;;New Zealand Patent Application No. 601730, which is a Divisional Application of New Zealand Patent Application 574408; Prolyl Hydroxylase Inhibitors and Methods of Use, National Stage Entry of PCT/US2007/014832, claiming priority to U.S. Appl. No. 60/816,522, filed Jun. 26, 2006.;;New Zealand Patent Application No. 601731, which is a Divisional Application of New Zealand Patent Application 574408; Prolyl Hydroxylase Inhibitors and Methods of Use, National Stage Entry of PCT/US2007/014832, claiming priority to U.S. Appl. No. 60/816,522, filed Jun. 26, 2006.;;Philippine Patent Application No. 1-2009-500030, Prolyl Hydroxylase Inhibitors and Methods of Use, National Stage Entry of PCT/US2007/014832, claiming priority to U.S. Appl. No. 60/816,522, filed Jun. 26, 2006.;;Philippine Patent Application No. 1-2009-500030; Response to Office Action, May 20, 2010.;;Philippine Patent Application No. 1-2009-500030; Office Action, Oct. 27, 2011.;;Philippine Patent Application No. 1-2009-500030; Notice of allowance, Sep. 17, 2012.;;Russian Patent Application No. 2009102220, Prolyl Hydroxylase Inhibitors and Methods of Use, National Stage Entry of PCT/US2007/014832, claiming priority to U.S. Appl. No. 60/816,522, filed Jun. 26, 2006, now RU 2429226.;;Russian Patent Application No. 2009102220; Office Action, Dec. 29, 2010.;;Russian Patent Application No. 2009102220; Response to Office Action, Jan. 5, 2011.;;Russian Patent Application No. 2009102220; Decision to Grant, May 10, 2011.;;Singapore Patent Application No. 200809595-2, Prolyl Hydroxylase Inhibitors and Methods of Use, National Stage Entry of PCT/US2007/014832, claiming priority to U.S. Appl. No. 60/816,522, filed Jun. 26, 2006, now SG 149144.;;Singapore Patent Application No. 200809595-2; Office Action, Feb. 5, 2010.;;Singapore Patent Application No. 200809595-2; Response to Office Action, Mar. 4, 2010.;;Singapore Patent Application No. 200809595-2; Office Action, Dec. 23, 2010.;;Singapore Patent Application No. 200809595-2; Response to Office Action, Feb. 15, 2011.;;Singapore Patent Application No. 200809595-2; Notice of Allowance, Jul. 15, 2011.;;South African Patent Application No. 2009/00560, Prolyl Hydroxylase Inhibitors and Methods of Use, National Stage Entry of PCT/US2007/014832, claiming priority to U.S. Appl. No. 60/816,522, filed Jun. 26, 2006, now ZA 2009/00560.;;Canadian Patent Application No. 2,659,682; Office Action, May 18, 2010.;;Canadian Patent Application No. 2,659,682; Response Office Action, Jun. 11, 2010.;;Canadian Patent Application No. 2,659,682; Notice of Allowance, Aug. 30, 2010.;;Chinese Patent Application No. 200780030720.0, Prolyl Hydroxylase Inhibitors and Methods of Use, National Stage Entry of PCT/US2007/014832, claiming priority to U.S. Appl. No. 60/816,522, filed Jun. 26, 2006; now CN 200780030720.0.;;Chinese Patent Application No. 200780030720.0; Preliminary Amendments, May 10, 2010.;;Chinese Patent Application No. 200780030720.0; Office Action, Aug. 19, 2011.;;Chinese Patent Application No. 200780030720.0; Response to Office Action, Aug. 22, 2011.;;Chinese Patent Application No. 200780030720.0; Office Action, Dec. 31, 2011.;;Chinese Patent Application No. 200780030720.0; Response to Office Action, Mar. 15, 2012.;;Chinese Patent Application No. 200780030720.0; Response to Examiner's Interview, May 5, 2012.;;Chinese Patent Application No. 200780030720.0; Notice of Allowance Jul. 16, 2012.;;Colombian Patent Application No. 09006711, Prolyl Hydroxylase Inhibitors and Methods of Use, National Stage Entry of PCT/US2007/014832, claiming priority to U.S. Appl. No. 60/816,522, filed Jun. 26, 2006.;;Colombian Patent Application No. 09006711; Preliminary Amendment, Apr. 29, 2010.;;Colombian Patent Application No. 09006711; Office Action, Aug. 23, 2012.;;Colombian Patent Application No. 09006711; Response to Office Action, Sep. 18, 2012.;;European Patent Application No. 07 835 890.0, Prolyl Hydroxylase Inhibitors and Methods of Use, National Stage Entry of PCT/US2007/014832, claiming priority to U.S. Appl. No. 60/816,522, filed Jun. 26, 2006; now EP 2 044 005.;;European Patent Application No. 07 835 890.0; Office Action, Mar. 3, 2010.;;European Patent Application No. 07 835 890.0; Response to Office Action, Mar. 28, 2010.;;European Patent Application No. 07 835 890.0; Notice of Allowance, Jun. 24, 2010.;;European Patent Application No. 07 835 890.0; Opposition Filed, Jul. 20, 2011.;;European Patent Application No. 07 835 890.0; Document Cited in Opposition: International Union of Pure and Applied Chemistry; Glossary of Class Names of Organic Compounds and Reactive Intermediates Based on Structure; Pure & Appl. Chem., vol. 67, Nos. 8/9, pp. 1307-1375, (1995).;;European Patent Application No. 07 835 890.0; Document Cited in Opposition: Certified U.S. Appl. No. 60/816,522, Priority Document of European Patent Application No. 07 835 890.0, 2007.;;European Patent Application No. 07 835 890.0; Document Cited in Opposition: US 5,620,995, 1997.;;European Patent Application No. 07 835 890.0; Document Cited in Opposition: US 5,658,933, 1997.;;European Patent Application No. 07 835 890.0; Document Cited in Opposition: WO 2003/049686, cited hereinabove, 2003.;;European Patent Application No. 07 835 890.0; Document Cited in Opposition: WO 2003/053997, cited hereinabove, 2003.;;Warshakoon et al., ""Design and synthesis of substituted pyridine derivatives as HIF-1alpha prolyl hydroxylase inhibitors,"" Bioorganic & Medicinal Chemistry Letters, 16 (2006) 5616-5620.;;European Patent Application No. 07 835 890.0; Response to Opposition, Dec. 28, 2011.;;European Patent Application No. 11 000 872.9, Divisional Application of European Patent Application No. 07 835 890.0, Prolyl Hydroxylase Inhibitors and Methods of Use, National Stage Entry of PCT/US2007/014832, claiming priority to U.S. Appl. No. 60/816,522, filed Jun. 26, 2006.;;European Patent Application No. 11 000 872.9; European Search Report, Apr. 28, 2011.;;Hong Kong Patent Application No. 09108318.9, Prolyl Hydroxylase Inhibitors and Methods of Use, National Stage Entry of PCT/US2007/014832, claiming priority to U.S. Appl. No. 60/816,522, filed Jun. 26, 2006; now HK1129369.;;Indonesian Patent Application No. W-00200804211, Prolyl Hydroxylase Inhibitors and Methods of Use, National Stage Entry of PCT/US2007/014832, claiming priority to U.S. Appl. No. 60/816,522, filed Jun. 26, 2006; now W-00200804211.;;Israeli Patent Application No. 196127, Prolyl Hydroxylase Inhibitors and Methods of Use, National Stage Entry of PCT/US2007/014832, claiming priority to U.S. Appl. No. 60/816,522, filed Jun. 26, 2006.;;Israeli Patent Application No. 196127; Preliminary Amendments, Apr. 12, 2010.;;Israeli Patent Application No. 196127; Office Action Feb. 15, 2012.;;Israeli Patent Application No. 196127; Response to Office Action Feb. 20, 2012.;;Indian Patent Application No. 509/DELNP/2009, Prolyl Hydroxylase Inhibitors and Methods of Use, National Stage Entry of PCT/US2007/014832, claiming priority to U.S. Appl. No. 60/816,522, filed Jun. 26, 2006.;;Japanese Patent Application No. 2009-518232, Prolyl Hydroxylase Inhibitors and Methods of Use, National Stage Entry of PCT/US2007/014832, claiming priority to U.S. Appl. No. 60/816,522, filed Jun. 26, 2006; now JP 5113838.;;Japanese Patent Application No. 2009-518232; Office Action, Nov. 11, 2011.;;Japanese Patent Application No. 2009-518232; Response to Office Action, Feb. 10, 2012.;;Japanese Patent Application No. 2009-518232; Office Action, May 24, 2012.;;Japanese Patent Application No. 2009-518232; Response to Office Action, Jul. 25, 2012.;;Japanese Patent Application No. 2009-518232; Notice of Allowance, Oct. 4, 2012.;;Korean Patent Application No. 2009-7001697, Prolyl Hydroxylase Inhibitors and Methods of Use, National Stage Entry of PCT/US2007/014832, claiming priority to U.S. Appl. No. 60/816,522, filed Jun. 26, 2006; now KR 1130592.;;Korean Patent Application No. 2009-7001697; Office Action, May 4, 2011.;;Korean Patent Application No. 2009-7001697; Response to Office Action, Jun. 8, 2011.;;Korean Patent Application No. 2009-7001697; Decision to Grant, Dec. 28, 2011.;;Mexican Patent Application No. MX/A/2009/000286, Prolyl Hydroxylase Inhibitors and Methods of Use, National Stage Entry of PCT/US2007/014832, claiming priority to U.S. Appl. No. 60/816,522, filed Jun. 26, 2006.;;New Zealand Patent Application No. 574408, Prolyl Hydroxylase Inhibitors and Methods of Use, National Stage Entry of PCT/US2007/014832, claiming priority to U.S. Appl. No. 60/816,522, filed Jun. 26, 2006.;;New Zealand Patent Application No. 574408; Examination Report, Sep. 28, 2010.;;Alesso et al., ""Improving resins for solid phase synthesis: incorporation of 1-[2-(2-methoxyethoxy)ethoxy]4-vinyl-benzene"" Tetrahedron: 59,7163-7169 (2003).;;Altschul et al., ""Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs,"" Nucleic Acids Res., 25(27):3389-3402 (1997).;;Anderson et al., ""Antileukemic Activity of Derivatives of 1,2-Dimethy1-3,4-bis(hydroxymethyl)-5-phenylpyrrole Bis(N-methylcarbamate)"" J. Med. Chem.: vol. 22(8), 977-980 (1979).",ACTIVE
641,US,B2,US 8793381 B2,104-644-089-304-531,2014-07-29,2014,US 201213533164 A,2012-06-26,US 201213533164 A,2012-06-26,Workload adaptive cloud computing resource allocation,"A workload associated with a task is assessed with respect to each of a plurality of computing paradigms offered by a cloud computing environment. Adaptive learning is employed by maintaining a table of Q-values corresponding to the computing paradigms and the workload is distributed according to a ratio of Q-values. The Q-values may be adjusted responsive to a performance metric and/or a value, reward, and/or decay function. The workload is then assigned to available computing paradigms to be performed with improved utilization of resources.",BAUGHMAN AARON K;;BOYER LINDA M;;CODELLA CHRISTOPHER F;;DARDEN RICHARD L;;DUBYAK WILLIAM G;;GREENLAND ARNOLD;;IBM,BAUGHMAN AARON K;;BOYER LINDA M;;CODELLA CHRISTOPHER F;;DARDEN RICHARD L;;DUBYAK WILLIAM G;;GREENLAND ARNOLD,INTERNATIONAL BUSINESS MACHINES CORPORATION (2012-05-31),https://lens.org/104-644-089-304-531,Granted Patent,yes,35,12,2,2,0,G06F9/5083;;G06F9/5083,G06F15/173,709/226;;709/223;;709/224,3,1,081-617-777-941-757,10.1109/i-span.2008.9,"Myerson et al., ""Craft a cloud performance metrics policy"", www.ibm.com/developerworks/cloud/library/cl-cloudperformmetrics/.;;Zi-Jin et al, ""Two New Push-Pull Balanced Data Dissemination Algorithms for Any-Type Queries in Large-Scale Wireless Sensor Networks"", The International Symposium on Parallel Architectures, Algorithms, and Networks, 2008, IEEE.;;Manfredi, Victoria, ""Q-learning (QL)"", http://www.cra.org/Activities/craw-archive/dmp/awards/2001/manfredi.",INACTIVE
642,US,A1,US 2015/0119425 A1,095-352-491-684-81X,2015-04-30,2015,US 201414568200 A,2014-12-12,US 201414568200 A;;US 201314062011 A;;US 201213681876 A;;US 86007310 A;;US 82193607 A;;US 81652206 P,2006-06-26,PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE,"The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.",AKEBIA THERAPEUTICS INC,KAWAMOTO RICHARD MASARU;;WU SHENGDE;;EVDOKIMOV ARTEM G;;GREIS KENNETH D;;BOYER ANGELIQUE SUN;;WARSHAKOON NAMAL C,THE PROCTER & GAMBLE COMPANY (2008-12-19);;AKEBIA THERAPEUTICS INC (2011-12-15);;WARNER CHILCOTT COMPANY LLC (2009-10-30),https://lens.org/095-352-491-684-81X,Patent Application,yes,0,19,83,83,1,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07D213/81;;C07D405/04,514/338;;514/346;;546/291;;546/282.4,4,2,141-317-043-329-438;;019-005-723-569-798,16373931;;10.2337/diacare.29.s1.06.s4;;10.2337/db14-0472;;24789921,"""Standards of Medical Care in Diabetes-2006"" Diabetes Care, January 2006, 29, s4-s42.;;Qian; Oral abstract FR-OR011 in J Am Soc Nephrol, 2013, 24, 38A.;;Langsetmo; International Stroke Conference, February 2006, Kissimmee, Florida, Presentation number 427.;;Rahtu-Korpela; Diabetes, 2014, 63, 3324-3333.",DISCONTINUED
643,US,B2,US 8722895 B2,143-839-513-411-825,2014-05-13,2014,US 201313859574 A,2013-04-09,US 201313859574 A;;US 201213681876 A;;US 86007310 A;;US 82193607 A;;US 81652206 P,2006-06-26,Prolyl hydroxylase inhibitors and method of use,"The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.",AKEBIA THERAPEUTICS INC;;AKEBIA THERAPEUTICS INC,KAWAMOTO RICHARD M;;WU SHENGDE;;EVDOKIMOV ARTEM G;;GREIS KENNETH D;;BOYER ANGELIQUE SUN;;WARSHAKOON NAMAL C,THE PROCTER & GAMBLE COMPANY (2008-12-19);;AKEBIA THERAPEUTICS INC (2011-12-15);;WARNER CHILCOTT COMPANY LLC (2009-10-30),https://lens.org/143-839-513-411-825,Granted Patent,yes,81,22,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,A01N43/40;;A61K31/44;;C07D211/70;;C07D211/82;;C07D213/00;;C07D213/46;;C07D213/62;;C07D213/78;;C07D213/90,546/298;;514/350;;514/351;;514/354;;514/357;;546/314;;546/323;;546/329,100,26,019-130-789-993-789;;003-330-211-576-597;;028-862-168-091-90X;;063-746-538-402-770;;093-087-601-151-305;;006-143-986-832-256;;064-865-149-673-057;;102-345-845-395-203;;015-199-257-732-502;;009-081-622-113-208;;052-512-054-021-225;;022-156-141-942-093;;081-136-747-247-898;;030-042-017-746-591;;131-046-096-401-339;;135-654-547-079-284;;077-106-322-076-470;;069-450-943-413-364;;025-178-564-355-938;;048-830-824-939-083;;102-949-159-342-256;;018-052-265-551-042;;064-406-626-054-484;;011-101-678-202-709;;129-297-815-048-32X;;023-017-724-234-140,10.1351/pac199567081307;;16908149;;10.1016/j.bmcl.2006.08.026;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;15664391;;10.1016/j.cardiores.2004.09.004;;15637314;;10.1161/01.str.0000153795.38388.72;;10.1373/49.1.32;;12507958;;3326854;;10.1111/j.1399-3011.1987.tb03385.x;;1583540;;10.1007/bf00124387;;10.1016/s0968-0004(97)01074-8;;9255066;;10.1021/jm00092a016;;1321909;;pmc312791;;10.1101/gad.914801;;11581158;;10.1016/s0304-4157(99)00006-4;;10548717;;1665444;;10.1042/bst0190812;;10.1021/jm00145a002;;3892003;;10.1002/prot.340080302;;2281083;;15952883;;10.1146/annurev.biochem.74.082803.133142;;10.1182/blood.v77.3.419.bloodjournal773419;;10.1182/blood.v77.3.419.419;;1991159;;7154081;;10.1016/0022-2836(82)90153-x;;12482756;;10.1074/jbc.m210385200;;10613823;;10.1038/71527;;10.1161/01.cir.0000044914.42696.6a;;12538431;;pmc1502536;;16782814;;10.1073/pnas.0601283103;;10.2210/pdb2g1m/pdb;;10.1002/prot.340110104;;1961699;;10.1016/s0074-7696(01)04002-5;;11243594;;10.1016/s0040-4020(01)86503-0;;7525077;;10.1016/0092-8674(94)90200-3,"Silverman; The Organic Chemistry of Drug Design and Drug Action, 2nd Edition, 2004, Elsevier, Section 2.2, E.4, pp. 29-34.;;New Zealand Patent Application No. 574408; Response to Examination Report, Apr. 13, 2011.;;New Zealand Patent Application No. 574408; Office Action, Nov. 10, 2011.;;New Zealand Patent Application No. 574408; Response to Office Action, Jan. 20, 2012.;;New Zealand Patent Application No. 574408; Office Action, Feb. 15, 2012.;;New Zealand Patent Application No. 574408; Response to Office Action, Jul. 24, 2012.;;New Zealand Patent Application No. 601730, which is a Divisional Application of New Zealand Patent Application 574408; Prolyl Hydroxylase Inhibitors and Methods of Use, National Stage Entry of PCT/US2007/014832, claiming priority to U.S. Appl. No. 60/816,522, filed Jun. 26, 2006.;;New Zealand Patent Application No. 601731, which is a Divisional Application of New Zealand Patent Application 574408; Prolyl Hydroxylase Inhibitors and Methods of Use, National Stage Entry of PCT/US2007/014832, claiming priority to U.S. Appl. No. 60/816,522, filed Jun. 26, 2006.;;Philippine Patent Application No. 1-2009-500030, Prolyl Hydroxylase Inhibitors and Methods of Use, National Stage Entry of PCT/US2007/014832, claiming priority to U.S. Appl. No. 60/816,522, filed Jun. 26, 2006.;;Philippine Patent Application No. 1-2009-500030; Response to Office Action, May 20, 2010.;;Philippine Patent Application No. 1-2009-500030; Office Action, Oct. 27, 2011.;;Philippine Patent Application No. 1-2009-500030; Notice of allowance, Sep. 17, 2012.;;Russian Patent Application No. 2009102220, Prolyl Hydroxylase Inhibitors and Methods of Use, National Stage Entry of PCT/US2007/014832, claiming priority to U.S. Appl. No. 60/816,522, filed Jun. 26, 2006, now RU 2429226.;;Russian Patent Application No. 2009102220; Office Action, Dec. 29, 2010.;;Russian Patent Application No. 2009102220; Response to Office Action, Jan. 5, 2011.;;Russian Patent Application No. 2009102220; Decision to Grant, May 10, 2011.;;Singapore Patent Application No. 200809595-2, Prolyl Hydroxylase Inhibitors and Methods of Use, National Stage Entry of PCT/US2007/014832, claiming priority to U.S. Appl. No. 60/816,522, filed Jun. 26, 2006, now SG 149144.;;Singapore Patent Application No. 200809595-2; Office Action, Feb. 5, 2010.;;Singapore Patent Application No. 200809595-2; Response to Office Action, Mar. 4, 2010.;;Singapore Patent Application No. 200809595-2; Office Action, Dec. 23, 2010.;;Singapore Patent Application No. 200809595-2; Response to Office Action, Feb. 15, 2011.;;Singapore Patent Application No. 200809595-2; Notice of Allowance, Jul. 15, 2011.;;South African Patent Application No. 2009/00560, Prolyl Hydroxylase Inhibitors and Methods of Use, National Stage Entry of PCT/US2007/014832, claiming priority to U.S. Appl. No. 60/816,522, filed Jun. 26, 2006, now ZA 2009/00560.;;Canadian Patent Application No. 2,659,682; Office Action, May 18, 2010.;;Canadian Patent Application No. 2,659,682; Response Office Action, Jun. 11, 2010.;;Canadian Patent Application No. 2,659,682; Notice of Allowance, Aug. 30, 2010.;;Chinese Patent Application No. 200780030720.0, Prolyl Hydroxylase Inhibitors and Methods of Use, National Stage Entry of PCT/US2007/014832, claiming priority to U.S. Appl. No. 60/816,522, filed Jun. 26, 2006; now CN 200780030720.0.;;Chinese Patent Application No. 200780030720.0; Preliminary Amendments, May 10, 2010.;;Chinese Patent Application No. 200780030720.0; Office Action, Aug. 19, 2011.;;Chinese Patent Application No. 200780030720.0; Response to Office Action, Aug. 22, 2011.;;Chinese Patent Application No. 200780030720.0; Office Action, Dec. 31, 2011.;;Chinese Patent Application No. 200780030720.0; Response to Office Action, Mar. 15, 2012.;;Chinese Patent Application No. 200780030720.0; Response to Examiner's Interview, May 5, 2012.;;Chinese Patent Application No. 200780030720.0; Notice of Allowance Jul. 16, 2012.;;Colombian Patent Application No. 09006711, Prolyl Hydroxylase Inhibitors and Methods of Use, National Stage Entry of PCT/US2007/014832, claiming priority to U.S. Appl. No. 60/816,522, filed Jun. 26, 2006.;;Colombian Patent Application No. 09006711; Preliminary Amendment, Apr. 29, 2010.;;Colombian Patent Application No. 09006711; Office Action, Aug. 23, 2012.;;Colombian Patent Application No. 09006711; Response to Office Action, Sep. 18, 2012.;;European Patent Application No. 07 835 890.0, Prolyl Hydroxylase Inhibitors and Methods of Use, National Stage Entry of PCT/US2007/014832, claiming priority to U.S. Appl. No. 60/816,522, filed Jun. 26, 2006; now EP 2 044 005.;;European Patent Application No. 07 835 890.0; Office Action, Mar. 3, 2010.;;European Patent Application No. 07 835 890.0; Response to Office Action, Mar. 28, 2010.;;European Patent Application No. 07 835 890.0; Notice of Allowance, Jun. 24, 2010.;;European Patent Application No. 07 835 890.0; Opposition Filed, Jul. 20, 2011.;;European Patent Application No. 07 835 890.0; Document Cited in Opposition: International Union of Pure and Applied Chemistry; Glossary of Class Names of Organic Compounds and Reactive Intermediates Based on Structure; Pure & Appl. Chem., vol. 67, Nos. 8/9, pp. 1307-1375, (1995).;;European Patent Application No. 07 835 890.0; Document Cited in Opposition: Certified Copy of U.S. Appl. No. 60/816,522, Priority Document of European Patent Application No. 07 835 890.0, 2006.;;European Patent Application No. 07 835 890.0; Document Cited in Opposition: US 5,620,995, 1997.;;European Patent Application No. 07 835 890.0; Document Cited in Opposition: US 5,658,933, 1997.;;European Patent Application No. 07 835 890.0; Document Cited in Opposition: WO 2003/049686, cited hereinabove, 2004.;;European Patent Application No. 07 835 890.0; Document Cited in Opposition: WO 2003/053997, cited hereinabove, 2004.;;Warshakoon et al., ""Design and synthesis of substituted pyridine derivatives as HIF-1alpha prolyl hydroxylase inhibitors,"" Bioorganic & Medicinal Chemistry Letters, 16 (2006) 5616-5620.;;European Patent Application No. 07 835 890.0; Response to Opposition, Dec. 28, 2011.;;European Patent Application No. 11 000 872.9, Divisional Application of European Patent Application No. 07 835 890.0, Prolyl Hydroxylase Inhibitors and Methods of Use, National Stage Entry of PCT/US2007/014832, claiming priority to U.S. Appl. No. 60/816,522, filed Jun. 26, 2006.;;European Patent Application No. 11 000 872.9; European Search Report, Apr. 28, 2011.;;Hong Kong Patent Application No. 09108318.9, Prolyl Hydroxylase Inhibitors and Methods of Use, National Stage Entry of PCT/US2007/014832, claiming priority to U.S. Appl. No. 60/816,522, filed Jun. 26, 2006; now HK1129369.;;Indonesian Patent Application No. W-00200804211, Prolyl Hydroxylase Inhibitors and Methods of Use, National Stage Entry of PCT/US2007/014832, claiming priority to U.S. Appl. No. 60/816,522, filed Jun. 26, 2006; now W-00200804211.;;Israeli Patent Application No. 196127, Prolyl Hydroxylase Inhibitors and Methods of Use, National Stage Entry of PCT/US2007/014832, claiming priority to U.S. Appl. No. 60/816,522, filed Jun. 26, 2006.;;Israeli Patent Application No. 196127; Preliminary Amendments, Apr. 12, 2010.;;Israeli Patent Application No. 196127; Office Action Feb. 15, 2012.;;Israeli Patent Application No. 196127; Response to Office Action Feb. 20, 2012.;;Indian Patent Application No. 509/DELNP/2009, Prolyl Hydroxylase Inhibitors and Methods of Use, National Stage Entry of PCT/US2007/014832, claiming priority to U.S. Appl. No. 60/816,522, filed Jun. 26, 2006.;;Japanese Patent Application No. 2009-518232, Prolyl Hydroxylase Inhibitors and Methods of Use, National Stage Entry of PCT/US2007/014832, claiming priority to U.S. Appl. No. 60/816,522, filed Jun. 26, 2006; now JP 5113838.;;Japanese Patent Application No. 2009-518232; Office Action, Nov. 11, 2011.;;Japanese Patent Application No. 2009-518232; Response to Office Action, Feb. 10, 2012.;;Japanese Patent Application No. 2009-518232; Office Action, May 24, 2012.;;Japanese Patent Application No. 2009-518232; Response to Office Action, Jul. 25, 2012.;;Japanese Patent Application No. 2009-518232; Notice of Allowance, Oct. 4, 2012.;;Korean Patent Application No. 2009-7001697, Prolyl Hydroxylase Inhibitors and Methods of Use, National Stage Entry of PCT/US2007/014832, claiming priority to U.S. Appl. No. 60/816,522, filed Jun. 26, 2006; now KR 1130592.;;Korean Patent Application No. 2009-7001697; Office Action, May 4, 2011.;;Korean Patent Application No. 2009-7001697; Response to Office Action, Jun. 8, 2011.;;Korean Patent Application No. 2009-7001697; Decision to Grant, Dec. 28, 2011.;;Mexican Patent Application No. MX/A/2009/000286, Prolyl Hydroxylase Inhibitors and Methods of Use, National Stage Entry of PCT/US2007/014832, claiming priority to U.S. Appl. No. 60/816,522, filed Jun. 26, 2006.;;New Zealand Patent Application No. 574408, Prolyl Hydroxylase Inhibitors and Methods of Use, National Stage Entry of PCT/US2007/014832, claiming priority to U.S. Appl. No. 60/816,522, filed Jun. 26, 2006.;;New Zealand Patent Application No. 574408; Examination Report, Sep. 28, 2010.;;Altschul et al., ""Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs,"" Nucleic Acids Res., 25(27):3389-3402 (1997).;;Annex et al., ""Growth Factor-Induced Therapeutic Angiogenesis in the Heart: Protein Therapy,"" Cardiovascular Research, 65(3):649-655 (2005).;;Ardelt et al., ""Estradiol Regulates Angiopoietin-1 mRNA Expression Through Estrogen Receptor-alpha in a Rodent Experimental Stroke Model,"" Stroke, 36:337-341 (2005).;;Auerbach et al., ""Angiogenesis Assays: A Critical Overview,"" Clinical Chemistry, 49:32-40 (2003).;;Barany et al., ""Solid-phase Peptide Synthesis: A Silver Anniversary Report,"" Int. J. Peptide Protein Res., 30 (6):705-739 (1987).;;Bartlett et al., ""Molecular Recognition in Chemical and Biological Problems,"" Special Pub., Royal Chem. Soc., 78, 182-196 Caveat: A Program to Facilitate the Structure-derived Design of Biologically Active Molecules (Apr. 1989).;;Böhm, ""The Computer Program LUDI: A New Method for the Novo Design of Enzyme Inhibitors,"" J. Computer-Aided Molecular Design,6:61-78 (1992).;;Branden et al., ""Introduction to Protein Structure Second Edition,"" Garland Publising Inc., New York, 1999, pp. 374-375.;;Bussolino, ""Molecular Mechanisms of Blood Vessel Formation,"" Trends Biochem. Sci.,22(7):251-256 (1997).;;Cunliffe et al., ""Novel Inhibitors of Prolyl 4-Hydroxylase. 3. Inhibition by the Substrate Analogue N-Oxaloglycine and Its Derivatives,"" J. Med.Chem. 35:2652-2658 (1992).;;Elson et al., ""Induction of Hypervascularity Without Leakage or Inflammation in Transgenic Mice Overexpressing Hypoxia-Indicible Factor-1alpha,"" Genes & Dev.,15:2520-2532 (2001).;;Flower, ""Modelling G-protein-coupled receptors for drug design,"" Biochimica et Biophysica Acta, 1422:207-234 (1999).;;Folkman et al., ""Tumor Angiogenesis,"" The Molecular Basis of Cancer, Mendelsohn et al., eds., W. B. Saunders, Chapter 10, pp. 206-232 (1995).;;Franklin et al., ""Approaches to the Design of Anti-Fibrotic Drugs,"" Biochem. Soc. Trans., 19(4):812-5 (Nov. 1991).;;Goodford, ""A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules,"" J. Med. Chem., 28(7):849-857 (1985).;;Goodsell et al., ""Automated Docking of Substrates to Proteins by Simulated Annealing,"" Proteins: Structure, Function, and Genetics, 8:195-202 (1990).;;Kaelin, ""Proline Hydroxylation and Gene Expression,"" Annu. Rev. Biochem., 74:115-125 (2005).;;Krantz, ""Erythropoietin,"" Blood, 77:419-434 (1991).;;Kuntz et al., ""A Geometric Approach to Macromolecule-Ligand Interactions,"" J. Mol. Biol., 161:269-288 (1982).;;Lee et al., ""Structure of Human FIH-1 Reveals a Unique Active Site Pocket and Interaction Sites for HIF-1 and von Hippel Lindau,"" JBC, 278:7558-7563 (2003).;;Li et al., ""PR39, a Peptide Regulator of Angiogenesis,"" Nat Med., 6(1):49-55 (2000).;;Mancini et al., ""Effect of Erythropoietin on Exercise Capacity in Patients with Moderate to Severe Chronic Heart Failure,"" Circulation, 107:294-299 (2003).;;McDonough et al., ""Cellular Oxygen Sensing: Crystal Structure of Hypoxia-Inducible Factor Prolyl Hydroxylase (PHD2),"" PNAS, 103(26):9814-9819 (2006).;;Miranker et al., ""Functionality Maps of Binding Sites: A Multiple Copy Simultaneous Search Method,"" Proteins: Structure, Function and Genetics, 11:29-34 (1991).;;Nguyen et al., ""Cellular Interactions in Vascular Growth and Differentiation,"" Int. Review of Cytology, 204:1-48 (2001).;;Nishibata et al., ""Automatic Creation of Drug Candidate Structures Based on Receptor Structure. Starting Point for Artificial Lead Generation,"" Tetrahedron, 47(43):8985-8990 (1991).;;O'Reilly et al., ""Angiostatin: A Novel Angiogenesis Inhibitor that Mediates the Suppression of Metastases by a Lewis Lung Carcinoma,"" Cell, 79:315-328 (1994).",ACTIVE
644,AU,A1,AU 2007/265460 A1,168-424-956-723-193,2008-01-03,2008,AU 2007/265460 A,2007-06-26,US 81652206 P;;US 2007/0014832 W,2006-06-26,Prolyl hydroxylase inhibitors and methods of use,,PROCTER & GAMBLE,BOYER ANGELIQUE SUN;;GREIS KENNETH DONALD;;EDOKIMOV ARTEM G;;WU SHENGDE;;KAWAMOTO RICHARD MASARU;;WARSHAKOON NAMAL CHITHRANGA,"WARNER CHILCOTT, LLC (2010-12-09)",https://lens.org/168-424-956-723-193,Patent Application,no,0,1,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07C235/60;;A61K31/44;;A61P9/10;;C07C235/52;;C07C237/42;;C07C255/57;;C07D213/81,,0,0,,,,ACTIVE
645,EP,A1,EP 2533831 A1,168-156-471-157-367,2012-12-19,2012,EP 11708127 A,2011-01-31,US 70421410 A;;US 2011/0023158 W,2010-02-11,FLOW PULSATILITY DAMPENING DEVICES,,BAXTER INT;;BAXTER HEALTHCARE SA,CHAN WILLIAM;;CASTELLANOS RAMIRO;;BHAGTANI REEMA A;;BERTOS GEORGIOS A;;LIN RONGSHENG;;BOYER RICHARD;;DELCASTILLO JORGE;;SCHULTZ GARY,,https://lens.org/168-156-471-157-367,Patent Application,yes,0,0,9,9,0,A61M5/14212;;A61M5/14212;;A61M5/14224;;A61M5/14224;;A61M5/14228;;A61M5/14228;;A61M5/14232;;A61M5/14232;;A61M5/16886;;A61M5/16886;;A61M2205/3334;;A61M2205/3334;;A61M2206/22;;A61M2206/22;;F16L55/04;;F16L55/04;;F04B11/0008;;F04B11/0008;;F04B11/0016;;F04B11/0016;;F04B11/0025;;F04B11/0025;;F04B11/0091;;F04B11/0091,A61M5/142;;A61M5/168;;F04B11/00;;F04B39/00;;F16L55/04,,1,0,,,See references of WO 2011100134A1,DISCONTINUED
646,WO,A1,WO 2011/100134 A1,181-058-307-662-750,2011-08-18,2011,US 2011/0023158 W,2011-01-31,US 70421410 A,2010-02-11,FLOW PULSATILITY DAMPENING DEVICES,"A medical fluid infusion system (10) including: a fluid pathway (16) for transporting a pulsatile flow of fluid; a dampening element (80) in communication with the fluid pathway, the dampening element configured to actively dampen pressure fluctuations of the pulsatile flow to smoothen the pulsatile fluid flow, the dampening element operable in any orientation; and a fluid flow sensor (50) disposed along the fluid pathway downstream of the dampening element to measure the flow rate of the smoothened fluid flow.",BAXTER INT;;BAXTER HEALTHCARE SA;;CHAN WILLIAM;;CASTELLANOS RAMIRO;;BHAGTANI REEMA A;;BERTOS GEORGIOS A;;LIN RONGSHENG;;BOYER RICHARD;;DELCASTILLO JORGE;;SCHULTZ GARY,CHAN WILLIAM;;CASTELLANOS RAMIRO;;BHAGTANI REEMA A;;BERTOS GEORGIOS A;;LIN RONGSHENG;;BOYER RICHARD;;DELCASTILLO JORGE;;SCHULTZ GARY,,https://lens.org/181-058-307-662-750,Patent Application,yes,7,4,9,9,0,A61M5/14212;;A61M5/14224;;A61M5/14228;;A61M5/14232;;A61M5/16886;;A61M2205/3334;;A61M2206/22;;F04B11/0008;;F04B11/0016;;F04B11/0025;;F04B11/0091;;F16L55/04;;F16L55/04;;A61M5/14224;;A61M2206/22;;F04B11/0091;;F04B11/0008;;F04B11/0025;;A61M5/14228;;F04B11/0016;;A61M5/16886;;A61M5/14232;;A61M5/14212;;A61M2205/3334,A61M5/142;;A61M5/168;;F04B11/00;;F04B39/00;;F16L55/04,,0,0,,,,PENDING
647,US,A1,US 2013/0134933 A1,022-310-129-182-004,2013-05-30,2013,US 201113306327 A,2011-11-29,US 201113306327 A,2011-11-29,POWER SAFETY SYSTEM AND METHOD HAVING A PLURALITY OF THERMALLY-TRIGGERED ELECTRICAL BREAKING ARRANGEMENTS,"A power safety system (PSS) includes a plurality of thermally-triggered electrical breaking arrangements (TTEBAs). The plurality of TTEBAs are associated with a plurality of electrical devices (EDs) disposed external to the PSS. The PSS further includes a plurality of electrical power connections (EPCs) associated with said plurality of TTEBAs that are configured to respectively electrically connect the PSS to the plurality of EDs. When at least one TTEBA in the plurality of TTEBAs is electrically operative and at least one thermal event occurs that is sufficient to thermally activate the at least one electrically operative TTEBA, at least the EPC associated with the at least one thermally activated TTEBA is electrically broken. A method to protect a human operator of the PSS from a thermal event is also presented. A PSS also extends to a primary and a secondary electrical charging system used to charge a battery of a vehicle.",DREW GEORGE ALBERT;;KIKO JEFFREY S;;MUSICK STEVEN A;;BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN VICTOR;;DELPHI TECH INC,DREW GEORGE ALBERT;;KIKO JEFFREY S;;MUSICK STEVEN A;;BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN VICTOR,DELPHI TECHNOLOGIES INC (2011-11-30),https://lens.org/022-310-129-182-004,Patent Application,yes,7,35,5,5,0,B60L50/51;;B60L50/51;;B60L50/66;;B60L50/66;;B60L53/16;;B60L53/16;;B60L53/31;;B60L53/31;;B60L2210/30;;B60L2210/30;;B60L2240/36;;B60L2240/36;;B60L2240/547;;B60L2240/547;;B60L2240/549;;B60L2240/549;;B60L2250/16;;B60L2250/16;;B60L2270/32;;B60L2270/32;;B60L2270/34;;B60L2270/34;;H02H5/04;;H02H5/04;;H02H5/04;;Y02T10/70;;Y02T10/70;;Y02T10/7072;;Y02T10/7072;;Y02T10/72;;Y02T10/72;;Y02T90/12;;Y02T90/12;;Y02T90/14;;Y02T90/14,H02J7/00;;B60L1/00;;G08B21/00;;H02H5/04;;H02H11/00,320/109;;361/103;;307/9.1;;361/104;;361/106;;307/326;;340/638;;180/65.275,0,0,,,,DISCONTINUED
648,EP,A1,EP 2600476 A1,056-793-575-805-649,2013-06-05,2013,EP 12192581 A,2012-11-14,US 201113306327 A,2011-11-29,Power safety system and method having a plurality of thermally-triggered electrical breaking arrangements,"A power safety system (PSS) includes a plurality of thermally-triggered electrical breaking arrangements (TTEBAs (11) ). The plurality of TTEBAs are associated with a plurality of electrical devices (EDs (12,13) ) disposed external to the PSS. The PSS further includes a plurality of electrical power connections (EPCs (19) ) associated with said plurality of TTEBAs (11) that are configured to respectively electrically connect the PSS to the plurality of EDs (12,13). When at least one TTEBA in the plurality of TTEBAs is electrically operative and at least one thermal event occurs that is sufficient to thermally activate the at least one electrically operative TTEBA, at least the EPC (19) associated with the at least one thermally activated TTEBA is electrically broken. A method to protect a human operator of the PSS from a thermal event is also presented. A PSS also extends to a primary and a secondary electrical charging system (10) used to charge a battery of a vehicle (14).
",DELPHI TECH INC,DREW GEORGE A;;KIKO JEFFREY S;;MUSICK STEVEN A;;BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN V,,https://lens.org/056-793-575-805-649,Patent Application,yes,7,1,5,5,0,B60L50/51;;B60L50/51;;B60L50/66;;B60L50/66;;B60L53/16;;B60L53/16;;B60L53/31;;B60L53/31;;B60L2210/30;;B60L2210/30;;B60L2240/36;;B60L2240/36;;B60L2240/547;;B60L2240/547;;B60L2240/549;;B60L2240/549;;B60L2250/16;;B60L2250/16;;B60L2270/32;;B60L2270/32;;B60L2270/34;;B60L2270/34;;H02H5/04;;H02H5/04;;H02H5/04;;Y02T10/70;;Y02T10/70;;Y02T10/7072;;Y02T10/7072;;Y02T10/72;;Y02T10/72;;Y02T90/12;;Y02T90/12;;Y02T90/14;;Y02T90/14,H02H5/04;;B60L11/18;;H02J7/02,,0,0,,,,DISCONTINUED
649,US,A1,US 2014/0316858 A1,073-587-232-139-751,2014-10-23,2014,US 201313864506 A,2013-04-17,US 201313864506 A,2013-04-17,VIRTUAL BUSINESS PROCESS,"A virtual process system includes a processor, a first physical business process coupled to the processor, and a second physical business process coupled to the processor. The processor is configured to execute a virtual business process according to a virtual business process definition. The processor is further configured to receive a first event relating to the first physical business process and a second event relating to the second physical business process. The processor is further configured to execute a first state transition in response to receiving the first event at the processor and execute a second state transition in response to receiving the second event at the processor and execute a behavior in response to a received event. The received event includes one of the first event or the second event.",IBM,AKOLKAR RAHUL P;;BALASUBRAMANIAN RAJESH;;BOYER JOHN M;;BUDDENBAUM DONALD E;;STANHOPE KAREN B;;WAUGAMAN JR RICHARD A,INTERNATIONAL BUSINESS MACHINES CORPORATION (2013-04-16);;GLOBALFOUNDRIES U.S. 2 LLC (2015-06-29);;GLOBALFOUNDRIES INC (2015-09-10),https://lens.org/073-587-232-139-751,Patent Application,yes,2,0,1,1,0,G06Q10/0637;;G06Q10/0637,G06Q10/06,705/7.36,0,0,,,,DISCONTINUED
650,WO,A4,WO 2011/100134 A4,119-498-523-576-84X,2011-10-27,2011,US 2011/0023158 W,2011-01-31,US 70421410 A,2010-02-11,FLOW PULSATILITY DAMPENING DEVICES,"A medical fluid infusion system (10) including: a fluid pathway (16) for transporting a pulsatile flow of fluid; a dampening element (80) in communication with the fluid pathway, the dampening element configured to actively dampen pressure fluctuations of the pulsatile flow to smoothen the pulsatile fluid flow, the dampening element operable in any orientation; and a fluid flow sensor (50) disposed along the fluid pathway downstream of the dampening element to measure the flow rate of the smoothened fluid flow.",BAXTER INT;;BAXTER HEALTHCARE SA;;CHAN WILLIAM;;CASTELLANOS RAMIRO;;BHAGTANI REEMA A;;BERTOS GEORGIOS A;;LIN RONGSHENG;;BOYER RICHARD;;DELCASTILLO JORGE;;SCHULTZ GARY,CHAN WILLIAM;;CASTELLANOS RAMIRO;;BHAGTANI REEMA A;;BERTOS GEORGIOS A;;LIN RONGSHENG;;BOYER RICHARD;;DELCASTILLO JORGE;;SCHULTZ GARY,,https://lens.org/119-498-523-576-84X,Patent Application,yes,0,0,9,9,0,A61M5/14212;;A61M5/14212;;A61M5/14224;;A61M5/14224;;A61M5/14228;;A61M5/14228;;A61M5/14232;;A61M5/14232;;A61M5/16886;;A61M5/16886;;A61M2205/3334;;A61M2205/3334;;A61M2206/22;;A61M2206/22;;F16L55/04;;F16L55/04;;F04B11/0008;;F04B11/0008;;F04B11/0016;;F04B11/0016;;F04B11/0025;;F04B11/0025;;F04B11/0091;;F04B11/0091,A61M5/142;;A61M5/168;;F04B11/00;;F04B39/00;;F16L55/04,,0,0,,,,PENDING
651,KR,A,KR 20130060141 A,024-079-460-297-77X,2013-06-07,2013,KR 20120136206 A,2012-11-28,US 201113306327 A,2011-11-29,POWER SAFETY SYSTEM AND METHOD HAVING A PLURALITY OF THERMALLY-TRIGGERED ELECTRICAL BREAKING ARRANGEMENTS,PURPOSE: A power safety system having a plurality of thermally-triggered electrical breaking arrangements and a method thereof are provided to electrically break connection between a plurality of thermally-triggered electrical breaking arrangements and a plurality of electrical devices disposed externally to the power safety system in a thermal event. CONSTITUTION: A power safety system(PSS)(10) comprises a plurality of thermally-triggered electrical breaking arrangements(TTEBAs) and a plurality of electrical power connections(EPCs)(52) associated with the TTEBAs. The PSS is configured to electrically charge a battery(12) disposed in a vehicle(14). A handle(18) is coupled to a vehicle inlet connector(22). The handle contains one or more wire conductors(24) that provide uni-directional or bi-directional flow of electrical signals between the handle and the vehicle.,DELPHI TECH INC,DREW GEORGE ALBERT;;KIKO JEFFREY S;;MUSICK STEVEN A;;BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN VICTOR,,https://lens.org/024-079-460-297-77X,Patent Application,no,0,0,5,5,0,B60L50/51;;B60L50/51;;B60L50/66;;B60L50/66;;B60L53/16;;B60L53/16;;B60L53/31;;B60L53/31;;B60L2210/30;;B60L2210/30;;B60L2240/36;;B60L2240/36;;B60L2240/547;;B60L2240/547;;B60L2240/549;;B60L2240/549;;B60L2250/16;;B60L2250/16;;B60L2270/32;;B60L2270/32;;B60L2270/34;;B60L2270/34;;H02H5/04;;H02H5/04;;H02H5/04;;Y02T10/70;;Y02T10/70;;Y02T10/7072;;Y02T10/7072;;Y02T10/72;;Y02T10/72;;Y02T90/12;;Y02T90/12;;Y02T90/14;;Y02T90/14,,,0,0,,,,DISCONTINUED
652,CA,A1,CA 2789139 A1,111-069-419-065-154,2011-08-18,2011,CA 2789139 A,2011-01-31,US 70421410 A;;US 2011/0023158 W,2010-02-11,FLOW PULSATILITY DAMPENING DEVICES,"A medical fluid infusion system (10) including: a fluid pathway (16) for transporting a pulsatile flow of fluid; a dampening element (80) in communication with the fluid pathway, the dampening element configured to actively dampen pressure fluctuations of the pulsatile flow to smoothen the pulsatile fluid flow, the dampening element operable in any orientation; and a fluid flow sensor (50) disposed along the fluid pathway downstream of the dampening element to measure the flow rate of the smoothened fluid flow.",BAXTER HEALTHCARE SA;;BAXTER INT,CHAN WILLIAM;;CASTELLANOS RAMIRO;;BHAGTANI REEMA A;;BERTOS GEORGIOS A;;LIN RONGSHENG;;BOYER RICHARD;;DELCASTILLO JORGE;;SCHULTZ GARY,,https://lens.org/111-069-419-065-154,Patent Application,no,0,0,9,9,0,A61M5/14212;;A61M5/14212;;A61M5/14224;;A61M5/14224;;A61M5/14228;;A61M5/14228;;A61M5/14232;;A61M5/14232;;A61M5/16886;;A61M5/16886;;A61M2205/3334;;A61M2205/3334;;A61M2206/22;;A61M2206/22;;F16L55/04;;F16L55/04;;F04B11/0008;;F04B11/0008;;F04B11/0016;;F04B11/0016;;F04B11/0025;;F04B11/0025;;F04B11/0091;;F04B11/0091,A61M5/142;;A61M5/168;;F04B11/00;;F04B39/00;;F16L55/04,,0,0,,,,DISCONTINUED
653,CN,A,CN 103138326 A,096-968-533-927-94X,2013-06-05,2013,CN 201210330788 A,2012-09-07,US 201113306327 A,2011-11-29,Power safety system and method having a plurality of thermally-triggered electrical breaking arrangements,"A power safety system (PSS) includes a plurality of thermally-triggered electrical breaking arrangements (TTEBAs). The plurality of TTEBAs are associated with a plurality of electrical devices (EDs) disposed external to the PSS. The PSS further includes a plurality of electrical power connections (EPCs) associated with said plurality of TTEBAs that are configured to respectively electrically connect the PSS to the plurality of EDs. When at least one TTEBA in the plurality of TTEBAs is electrically operative and at least one thermal event occurs that is sufficient to thermally activate the at least one electrically operative TTEBA, at least the EPC associated with the at least one thermally activated TTEBA is electrically broken. A method to protect a human operator of the PSS from a thermal event is also presented. A PSS also extends to a primary and a secondary electrical charging system used to charge a battery of a vehicle.",DELPHI TECH INC,DREW GEORGE ALBERT;;KIKO JEFFREY S;;MUSICK STEVEN A;;BOYER RICHARD J;;PASHA BRIAN D;;FUZO JOHN VICTOR,,https://lens.org/096-968-533-927-94X,Patent Application,no,0,3,5,5,0,B60L50/51;;B60L50/51;;B60L50/66;;B60L50/66;;B60L53/16;;B60L53/16;;B60L53/31;;B60L53/31;;B60L2210/30;;B60L2210/30;;B60L2240/36;;B60L2240/36;;B60L2240/547;;B60L2240/547;;B60L2240/549;;B60L2240/549;;B60L2250/16;;B60L2250/16;;B60L2270/32;;B60L2270/32;;B60L2270/34;;B60L2270/34;;H02H5/04;;H02H5/04;;H02H5/04;;Y02T10/70;;Y02T10/70;;Y02T10/7072;;Y02T10/7072;;Y02T10/72;;Y02T10/72;;Y02T90/12;;Y02T90/12;;Y02T90/14;;Y02T90/14,H02J7/00;;H02H5/04;;H02J17/00,,0,0,,,,DISCONTINUED
654,MX,A,MX 2012009320 A,020-360-381-614-502,2012-11-21,2012,MX 2012009320 A,2011-01-31,US 70421410 A;;US 2011/0023158 W,2010-02-11,FLOW PULSATILITY DAMPENING DEVICES.,"A medical fluid infusion system (10) including: a fluid pathway (16) for transporting a pulsatile flow of fluid; a dampening element (80) in communication with the fluid pathway, the dampening element configured to actively dampen pressure fluctuations of the pulsatile flow to smoothen the pulsatile fluid flow, the dampening element operable in any orientation; and a fluid flow sensor (50) disposed along the fluid pathway downstream of the dampening element to measure the flow rate of the smoothened fluid flow.",BAXTER HEALTHCARE SA,CHAN WILLIAM;;BHAGTANI REEMA A;;BERTOS GEORGIOS A;;LIN RONGSHENG;;BOYER RICHARD;;DELCASTILLO JORGE;;SCHULTZ GARY;;CASTELLANOS RAMIRO,,https://lens.org/020-360-381-614-502,Patent Application,no,0,0,9,9,0,A61M5/14212;;A61M5/14212;;A61M5/14224;;A61M5/14224;;A61M5/14228;;A61M5/14228;;A61M5/14232;;A61M5/14232;;A61M5/16886;;A61M5/16886;;A61M2205/3334;;A61M2205/3334;;A61M2206/22;;A61M2206/22;;F16L55/04;;F16L55/04;;F04B11/0008;;F04B11/0008;;F04B11/0016;;F04B11/0016;;F04B11/0025;;F04B11/0025;;F04B11/0091;;F04B11/0091,A61M5/142;;A61M5/168;;F04B11/00;;F04B39/00;;F16L55/04,,0,0,,,,ACTIVE
655,US,B2,US 8366667 B2,020-859-355-553-77X,2013-02-05,2013,US 70421410 A,2010-02-11,US 70421410 A,2010-02-11,Flow pulsatility dampening devices,"A medical fluid infusion system including: a fluid pathway for transporting a pulsatile flow of fluid; a dampening element in communication with the fluid pathway, the dampening element configured to actively dampen pressure fluctuations of the pulsatile flow to smoothen the pulsatile fluid flow, the dampening element operable in any orientation; and a fluid flow sensor disposed along the fluid pathway downstream of the dampening element to measure the flow rate of the smoothened fluid flow.",BAXTER INT;;BAXTER HEALTHCARE SA;;CHAN WILLIAM;;CASTELLANOS RAMIRO;;BHAGTANI REEMA A;;BERTOS GEORGIOS A;;LIN RONGSHENG;;BOYER RICHARD;;DELCASTILLO JORGE;;SCHULTZ GARY,CHAN WILLIAM;;CASTELLANOS RAMIRO;;BHAGTANI REEMA A;;BERTOS GEORGIOS A;;LIN RONGSHENG;;BOYER RICHARD;;DELCASTILLO JORGE;;SCHULTZ GARY,BAXTER HEALTHCARE S.A (2009-10-27);;BAXTER INTERNATIONAL INC (2009-10-27),https://lens.org/020-859-355-553-77X,Granted Patent,yes,134,16,9,9,0,A61M5/14212;;A61M5/14212;;A61M5/14224;;A61M5/14224;;A61M5/14228;;A61M5/14228;;A61M5/14232;;A61M5/14232;;A61M5/16886;;A61M5/16886;;A61M2205/3334;;A61M2205/3334;;A61M2206/22;;A61M2206/22;;F16L55/04;;F16L55/04;;F04B11/0008;;F04B11/0008;;F04B11/0016;;F04B11/0016;;F04B11/0025;;F04B11/0025;;F04B11/0091;;F04B11/0091,A61M37/00;;A61M1/00;;A61M31/00,604/132;;604/67;;604/153,11,0,,,"International Search Report and Written Opinion for International Application No. PCT/US2009/030299 mailed on May 29, 2009.;;International Search Report and Written Opinion for PCT/US2008/066101 mailed Feb. 12, 2009.;;Non-Final Office Action for U.S. Appl. No. 11/941,840 dated Jul. 24, 2009.;;Final Office Action for U.S. Appl. No. 11/941,840 dated Feb. 8, 2010.;;Non-Final Office Action for U.S. Appl. No. 11/941,840 dated Sep. 17, 2010.;;Notification of Transmittal of the International Preliminary Report on Patentability for International Application No. PCT/US2009/047585 dated Oct. 12, 2010.;;International Search Report and Written Opinion for International Application No. PCT/US2009/047585 dated Feb. 1, 2010.;;Non-Final Office Action for U.S. Appl. No. 12/180,324 dated Aug. 12, 2010.;;Written Opinion for International Application No. PCT/US2011/023158 dated May 9, 2011.;;International Search Report for International Application No. PCT/US2011/023158 dated May 9, 2011.;;Notification of Transmittal of the International Preliminary Report on Patentability for International Application No. PCT/US2011/023158 dated Feb. 3, 2012.",INACTIVE
656,JP,A,JP 2013118798 A,038-590-583-155-09X,2013-06-13,2013,JP 2012125630 A,2012-06-01,US 201113306327 A,2011-11-29,POWER SAFETY SYSTEM AND METHOD HAVING PLURAL THERMALLY-TRIGGERED ELECTRICAL BREAKING ARRANGEMENTS,"PROBLEM TO BE SOLVED: To provide a power safety system and method having a plurality of thermally-triggered electrical breaking arrangements.SOLUTION: A plurality of TTEBAs 11 are associated with a plurality of electrical devices (EDs) disposed external to the PSS. The PSS further includes a plurality of electrical power connections (EPCs) 19 associated with the plurality of TTEBAs that are configured to respectively electrically connect the PSS to the plurality of EDs. When at least one of the plurality of TTEBAs 11 is electrically operative and at least one thermal event occurs that is sufficient to thermally activate the at least one electrically operative TTEBA 11, at least the EPC associated with the at least one thermally activated TTEBA 11 is electrically broken. A method for protecting a human operator of the PSS from a thermal event is also presented. A PSS is also extended to a primary and a secondary electrical charging system used to charge a battery of a vehicle.",DELPHI TECH INC,GEORGE ALBERT DREW;;JEFFREY S KIKO;;STEVEN A MUSICK;;RICHARD J BOYER;;BRIAN D PASHA;;JOHN VICTOR FUZO,,https://lens.org/038-590-583-155-09X,Patent Application,no,0,2,5,5,0,B60L50/51;;B60L50/51;;B60L50/66;;B60L50/66;;B60L53/16;;B60L53/16;;B60L53/31;;B60L53/31;;B60L2210/30;;B60L2210/30;;B60L2240/36;;B60L2240/36;;B60L2240/547;;B60L2240/547;;B60L2240/549;;B60L2240/549;;B60L2250/16;;B60L2250/16;;B60L2270/32;;B60L2270/32;;B60L2270/34;;B60L2270/34;;H02H5/04;;H02H5/04;;H02H5/04;;Y02T10/70;;Y02T10/70;;Y02T10/7072;;Y02T10/7072;;Y02T10/72;;Y02T10/72;;Y02T90/12;;Y02T90/12;;Y02T90/14;;Y02T90/14,H02J7/00;;B60L11/18;;H01M10/44,,0,0,,,,PENDING
657,US,A1,US 2011/0196303 A1,050-529-968-094-891,2011-08-11,2011,US 70421410 A,2010-02-11,US 70421410 A,2010-02-11,FLOW PULSATILITY DAMPENING DEVICES,"A medical fluid infusion system including: a fluid pathway for transporting a pulsatile flow of fluid; a dampening element in communication with the fluid pathway, the dampening element configured to actively dampen pressure fluctuations of the pulsatile flow to smoothen the pulsatile fluid flow, the dampening element operable in any orientation; and a fluid flow sensor disposed along the fluid pathway downstream of the dampening element to measure the flow rate of the smoothened fluid flow.",BAXTER INT;;BAXTER HEALTHCARE SA,CHAN WILLIAM;;CASTELLANOS RAMIRO;;BHAGTANI REEMA A;;BERTOS GEORGIOS A;;LIN RONGSHENG;;BOYER RICHARD;;DELCASTILLO JORGE;;SCHULTZ GARY,BAXTER HEALTHCARE S.A (2009-10-27);;BAXTER INTERNATIONAL INC (2009-10-27),https://lens.org/050-529-968-094-891,Patent Application,yes,37,24,9,9,0,A61M5/14212;;A61M5/14212;;A61M5/14224;;A61M5/14224;;A61M5/14228;;A61M5/14228;;A61M5/14232;;A61M5/14232;;A61M5/16886;;A61M5/16886;;A61M2205/3334;;A61M2205/3334;;A61M2206/22;;A61M2206/22;;F16L55/04;;F16L55/04;;F04B11/0008;;F04B11/0008;;F04B11/0016;;F04B11/0016;;F04B11/0025;;F04B11/0025;;F04B11/0091;;F04B11/0091,A61M5/142,604/151,0,0,,,,INACTIVE
658,US,A1,US 2016/0252026 A1,005-249-748-168-045,2016-09-01,2016,US 201615151337 A,2016-05-10,US 201615151337 A;;US 201313975068 A,2013-08-23,METHOD AND SYSTEM FOR IMPROVED DILUTION TOLERANCE,"Methods and systems are provided for improving combustion stability, in particular during transient operations such as tip-out to lower load conditions, when EGR is being purged. Until a desired LP-EGR rate is achieved, fuel may be delivered as a split injection with at least an intake stroke injection and a compression stroke injection. Subsequently, single fuel injection may be resumed.",FORD GLOBAL TECH LLC,WOOLDRIDGE STEVEN;;SURNILLA GOPICHANDRA;;YI JIANWEN JAMES;;BOYER BRAD ALAN;;HILDITCH JAMES ALFRED;;SHELBY MICHAEL HOWARD;;PETERSEN BENJAMIN RICHARD,FORD GLOBAL TECHNOLOGIES LLC (2013-08-08),https://lens.org/005-249-748-168-045,Patent Application,yes,2,0,11,11,0,F02D41/045;;F02D41/107;;F02D41/1498;;F02D41/402;;F02D35/027;;F02D41/0005;;F02D2200/602;;F02D41/005;;F02M26/06;;Y02T10/40;;F02D41/045;;F02D41/107;;F02D41/1498;;F02D41/402;;F02D35/027;;F02D41/0005;;F02D2200/602;;Y02T10/40;;F02D43/00;;F02D41/005;;F02M26/06;;F02D41/0007;;F02D41/0052;;F02D41/0077;;F02D43/04,F02D41/00;;F02D35/02;;F02D41/14;;F02D41/40;;F02M26/06,,0,0,,,,ACTIVE
659,WO,A2,WO 2006/071672 A2,077-965-367-388-270,2006-07-06,2006,US 2005/0046364 W,2005-12-21,US 63814304 P;;US 71333905 P,2004-12-23,MODIFIED AMINE-ALDEHYDE RESINS AND USES THEREOF IN SEPARATION PROCESSES,"Modified resins are disclosed for removing a wide variety of solids and/or ionic species from the liquids in which they are suspended and/or dissolved. These modified resins are especially useful as froth flotation depressants in the beneficiation of many types of materials (e.g., mineral and metal ores), including the beneficiation of impure coal comprising clay impurities, as well as in the separation of valuable bitumen from solid contaminants such as sand. The modified resins are also useful for treating aqueous liquid suspensions to remove solid particulates, as well as for removing metallic ions in the purification of water. The modified resins comprise a base resin that is modified with a coupling agent, which is highly selective for binding to solid contaminants and especially siliceous materials such as sand or clay.",GEORGIA PACIFIC RESINS;;WRIGHT JAMES;;HURD PHILLIP W;;BOYER PETER;;ARTHUR LISA M;;MILLS JEFFREY;;HART PAUL;;REDIGER RICHARD;;KELLY ROBBIE D,WRIGHT JAMES;;HURD PHILLIP W;;BOYER PETER;;ARTHUR LISA M;;MILLS JEFFREY;;HART PAUL;;REDIGER RICHARD;;KELLY ROBBIE D,,https://lens.org/077-965-367-388-270,Patent Application,yes,0,11,19,56,0,B01D21/0012;;B01D21/01;;B01D61/14;;B03D1/01;;B03D1/012;;B03D1/016;;B03D1/02;;B03D1/08;;B03D3/06;;B28C1/08;;C01P2006/80;;C02F1/001;;C02F1/24;;C02F1/44;;C02F1/54;;C02F1/56;;C02F1/683;;C02F2101/103;;C02F2101/20;;C02F2103/10;;C02F2103/12;;C02F2103/28;;C09C1/42;;C10G1/045;;C22B3/24;;E21B21/068;;C10G2300/1003;;C10G2300/1033;;C10G2300/208;;B03D1/0046;;B03D2201/06;;B03D2203/006;;B03D2203/02;;B03D2203/10;;Y02P10/20;;B01D21/01;;B01D37/02;;B01D37/03;;B03B1/04;;C22B3/24;;C02F1/683;;B03D1/01;;C22B3/24;;B03D3/06;;C01P2006/80;;B01D61/14;;C02F1/24;;B28C1/08;;C10G1/045;;B03D1/08;;C02F1/56;;B01D21/0012;;E21B21/068;;C09C1/42;;C02F2101/20;;C02F2103/10;;B03D1/012;;B03D1/016;;C02F1/54;;C02F1/001;;C02F2101/103;;B01D21/01;;B03D1/02;;C02F1/44;;C02F2103/12;;C02F2103/28;;C10G2300/208;;C10G2300/1033;;C10G2300/1003;;B03D2201/06;;B03D1/0046;;B03D2203/02;;B03D2203/006;;B03D2203/10;;Y02P10/20,B03D1/02;;B01D21/01;;B01D37/02;;B01D37/03;;B03B1/04;;B03D1/01;;B03D1/016;;B28C1/08;;C02F1/56;;C09C1/42;;C10G1/04,,0,0,,,,PENDING
660,CN,A,CN 109723562 A,112-430-853-718-083,2019-05-07,2019,CN 201910006711 A,2014-08-22,US 201313975063 A;;CN 201410419590 A,2013-08-23,Method and system for knock control,"The invention relates to a method and a system for knock control. Methods and systems are provided for improving engine knock tolerance, in particular when rapidly ramping in LP-EGR from low levels ofEGR. Until a desired LP-EGR rate is achieved, fuel may be delivered as a split injection with at least an intake stroke injection and a compression stroke injection to compensate for the transport delay in EGR filling the intake system. Subsequently, single fuel injection may be resumed.",FORD GLOBAL TECH LLC,STEVEN WOOLDRIDGE;;GOPICHANDRA SURNILLA;;BRAD ALAN BOYER;;JAMES ALFRED HILDITCH;;MICHAEL HOWARD SHELBY;;CHRIS PAUL GLUGLA;;BENJAMIN RICHARD PETERSEN,,https://lens.org/112-430-853-718-083,Patent Application,no,7,0,12,12,0,F02D41/10;;F02D41/12;;F02D41/3023;;F02D41/402;;F02M26/06;;F02D41/0072;;F02D41/005;;Y02T10/40;;F02M26/06;;F02D41/10;;F02D41/12;;F02D41/3023;;F02D41/402;;Y02T10/40;;F02D43/00;;F02D41/0072;;F02D41/005;;F02D41/3076;;F02P5/145;;F02B47/08;;F02D41/0007,F02D41/40;;F02D41/00;;F02D41/30;;F02P5/152,,0,0,,,,PENDING
661,US,B2,US 9334826 B2,113-198-480-184-615,2016-05-10,2016,US 201313975068 A,2013-08-23,US 201313975068 A,2013-08-23,Method and system for improved dilution tolerance,"Methods and systems are provided for improving combustion stability, in particular during transient operations such as tip-out to lower load conditions, when EGR is being purged. Until a desired LP-EGR rate is achieved, fuel may be delivered as a split injection with at least an intake stroke injection and a compression stroke injection. Subsequently, single fuel injection may be resumed.",FORD GLOBAL TECH LLC,WOOLDRIDGE STEVEN;;SURNILLA GOPICHANDRA;;YI JIANWEN JAMES;;BOYER BRAD ALAN;;HILDITCH JAMES ALFRED;;SHELBY MICHAEL HOWARD;;PETERSEN BENJAMIN RICHARD,FORD GLOBAL TECHNOLOGIES LLC (2013-08-08),https://lens.org/113-198-480-184-615,Granted Patent,yes,9,10,11,11,0,F02D41/045;;F02D41/107;;F02D41/1498;;F02D41/402;;F02D35/027;;F02D41/0005;;F02D2200/602;;F02D41/005;;F02M26/06;;Y02T10/40;;F02D41/045;;F02D41/107;;F02D41/1498;;F02D41/402;;F02D35/027;;F02D41/0005;;F02D2200/602;;Y02T10/40;;F02D43/00;;F02D41/005;;F02M26/06;;F02D41/0007;;F02D41/0052;;F02D41/0077;;F02D43/04,F02D35/02;;F02D41/00;;F02D41/04;;F02D41/10;;F02D41/14;;F02D41/40;;F02D43/00,,2,0,,,"Leone, Thomas G., ""Octane Separation System and Operating Method,"" U.S. Appl. No. 13/973,886, filed Aug. 22, 2013, 80 pages.;;Wooldridge, Stephen et al., ""Method and System for Knock Control,"" U.S. Appl. No. 13/975,063, filed Aug. 23, 2013, 58 pages.",ACTIVE
662,US,A1,US 2015/0057911 A1,180-808-367-176-600,2015-02-26,2015,US 201313975068 A,2013-08-23,US 201313975068 A,2013-08-23,METHOD AND SYSTEM FOR IMPROVED DILUTION TOLERANCE,"Methods and systems are provided for improving combustion stability, in particular during transient operations such as tip-out to lower load conditions, when EGR is being purged. Until a desired LP-EGR rate is achieved, fuel may be delivered as a split injection with at least an intake stroke injection and a compression stroke injection. Subsequently, single fuel injection may be resumed.",FORD GLOBAL TECH LLC,WOOLDRIDGE STEVEN;;SURNILLA GOPICHANDRA;;YI JIANWEN JAMES;;BOYER BRAD ALAN;;HILDITCH JAMES ALFRED;;SHELBY MICHAEL HOWARD;;PETERSEN BENJAMIN RICHARD,FORD GLOBAL TECHNOLOGIES LLC (2013-08-08),https://lens.org/180-808-367-176-600,Patent Application,yes,5,24,11,11,0,F02D41/045;;F02D41/107;;F02D41/1498;;F02D41/402;;F02D35/027;;F02D41/0005;;F02D2200/602;;F02D41/005;;F02M26/06;;Y02T10/40;;F02D41/045;;F02D41/107;;F02D41/1498;;F02D41/402;;F02D35/027;;F02D41/0005;;F02D2200/602;;Y02T10/40;;F02D43/00;;F02D41/005;;F02M26/06;;F02D41/0007;;F02D41/0052;;F02D41/0077;;F02D43/04,F02D43/00,701/108,0,0,,,,ACTIVE
663,WO,A3,WO 2006/071672 A3,196-479-794-354-295,2007-02-08,2007,US 2005/0046364 W,2005-12-21,US 63814304 P;;US 71333905 P,2004-12-23,MODIFIED AMINE-ALDEHYDE RESINS AND USES THEREOF IN SEPARATION PROCESSES,"Modified resins are disclosed for removing a wide variety of solids and/or ionic species from the liquids in which they are suspended and/or dissolved. These modified resins are especially useful as froth flotation depressants in the beneficiation of many types of materials (e.g., mineral and metal ores), including the beneficiation of impure coal comprising clay impurities, as well as in the separation of valuable bitumen from solid contaminants such as sand. The modified resins are also useful for treating aqueous liquid suspensions to remove solid particulates, as well as for removing metallic ions in the purification of water. The modified resins comprise a base resin that is modified with a coupling agent, which is highly selective for binding to solid contaminants and especially siliceous materials such as sand or clay.",GEORGIA PACIFIC RESINS;;WRIGHT JAMES;;HURD PHILLIP W;;BOYER PETER;;ARTHUR LISA M;;MILLS JEFFREY;;HART PAUL;;REDIGER RICHARD;;KELLY ROBBIE D,WRIGHT JAMES;;HURD PHILLIP W;;BOYER PETER;;ARTHUR LISA M;;MILLS JEFFREY;;HART PAUL;;REDIGER RICHARD;;KELLY ROBBIE D,,https://lens.org/196-479-794-354-295,Search Report,yes,10,0,19,56,0,B01D21/0012;;B01D21/01;;B01D61/14;;B03D1/01;;B03D1/012;;B03D1/016;;B03D1/02;;B03D1/08;;B03D3/06;;B28C1/08;;C01P2006/80;;C02F1/001;;C02F1/24;;C02F1/44;;C02F1/54;;C02F1/56;;C02F1/683;;C02F2101/103;;C02F2101/20;;C02F2103/10;;C02F2103/12;;C02F2103/28;;C09C1/42;;C10G1/045;;C22B3/24;;E21B21/068;;C10G2300/1003;;C10G2300/1033;;C10G2300/208;;B03D1/0046;;B03D2201/06;;B03D2203/006;;B03D2203/02;;B03D2203/10;;Y02P10/20;;B01D21/01;;B01D37/02;;B01D37/03;;B03B1/04;;C22B3/24;;C02F1/683;;B03D1/01;;C22B3/24;;B03D3/06;;C01P2006/80;;B01D61/14;;C02F1/24;;B28C1/08;;C10G1/045;;B03D1/08;;C02F1/56;;B01D21/0012;;E21B21/068;;C09C1/42;;C02F2101/20;;C02F2103/10;;B03D1/012;;B03D1/016;;C02F1/54;;C02F1/001;;C02F2101/103;;B01D21/01;;B03D1/02;;C02F1/44;;C02F2103/12;;C02F2103/28;;C10G2300/208;;C10G2300/1033;;C10G2300/1003;;B03D2201/06;;B03D1/0046;;B03D2203/02;;B03D2203/006;;B03D2203/10;;Y02P10/20,B03D1/02;;B01D21/01;;B01D37/02;;B01D37/03;;B03B1/04;;B03D1/01;;B03D1/016;;B28C1/08;;C02F1/56;;C02F11/14;;C09C1/42;;C10G1/04;;C10G33/00;;C22B3/00,,4,0,,,"DATABASE WPI Section Ch Week 200137, Derwent World Patents Index; Class A97, AN 2001-352611, XP002382866;;DATABASE WPI Section Ch Week 198045, Derwent World Patents Index; Class A97, AN 1980-80270C, XP002382867;;DATABASE WPI Section Ch Week 197940, Derwent World Patents Index; Class A97, AN 1979-73327B, XP002382868;;DATABASE WPI Section Ch Week 197546, Derwent World Patents Index; Class D16, AN 1975-76952W, XP002382869",PENDING
664,DE,B4,DE 102014216663 B4,006-274-968-665-669,2022-11-10,2022,DE 102014216663 A,2014-08-21,US 201313975068 A,2013-08-23,Verfahren für verbesserte Verdünnungstoleranz,"Verfahren (200), umfassend:als Reaktion auf abfallende Motorlast, während ein Motor (10) mit AGR betrieben wird, Vermindern von AGR;Versorgen des Motors (10) mit Kraftstoff mit geteilter Kraftstoffeinspritzung pro Zyklus, bis die AGR weniger als ein Schwellenwert beträgt; undwenn AGR weniger als der Schwellenwert beträgt, Versorgen des Motors (10) mit einer einzelnen Kraftstoffeinspritzung pro Zyklus, und wobei die geteilte Kraftstoffeinspritzung mindestens zwei Einspritzungen pro Zyklus aufweist, wobei die mindestens zwei Einspritzungen zusammen über Funkenzündung verbrannt werden.",FORD GLOBAL TECH LLC,WOOLDRIDGE STEVEN;;SUMILLA GOPICHANDRA;;YI JIANWEN JAMES;;BOYER BRAD ALAN;;HILDITCH JAMES ALFRED;;SHELBY MICHAEL HOWARD;;PETERSEN BENJAMIN RICHARD,,https://lens.org/006-274-968-665-669,Granted Patent,no,3,0,11,11,0,F02D41/045;;F02D41/107;;F02D41/1498;;F02D41/402;;F02D35/027;;F02D41/0005;;F02D2200/602;;F02D41/005;;F02M26/06;;Y02T10/40;;F02D41/045;;F02D41/107;;F02D41/1498;;F02D41/402;;F02D35/027;;F02D41/0005;;F02D2200/602;;Y02T10/40;;F02D43/00;;F02D41/005;;F02M26/06;;F02D41/0007;;F02D41/0052;;F02D41/0077;;F02D43/04,F02D43/00;;F02D21/08;;F02D41/04;;F02D41/12;;F02D41/40,,0,0,,,,ACTIVE
665,DE,B4,DE 102014216496 B4,150-772-151-366-085,2023-01-05,2023,DE 102014216496 A,2014-08-20,US 201313975063 A,2013-08-23,VERFAHREN UND SYSTEM FÜR DIE KLOPFSTEUERUNG,"Verfahren, das Folgendes umfasst:in Reaktion auf eine zunehmende Kraftmaschinenlast, während eine Kraftmaschine mit niedrigerer AGR betrieben wird,Vergrößern der AGR; undKraftstoffbeaufschlagung der Kraftmaschine mit einer geteilten Kraftstoffeinspritzung pro Zyklus, bis die AGR höher als ein Schwellenwert ist, wobei das Arbeiten mit einer niedrigeren AGR das Arbeiten ohne eine Niederdruck-AGR enthält und wobei das Vergrößern der AGR das Vergrößern der Niederdruck-AGR enthält, wobei das Vergrößern der Niederdruck-AGR das Vergrößern der Rückführung gekühlter Abgasreste von einem Auslasskrümmer stromabwärts einer Abgasturbine zu einem Einlasskrümmer stromaufwärts eines Einlasskompressors enthält.",FORD GLOBAL TECH LLC,WOOLDRIDGE STEVEN;;GOPICHANDRA SURNILLA;;BOYER BRAD ALAN;;HILDITCH JAMES ALFRED;;SHELBY MICHAEL HOWARD;;GLUGLA CHRIS PAUL;;PETERSEN BENJAMIN RICHARD,,https://lens.org/150-772-151-366-085,Granted Patent,no,4,0,12,12,0,F02D41/10;;F02D41/12;;F02D41/3023;;F02D41/402;;F02M26/06;;F02D41/0072;;F02D41/005;;Y02T10/40;;F02M26/06;;F02D41/10;;F02D41/12;;F02D41/3023;;F02D41/402;;Y02T10/40;;F02D43/00;;F02D41/0072;;F02D41/005;;F02D41/3076;;F02P5/145;;F02B47/08;;F02D41/0007,F02D43/00;;F02D21/08,,0,0,,,,ACTIVE
666,US,A1,US 2017/0241355 A1,032-700-214-076-878,2017-08-24,2017,US 201715589566 A,2017-05-08,US 201715589566 A;;US 201615000800 A;;US 201313975063 A,2013-08-23,METHOD AND SYSTEM FOR KNOCK CONTROL,"Methods and systems are provided for improving engine knock tolerance, in particular when rapidly ramping in LP-EGR from low levels of EGR. Until a desired LP-EGR rate is achieved, fuel may be delivered as a split injection with at least an intake stroke injection and a compression stroke injection to compensate for the transport delay in EGR filling the intake system. Subsequently, single fuel injection may be resumed.",FORD GLOBAL TECH LLC,WOOLDRIDGE STEVEN;;SURNILLA GOPICHANDRA;;BOYER BRAD ALAN;;HILDITCH JAMES ALFRED;;SHELBY MICHAEL HOWARD;;GLUGLA CHRIS PAUL;;PETERSEN BENJAMIN RICHARD,FORD GLOBAL TECHNOLOGIES LLC (2013-08-08),https://lens.org/032-700-214-076-878,Patent Application,yes,2,3,12,12,0,F02D41/10;;F02D41/12;;F02D41/3023;;F02D41/402;;F02M26/06;;F02D41/0072;;F02D41/005;;Y02T10/40;;F02M26/06;;F02D41/10;;F02D41/12;;F02D41/3023;;F02D41/402;;Y02T10/40;;F02D43/00;;F02D41/0072;;F02D41/005;;F02D41/3076;;F02P5/145;;F02B47/08;;F02D41/0007,F02D41/00;;F02B47/08;;F02D41/30;;F02D41/40;;F02D43/00;;F02M26/06;;F02P5/145,,0,0,,,,ACTIVE
667,AU,A1,AU 2005/322209 A1,059-860-856-388-93X,2006-07-06,2006,AU 2005/322209 A,2005-12-21,US 71333905 P;;US 63814304 P;;US 2005/0046364 W,2004-12-23,Modified amine-aldehyde resins and uses thereof in separation processes,,GEORGIA PACIFIC CHEMICALS LLC,MILLS JEFFREY;;HURD PHILLIP W;;KELLY ROBBIE D;;WRIGHT JAMES;;ARTHUR LISA M;;REDIGER RICHARD;;BOYER PETER;;HART PAUL,,https://lens.org/059-860-856-388-93X,Patent Application,no,0,1,19,56,0,B01D21/0012;;B01D21/01;;B01D61/14;;B03D1/01;;B03D1/012;;B03D1/016;;B03D1/02;;B03D1/08;;B03D3/06;;B28C1/08;;C01P2006/80;;C02F1/001;;C02F1/24;;C02F1/44;;C02F1/54;;C02F1/56;;C02F1/683;;C02F2101/103;;C02F2101/20;;C02F2103/10;;C02F2103/12;;C02F2103/28;;C09C1/42;;C10G1/045;;C22B3/24;;E21B21/068;;C10G2300/1003;;C10G2300/1033;;C10G2300/208;;B03D1/0046;;B03D2201/06;;B03D2203/006;;B03D2203/02;;B03D2203/10;;Y02P10/20;;B01D21/01;;B01D37/02;;B01D37/03;;B03B1/04;;C22B3/24;;C02F1/683;;B03D1/01;;C22B3/24;;B03D3/06;;C01P2006/80;;B01D61/14;;C02F1/24;;B28C1/08;;C10G1/045;;B03D1/08;;C02F1/56;;B01D21/0012;;E21B21/068;;C09C1/42;;C02F2101/20;;C02F2103/10;;B03D1/012;;B03D1/016;;C02F1/54;;C02F1/001;;C02F2101/103;;B01D21/01;;B03D1/02;;C02F1/44;;C02F2103/12;;C02F2103/28;;C10G2300/208;;C10G2300/1033;;C10G2300/1003;;B03D2201/06;;B03D1/0046;;B03D2203/02;;B03D2203/006;;B03D2203/10;;Y02P10/20,B03D1/02;;B01D21/01;;B01D37/02;;B01D37/03;;B03B1/04;;B03D1/01;;B03D1/016;;B28C1/08;;C02F1/56;;C02F11/14;;C09C1/42;;C10G1/04;;C10G33/00;;C22B3/00,,0,0,,,,INACTIVE
668,US,B2,US 9664128 B2,039-757-337-326-47X,2017-05-30,2017,US 201615000800 A,2016-01-19,US 201615000800 A;;US 201313975063 A,2013-08-23,Method and system for knock control,"Methods and systems are provided for improving engine knock tolerance, in particular when rapidly ramping in LP-EGR from low levels of EGR. Until a desired LP-EGR rate is achieved, fuel may be delivered as a split injection with at least an intake stroke injection and a compression stroke injection to compensate for the transport delay in EGR filling the intake system. Subsequently, single fuel injection may be resumed.",FORD GLOBAL TECH LLC,WOOLDRIDGE STEVEN;;SURNILLA GOPICHANDRA;;BOYER BRAD ALAN;;HILDITCH JAMES ALFRED;;SHELBY MICHAEL HOWARD;;GLUGLA CHRIS PAUL;;PETERSEN BENJAMIN RICHARD,FORD GLOBAL TECHNOLOGIES LLC (2013-08-08),https://lens.org/039-757-337-326-47X,Granted Patent,yes,17,3,12,12,0,F02D41/10;;F02D41/12;;F02D41/3023;;F02D41/402;;F02M26/06;;F02D41/0072;;F02D41/005;;Y02T10/40;;F02M26/06;;F02D41/10;;F02D41/12;;F02D41/3023;;F02D41/402;;Y02T10/40;;F02D43/00;;F02D41/0072;;F02D41/005;;F02D41/3076;;F02P5/145;;F02B47/08;;F02D41/0007,F02D41/00;;F02D41/10;;F02D41/12;;F02D41/30;;F02D41/40;;F02D43/00;;F02M26/06;;F02P5/145,,0,0,,,,ACTIVE
669,US,B2,US 9845751 B2,005-689-140-861-908,2017-12-19,2017,US 201715418580 A,2017-01-27,US 201715418580 A;;US 201615151337 A;;US 201313975068 A,2013-08-23,Method and system for improved dilution tolerance,"Methods and systems are provided for improving combustion stability, in particular during transient operations such as tip-out to lower load conditions, when EGR is being purged. Until a desired LP-EGR rate is achieved, fuel may be delivered as a split injection with at least an intake stroke injection and a compression stroke injection. Subsequently, single fuel injection may be resumed.",FORD GLOBAL TECH LLC,WOOLDRIDGE STEVEN;;SURNILLA GOPICHANDRA;;YI JIANWEN JAMES;;BOYER BRAD ALAN;;HILDITCH JAMES ALFRED;;SHELBY MICHAEL HOWARD;;PETERSEN BENJAMIN RICHARD,FORD GLOBAL TECHNOLOGIES LLC (2013-08-08),https://lens.org/005-689-140-861-908,Granted Patent,yes,15,0,11,11,0,F02D41/045;;F02D41/107;;F02D41/1498;;F02D41/402;;F02D35/027;;F02D41/0005;;F02D2200/602;;F02D41/005;;F02M26/06;;Y02T10/40;;F02D41/045;;F02D41/107;;F02D41/1498;;F02D41/402;;F02D35/027;;F02D41/0005;;F02D2200/602;;Y02T10/40;;F02D43/00;;F02D41/005;;F02M26/06;;F02D41/0007;;F02D41/0052;;F02D41/0077;;F02D43/04,B60T7/12;;F02D41/00;;F02D41/40;;F02D43/04;;F02M26/06,,0,0,,,,ACTIVE
670,US,B2,US 9611792 B2,090-483-339-312-42X,2017-04-04,2017,US 201615151337 A,2016-05-10,US 201615151337 A;;US 201313975068 A,2013-08-23,Method and system for improved dilution tolerance,"Methods and systems are provided for improving combustion stability, in particular during transient operations such as tip-out to lower load conditions, when EGR is being purged. Until a desired LP-EGR rate is achieved, fuel may be delivered as a split injection with at least an intake stroke injection and a compression stroke injection. Subsequently, single fuel injection may be resumed.",FORD GLOBAL TECH LLC,WOOLDRIDGE STEVEN;;SURNILLA GOPICHANDRA;;YI JIANWEN JAMES;;BOYER BRAD ALAN;;HILDITCH JAMES ALFRED;;SHELBY MICHAEL HOWARD;;PETERSEN BENJAMIN RICHARD,FORD GLOBAL TECHNOLOGIES LLC (2013-08-08),https://lens.org/090-483-339-312-42X,Granted Patent,yes,13,7,11,11,0,F02D41/045;;F02D41/107;;F02D41/1498;;F02D41/402;;F02D35/027;;F02D41/0005;;F02D2200/602;;F02D41/005;;F02M26/06;;Y02T10/40;;F02D41/045;;F02D41/107;;F02D41/1498;;F02D41/402;;F02D35/027;;F02D41/0005;;F02D2200/602;;Y02T10/40;;F02D43/00;;F02D41/005;;F02M26/06;;F02D41/0007;;F02D41/0052;;F02D41/0077;;F02D43/04,F02D35/02;;F02D41/00;;F02D41/04;;F02D41/10;;F02D41/14;;F02D41/40;;F02D43/00;;F02M26/06,,0,0,,,,ACTIVE
671,DE,C2,DE 2126246 C2,010-867-446-070-498,1986-04-24,1986,DE 2126246 A,1971-05-26,US 4111670 A,1970-05-27,DE 2126246 C2,,"MONSANTO CO., ST. LOUIS, MO., US","STENSETH, RAYMOND EUGENE, CLAYTON, MO., US;;BOYER, RONALD JOSEPH, FESTUS, MO., US;;SHEEHAN, RICHARD JOHN, PALOS HILLS, ILL., US",,https://lens.org/010-867-446-070-498,Granted Patent,no,0,0,7,9,0,C07C51/573,C07C51/573,,0,0,,,,EXPIRED
672,CN,A,CN 104421056 A,007-059-428-300-874,2015-03-18,2015,CN 201410419259 A,2014-08-22,US 201313975068 A,2013-08-23,Method and system for improved dilution tolerance,"The invention relates to a method and system for improved dilution tolerance. The method and system are provided for improving combustion stability, in particular during transient operations such as tip-out to lower load conditions, when EGR is being purged. Until a desired LP-EGR rate is achieved, fuel may be delivered as a split injection with at least an intake stroke injection and a compression stroke injection. Subsequently, single fuel injection may be resumed.",FORD GLOBAL TECH LLC,BENJAMIN RICHARD PETERSEN;;MICHAEL HOWARD SHELBY;;GOPICHANDRA SURNILLA;;JAMES ALFRED HILDITCH;;STEVEN WOOLDRIDGE;;JIANWEN JAMES YI;;BRAD ALAN BOYER,,https://lens.org/007-059-428-300-874,Patent Application,no,6,4,11,11,0,F02D41/045;;F02D41/107;;F02D41/1498;;F02D41/402;;F02D35/027;;F02D41/0005;;F02D2200/602;;F02D41/005;;F02M26/06;;Y02T10/40;;F02D41/045;;F02D41/107;;F02D41/1498;;F02D41/402;;F02D35/027;;F02D41/0005;;F02D2200/602;;Y02T10/40;;F02D43/00;;F02D41/005;;F02M26/06;;F02D41/0007;;F02D41/0052;;F02D41/0077;;F02D43/04,F02M25/07;;F02D41/00,,0,0,,,,ACTIVE
673,US,A1,US 2017/0138282 A1,187-030-279-948-279,2017-05-18,2017,US 201715418580 A,2017-01-27,US 201715418580 A;;US 201615151337 A;;US 201313975068 A,2013-08-23,METHOD AND SYSTEM FOR IMPROVED DILUTION TOLERANCE,"Methods and systems are provided for improving combustion stability, in particular during transient operations such as tip-out to lower load conditions, when EGR is being purged. Until a desired LP-EGR rate is achieved, fuel may be delivered as a split injection with at least an intake stroke injection and a compression stroke injection. Subsequently, single fuel injection may be resumed.",FORD GLOBAL TECH LLC,WOOLDRIDGE STEVEN;;SURNILLA GOPICHANDRA;;YI JIANWEN JAMES;;BOYER BRAD ALAN;;HILDITCH JAMES ALFRED;;SHELBY MICHAEL HOWARD;;PETERSEN BENJAMIN RICHARD,FORD GLOBAL TECHNOLOGIES LLC (2013-08-08),https://lens.org/187-030-279-948-279,Patent Application,yes,1,5,11,11,0,F02D41/045;;F02D41/107;;F02D41/1498;;F02D41/402;;F02D35/027;;F02D41/0005;;F02D2200/602;;F02D41/005;;F02M26/06;;Y02T10/40;;F02D41/045;;F02D41/107;;F02D41/1498;;F02D41/402;;F02D35/027;;F02D41/0005;;F02D2200/602;;Y02T10/40;;F02D43/00;;F02D41/005;;F02M26/06;;F02D41/0007;;F02D41/0052;;F02D41/0077;;F02D43/04,F02D41/00;;F02D41/40;;F02D43/04;;F02M26/06,,0,0,,,,ACTIVE
674,DE,A1,DE 102014216496 A1,015-818-780-400-676,2015-02-26,2015,DE 102014216496 A,2014-08-20,US 201313975063 A,2013-08-23,VERFAHREN UND SYSTEM FÜR DIE KLOPFSTEUERUNG,"Es werden Verfahren und Systeme zum Verbessern der Klopftoleranz der Kraftmaschine bereitgestellt, insbesondere wenn die LP-AGR von niedrigen Niveaus der AGR schnell kontinuierlich erhöht wird. Bis eine LP-AGR-Sollrate erreicht ist, kann der Kraftstoff als eine geteilte Einspritzung mit wenigstens einer Einlasstakt-Einspritzung und einer Verdichtungstakt-Einspritzung zugeführt werden, um die Transportverzögerung der AGR, die das Einlasssystem füllt, zu kompensieren. Anschließend kann die einzige Kraftstoffeinspritzung wiederaufgenommen werden.",FORD GLOBAL TECH LLC,WOOLDRIDGE STEVEN;;GOPICHANDRA SURNILLA;;BOYER BRAD ALAN;;HILDITCH JAMES ALFRED;;SHELBY MICHAEL HOWARD;;GLUGLA CHRIS PAUL;;PETERSEN BENJAMIN RICHARD,,https://lens.org/015-818-780-400-676,Patent Application,no,1,3,12,12,0,F02D41/10;;F02D41/12;;F02D41/3023;;F02D41/402;;F02M26/06;;F02D41/0072;;F02D41/005;;Y02T10/40;;F02M26/06;;F02D41/10;;F02D41/12;;F02D41/3023;;F02D41/402;;Y02T10/40;;F02D43/00;;F02D41/0072;;F02D41/005;;F02D41/3076;;F02P5/145;;F02B47/08;;F02D41/0007,F02D43/00;;F02D21/08,,0,0,,,,ACTIVE
675,AU,A2,AU 2005/322209 A2,113-701-987-874-688,2006-07-06,2006,AU 2005/322209 A,2005-12-21,US 71333905 P;;US 63814304 P;;US 2005/0046364 W,2004-12-23,Modified amine-aldehyde resins and uses thereof in separation processes,,GEORGIA PACIFIC CHEMICALS LLC,MILLS JEFFREY;;HURD PHILLIP W;;KELLY ROBBIE D;;WRIGHT JAMES;;ARTHUR LISA M;;REDIGER RICHARD;;BOYER PETER;;HART PAUL,,https://lens.org/113-701-987-874-688,Patent Application,no,0,0,19,56,0,B01D21/0012;;B01D21/01;;B01D61/14;;B03D1/01;;B03D1/012;;B03D1/016;;B03D1/02;;B03D1/08;;B03D3/06;;B28C1/08;;C01P2006/80;;C02F1/001;;C02F1/24;;C02F1/44;;C02F1/54;;C02F1/56;;C02F1/683;;C02F2101/103;;C02F2101/20;;C02F2103/10;;C02F2103/12;;C02F2103/28;;C09C1/42;;C10G1/045;;C22B3/24;;E21B21/068;;C10G2300/1003;;C10G2300/1033;;C10G2300/208;;B03D1/0046;;B03D2201/06;;B03D2203/006;;B03D2203/02;;B03D2203/10;;Y02P10/20;;B01D21/01;;B01D37/02;;B01D37/03;;B03B1/04;;C22B3/24;;C02F1/683;;B03D1/01;;C22B3/24;;B03D3/06;;C01P2006/80;;B01D61/14;;C02F1/24;;B28C1/08;;C10G1/045;;B03D1/08;;C02F1/56;;B01D21/0012;;E21B21/068;;C09C1/42;;C02F2101/20;;C02F2103/10;;B03D1/012;;B03D1/016;;C02F1/54;;C02F1/001;;C02F2101/103;;B01D21/01;;B03D1/02;;C02F1/44;;C02F2103/12;;C02F2103/28;;C10G2300/208;;C10G2300/1033;;C10G2300/1003;;B03D2201/06;;B03D1/0046;;B03D2203/02;;B03D2203/006;;B03D2203/10;;Y02P10/20,B03D1/02;;B01D21/01;;B01D37/02;;B01D37/03;;B03B1/04;;B03D1/01;;B03D1/016;;B28C1/08;;C02F1/56;;C02F11/14;;C09C1/42;;C10G1/04;;C10G33/00;;C22B3/00,,0,0,,,,INACTIVE
676,US,B2,US 9284909 B2,101-417-868-687-157,2016-03-15,2016,US 201313975063 A,2013-08-23,US 201313975063 A,2013-08-23,Method and system for knock control,"Methods and systems are provided for improving engine knock tolerance, in particular when rapidly ramping in LP-EGR from low levels of EGR. Until a desired LP-EGR rate is achieved, fuel may be delivered as a split injection with at least an intake stroke injection and a compression stroke injection to compensate for the transport delay in EGR filling the intake system. Subsequently, single fuel injection may be resumed.",FORD GLOBAL TECH LLC,WOOLDRIDGE STEVEN;;SURNILLA GOPICHANDRA;;BOYER BRAD ALAN;;HILDITCH JAMES ALFRED;;SHELBY MICHAEL HOWARD;;GLUGLA CHRIS PAUL;;PETERSEN BENJAMIN RICHARD,FORD GLOBAL TECHNOLOGIES LLC (2013-08-08),https://lens.org/101-417-868-687-157,Granted Patent,yes,13,11,12,12,0,F02D41/10;;F02D41/12;;F02D41/3023;;F02D41/402;;F02M26/06;;F02D41/0072;;F02D41/005;;Y02T10/40;;F02M26/06;;F02D41/10;;F02D41/12;;F02D41/3023;;F02D41/402;;Y02T10/40;;F02D43/00;;F02D41/0072;;F02D41/005;;F02D41/3076;;F02P5/145;;F02B47/08;;F02D41/0007,F02B47/08;;F02D41/00;;F02D41/10;;F02D41/12;;F02D41/30;;F02D41/40;;F02D43/00,,1,0,,,"Wooldridge, Steven et al., ""Method and System for Improved Dilution Tolerance,"" U.S. Appl. No. 13/975,068, filed Aug. 23, 2013, 57 pages.",ACTIVE
677,US,A1,US 2015/0053177 A1,197-635-279-269-270,2015-02-26,2015,US 201313975063 A,2013-08-23,US 201313975063 A,2013-08-23,METHOD AND SYSTEM FOR KNOCK CONTROL,"Methods and systems are provided for improving engine knock tolerance, in particular when rapidly ramping in LP-EGR from low levels of EGR. Until a desired LP-EGR rate is achieved, fuel may be delivered as a split injection with at least an intake stroke injection and a compression stroke injection to compensate for the transport delay in EGR filling the intake system. Subsequently, single fuel injection may be resumed.",FORD GLOBAL TECH LLC,WOOLDRIDGE STEVEN;;SURNILLA GOPICHANDRA;;BOYER BRAD ALAN;;HILDITCH JAMES ALFRED;;SHELBY MICHAEL HOWARD;;GLUGLA CHRIS PAUL;;PETERSEN BENJAMIN RICHARD,FORD GLOBAL TECHNOLOGIES LLC (2013-08-08),https://lens.org/197-635-279-269-270,Patent Application,yes,6,22,12,12,0,F02D41/10;;F02D41/12;;F02D41/3023;;F02D41/402;;F02M26/06;;F02D41/0072;;F02D41/005;;Y02T10/40;;F02M26/06;;F02D41/10;;F02D41/12;;F02D41/3023;;F02D41/402;;Y02T10/40;;F02D43/00;;F02D41/0072;;F02D41/005;;F02D41/3076;;F02P5/145;;F02B47/08;;F02D41/0007,F02D43/00,123/406.3;;701/108,0,0,,,,ACTIVE
678,US,B1,US 10338325 B1,192-003-413-549-082,2019-07-02,2019,US 201815995559 A,2018-06-01,US 201815995559 A,2018-06-01,Nanofiller in an optical interface,"Systems and methods for nanofiller in an optical interface are provided. One system includes a fiber-optic interface for one or more optical fibers that includes a body including one or more grooves defined therein. At least one groove in the one or more grooves is configured to receive a corresponding optical fiber of the one or more optical fibers. The at least one groove of the one or more grooves is further configured to receive an adhesive to attach the body to a portion of the corresponding optical fiber. Further, fiber-optic interface includes a suspended structure associated with the at least one groove configured to couple light between the suspended structure and the corresponding optical fiber. Also, the adhesive comprises nanofiller configured to support an alignment of the suspended structure with the corresponding optical fiber within the at least one groove.",IBM,JANTA-POLCZYNSKI BARNIM ALEXANDER;;BARWICZ TYMON;;CYR ELAINE;;BOYER NICOLAS;;PAQUET MARIE-CLAUDE;;LANGLOIS RICHARD D;;FORTIER PAUL FRANCIS,INTERNATIONAL BUSINESS MACHINES CORPORATION (2018-05-22),https://lens.org/192-003-413-549-082,Granted Patent,yes,19,1,1,1,0,G02B6/3636;;G02B6/305;;G02B6/4239;;G02B6/4243;;G02B6/02295;;G02B6/4206;;G02B6/305;;G02B6/3636;;G02B6/4239;;G02B6/4243,G02B6/42;;G02B6/02,,3,1,037-234-500-568-159,10.1109/ectc.2014.6897555,"Zhang, Yan et al. “Characterization of nano-enchanced interconnect materials for find pitch assembly”, Soldering & Surface Mount Technology, www.Emeraldinsight.com/0954-0911.htm, Oct. 18, 2015, pp. 12-18.;;Taira, Yoichi et al., “Nanofiller based spin-on materials for negligible reflection of silicon photonic external coupling”, Electronic Components and Technology Conference (ECTC), May 27-30, 2014, pp. 1-3.;;Li, Zhuo, “Nano filler dispersion in polymer composites for electronic packaging”, Electronic Components and Technology Conference (ECTC), May 29-Jun. 1, 2012, pp. 1-3.",ACTIVE
679,DE,A1,DE 102014216663 A1,017-577-081-941-121,2015-02-26,2015,DE 102014216663 A,2014-08-21,US 201313975068 A,2013-08-23,Verfahren und System für verbesserte Verdünnungstoleranz,"Es werden Verfahren und Systeme zum Verbessern der Verbrennungsstabilität, insbesondere bei Übergangsvorgängen zur Verfügung gestellt, wie beispielsweise Gaswegnehmen zu niedrigeren Lastzuständen, wenn AGR gerade ausgespült wird. Bis eine gewünschte ND-AGR-Rate erreicht ist, kann Kraftstoff als eine geteilte Kraftstoffeinspritzung mit mindestens einer Ansaughub-Einspritzung und einer Verdichtungshub-Einspritzung zugeführt werden. Anschließend kann die einzelne Kraftstoffeinspritzung wieder aufgenommen werden.",FORD GLOBAL TECH LLC,WOOLDRIDGE STEVEN;;SUMILLA GOPICHANDRA;;YI JIANWEN JAMES;;BOYER BRAD ALAN;;HILDITCH JAMES ALFRED;;SHELBY MICHAEL HOWARD;;PETERSEN BENJAMIN RICHARD,,https://lens.org/017-577-081-941-121,Patent Application,no,1,0,11,11,0,F02D41/045;;F02D41/107;;F02D41/1498;;F02D41/402;;F02D35/027;;F02D41/0005;;F02D2200/602;;F02D41/005;;F02M26/06;;Y02T10/40;;F02D41/045;;F02D41/107;;F02D41/1498;;F02D41/402;;F02D35/027;;F02D41/0005;;F02D2200/602;;Y02T10/40;;F02D43/00;;F02D41/005;;F02M26/06;;F02D41/0007;;F02D41/0052;;F02D41/0077;;F02D43/04,F02D43/00;;F02D21/08;;F02D41/30,,0,0,,,,ACTIVE
680,US,A1,US 2016/0131053 A1,021-654-598-583-524,2016-05-12,2016,US 201615000800 A,2016-01-19,US 201615000800 A;;US 201313975063 A,2013-08-23,METHOD AND SYSTEM FOR KNOCK CONTROL,"Methods and systems are provided for improving engine knock tolerance, in particular when rapidly ramping in LP-EGR from low levels of EGR. Until a desired LP-EGR rate is achieved, fuel may be delivered as a split injection with at least an intake stroke injection and a compression stroke injection to compensate for the transport delay in EGR filling the intake system. Subsequently, single fuel injection may be resumed.",FORD GLOBAL TECH LLC,WOOLDRIDGE STEVEN;;SURNILLA GOPICHANDRA;;BOYER BRAD ALAN;;HILDITCH JAMES ALFRED;;SHELBY MICHAEL HOWARD;;GLUGLA CHRIS PAUL;;PETERSEN BENJAMIN RICHARD,FORD GLOBAL TECHNOLOGIES LLC (2013-08-08),https://lens.org/021-654-598-583-524,Patent Application,yes,5,0,12,12,0,F02D41/10;;F02D41/12;;F02D41/3023;;F02D41/402;;F02M26/06;;F02D41/0072;;F02D41/005;;Y02T10/40;;F02M26/06;;F02D41/10;;F02D41/12;;F02D41/3023;;F02D41/402;;Y02T10/40;;F02D43/00;;F02D41/0072;;F02D41/005;;F02D41/3076;;F02P5/145;;F02B47/08;;F02D41/0007,F02D41/00;;F02D41/30;;F02D41/40;;F02M26/06;;F02P5/145,,0,0,,,,ACTIVE
681,US,A1,US 2006/0151360 A1,050-495-090-679-097,2006-07-13,2006,US 29894805 A,2005-12-12,US 29894805 A;;US 63814304 P;;US 71333905 P,2004-12-23,Modified amine-aldehyde resins and uses thereof in separation processes,"Modified resins are disclosed for removing a wide variety of solids and/or ionic species from the liquids in which they are suspended and/or dissolved. These modified resins are especially useful as froth flotation depressants in the beneficiation of many types of materials (e.g., mineral and metal ores), including the beneficiation of impure coal comprising clay impurities, as well as in the separation of valuable bitumen from solid contaminants such as sand. The modified resins are also useful for treating aqueous liquid suspensions to remove solid particulates, as well as for removing metallic ions in the purification of water. The modified resins comprise a base resin that is modified with a coupling agent, which is highly selective for binding to solid contaminants and especially siliceous materials such as sand or clay.",GEORGIA PACIFIC RESINS,WRIGHT JAMES;;HURD PHILLIP W;;BOYER PETER;;ARTHUR LISA M;;MILLS JEFFREY;;HART PAUL;;REDIGER RICHARD;;KELLY ROBBIE D,INGEVITY SOUTH CAROLINA LLC (2018-03-08);;GEORGIA-PACIFIC CHEMICALS LLC (2006-12-31);;GEORGIA-PACIFIC RESINS INC (2006-10-10),https://lens.org/050-495-090-679-097,Patent Application,yes,31,57,19,56,0,B01D21/0012;;B01D21/01;;B01D61/14;;B03D1/01;;B03D1/012;;B03D1/016;;B03D1/02;;B03D1/08;;B03D3/06;;B28C1/08;;C01P2006/80;;C02F1/001;;C02F1/24;;C02F1/44;;C02F1/54;;C02F1/56;;C02F1/683;;C02F2101/103;;C02F2101/20;;C02F2103/10;;C02F2103/12;;C02F2103/28;;C09C1/42;;C10G1/045;;C22B3/24;;E21B21/068;;C10G2300/1003;;C10G2300/1033;;C10G2300/208;;B03D1/0046;;B03D2201/06;;B03D2203/006;;B03D2203/02;;B03D2203/10;;Y02P10/20;;B01D21/01;;B01D37/02;;B01D37/03;;B03B1/04;;C22B3/24;;C02F1/683;;B03D1/01;;C22B3/24;;B03D3/06;;C01P2006/80;;B01D61/14;;C02F1/24;;B28C1/08;;C10G1/045;;B03D1/08;;C02F1/56;;B01D21/0012;;E21B21/068;;C09C1/42;;C02F2101/20;;C02F2103/10;;B03D1/012;;B03D1/016;;C02F1/54;;C02F1/001;;C02F2101/103;;B01D21/01;;B03D1/02;;C02F1/44;;C02F2103/12;;C02F2103/28;;C10G2300/208;;C10G2300/1033;;C10G2300/1003;;B03D2201/06;;B03D1/0046;;B03D2203/02;;B03D2203/006;;B03D2203/10;;Y02P10/20,B03D1/14;;B03D1/016;;C02F1/56,209/166;;209/167;;208/390;;208/391;;208/425,0,0,,,,INACTIVE
682,US,B2,US 9840976 B2,053-404-115-810-833,2017-12-12,2017,US 201715589566 A,2017-05-08,US 201715589566 A;;US 201615000800 A;;US 201313975063 A,2013-08-23,Method and system for knock control,"Methods and systems are provided for improving engine knock tolerance, in particular when rapidly ramping in LP-EGR from low levels of EGR. Until a desired LP-EGR rate is achieved, fuel may be delivered as a split injection with at least an intake stroke injection and a compression stroke injection to compensate for the transport delay in EGR filling the intake system. Subsequently, single fuel injection may be resumed.",FORD GLOBAL TECH LLC,WOOLDRIDGE STEVEN;;SURNILLA GOPICHANDRA;;BOYER BRAD ALAN;;HILDITCH JAMES ALFRED;;SHELBY MICHAEL HOWARD;;GLUGLA CHRIS PAUL;;PETERSEN BENJAMIN RICHARD,FORD GLOBAL TECHNOLOGIES LLC (2013-08-08),https://lens.org/053-404-115-810-833,Granted Patent,yes,19,1,12,12,0,F02D41/10;;F02D41/12;;F02D41/3023;;F02D41/402;;F02M26/06;;F02D41/0072;;F02D41/005;;Y02T10/40;;F02M26/06;;F02D41/10;;F02D41/12;;F02D41/3023;;F02D41/402;;Y02T10/40;;F02D43/00;;F02D41/0072;;F02D41/005;;F02D41/3076;;F02P5/145;;F02B47/08;;F02D41/0007,B60T7/12;;F02B47/08;;F02D41/00;;F02D41/30;;F02D41/40;;F02D43/00;;F02M26/06;;F02P5/145,,0,0,,,,ACTIVE
683,CN,A,CN 104421019 A,106-298-320-529-586,2015-03-18,2015,CN 201410419590 A,2014-08-22,US 201313975063 A,2013-08-23,Method and system for knock control,"The invention relates to a method and a system for knock control. Methods and systems are provided for improving engine knock tolerance, in particular when rapidly ramping in LP-EGR from low levels of EGR. Until a desired LP-EGR rate is achieved, fuel may be delivered as a split injection with at least an intake stroke injection and a compression stroke injection to compensate for the transport delay in EGR filling the intake system. Subsequently, single fuel injection may be resumed.",FORD GLOBAL TECH LLC,GOPICHANDRA SURNILLA;;MICHAEL HOWARD SHELBY;;BRAD ALAN BOYER;;STEVEN WOOLDRIDGE;;CHRIS PAUL GLUGLA;;BENJAMIN RICHARD PETERSEN;;JAMES ALFRED HILDITCH,,https://lens.org/106-298-320-529-586,Patent Application,no,4,5,12,12,0,F02D41/10;;F02D41/12;;F02D41/3023;;F02D41/402;;F02M26/06;;F02D41/0072;;F02D41/005;;Y02T10/40;;F02M26/06;;F02D41/10;;F02D41/12;;F02D41/3023;;F02D41/402;;Y02T10/40;;F02D43/00;;F02D41/0072;;F02D41/005;;F02D41/3076;;F02P5/145;;F02B47/08;;F02D41/0007,F02D41/00;;F02M25/07,,0,0,,,,ACTIVE
684,EP,B1,EP 0848394 B1,071-493-112-853-109,2004-08-18,2004,EP 97203510 A,1997-11-11,US 76357496 A,1996-12-10,Integrated ignition coil and spark plug,,DELPHI TECH INC,BOYER JAMES ALVA;;HUNTZINGER DWAYNE ALLEN;;LEVERS JR HARRY OLIVER;;SKINNER ALBERT ANTHONY;;HAISLEY RICHARD LAURENCE;;BUTLER JR RAYMOND ORA,"DELPHI TECHNOLOGIES, INC. (2000-11-29)",https://lens.org/071-493-112-853-109,Granted Patent,yes,6,0,7,7,0,F02P13/00;;F02P13/00;;H01F38/12;;H01F38/12;;H01F2038/122;;H01F2038/122;;H01F2038/125;;H01F2038/125,F02P13/00;;F02P15/00;;H01F38/12;;H01T13/20;;H01T15/00,,0,0,,,,EXPIRED
685,EP,A1,EP 0398672 A1,011-211-223-667-435,1990-11-22,1990,EP 90305256 A,1990-05-16,US 35301089 A,1989-05-17,Microwave absorber for direct surface application.,"A layered microwave radiation absorber comprises an absorbing layer bound to one side of a conductive layer (such as a metallic plate or foil), and an adhesive layer bound on the other side of the conductive layer. The combination may be applied directly to the surface of any object, but especially to an existing conductive object coated with an nonconductive coating (such as paint) without removing the nonconductive coating from the surface. Several types of absorbing materials may be used, and other layers may be included. The absorber has superior resistance to delamination.  ",MINNESOTA MINING & MFG,BOYER CHARLES E III C O MINNES;;KUO RICHARD J C O MINNESOTA MI;;LOGIUDICE STEPHEN M C O MINNES,,https://lens.org/011-211-223-667-435,Patent Application,yes,10,20,7,7,0,H01Q17/004;;H05K9/0088;;Y10T428/256;;Y10T428/268;;Y10T428/28;;B32B7/025;;H01Q17/00;;B32B7/025;;Y10T428/256;;Y10T428/268;;Y10T428/28;;B32B7/12;;B32B2307/208;;B32B2307/202;;H05K9/0088;;H01Q17/004;;B32B7/025,B32B5/02;;B32B7/025;;B32B5/16;;B32B7/12;;H01Q17/00;;H05K9/00,,0,0,,,,EXPIRED
686,WO,A1,WO 1997/036985 A1,059-166-786-376-852,1997-10-09,1997,US 9704650 W,1997-03-21,AU 1996/050383 A,1996-03-29,LOW MOISTURE LAUNDRY DETERGENT BAR WITH IMPROVED ENZYME STABILITY,This invention relates to a laundry detergent bar composition having a low moisture content with improved cellulase enzyme stability. The process to make such compositions is also included herein.,PROCTER & GAMBLE;;MISAJON ISAURO MANUEL E;;MURKUNDE ROHAN GOVIND;;MIRASOL MA AMELITA;;BOYER STANTON LANE;;BARANGAN ANASTACIA ROSARIO A;;LASAP RICHARD TUGAO,MISAJON ISAURO MANUEL E;;MURKUNDE ROHAN GOVIND;;MIRASOL MA AMELITA;;BOYER STANTON LANE;;BARANGAN ANASTACIA ROSARIO A;;LASAP RICHARD TUGAO,,https://lens.org/059-166-786-376-852,Patent Application,yes,6,8,4,4,0,C11D17/0069;;C11D1/146;;C11D1/22;;C11D1/523;;C11D1/835;;C11D3/124;;C11D3/38645;;C11D17/006,C11D1/14;;C11D1/22;;C11D1/52;;C11D1/835;;C11D3/12;;C11D3/386;;C11D17/00,,0,0,,,,PENDING
687,EP,A1,EP 0848394 A1,161-434-578-412-965,1998-06-17,1998,EP 97203510 A,1997-11-11,US 76357496 A,1996-12-10,Integrated ignition coil and spark plug,A spark plug and ignition coil having concentrically wound primary (23) and secondary (37) coils about a plastic coated iron core (25) are integrated in a dielectric fluid filled assembly (10) characterized by advantageous employment of structurally inherent capacitances for radio frequency attenuation.,GEN MOTORS CORP,BOYER JAMES ALVA;;HUNTZINGER DWAYNE ALLEN;;LEVERS JR HARRY OLIVER;;SKINNER ALBERT ANTHONY;;HAISLEY RICHARD LAURENCE;;BUTLER JR RAYMOND ORA,"DELPHI TECHNOLOGIES, INC. (2000-11-29)",https://lens.org/161-434-578-412-965,Patent Application,yes,6,0,7,7,0,F02P13/00;;F02P13/00;;H01F38/12;;H01F38/12;;H01F2038/122;;H01F2038/122;;H01F2038/125;;H01F2038/125,F02P13/00;;F02P15/00;;H01F38/12;;H01T13/20;;H01T15/00,,0,0,,,,EXPIRED
688,EP,B1,EP 0398672 B1,097-490-010-157-890,1996-02-21,1996,EP 90305256 A,1990-05-16,US 35301089 A,1989-05-17,Microwave absorber for direct surface application,,MINNESOTA MINING & MFG,BOYER CHARLES E III C O MINNES;;KUO RICHARD J C O MINNESOTA MI;;LOGIUDICE STEPHEN M C O MINNES,,https://lens.org/097-490-010-157-890,Granted Patent,yes,10,0,7,7,0,H01Q17/004;;H05K9/0088;;Y10T428/256;;Y10T428/268;;Y10T428/28;;B32B7/025;;H01Q17/00;;B32B7/025;;Y10T428/256;;Y10T428/268;;Y10T428/28;;B32B7/12;;B32B2307/208;;B32B2307/202;;H05K9/0088;;H01Q17/004;;B32B7/025,B32B5/02;;B32B7/025;;B32B5/16;;B32B7/12;;H01Q17/00;;H05K9/00,,0,0,,,,EXPIRED
689,US,A,US 5706792 A,053-957-360-287-492,1998-01-13,1998,US 76357496 A,1996-12-10,US 76357496 A,1996-12-10,Integrated ignition coil and spark plug,A spark plug and ignition coil having concentrically wound primary and secondary coils about a plastic coated iron core are integrated in a dielectric fluid filled assembly characterized by advantageous employment of structurally inherent capacitances for radio frequency attenuation.,GEN MOTORS CORP,BOYER JAMES ALVA;;HUNTZINGER DWAYNE ALLEN;;LEVERS JR HARRY OLIVER;;SKINNER ALBERT ANTHONY;;HAISLEY RICHARD LAURENCE;;BUTLER JR RAYMOND ORA,DELPHI TECHNOLOGIES INC (1999-01-01);;GENERAL MOTORS CORPORATION (1996-11-21),https://lens.org/053-957-360-287-492,Granted Patent,yes,12,42,7,7,0,F02P13/00;;F02P13/00;;H01F38/12;;H01F38/12;;H01F2038/122;;H01F2038/122;;H01F2038/125;;H01F2038/125,F02P13/00;;F02P15/00;;H01F38/12;;H01T13/20;;H01T15/00,123/634;;X123167 PA,0,0,,,,EXPIRED
690,DE,T2,DE 69730301 T2,085-950-874-036-024,2004-12-30,2004,DE 69730301 T,1997-11-11,US 76357496 A,1996-12-10,Integrierte Zündspule und Zündkerze,,DELPHI TECH INC,BOYER JAMES ALVA;;HUNTZINGER DWAYNE ALLEN;;LEVERS JR HARRY OLIVER;;SKINNER ALBERT ANTHONY;;HAISLEY RICHARD LAURENCE;;BUTLER JR RAYMOND ORA,,https://lens.org/085-950-874-036-024,Granted Patent,no,0,2,7,7,0,F02P13/00;;F02P13/00;;H01F38/12;;H01F38/12;;H01F2038/122;;H01F2038/122;;H01F2038/125;;H01F2038/125,F02P13/00;;F02P15/00;;H01F38/12;;H01T13/20;;H01T15/00,,0,0,,,,EXPIRED
691,MX,A,MX 9710015 A,162-709-871-900-593,1998-07-31,1998,MX 9710015 A,1997-12-10,US 76357496 A,1996-12-10,INTEGRATED IGNITION COIL AND SPARK PLUG.,A spark plug and ignition coil having concentrically wound primary and secondary coils about a plastic coated iron core are integrated in a dielectric fluid filled assembly characterized by advantageous employment of structurally inherent capacitances for radio frequency attenuation.,GEN MOTORS CORP,BOYER JAMES ALVA;;HUNTZINGER DWAYNE ALLEN;;LEVERS HARRY OLIVER JR;;SKINNER ALBERT ANTHONY;;HAISLEY RICHARD LAURENCE;;BUTLER RAYMOND ORA JR,,https://lens.org/162-709-871-900-593,Patent Application,no,0,0,7,7,0,F02P13/00;;F02P13/00;;H01F38/12;;H01F38/12;;H01F2038/122;;H01F2038/122;;H01F2038/125;;H01F2038/125,F02P13/00;;F02P15/00;;H01F38/12;;H01T13/20;;H01T15/00,,0,0,,,,PENDING
692,JP,A,JP H10172716 A,063-018-776-406-632,1998-06-26,1998,JP 33711597 A,1997-12-08,US 76357496 A,1996-12-10,INTEGRATED IGNITION COIL AND SPARK PLUG,"PROBLEM TO BE SOLVED: To provide an integrated spark plug and ignition coil device whose dimension can be decided so as to fit to a thin spark plug installing cavity part by surrounding a magnetic core round which a primary coil is directly wound, by a secondary coil and a case formed of a magnetic substance on the further outside. SOLUTION: An integrated assembly 10 is installed in a conventional internal combustion engine through a park plug cavity part 53 so as to be screw-fitted to a plug opening to a combustion cylinder. A spark plug assembly 59 exists in one end part of the assembly 10, and a substantially strong outside case 51 having a connector barrell part 11 as an electric external interface is provided in the other end part. This assembly 10 also contains a substantially thin high voltage transformer containing a primary coil, 23, a secondary coil 37 and a magnetic core 25 having high magnetic permeability which are substantially arranged in a coaxial shape. The whole assembly is filled with an inductive fulid suitable for an environment of a high temperature and high voltage.",GEN MOTORS CORP,BOYER JAMES ALVA;;HUNTZINGER DWAYNE ALLEN;;LEVERS JR HARRY OLIVER;;SKINNER ALBERT ANTHONY;;HAISLEY RICHARD LAURENCE;;BUTLER JR RAYMOND ORA,,https://lens.org/063-018-776-406-632,Patent Application,no,0,5,7,7,0,F02P13/00;;F02P13/00;;H01F38/12;;H01F38/12;;H01F2038/122;;H01F2038/122;;H01F2038/125;;H01F2038/125,F02P13/00;;F02P15/00;;H01F38/12;;H01T13/20;;H01T15/00,,0,0,,,,PENDING
693,DE,D1,DE 69730301 D1,025-843-275-408-666,2004-09-23,2004,DE 69730301 T,1997-11-11,US 76357496 A,1996-12-10,Integrierte Zündspule und Zündkerze,,DELPHI TECH INC,BOYER JAMES ALVA;;HUNTZINGER DWAYNE ALLEN;;LEVERS JR HARRY OLIVER;;SKINNER ALBERT ANTHONY;;HAISLEY RICHARD LAURENCE;;BUTLER JR RAYMOND ORA,,https://lens.org/025-843-275-408-666,Granted Patent,no,0,0,7,7,0,F02P13/00;;F02P13/00;;H01F38/12;;H01F38/12;;H01F2038/122;;H01F2038/122;;H01F2038/125;;H01F2038/125,F02P13/00;;F02P15/00;;H01F38/12;;H01T13/20;;H01T15/00,,0,0,,,,EXPIRED
694,WO,A2,WO 2007/021700 A2,109-042-996-274-560,2007-02-22,2007,US 2006/0030942 W,2006-08-09,US 70686505 P,2005-08-10,PRINTING DEVICES AND RELATED DEVICES AND METHODS,Devices and methods are described that utilize material-handling systems in which material in the systems has enhanced stability.,MARKEM CORP;;APKARIAN SAMUEL E;;BOWBLIS ROBERT J;;BOYER ALAN H;;BROOKS JEFFREY B;;BROWN BENJAMIN J;;JOHANNESSEN ARNE;;LARSON RICHARD J JR,APKARIAN SAMUEL E;;BOWBLIS ROBERT J;;BOYER ALAN H;;BROOKS JEFFREY B;;BROWN BENJAMIN J;;JOHANNESSEN ARNE;;LARSON RICHARD J JR,,https://lens.org/109-042-996-274-560,Patent Application,yes,0,0,3,3,0,B41J2/175;;B41J2/175;;B41J2/17509;;B41J2/17509;;B41J2/17556;;B41J2/17556;;B41J2/195;;B41J2/195;;B41J11/00214;;B41J11/00214,B41J2/14;;B41J2/16,,0,0,,,,PENDING
695,WO,A3,WO 2007/021700 A3,190-682-693-975-207,2008-01-10,2008,US 2006/0030942 W,2006-08-09,US 70686505 P,2005-08-10,PRINTING DEVICES AND RELATED DEVICES AND METHODS,Devices and methods are described that utilize material-handling systems in which material in the systems has enhanced stability.,MARKEM CORP;;APKARIAN SAMUEL E;;BOWBLIS ROBERT J;;BOYER ALAN H;;BROOKS JEFFREY B;;BROWN BENJAMIN J;;JOHANNESSEN ARNE;;LARSON RICHARD J JR,APKARIAN SAMUEL E;;BOWBLIS ROBERT J;;BOYER ALAN H;;BROOKS JEFFREY B;;BROWN BENJAMIN J;;JOHANNESSEN ARNE;;LARSON RICHARD J JR,,https://lens.org/190-682-693-975-207,Search Report,yes,4,0,3,3,0,B41J2/175;;B41J2/175;;B41J2/17509;;B41J2/17509;;B41J2/17556;;B41J2/17556;;B41J2/195;;B41J2/195;;B41J11/00214;;B41J11/00214,B41J2/175;;B41J2/17,,0,0,,,,PENDING
696,AU,A,AU 1996/050383 A,026-340-409-035-036,1997-10-02,1997,AU 1996/050383 A,1996-03-29,AU 1996/050383 A,1996-03-29,Low moisture laundry detergent bar with improved enzyme stability,,PROCTER & GAMBLE,MISAJON ISAURO MANUEL E;;MURKUNDE ROHAN GOVIND;;MIRASOL MA AMELITA G;;BOYER STANTON LANE;;BARANGAN ANASTACIA ROSARIO A;;LASAP RICHARD TUGAO,,https://lens.org/026-340-409-035-036,Patent Application,no,0,0,4,4,0,C11D17/0069;;C11D1/146;;C11D1/22;;C11D1/523;;C11D1/835;;C11D3/124;;C11D3/38645;;C11D17/006,C11D1/14;;C11D1/22;;C11D1/52;;C11D1/835;;C11D3/12;;C11D3/386;;C11D17/00,,0,0,,,,PENDING
697,US,A1,US 2007/0035586 A1,155-930-461-621-881,2007-02-15,2007,US 50134606 A,2006-08-09,US 50134606 A;;US 70686505 P,2005-08-10,Printing devices and related devices and methods,Devices and methods are described that utilize material-handling systems in which material in the systems has enhanced stability.,APKARIAN SAMUEL E;;BOWBLIS ROBERT J;;BOYER ALAN H;;BROOKS JEFFREY B;;BROWN BENJAMIN J;;JOHANNESSEN ARNE;;LARSON RICHARD J JR,APKARIAN SAMUEL E;;BOWBLIS ROBERT J;;BOYER ALAN H;;BROOKS JEFFREY B;;BROWN BENJAMIN J;;JOHANNESSEN ARNE;;LARSON RICHARD J JR,MARKEM CORPORATION (2006-09-14),https://lens.org/155-930-461-621-881,Patent Application,yes,13,0,3,3,0,B41J2/175;;B41J2/175;;B41J2/17509;;B41J2/17509;;B41J2/17556;;B41J2/17556;;B41J2/195;;B41J2/195;;B41J11/00214;;B41J11/00214,B41J2/16;;B41J2/14,347/52,0,0,,,,DISCONTINUED
698,WO,A1,WO 2013/057244 A1,057-351-960-799-36X,2013-04-25,2013,EP 2012070747 W,2012-10-19,EP 11185710 A,2011-10-19,CATALYST COMPOSITION FOR SELECTIVE HYDROGENATION WITH IMPROVED CHARACTERISTICS,"This invention relates to heterogeneous catalysts useful for selective hydrogenation of unsaturated hydrocarbons, comprising palladium and optionally a promoter, supported on a substrate, having an uncoated BET surface area of < 9 m 2 /g, the surface being coated with an ionic liquid. Also described are methods of making the catalysts and methods of selective hydrogenation of acetylene in front-end mixed olefin feed streams.",CLARIANT PRODUKTE DEUTSCHLAND,SZESNI NORMEN;;FISCHER RICHARD;;HAGEMEYER ALFRED;;GROSMANN FRANK;;HOU HONGYI C;;BOYER JENNIFER;;SUN MINGYONG;;URBANCIC MICHAEL;;LUGMAIR CLAUS;;LOWE DAVID MICHAEL,,https://lens.org/057-351-960-799-36X,Patent Application,yes,7,3,8,8,0,B01J23/44;;B01J31/0277;;B01J31/0279;;B01J31/0281;;B01J31/0282;;B01J31/0284;;B01J37/0215;;C07C7/167;;B01J2531/824;;B01J21/04;;B01J23/50;;B01J2231/645;;Y02P20/52;;B01J35/612,B01J31/02;;B01J23/44;;B01J37/02;;C07C5/09;;C07C7/167,,7,7,048-912-603-605-767;;076-478-814-327-61X;;160-943-767-294-40X;;094-369-268-562-902;;146-456-061-490-577;;076-478-814-327-61X;;011-098-737-829-911,10.1039/b822992a;;10.1039/b810291k;;18758625;;10.1039/b811587g;;10.1002/1521-3757(20001103)112:21<3926::aid-ange3926>3.0.co;2-u;;10.1002/ceat.200700050;;10.1039/b810291k;;18758625;;10.1021/jp806603f,"ARRAS ET AL: ""Regioselective catalytic hydrogenation of citral with ionic liquids as reaction modifiers"", GREEN CHEMISTRY, ROYAL SOCIETY OF CHEMISTRY, CAMBRIDGE, GB, vol. 11, 1 January 2009 (2009-01-01), pages 716 - 723, XP009150913, ISSN: 1463-9262;;JÜRGEN ARRAS ET AL: ""The promoting effect of a dicyanamide based ionic liquid in the selective hydrogenation of citral"", CHEMICAL COMMUNICATIONS, no. 34, 1 January 2008 (2008-01-01), pages 4058, XP055047529, ISSN: 1359-7345, DOI: 10.1039/b810291k;;RANTING TAO ET AL: ""Pd nanoparticles immobilized on sepiolite by ionic liquids: efficient catalysts for hydrogenation of alkenes and Heck reactions"", GREEN CHEMISTRY, vol. 11, no. 1, 1 January 2009 (2009-01-01), pages 96, XP055047524, ISSN: 1463-9262, DOI: 10.1039/b811587g;;WASSERSCHEID; KEIM, ANGEWANDTE CHEMIE, vol. 112, 2000, pages 3926 - 3945;;U. KERNCHEN; B. ETZOLD; W. KORTH; A. JESS, CHEM. ENG. TECHNOL., vol. 30, 2007, pages 985 - 994;;J. ARRAS; M. STEFFAN; Y. SHAYEGHI; P. CLAUS, CHEM. COMMUN., 2008, pages 4058 - 4060;;M. RUTA; G. LAURENCZY; P. J. DYSON; L. KIWI-MINSKER, J. PHYS. CHEM. C, vol. 112, 2008, pages 17814 - 17819",PENDING
699,US,A1,US 2020/0094226 A1,051-795-394-226-776,2020-03-26,2020,US 201916681196 A,2019-11-12,US 201916681196 A;;US 201113276403 A,2011-10-19,CATALYST COMPOSITION FOR SELECTIVE HYDROGENATION WITH IMPROVED CHARACTERISTICS,"This invention relates to heterogeneous catalysts useful for selective hydrogenation of unsaturated hydrocarbons, comprising palladium and optionally a promoter, supported on a substrate, having an uncoated BET surface area of ≤9 m 2 /g, the surface being coated with an ionic liquid. Also described are methods of making the catalysts and methods of selective hydrogenation of acetylene and/or dienes in front-end mixed olefin feed streams.",SUED CHEMIE INC,SZESNI NORMEN;;HAGEMEYER ALFRED;;GROSSMANN FRANK;;FISCHER RICHARD;;URBANCIC MICHAEL;;LUGMAIR CLAUS;;SUN MINGYONG;;HOU HONGYI C;;LOWE DAVID MICHAEL;;BOYER JENNIFER,CLARIANT INTERNATIONAL LTD (2019-12-03),https://lens.org/051-795-394-226-776,Patent Application,yes,0,0,3,3,0,B01J23/44;;B01J23/50;;B01J23/52;;B01J23/58;;B01J23/60;;B01J23/62;;C07C7/167;;B01J37/024;;B01J23/626;;B01J23/628;;B01J23/6447;;B01J23/8926;;B01J31/0277;;B01J37/0201;;B01J37/16;;B01J21/04;;B01J31/0279;;B01J31/0284;;B01J2231/645;;B01J2531/824;;C10G45/40;;C10G2400/20;;Y02P20/52;;C07C2523/44;;C07C2523/50;;B01J35/397;;B01J35/612;;B01J35/633;;B01J23/44;;B01J23/58;;B01J23/52;;B01J23/50;;B01J23/60;;B01J23/62;;C07C7/167;;B01J37/024;;B01J23/6447;;B01J21/04;;B01J23/628;;B01J23/626;;B01J23/8926;;B01J31/0277;;B01J37/0201;;B01J31/0284;;C10G45/40;;B01J37/16;;B01J31/0279;;B01J2531/824;;B01J2231/645;;C10G2400/20;;Y02P20/52;;B01J35/397;;B01J35/633;;B01J35/612,B01J23/44;;B01J23/50;;B01J23/52;;B01J23/58;;B01J23/60;;B01J23/62;;B01J23/644;;B01J23/89;;B01J31/02;;B01J35/00;;B01J35/10;;B01J37/02;;C07C7/167;;C10G45/40,,0,0,,,,PENDING
700,IN,A,IN 825KON2014 A,172-049-575-244-474,2015-10-02,2015,IN 825KON2014 A,2014-04-12,EP 11185710 A;;EP 2012070747 W,2011-10-19,CATALYST COMPOSITION FOR SELECTIVE HYDROGENATION WITH IMPROVED CHARACTERISTICS,2This invention relates to heterogeneous catalysts useful for selective hydrogenation of unsaturated hydrocarbons comprising palladium and optionally a promoter supported on a substrate having an uncoated BET surface area of < 9 m/g the surface being coated with an ionic liquid. Also described are methods of making the catalysts and methods of selective hydrogenation of acetylene in front end mixed olefin feed streams.,CLARIANT PRODUKTE DEUTSCHLAND,SZESNI NORMEN;;FISCHER RICHARD;;HAGEMEYER ALFRED;;GROSSMANN FRANK;;HOU HONGYI C;;BOYER JENNIFER;;SUN MINGYONG;;URBANCIC MICHAEL;;LUGMAIR CLAUS;;LOWE DAVID MICHAEL,,https://lens.org/172-049-575-244-474,Patent Application,no,0,0,8,8,0,B01J23/44;;B01J31/0277;;B01J31/0279;;B01J31/0281;;B01J31/0282;;B01J31/0284;;B01J37/0215;;C07C7/167;;B01J2531/824;;B01J21/04;;B01J23/50;;B01J2231/645;;Y02P20/52;;B01J35/612,B01J31/02;;B01J23/44;;B01J37/02,,0,0,,,,PENDING
701,CN,A,CN 103958057 A,086-368-949-124-022,2014-07-30,2014,CN 201280058140 A,2012-10-19,EP 2012070747 W;;EP 11185710 A,2011-10-19,Catalyst composition for selective hydrogenation with improved characteristics,"This invention relates to heterogeneous catalysts useful for selective hydrogenation of unsaturated hydrocarbons, comprising palladium and optionally a promoter, supported on a substrate, having an uncoated BET surface area of <9 m2/g, the surface being coated with an ionic liquid. Also described are methods of making the catalysts and methods of selective hydrogenation of acetylene in front-end mixed olefin feed streams.",CLARIANT PRODUKTE DEUTSCHLAND,SZESNI NORMEN;;FISCHER RICHARD;;HAGEMEYER ALFRED;;GROSMANN FRANK;;HOU HONGYI C;;BOYER JENNIFER;;SUN MINGYONG;;URBANCIC MICHAEL;;LUGMAIR CLAUS;;LOWE DAVID MICHAEL,,https://lens.org/086-368-949-124-022,Patent Application,no,3,5,8,8,0,B01J23/44;;B01J31/0277;;B01J31/0279;;B01J31/0281;;B01J31/0282;;B01J31/0284;;B01J37/0215;;C07C7/167;;B01J2531/824;;B01J21/04;;B01J23/50;;B01J2231/645;;Y02P20/52;;B01J35/612,B01J31/02;;B01J23/44;;B01J37/02;;C07C5/09;;C07C7/167,,0,0,,,,ACTIVE
702,US,A1,US 2020/0101446 A1,193-595-586-928-548,2020-04-02,2020,US 201916694149 A,2019-11-25,US 201916694149 A;;US 201113276403 A,2011-10-19,CATALYST COMPOSITION FOR SELECTIVE HYDROGENATION WITH IMPROVED CHARACTERISTICS,"This invention relates to heterogeneous catalysts useful for selective hydrogenation of unsaturated hydrocarbons, comprising palladium and optionally a promoter, supported on a substrate, having an uncoated BET surface area of ≤9 m 2 /g, the surface being coated with an ionic liquid. Also described are methods of making the catalysts and methods of selective hydrogenation of acetylene and/or dienes in front-end mixed olefin feed streams.",SUED CHEMIE INC,SZESNI NORMEN;;HAGEMEYER ALFRED;;GROSSMANN FRANK;;FISCHER RICHARD;;URBANCIC MICHAEL;;LUGMAIR CLAUS;;SUN MINGYONG;;HOU HONGYI C;;LOWE DAVID MICHAEL;;BOYER JENNIFER,CLARIANT INTERNATIONAL LTD (2019-12-03),https://lens.org/193-595-586-928-548,Patent Application,yes,0,0,3,3,0,B01J23/44;;B01J23/50;;B01J23/52;;B01J23/58;;B01J23/60;;B01J23/62;;C07C7/167;;B01J37/024;;B01J23/626;;B01J23/628;;B01J23/6447;;B01J23/8926;;B01J31/0277;;B01J37/0201;;B01J37/16;;B01J21/04;;B01J31/0279;;B01J31/0284;;B01J2231/645;;B01J2531/824;;C10G45/40;;C10G2400/20;;Y02P20/52;;C07C2523/44;;C07C2523/50;;B01J35/397;;B01J35/612;;B01J35/633;;B01J23/44;;B01J23/58;;B01J23/52;;B01J23/50;;B01J23/60;;B01J23/62;;C07C7/167;;B01J37/024;;B01J23/6447;;B01J21/04;;B01J23/628;;B01J23/626;;B01J23/8926;;B01J31/0277;;B01J37/0201;;B01J31/0284;;C10G45/40;;B01J37/16;;B01J31/0279;;B01J2531/824;;B01J2231/645;;C10G2400/20;;Y02P20/52;;B01J35/397;;B01J35/633;;B01J35/612,B01J23/44;;B01J23/50;;B01J23/52;;B01J23/58;;B01J23/60;;B01J23/62;;B01J23/644;;B01J23/89;;B01J31/02;;B01J35/00;;B01J35/10;;B01J37/02;;C07C7/167;;C10G45/40,,0,0,,,,PENDING
703,CY,T1,CY 1112021 T1,007-369-233-254-39X,2015-11-04,2015,CY 101101197 T,2010-12-28,EP 07835890 A;;US 81652206 P,2006-06-26,ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ ΠΡΟΛΥΛ ΥΔΡΟΞΥΛΑΣΗΣ ΚΑΙ ΜΕΘΟΔΟΙ ΧΡΗΣΗΣ,"Η παρούσα γνωστοποίηση αφορά τους αναστολείς της HIF-1α προλυλ υδροξυλάσης, συνθέσεις, οι οποίες περιλαμβάνουν τους αναστολείς της HIF-1a προλυλ υδροξυλάσης που περιγράφονται στο παρόν και μεθόδους για έλεγχο, μεταξύ άλλων, των: Περιφερειακής Αγγειακής Νόσου (PVD), Νόσου της Στεφανιαίας (CAD), καρδιακής ανεπάρκειας, ισχαιμίας και αναιμίας.",WARNER CHILCOTT CO LLC,KAWAMOTO RICHARD MASARU;;WARSHAKOON NAMAL CHITHRANGA;;WU SHENGDE;;BOYER ANGELIQUE SUN;;GREIS KENNETH DONALD;;THE OTHER INVENTORS HAVE AGREED TO WAIVE THEIR ENT,,https://lens.org/007-369-233-254-39X,Granted Patent,no,0,0,83,83,0,C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;C07D213/81;;C07D213/65;;C07D405/10;;A61P1/04;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/08;;A61P27/02;;A61P31/04;;A61P31/18;;A61P35/00;;A61P43/00;;A61P7/00;;A61P7/06;;A61P9/10;;Y02A50/30;;C07D213/81;;C07C235/60;;C07C237/42;;C07C255/57;;C07C235/60;;C07C237/42;;C07C255/57;;Y02A50/30;;C07D213/81;;C07D213/65;;C07D405/10;;C07D405/04;;C07D295/192;;C07D401/04;;C07D401/10;;C07D417/04;;A61K31/4418;;A61K31/4433,C07C235/60;;C07C237/42;;C07C255/57;;C07D213/81,,0,0,,,,ACTIVE
704,US,A1,US 2019/0282446 A1,192-956-527-168-950,2019-09-19,2019,US 201815958809 A,2018-04-20,US 201815958809 A;;US 201862644145 P,2018-03-16,COMPUTERIZED ORAL PRESCRIPTION ADMINISTRATION WITH REFILLABLE MEDICATION DISPENSING DEVICES AND ASSOCIATED SYSTEMS AND METHODS,"Computerized oral prescription administration with refillable medication dispensing devices and associated systems and methods are provided. In one embodiment, a substance dispensing apparatus includes a housing sized and shaped for handheld use, the housing having at least one wall and a biometric sensor coupled to the at least one wall; a processor in communication with the biometric sensor, the processor configured to determine whether an intended user's unique biometric attribute is detected by the biometric sensor based on input received from the biometric sensor; and a pump in communication with the processor, the pump configured to dispense a substance from a reservoir to a mouth of the intended user in response to the processor determining that the intended user's unique biometric attribute is detected by the biometric sensor.",BERKSHIRE BIOMEDICAL LLC,ROUSE THOMAS M;;OWEN SUSAN B;;COREY CHRISTY;;CHOW CARLTON;;TURI MICHAEL;;BISCHOFF LARRY;;HARTMAN STEVEN;;BOYER ROBERT;;CRONENBERG RICHARD;;QUINN MICHAEL;;LYNCH JAMES,BERKSHIRE BIOMEDICAL CORPORATION (2018-03-21),https://lens.org/192-956-527-168-950,Patent Application,yes,0,3,21,21,0,A61B5/682;;A61J7/0418;;A61J1/065;;A61J1/1412;;A61J7/0053;;A61J7/0092;;A61J7/0427;;G16H20/13;;A61B2562/0214;;A61J2200/70;;A61B5/682;;A61B5/1178;;G16H40/63;;G16H20/17;;A61J2200/70;;A61J17/02;;A61J7/0427;;A61J7/0418;;A61J7/0053;;A61J1/1412;;A61J1/065;;A61C19/063;;A61J7/0092;;G06V40/10;;A61J7/0053;;A61B2562/0214;;A61B5/682;;G16H20/13;;A61J17/02,A61J7/00;;A61B5/00;;G16H20/13,,0,0,,,,ACTIVE
705,US,A1,US 2020/0038295 A1,006-274-130-186-031,2020-02-06,2020,US 201916597730 A,2019-10-09,US 201916597730 A;;US 201815958809 A;;US 201862644145 P,2018-03-16,COMPUTERIZED ORAL PRESCRIPTION ADMINISTRATION WITH REFILLABLE MEDICATION DISPENSING DEVICES AND ASSOCIATED SYSTEMS AND METHODS,"Computerized oral prescription administration with refillable medication dispensing devices and associated systems and methods are provided. In one embodiment, a method of dispensing a substance to an intended user is provided. The method comprises receiving an input from a biometric sensor; determining, based on the received input, whether an intended user's unique biometric attribute is detected by the biometric sensor; receiving an input from an environmental sensor; determining, based on the received input, whether a mouthpiece is positioned within a user's mouth; receiving an input from a capacitive sensor array of the mouthpiece; determining, based on the received input, whether an intended user's unique dentition is positioned within a recess of the mouthpiece; and dispensing a substance from a reservoir to a mouth of the intended user in response to determining that the intended user's unique biometric attribute is detected by the biometric sensor.",BERKSHIRE BIOMEDICAL LLC,ROUSE THOMAS M;;OWEN SUSAN B;;COREY CHRISTY;;CHOW CARLTON;;TURI MICHAEL;;BISCHOFF LARRY;;HARTMAN STEVEN;;BOYER ROBERT;;CRONENBERG RICHARD;;QUINN MICHAEL;;LYNCH JAMES,BERKSHIRE BIOMEDICAL CORPORATION (2018-03-21),https://lens.org/006-274-130-186-031,Patent Application,yes,0,0,21,21,0,A61B5/682;;A61J7/0418;;A61J1/065;;A61J1/1412;;A61J7/0053;;A61J7/0092;;A61J7/0427;;G16H20/13;;A61B2562/0214;;A61J2200/70;;A61B5/682;;A61B5/1178;;G16H40/63;;G16H20/17;;A61J2200/70;;A61J17/02;;A61J7/0427;;A61J7/0418;;A61J7/0053;;A61J1/1412;;A61J1/065;;A61C19/063;;A61J7/0092;;G06V40/10;;A61J7/0053;;A61B2562/0214;;A61B5/682;;G16H20/13;;A61J17/02,A61J7/00;;A61B5/00;;G16H20/13,,0,0,,,,ACTIVE
706,AU,B2,AU 2019/235911 B2,059-864-319-251-530,2021-11-18,2021,AU 2019/235911 A,2019-03-14,US 201862644145 P;;US 201815958809 A;;US 2019/0022287 W,2018-03-16,Computerized oral prescription administration with refillable medication dispensing devices and associated systems and methods,"Computerized oral prescription administration with refillable medication dispensing devices and associated systems and methods are provided. In one embodiment, a substance dispensing apparatus includes a housing sized and shaped for handheld use, the housing having at least one wall and a biometric sensor coupled to the at least one wall; a processor in communication with the biometric sensor, the processor configured to determine whether an intended user's unique biometric attribute is detected by the biometric sensor based on input received from the biometric sensor; and a pump in communication with the processor, the pump configured to dispense a substance from a reservoir to a mouth of the intended user in response to the processor determining that the intended user's unique biometric attribute is detected by the biometric sensor.",BERKSHIRE BIOMEDICAL CORP,ROUSE THOMAS M;;OWEN SUSAN B;;COREY CHRISTY;;CHOW CARLTON;;TURI MICHAEL;;BISCHOFF LARRY;;HARTMAN STEVEN;;BOYER ROBERT;;CRONENBERG RICHARD;;QUINN MICHAEL;;LYNCH JAMES,BERKSHIRE BIOMEDICAL CORPORATION (2021-11-25),https://lens.org/059-864-319-251-530,Granted Patent,no,3,0,21,21,0,A61B5/682;;A61J7/0418;;A61J1/065;;A61J1/1412;;A61J7/0053;;A61J7/0092;;A61J7/0427;;G16H20/13;;A61B2562/0214;;A61J2200/70;;A61B5/682;;A61B5/1178;;G16H40/63;;G16H20/17;;A61J2200/70;;A61J17/02;;A61J7/0427;;A61J7/0418;;A61J7/0053;;A61J1/1412;;A61J1/065;;A61C19/063;;A61J7/0092;;G06V40/10;;A61J7/0053;;A61B2562/0214;;A61B5/682;;G16H20/13;;A61J17/02,A61M31/00,,0,0,,,,ACTIVE
707,EP,A1,EP 3746171 A1,181-303-230-040-027,2020-12-09,2020,EP 19768054 A,2019-03-14,US 201862644145 P;;US 201815958809 A;;US 2019/0022287 W,2018-03-16,COMPUTERIZED ORAL PRESCRIPTION ADMINISTRATION WITH REFILLABLE MEDICATION DISPENSING DEVICES AND ASSOCIATED SYSTEMS AND METHODS,,BERKSHIRE BIOMEDICAL LLC,ROUSE THOMAS M;;OWEN SUSAN B;;COREY CHRISTY;;CHOW CARLTON;;TURI MICHAEL;;BISCHOFF LARRY;;HARTMAN STEVEN;;BOYER ROBERT;;CRONENBERG RICHARD;;QUINN MICHAEL;;LYNCH JAMES,BERKSHIRE BIOMEDICAL CORPORATION (2022-03-23),https://lens.org/181-303-230-040-027,Patent Application,yes,0,0,21,21,0,A61B5/682;;A61J7/0418;;A61J1/065;;A61J1/1412;;A61J7/0053;;A61J7/0092;;A61J7/0427;;G16H20/13;;A61B2562/0214;;A61J2200/70;;A61B5/682;;A61B5/1178;;G16H40/63;;G16H20/17;;A61J2200/70;;A61J17/02;;A61J7/0427;;A61J7/0418;;A61J7/0053;;A61J1/1412;;A61J1/065;;A61C19/063;;A61J7/0092;;G06V40/10;;A61J7/0053;;A61B2562/0214;;A61B5/682;;G16H20/13;;A61J17/02,A61M31/00,,0,0,,,,PENDING
708,US,B2,US 11412983 B2,094-274-159-469-694,2022-08-16,2022,US 201916597730 A,2019-10-09,US 201916597730 A;;US 201815958809 A;;US 201862644145 P,2018-03-16,Computerized oral prescription administration with refillable medication dispensing devices and associated systems and methods,"Computerized oral prescription administration with refillable medication dispensing devices and associated systems and methods are provided. In one embodiment, a method of dispensing a substance to an intended user is provided. The method comprises receiving an input from a biometric sensor; determining, based on the received input, whether an intended user's unique biometric attribute is detected by the biometric sensor; receiving an input from an environmental sensor; determining, based on the received input, whether a mouthpiece is positioned within a user's mouth; receiving an input from a capacitive sensor array of the mouthpiece; determining, based on the received input, whether an intended user's unique dentition is positioned within a recess of the mouthpiece; and dispensing a substance from a reservoir to a mouth of the intended user in response to determining that the intended user's unique biometric attribute is detected by the biometric sensor.",BERKSHIRE BIOMEDICAL LLC;;BERKSHIRE BIOMEDICAL CORP,ROUSE THOMAS M;;OWEN SUSAN B;;COREY CHRISTY;;CHOW CARLTON;;TURI MICHAEL;;BISCHOFF LARRY;;HARTMAN STEVEN;;BOYER ROBERT;;CRONENBERG RICHARD;;QUINN MICHAEL;;LYNCH JAMES,BERKSHIRE BIOMEDICAL CORPORATION (2018-03-21),https://lens.org/094-274-159-469-694,Granted Patent,yes,353,0,21,21,0,A61B5/682;;A61J7/0418;;A61J1/065;;A61J1/1412;;A61J7/0053;;A61J7/0092;;A61J7/0427;;G16H20/13;;A61B2562/0214;;A61J2200/70;;A61B5/682;;A61B5/1178;;G16H40/63;;G16H20/17;;A61J2200/70;;A61J17/02;;A61J7/0427;;A61J7/0418;;A61J7/0053;;A61J1/1412;;A61J1/065;;A61C19/063;;A61J7/0092;;G06V40/10;;A61J7/0053;;A61B2562/0214;;A61B5/682;;G16H20/13;;A61J17/02,A61J7/00;;A61B5/00;;A61J17/02;;G16H20/13,,12,0,,,"International Search Report issued in PCT/US2018/013440 dated Mar. 9, 2018.;;Written Opinion issued in PCT/US2018/013440 dated Mar. 9, 2018.;;International Search Report issued in PCT/US2019/022287 dated Jul. 16, 2019.;;Written Opinion issued in PCT/US2019/022287 dated Jul. 16, 2019.;;Australian Office Action, Application No. 2019235911, dated Mar. 25, 2021, 3 pages.;;Chinese Office Action, Application No. 201880013266.6, dated Dec. 18, 2020, 7 pages.;;Australian Office Action, Application No. 2019235911, dated Jan. 13, 2021, 6 pages.;;New Zealand Patent Office, Examination Report, Application No. 767645, dated Aug. 5, 2021, 4 pages.;;Australian Patent Office, Australian Office Action—Notice of Acceptance, for Application No. 2019235911, dated Nov. 3, 2021, 3 pages.;;Australian Patent Office, Examination Report, Application No. 2019235911, dated Jul. 14, 2021, 5 pages.;;Japanese Patent Office, Japanese Office Action—for Application No. 2020-548946, dated Nov. 9, 2021, with Translation, 7 pages.;;European Patent Office, European Office Action, for Application No. 19768054.9-1113, dated Oct. 22, 2021, 7 pages.",ACTIVE
709,US,A1,US 2022/0386956 A1,098-668-568-689-724,2022-12-08,2022,US 202217888327 A,2022-08-15,US 202217888327 A;;US 201916597730 A;;US 201815958809 A;;US 201862644145 P,2018-03-16,COMPUTERIZED ORAL PRESCRIPTION ADMINISTRATION WITH REFILLABLE MEDICATION DISPENSING DEVICES AND ASSOCIATED SYSTEMS AND METHODS,"A substance dispensing apparatus comprises a housing for handheld use and a mouthpiece coupled to the housing. The housing comprises a biometric sensor and a cavity sized to receive a reservoir. The mouthpiece comprises a recess and a capacitive sensor array. The apparatus further comprises a pump coupled to the mouthpiece and couplable to the reservoir and comprises a processor in communication with the biometric sensor, capacitive sensor array, and pump. The processor is configured to cause the pump to automatically dispense a substance from the reservoir to a mouth of an intended user via the mouthpiece in response to determining that: a unique biometric attribute of the intended user is detected by the biometric sensor based on biometric data from the biometric sensor; and a unique dentition of the intended user is positioned within the recess of the mouthpiece based on dentition data from the capacitive sensor array.",BERKSHIRE BIOMEDICAL CORP,ROUSE THOMAS M;;OWEN SUSAN B;;COREY CHRISTY;;CHOW CARLTON;;TURI MICHAEL;;BISCHOFF LARRY;;HARTMAN STEVEN;;BOYER ROBERT;;CRONENBERG RICHARD;;QUINN MICHAEL;;LYNCH JAMES,BERKSHIRE BIOMEDICAL LLC (2018-03-21),https://lens.org/098-668-568-689-724,Patent Application,yes,0,0,21,21,0,A61B5/682;;A61J7/0418;;A61J1/065;;A61J1/1412;;A61J7/0053;;A61J7/0092;;A61J7/0427;;G16H20/13;;A61B2562/0214;;A61J2200/70;;A61B5/682;;A61B5/1178;;G16H40/63;;G16H20/17;;A61J2200/70;;A61J17/02;;A61J7/0427;;A61J7/0418;;A61J7/0053;;A61J1/1412;;A61J1/065;;A61C19/063;;A61J7/0092;;G06V40/10;;A61J7/0053;;A61B2562/0214;;A61B5/682;;G16H20/13;;A61J17/02,A61B5/00;;A61J7/00;;G16H20/13,,0,0,,,,PENDING
710,AU,B2,AU 2022/200529 B2,051-722-865-269-696,2023-08-17,2023,AU 2022/200529 A,2022-01-27,AU 2022/200529 A;;AU 2019/235911 A;;US 201862644145 P;;US 201815958809 A;;US 2019/0022287 W,2018-03-16,Computerized oral prescription administration with refillable medication dispensing devices and associated systems and methods,"COMPUTERIZED ORAL PRESCRIPTION ADMINISTRATION WITH REFILLABLE MEDICATION DISPENSING DEVICES AND ASSOCIATED SYSTEMS AND METHODS Computerized oral prescription administration with refillable medication dispensing devices and associated systems and methods are provided. In one embodiment, a substance dispensing apparatus includes a housing sized and shaped for handheld use, the housing having at least one wall and a biometric sensor coupled to the at least one wall; a processor in communication with the biometric sensor, the processor configured to determine whether an intended user's unique biometric attribute is detected by the biometric sensor based on input received from the biometric sensor; and a pump in communication with the processor, the pump configured to dispense a substance from a reservoir to a mouth of the intended user in response to the processor determining that the intended user's unique biometric attribute is detected by the biometric sensor.",BERKSHIRE BIOMEDICAL CORP,ROUSE THOMAS M;;OWEN SUSAN B;;COREY CHRISTY;;CHOW CARLTON;;TURI MICHAEL;;BISCHOFF LARRY;;HARTMAN STEVEN;;BOYER ROBERT;;CRONENBERG RICHARD;;QUINN MICHAEL;;LYNCH JAMES,,https://lens.org/051-722-865-269-696,Granted Patent,no,8,0,21,21,0,A61B5/682;;A61J7/0418;;A61J1/065;;A61J1/1412;;A61J7/0053;;A61J7/0092;;A61J7/0427;;G16H20/13;;A61B2562/0214;;A61J2200/70;;A61B5/682;;A61B5/1178;;G16H40/63;;G16H20/17;;A61J2200/70;;A61J17/02;;A61J7/0427;;A61J7/0418;;A61J7/0053;;A61J1/1412;;A61J1/065;;A61C19/063;;A61J7/0092;;G06V40/10;;A61J7/0053;;A61B2562/0214;;A61B5/682;;G16H20/13;;A61J17/02,A61M31/00,,0,0,,,,ACTIVE
711,AU,A1,AU 2022/200529 A1,141-122-636-540-191,2022-02-17,2022,AU 2022/200529 A,2022-01-27,AU 2022/200529 A;;AU 2019/235911 A;;US 201862644145 P;;US 201815958809 A;;US 2019/0022287 W,2018-03-16,Computerized oral prescription administration with refillable medication dispensing devices and associated systems and methods,"COMPUTERIZED ORAL PRESCRIPTION ADMINISTRATION WITH REFILLABLE MEDICATION DISPENSING DEVICES AND ASSOCIATED SYSTEMS AND METHODS Computerized oral prescription administration with refillable medication dispensing devices and associated systems and methods are provided. In one embodiment, a substance dispensing apparatus includes a housing sized and shaped for handheld use, the housing having at least one wall and a biometric sensor coupled to the at least one wall; a processor in communication with the biometric sensor, the processor configured to determine whether an intended user's unique biometric attribute is detected by the biometric sensor based on input received from the biometric sensor; and a pump in communication with the processor, the pump configured to dispense a substance from a reservoir to a mouth of the intended user in response to the processor determining that the intended user's unique biometric attribute is detected by the biometric sensor.",BERKSHIRE BIOMEDICAL CORP,ROUSE THOMAS M;;OWEN SUSAN B;;COREY CHRISTY;;CHOW CARLTON;;TURI MICHAEL;;BISCHOFF LARRY;;HARTMAN STEVEN;;BOYER ROBERT;;CRONENBERG RICHARD;;QUINN MICHAEL;;LYNCH JAMES,,https://lens.org/141-122-636-540-191,Patent Application,no,0,0,21,21,0,A61B5/682;;A61J7/0418;;A61J1/065;;A61J1/1412;;A61J7/0053;;A61J7/0092;;A61J7/0427;;G16H20/13;;A61B2562/0214;;A61J2200/70;;A61B5/682;;A61B5/1178;;G16H40/63;;G16H20/17;;A61J2200/70;;A61J17/02;;A61J7/0427;;A61J7/0418;;A61J7/0053;;A61J1/1412;;A61J1/065;;A61C19/063;;A61J7/0092;;G06V40/10;;A61J7/0053;;A61B2562/0214;;A61B5/682;;G16H20/13;;A61J17/02,A61M31/00,,0,0,,,,ACTIVE
712,CN,A,CN 116602621 A,006-148-223-562-289,2023-08-18,2023,CN 202310506716 A,2019-03-14,US 201815958809 A;;CN 201980019781 A;;US 201862644145 P;;US 2019/0022287 W,2018-03-16,"Computerized oral prescription administers with refillable drug dispensing devices, and associated systems and methods","The present disclosure relates to computerized oral prescription administers with refillable drug dispensing devices and associated systems and methods. Computerized oral prescription administers with a refillable drug dispensing device and associated systems and methods are provided. In one embodiment, a substance dispensing device includes a housing sized and shaped for handheld use, the housing having at least one wall and a biometric sensor coupled to the at least one wall; a processor in communication with the biometric sensor, the processor configured to determine whether the biometric sensor detects a unique biometric attribute of an expected user based on input received from the biometric sensor; and a pump in communication with the processor, the pump configured to dispense a substance from the reservoir to the mouth of the intended user in response to the processor determining that the biometric sensor detects the unique biometric attribute of the intended user.",BERKSHIRE BIOMEDICAL INC,LOS THOMAS M;;OWEN SUSAN B;;COREY COLIN;;CHOU CHIACHEN;;TURI MARIANO;;BISCHOF LARS;;HARTMANN SVEN;;BOYER ROBERT;;CRONENBERG RICHARD;;QUINN MICHAEL;;LYNCH JENNIFER,,https://lens.org/006-148-223-562-289,Patent Application,no,0,0,21,21,0,A61B5/682;;A61J7/0418;;A61J1/065;;A61J1/1412;;A61J7/0053;;A61J7/0092;;A61J7/0427;;G16H20/13;;A61B2562/0214;;A61J2200/70;;A61B5/682;;A61B5/1178;;G16H40/63;;G16H20/17;;A61J2200/70;;A61J17/02;;A61J7/0427;;A61J7/0418;;A61J7/0053;;A61J1/1412;;A61J1/065;;A61C19/063;;A61J7/0092;;G06V40/10;;A61J7/0053;;A61B2562/0214;;A61B5/682;;G16H20/13;;A61J17/02,A61B5/00;;A61J1/06;;A61J1/14;;A61J7/00;;A61J7/04;;G16H20/13,,0,0,,,,PENDING
713,EP,A4,EP 3746171 A4,149-599-577-361-407,2021-11-24,2021,EP 19768054 A,2019-03-14,US 201862644145 P;;US 201815958809 A;;US 2019/0022287 W,2018-03-16,COMPUTERIZED ORAL PRESCRIPTION ADMINISTRATION WITH REFILLABLE MEDICATION DISPENSING DEVICES AND ASSOCIATED SYSTEMS AND METHODS,,BERKSHIRE BIOMEDICAL LLC,ROUSE THOMAS M;;OWEN SUSAN B;;COREY CHRISTY;;CHOW CARLTON;;TURI MICHAEL;;BISCHOFF LARRY;;HARTMAN STEVEN;;BOYER ROBERT;;CRONENBERG RICHARD;;QUINN MICHAEL;;LYNCH JAMES,BERKSHIRE BIOMEDICAL CORPORATION (2022-03-23),https://lens.org/149-599-577-361-407,Search Report,no,2,0,21,21,0,A61B5/682;;A61J7/0418;;A61J1/065;;A61J1/1412;;A61J7/0053;;A61J7/0092;;A61J7/0427;;G16H20/13;;A61B2562/0214;;A61J2200/70;;A61B5/682;;A61B5/1178;;G16H40/63;;G16H20/17;;A61J2200/70;;A61J17/02;;A61J7/0427;;A61J7/0418;;A61J7/0053;;A61J1/1412;;A61J1/065;;A61C19/063;;A61J7/0092;;G06V40/10;;A61J7/0053;;A61B2562/0214;;A61B5/682;;G16H20/13;;A61J17/02,A61M31/00;;A61J1/06;;A61J1/14;;A61J7/00;;A61J7/04,,1,0,,,See also references of WO 2019178367A1,PENDING
714,AU,A1,AU 2023/266255 A1,109-128-618-183-909,2023-12-07,2023,AU 2023/266255 A,2023-11-14,AU 2023/266255 A;;AU 2022/200529 A;;AU 2019/235911 A;;US 201862644145 P;;US 201815958809 A;;US 2019/0022287 W,2018-03-16,Computerized oral prescription administration with refillable medication dispensing devices and associated systems and methods,"Computerized oral prescription administration with refillable medication dispensing devices and associated systems and methods are provided. In one embodiment, a substance dispensing apparatus includes a housing sized and shaped for handheld use, the housing having at least one wall and a biometric sensor coupled to the at least one wall; a processor in communication with the biometric sensor, the processor configured to determine whether an intended user's unique biometric attribute is detected by the biometric sensor based on input received from the biometric sensor; and a pump in communication with the processor, the pump configured to dispense a substance from a reservoir to a mouth of the intended user in response to the processor determining that the intended user's unique biometric attribute is detected by the biometric sensor.",BERKSHIRE BIOMEDICAL CORP,THOMAS M ROUSE;;SUSAN B OWEN;;CHRISTY COREY;;CARLTON CHOW;;MICHAEL TURI;;LARRY BISCHOFF;;STEVEN HARTMAN;;ROBERT BOYER;;RICHARD CRONENBERG;;MICHAEL QUINN;;JAMES LYNCH,,https://lens.org/109-128-618-183-909,Patent Application,no,0,0,21,21,0,A61B5/682;;A61J7/0418;;A61J1/065;;A61J1/1412;;A61J7/0053;;A61J7/0092;;A61J7/0427;;G16H20/13;;A61B2562/0214;;A61J2200/70;;A61B5/682;;A61B5/1178;;G16H40/63;;G16H20/17;;A61J2200/70;;A61J17/02;;A61J7/0427;;A61J7/0418;;A61J7/0053;;A61J1/1412;;A61J1/065;;A61C19/063;;A61J7/0092;;G06V40/10;;A61J7/0053;;A61B2562/0214;;A61B5/682;;G16H20/13;;A61J17/02,A61M31/00,,0,0,,,,PENDING
715,NZ,A,NZ 767645 A,132-846-433-446-776,2022-07-01,2022,NZ 76764519 A,2019-03-14,US 2019/0022287 W;;US 201862644145 P;;US 201815958809 A,2018-03-16,Computerized oral prescription administration with refillable medication dispensing devices and associated systems and methods,"Computerized oral prescription administration with refillable medication dispensing devices and associated systems and methods are provided. In one embodiment, a substance dispensing apparatus includes a housing sized and shaped for handheld use, the housing having at least one wall and a biometric sensor coupled to the at least one wall; a processor in communication with the biometric sensor, the processor configured to determine whether an intended user’s unique biometric attribute is detected by the biometric sensor based on input received from the biometric sensor; and a pump in communication with the processor, the pump configured to dispense a substance from a reservoir to a mouth of the intended user in response to the processor determining that the intended user’s unique biometric attribute is detected by the biometric sensor.",BERKSHIRE BIOMEDICAL CORP,ROUSE THOMAS M;;OWEN SUSAN B;;COREY CHRISTY;;CHOW CARLTON;;TURI MICHAEL;;BISCHOFF LARRY;;HARTMAN STEVEN;;BOYER ROBERT;;CRONENBERG RICHARD;;QUINN MICHAEL;;LYNCH JAMES,,https://lens.org/132-846-433-446-776,Patent Application,no,0,0,21,21,0,A61B5/682;;A61J7/0418;;A61J1/065;;A61J1/1412;;A61J7/0053;;A61J7/0092;;A61J7/0427;;G16H20/13;;A61B2562/0214;;A61J2200/70;;A61B5/682;;A61B5/1178;;G16H40/63;;G16H20/17;;A61J2200/70;;A61J17/02;;A61J7/0427;;A61J7/0418;;A61J7/0053;;A61J1/1412;;A61J1/065;;A61C19/063;;A61J7/0092;;G06V40/10;;A61J7/0053;;A61B2562/0214;;A61B5/682;;G16H20/13;;A61J17/02,A61M31/00;;G16H20/13,,0,0,,,,PENDING
716,AU,A1,AU 2019/235911 A1,143-695-808-577-427,2020-09-24,2020,AU 2019/235911 A,2019-03-14,US 201862644145 P;;US 201815958809 A;;US 2019/0022287 W,2018-03-16,Computerized oral prescription administration with refillable medication dispensing devices and associated systems and methods,"Computerized oral prescription administration with refillable medication dispensing devices and associated systems and methods are provided. In one embodiment, a substance dispensing apparatus includes a housing sized and shaped for handheld use, the housing having at least one wall and a biometric sensor coupled to the at least one wall; a processor in communication with the biometric sensor, the processor configured to determine whether an intended user's unique biometric attribute is detected by the biometric sensor based on input received from the biometric sensor; and a pump in communication with the processor, the pump configured to dispense a substance from a reservoir to a mouth of the intended user in response to the processor determining that the intended user's unique biometric attribute is detected by the biometric sensor.",BERKSHIRE BIOMEDICAL LLC,ROUSE THOMAS M;;OWEN SUSAN B;;COREY CHRISTY;;CHOW CARLTON;;TURI MICHAEL;;BISCHOFF LARRY;;HARTMAN STEVEN;;BOYER ROBERT;;CRONENBERG RICHARD;;QUINN MICHAEL;;LYNCH JAMES,BERKSHIRE BIOMEDICAL CORPORATION (2021-11-25),https://lens.org/143-695-808-577-427,Patent Application,no,0,0,21,21,0,A61B5/682;;A61J7/0418;;A61J1/065;;A61J1/1412;;A61J7/0053;;A61J7/0092;;A61J7/0427;;G16H20/13;;A61B2562/0214;;A61J2200/70;;A61B5/682;;A61B5/1178;;G16H40/63;;G16H20/17;;A61J2200/70;;A61J17/02;;A61J7/0427;;A61J7/0418;;A61J7/0053;;A61J1/1412;;A61J1/065;;A61C19/063;;A61J7/0092;;G06V40/10;;A61J7/0053;;A61B2562/0214;;A61B5/682;;G16H20/13;;A61J17/02,A61M31/00,,0,0,,,,ACTIVE
717,WO,A1,WO 2019/178367 A1,168-333-654-179-344,2019-09-19,2019,US 2019/0022287 W,2019-03-14,US 201862644145 P;;US 201815958809 A,2018-03-16,COMPUTERIZED ORAL PRESCRIPTION ADMINISTRATION WITH REFILLABLE MEDICATION DISPENSING DEVICES AND ASSOCIATED SYSTEMS AND METHODS,"Computerized oral prescription administration with refillable medication dispensing devices and associated systems and methods are provided. In one embodiment, a substance dispensing apparatus includes a housing sized and shaped for handheld use, the housing having at least one wall and a biometric sensor coupled to the at least one wall; a processor in communication with the biometric sensor, the processor configured to determine whether an intended user's unique biometric attribute is detected by the biometric sensor based on input received from the biometric sensor; and a pump in communication with the processor, the pump configured to dispense a substance from a reservoir to a mouth of the intended user in response to the processor determining that the intended user's unique biometric attribute is detected by the biometric sensor.",BERKSHIRE BIOMEDICAL LLC,ROUSE THOMAS M;;OWEN SUSAN B;;COREY CHRISTY;;CHOW CARLTON;;TURI MICHAEL;;BISCHOFF LARRY;;HARTMAN STEVEN;;BOYER ROBERT;;CRONENBERG RICHARD;;QUINN MICHAEL;;LYNCH JAMES,,https://lens.org/168-333-654-179-344,Patent Application,yes,11,2,21,21,0,A61B5/682;;A61J7/0418;;A61J1/065;;A61J1/1412;;A61J7/0053;;A61J7/0092;;A61J7/0427;;G16H20/13;;A61B2562/0214;;A61J2200/70;;A61B5/682;;A61B5/1178;;G16H40/63;;G16H20/17;;A61J2200/70;;A61J17/02;;A61J7/0427;;A61J7/0418;;A61J7/0053;;A61J1/1412;;A61J1/065;;A61C19/063;;A61J7/0092;;G06V40/10;;A61J7/0053;;A61B2562/0214;;A61B5/682;;G16H20/13;;A61J17/02,A61M31/00,,1,0,,,See also references of EP 3746171A4,PENDING
718,US,B2,US 10441509 B2,131-629-909-660-042,2019-10-15,2019,US 201815958809 A,2018-04-20,US 201815958809 A;;US 201862644145 P,2018-03-16,Computerized oral prescription administration with refillable medication dispensing devices and associated systems and methods,"Computerized oral prescription administration with refillable medication dispensing devices and associated systems and methods are provided. In one embodiment, a substance dispensing apparatus includes a housing sized and shaped for handheld use, the housing having at least one wall and a biometric sensor coupled to the at least one wall; a processor in communication with the biometric sensor, the processor configured to determine whether an intended user's unique biometric attribute is detected by the biometric sensor based on input received from the biometric sensor; and a pump in communication with the processor, the pump configured to dispense a substance from a reservoir to a mouth of the intended user in response to the processor determining that the intended user's unique biometric attribute is detected by the biometric sensor.",BERKSHIRE BIOMEDICAL LLC,ROUSE THOMAS M;;OWEN SUSAN B;;COREY CHRISTY;;CHOW CARLTON;;TURI MICHAEL;;BISCHOFF LARRY;;HARTMAN STEVEN;;BOYER ROBERT;;CRONENBERG RICHARD;;QUINN MICHAEL;;LYNCH JAMES,BERKSHIRE BIOMEDICAL CORPORATION (2018-03-21),https://lens.org/131-629-909-660-042,Granted Patent,yes,329,2,21,21,0,A61B5/682;;A61J7/0418;;A61J1/065;;A61J1/1412;;A61J7/0053;;A61J7/0092;;A61J7/0427;;G16H20/13;;A61B2562/0214;;A61J2200/70;;A61B5/682;;A61B5/1178;;G16H40/63;;G16H20/17;;A61J2200/70;;A61J17/02;;A61J7/0427;;A61J7/0418;;A61J7/0053;;A61J1/1412;;A61J1/065;;A61C19/063;;A61J7/0092;;G06V40/10;;A61J7/0053;;A61B2562/0214;;A61B5/682;;G16H20/13;;A61J17/02,A61C17/00;;A61B5/00;;A61C17/02;;A61J7/00;;A61M31/00;;G16H20/13,,4,0,,,"International Search Report issued in PCT/US2018/013440 dated Mar. 9, 2018.;;Written Opinion issued in PCT/US2018/013440 dated Mar. 9, 2018.;;International Search Report issued in PCT/US2019/022287 dated Jul. 16, 2019.;;Written Opinion issued in PCT/US2019/022287 dated Jul. 16, 2019.",ACTIVE
719,CN,A,CN 111902184 A,157-747-741-007-330,2020-11-06,2020,CN 201980019781 A,2019-03-14,US 201862644145 P;;US 201815958809 A;;US 2019/0022287 W,2018-03-16,Computerized oral prescription administration with refillable medication dispensing devices and associated systems and methods,"Computerized oral prescription administration with refillable medication dispensing devices and associated systems and methods are provided. In one embodiment, a substance dispensing apparatus includes a housing sized and shaped for handheld use, the housing having at least one wall and a biometric sensor coupled to the at least one wall; a processor in communication with the biometric sensor, theprocessor configured to determine whether an intended user's unique biometric attribute is detected by the biometric sensor based on input received from the biometric sensor; and a pump in communication with the processor, the pump configured to dispense a substance from a reservoir to a mouth of the intended user in response to the processor determining that the intended user's unique biometricattribute is detected by the biometric sensor.",BERKSHIRE BIOMEDICAL LLC,ROUSE THOMAS M;;OWEN SUSAN B;;COREY CHRISTY;;CHOW CARLTON;;TURI MICHAEL;;BISCHOFF LARRY;;HARTMAN STEVEN;;BOYER ROBERT;;CRONENBERG RICHARD;;QUINN MICHAEL;;LYNCH JAMES,,https://lens.org/157-747-741-007-330,Patent Application,no,6,1,21,21,0,A61B5/682;;A61J7/0418;;A61J1/065;;A61J1/1412;;A61J7/0053;;A61J7/0092;;A61J7/0427;;G16H20/13;;A61B2562/0214;;A61J2200/70;;A61B5/682;;A61B5/1178;;G16H40/63;;G16H20/17;;A61J2200/70;;A61J17/02;;A61J7/0427;;A61J7/0418;;A61J7/0053;;A61J1/1412;;A61J1/065;;A61C19/063;;A61J7/0092;;G06V40/10;;A61J7/0053;;A61B2562/0214;;A61B5/682;;G16H20/13;;A61J17/02,A61M31/00,,0,0,,,,ACTIVE
720,US,A1,US 2002/0161719 A1,038-864-038-343-242,2002-10-31,2002,US 84266101 A,2001-04-27,US 84266101 A,2001-04-27,Method of and apparatus for on-line enrolment,"
   A system for on-line enrolment includes an application server for controlling and communicating with an end-user and an institution with which the end-user desires to enroll. The application server has an evaluation service for providing workflow and logic in accordance with the institution's business criteria. When initiated by an end-user a management server determines and downloads appropriate client software to the end-user, which includes a signing agent, that allows the end-user to digitally sign the business agreements needed to complete an account enrolment with an institution such as a bank, stock broker or other financial institution. A verification service authenticates information provided by the end-user. A certificate service sends a digital certificate to an end-user. An evaluation service receives a digitally signed electronic business agreement from the end-user to complete enrolment of the end-user and forms a complete enrolment package. An audit service creates a log of all transaction records. A payment service may be included to effect payment from the end-user to the institution. An e-business archive stores the complete enrolment package. 
",MANNING DAVID FRANKLIN;;MANSELL MICHAEL CAIN;;BOYER JOHN MICHAEL;;NEUSTAEDTER THEODORE EDWARD;;REEVE BENNETT RICHARD WILLIAM;;DEBRONI BRADLEY MICHAEL;;ROWLING MICHAEL GRAHAM;;KAPUSCINSKI RANDALL JOSEPH,MANNING DAVID FRANKLIN;;MANSELL MICHAEL CAIN;;BOYER JOHN MICHAEL;;NEUSTAEDTER THEODORE EDWARD;;REEVE BENNETT RICHARD WILLIAM;;DEBRONI BRADLEY MICHAEL;;ROWLING MICHAEL GRAHAM;;KAPUSCINSKI RANDALL JOSEPH,PUREEDGE SOLUTIONS INC (2001-05-04),https://lens.org/038-864-038-343-242,Patent Application,yes,3,50,1,1,0,G06Q20/02;;G06Q20/02;;G06Q20/04;;G06Q20/04;;G06Q20/382;;G06Q20/382;;G06Q20/3829;;G06Q20/3829;;G06Q30/06;;G06Q30/06;;H04L63/0823;;H04L63/0823;;H04L63/12;;H04L63/12,G06Q20/02;;G06Q20/04;;G06Q20/38;;G06Q30/06;;H04L29/06,705/64,0,0,,,,DISCONTINUED
721,US,A1,US 2002/0124271 A1,054-024-729-210-893,2002-09-05,2002,US 6643402 A,2002-01-31,US 6643402 A;;US 26564401 P;;US 34000401 P,2001-01-31,Interactive media terminal,"
   An interactive public media display terminal capable of presenting different presentations to the viewing public simultaneously is presented. The media terminal includes a large vertically orientated display that can be partitioned to display varied content to attract different factions of a viewing audience. The content can be configured to attract viewers based on the distance they are away from the terminal. To accomplish this, the display can be coupled among a computer and a communication device configured to exchange data with a network such as the Internet. The display can also include a touch sensitive screen and other input devices that allow a user to physically interact with the terminal based on the content being presented. Furthermore, the terminal can be configured to gather data regarding the audience that views the content that is displayed. 
",HERRMANN R. SCOTT;;SHERWOOD TIMOTHY J.;;DIXON JIM L.;;GRIEVE ROBSON B.;;O'ROURKE TOM C.;;BECKER WILLIAM;;DAHLANDER HELENE;;TURNER DOUGLAS;;BOYER RICHARD;;LAFERTE DARRYL,HERRMANN R SCOTT;;SHERWOOD TIMOTHY J;;DIXON JIM L;;GRIEVE ROBSON B;;O'ROURKE TOM C;;BECKER WILLIAM;;DAHLANDER HELENE;;TURNER DOUGLAS;;BOYER RICHARD;;LAFERTE DARRYL,CIVIA INC (2002-04-18),https://lens.org/054-024-729-210-893,Patent Application,yes,5,65,1,1,0,G06Q30/02;;H04N21/4622;;H04N21/4782;;H04N21/4622;;H04N21/4782;;G06Q30/02,G06Q30/02;;H04N21/462;;H04N21/4782,725/151;;725/139;;725/131,0,0,,,,DISCONTINUED
722,EP,A1,EP 0380267 A1,183-872-417-371-558,1990-08-01,1990,EP 90300632 A,1990-01-22,US 30242789 A,1989-01-26,Microwave absorber employing acicular magnetic metallic filaments.,"An electromagnetic radiation absorber is formed by dispersing into a dielectric binder acicular magnetic metallic filaments with an average length of about 10 µm or less, diameters of 0.1 µm or more, and aspect (length/diameter) ratios between 10:1 and 50:1. Preferably the average length is about 5 µm, the aspect ratios are between 10:1 and 25:1, and the dielectric binder is polymeric. The volume fraction of the filaments may be lower than 35% of the total and still provide satisfactory absorption. An absorbing paint is formed by dissolving the absorber in a base liquid. The absorber or absorbing paint may be applied to a conductive surface, such as a metallic wire, plate or foil. Impedance matching materials are preferred but not required.  ",MINNESOTA MINING & MFG,BOYER CHARLES E III C O MINNES;;BORCHERS ERIC J C O MINNESOTA;;KUO RICHARD J C O MINNESOTA MI;;HOYLE CHARLES D C O MINNESOTA,,https://lens.org/183-872-417-371-558,Patent Application,yes,3,12,8,9,0,H01Q17/005,B32B7/02;;H01Q17/00;;H05K9/00,,0,0,,,,EXPIRED
723,EP,B1,EP 2583751 B1,188-504-467-637-409,2014-12-03,2014,EP 11185710 A,2011-10-19,EP 11185710 A,2011-10-19,Catalyst composition for selective hydrogenation with improved characteristics,,CLARIANT PRODUKTE DEUTSCHLAND,SZESNI NORMEN DR;;FISCHER RICHARD DR;;HAGEMEYER ALFRED DR;;GROSSMANN FRANK DR;;BOYER JENNIFER;;HOU HONGYI C;;LOWE DAVID MICHAEL;;LUGMAIR CLAUS;;SUN MINGYONG;;URBANCIC MICHAEL,,https://lens.org/188-504-467-637-409,Granted Patent,yes,2,0,8,8,0,B01J23/44;;B01J31/0277;;B01J31/0279;;B01J31/0281;;B01J31/0282;;B01J31/0284;;B01J37/0215;;C07C7/167;;B01J2531/824;;B01J21/04;;B01J23/50;;B01J2231/645;;Y02P20/52;;B01J35/612,B01J23/44;;B01J31/02;;B01J37/02;;C07C5/09;;C07C7/167,,3,0,,,"TANJA HERRMANN ET AL: ""High-performance supported catalysts with an ionic liquid layer for the selective hydrogenation of acetylene"", CHEMICAL COMMUNICATIONS, vol. 47, no. 45, 1 January 2011 (2011-01-01), page 12310, XP55013881, ISSN: 1359-7345, DOI: 10.1039/c1cc15325k;;KIWI-MINSKER L ET AL: ""Structured catalytic wall microreactor for efficient performance of exothermic reactions"", CHEMICAL ENGINEERING AND PROCESSING, ELSEVIER SEQUOIA, LAUSANNE, CH, vol. 49, no. 9, 1 September 2010 (2010-09-01), pages 973-978, XP027382313, ISSN: 0255-2701 [retrieved on 2010-04-28];;ARRAS ET AL: ""Regioselective catalytic hydrogenation of citral with ionic liquids as reaction modifiers"", GREEN CHEMISTRY, ROYAL SOCIETY OF CHEMISTRY, CAMBRIDGE, GB, vol. 11, 1 January 2009 (2009-01-01), pages 716-723, XP009150913, ISSN: 1463-9262",ACTIVE
724,EP,B1,EP 0380267 B1,199-875-911-329-878,1993-10-27,1993,EP 90300632 A,1990-01-22,US 30242789 A,1989-01-26,Microwave absorber employing acicular magnetic metallic filaments.,,MINNESOTA MINING & MFG,BOYER CHARLES E III C O MINNES;;BORCHERS ERIC J C O MINNESOTA;;KUO RICHARD J C O MINNESOTA MI;;HOYLE CHARLES D C O MINNESOTA,,https://lens.org/199-875-911-329-878,Granted Patent,yes,3,0,8,9,0,H01Q17/005,B32B7/02;;H01Q17/00;;H05K9/00,,0,0,,,,EXPIRED
725,EP,A1,EP 2583751 A1,054-154-660-975-569,2013-04-24,2013,EP 11185710 A,2011-10-19,EP 11185710 A,2011-10-19,Catalyst composition for selective hydrogenation with improved characteristics,"This invention relates to heterogeneous catalysts useful for selective hydrogenation of unsaturated hydrocarbons, comprising palladium and optionally a promoter, supported on a substrate, having an uncoated BET surface area of ≤ 9 m 2 /g, the surface being coated with an ionic liquid. Also described are methods of making the catalysts and methods of selective hydrogenation of acetylene and/or dienes in front-end mixed olefin feed streams.",CLARIANT PRODUKTE DEUTSCHLAND,SZESNI NORMEN DR;;FISCHER RICHARD DR;;HAGEMEYER ALFRED DR;;GROSMANN FRANK DR;;BOYER JENNIFER;;HOU HONGYI C;;LOWE DAVID MICHAEL;;LUGMAIR CLAUS;;SUN MINGYONG;;URBANCIC MICHAEL,,https://lens.org/054-154-660-975-569,Patent Application,yes,8,11,8,8,0,B01J23/44;;B01J31/0277;;B01J31/0279;;B01J31/0281;;B01J31/0282;;B01J31/0284;;B01J37/0215;;C07C7/167;;B01J2531/824;;B01J21/04;;B01J23/50;;B01J2231/645;;Y02P20/52;;B01J35/612,B01J23/44;;B01J31/02;;B01J37/02;;C07C5/09;;C07C7/167,,7,7,164-425-813-677-715;;137-646-280-198-665;;048-912-603-605-767;;094-369-268-562-902;;146-456-061-490-577;;076-478-814-327-61X;;011-098-737-829-911,22008709;;10.1039/c1cc15325k;;10.1016/j.cep.2010.04.007;;10.1039/b822992a;;10.1002/1521-3757(20001103)112:21<3926::aid-ange3926>3.0.co;2-u;;10.1002/ceat.200700050;;10.1039/b810291k;;18758625;;10.1021/jp806603f,"TANJA HERRMANN ET AL: ""High-performance supported catalysts with an ionic liquid layer for the selective hydrogenation of acetylene"", CHEMICAL COMMUNICATIONS, vol. 47, no. 45, 1 January 2011 (2011-01-01), pages 12310, XP055013881, ISSN: 1359-7345, DOI: 10.1039/c1cc15325k;;KIWI-MINSKER L ET AL: ""Structured catalytic wall microreactor for efficient performance of exothermic reactions"", CHEMICAL ENGINEERING AND PROCESSING, ELSEVIER SEQUOIA, LAUSANNE, CH, vol. 49, no. 9, 1 September 2010 (2010-09-01), pages 973 - 978, XP027382313, ISSN: 0255-2701, [retrieved on 20100428];;ARRAS ET AL: ""Regioselective catalytic hydrogenation of citral with ionic liquids as reaction modifiers"", GREEN CHEMISTRY, ROYAL SOCIETY OF CHEMISTRY, CAMBRIDGE, GB, vol. 11, 1 January 2009 (2009-01-01), pages 716 - 723, XP009150913, ISSN: 1463-9262;;WASSERSCHEID, KEIM, ANGEWANDTE CHEMIE, vol. 112, 2000, pages 3926 - 3945;;U. KERNCHEN, B. ETZOLD, W. KORTH, A. JESS, CHEM. ENG. TECHNOL., vol. 30, 2007, pages 985 - 994;;J. ARRAS, M. STEFFAN, Y. SHAYEGHI, P. CLAUS, CHEM. COMMUN., 2008, pages 4058 - 4060;;M. RUTA, G. LAURENCZY, P. J. DYSON, L. KIWI-MINSKER, J. PHYS. CHEM. C, vol. 112, 2008, pages 17814 - 17819",ACTIVE
726,BR,A2,BR PI0519363 A2,012-924-104-824-035,2009-01-20,2009,BR PI0519363 A,2005-12-21,US 63814304 P;;US 71334005 P;;US 2005/0046365 W,2004-12-23,resinas amina-aldeÍdo e usos destas em processos de separaÇço,"RESINAS AMINA-ALDEÍDO E USOS DESTAS EM PROCESSOS DE SEPARAÇçO. São reveladas resinas amina-aldeído para remoção de uma gama de sólidos e/ou espécies iônicas de líquidos, nos quais eles estão suspensos e/ou dissolvidos. Essas resinas são especialmente úteis como agentes depressores de flotação de espuma na separação de betume da areia e/ou argila ou no beneficiamento da argila (por exemplo, argila caulim) de um minério contendo argila impura. As resinas também são úteis para tratamento de suspensões líquidas aquosas na remoção de particulados sólidos, bem como na remoção de íons metálicos na purificação da água.",GEORGIA PACIFIC CHEMICALS LLC,WRIGHT JAMES;;HURD PHILLIP W;;BOYER PETER;;ARTHUR LISA M;;MILLS JEFFREY;;HART PAUL;;REDIGER RICHARD;;KELLY ROBBIE D;;WHITE CARL R;;GABRIELSON KURT;;HINES JOHN B,,https://lens.org/012-924-104-824-035,Patent Application,no,0,0,24,56,0,B01D21/0012;;B01D21/01;;B01D61/16;;B01D2311/04;;B01J45/00;;B03D1/008;;B03D1/01;;B03D1/016;;B03D1/02;;B03D3/06;;B28C1/08;;C02F1/001;;C02F1/24;;C02F1/285;;C02F1/444;;C02F1/52;;C02F1/56;;C02F1/683;;C02F2101/103;;C02F2101/20;;C02F2103/10;;C02F2103/12;;C02F2103/28;;C10G1/00;;C10G25/02;;E21B21/068;;C10G2300/1033;;C10G2300/205;;B03D1/085;;B03D1/16;;B01D61/145;;B03D2201/06;;B03D2203/006;;B03D2203/04;;B03D1/02;;B03D1/016;;B03D1/01;;B01D21/01;;C02F1/683;;C02F1/001;;B03D1/02;;C02F1/24;;C02F2101/103;;C10G1/00;;E21B21/068;;B03D3/06;;B01D21/01;;C02F1/285;;C02F1/444;;B01D21/0012;;B01D2311/04;;B01D61/16;;C02F1/52;;C02F2103/10;;C02F2101/20;;B03D1/016;;C02F1/56;;B01J45/00;;B03D1/008;;C10G25/02;;C02F2103/28;;B28C1/08;;B03D1/01;;C02F2103/12;;C10G2300/205;;C10G2300/1033;;B03D1/16;;B03D1/085;;B01D61/145;;B03D2203/006;;B03D2201/06;;B03D2203/04,B03D1/02;;B01D21/01;;B01D37/02;;B01D37/03;;B03B1/04;;B03D1/01;;B03D1/016;;B28C1/08;;C02F1/56;;C09C1/42;;C10G1/04,,0,0,,,,INACTIVE
727,CA,A1,CA 2594243 A1,167-123-333-520-861,2006-07-06,2006,CA 2594243 A,2005-12-21,US 63814304 P;;US 71334005 P;;US 2005/0046365 W,2004-12-23,AMINE-ALDEHYDE RESINS AND USES THEREOF IN SEPARATION PROCESSES,,GEORGIA PACIFIC CHEMICALS LLC,MILLS JEFFREY;;ARTHUR LISA M;;HINES JOHN B;;WRIGHT JAMES;;HART PAUL;;HURD PHILLIP W;;BOYER PETER;;REDIGER RICHARD;;GABRIELSON KURT;;WHITE CARL R;;KELLY ROBBIE D,,https://lens.org/167-123-333-520-861,Patent Application,no,0,3,24,56,0,B01D21/0012;;B01D21/01;;B01D61/16;;B01D2311/04;;B01J45/00;;B03D1/008;;B03D1/01;;B03D1/016;;B03D1/02;;B03D3/06;;B28C1/08;;C02F1/001;;C02F1/24;;C02F1/285;;C02F1/444;;C02F1/52;;C02F1/56;;C02F1/683;;C02F2101/103;;C02F2101/20;;C02F2103/10;;C02F2103/12;;C02F2103/28;;C10G1/00;;C10G25/02;;E21B21/068;;C10G2300/1033;;C10G2300/205;;B03D1/085;;B03D1/16;;B01D61/145;;B03D2201/06;;B03D2203/006;;B03D2203/04;;B03D1/02;;B03D1/016;;B03D1/01;;B01D21/01;;C02F1/683;;C02F1/001;;B03D1/02;;C02F1/24;;C02F2101/103;;C10G1/00;;E21B21/068;;B03D3/06;;B01D21/01;;C02F1/285;;C02F1/444;;B01D21/0012;;B01D2311/04;;B01D61/16;;C02F1/52;;C02F2103/10;;C02F2101/20;;B03D1/016;;C02F1/56;;B01J45/00;;B03D1/008;;C10G25/02;;C02F2103/28;;B28C1/08;;B03D1/01;;C02F2103/12;;C10G2300/205;;C10G2300/1033;;B03D1/16;;B03D1/085;;B01D61/145;;B03D2203/006;;B03D2201/06;;B03D2203/04,B03D1/02;;B01D21/01;;B01D37/02;;B01D37/03;;B03B1/04;;B03D1/01;;B03D1/016;;B28C1/08;;C02F1/56;;C09C1/42;;C10G1/04,,0,0,,,,INACTIVE
728,AU,A1,AU 2005/322210 A1,078-369-592-550-671,2006-07-06,2006,AU 2005/322210 A,2005-12-21,US 63814304 P;;US 71334005 P;;US 2005/0046365 W,2004-12-23,Amine-aldehyde resins and uses thereof in separation processes,,GEORGIA PACIFIC CHEMICALS LLC,BOYER PETER;;ARTHUR LISA M;;HART PAUL;;HINES JOHN B;;HURD PHILLIP W;;REDIGER RICHARD;;GABRIELSON KURT;;WRIGHT JAMES;;KELLY ROBBIE D;;WHITE CARL R;;MILLS JEFFREY,,https://lens.org/078-369-592-550-671,Patent Application,no,0,0,24,56,0,B01D21/0012;;B01D21/01;;B01D61/16;;B01D2311/04;;B01J45/00;;B03D1/008;;B03D1/01;;B03D1/016;;B03D1/02;;B03D3/06;;B28C1/08;;C02F1/001;;C02F1/24;;C02F1/285;;C02F1/444;;C02F1/52;;C02F1/56;;C02F1/683;;C02F2101/103;;C02F2101/20;;C02F2103/10;;C02F2103/12;;C02F2103/28;;C10G1/00;;C10G25/02;;E21B21/068;;C10G2300/1033;;C10G2300/205;;B03D1/085;;B03D1/16;;B01D61/145;;B03D2201/06;;B03D2203/006;;B03D2203/04;;B03D1/02;;B03D1/016;;B03D1/01;;B01D21/01;;C02F1/683;;C02F1/001;;B03D1/02;;C02F1/24;;C02F2101/103;;C10G1/00;;E21B21/068;;B03D3/06;;B01D21/01;;C02F1/285;;C02F1/444;;B01D21/0012;;B01D2311/04;;B01D61/16;;C02F1/52;;C02F2103/10;;C02F2101/20;;B03D1/016;;C02F1/56;;B01J45/00;;B03D1/008;;C10G25/02;;C02F2103/28;;B28C1/08;;B03D1/01;;C02F2103/12;;C10G2300/205;;C10G2300/1033;;B03D1/16;;B03D1/085;;B01D61/145;;B03D2203/006;;B03D2201/06;;B03D2203/04,B03D1/02;;B01D21/01;;B01D37/02;;B01D37/03;;B03B1/04;;B03D1/01;;B03D1/016;;B28C1/08;;C02F1/56;;C09C1/42;;C10G1/04,,0,0,,,,INACTIVE
729,AU,A2,AU 2005/322210 A2,088-371-722-538-765,2006-07-06,2006,AU 2005/322210 A,2005-12-21,US 63814304 P;;US 71334005 P;;US 2005/0046365 W,2004-12-23,Amine-aldehyde resins and uses thereof in separation processes,,GEORGIA PACIFIC CHEMICALS LLC,BOYER PETER;;ARTHUR LISA M;;HART PAUL;;HINES JOHN B;;HURD PHILLIP W;;REDIGER RICHARD;;GABRIELSON KURT;;WRIGHT JAMES;;KELLY ROBBIE D;;WHITE CARL R;;MILLS JEFFREY,,https://lens.org/088-371-722-538-765,Patent Application,no,0,0,24,56,0,B01D21/0012;;B01D21/01;;B01D61/16;;B01D2311/04;;B01J45/00;;B03D1/008;;B03D1/01;;B03D1/016;;B03D1/02;;B03D3/06;;B28C1/08;;C02F1/001;;C02F1/24;;C02F1/285;;C02F1/444;;C02F1/52;;C02F1/56;;C02F1/683;;C02F2101/103;;C02F2101/20;;C02F2103/10;;C02F2103/12;;C02F2103/28;;C10G1/00;;C10G25/02;;E21B21/068;;C10G2300/1033;;C10G2300/205;;B03D1/085;;B03D1/16;;B01D61/145;;B03D2201/06;;B03D2203/006;;B03D2203/04;;B03D1/02;;B03D1/016;;B03D1/01;;B01D21/01;;C02F1/683;;C02F1/001;;B03D1/02;;C02F1/24;;C02F2101/103;;C10G1/00;;E21B21/068;;B03D3/06;;B01D21/01;;C02F1/285;;C02F1/444;;B01D21/0012;;B01D2311/04;;B01D61/16;;C02F1/52;;C02F2103/10;;C02F2101/20;;B03D1/016;;C02F1/56;;B01J45/00;;B03D1/008;;C10G25/02;;C02F2103/28;;B28C1/08;;B03D1/01;;C02F2103/12;;C10G2300/205;;C10G2300/1033;;B03D1/16;;B03D1/085;;B01D61/145;;B03D2203/006;;B03D2201/06;;B03D2203/04,B03D1/02;;B01D21/01;;B01D37/02;;B01D37/03;;B03B1/04;;B03D1/01;;B03D1/016;;B28C1/08;;C02F1/56;;C09C1/42;;C10G1/04,,0,0,,,,INACTIVE
730,US,A1,US 2006/0151397 A1,104-938-599-274-655,2006-07-13,2006,US 29893605 A,2005-12-12,US 29893605 A;;US 63814304 P;;US 71334005 P,2004-12-23,Amine-aldehyde resins and uses thereof in separation processes,"Amine-aldehyde resins are disclosed for removing a wide variety of solids and/or ionic species from the liquids in which they are suspended and/or dissolved. These resins are especially useful as froth flotation depressants in the separation of bitumen from sand and/or clay or in the beneficiation of clay (e.g., kaolin clay) from an impure clay-containing ore. The resins are also useful for treating aqueous liquid suspensions to remove solid particulates, as well as for removing metallic ions in the purification of water.",GEORGIA PACIFIC RESINS,WRIGHT JAMES;;WHITE CARL R;;GABRIELSON KURT;;HINES JOHN B;;HURD PHILLIP W;;BOYER PETER;;ARTHUR LISA M;;MILLS JEFFREY;;HART PAUL;;REDIGER RICHARD;;KELLY ROBBIE D,INGEVITY SOUTH CAROLINA LLC (2018-03-08);;GEORGIA-PACIFIC CHEMICALS LLC (2006-12-31);;GEORGIA-PACIFIC RESINS INC (2006-03-17),https://lens.org/104-938-599-274-655,Patent Application,yes,39,37,24,56,0,B01D21/0012;;B01D21/01;;B01D61/16;;B01D2311/04;;B01J45/00;;B03D1/008;;B03D1/01;;B03D1/016;;B03D1/02;;B03D3/06;;B28C1/08;;C02F1/001;;C02F1/24;;C02F1/285;;C02F1/444;;C02F1/52;;C02F1/56;;C02F1/683;;C02F2101/103;;C02F2101/20;;C02F2103/10;;C02F2103/12;;C02F2103/28;;C10G1/00;;C10G25/02;;E21B21/068;;C10G2300/1033;;C10G2300/205;;B03D1/085;;B03D1/16;;B01D61/145;;B03D2201/06;;B03D2203/006;;B03D2203/04;;B03D1/02;;B03D1/016;;B03D1/01;;B01D21/01;;C02F1/683;;C02F1/001;;B03D1/02;;C02F1/24;;C02F2101/103;;C10G1/00;;E21B21/068;;B03D3/06;;B01D21/01;;C02F1/285;;C02F1/444;;B01D21/0012;;B01D2311/04;;B01D61/16;;C02F1/52;;C02F2103/10;;C02F2101/20;;B03D1/016;;C02F1/56;;B01J45/00;;B03D1/008;;C10G25/02;;C02F2103/28;;B28C1/08;;B03D1/01;;C02F2103/12;;C10G2300/205;;C10G2300/1033;;B03D1/16;;B03D1/085;;B01D61/145;;B03D2203/006;;B03D2201/06;;B03D2203/04,C02F1/24,210/704,0,0,,,,INACTIVE
731,BR,B1,BR PI0519363 B1,139-681-110-381-172,2017-12-12,2017,BR PI0519363 A,2005-12-21,US 63814304 P;;US 71334005 P;;US 2005/0046365 W,2004-12-23,método para remoção de impurezas de uma lama contendo betume,"resinas amina-aldeído e usos destas em processos de separação. são reveladas resinas amina-aldeído para remoção de uma gama de sólidos e/ou espécies iônicas de líquidos, nos quais eles estão suspensos e/ou dissolvidos. essas resinas são especialmente úteis como agentes depressores de flotação de espuma na separação de betume da areia e/ou argila ou no beneficiamento da argila (por exemplo, argila caulim) de um minério contendo argila impura. as resinas também são úteis para tratamento de suspensões líquidas aquosas na remoção de particulados sólidos, bem como na remoção de íons metálicos na purificação da água.",GEORGIA PACIFIC CHEMICALS LLC,CARL R WHITE;;JAMES WRIGHT;;JEFFREY MILLS;;JOHN B HINES;;KURT GABRIELSON;;LISA M ARTHUR;;PAUL HART;;PETER BOYER;;PHILLIP W HURD;;RICHARD REDIGER;;ROBBIE D KELLY,,https://lens.org/139-681-110-381-172,Granted Patent,no,0,0,24,56,0,B01D21/0012;;B01D21/01;;B01D61/16;;B01D2311/04;;B01J45/00;;B03D1/008;;B03D1/01;;B03D1/016;;B03D1/02;;B03D3/06;;B28C1/08;;C02F1/001;;C02F1/24;;C02F1/285;;C02F1/444;;C02F1/52;;C02F1/56;;C02F1/683;;C02F2101/103;;C02F2101/20;;C02F2103/10;;C02F2103/12;;C02F2103/28;;C10G1/00;;C10G25/02;;E21B21/068;;C10G2300/1033;;C10G2300/205;;B03D1/085;;B03D1/16;;B01D61/145;;B03D2201/06;;B03D2203/006;;B03D2203/04;;B03D1/02;;B03D1/016;;B03D1/01;;B01D21/01;;C02F1/683;;C02F1/001;;B03D1/02;;C02F1/24;;C02F2101/103;;C10G1/00;;E21B21/068;;B03D3/06;;B01D21/01;;C02F1/285;;C02F1/444;;B01D21/0012;;B01D2311/04;;B01D61/16;;C02F1/52;;C02F2103/10;;C02F2101/20;;B03D1/016;;C02F1/56;;B01J45/00;;B03D1/008;;C10G25/02;;C02F2103/28;;B28C1/08;;B03D1/01;;C02F2103/12;;C10G2300/205;;C10G2300/1033;;B03D1/16;;B03D1/085;;B01D61/145;;B03D2203/006;;B03D2201/06;;B03D2203/04,B01D21/01;;B01D37/02;;B01D37/03;;B03B1/04;;B03D1/01;;B03D1/016;;B03D1/02;;B28C1/08;;C02F1/56;;C09C1/42;;C10G1/04,,0,0,,,,INACTIVE
732,WO,A2,WO 2006/071673 A2,046-566-948-027-470,2006-07-06,2006,US 2005/0046365 W,2005-12-21,US 63814304 P;;US 71334005 P,2004-12-23,AMINE-ALDEHYDE RESINS AND USES THEREOF IN SEPARATION PROCESSES,"Amine-aldehyde resins are disclosed for removing a wide variety of solids and/or ionic species from the liquids in which they are suspended and/or dissolved. These resins are especially useful as froth flotation depressants in the separation of bitumen from sand and/or clay or in the beneficiation of clay (e.g., kaolin clay) from an impure clay-containing ore. The resins are also useful for treating aqueous liquid suspensions to remove solid particulates, as well as for removing metallic ions in the purification of water.",GEORGIA PACIFIC RESINS;;WRIGHT JAMES;;HURD PHILLIP W;;BOYER PETER;;ARTHUR LISA M;;MILLS JEFFREY;;HART PAUL;;REDIGER RICHARD;;KELLY ROBBIE D;;WHITE CARL R;;GABRIELSON KURT;;HINES JOHN B,WRIGHT JAMES;;HURD PHILLIP W;;BOYER PETER;;ARTHUR LISA M;;MILLS JEFFREY;;HART PAUL;;REDIGER RICHARD;;KELLY ROBBIE D;;WHITE CARL R;;GABRIELSON KURT;;HINES JOHN B,,https://lens.org/046-566-948-027-470,Patent Application,yes,0,10,24,56,0,B01D21/0012;;B01D21/01;;B01D61/16;;B01D2311/04;;B01J45/00;;B03D1/008;;B03D1/01;;B03D1/016;;B03D1/02;;B03D3/06;;B28C1/08;;C02F1/001;;C02F1/24;;C02F1/285;;C02F1/444;;C02F1/52;;C02F1/56;;C02F1/683;;C02F2101/103;;C02F2101/20;;C02F2103/10;;C02F2103/12;;C02F2103/28;;C10G1/00;;C10G25/02;;E21B21/068;;C10G2300/1033;;C10G2300/205;;B03D1/085;;B03D1/16;;B01D61/145;;B03D2201/06;;B03D2203/006;;B03D2203/04;;B03D1/02;;B03D1/016;;B03D1/01;;B01D21/01;;C02F1/683;;C02F1/001;;B03D1/02;;C02F1/24;;C02F2101/103;;C10G1/00;;E21B21/068;;B03D3/06;;B01D21/01;;C02F1/285;;C02F1/444;;B01D21/0012;;B01D2311/04;;B01D61/16;;C02F1/52;;C02F2103/10;;C02F2101/20;;B03D1/016;;C02F1/56;;B01J45/00;;B03D1/008;;C10G25/02;;C02F2103/28;;B28C1/08;;B03D1/01;;C02F2103/12;;C10G2300/205;;C10G2300/1033;;B03D1/16;;B03D1/085;;B01D61/145;;B03D2203/006;;B03D2201/06;;B03D2203/04,B03D1/02;;B01D21/01;;B01D37/02;;B01D37/03;;B03B1/04;;B03D1/01;;B03D1/016;;B28C1/08;;C02F1/56;;C09C1/42;;C10G1/04,,0,0,,,,PENDING
733,WO,A3,WO 2006/071673 A3,040-194-801-483-452,2006-12-07,2006,US 2005/0046365 W,2005-12-21,US 63814304 P;;US 71334005 P,2004-12-23,AMINE-ALDEHYDE RESINS AND USES THEREOF IN SEPARATION PROCESSES,"Amine-aldehyde resins are disclosed for removing a wide variety of solids and/or ionic species from the liquids in which they are suspended and/or dissolved. These resins are especially useful as froth flotation depressants in the separation of bitumen from sand and/or clay or in the beneficiation of clay (e.g., kaolin clay) from an impure clay-containing ore. The resins are also useful for treating aqueous liquid suspensions to remove solid particulates, as well as for removing metallic ions in the purification of water.",GEORGIA PACIFIC RESINS;;WRIGHT JAMES;;HURD PHILLIP W;;BOYER PETER;;ARTHUR LISA M;;MILLS JEFFREY;;HART PAUL;;REDIGER RICHARD;;KELLY ROBBIE D;;WHITE CARL R;;GABRIELSON KURT;;HINES JOHN B,WRIGHT JAMES;;HURD PHILLIP W;;BOYER PETER;;ARTHUR LISA M;;MILLS JEFFREY;;HART PAUL;;REDIGER RICHARD;;KELLY ROBBIE D;;WHITE CARL R;;GABRIELSON KURT;;HINES JOHN B,,https://lens.org/040-194-801-483-452,Search Report,yes,4,0,24,56,0,B01D21/0012;;B01D21/01;;B01D61/16;;B01D2311/04;;B01J45/00;;B03D1/008;;B03D1/01;;B03D1/016;;B03D1/02;;B03D3/06;;B28C1/08;;C02F1/001;;C02F1/24;;C02F1/285;;C02F1/444;;C02F1/52;;C02F1/56;;C02F1/683;;C02F2101/103;;C02F2101/20;;C02F2103/10;;C02F2103/12;;C02F2103/28;;C10G1/00;;C10G25/02;;E21B21/068;;C10G2300/1033;;C10G2300/205;;B03D1/085;;B03D1/16;;B01D61/145;;B03D2201/06;;B03D2203/006;;B03D2203/04;;B03D1/02;;B03D1/016;;B03D1/01;;B01D21/01;;C02F1/683;;C02F1/001;;B03D1/02;;C02F1/24;;C02F2101/103;;C10G1/00;;E21B21/068;;B03D3/06;;B01D21/01;;C02F1/285;;C02F1/444;;B01D21/0012;;B01D2311/04;;B01D61/16;;C02F1/52;;C02F2103/10;;C02F2101/20;;B03D1/016;;C02F1/56;;B01J45/00;;B03D1/008;;C10G25/02;;C02F2103/28;;B28C1/08;;B03D1/01;;C02F2103/12;;C10G2300/205;;C10G2300/1033;;B03D1/16;;B03D1/085;;B01D61/145;;B03D2203/006;;B03D2201/06;;B03D2203/04,B03D1/02;;B01D21/01;;B01D37/02;;B01D37/03;;B03B1/04;;B03D1/01;;B03D1/016;;B28C1/08;;C02F1/56;;C09C1/42;;C10G1/04,,2,0,,,"DATABASE WPI Section Ch Week 198242, Derwent World Patents Index; Class A97, AN 1982-89783E, XP002382738;;DATABASE WPI Section Ch Week 198045, Derwent World Patents Index; Class A97, AN 1980-80270C, XP002382739",PENDING
734,DE,D1,DE 69735824 D1,147-331-713-020-835,2006-06-08,2006,DE 69735824 T,1997-12-12,US 76619296 A;;US 98874597 A;;US 9722886 W,1996-12-12,"MOBILE,STEUERBARE STROBOSKOPISCHE LICHTANLAGE UND VERFAHREN ZUR STEUERUNG DER BEWEGUNG EINES FISCHES",,FLASH TECHNOLOGY CORP OF AMERI,BAUGHER ANN;;BROWN EARL;;JOHNSON A;;SCHIPP ROBERTO;;NEWSOM STEVENS;;NGUYEN TIEN;;SHUMATE JOEL;;TERRY MICHAEL;;MARK FRED;;NORTHRUP RICHARD;;OUELLETTE LARRY;;IHRIE RONALD;;BOYER EDWARD;;SOMMERS WILLIAM,,https://lens.org/147-331-713-020-835,Granted Patent,no,0,0,14,16,0,A01K79/02;;A01K79/02,A01K29/00;;A01K61/00;;A01K79/02;;A01M29/00;;H05B43/00;;H05C1/04,,0,0,,,,EXPIRED
735,US,B1,US 6319466 B1,008-545-819-123-481,2001-11-20,2001,US 11813598 A,1998-07-16,US 11813598 A;;US 177597 A;;US 5264497 P;;US 8893798 P,1997-07-16,Test device for detecting the presence of a residue analyte in a sample,A test device for detecting the presence of a residue analyte in a sample includes a support strip and a sample-absorbing matrix attached to the support strip. The sample-absorbing matrix has a material for absorbing an amount of the sample. The test device also includes a mobile-phase support for holding a mobile-phase composition. The mobile-phase support is attached to the support strip and in contact with the sample-absorbing matrix. A mobile-phase composition is disposed on the mobile-phase support and has a receptor for binding with the analyte. The mobile-phase composition can be carried in the sample. A stationary-phase membrane is attached to the support strip and has a first membrane end in contact with the mobile-phase composition and a second membrane end. The membrane allows lateral capillary flow of the sample from the first membrane end to the second membrane end. A test zone is on the stationary-phase membrane between the first membrane end and second membrane end and having a first binder for binding with an unbound receptor. A control zone is the stationary-phase a membrane between the test zone and second membrane end and has a second binder for binding with an analyte-bound receptor or residual unbound receptor.,CHARM SCIENCES INC,MARKOVSKY ROBERT J;;BOYER CHERYL A;;CHARM STANLEY E;;DONAHUE PAUL R;;GLICKMAN YAEL AGI;;SAUL STEVEN J;;SCHEEMAKER JOAN L;;SKIFFINGTON RICHARD T;;TRIVEDI SHEFALI B;;ZOMER ELIEZER,CHARM SCIENCES INC (1998-08-27),https://lens.org/008-545-819-123-481,Granted Patent,yes,28,97,14,29,0,A23D9/00;;A23D9/00;;A23K10/30;;A23K10/30;;A23K20/158;;A23K20/158;;C11B3/001;;C11B3/001;;C11B7/00;;C11B7/00;;C11C1/04;;C11C1/04;;C11C3/10;;C11C3/10;;C11C3/123;;C11C3/123;;C12N9/0083;;C12N9/0083;;C12N15/8216;;C12N15/8216;;C12N15/8222;;C12N15/8222;;C12N15/8234;;C12N15/8234;;C12N15/8247;;C12N15/8247;;G01N33/558;;G01N33/558;;G01N33/537;;G01N33/537;;G01N33/54366;;G01N33/54366;;G01N2201/0221;;G01N2201/0221;;Y10S435/805;;Y10S435/805;;Y10S435/97;;Y10S435/97;;Y10T436/10;;Y10T436/10;;Y10T436/105831;;Y10T436/105831,A23D9/00;;A23K1/14;;A23K1/16;;C11B3/00;;C11B7/00;;C11C1/04;;C11C3/10;;C11C3/12;;C12N9/02;;C12N15/82;;G01N33/537;;G01N33/543;;G01N33/558;;G01N37/00,422/56;;422/57;;422/58;;422/61;;422/187;;422/188;;436/514;;436/524;;436/525,5,2,062-513-803-873-685;;060-601-143-009-521,31084085;;10.4315/0362-028x-56.3.229;;10.1093/jaoac/71.2.304;;3260233,"Brady et al., Journal of Food Protection, 56(3):229-233, Mar. 1993.*;;Charm et al., Journal of the Association of Food and Drug Officials, 58(1), 17-29, Jan. 1994.*;;Charm, et al., J. Assoc. Off. Anal. Chem., 71(2), 1988.*;;Hassnoot et al., ""Evaluation of a Sol Particle Immunoassay (SPIA) Based Single-Step Strip Test for the Detection of Sulfadimidine Residues"", Euro Residue III (1996) 461-465.;;Verheijen et al., ""Single-Step Strip Tests for Residue Analyses"", DLO-State Institute for Quality Control of Agricultural Products (RIKILT-DLO) (Jun. 3, 1998).",EXPIRED
736,DE,D1,DE 69837544 D1,054-871-527-439-400,2007-05-24,2007,DE 69837544 T,1998-07-16,US 5264497 P;;US 177597 A;;US 8893798 P;;US 9814705 W,1997-07-16,TESTGERÄT UND METHODE ZUR ENTDECKUNG VON ANALYTEN IN PROBEN,,CHARM SCIENCES INC,MARKOVSKY ROBERT J;;BOYER CHERYL A;;CHARM STANLEY E;;DONAHUE PAUL R;;AGI-GLICKMAN YAEL;;SAUL STEVEN J;;SCHEEMAKER JOAN L;;SKIFFINGTON RICHARD T;;TRIVEDI SHIFALI B;;ZOMER ELIEZER,,https://lens.org/054-871-527-439-400,Granted Patent,no,0,0,14,29,0,A23D9/00;;A23D9/00;;A23K10/30;;A23K10/30;;A23K20/158;;A23K20/158;;C11B3/001;;C11B3/001;;C11B7/00;;C11B7/00;;C11C1/04;;C11C1/04;;C11C3/10;;C11C3/10;;C11C3/123;;C11C3/123;;C12N9/0083;;C12N9/0083;;C12N15/8216;;C12N15/8216;;C12N15/8222;;C12N15/8222;;C12N15/8234;;C12N15/8234;;C12N15/8247;;C12N15/8247;;G01N33/558;;G01N33/558;;G01N33/537;;G01N33/537;;G01N33/54366;;G01N33/54366;;G01N2201/0221;;G01N2201/0221;;Y10S435/805;;Y10S435/805;;Y10S435/97;;Y10S435/97;;Y10T436/10;;Y10T436/10;;Y10T436/105831;;Y10T436/105831,G01N33/68;;A23D9/00;;A23K1/14;;A23K1/16;;C11B3/00;;C11B7/00;;C11C1/04;;C11C3/10;;C11C3/12;;C12N9/02;;C12N15/82;;G01N33/537;;G01N33/543;;G01N33/558;;G01N37/00,,0,0,,,,EXPIRED
737,US,B1,US 10891282 B1,052-487-463-961-777,2021-01-12,2021,US 201715821698 A,2017-11-22,US 201715821698 A,2017-11-22,Mutations with immediate feedback,A technology is provided for mutations with immediate feedback. A mutation may be received at a data proxy from an application. The mutation may be sent to a data source via a data access resolver associated with the data proxy. Results of the mutation may be received from the data source. A subscription may be triggered based on receiving the results of the mutation. A message may be sent via a topic provided by the subscription by using a messaging service such that the messaging service publishes the message with the mutation to devices subscribed to the topic.,AMAZON TECH INC,WILLINGHAM MICHAEL B;;DESHPANDE ROHAN;;SHON LISA MEENHEE;;SALIGRAMA SHREERAM KARTHIK;;DOWLING CHRISTOPHER NATHAN;;PATEL AMIT;;BAILEY JEFFREY H;;BOYER ANTOINE FRANCOIS CHARLES;;THRELKELD RICHARD;;PARIS MICHAEL;;SRIVASTAVA MOHIT,AMAZON TECHNOLOGIES INC (2017-12-07),https://lens.org/052-487-463-961-777,Granted Patent,yes,21,9,1,1,0,G06F16/2358;;G06F16/9535;;H04L63/101;;H04L63/1458;;G06F21/554;;G06F21/64;;H04L67/56;;H04L63/10;;G06F16/2358;;G06F16/27;;G06F16/951,G06F17/00;;G06F16/23;;G06F16/27;;G06F16/951;;H04L29/06,,0,0,,,,ACTIVE
738,AU,A,AU 1998/084896 A,098-029-428-312-975,1999-02-10,1999,AU 1998/084896 A,1998-07-16,US 5264497 P;;US 177597 A;;US 8893798 P;;US 9814705 W,1997-07-16,A test device and method for detecting the presence of a residue analyte in a sample,,CHARM SCIENCES INC,MARKOVSKY ROBERT J;;BOYER CHERYL A;;CHARM STANLEY E;;DONAHUE PAUL R;;AGI-GLICKMAN YAEL;;SAUL STEVEN J;;SCHEEMAKER JOAN L;;SKIFFINGTON RICHARD T;;TRIVEDI SHIFALI B;;ZOMER ELIEZER,,https://lens.org/098-029-428-312-975,Patent Application,no,0,2,14,29,0,A23D9/00;;A23D9/00;;A23K10/30;;A23K10/30;;A23K20/158;;A23K20/158;;C11B3/001;;C11B3/001;;C11B7/00;;C11B7/00;;C11C1/04;;C11C1/04;;C11C3/10;;C11C3/10;;C11C3/123;;C11C3/123;;C12N9/0083;;C12N9/0083;;C12N15/8216;;C12N15/8216;;C12N15/8222;;C12N15/8222;;C12N15/8234;;C12N15/8234;;C12N15/8247;;C12N15/8247;;G01N33/558;;G01N33/558;;G01N33/537;;G01N33/537;;G01N33/54366;;G01N33/54366;;G01N2201/0221;;G01N2201/0221;;Y10S435/805;;Y10S435/805;;Y10S435/97;;Y10S435/97;;Y10T436/10;;Y10T436/10;;Y10T436/105831;;Y10T436/105831,A23D9/00;;A23K1/14;;A23K1/16;;C11B3/00;;C11B7/00;;C11C1/04;;C11C3/10;;C11C3/12;;C12N9/02;;C12N15/82;;G01N33/537;;G01N33/543;;G01N33/558;;G01N37/00,,0,0,,,,DISCONTINUED
739,DE,T2,DE 69837544 T2,000-740-339-041-180,2007-12-20,2007,DE 69837544 T,1998-07-16,US 5264497 P;;US 177597 A;;US 8893798 P;;US 9814705 W,1997-07-16,TESTGERÄT UND METHODE ZUR ENTDECKUNG VON ANALYTEN IN PROBEN,,CHARM SCIENCES INC,MARKOVSKY ROBERT J;;BOYER CHERYL A;;CHARM STANLEY E;;DONAHUE PAUL R;;AGI-GLICKMAN YAEL;;SAUL STEVEN J;;SCHEEMAKER JOAN L;;SKIFFINGTON RICHARD T;;TRIVEDI SHIFALI B;;ZOMER ELIEZER,,https://lens.org/000-740-339-041-180,Granted Patent,no,0,0,14,29,0,A23D9/00;;A23D9/00;;A23K10/30;;A23K10/30;;A23K20/158;;A23K20/158;;C11B3/001;;C11B3/001;;C11B7/00;;C11B7/00;;C11C1/04;;C11C1/04;;C11C3/10;;C11C3/10;;C11C3/123;;C11C3/123;;C12N9/0083;;C12N9/0083;;C12N15/8216;;C12N15/8216;;C12N15/8222;;C12N15/8222;;C12N15/8234;;C12N15/8234;;C12N15/8247;;C12N15/8247;;G01N33/558;;G01N33/558;;G01N33/537;;G01N33/537;;G01N33/54366;;G01N33/54366;;G01N2201/0221;;G01N2201/0221;;Y10S435/805;;Y10S435/805;;Y10S435/97;;Y10S435/97;;Y10T436/10;;Y10T436/10;;Y10T436/105831;;Y10T436/105831,G01N33/68;;A23D9/00;;A23K1/14;;A23K1/16;;C11B3/00;;C11B7/00;;C11C1/04;;C11C3/10;;C11C3/12;;C12N9/02;;C12N15/82;;G01N33/537;;G01N33/543;;G01N33/558;;G01N37/00,,0,0,,,,EXPIRED
740,US,B2,US 7097983 B2,076-077-442-300-522,2006-08-29,2006,US 96199801 A,2001-09-24,US 96199801 A;;US 11813598 A;;US 177597 A;;US 5264497 P;;US 8893798 P,1997-07-16,Method for detecting the presence of an analyte in a sample,"The invention features a method of determining whether one or more members of an analyte family are present in a sample. The method makes use of a test zone binder, e.g., a receptor that can bind one or a plurality of analytes within an analyte family, the analytes family defined by similar structural binding sites. Members of an analyte family can have different detection level requirements and, therefore, additional analyte binders can be employed to adjust test sensitivity for a subset of the analytes in the analyte family individually, so that each analyte can be detected only if it is present in the sample above a predetermined threshold.",CHARM SCIENCES INC,MARKOVSKY ROBERT J;;BOYER CHERYL A;;CHARM STANLEY E;;DONAHUE PAUL R;;GLICKMAN YAEL AGI;;SAUL STEVEN J;;SCHEEMAKER JOAN L;;SKIFFINGTON RICHARD T;;TRIVEDI SHEFALI B;;ZOMER ELIEZER,,https://lens.org/076-077-442-300-522,Granted Patent,yes,48,60,14,29,0,A23D9/00;;A23D9/00;;A23K10/30;;A23K10/30;;A23K20/158;;A23K20/158;;C11B3/001;;C11B3/001;;C11B7/00;;C11B7/00;;C11C1/04;;C11C1/04;;C11C3/10;;C11C3/10;;C11C3/123;;C11C3/123;;C12N9/0083;;C12N9/0083;;C12N15/8216;;C12N15/8216;;C12N15/8222;;C12N15/8222;;C12N15/8234;;C12N15/8234;;C12N15/8247;;C12N15/8247;;G01N33/558;;G01N33/558;;G01N33/537;;G01N33/537;;G01N33/54366;;G01N33/54366;;G01N2201/0221;;G01N2201/0221;;Y10S435/805;;Y10S435/805;;Y10S435/97;;Y10S435/97;;Y10T436/10;;Y10T436/10;;Y10T436/105831;;Y10T436/105831,G01N33/53;;A23D9/00;;A23K1/14;;A23K1/16;;C11B3/00;;C11B7/00;;C11C1/04;;C11C3/10;;C11C3/12;;C12N9/02;;C12N15/82;;G01N31/00;;G01N33/537;;G01N33/543;;G01N33/558;;G01N37/00,435/7.1;;435/7.92;;435/970;;435/805;;436/8;;436/15;;436/501;;436/514;;436/535;;436/524;;436/536;;422/56;;422/60;;422/61,7,2,062-513-803-873-685;;060-601-143-009-521,31084085;;10.4315/0362-028x-56.3.229;;10.1093/jaoac/71.2.304;;3260233,"Brady et al., Journal of Food Protection, 56(3):229-233, Mar. 1993.;;Charm et al., Journal of the Association of Food and Drug Officials, 58(1), 17-29, Jan. 1994.;;Charm et al., J. Assoc. Off. Anal. Chem., 71(2), 1988.;;Hassnoot et al., ""Evaluation of a Sol Particle Immunoassay (SPIA) Based Single-Step Strip Test for the Dectection of Sulfadimidine Residues,"" Euro Residue III (1996) 461-465.;;""A Short Guide-Developing Immunochromatographic Test Strips,"" 1996, Lit. No. TB500, Millipore Corporation, Bedford, MA, USA.;;Verheijen et al., ""Single-Step Strip Tests for Residue Analyses,"" DLO-State Institute for Quality Control of Agricultural Products (RIKILT-DLO) (Jun. 3, 1998).;;European Search Report, dated Aug. 20, 2004, for EP Application No. 04 00 4322.6.",EXPIRED
741,US,B1,US 11126610 B1,137-919-405-551-946,2021-09-21,2021,US 201715821658 A,2017-11-22,US 201715821658 A,2017-11-22,Conflict resolution in a data proxy,"A technology is provided for conflict resolution in a data proxy for a mutation. A mutation may be received at a data proxy from an application, and the data proxy is in a service provider environment. The mutation may be sent to be processed by a data store via a data access resolver. A conflict message may be received at the data proxy via the data access resolver for a conflict mutation at the data store for the mutation. The conflict may be resolved at the data proxy using a conflict resolution function in the data proxy.",AMAZON TECH INC,DESHPANDE ROHAN;;SHON LISA MEENHEE;;SALIGRAMA SHREERAM KARTHIK;;DOWLING CHRISTOPHER NATHAN;;PATEL AMIT;;BAILEY JEFFREY H;;BOYER ANTOINE FRANCOIS CHARLES;;THRELKELD RICHARD;;PARIS MICHAEL;;WILLINGHAM MICHAEL B;;SRIVASTAVA MOHIT,AMAZON TECHNOLOGIES INC (2017-11-27),https://lens.org/137-919-405-551-946,Granted Patent,yes,22,3,1,1,0,G06F16/2365;;G06F16/9574;;G06F16/2315;;G06F16/2379,G06F16/23,,0,0,,,,ACTIVE
742,US,A1,US 2003/0207442 A1,097-755-906-431-785,2003-11-06,2003,US 96199801 A,2001-09-24,US 96199801 A;;US 11813598 A;;US 177597 A;;US 5264497 P;;US 8893798 P,1997-07-16,Method for detecting the presence of an analyte in a sample,"
   A test device for detecting the presence of a residue analyte in a sample, which test device includes a support strip and a sample-absorbing matrix attached to the support strip. The sample-absorbing matrix has a material for absorbing an amount of the sample. The test device also includes a mobile-phase support for holding a mobile-phase composition. The mobile-phase support is attached to the support strip and in contact with the sample-absorbing matrix. A mobile-phase composition is disposed on the mobile-phase support and has a receptor for binding with the analyte. The mobile-phase composition can be carried in the sample. A stationary-phase membrane is attached to the support strip and has a first membrane end in contact with the mobile-phase composition and a second membrane end. The membrane allows lateral capillary flow of the sample from the first membrane end to the second membrane end. A test zone is on the stationary-phase membrane between the first membrane end and second membrane end and having a first binder for binding with an unbound receptor. A control zone is the stationary-phase membrane between the test zone and second membrane end and has a second binder for binding with an analyte-bound receptor or residual unbound receptor. 
",MARKOVSKY ROBERT J.;;BOYER CHERYL A.;;CHARM STANLEY E.;;DONAHUE PAUL R.;;GLICKMAN YAEL AGI;;SAUL STEVEN J.;;SCHEEMAKER JOAN L.;;SKIFFINGTON RICHARD T.;;TRIVEDI SHEFALI B.;;ZOMER ELIEZER,MARKOVSKY ROBERT J;;BOYER CHERYL A;;CHARM STANLEY E;;DONAHUE PAUL R;;GLICKMAN YAEL AGI;;SAUL STEVEN J;;SCHEEMAKER JOAN L;;SKIFFINGTON RICHARD T;;TRIVEDI SHEFALI B;;ZOMER ELIEZER,,https://lens.org/097-755-906-431-785,Patent Application,yes,6,48,14,29,0,A23D9/00;;A23D9/00;;A23K10/30;;A23K10/30;;A23K20/158;;A23K20/158;;C11B3/001;;C11B3/001;;C11B7/00;;C11B7/00;;C11C1/04;;C11C1/04;;C11C3/10;;C11C3/10;;C11C3/123;;C11C3/123;;C12N9/0083;;C12N9/0083;;C12N15/8216;;C12N15/8216;;C12N15/8222;;C12N15/8222;;C12N15/8234;;C12N15/8234;;C12N15/8247;;C12N15/8247;;G01N33/558;;G01N33/558;;G01N33/537;;G01N33/537;;G01N33/54366;;G01N33/54366;;G01N2201/0221;;G01N2201/0221;;Y10S435/805;;Y10S435/805;;Y10S435/97;;Y10S435/97;;Y10T436/10;;Y10T436/10;;Y10T436/105831;;Y10T436/105831,A23D9/00;;A23K1/14;;A23K1/16;;C11B3/00;;C11B7/00;;C11C1/04;;C11C3/10;;C11C3/12;;C12N9/02;;C12N15/82;;G01N33/537;;G01N33/543;;G01N33/558;;G01N37/00,435/287.2;;436/514,0,0,,,,EXPIRED
743,US,A1,US 2007/0112833 A1,089-415-481-411-47X,2007-05-17,2007,US 28129005 A,2005-11-17,US 28129005 A,2005-11-17,System and method for annotating patents with MeSH data,A system and method for enhancing patent documents. A system is disclosed that includes: an extraction system for extracting non-patent references from a patent document; a system for cross-referencing an extracted non-patent reference with a metadata database to identify metadata information associated with the extracted non-patent reference; and a system for annotating the patent document with the metadata information.,IBM,ANGELL ROBERT L;;BOYER STEPHEN K;;COOPER JAMES W;;HENNESSY RICHARD A;;KANUNGO TAPAS;;KREULEN JEFFREY T;;MARTIN DAVID C;;RHODES JAMES J;;SPANGLER W S;;WEINTRAUB HERSCHEL J,INTERNATIONAL BUSINESS MACHINES CORPORATION (2005-10-17),https://lens.org/089-415-481-411-47X,Patent Application,yes,44,9,1,1,0,G06F16/382;;G06F16/353;;G06F16/353;;G06F16/382,G06F7/00,707/102,0,0,,,,DISCONTINUED
744,US,A1,US 2007/0112748 A1,002-101-855-651-251,2007-05-17,2007,US 28129105 A,2005-11-17,US 28129105 A,2005-11-17,System and method for using text analytics to identify a set of related documents from a source document,A system and method for processing a document to generate a set of related documents. A system is provided that includes a textual analytics system that analyzes unstructured data contained in a source document and extracts a set of structured information about the source document; and a compare system that identifies a set of related documents by comparing the set of structured information with metadata indexed from a set of publications.,IBM,ANGELL ROBERT L;;BOYER STEPHEN K;;COOPER JAMES W;;HENNESSY RICHARD A;;KANUNGO TAPAS;;KREULEN JEFFREY T;;MARTIN DAVID C;;RHODES JAMES J;;SPANGLER W S;;WEINTRAUB HERSCHEL J,INTERNATIONAL BUSINESS MACHINES CORPORATION (2005-10-17),https://lens.org/002-101-855-651-251,Patent Application,yes,34,45,4,4,0,G06F40/237;;G06F40/237,G06F17/30;;G06F40/237,707/4,0,0,,,,ACTIVE
745,US,B1,US 11089133 B1,193-254-092-386-165,2021-08-10,2021,US 201715821690 A,2017-11-22,US 201715821690 A,2017-11-22,Synchronizing data with delayed subscriptions,A technology is provided for synchronizing data with delayed subscriptions. A request may be received at a data proxy for a data snapshot for an application that has been offline at the client. A subscription may be held for a pre-determined amount of time after the request for the snapshot. The data snapshot may be sent to the client. The data for the subscription may be sent after the pre-determined amount of time.,AMAZON TECH INC,PATEL AMIT;;DESHPANDE ROHAN;;SHON LISA MEENHEE;;SALIGRAMA SHREERAM KARTHIK;;DOWLING CHRISTOPHER NATHAN;;BAILEY JEFFREY H;;BOYER ANTOINE FRANCOIS CHARLES;;THRELKELD RICHARD;;PARIS MICHAEL;;WILLINGHAM MICHAEL B;;SRIVASTAVA MOHIT,AMAZON TECHNOLOGIES INC (2017-12-07),https://lens.org/193-254-092-386-165,Granted Patent,yes,21,5,1,1,0,H04L67/1095;;G06F16/273;;H04L67/59;;H04L67/2895;;G06F16/273;;H04L67/62;;H04L67/01;;H04L67/562,G06F15/16;;G06F16/27;;H04L29/06;;H04L29/08,,0,0,,,,ACTIVE
746,WO,A2,WO 1999/004267 A2,051-430-206-975-007,1999-01-28,1999,US 9814705 W,1998-07-16,US 5264497 P;;US 177597 A;;US 8893798 P,1997-07-16,A TEST DEVICE AND METHOD FOR DETECTING THE PRESENCE OF A RESIDUE ANALYTE IN A SAMPLE,A test device for detecting the presence of a residue analyte in a sample includes a support strip and a sample-absorbing matrix attached to the support strip. The sample-absorbing matrix has a material for absorbing an amount of the sample. The test device also includes a mobile-phase support for holding a mobile-phase composition. The mobile-phase support is attached to the support strip and in contact with the sample-absorbing matrix. A mobile-phase composition is disposed on the mobile-phase support and has a receptor for binding with the analyte. The mobile-phase composition can be carried in the sample. A stationary-phase membrane is attached to the support strip and has a first membrane end in contact with the mobile-phase composition and a second membrane end. The membrane allows lateral capillary flow of the sample from the first membrane end to the second membrane end. A test zone is on the stationary-phase membrane between the first membrane end and second membrane end and having a first binder for binding with an unbound receptor. A control zone is the stationary-phase membrane between the test zone and second membrane end and has a second binder for binding with an analyte-bound receptor or residual unbound receptor.,CHARM SCIENCES INC,MARKOVSKY ROBERT J;;BOYER CHERYL A;;CHARM STANLEY E;;DONAHUE PAUL R;;AGI-GLICKMAN YAEL;;SAUL STEVEN J;;SCHEEMAKER JOAN L;;SKIFFINGTON RICHARD T;;TRIVEDI SHIFALI B;;ZOMER ELIEZER,,https://lens.org/051-430-206-975-007,Patent Application,no,0,11,14,29,0,A23D9/00;;A23D9/00;;A23K10/30;;A23K10/30;;A23K20/158;;A23K20/158;;C11B3/001;;C11B3/001;;C11B7/00;;C11B7/00;;C11C1/04;;C11C1/04;;C11C3/10;;C11C3/10;;C11C3/123;;C11C3/123;;C12N9/0083;;C12N9/0083;;C12N15/8216;;C12N15/8216;;C12N15/8222;;C12N15/8222;;C12N15/8234;;C12N15/8234;;C12N15/8247;;C12N15/8247;;G01N33/558;;G01N33/558;;G01N33/537;;G01N33/537;;G01N33/54366;;G01N33/54366;;G01N2201/0221;;G01N2201/0221;;Y10S435/805;;Y10S435/805;;Y10S435/97;;Y10S435/97;;Y10T436/10;;Y10T436/10;;Y10T436/105831;;Y10T436/105831,A23D9/00;;A23K1/14;;A23K1/16;;C11B3/00;;C11B7/00;;C11C1/04;;C11C3/10;;C11C3/12;;C12N9/02;;C12N15/82;;G01N33/537;;G01N33/543;;G01N33/558;;G01N37/00,,0,0,,,,PATENTED
747,CN,C,CN 100594495 C,023-297-053-345-286,2010-03-17,2010,CN 200610110127 A,2006-07-31,US 28129105 A,2005-11-17,System and method for using text analytics to identify a set of related documents from a source document,A system and method for processing a document to generate a set of related documents. A system is provided that includes a textual analytics system that analyzes unstructured data contained in a source document and extracts a set of structured information about the source document; and a compare system that identifies a set of related documents by comparing the set of structured information with metadata indexed from a set of publications.,IBM,ANGELL ROBERT L;;BOYER STEPHEN K;;COOPER JAMES W;;HENNESSY RICHARD A;;TAPAS KANUNGO;;KREULEN JEFFREY T;;MARTIN DAVID C;;RHODES JAMES J;;SPANGLER W S;;WEINTRAUB HERSCHEL J,,https://lens.org/023-297-053-345-286,Granted Patent,no,0,0,4,4,0,G06F40/237;;G06F40/237,G06F17/30;;G06F40/237,,0,0,,,,ACTIVE
748,WO,A3,WO 1999/004267 A3,023-419-344-479-930,1999-04-22,1999,US 9814705 W,1998-07-16,US 5264497 P;;US 177597 A;;US 8893798 P,1997-07-16,TEST DEVICE AND METHOD FOR DETECTING AN ANALYTE IN A SAMPLE,A test device for detecting the presence of a residue analyte in a sample includes a support strip and a sample-absorbing matrix attached to the support strip. The sample-absorbing matrix has a material for absorbing an amount of the sample. The test device also includes a mobile-phase support for holding a mobile-phase composition. The mobile-phase support is attached to the support strip and in contact with the sample-absorbing matrix. A mobile-phase composition is disposed on the mobile-phase support and has a receptor for binding with the analyte. The mobile-phase composition can be carried in the sample. A stationary-phase membrane is attached to the support strip and has a first membrane end in contact with the mobile-phase composition and a second membrane end. The membrane allows lateral capillary flow of the sample from the first membrane end to the second membrane end. A test zone is on the stationary-phase membrane between the first membrane end and second membrane end and having a first binder for binding with an unbound receptor. A control zone is the stationary-phase membrane between the test zone and second membrane end and has a second binder for binding with an analyte-bound receptor or residual unbound receptor.,CHARM SCIENCES INC,MARKOVSKY ROBERT J;;BOYER CHERYL A;;CHARM STANLEY E;;DONAHUE PAUL R;;AGI-GLICKMAN YAEL;;SAUL STEVEN J;;SCHEEMAKER JOAN L;;SKIFFINGTON RICHARD T;;TRIVEDI SHIFALI B;;ZOMER ELIEZER,,https://lens.org/023-419-344-479-930,Search Report,yes,8,0,14,29,0,A23D9/00;;A23D9/00;;A23K10/30;;A23K10/30;;A23K20/158;;A23K20/158;;C11B3/001;;C11B3/001;;C11B7/00;;C11B7/00;;C11C1/04;;C11C1/04;;C11C3/10;;C11C3/10;;C11C3/123;;C11C3/123;;C12N9/0083;;C12N9/0083;;C12N15/8216;;C12N15/8216;;C12N15/8222;;C12N15/8222;;C12N15/8234;;C12N15/8234;;C12N15/8247;;C12N15/8247;;G01N33/558;;G01N33/558;;G01N33/537;;G01N33/537;;G01N33/54366;;G01N33/54366;;G01N2201/0221;;G01N2201/0221;;Y10S435/805;;Y10S435/805;;Y10S435/97;;Y10S435/97;;Y10T436/10;;Y10T436/10;;Y10T436/105831;;Y10T436/105831,A23D9/00;;A23K1/14;;A23K1/16;;C11B3/00;;C11B7/00;;C11C1/04;;C11C3/10;;C11C3/12;;C12N9/02;;C12N15/82;;G01N33/537;;G01N33/543;;G01N33/558;;G01N37/00,,0,0,,,,PATENTED
749,WO,A3,WO 1999/004267 A3,049-457-767-569-146,1999-01-28,1999,US US9814705,1998-07-16,"US 60/0/052,644;;US 09/0/001,775;;US 60/0/088,937",1997-07-16,TEST DEVICE AND METHOD FOR DETECTING AN ANALYTE IN A SAMPLE,A test device for detecting the presence of a residue analyte in a sample includes a support strip and a sample-absorbing matrix attached to the support strip. The sample-absorbing matrix has a material for absorbing an amount of the sample. The test device also includes a mobile-phase support for holding a mobile-phase composition. The mobile-phase support is attached to the support strip and in contact with the sample-absorbing matrix. A mobile-phase composition is disposed on the mobile-phase support and has a receptor for binding with the analyte. The mobile-phase composition can be carried in the sample. A stationary-phase membrane is attached to the support strip and has a first membrane end in contact with the mobile-phase composition and a second membrane end. The membrane allows lateral capillary flow of the sample from the first membrane end to the second membrane end. A test zone is on the stationary-phase membrane between the first membrane end and second membrane end and having a first binder for binding with an unbound receptor. A control zone is the stationary-phase membrane between the test zone and second membrane end and has a second binder for binding with an analyte-bound receptor or residual unbound receptor.,"CHARM SCIENCES, INC.","MARKOVSKY, Robert, J.;;BOYER, Cheryl, A.;;CHARM, Stanley, E.;;DONAHUE, Paul, R.;;AGI-GLICKMAN, Yael;;SAUL, Steven, J.;;SCHEEMAKER, Joan, L.;;SKIFFINGTON, Richard, T.;;TRIVEDI, Shifali, B.;;ZOMER, Eliezer",,https://lens.org/049-457-767-569-146,Search Report,yes,0,0,1,1,0,,G01N33/537;;G01N33/543;;G01N37/00,,0,0,,,,UNKNOWN
750,EP,A1,EP 0998676 A1,064-306-743-481-479,2000-05-10,2000,EP 98935709 A,1998-07-16,US 9814705 W;;US 5264497 P;;US 177597 A;;US 8893798 P,1997-07-16,A TEST DEVICE AND METHOD FOR DETECTING THE PRESENCE OF A RESIDUE ANALYTE IN A SAMPLE,,CHARM SCIENCES INC,MARKOVSKY ROBERT J;;BOYER CHERYL A;;CHARM STANLEY E;;DONAHUE PAUL R;;AGI-GLICKMAN YAEL;;SAUL STEVEN J;;SCHEEMAKER JOAN L;;SKIFFINGTON RICHARD T;;TRIVEDI SHIFALI B;;ZOMER ELIEZER,CHARM SCIENCES INC. (2006-05-03),https://lens.org/064-306-743-481-479,Patent Application,yes,0,0,14,29,0,A23D9/00;;A23D9/00;;A23K10/30;;A23K10/30;;A23K20/158;;A23K20/158;;C11B3/001;;C11B3/001;;C11B7/00;;C11B7/00;;C11C1/04;;C11C1/04;;C11C3/10;;C11C3/10;;C11C3/123;;C11C3/123;;C12N9/0083;;C12N9/0083;;C12N15/8216;;C12N15/8216;;C12N15/8222;;C12N15/8222;;C12N15/8234;;C12N15/8234;;C12N15/8247;;C12N15/8247;;G01N33/558;;G01N33/558;;G01N33/537;;G01N33/537;;G01N33/54366;;G01N33/54366;;G01N2201/0221;;G01N2201/0221;;Y10S435/805;;Y10S435/805;;Y10S435/97;;Y10S435/97;;Y10T436/10;;Y10T436/10;;Y10T436/105831;;Y10T436/105831,A23D9/00;;A23K1/14;;A23K1/16;;C11B3/00;;C11B7/00;;C11C1/04;;C11C3/10;;C11C3/12;;C12N9/02;;C12N15/82;;G01N33/537;;G01N33/543;;G01N33/558;;G01N37/00,,1,0,,,See references of WO 9904267A3,EXPIRED
751,EP,B1,EP 0998676 B1,174-143-181-236-803,2007-04-11,2007,EP 98935709 A,1998-07-16,US 9814705 W;;US 5264497 P;;US 177597 A;;US 8893798 P,1997-07-16,A TEST DEVICE AND METHOD FOR DETECTING THE PRESENCE OF A RESIDUE ANALYTE IN A SAMPLE,,CHARM SCIENCES INC,MARKOVSKY ROBERT J;;BOYER CHERYL A;;CHARM STANLEY E;;DONAHUE PAUL R;;AGI-GLICKMAN YAEL;;SAUL STEVEN J;;SCHEEMAKER JOAN L;;SKIFFINGTON RICHARD T;;TRIVEDI SHIFALI B;;ZOMER ELIEZER,CHARM SCIENCES INC. (2006-05-03),https://lens.org/174-143-181-236-803,Granted Patent,yes,8,1,14,29,0,A23D9/00;;A23D9/00;;A23K10/30;;A23K10/30;;A23K20/158;;A23K20/158;;C11B3/001;;C11B3/001;;C11B7/00;;C11B7/00;;C11C1/04;;C11C1/04;;C11C3/10;;C11C3/10;;C11C3/123;;C11C3/123;;C12N9/0083;;C12N9/0083;;C12N15/8216;;C12N15/8216;;C12N15/8222;;C12N15/8222;;C12N15/8234;;C12N15/8234;;C12N15/8247;;C12N15/8247;;G01N33/558;;G01N33/558;;G01N33/537;;G01N33/537;;G01N33/54366;;G01N33/54366;;G01N2201/0221;;G01N2201/0221;;Y10S435/805;;Y10S435/805;;Y10S435/97;;Y10S435/97;;Y10T436/10;;Y10T436/10;;Y10T436/105831;;Y10T436/105831,G01N33/68;;A23D9/00;;A23K1/14;;A23K1/16;;C11B3/00;;C11B7/00;;C11C1/04;;C11C3/10;;C11C3/12;;C12N9/02;;C12N15/82;;G01N33/537;;G01N33/543;;G01N33/558;;G01N37/00,,0,0,,,,EXPIRED
752,US,B2,US 9495349 B2,146-165-464-175-571,2016-11-15,2016,US 28129105 A,2005-11-17,US 28129105 A,2005-11-17,System and method for using text analytics to identify a set of related documents from a source document,A system and method for processing a document to generate a set of related documents. A system is provided that includes a textual analytics system that analyzes unstructured data contained in a source document and extracts a set of structured information about the source document; and a compare system that identifies a set of related documents by comparing the set of structured information with metadata indexed from a set of publications.,ANGELL ROBERT L;;BOYER STEPHEN K;;COOPER JAMES W;;HENNESSY RICHARD A;;KANUNGO TAPAS;;KREULEN JEFFREY T;;MARTIN DAVID C;;RHODES JAMES J;;SPANGLER W SCOTT;;WEINTRAUB HERSCHEL J R;;IBM,ANGELL ROBERT L;;BOYER STEPHEN K;;COOPER JAMES W;;HENNESSY RICHARD A;;KANUNGO TAPAS;;KREULEN JEFFREY T;;MARTIN DAVID C;;RHODES JAMES J;;SPANGLER W SCOTT;;WEINTRAUB HERSCHEL J R,INTERNATIONAL BUSINESS MACHINES CORPORATION (2005-10-17),https://lens.org/146-165-464-175-571,Granted Patent,yes,43,11,4,4,0,G06F40/237;;G06F40/237,G06F7/00;;G06F40/237,,25,10,091-916-331-832-102;;019-761-361-594-42X;;056-971-725-855-254;;119-601-645-744-381;;036-326-862-715-891;;005-714-099-126-750;;125-900-196-879-13X;;081-094-979-169-814;;078-969-833-805-532;;098-951-012-309-187,10.1023/a:1013685612819;;10.1145/276304.276332;;10.1145/945546.945547;;pmc2232672;;10566344;;12603047;;10.1142/9789812776303_0040;;10.1021/ci00039a002;;10.1021/ci980324v;;10.1021/c160019a010;;10.1109/2.179115;;10.1021/ci00016a011,"Yang et al., ""A Study of Approaches to Hypertext Categorization,"" Mar. 2002, pp. 219-241, Journal of Intelligent Information Systems, vol. 18:2/3.;;Chakrabarti et al., ""Enhanced Hypertext Categorization Using Hyperlinks,"" 1998, pp. 307-318, Proceedings of the 1998 ACM SIGMOD International Conference on Management of Data.;;Fall et al., ""Automated Categorization in the International Patent Classification,"" Spring 2003, pp. 10-25, ACM SIGIR Forum, vol. 37, No. 1.;;Si et al., ""On the Use of Hierachy Information in Mapping Patents to Biomedical Ontologies,"" IBM Research Report, Oct. 2005, pp. 1-21, RJ10365 (A0541-017).;;Li et al., ""Automatic Patent Classification Using Citation Network Information: An Experimental Study in Nanotechnology,"" Jun. 2007, pp. 419-427, Proceedings of the 7th ACM/IEEE-CS Joint Conference on Digital Libraries.;;Wassum, Office Communication for U.S. Appl. No. 11/281,290 dated Mar. 4, 2009, 7 pages.;;Wassum, Office Communication for U.S. Appl. No. 11/281,290 dated Jul. 10, 2009, 3 pages.;;Wassum, Office Communication for U.S. Appl. No. 11/281,290 dated Nov. 17, 2009, 18 pages.;;Wassum, Office Communication for U.S. Appl. No. 11/281,290 dated Jun. 29, 2010, 20 pages.;;Wassum, Examiner's Answer for U.S. Appl. No. 11/281,290 dated Jan. 19, 2011, 28 pages.;;Volk, Martin et al., ""A Systematic Evaluation of Concept-based Cross-Lingual Information Retrieval in the Medical Domain,"" pp. 1-6, Proceeding of 3rd Dutch-Belgian Information, Oct. 31, 2002.;;""Smiles Parser"", http://www.wag.caltech.edu/home/meulbroek/smiles/smiles-parser.htm, Feb. 24, 2004, 1pg.;;Eugene Garfield, ""An Algorithm for Translating Chemical Names to Molecular Formulas"", Essays of an Information Scientist, vol. 7, pp. 441-513, 1984.;;Wilber et al., ""Analysis of Biomedical Text for Chemical Names: A Comparison of Three Methods"", pp. 176-180, 1999.;;Narayanaswamy et al., ""A Biological Named Entity Recognizer"", Pacific Symposium on Biocomputing 8: pp. 427-438, 2003.;;Dittmar et al., ""The CAS Online Search System. 1. General System Design and Selection, Generation, and Use of Search Screens"", J. Chem. Inf. Comput. Sci. 1983, 23, 93-102.;;Nick Kemp and Michael Lynch; ""Extraction of Information from the Text of Chemical Patents. 1. Identification of Specific Chemical Names"", J. Chem. Inf. Comput. Sci. 1998, vol. 38, pp. 544-551. Jan. 6, 1998.;;Leiter et al.; ""Installation and Operation of a Registry for Chemical Compounds"" Journal of Chemical Documentation, Jul. 7, 1965, pp. 238-242.;;Shivaratri et al.; ""Load Distibuting for Locally Distributed Systems"", IEEE, Dec. 1992, pp. 33-44.;;Drefahl et al.; ""Similarity-Based Search and Evaluation of Environmentally Relevant Properties for Organic Compounds in Combination with the Group Contribution Approach"", J. Chem. Inf. Comput. Sci. vol. 33 pp. 886-895, Feb. 17, 1993.;;Jackson: U.S. Appl. No. 10/670,675, Office Action Mar. 3, 2009, 17 pgs.;;Jackson: U.S. Appl. No. 10/670,675, Office Action Sep. 11, 2009, 7 pgs.;;Jackson: U.S. Appl. No. 10/670,675, Office Action Aug. 6, 2008, 16 pgs.;;Jackson: U.S. Appl. No. 10/670,675, Notice of Allowance Oct. 20, 2009, 6 pgs.;;Shimatov, Office Action Communication for U.S. Appl. No. 11/281,290 dated Jul. 28, 2014, 53 pages.",ACTIVE
753,US,A1,US 2022/0253943 A1,022-602-312-876-164,2022-08-11,2022,US 202217668203 A,2022-02-09,US 202217668203 A;;US 202163147661 P,2021-02-09,USER INTERFACE ASSOCIATED WITH HOLISTIC DIGITAL CLAIMS PLATFORM,"This technology relates to providing a web-based digital claims platform to provide users with a simple and customized experience when filing insurance claims. The platform is enabled by a plurality of back-end application programming interface (API) resources. These API resources are event-driven (e.g., when an “event” associated with the claim occurs, the status of the claim changes and the API is provided with updated information indicative of the change). The platform includes a customized user interface (UI) that tailors the claim experience to a particular user's needs. The customization can be based off of stated user preferences and/or learned user preferences associated with the user's past behavior. A user can perform/request various services through the customized UI's self-service function (e.g., rent a car, find a hotel room, select a repair shop, etc.). Additionally, the customized UI can enable the user upload documents, track claim status, find relevant help topics, etc.",STATE FARM MUTUAL AUTOMOBILE INSURANCE CO,SIMONOVICH WILLIAM;;LEACH JORDAN;;SMITH NATALIE;;BOYER BRITTANY;;SANTOS YOHAN;;NIEDBALSKI KENRICK;;KIM RICHARD;;TAYLOR DEBORAH;;MUSIL JARED;;NTABONA ARCHY;;WAHAB ABDUL;;FASSI LOUBNA;;GONSALVES MARY;;TARMANN BENJAMIN;;YEARGIN SAM,STATE FARM MUTUAL AUTOMOBILE INSURANCE COMPANY (2021-01-27);;TEKSYSTEMS INC (2021-02-03),https://lens.org/022-602-312-876-164,Patent Application,yes,1,0,1,1,0,G06Q40/08;;G06Q10/10;;G06F3/0482;;H04L67/02;;H04L67/535;;H04L67/53;;H04L67/12;;H04L67/55;;G06Q40/08;;H04L67/02;;G06F3/04842;;G06Q10/10,G06Q40/08;;G06F3/04842;;G06Q10/10;;H04L67/02,,0,0,,,,PENDING
754,EP,A1,EP 3035011 A1,051-192-421-766-67X,2016-06-22,2016,EP 16152477 A,2013-09-25,US 201261714394 P;;US 201313784933 A;;US 201313785177 A;;US 201361787414 P;;US 201361833517 P;;US 201361841717 P;;EP 13186043 A,2012-10-16,INTEGRATED DIMENSIONING SYSTEM,"An object analysis system includes a scale for measuring the weight of the object, a range camera configured to produce a range image of an area in which the object is located, and a computing device configured to determine the dimensions of the object based, at least in part, on the range image. Methods for determining the dimensions of an object include capturing a range image and/or a visible image of a scene that includes the object.
",HAND HELD PROD INC,MCCLOSKEY SCOTT;;WANG YNJIUN PAUL;;LLOYD RYAN ANDREW;;KHURANA HIMANSHU;;SMITH TAYLOR;;LI JINGQUAN;;JOVANOVSKI BRIAN L;;BOYER RICHARD M;;GIORDANO PATRICK ANTHONY;;GOOD TIMOTHY;;KEARNEY SEAN PHILLIP;;FLETCHER DONNA MARIE;;VAN HORN ERIK,,https://lens.org/051-192-421-766-67X,Patent Application,yes,2,2,6,10,0,G01G19/4148;;G01B11/022;;G06Q10/083;;G06Q30/04;;G01B11/00;;G01B11/02;;G01B11/2513;;G07B2017/00685;;G07B2017/00701;;G01G19/002;;G01G19/4148;;G01B11/022;;G06Q10/083;;G06Q30/04;;G01B11/00;;G01B11/02;;G01B11/2513;;G07B2017/00685;;G07B2017/00701;;H04N7/18,G01G19/414;;G01B11/02;;G01B11/25;;G07B17/00,,0,0,,,,DISCONTINUED
755,EP,A1,EP 2722656 A1,169-563-232-041-337,2014-04-23,2014,EP 13186043 A,2013-09-25,US 201261714394 P;;US 201313784933 A;;US 201313785177 A;;US 201361787414 P;;US 201361833517 P;;US 201361841717 P,2012-10-16,Integrated dimensioning and weighing system,"An object analysis system includes a scale for measuring the weight of the object, a range camera configured to produce a range image of an area in which the object is located, and a computing device configured to determine the dimensions of the object based, at least in part, on the range image. Methods for determining the dimensions of an object include capturing a range image and/or a visible image of a scene that includes the object.
",HAND HELD PROD INC,MCCLOSKEY SCOTT;;WANG YNJIUN PAUL;;LLOYD RYAN ANDREW;;KHURANA HIMANSHU;;SMITH TAYLOR;;LI JINGQUAN;;JOVANOVSKI BRIAN L;;BOYER RICHARD M;;GIORDANO PATRICK ANTHONY;;GOOD TIMOTHY;;KEARNEY SEAN PHILLIP;;VAN HORN ERIK;;FLETCHER DONNA MARIE,,https://lens.org/169-563-232-041-337,Patent Application,yes,9,94,1,10,0,G01B11/02;;G01B11/00;;G01B11/2513;;G01G19/4148;;G07B2017/00685;;G07B2017/00701,G01G19/414;;G01B11/02;;G01B11/25;;G07B17/00,,0,0,,,,DISCONTINUED
756,NZ,A,NZ 333432 A,100-974-694-677-455,2000-06-23,2000,NZ 33343297 A,1997-12-12,US 76619296 A;;US 98874597 A;;US 9722886 W,1996-12-12,Controllable underwater strobe light system for directing movement of fish,"A system for directing fish away from danger points at an underwater structure includes multiple submersible flash heads 13 connected to a flash head control unit 99. The control unit may be mobile or stationary as required. The flash sequence, rate and intensity are adjustable by an operator in real time using a system control unit which can be remotely located. The flash heads 13, either singly or connected together, are strobed in a manner intended to alter the behaviour of the fish. The system may include a way to generate an air curtain near the flash heads to improve light dispersion, and a water jet to clean the lenses on the flash heads.",FLASH TECHNOLOGY CORP OF AMERI,BAUGHER SUSAN ANN;;BROWN RONALD EARL;;JOHNSON DALE A;;SCHIPP ROBERTO;;NEWSOM MARK STEVENS;;NGUYEN TIEN;;SHUMATE CHRISTOPHER JOEL;;TERRY DAVID MICHAEL;;MARK FRED;;NORTHRUP RICHARD;;OUELLETTE LARRY;;IHRIE RONALD;;BOYER EDWARD;;BOYERS WILLIAM F,,https://lens.org/100-974-694-677-455,Patent Application,no,0,0,14,16,0,A01K79/02;;A01K79/02,A01K29/00;;A01K61/00;;A01K79/02;;A01M29/00;;H05B43/00;;H05C1/04,,0,0,,,,PENDING
757,DK,T3,DK 1014783 T3,102-995-516-396-680,2006-08-28,2006,DK 97953192 T,1997-12-12,US 76619296 A;;US 98874597 A,1996-12-12,"Mobilt, styrbart stroboskoplyssystem og fremgangsmåde til at dirigere en fisks bevægelser",,FLASH TECHNOLOGY CORP OF AMERI,BAUGHER SUSAN ANN;;BROWN RONALD EARL;;JOHNSON DALE A;;SCHIPP ROBERTO;;NEWSOM MARK STEVENS;;NGUYEN TIEN;;SHUMATE CHRISTOPHER JOEL;;MARK FRED;;NORTHRUP RICHARD;;OUELLETTE LARRY;;IHRIE RONALD;;BOYER EDWARD;;TERRY DAVID MICHAEL;;SOMMERS WILLIAM F,,https://lens.org/102-995-516-396-680,Granted Patent,no,0,0,14,16,0,A01K79/02;;A01K79/02,A01K29/00;;A01K61/00;;A01K79/02;;A01M29/00;;H05B43/00;;H05C1/04,,0,0,,,,EXPIRED
758,CA,C,CA 2253714 C,115-750-795-286-148,2008-02-05,2008,CA 2253714 A,1997-12-12,US 76619296 A;;US 98874597 A;;US 9722886 W,1996-12-12,MOBILE CONTROLLABLE STROBE LIGHT SYSTEM AND METHOD FOR DIRECTING THE MOVEMENTS OF A FISH,"A system (10) for directing fish away from danger points at an underwater structure includes multiple submersible flash heads (13) operatively connected to a flash head control unit (99), which can be either stationary or mobile according to the embodiment of the system chosen. The flash sequence, rate and intensity are adjustable by the system operator in real time using a system control unit (100) which can be remotely located. The flash heads (13), either singularly or connecte d together in a tri-pack configuration, are strobed in a manner intended to alter the behavior of the fish. The system (10) may include a wa y to generate an air curtain (72) near the flash heads (13) to improve light dispersion and a water jet (74) to clean the lenses on the fla sh heads (13).",FLASH TECHNOLOGY CORP OF AMERI,SCHIPP ROBERTO;;JOHNSON DALE A;;BROWN RONALD EARL;;NEWSOM MARK STEVENS;;IHRIE RONALD;;BOYER EDWARD;;OUELLETTE LARRY;;BAUGHER SUSAN ANN;;SCHUMATE CHRISTOPHER JOEL;;SOMERS WILLIAM F;;MARK FRED;;TERRY DAVID MICHAEL;;NORTHRUP RICHARD;;NGUYEN TIEN,,https://lens.org/115-750-795-286-148,Granted Patent,no,0,0,14,16,0,A01K79/02;;A01K79/02,H05C1/04;;A01K29/00;;A01K61/00;;A01K79/02;;A01M29/00;;H05B43/00,,0,0,,,,EXPIRED
759,AU,B2,AU 723642 B2,049-308-522-938-901,2000-08-31,2000,AU 1998/056995 A,1997-12-12,US 76619296 A;;US 98874597 A;;US 9722886 W,1996-12-12,Mobile controllable strobe light system and method for directing the movements of a fish,,FLASH TECHNOLOGY CORP OF AMERI,BAUGHER SUSAN ANN;;BROWN RONALD EARL;;JOHNSON DALE A;;SCHIPP ROBERTO;;NEWSOM MARK STEVENS;;NGUYEN TIEN;;SHUMATE CHRISTOPHER JOEL;;TERRY DAVID MICHAEL;;MARK FRED;;NORTHRUP RICHARD;;OUELLETTE LARRY;;IHRIE RONALD;;BOYER EDWARD;;BOYERS WILLIAM F,,https://lens.org/049-308-522-938-901,Granted Patent,no,2,0,14,16,0,A01K79/02;;A01K79/02,A01K29/00;;A01K61/00;;A01K79/02;;A01M29/00;;H05B43/00;;H05C1/04,,0,0,,,,EXPIRED
760,NO,D0,NO 992848 D0,043-935-318-835-766,1999-06-11,1999,NO 992848 A,1999-06-11,US 76619296 A;;US 98874597 A;;US 9722886 W,1996-12-12,"Mobilt, styrbart stroboskoplyssystem og fremgangsmÕte for dirigering av bevegelser til fisk",,FLASH TECHNOLOGY CORP OF AMERI,BAUGHER SUSAN ANN;;BROWN RONALD EARL;;JOHNSON DALE A;;SCHIPP ROBERTO;;NEWSOM MARK STEVENS;;NGUYEN TIEN;;SHUMATE CHRISTOPHER JOEL;;TERRY DAVID MICHAEL;;MARK FRED;;NORTHRUP RICHARD;;OUELLETTE LARRY;;IHRIE RONALD;;BOYER EDWARD;;BOYERS WILLIAM F,,https://lens.org/043-935-318-835-766,Patent Application,no,0,0,14,16,0,A01K79/02;;A01K79/02,A01K29/00;;A01K61/00;;A01K79/02;;A01M29/00;;H05B43/00;;H05C1/04,,0,0,,,,EXPIRED
761,WO,A1,WO 1998/025450 A1,067-320-702-659-525,1998-06-18,1998,US 9722886 W,1997-12-12,US 76619296 A,1996-12-12,MOBILE CONTROLLABLE STROBE LIGHT SYSTEM AND METHOD FOR DIRECTING THE MOVEMENTS OF A FISH,"A system (10) for directing fish away from danger points at an underwater structure includes multiple submersible flash heads (13) operatively connected to a flash head control unit (99), which can be either stationary or mobile according to the embodiment of the system chosen. The flash sequence, rate and intensity are adjustable by the system operator in real time using a system control unit (100) which can be remotely located. The flash heads (13), either singularly or connected together in a tri-pack configuration, are strobed in a manner intended to alter the behavior of the fish. The system (10) may include a way to generate an air curtain (72) near the flash heads (13) to improve light dispersion and a water jet (74) to clean the lenses on the flash heads (13).",FLASH TECHNOLOGY CORP OF AMERI,BAUGHER SUSAN ANN;;BROWN RONALD EARL;;JOHNSON DALE A;;SCHIPP ROBERTO;;NEWSOM MARK STEVENS;;NGUYEN TIEN;;SHUMATE CHRISTOPHER JOEL;;TERRY DAVID MICHAEL;;MARK FRED;;NORTHRUP RICHARD;;OUELLETTE LARRY;;IHRIE RONALD;;BOYER EDWARD;;BOYERS WILLIAM F,,https://lens.org/067-320-702-659-525,Patent Application,yes,1,3,2,16,0,A01K79/02;;A01K79/02,A01K79/02,,0,0,,,,PATENTED
762,EP,B1,EP 1014783 B1,039-795-445-427-371,2006-05-03,2006,EP 97953192 A,1997-12-12,US 9722886 W;;US 76619296 A;;US 98874597 A,1996-12-12,MOBILE CONTROLLABLE STROBE LIGHT SYSTEM AND METHOD FOR DIRECTING THE MOVEMENTS OF A FISH,,FLASH TECHNOLOGY CORP OF AMERI,BAUGHER SUSAN ANN;;BROWN RONALD EARL;;JOHNSON DALE A;;SCHIPP ROBERTO;;NEWSOM MARK STEVENS;;NGUYEN TIEN;;SHUMATE CHRISTOPHER JOEL;;TERRY DAVID MICHAEL;;MARK FRED;;NORTHRUP RICHARD;;OUELLETTE LARRY;;IHRIE RONALD;;BOYER EDWARD;;SOMMERS WILLIAM F,,https://lens.org/039-795-445-427-371,Granted Patent,yes,3,0,14,16,0,A01K79/02;;A01K79/02,A01K29/00;;A01K61/00;;A01K79/02;;A01M29/00;;H05B43/00;;H05C1/04,,0,0,,,,EXPIRED
763,NO,L,NO 992848 L,036-417-398-160-602,1999-06-11,1999,NO 992848 A,1999-06-11,US 76619296 A;;US 98874597 A;;US 9722886 W,1996-12-12,"Mobilt, styrbart stroboskoplyssystem og fremgangsmÕte for dirigering av bevegelser til fisk",,FLASH TECHNOLOGY CORP OF AMERI,BAUGHER SUSAN ANN;;BROWN RONALD EARL;;JOHNSON DALE A;;SCHIPP ROBERTO;;NEWSOM MARK STEVENS;;NGUYEN TIEN;;SHUMATE CHRISTOPHER JOEL;;TERRY DAVID MICHAEL;;MARK FRED;;NORTHRUP RICHARD;;OUELLETTE LARRY;;IHRIE RONALD;;BOYER EDWARD;;BOYERS WILLIAM F,,https://lens.org/036-417-398-160-602,Abstract,no,0,0,14,16,0,A01K79/02;;A01K79/02,A01K29/00;;A01K61/00;;A01K79/02;;A01M29/00;;H05B43/00;;H05C1/04,,0,0,,,,EXPIRED
764,CA,A1,CA 2253714 A1,152-354-266-082-729,1998-06-18,1998,CA 2253714 A,1997-12-12,US 76619296 A;;US 98874597 A;;US 9722886 W,1996-12-12,MOBILE CONTROLLABLE STROBE LIGHT SYSTEM AND METHOD FOR DIRECTING THE MOVEMENTS OF A FISH,"A system (10) for directing fish away from danger points at an underwater structure includes multiple submersible flash heads (13) operatively connected to a flash head control unit (99), which can be either stationary or mobile according to the embodiment of the system chosen. The flash sequence, rate and intensity are adjustable by the system operator in real time using a system control unit (100) which can be remotely located. The flash heads (13), either singularly or connected together in a tri-pack configuration, are strobed in a manner intended to alter the behavior of the fish. The system (10) may include a way to generate an air curtain (72) near the flash heads (13) to improve light dispersion and a water jet (74) to clean the lenses on the flash heads (13).",FLASH TECHNOLOGY CORP OF AMERI,SCHIPP ROBERTO;;SCHUMATE CHRISTOPHER JOEL;;BAUGHER SUSAN ANN;;NEWSOM MARK STEVENS;;NGUYEN TIEN;;JOHNSON DALE A;;IHRIE RONALD;;TERRY DAVID MICHAEL;;BOYER EDWARD;;SOMERS WILLIAM F;;MARK FRED;;NORTHRUP RICHARD;;OUELLETTE LARRY;;BROWN RONALD EARL,,https://lens.org/152-354-266-082-729,Patent Application,no,0,1,14,16,0,A01K79/02;;A01K79/02,A01K29/00;;A01K61/00;;A01K79/02;;A01M29/00;;H05B43/00;;H05C1/04,,0,0,,,,EXPIRED
765,NO,B1,NO 310592 B1,162-510-969-440-507,2001-07-30,2001,NO 992848 A,1999-06-11,US 76619296 A;;US 98874597 A;;US 9722886 W,1996-12-12,"Mobilt, styrbart stroboskoplyssystem og fremgangsmåte for dirigering av bevegelser til fisk",,FLASH TECHNOLOGY CORP OF AMERI,BAUGHER SUSAN ANN;;BROWN RONALD EARL;;JOHNSON DALE A;;SCHIPP ROBERTO;;NEWSOM MARK STEVENS;;NGUYEN TIEN;;SHUMATE CHRISTOPHER JOEL;;TERRY DAVID MICHAEL;;MARK FRED;;NORTHRUP RICHARD;;OUELLETTE LARRY;;IHRIE RONALD;;BOYER EDWARD;;SOMERS WILLIAM F,,https://lens.org/162-510-969-440-507,Granted Patent,no,0,0,14,16,0,A01K79/02;;A01K79/02,A01K29/00;;A01K61/00;;A01K79/02;;A01M29/00;;H05B43/00;;H05C1/04,,0,0,,,,EXPIRED
766,AU,A,AU 1998/056995 A,039-188-259-429-184,1998-07-03,1998,AU 1998/056995 A,1997-12-12,US 76619296 A;;US 98874597 A;;US 9722886 W,1996-12-12,Mobile controllable strobe light system and method for directing the movements of a fish,,FLASH TECH CORPORATION OF AMERICA,BAUGHER SUSAN ANN;;BROWN RONALD EARL;;JOHNSON DALE A;;SCHIPP ROBERTO;;NEWSOM MARK STEVENS;;NGUYEN TIEN;;SHUMATE CHRISTOPHER JOEL;;TERRY DAVID MICHAEL;;MARK FRED;;NORTHRUP RICHARD;;OUELLETTE LARRY;;IHRIE RONALD;;BOYER EDWARD;;BOYERS WILLIAM F,,https://lens.org/039-188-259-429-184,Patent Application,no,0,0,14,16,0,A01K79/02;;A01K79/02,A01K29/00;;A01K61/00;;A01K79/02;;A01M29/00;;H05B43/00;;H05C1/04,,0,0,,,,EXPIRED
767,EP,A1,EP 1014783 A1,130-702-379-558-930,2000-07-05,2000,EP 97953192 A,1997-12-12,US 9722886 W;;US 76619296 A;;US 98874597 A,1996-12-12,MOBILE CONTROLLABLE STROBE LIGHT SYSTEM AND METHOD FOR DIRECTING THE MOVEMENTS OF A FISH,,FLASH TECHNOLOGY CORP OF AMERI,BAUGHER SUSAN ANN;;BROWN RONALD EARL;;JOHNSON DALE A;;SCHIPP ROBERTO;;NEWSOM MARK STEVENS;;NGUYEN TIEN;;SHUMATE CHRISTOPHER JOEL;;TERRY DAVID MICHAEL;;MARK FRED;;NORTHRUP RICHARD;;OUELLETTE LARRY;;IHRIE RONALD;;BOYER EDWARD;;SOMMERS WILLIAM F,,https://lens.org/130-702-379-558-930,Patent Application,yes,0,1,14,16,0,A01K79/02;;A01K79/02,A01K29/00;;A01K61/00;;A01K79/02;;A01M29/00;;H05B43/00;;H05C1/04,,0,0,,,,EXPIRED
768,EP,A4,EP 1014783 A4,173-329-965-479-44X,2001-03-07,2001,EP 97953192 A,1997-12-12,US 9722886 W;;US 76619296 A;;US 98874597 A,1996-12-12,MOBILE CONTROLLABLE STROBE LIGHT SYSTEM AND METHOD FOR DIRECTING THE MOVEMENTS OF A FISH,,FLASH TECHNOLOGY CORP OF AMERI,BAUGHER SUSAN ANN;;BROWN RONALD EARL;;JOHNSON DALE A;;SCHIPP ROBERTO;;NEWSOM MARK STEVENS;;NGUYEN TIEN;;SHUMATE CHRISTOPHER JOEL;;TERRY DAVID MICHAEL;;MARK FRED;;NORTHRUP RICHARD;;OUELLETTE LARRY;;IHRIE RONALD;;BOYER EDWARD;;SOMMERS WILLIAM F,,https://lens.org/173-329-965-479-44X,Search Report,no,3,0,14,16,0,A01K79/02;;A01K79/02,A01K29/00;;A01K61/00;;A01K79/02;;A01M29/00;;H05B43/00;;H05C1/04,,0,0,,,,EXPIRED
769,WO,A1,WO 2018/049172 A1,060-060-972-507-596,2018-03-15,2018,US 2017/0050694 W,2017-09-08,US 201662384849 P,2016-09-08,HANDHELD DEVICE AND MULTIMODAL CONTRAST AGENT FOR EARLY DETECTION OF HUMAN DISEASE,"Systems comprising a combination of the handheld imaging system with a nanoparticle multimodal contrast agent are disclosed. The imaging system exploits the advantages of both near-infrared emission and the photoacoustic effect by employing calcium phosphosilicate nanocolloid that encapsulates NIR and CT/MRI contrast agents for enhanced deep tissue imaging as well as a portable NIR/PA system using a tunable pulsed laser, CCD imaging technology and acoustic transducer arrays. Methods for using the system, for example in rapid diagnosis of trauma such as that inflicted on a battlefield, are provided.",PENN STATE RES FOUND,ADAIR JAMES H;;KNECHT SEAN D;;BOYER J ERIC;;TUTWILER RICHARD L;;CARR CONNOR;;TANG XIAOMENG;;NEUBERGER THOMAS;;LOC WELLEY S;;ADAIR BERNADETTE M;;WILCZYNSKI ZACHARY R;;MCGOVERN CHRISTOPHER;;MATTERS GAIL L;;CHENG KEITH;;KESTER MARK;;SINOWAY LAWRENCE,,https://lens.org/060-060-972-507-596,Patent Application,yes,9,0,2,2,0,A61B2560/0431;;A61B5/0035;;A61K49/225;;A61B5/0095;;A61K49/221;;A61B2560/0431;;A61B5/0035;;A61K49/225;;A61B5/0095;;A61B2503/40;;A61K49/221;;A61K49/222,A61B5/00;;A61K49/00,,1,1,164-571-129-637-931,10.1109/tmm.2013.2244203,"MANSIK JEON ET AL: ""Multimodal Photoacoustic Tomography"", IEEE TRANSACTIONS ON MULTIMEDIA, IEEE SERVICE CENTER, PISCATAWAY, NJ, US, vol. 15, no. 5, 1 August 2013 (2013-08-01), pages 975 - 982, XP011520554, ISSN: 1520-9210, DOI: 10.1109/TMM.2013.2244203",PENDING
770,US,A1,US 2018/0064347 A1,069-446-465-855-552,2018-03-08,2018,US 201715699215 A,2017-09-08,US 201715699215 A;;US 201662384849 P,2016-09-08,HANDHELD DEVICE AND MULTIMODAL CONTRAST AGENT FOR EARLY DETECTION OF HUMAN DISEASE,"Systems comprising a combination of the handheld imaging system with a nanoparticle multimodal contrast agent are disclosed. The imaging system exploits the advantages of both near-infrared emission and the photoacoustic effect by employing calcium phosphosilicate nanocolloid that encapsulates NIR and CT/MRI contrast agents for enhanced deep tissue imaging as well as a portable NIR/PA system using a tunable pulsed laser, CCD imaging technology and acoustic transducer arrays. Methods for using the system, for example in rapid diagnosis of trauma such as that inflicted on a battlefield, are provided.",PENN STATE RES FOUND,ADAIR JAMES H;;KNECHT SEAN D;;BOYER J ERIC;;TUTWILER RICHARD L;;CARR CONNOR;;TANG XIAOMENG;;ADAIR BERNADETTE M;;NEUBERGER THOMAS;;LOC WELLEY S;;WILCZYNSKI ZACHARY R;;MCGOVERN CHRISTOPHER;;MATTERS GAIL L;;CHENG KEITH;;KESTER MARK;;SINOWAY LAWRENCE,THE PENN STATE RESEARCH FOUNDATION (2016-05-10),https://lens.org/069-446-465-855-552,Patent Application,yes,0,5,2,2,0,A61B2560/0431;;A61B5/0035;;A61K49/225;;A61B5/0095;;A61K49/221;;A61B2560/0431;;A61B5/0035;;A61K49/225;;A61B5/0095;;A61B2503/40;;A61K49/221;;A61K49/222,A61B5/00;;A61K49/22,,0,0,,,,DISCONTINUED
771,CN,A,CN 115715322 A,091-774-657-052-850,2023-02-24,2023,CN 202180031347 A,2021-04-28,US 202063017542 P;;US 202063040943 P;;US 2021/0029684 W,2020-04-29,Integrated biomarkers for cancer immunotherapy,Methods are provided for generating a synthetic biomarker that identifies a predicted level of responsiveness of a subject to treatment with a particular type of immunotherapy. The method may include generating a genomic metric representative of one or more features corresponding to one or more DNA sequences. The method may also include generating transcriptome metrics representative of one or more features corresponding to a set of peptides translated from respective RNA sequences of the one or more RNA sequences. The method may also include generating a comprehensive biomarker score derived from the set of genomic metrics and the set of transcriptome metrics. The method may also include determining a predicted level of responsiveness of the subject to a particular type of immunotherapy treatment based on the comprehensive biomarker score.,PERSONALIS INC,ABBOTT III CHARLES WILBER;;BOYER SEAN MICHAEL;;PIKE RACHEL MARTY;;LAVIE ERIC;;MELLERUVAR DATTARIA;;MCCLORY RAINER;;CHEN RICHARD;;BAUER ROBERT;;BASA GABOR;;HARRIS JASON;;PAMELA MILANI;;TANDON PRATIK;;MCNITT PAUL;;MORA MASSIMO;;DESAI SEGAL;;SARVIDAL JUAN-SEBASTIAN;;CLARK MICHAEL;;HAUDENCHILD CHRISTIAN;;WEST JOHN;;NICK PHILLIPS;;TRUONG THIMO V,,https://lens.org/091-774-657-052-850,Patent Application,no,0,0,5,10,0,C12Q1/6886;;C12Q2600/156;;C12Q2600/158;;C12Q2600/106;;G16B5/00;;G16B20/00;;G16B40/20,C12N15/09,,0,0,,,,PENDING
772,CN,A,CN 116601309 A,056-724-084-437-811,2023-08-15,2023,CN 202180050278 A,2021-06-17,US 202063111007 P;;US 2021/0037902 W,2020-11-07,Machine learning techniques for predicting surface presenting peptides,"The present disclosure provides methods for predicting surface presenting peptides using binding and surface presenting characteristics. The method may include accessing a trained machine learning model configured to generate an output indicative of a degree to which one or more expression levels are associated with one or more peptide presentation metrics according to a population-level relationship between the expression and presentation. For each peptide in a set of peptides of a tissue sample, a score may be determined using a machine learning model and genomic and transcriptome data corresponding to the peptide. The score may predict whether the corresponding peptide is a surface presenting peptide that binds to an MHC molecule and is presented on the surface of the cell.",PERSONALIS INC,ABBOTT CHARLES WILBUR III;;BOYER SEAN MICHAEL;;PARKER RACHEL MARTY;;LAVIE ERIC;;MELAH-RUWO DATTAREYA;;MCCLORY RAINER;;CHEN RICHARD;;BAUER ROBERT;;BASA GABOR;;HARRIS JASON;;PAMELA MILANI;;TANDON PRATIK;;MCNETT PAUL;;MORA MASSIMO;;DESAI SEGAL;;SALVIDAL JUAN-SEBASTIEN;;CLARK MICHAEL;;H 1DENKJAERD CHRISTIAN;;WEST JOHN;;NICK PHILLIPS;;TRUONG SIMO V,,https://lens.org/056-724-084-437-811,Patent Application,no,0,0,1,10,0,,C12Q1/6869,,0,0,,,,PENDING
